FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Oaklander, AL Horowitz, SH AF Oaklander, Anne Louise Horowitz, Steven H. BE Toth, C Moulin, DE TI The complex regional pain syndromes and post-traumatic neuralgias SO NEUROPATHIC PAIN: CAUSES, MANAGEMENT, AND UNDERSTANDING LA English DT Article; Book Chapter ID SYNDROME TYPE-I; REFLEX SYMPATHETIC DYSTROPHY; SPINAL-CORD STIMULATION; NEUROPATHIC PAIN; SYNDROME CRPS; CORTICAL REORGANIZATION; DIAGNOSTIC-CRITERIA; PERIPHERAL-NERVE; BOTULINUM-TOXIN; SYNDROME TYPE-1 C1 [Oaklander, Anne Louise] Massachusetts Gen Hosp, Dept Neurol & Neuropathol, Boston, MA 02114 USA. [Oaklander, Anne Louise] Harvard Univ, Sch Med, Boston, MA USA. [Horowitz, Steven H.] Univ Vermont, Coll Med, Burlington, VT USA. RP Oaklander, AL (reprint author), Massachusetts Gen Hosp, Dept Neurol & Neuropathol, Boston, MA 02114 USA. NR 94 TC 0 Z9 0 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-02371-0 PY 2013 BP 177 EP 190 PG 14 WC Neurosciences SC Neurosciences & Neurology GA BHQ97 UT WOS:000326439500016 ER PT J AU Beghi, M Rosenbaum, JF Cerri, C Cornaggia, CM AF Beghi, Massimiliano Rosenbaum, Jerrold F. Cerri, Cesare Cornaggia, Cesare M. TI Risk factors for fatal and nonfatal repetition of suicide attempts: a literature review SO NEUROPSYCHIATRIC DISEASE AND TREATMENT LA English DT Review DE suicide; deliberate self-harm; suicide attempt; repetition; predictors ID DELIBERATE SELF-HARM; TERM-FOLLOW-UP; TOWER-OF-BABEL; REVISED NOMENCLATURE; SUBSEQUENT SUICIDE; SURVIVAL ANALYSIS; INTENT; PARASUICIDE; BEHAVIOR; MULTICENTER AB Objectives: This review aimed to identify the evidence for predictors of repetition of suicide attempts, and more specifically for subsequent completed suicide. Methods: We conducted a literature search of PubMed and Embase between January 1, 1991 and December 31, 2009, and we excluded studies investigating only special populations (eg, male and female only, children and adolescents, elderly, a specific psychiatric disorder) and studies with sample size fewer than 50 patients. Results: The strongest predictor of a repeated attempt is a previous attempt, followed by being a victim of sexual abuse, poor global functioning, having a psychiatric disorder, being on psychiatric treatment, depression, anxiety, and alcohol abuse or dependence. For other variables examined (Caucasian ethnicity, having a criminal record, having any mood disorders, bad family environment, and impulsivity) there are indications for a putative correlation as well. For completed suicide, the strongest predictors are older age, suicide ideation, and history of suicide attempt. Living alone, male sex, and alcohol abuse are weakly predictive with a positive correlation (but sustained by very scarce data) for poor impulsivity and a somatic diagnosis. Conclusion: It is difficult to find predictors for repetition of nonfatal suicide attempts, and even more difficult to identify predictors of completed suicide. Suicide ideation and alcohol or substance abuse/dependence, which are, along with depression, the most consistent predictors for initial nonfatal attempt and suicide, are not consistently reported to be very strong predictors for nonfatal repetition. C1 [Beghi, Massimiliano; Cerri, Cesare; Cornaggia, Cesare M.] Univ Milano Bicocca, Psychiat Clin, Milan, Italy. [Beghi, Massimiliano] Salvini Hosp, Dept Psychiat, Rho, Italy. [Rosenbaum, Jerrold F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Cerri, Cesare] Zucchi Clin Inst, Dept Rehabil Med, Carate Brianza, Italy. [Cornaggia, Cesare M.] Forens Psychiat Hosp, Castiglione delle Stivie, Mantua, Italy. RP Beghi, M (reprint author), Psychosocial Ctr, 28 Via Beatrice Este, Milan, Italy. EM mbeghi@aogarbagnate.lombardia.it NR 87 TC 34 Z9 38 U1 2 U2 24 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-6328 EI 1178-2021 J9 NEUROPSYCH DIS TREAT JI Neuropsychiatr. Dis. Treat. PY 2013 VL 9 BP 1725 EP 1735 DI 10.2147/NDT.S40213 PG 11 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 247RG UT WOS:000326636300001 PM 24235836 ER PT B AU Becker, A Motgi, A Weigel, J Raviola, G Keshavjee, S Kleinman, A AF Becker, Anne Motgi, Anjali Weigel, Jonathan Raviola, Giuseppe Keshavjee, Salmaan Kleinman, Arthur BA Farmer, P Kim, JY Kleinman, A Basilico, M BF Farmer, P Kim, JY Kleinman, A Basilico, M TI The Unique Challenges of Mental Health and MDRTB SO REIMAGINING GLOBAL HEALTH: AN INTRODUCTION SE California Series in Public Anthropology LA English DT Article; Book Chapter ID ADJUSTED LIFE YEARS; RESISTANT TUBERCULOSIS; DRUG-RESISTANCE; COUNTRIES; DISORDERS; POVERTY; DISEASE C1 [Becker, Anne; Raviola, Giuseppe; Keshavjee, Salmaan; Kleinman, Arthur] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Becker, Anne] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Cambridge, MA 02138 USA. [Becker, Anne] Harvard Univ, Sch Med, Social Sci MD PhD Program, Cambridge, MA 02138 USA. [Becker, Anne] Massachusetts Gen Hosp, Dept Psychiat, Eating Disorders Clin & Res Program, Boston, MA 02114 USA. [Motgi, Anjali] Global Hlth Strategies LLC, New York, NY USA. [Weigel, Jonathan; Kleinman, Arthur] Harvard Univ, Cambridge, MA 02138 USA. [Raviola, Giuseppe] Boston Childrens Hosp, Dept Psychiat, Psychiat Qual Program, Boston, MA USA. [Raviola, Giuseppe] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Program Global Mental Hlth & Social Change, Cambridge, MA 02138 USA. [Keshavjee, Salmaan] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Program Infect Dis & Social Change, Cambridge, MA 02138 USA. [Keshavjee, Salmaan] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. RP Becker, A (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 20 TC 4 Z9 4 U1 0 U2 1 PU UNIV CALIFORNIA PRESS PI BERKELEY PA 2120 BERKELEY WAY, BERKELEY, CA 94720 USA BN 978-0-520-95463-2; 978-0-520-27197-5 J9 CALIF SER PUB ANTHR PY 2013 VL 26 BP 212 EP + PG 44 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA BHQ41 UT WOS:000326341100009 ER PT B AU Farmer, P Basilico, M Kerry, V Ballard, M Becker, A Bukhman, G Dahl, O Ellner, A Ivers, L Jones, D Meara, J Mukherjee, J Sievers, A Yamamoto, A AF Farmer, Paul Basilico, Matthew Kerry, Vanessa Ballard, Madeleine Becker, Anne Bukhman, Gene Dahl, Ophelia Ellner, Andy Ivers, Louise Jones, David Meara, John Mukherjee, Joia Sievers, Amy Yamamoto, Alyssa BA Farmer, P Kim, JY Kleinman, A Basilico, M BF Farmer, P Kim, JY Kleinman, A Basilico, M TI Global Health Priorities for the Early Twenty-First Century SO REIMAGINING GLOBAL HEALTH: AN INTRODUCTION SE California Series in Public Anthropology LA English DT Article; Book Chapter C1 [Farmer, Paul; Becker, Anne; Mukherjee, Joia] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Cambridge, MA 02138 USA. [Farmer, Paul; Ellner, Andy; Ivers, Louise; Mukherjee, Joia] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Basilico, Matthew; Jones, David] Harvard Univ, Cambridge, MA 02138 USA. [Kerry, Vanessa; Becker, Anne; Bukhman, Gene; Ivers, Louise] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Kerry, Vanessa; Jones, David] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kerry, Vanessa] Massachusetts Gen Hosp, Ctr Global Hlth, Dept Global Hlth & Social Med, Global Publ Policy & Social Change Program, Boston, MA 02114 USA. [Kerry, Vanessa] Massachusetts Gen Hosp, Ctr Global Hlth, Partnerships & Global Initiat, Boston, MA 02114 USA. [Ballard, Madeleine] Tiyatien Hlth, Konobo, Liberia. [Becker, Anne] Harvard Univ, Sch Med, Social Sci MD PhD Program, Cambridge, MA 02138 USA. [Becker, Anne] Massachusetts Gen Hosp, Dept Psychiat, Eating Disorders Clin & Res Program, Boston, MA 02114 USA. [Bukhman, Gene; Ellner, Andy] Harvard Univ, Sch Med, Program Global Noncommunicable Dis & Social Chang, Cambridge, MA 02138 USA. [Ellner, Andy] Harvard Univ, Sch Med, Ctr Primary Care, Cambridge, MA 02138 USA. [Jones, David] Boston Med Ctr, Boston, MA USA. [Meara, John] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Program Global Surg & Social Change, Cambridge, MA 02138 USA. [Meara, John] Boston Childrens Hosp, Dept Plast & Oral Surg, Boston, MA USA. [Mukherjee, Joia] WHO, Washington, DC USA. [Yamamoto, Alyssa] Harvard Global Hlth Inst, Forum Global Governance Hlth, Cambridge, MA USA. [Yamamoto, Alyssa] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. NR 14 TC 3 Z9 3 U1 0 U2 1 PU UNIV CALIFORNIA PRESS PI BERKELEY PA 2120 BERKELEY WAY, BERKELEY, CA 94720 USA BN 978-0-520-95463-2; 978-0-520-27197-5 J9 CALIF SER PUB ANTHR PY 2013 VL 26 BP 302 EP + PG 58 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA BHQ41 UT WOS:000326341100012 ER PT B AU Basilico, M Kerry, V Messac, L Suri, A Weigel, J Basilico, MT Mukherjee, J Farmer, P AF Basilico, Matthew Kerry, Vanessa Messac, Luke Suri, Arjun Weigel, Jonathan Basilico, Marguerite Thorp Mukherjee, Joia Farmer, Paul BA Farmer, P Kim, JY Kleinman, A Basilico, M BF Farmer, P Kim, JY Kleinman, A Basilico, M TI A Movement for Global Health Equity? A Closing Reflection SO REIMAGINING GLOBAL HEALTH: AN INTRODUCTION SE California Series in Public Anthropology LA English DT Article; Book Chapter C1 [Basilico, Matthew; Weigel, Jonathan] Harvard Univ, Cambridge, MA 02138 USA. [Kerry, Vanessa; Suri, Arjun; Basilico, Marguerite Thorp] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Kerry, Vanessa] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kerry, Vanessa] Massachusetts Gen Hosp, Ctr Global Hlth, Dept Global Hlth & Social Med, Global Publ Policy & Social Change Program, Boston, MA 02114 USA. [Kerry, Vanessa] Massachusetts Gen Hosp, Ctr Global Hlth, Partnerships Initiat, Boston, MA 02114 USA. [Kerry, Vanessa] Massachusetts Gen Hosp, Ctr Global Hlth, Global Initiat, Boston, MA 02114 USA. [Messac, Luke] Univ Penn, Philadelphia, PA 19104 USA. [Mukherjee, Joia; Farmer, Paul] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Mukherjee, Joia; Farmer, Paul] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Cambridge, MA 02138 USA. RP Basilico, M (reprint author), Harvard Univ, Cambridge, MA 02138 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU UNIV CALIFORNIA PRESS PI BERKELEY PA 2120 BERKELEY WAY, BERKELEY, CA 94720 USA BN 978-0-520-95463-2; 978-0-520-27197-5 J9 CALIF SER PUB ANTHR PY 2013 VL 26 BP 340 EP + PG 16 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA BHQ41 UT WOS:000326341100013 ER PT S AU Namura, S Ooboshi, H Liu, JL Yenari, MA AF Namura, Shobu Ooboshi, Hiroaki Liu, Jialing Yenari, Midori A. GP Annals NY Acad Sci TI Neuroprotection after cerebral ischemia SO ANNALS MEETING REPORTS SE Annals of the New York Academy of Sciences LA English DT Article DE stroke; cerebral ischemia; cerebrovascular disease; neurovascular unit; cell therapy; repair; immune response ID EXPERIMENTAL STROKE; BRAIN; RECOVERY; INJURY; CELLS AB Cerebral ischemia, a focal or global insufficiency of blood flow to the brain, can arise through multiple mechanisms, including thrombosis and arterial hemorrhage. Ischemia is a major driver of stroke, one of the leading causes of morbidity and mortality worldwide. While the general etiology of cerebral ischemia and stroke has been known for some time, the conditions have only recently been considered treatable. This report describes current research in this field seeking to fully understand the pathomechanisms underlying stroke; to characterize the brain's intrinsic injury, survival, and repair mechanisms; to identify putative drug targets as well as cell-based therapies; and to optimize the delivery of therapeutic agents to the damaged cerebral tissue. C1 [Namura, Shobu] Morehouse Sch Med, Inst Neurosci, Dept Neurobiol, Atlanta, GA 30310 USA. [Ooboshi, Hiroaki] Med & Dent Hosp, Fukuoka Dent Coll, Dept Internal Med, Fukuoka, Japan. [Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA. [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu RI Liu, Jialing/A-8627-2012 OI Liu, Jialing/0000-0003-4420-4382 FU NIH through the U.S.-Japan Brain Research Cooperative Program [3R01 NS040516-11S1]; Japan-U.S. Science and Technology Cooperation Program; Brain Research Division FX This meeting was funded by an NIH R13 Grant through the U.S.-Japan Brain Research Cooperative Program (3R01 NS040516-11S1) to Midori A. Yenari; and from the Japan-U.S. Science and Technology Cooperation Program, Brain Research Division, to Hiroaki Ooboshi, Genentech (a member of the Roche Group), and Peter R. MacLeish (Neuroscience Institute, Morehouse School of Medicine). Grant funds were administered by the Northern California Institute for Research and Education. The organizers of the "Trans-Pacific Workshop on Stroke" thank the presenters and attendees for their contributions and lively and insightful discussions. The attendees dedicated the meeting to the memory of Akira Arimura, an American scientist at Tulane University with beginnings in Japan, whose remarkable career included many U.S.-Japan collaborations. NR 19 TC 3 Z9 6 U1 0 U2 7 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2013 VL 1278 BP 25 EP 32 DI 10.1111/nyas.12087 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BHO53 UT WOS:000326100700003 PM 23488559 ER PT J AU Walker, A AF Walker, A. TI THE ROLE OF HUMAN MILK OLIGOSACCHARIDES IN INTESTINAL COLONIZATION SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Human milk; intestine; oligosaccharides; immune system; prebiotics; probiotics C1 [Walker, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 107 EP 107 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201226 ER PT J AU Santiago, M Cui, Y Adams, A Carrel, A Allen, D Delgado, A Gonzalez, M Schoeller, D LaRowe, T AF Santiago, M. Cui, Y. Adams, A. Carrel, A. Allen, D. Delgado, A. Gonzalez, M. Schoeller, D. LaRowe, T. TI INDIVIDUAL AND FAMILIAL DIETARY PREDICTORS OF OBESITY AMONG HISPANIC CHILDREN FROM AN URBAN COMMUNITY IN THE US SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Obesity; sugar-sweetened beverages; home food environment; Hispanic children C1 [Santiago, M.; Adams, A.; Carrel, A.; Allen, D.; Schoeller, D.; LaRowe, T.] Univ Wisconsin, Madison, WI USA. [Cui, Y.] Univ Maryland, Natl Ctr Smart Growth Res & Educ, College Pk, MD 20742 USA. [Delgado, A.] Univ So Calif, Inst Hlth Promot & Dis Prevent Res IPR, Alhambra, CA USA. [Gonzalez, M.] US Dept Vet Affairs, RORC, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 356 EP 356 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548201731 ER PT J AU Lindsay, A Greaney, M Sussner, K Wang, M Pheiffer, E Peterson, K AF Lindsay, A. Greaney, M. Sussner, K. Wang, M. Pheiffer, E. Peterson, K. TI SOCIO-CULTURAL, ORGANIZATIONAL, AND COMMUNITY LEVEL INFLUENCES ON PHYSICAL ACTIVITY LEVELS OF LATINO PRESCHOOL-AGED CHILDREN: A QUALITATIVE STUDY SO ANNALS OF NUTRITION AND METABOLISM LA English DT Meeting Abstract DE Physical Activity; Latino; Obesity; Children; WIC Program C1 [Lindsay, A.] Univ Massachusetts, Coll Nursing & Hlth Sci, Dept Exercise & Hlth Sci, Boston, MA 02125 USA. [Greaney, M.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Sussner, K.] Mt Sinai Sch Med, Div Canc Prevent & Control, Dept Oncol Sci, New York, NY USA. [Wang, M.] Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA USA. [Pheiffer, E.] Curamericas Global Inc, Raleigh, NC USA. [Peterson, K.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 EI 1421-9697 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2013 VL 63 SU 1 BP 432 EP 432 PG 1 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 219YR UT WOS:000324548202065 ER PT J AU Rossin, EJ Neale, BM AF Rossin, Elizabeth J. Neale, Benjamin M. BA Shaw, P Tafti, M Thorpy, M BF Shaw, P Tafti, M Thorpy, M TI Linkage and associations SO GENETIC BASIS OF SLEEP AND SLEEP DISORDERS LA English DT Article; Book Chapter ID RESTLESS LEGS SYNDROME; GENOME-WIDE ASSOCIATION; SLEEP PHASE SYNDROME; SUSCEPTIBILITY LOCUS; COMMON VARIANTS; CHROMOSOME 12Q; NARCOLEPSY; GENETICS; POPULATION; POLYMORPHISM C1 [Rossin, Elizabeth J.; Neale, Benjamin M.] Massachusetts Gen Hosp, Broad Inst, Analyt & Translat Genet Unit, Boston, MA 02114 USA. RP Rossin, EJ (reprint author), Massachusetts Gen Hosp, Broad Inst, Analyt & Translat Genet Unit, Boston, MA 02114 USA. NR 61 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-04125-7 PY 2013 BP 1 EP 12 D2 10.1017/CBO9781139649469 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA BHL19 UT WOS:000325766000003 ER PT J AU Pelluru, D Konadhode, R Blanco-Centurion, C Liu, M Shiromani, PJ AF Pelluru, Dheeraj Konadhode, RodaRani Blanco-Centurion, Carlos Liu, Meng Shiromani, Priyattam J. BA Shaw, P Tafti, M Thorpy, M BF Shaw, P Tafti, M Thorpy, M TI Gene therapy for sleep disorders SO GENETIC BASIS OF SLEEP AND SLEEP DISORDERS LA English DT Article; Book Chapter ID X-LINKED ADRENOLEUKODYSTROPHY; OREXIN KNOCKOUT MICE; PHASE SYNDROME; DORSOLATERAL PONS; HUMAN NARCOLEPSY; RAT-BRAIN; NEURONS; EXPRESSION; MUTATION; HYPOTHALAMUS C1 [Pelluru, Dheeraj; Konadhode, RodaRani; Blanco-Centurion, Carlos; Liu, Meng; Shiromani, Priyattam J.] Ralph H Johnson VA, Charleston, SC USA. [Pelluru, Dheeraj; Konadhode, RodaRani; Blanco-Centurion, Carlos; Liu, Meng; Shiromani, Priyattam J.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Pelluru, D (reprint author), Ralph H Johnson VA, Charleston, SC USA. NR 41 TC 0 Z9 0 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-04125-7 PY 2013 BP 375 EP 380 D2 10.1017/CBO9781139649469 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA BHL19 UT WOS:000325766000037 ER PT J AU Brown, CJ Bearden, DM AF Brown, Cynthia J. Bearden, Donna M. BE Williams, BC Malani, PN Wesorick, DH TI FALLS AND MOBILITY DURING HOSPITALIZATION SO HOSPITALISTS' GUIDE TO THE CARE OF OLDER PATIENTS SE Hospital Medicine-Current Concepts LA English DT Article; Book Chapter ID OLDER-ADULTS; EARLY MOBILIZATION; RANDOMIZED-TRIAL; PREVENTING FALLS; INPATIENT FALLS; CARE; PROGRAM; NONPAYMENT; DISCHARGE; MEDICARE C1 [Brown, Cynthia J.; Bearden, Donna M.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Brown, Cynthia J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Brown, CJ (reprint author), Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. NR 39 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-118-12792-6 J9 HOSP MED-CURR CONCEP PY 2013 BP 165 EP 179 D2 10.1002/9781118674963 PG 15 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA BHQ14 UT WOS:000326288000010 ER PT J AU Kostas, TRM Rudolph, JL AF Kostas, Tia R. M. Rudolph, James L. BE Williams, BC Malani, PN Wesorick, DH TI DELIRIUM SO HOSPITALISTS' GUIDE TO THE CARE OF OLDER PATIENTS SE Hospital Medicine-Current Concepts LA English DT Article; Book Chapter ID INTENSIVE-CARE-UNIT; CONFUSION ASSESSMENT METHOD; MECHANICALLY VENTILATED PATIENTS; PATIENT-CONTROLLED ANALGESIA; POSTACUTE FACILITY PATIENTS; RANDOMIZED CONTROLLED-TRIAL; HOSPITALIZED OLDER PATIENTS; PLACEBO-CONTROLLED TRIAL; CRITICALLY-ILL PATIENTS; POSTOPERATIVE DELIRIUM C1 [Kostas, Tia R. M.] Vet Affairs Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA. [Kostas, Tia R. M.; Rudolph, James L.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA. [Kostas, Tia R. M.; Rudolph, James L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Rudolph, James L.] VA Boston Healthcare Syst, Sect Geriatr & Palliat Care, Geriatr Res Educ & Clin Ctr, Boston, MA USA. RP Kostas, TRM (reprint author), Vet Affairs Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA. NR 76 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-118-12792-6 J9 HOSP MED-CURR CONCEP PY 2013 BP 203 EP 223 D2 10.1002/9781118674963 PG 21 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA BHQ14 UT WOS:000326288000012 ER PT J AU Pena, JRA Berces, A Kent, H Major, E Hague, T Saidman, SL AF Pena, J. Ryan A. Berces, Attila Kent, Heather Major, Endre Hague, Tim Saidman, Susan L. TI HIGH-RESOLUTION TYPING BY NEXT-GENERATION SEQUENCING IN A CLINICAL HLA LABORATORY. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 39th Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics (ASHI) CY NOV 17-21, 2013 CL Chicago, IL SP Amer Soc Histocompatibil & Immunogenet C1 [Pena, J. Ryan A.; Kent, Heather; Saidman, Susan L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Berces, Attila; Major, Endre; Hague, Tim] Omixon Biocomp Kft, Omixon, Budapest, Hungary. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 EI 1879-1166 J9 HUM IMMUNOL JI Hum. Immunol. PY 2013 VL 74 SU S BP 154 EP 154 PG 1 WC Immunology SC Immunology GA 239YC UT WOS:000326060900215 ER PT J AU Willsky, GR Halvorsen, K Godzala, ME Chi, LH Most, MJ Kaszynski, P Crans, DC Goldfine, AB Kostyniak, PJ AF Willsky, Gail R. Halvorsen, Katherine Godzala, Michael E., III Chi, Lai-Har Most, Mathew J. Kaszynski, Peter Crans, Debbie C. Goldfine, Allison B. Kostyniak, Paul J. TI Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients SO METALLOMICS LA English DT Article ID HUMAN-SERUM TRANSFERRIN; IN-VIVO; BLOOD-SERUM; INSULIN SENSITIVITY; BIOLOGICAL-SYSTEMS; AQUEOUS CHEMISTRY; URINARY VANADIUM; VO2+ COMPLEXES; SPECIATION; VITRO AB Vanadium, abbreviated V, is an early transition metal that readily forms coordination complexes with a variety of biological products such as proteins, metabolites, membranes and other structures. The formation of coordination complexes stabilizes metal ions, which in turn impacts the biodistribution of the metal. To understand the biodistribution of V, V in oxidation state IV in the form of vanadyl sulfate (25, 50, 100 mg V daily) was given orally for 6 weeks to 16 persons with type 2 diabetes. Elemental V was determined using Graphite Furnas Atomic Absorption Spectrometry against known concentrations of V in serum, blood or urine. Peak serum V levels were 15.4 +/- 6.5, 81.7 +/- 40 and 319 +/- 268 ng ml(-1) respectively, and mean peak serum V was positively correlated with dose administered (r = 0.992, p = 0.079), although large inter-individual variability was found. Total serum V concentration distribution fit a one compartment open model with a first order rate constant for excretion with mean half times of 4.7 +/- 1.6 days and 4.6 +/- 2.5 days for the 50 and 100 mg V dose groups respectively. At steady state, 24 hour urinary V output was 0.18 +/- 0.24 and 0.97 +/- 0.84 mg in the 50 and 100 mg V groups respectively, consistent with absorption of 1 percent or less of the administered dose. Peak V in blood and serum were positively correlated (r = 0.971, p < 0.0005). The serum to blood V ratio for the patients receiving 100 mg V was 1.7 +/- 0.45. Regression analysis showed that glycohemoglobin was a negative predictor of the natural log(ln) peak serum V (R-2 = 0.40, p = 0.009) and a positive predictor of the euglycemic-hyperinsulinemic clamp results at high insulin values (R-2 = 0.39, p = 0.010). Insulin sensitivity measured by euglycemic-hyperinsulinemic clamp was not significantly correlated with ln peak serum V. Globulin and glycohemoglobin levels taken together were negative predictors of fasting blood glucose (R-2 = 0.49, p = 0.013). Although V accumulation in serum was dose-dependent, no correlation between total serum V concentration and the insulin-like response was found in this first attempt to correlate anti-diabetic activity with total serum V. This study suggests that V pools other than total serum V are likely related to the insulin-like effect of this metal. These results, obtained in diabetic patients, document the need for consideration of the coordination chemistry of metabolites and proteins with vanadium in anti-diabetic vanadium complexes. C1 [Willsky, Gail R.; Godzala, Michael E., III; Chi, Lai-Har; Most, Mathew J.; Kaszynski, Peter; Kostyniak, Paul J.] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14214 USA. [Halvorsen, Katherine] Smith Coll, Dept Math & Stat, Northampton, MA 01063 USA. [Crans, Debbie C.] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA. [Goldfine, Allison B.] Harvard Univ, Brigham & Womens Hosp, Joslin Diabet Ctr, Dept Med,Res Div, Boston, MA 02155 USA. [Goldfine, Allison B.] Harvard Univ, Sch Med, Boston, MA 02155 USA. RP Willsky, GR (reprint author), SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14214 USA. EM gwillsky@buffalo.edu FU American Diabetes Foundation; General Medicine Institute at the National Institutes of Health [R01 GM40525]; National Institutes of Health [RO1 DK47462-05]; General Clinical Research Center [M01 RR-02635-15] FX The authors would like to acknowledge technical assistance of Marian Pazik. DCC and GRW thank the American Diabetes Foundation and the General Medicine Institute at the National Institutes of Health for funding this work R01 GM40525. ABG greatfully acknowledges the mentorship of C. Ronald Kahn, MD and support from the National Institutes of Health RO1 DK47462-05 and General Clinical Research Center M01 RR-02635-15. GRW would like to acknowledge the contributions of Elizabeth Johns and Alexander Salloum to this study. NR 85 TC 22 Z9 22 U1 7 U2 34 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1756-5901 EI 1756-591X J9 METALLOMICS JI Metallomics PY 2013 VL 5 IS 11 BP 1491 EP 1502 DI 10.1039/c3mt00162h PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 242MC UT WOS:000326245100004 PM 23982218 ER PT S AU Sethi, RV MacDonald, SM Kim, DY Mukai, S AF Sethi, Roshan V. MacDonald, Shannon M. Kim, David Y. Mukai, Shizuo BE Singh, AD Pelayes, DE Seregard, S Macklis, R TI Radiation Therapy: Retinal Tumors SO OPHTHALMIC RADIATION THERAPY: TECHNIQUES AND APPLICATIONS SE Developments in Ophthalmology LA English DT Article; Book Chapter ID EXTERNAL-BEAM RADIOTHERAPY; HIPPEL-LINDAU-DISEASE; LONG-TERM SURVIVORS; VASOPROLIFERATIVE TUMORS; PLAQUE RADIOTHERAPY; EXTRAOCULAR RETINOBLASTOMA; TRILATERAL RETINOBLASTOMA; METASTATIC RETINOBLASTOMA; CAPILLARY HEMANGIOMA; BILATERAL RADIATION AB The major retinal tumor that requires radiotherapy (RT) is retinoblastoma (RB); to a lesser degree, RT is used for some cases of retinal capillary hemangioma and lymphoma of the retina. Although there are concerns about the risk of RT-induced second malignancy in patients who carry a germline mutation in the RB1 gene, RT remains a very important part of our approach to intra-ocular and extra-ocular RB. Technical innovations in RT allow more precise targeting of retinal tumors and decreased exposure of adjacent normal tissue, an advance that is particularly significant for patients with hereditary RB who are at risk of additional malignancies. Copyright (C) 2013 S. Karger AG, Basel C1 [Sethi, Roshan V.; MacDonald, Shannon M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA. [Kim, David Y.; Mukai, Shizuo] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA. RP Sethi, RV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA. EM rsethi2@partners.org; smacdonald@partners.org; David_Kim@meei.harvard.edu; Shizuo_Mukai@meei.harvard.edu NR 62 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0250-3751 BN 978-3-318-02441-8; 978-3-318-02440-1 J9 DEV OPHTHALMOL JI Dev. Ophthalmol. PY 2013 VL 52 BP 58 EP 74 DI 10.1159/000351058 PG 17 WC Oncology; Ophthalmology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Ophthalmology; Radiology, Nuclear Medicine & Medical Imaging GA BHT15 UT WOS:000326603700007 PM 23989127 ER PT S AU Locke, GR Horwhat, J Mashimo, H Savarino, E Zentilin, P Savarino, V Zerbib, F Armbruster, SP Wong, RK Moawad, F AF Locke, G. Richard, III Horwhat, John Mashimo, Hiroshi Savarino, Edoardo Zentilin, Patrizia Savarino, Vincenzo Zerbib, Frank Armbruster, Steven P. Wong, Roy K. Moawad, Fouad BE Giuli, R Umar, A TI Endotherapy for and tailored approaches to treating GERD, and refractory GERD SO 11TH OESO WORLD CONFERENCE: REFLUX DISEASE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 11th OESO World Conference - Reflux disease, from LES to UES, and Beyond CY SEP 01-04, 2012 CL Como, ITALY SP World Org Specialized Studies Dis Esophagus DE GABA agonists; TRPV1; IBS; NERD; antidepressants; functional heartburn; PPI ID GASTROESOPHAGEAL-REFLUX DISEASE; LOWER ESOPHAGEAL SPHINCTER; IRRITABLE-BOWEL-SYNDROME; PROTON PUMP INHIBITORS; DILATED INTERCELLULAR SPACES; RADIOFREQUENCY ENERGY DELIVERY; RANDOMIZED CLINICAL-TRIAL; CAPSAICIN RECEPTOR TRPV1; GABA(B) AGONIST BACLOFEN; PLACEBO-CONTROLLED TRIAL AB This paper presents commentaries on how endoluminal antireflux procedures compare to laparoscopic fundoplication; new endoscopic procedures being studied to treat refractory gastroesophageal reflux disease (GERD); the new Stretta; the relationship between obesity and proton pump inhibitor (PPI) resistance; data concerning acid hypersensitivity and sensory receptors (vallinoid, TRPV1) causing refractory GERD; whether microscopic esophagitis is relevant in determining symptoms of non-erosive reflux disease (NERD); how concomitant functional gastrointestinal disorders affect the PPI response in NERD; the evidence that a functional esophagus is associated with inflammatory bowel syndrome (IBS); the role of GABA agonists in the treatment of refractory GERD; the role of biofeedback and antidepressants in refractory GERD; and endoluminal fundoplication using the EsophyX device. C1 [Locke, G. Richard, III] Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN 55905 USA. [Horwhat, John] Walter Reed Natl Mil Med Ctr, Dept Med, Bethesda, MD USA. [Mashimo, Hiroshi] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA. Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Padua, Italy. [Zentilin, Patrizia; Savarino, Vincenzo] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy. [Zerbib, Frank] St Andre Hosp, CHU Bordeaux, Dept Gastroenterol, Bordeaux, France. [Armbruster, Steven P.; Wong, Roy K.; Moawad, Fouad] Walter Reed Natl Mil Med Ctr, Dept Gastroenterol, Bethesda, MD USA. RP Locke, GR (reprint author), Mayo Clin, Dept Gastroenterol & Hepatol, Rochester, MN 55905 USA. EM annals@nyas.org OI Savarino, Edoardo/0000-0002-3187-2894; Zentilin, Patrizia/0000-0002-9235-6308 NR 91 TC 5 Z9 5 U1 0 U2 4 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2013 VL 1300 BP 166 EP 186 DI 10.1111/nyas.12240 PG 21 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BHM41 UT WOS:000325920700013 PM 24117641 ER PT S AU Awosogba, T Betancourt, JR Conyers, FG Estape, ES Francois, F Gard, SJ Kaufman, A Lunn, MR Nivet, MA Oppenheim, JD Pomeroy, C Yeung, H AF Awosogba, Temitope Betancourt, Joseph R. Conyers, F. Garrett Estape, Estela S. Francois, Fritz Gard, Sabrina J. Kaufman, Arthur Lunn, Mitchell R. Nivet, Marc A. Oppenheim, Joel D. Pomeroy, Claire Yeung, Howa GP Annals New York Acad Sci TI Prioritizing health disparities in medical education to improve care SO ANNALS MEETING REPORTS SE Annals of the New York Academy of Sciences LA English DT Article DE health disparities; social determinants; diversity; cross-cultural education ID SOCIAL DETERMINANTS; NEW-MEXICO; PHYSICIANS AB Despite yearly advances in life-saving and preventive medicine, as well as strategic approaches by governmental and social agencies and groups, significant disparities remain in health, health quality, and access to health care within the United States. The determinants of these disparities include baseline health status, race and ethnicity, culture, gender identity and expression, socioeconomic status, region or geography, sexual orientation, and age. In order to renew the commitment of the medical community to address health disparities, particularly at the medical school level, we must remind ourselves of the roles of doctors and medical schools as the gatekeepers and the value setters for medicine. Within those roles are responsibilities toward the social mission of working to eliminate health disparities. This effort will require partnerships with communities as well as with academic centers to actively develop and to implement diversity and inclusion strategies. Besides improving the diversity of trainees in the pipeline, access to health care can be improved, and awareness can be raised regarding population-based health inequalities. C1 [Awosogba, Temitope] Mt Sinai Sch Med, New York, NY 10029 USA. [Betancourt, Joseph R.] Massachusetts Gen Hosp, Dispar Solut Ctr, Boston, MA 02114 USA. [Betancourt, Joseph R.; Conyers, F. Garrett; Lunn, Mitchell R.] Harvard Univ, Sch Med, Boston, MA USA. [Estape, Estela S.] Univ Puerto Rico, San Juan, PR 00936 USA. [Francois, Fritz; Gard, Sabrina J.; Oppenheim, Joel D.; Yeung, Howa] NYU, Sch Med, Off Div Affairs, New York, NY USA. [Kaufman, Arthur] Univ New Mexico, Albuquerque, NM 87131 USA. [Lunn, Mitchell R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Nivet, Marc A.] Assoc Amer Med Colleges, Washington, DC USA. [Pomeroy, Claire] Univ Calif Davis, Sch Med, Davis, CA 95616 USA. RP Awosogba, T (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA. EM annals@nyas.org OI Lunn, Mitchell/0000-0002-0068-0814; Francois, Fritz/0000-0003-4491-2637; Oppenheim, Joel/0000-0002-6920-5624 FU Hispanic Clinical and Translational Research Education and Career Development (HCTRECD) program [R25MD007607] FX E. Estape acknowledges the NIH/NIMHD for their support to continue building research infrastructure and capacity in Puerto Rico: Endowment Program "Hispanics in Research Capability: School of Health Professions & School of Medicine Partnership (HiREC)" S21MD001830, and the Hispanic Clinical and Translational Research Education and Career Development (HCTRECD) program R25MD007607. NR 38 TC 11 Z9 11 U1 1 U2 22 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 BN 978-1-57331-930-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2013 VL 1287 BP 17 EP 30 DI 10.1111/nyas.12117 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BHL82 UT WOS:000325809400002 PM 23659676 ER PT J AU Palmer, SC Navaneethan, SD Craig, JC Johnson, DW Perkovic, V Nigwekar, SU Hegbrant, J Strippoli, GFM AF Palmer, Suetonia C. Navaneethan, Sankar D. Craig, Jonathan C. Johnson, David W. Perkovic, Vlado Nigwekar, Sagar U. Hegbrant, Jorgen Strippoli, Giovanni F. M. TI HMG CoA reductase inhibitors (statins) for dialysis patients SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Renal Dialysis [mortality]; Cardiovascular Diseases [mortality; prevention & control]; Cholesterol [blood]; Dyslipidemias [drug therapy; mortality]; Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use]; Kidney Failure, Chronic [blood; therapy]; Peritoneal Dialysis, Continuous Ambulatory [mortality]; Randomized Controlled Trials as Topic; Triglycerides [blood]; Humans ID C-REACTIVE PROTEIN; CHRONIC KIDNEY-DISEASE; TYPE-2 DIABETES-MELLITUS; DENSITY-LIPOPROTEIN CHOLESTEROL; CHRONIC-HEMODIALYSIS PATIENTS; PLACEBO-CONTROLLED TRIAL; AMBULATORY PERITONEAL-DIALYSIS; RANDOMIZED-CONTROLLED-TRIAL; CHRONIC RENAL-INSUFFICIENCY; LEFT-VENTRICULAR MASS AB Background People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitors) report conflicting conclusions for people on dialysis and existing meta-analyses have not had sufficient power to determine whether the effects of statins vary with severity of kidney disease. Recently, additional data for the effects of statins in dialysis patients have become available. This is an update of a review first published in 2004 and last updated in 2009. Objectives To assess the benefits and harms of statin use in adults who require dialysis (haemodialysis or peritoneal dialysis). Search methods We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review. Selection criteria Randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of statins with placebo, no treatment, standard care or other statins on mortality, cardiovascular events and treatment-related toxicity in adults treated with dialysis were sought for inclusion. Data collection and analysis Two or more authors independently extracted data and assessed study risk of bias. Treatment effects were summarised using a random-effects model and subgroup analyses were conducted to explore sources of heterogeneity. Treatment effects were expressed as mean difference (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes together with 95% confidence intervals (CI). Main results The risk of bias was high in many of the included studies. Random sequence generation and allocation concealment was reported in three (12%) and four studies (16%), respectively. Participants and personnel were blinded in 13 studies (52%), and outcome assessors were blinded in five studies (20%). Complete outcome reporting occurred in nine studies (36%). Adverse events were only reported in nine studies (36%); 11 studies (44%) reported industry funding. We included 25 studies (8289 participants) in this latest update; 23 studies (24 comparisons, 8166 participants) compared statins with placebo or no treatment, and two studies (123 participants) compared statins directly with one or more other statins. Statins had little or no effect on major cardiovascular events (4 studies, 7084 participants: RR 0.95, 95% CI 0.88 to 1.03), all-cause mortality (13 studies, 4705 participants: RR 0.96, 95% CI 0.90 to 1.02), cardiovascular mortality (13 studies, 4627 participants: RR 0.94, 95% CI 0.84 to 1.06) and myocardial infarction (3 studies, 4047 participants: RR 0.87, 95% CI 0.71 to 1.07); and uncertain effects on stroke (2 studies, 4018 participants: RR 1.29, 95% CI 0.96 to 1.72). Risks of adverse events from statin therapy were uncertain; these included effects on elevated creatine kinase (5 studies, 3067 participants: RR 1.25, 95% CI 0.55 to 2.83) or liver function enzymes (4 studies, 3044 participants; RR 1.09, 95% CI 0.41 to 1.25), withdrawal due to adverse events (9 studies, 1832 participants: RR 1.04, 95% CI 0.87 to 1.25) or cancer (2 studies, 4012 participants: RR 0.90, 95% CI 0.72 to 1.11). Statins reduced total serum cholesterol (14 studies, 1803 participants; MD -44.86 mg/dL, 95% CI -55.19 to -34.53) and low-density lipoprotein cholesterol (12 studies, 1747 participants: MD -39.99 mg/dL, 95% CI -52.46 to -27.52) levels. Data comparing statin therapy directly with another statin were sparse. Authors' conclusions Statins have little or no beneficial effects on mortality or cardiovascular events and uncertain adverse effects in adults treated with dialysis despite clinically relevant reductions in serum cholesterol levels. C1 [Palmer, Suetonia C.] Univ Otago, Dept Med, Christchurch, New Zealand. [Navaneethan, Sankar D.] Cleveland Clin, Dept Nephrol & Hypertens, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA. [Craig, Jonathan C.; Strippoli, Giovanni F. M.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Craig, Jonathan C.; Strippoli, Giovanni F. M.] Childrens Hosp, Ctr Kidney Res, Cochrane Renal Grp, Westmead, NSW, Australia. [Johnson, David W.] Princess Alexandra Hosp, Dept Nephrol, Woolloongabba, Qld 4102, Australia. [Perkovic, Vlado] George Inst Global Hlth, Renal & Metab Div, Camperdown, NSW, Australia. [Nigwekar, Sagar U.] Harvard Univ, Brigham & Womens Hosp, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Hegbrant, Jorgen] Diaverum, Med Off, Lund, Sweden. [Strippoli, Giovanni F. M.] Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy. [Strippoli, Giovanni F. M.] Mario Negri Sud Consortium, Dept Clin Pharmacol & Epidemiol, Santa Maria Imbaro, Italy. [Strippoli, Giovanni F. M.] Diaverum, Med Sci Off, Lund, Sweden. RP Strippoli, GFM (reprint author), Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. EM strippoli@negrisud.it RI Craig, Jonathan/E-2813-2013 OI Craig, Jonathan/0000-0002-2548-4035 FU Consorzio Mario Negri Sud, Amgen Dompe, Italy FX External sources; SP receives a Fellowship from the Consorzio Mario Negri Sud from an unrestricted grant from Amgen Dompe, Italy. NR 135 TC 10 Z9 10 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 9 AR UNSP CD004289 DI 10.1002/14651858.CD004289.pub5 PG 83 WC Medicine, General & Internal SC General & Internal Medicine GA 227QV UT WOS:000325129500021 PM 24022428 ER PT J AU Farook, VS Coletta, DK Puppala, S Schneider, J Chittoor, G Hu, SL Winnier, DA Norton, L Dyer, TD Arya, R Cole, SA Carless, M Goring, HH Almasy, L Mahaney, MC Comuzzie, AG Curran, JE Blangero, J Duggirala, R Lehman, DM Jenkinson, CP DeFronzo, RA AF Farook, Vidya S. Coletta, Dawn K. Puppala, Sobha Schneider, Jennifer Chittoor, Geetha Hu, Shirley L. Winnier, Deidre A. Norton, Luke Dyer, Thomas D. Arya, Rector Cole, Shelley A. Carless, Melanie Goering, Harald H. Almasy, Laura Mahaney, Michael C. Comuzzie, Anthony G. Curran, Joanne E. Blangero, John Duggirala, Ravindranath Lehman, Donna M. Jenkinson, Christopher P. DeFronzo, Ralph A. TI Linkage of Type 2 Diabetes on Chromosome 9p24 in Mexican Americans: Additional Evidence from the Veterans Administration Genetic Epidemiology Study (VAGES) SO HUMAN HEREDITY LA English DT Article DE Type 2 diabetes; Linkage; Chromosome 9p24; Mexican Americans; VAGES ID GENOME-WIDE ASSOCIATION; DENSITY-LIPOPROTEIN-CHOLESTEROL; QUANTITATIVE TRAIT LOCI; SUSCEPTIBILITY LOCI; INSULIN-RESISTANCE; RISK LOCI; TRIGLYCERIDE LEVELS; GLUCOSE-TOLERANCE; GLYCEMIC TRAITS; STARR COUNTY AB Objective: Type 2 diabetes (T2DM) is a complex metabolic disease and is more prevalent in certain ethnic groups such as the Mexican Americans. The goal of our study was to perform a genome-wide linkage (GWL) analysis to localize T2DM susceptibility loci in Mexican Americans. Methods: We used the phenotypic and genotypic data from 1,122 Mexican-American individuals (307 families) who participated in the Veterans Administration Genetic Epidemiology Study (VAGES). GWL analysis was performed using the variance components approach. Data from 2 additional Mexican-American family studies, the San Antonio Family Heart Study (SAFHS) and the San Antonio Family Diabetes/Gallbladder Study (SAFDGS), were combined with the VAGES data to test for improved linkage evidence. Results: After adjusting for covariate effects, T2DM was found to be under significant genetic influences (h(2) = 0.62, p = 2.7 x 10(-6)). The strongest evidence for linkage of T2DM occurred between markers D9S1871 and D9S2169 on chromosome 9p24.2-p24.1 CLOD = 1.8). Given that we previously reported suggestive evidence for linkage of T2DM at this region also in SAFDGS, we found the significant and increased linkage evidence (LOD = 4.3, empirical p = 1.0 x 10(-5), genome-wide p = 1.6 x 10(-3)) for T2DM at the same chromosomal region, when we performed a GWL analysis of the VAGES data combined with the SAFHS and SAFDGS data. Conclusion: Significant T2DM linkage evidence was found on chromosome 9p24 in Mexican Americans. Importantly, the chromosomal region of interest in this study overlaps with several recent genome-wide association studies involving T2DM-related traits. Given its overlap with such findings and our own initial T2DM association findings in the 9p24 chromosomal region, high throughput sequencing of the linked chromosomal region could identify the potential causal T2DM genes. (C) 2013 S. Karger AG, Basel C1 [Farook, Vidya S.; Puppala, Sobha; Schneider, Jennifer; Chittoor, Geetha; Dyer, Thomas D.; Cole, Shelley A.; Carless, Melanie; Goering, Harald H.; Almasy, Laura; Mahaney, Michael C.; Comuzzie, Anthony G.; Curran, Joanne E.; Blangero, John; Duggirala, Ravindranath; Jenkinson, Christopher P.] SW Fdn Biomed Res, San Antonio, TX 78284 USA. [Coletta, Dawn K.] Arizona State Univ, Ctr Metab Biol, Phoenix, AZ USA. [Hu, Shirley L.; Jenkinson, Christopher P.; DeFronzo, Ralph A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Winnier, Deidre A.; Norton, Luke; Jenkinson, Christopher P.; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX 78229 USA. [Lehman, Donna M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Arya, Rector] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, Div Endocrinol & Diabet, San Antonio, TX 78229 USA. RP DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM albarado@uthscsa.edu RI Coletta, Dawn/G-6382-2016; OI Coletta, Dawn/0000-0001-5819-5152; Norton, Luke/0000-0002-0231-5722 FU Veterans Administration; National Institutes of Health [DK42273, DK47482, DK53889, DK70746, HD41111, MH59490] FX We thank Marcel J. Fourcaudot and Lenore M. Rodriguez for their excellent technical assistance. We thank our nurses, James King, John Kincaid, Rose Kaminski-Graham, and Norma Diaz, for their excellent care of the participants throughout the study. This work was supported by a Veterans Administration Epidemiologic grant to R.A.D. This study was also supported in part by grants from the National Institutes of Health (DK42273, DK47482, DK53889, DK70746, HD41111, and MH59490). We thank the CIDR for providing genome scans using the VAGES and SAFDGS data sets, respectively. We thank the participants of VAGES, SAFHS, and SAFDGS, and are grateful for their generous partaking and cooperation. NR 64 TC 3 Z9 3 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 EI 1423-0062 J9 HUM HERED JI Hum. Hered. PY 2013 VL 76 IS 1 BP 36 EP 46 DI 10.1159/000354849 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 239FX UT WOS:000326009100005 PM 24060607 ER PT J AU Qazi, H Palomino, R Shi, ZD Munn, LL Tarbell, JM AF Qazi, Henry Palomino, Rocio Shi, Zhong-Dong Munn, Lance L. Tarbell, John M. TI Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion SO INTEGRATIVE BIOLOGY LA English DT Article ID FLUID SHEAR-STRESS; INTERSTITIAL FLOW; ENDOTHELIAL GLYCOCALYX; TUMOR PROGRESSION; MATRIX METALLOPROTEINASES; ANTIANGIOGENIC THERAPY; GENE-EXPRESSION; NUDE-MICE; HYALURONAN; CD44 AB Mammalian cells are covered by a surface proteoglycan (glycocalyx) layer, and it is known that blood vessel-lining endothelial cells use the glycocalyx to sense and transduce the shearing forces of blood flow into intracellular signals. Tumor cells in vivo are exposed to forces from interstitial fluid flow that may affect metastatic potential but are not reproduced by most in vitro cell motility assays. We hypothesized that glycocalyx-mediated mechanotransduction of interstitial flow shear stress is an un-recognized factor that can significantly enhance metastatic cell motility and play a role in augmentation of invasion. Involvement of MMP levels, cell adhesion molecules (CD44, alpha 3 integrin), and glycocalyx components (heparan sulfate and hyaluronan) was investigated in a cell/collagen gel suspension model designed to mimic the interstitial flow microenvironment. Physiological levels of flow upregulated MMP levels and enhanced the motility of metastatic cells. Blocking the flow-enhanced expression of MMP activity or adhesion molecules (CD44 and integrins) resulted in blocking the flow-enhanced migratory activity. The presence of a glycocalyx-like layer was verified around tumor cells, and the degradation of this layer by hyaluronidase and heparinase blocked the flow-regulated invasion. This study shows for the first time that interstitial flow enhancement of metastatic cell motility can be mediated by the cell surface glycocalyx - a potential target for therapeutics. C1 [Qazi, Henry; Palomino, Rocio; Shi, Zhong-Dong; Tarbell, John M.] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA. [Shi, Zhong-Dong] Sloan Kettering Inst, Dev Biol Program, New York, NY USA. [Munn, Lance L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Charlestown, MA USA. [Munn, Lance L.] Harvard Univ, Sch Med, Charlestown, MA USA. RP Tarbell, JM (reprint author), CUNY City Coll, Dept Biomed Engn, Steinman Hall,T-404C,Convent Ave 140th St, New York, NY 10031 USA. EM tarbell@ccny.cuny.edu RI Munn, Lance/L-3950-2016 OI Munn, Lance/0000-0003-0698-7232 FU National Heart, Lung, and Blood Institute [RO1-HL-35549, RO1-HL-57093]; CCNY/MSKCC Partnership for Cancer Research Grant NIH/NCI [U54CA137788/U54CA132378] FX This study was supported by National Heart, Lung, and Blood Institute Grants RO1-HL-35549 and RO1-HL-57093, and in part by the CCNY/MSKCC Partnership for Cancer Research Grant NIH/NCI U54CA137788/U54CA132378. The authors are grateful for the contributions made by Andrew Qazi towards the migration data and Dr X.Y. Ji for the technical assistance provided. NR 51 TC 19 Z9 19 U1 3 U2 25 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 EI 1757-9708 J9 INTEGR BIOL-UK JI Integr. Biol. PY 2013 VL 5 IS 11 BP 1334 EP 1343 DI 10.1039/c3ib40057c PG 10 WC Cell Biology SC Cell Biology GA 239VA UT WOS:000326052600003 PM 24077103 ER PT J AU Lau, KS Schrier, SB Gierut, J Lyons, J Lauffenburger, DA Haigis, KM AF Lau, Ken S. Schrier, Sarah B. Gierut, Jessica Lyons, Jesse Lauffenburger, Douglas A. Haigis, Kevin M. TI Network analysis of differential Ras isoform mutation effects on intestinal epithelial responses to TNF-alpha SO INTEGRATIVE BIOLOGY LA English DT Article ID INDUCED APOPTOSIS; CANCER-CELLS; K-RAS; N-RAS; PLASMA-MEMBRANE; PROLIFERATION; GROWTH; MICRODOMAINS; PROGRESSION; ACTIVATION AB Tumor necrosis factor alpha (TNF-alpha) is an inflammatory cytokine that can elicit distinct cellular behaviors under different molecular contexts. Mitogen activated protein kinase (MAPK) pathways, especially the extracellular signal-regulated kinase (Erk) pathway, help to integrate influences from the environmental context, and therefore modulate the phenotypic effect of TNF-alpha exposure. To test how variations in flux through the Erk pathway modulate TNF-alpha-elicited phenotypes in a complex physiological environment, we exposed mice with different Ras mutations (K-Ras activation, N-Ras activation, and N-Ras ablation) to TNF-alpha and observed phenotypic and signaling changes in the intestinal epithelium. Hyperactivation of Mek1, an Erk kinase, was observed in the intestine of mice with K-Ras activation and, surprisingly, in N-Ras null mice. Nevertheless, these similar Mek1 outputs did not give rise to the same phenotype, as N-Ras null intestine was hypersensitive to TNF-alpha-induced intestinal cell death while K-Ras mutant intestine was not. A systems biology approach applied to sample the network state revealed that the signaling contexts presented by these two Ras isoform mutations were different. Consistent with our experimental data, N-Ras ablation induced a signaling network state that was mathematically predicted to be pro-death, while K-Ras activation did not. Further modeling by constrained Fuzzy Logic (cFL) revealed that N-Ras and K-Ras activate the signaling network with different downstream distributions and dynamics, with N-Ras effects being more transient and diverted more towards PI3K-Akt signaling and K-Ras effects being more sustained and broadly activating many pathways. Our study highlights the necessity to consider both environmental and genomic contexts of signaling pathway activation in dictating phenotypic responses, and demonstrates how modeling can provide insight into complex in vivo biological mechanisms, such as the complex interplay between K-Ras and N-Ras in their downstream effects. C1 [Lau, Ken S.; Gierut, Jessica; Lyons, Jesse; Haigis, Kevin M.] Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Canc Res, Charlestown, MA 02129 USA. [Lau, Ken S.; Gierut, Jessica; Lyons, Jesse; Haigis, Kevin M.] Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA. [Lau, Ken S.; Schrier, Sarah B.; Lyons, Jesse; Lauffenburger, Douglas A.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. RP Haigis, KM (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Canc Res, 149 13th St, Charlestown, MA 02129 USA. EM lauffen@mit.edu; khaigis@partners.org OI Lau, Ken/0000-0001-8438-0319; Lyons, Jesse/0000-0002-9272-4094 FU National Institute of General Medical Sciences [R01-GM088827]; National Cancer Institute [U54-CA112967]; Institute for Collaborative Biotechnologies from the U.S. Army Research Office [W911NF-09-D-000] FX This work was supported by grants from the National Institute of General Medical Sciences (R01-GM088827 to K.M.H., D.A.L.), the National Cancer Institute (U54-CA112967 to D.A.L.) and the Institute for Collaborative Biotechnologies from the U.S. Army Research Office (W911NF-09-D-000 to D.A.L). K.S.L. was a Robert Black Fellow of the Damon Runyon Cancer Research Foundation. NR 35 TC 5 Z9 5 U1 0 U2 3 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 EI 1757-9708 J9 INTEGR BIOL-UK JI Integr. Biol. PY 2013 VL 5 IS 11 BP 1355 EP 1365 DI 10.1039/c3ib40062j PG 11 WC Cell Biology SC Cell Biology GA 239VA UT WOS:000326052600005 PM 24084984 ER PT J AU Wells, JM Dransfield, MT AF Wells, J. Michael Dransfield, Mark T. TI Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Review DE pulmonary artery enlargement; aorta; ratio; pulmonary hypertension; chronic obstructive pulmonary disease; computed tomography ID OBSTRUCTIVE SLEEP-APNEA; VENTRICULAR DIASTOLIC FUNCTION; EXPERT CONSENSUS DOCUMENTS; AMERICAN-HEART-ASSOCIATION; FOUNDATION TASK-FORCE; NITRIC-OXIDE SYNTHASE; LUNG-DISEASE; COMPUTED-TOMOGRAPHY; ECHOCARDIOGRAPHIC EVALUATION; CARDIOVASCULAR DEATH AB Chronic obstructive pulmonary disease (COPD) is a complex condition defined by progressive airflow limitation in response to noxious stimuli, inflammation, and vascular changes. COPD exacerbations are critical events in the natural history of the disease, accounting for the majority of disease burden, cost, and mortality. Pulmonary vascular disease is an important risk factor for disease progression and exacerbation risk. Relative pulmonary artery enlargement on computed tomography scan, defined by a pulmonary artery to aortic (PA:A) ratio >1, has been evaluated as a marker of pulmonary vascular disease. The PA: A ratio can be measured reliably independent of electrocardiographic gating or the use of contrast, and in healthy patients a PA:A ratio >0.9 is considered to be abnormal. The PA:A ratio has been compared with invasive hemodynamic parameters, primarily mean pulmonary artery pressure in various disease conditions and is more strongly correlated with mean pulmonary artery pressure in obstructive as compared with interstitial lung disease. In patients without known cardiac or pulmonary disease, the PA:A ratio is predictive of mortality, while in COPD, an elevated PA:A ratio is correlated with increased exacerbation risk, outperforming other well established predictors of these events. Future studies should be aimed at determining the stability of the metric over time and evaluating the utility of the PA:A ratio in guiding specific therapies. C1 Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Wells, JM (reprint author), Univ Alabama Birmingham, Dept Med, 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA. EM jmwells@uab.edu FU National Institutes of Health; Aeris; Astra Zeneca; Boehringer Ingelheim; Boston Scientific; Centocor; Forest; GlaxoSmithKline; Ikaria; Medimmune; Olmstead Medical Center; Otsuka; Pfizer; Pulmonx FX JMW has no conflicts of interest to declare. MTD has served as a consultant to Boehringer Ingelheim, GlaxoSmithKline, and Ikaria and his institution has received research support from the National Institutes of Health, Aeris, Astra Zeneca, Boehringer Ingelheim, Boston Scientific, Centocor, Forest, GlaxoSmithKline, Ikaria, Medimmune, Olmstead Medical Center, Otsuka, Pfizer, and Pulmonx. NR 102 TC 10 Z9 11 U1 1 U2 7 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9106 EI 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2013 VL 8 BP 509 EP 521 DI 10.2147/COPD.S52204 PG 13 WC Respiratory System SC Respiratory System GA 241EV UT WOS:000326150100001 PM 24235822 ER PT J AU El Ouaamari, A Minehira, K AF El Ouaamari, Abdelfattah Minehira, Kaori TI Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications SO INTERNATIONAL JOURNAL OF ENDOCRINOLOGY LA English DT Editorial Material C1 [El Ouaamari, Abdelfattah] Joslin Diabet Ctr, Sect Islet Cell & Regenerat Med, Boston, MA 02215 USA. [Minehira, Kaori] Nestle Res Ctr, CH-1000 Lausanne, Switzerland. RP Minehira, K (reprint author), Nestle Res Ctr, CH-1000 Lausanne, Switzerland. EM kaori.minehiracastelli@rdls.nestle.com NR 3 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-8337 EI 1687-8345 J9 INT J ENDOCRINOL JI Int. J. Endocrinol. PY 2013 AR 969748 DI 10.1155/2013/969748 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 240SQ UT WOS:000326117700001 ER PT J AU Quan, SF Budhiraja, R Clarke, DP Goodwin, JL Gottlieb, DJ Nichols, DA Simon, RD Smith, TW Walsh, JK Kushida, CA AF Quan, Stuart F. Budhiraja, Rohit Clarke, Denise P. Goodwin, James L. Gottlieb, Daniel J. Nichols, Deborah A. Simon, Richard D. Smith, Terry W. Walsh, James K. Kushida, Clete A. TI Impact of Treatment with Continuous Positive Airway Pressure (CPAP) on Weight in Obstructive Sleep Apnea SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Continuous positive airway pressure; weight; obstructive sleep apnea ID ENERGY-EXPENDITURE; CARDIOVASCULAR EVENTS; OBESITY; CYTOKINES; WORK; GAIN AB Study Objective: To determine the impact of continuous positive airway pressure (CPAP) on weight change in persons with obstructive sleep apnea (OSA). Design, Setting, and Participants: The Apnea Positive Pressure Long-term Efficacy Study (APPLES) was a 6-month, randomized, double-blinded sham-controlled multicenter clinical trial conducted at 5 sites in the United States. Of 1,105 participants with an apnea hypopnea index >= 10 events/hour initially randomized, 812 had body weight measured at baseline and after 6 months of study. Intervention: CPAP or Sham CPAP. Measurements: Body weight, height, hours of CPAP or Sham CPAP use, Epworth Sleepiness Scale score. Results: Participants randomized to CPAP gained 0.35 +/- 5.01 kg, whereas those on Sham CPAP lost 0.70 +/- 4.03 kg (mean +/- SD, p = 0.001). Amount of weight gain with CPAP was related to hours of device adherence, with each hour per night of use predicting a 0.42 kg increase in weight. This association was not noted in the Sham CPAP group. CPAP participants who used their device >= 4 h per night on >= 70% of nights gained the most weight over 6 months in comparison to non-adherent CPAP participants (1.0 +/- 5.3 vs. -0.3 +/- 5.0 kg, p = 0.014). Conclusions: OSA patients using CPAP may gain a modest amount of weight with the greatest weight gain found in those most compliant with CPAP. C1 [Quan, Stuart F.; Clarke, Denise P.; Gottlieb, Daniel J.] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA. [Quan, Stuart F.; Clarke, Denise P.; Gottlieb, Daniel J.] Harvard Univ, Sch Med, Boston, MA USA. [Quan, Stuart F.; Budhiraja, Rohit; Goodwin, James L.; Smith, Terry W.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA. [Nichols, Deborah A.; Kushida, Clete A.] Stanford Univ, Stanford, CA 94305 USA. [Simon, Richard D.] Providence St Mary Med Ctr, Walla Walla, WA USA. [Walsh, James K.] St Lukes Hosp, Chesterfield, MO USA. [Gottlieb, Daniel J.] VA Boston Healthcare Syst, Boston, MA USA. RP Quan, SF (reprint author), Harvard Univ, Sch Med, Div Sleep Med, 401 Pk Dr,2nd Floor East, Boston, MA 02215 USA. EM squan@arc.arizona.edu FU NHLBI NIH HHS [U01 HL068060, 5UO1-HL-068060] NR 32 TC 29 Z9 29 U1 0 U2 7 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2013 VL 9 IS 10 BP 989 EP 993 DI 10.5664/jcsm.3064 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 235YN UT WOS:000325759400002 PM 24127141 ER PT J AU Stern, SL Donahue, DA Allison, S Hatch, JP Lancaster, CL Benson, TA Johnson, AL Jeffreys, MD Pride, D Moreno, C Peterson, AL AF Stern, Stephen L. Donahue, D. Allen Allison, Sybil Hatch, John P. Lancaster, Cynthia L. Benson, Trisha A. Johnson, Allegro L. Jeffreys, Matthew D. Pride, Denise Moreno, Carlos Peterson, Alan L. TI Potential Benefits of Canine Companionship for Military Veterans with Posttraumatic Stress Disorder (PTSD) SO SOCIETY & ANIMALS LA English DT Article DE anxiety; canine companionship; nonhuman animal; posttraumatic stress disorder (PTSD); veteran ID COGNITIVE PROCESSING THERAPY; PET OWNERSHIP; BLOOD-PRESSURE; PROLONGED EXPOSURE; US VETERANS; HEALTH; SYMPTOMS; TRIAL; DOG; AFGHANISTAN AB Investigators surveyed 30 U.S. military veterans with PTSD who reported having benefited from living with a dog. The subject population included men and women aged 34 to 67, with a mean of 56.9 years (SD = 8.1), who were being treated at two Department of Veterans Affairs (VA) outpatient clinics. Participants received a questionnaire packet designed to assess aspects of their mental and physical health and relationship with a canine companion, which they completed at home and returned either in person or by mail. The packet consisted of the PTSD ChecklistMilitary Version (PCL-M); Beck Depression Inventory, Second Edition (BDI-II); Veterans Short Form Health Survey and Health Behaviors Questionnaire (SF-36); Dog Information Sheet; Dog Relationship Questionnaire; and Lexington Attachment to Pets Scale. Respondents indicated that since adopting their dog they had experienced improvement in several areas, including feeling calmer, less lonely, less depressed, and less worried about their and their family's safety. These results suggest that living with a companion dog may help relieve some of the psychological distress associated with PTSD in some veterans. C1 [Stern, Stephen L.; Jeffreys, Matthew D.] South Texas Vet Hlth Care Syst, Psychiat Serv, San Antonio, TX USA. [Stern, Stephen L.; Donahue, D. Allen; Allison, Sybil; Hatch, John P.; Benson, Trisha A.; Jeffreys, Matthew D.; Peterson, Alan L.] Univ Texas San Antonio, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX USA. [Lancaster, Cynthia L.] Univ Texas Austin, Lab Study Anxiety Disorders, Austin, TX 78712 USA. [Johnson, Allegro L.] South Texas Vet Hlth Care Syst, Psychol Serv, Kerrville, TX USA. [Pride, Denise] San Antonio Mil Med Ctr, Dept Psychiat, San Antonio, TX USA. [Moreno, Carlos] South Texas Vet Hlth Care Syst, Nursing Serv, San Antonio, TX USA. RP Stern, SL (reprint author), South Texas Vet Hlth Care Syst, Psychiat Serv, San Antonio, TX USA. NR 42 TC 3 Z9 3 U1 15 U2 91 PU BRILL ACADEMIC PUBLISHERS PI LEIDEN PA PLANTIJNSTRAAT 2, P O BOX 9000, 2300 PA LEIDEN, NETHERLANDS SN 1063-1119 J9 SOC ANIM JI Soc. Anim. PY 2013 VL 21 IS 6 BP 568 EP 581 DI 10.1163/15685306-12341286 PG 14 WC Sociology; Veterinary Sciences SC Sociology; Veterinary Sciences GA 235VT UT WOS:000325749800004 ER PT J AU Li, QZ AF Li, Quanzheng TI Quantitative Methods for Molecular Diagnostic and Therapeutic Imaging SO THERANOSTICS LA English DT Article DE tomography; image quality metrics; local impulse response; resolution; variance ID POSITRON-EMISSION-TOMOGRAPHY; BEAM RANGE VERIFICATION; PROTON RADIATION-THERAPY; IN-VIVO VERIFICATION; ONLINE PET SYSTEM; PROMPT GAMMA; CLINICAL-APPLICATION; DOSE RECONSTRUCTION; TUMOR-THERAPY; RADIOTHERAPY AB This theme issue provides an overview on the basic quantitative methods, an in-depth discussion on the cutting-edge quantitative analysis approaches as well as their applications for both static and dynamic molecular diagnostic and therapeutic imaging. C1 [Li, Quanzheng] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02115 USA. RP Li, QZ (reprint author), 55 Fruit St,White 427, Boston, MA 02114 USA. EM Li.Quanzheng@mgh.harvard.edu FU NIBIB NIH HHS [R01 EB013293] NR 50 TC 0 Z9 0 U1 0 U2 3 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2013 VL 3 IS 10 BP 729 EP 740 DI 10.7150/thno.7453 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 235GM UT WOS:000325705000001 PM 24312146 ER PT J AU Dutta, J Ahn, S Li, QZ AF Dutta, Joyita Ahn, Sangtae Li, Quanzheng TI Quantitative Statistical Methods for Image Quality Assessment SO THERANOSTICS LA English DT Review DE tomography; image quality metrics; local impulse response; resolution; variance ID ITERATIVE RECONSTRUCTION ALGORITHMS; SPATIAL-RESOLUTION PROPERTIES; PENALIZED MAXIMUM-LIKELIHOOD; POSITRON-EMISSION-TOMOGRAPHY; IN PET SYSTEM; NOISE PROPERTIES; EM ALGORITHM; LESION DETECTION; QUADRATIC REGULARIZATION; TRANSMISSION TOMOGRAPHY AB Quantitative measures of image quality and reliability are critical for both qualitative interpretation and quantitative analysis of medical images. While, in theory, it is possible to analyze reconstructed images by means of Monte Carlo simulations using a large number of noise realizations, the associated computational burden makes this approach impractical. Additionally, this approach is less meaningful in clinical scenarios, where multiple noise realizations are generally unavailable. The practical alternative is to compute closed-form analytical expressions for image quality measures. The objective of this paper is to review statistical analysis techniques that enable us to compute two key metrics: resolution (determined from the local impulse response) and covariance. The underlying methods include fixed-point approaches, which compute these metrics at a fixed point (the unique and stable solution) independent of the iterative algorithm employed, and iteration-based approaches, which yield results that are dependent on the algorithm, initialization, and number of iterations. We also explore extensions of some of these methods to a range of special contexts, including dynamic and motion-compensated image reconstruction. While most of the discussed techniques were developed for emission tomography, the general methods are extensible to other imaging modalities as well. In addition to enabling image characterization, these analysis techniques allow us to control and enhance imaging system performance. We review practical applications where performance improvement is achieved by applying these ideas to the contexts of both hardware (optimizing scanner design) and image reconstruction (designing regularization functions that produce uniform resolution or maximize task-specific figures of merit). C1 [Dutta, Joyita; Li, Quanzheng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Adv Med Imaging Sci, Boston, MA 02115 USA. [Ahn, Sangtae] GE Global Res Ctr, Niskayuna, NY USA. RP Li, QZ (reprint author), 55 Fruit St,White 427, Boston, MA 02114 USA. EM Li.Quanzheng@mgh.harvard.edu FU NIH [R21CA149587, R01EB013293] FX This work was funded in part by NIH R21CA149587 and R01EB013293. NR 77 TC 13 Z9 13 U1 1 U2 16 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2013 VL 3 IS 10 BP 741 EP 756 DI 10.7150/thno.6815 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 235GM UT WOS:000325705000002 PM 24312148 ER PT S AU Schulz, TJ Tseng, YH AF Schulz, Tim J. Tseng, Yu-Hua GP Annals New York Acad Sci TI Systemic control of brown fat thermogenesis: integration of peripheral and central signals SO UNDERSTANDING ADIPOGENESIS AND FUNCTIONS OF BROWN FAT SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE brown adipose tissue; bone morphogenetic proteins; systemic thermogenic capacity ID BONE MORPHOGENETIC PROTEIN-7; ADIPOSE-TISSUE THERMOGENESIS; ADAPTIVE THERMOGENESIS; WHITE FAT; INSULIN SENSITIVITY; ENERGY HOMEOSTASIS; GROWTH-FACTOR; ADIPOCYTES; MOUSE; EXPENDITURE AB Brown adipose tissue (BAT) is of great scientific interest as a potential target to treat obesity. The development of novel strategies to quantify brown fat thermogenesis in adult humans now enables minimally invasive assessment of novel pharmacotherapeutics. Input from the central nervous system via sympathetic efferents is widely regarded as the key controller of BAT-mediated thermogenesis in response to changes in body temperature or nutrient availability. More recently, however, it has become clear that locally secreted signals and endocrine factors originating from multiple organs can control the recruitment of brown adipocytes and, more importantly, induce thermogenesis in brown fat. Thus, they provide an attractive strategy to fine-tune brown fat thermogenesis independent of classical temperature sensing. Here, we summarize recent findings on bone morphogenetic protein signaling as an example of secreted factors in the regulation of brown adipocyte formation and systemic control of energy metabolism. We further highlight endocrine communication routes between the different types of brown adipocytes and other organs that contribute to regulation of thermogenesis. Thus, emerging evidence suggests that the classical mechanisms of central temperature sensing and sympathetic nervous system-driven thermogenesis are complemented by local and endocrine signals to determine systemic energy homeostasis. C1 [Schulz, Tim J.] German Inst Human Nutr, Res Grp Adipocyte Dev, Nuthetal, Germany. [Tseng, Yu-Hua] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Tseng, Yu-Hua] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Tseng, YH (reprint author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM yu-hua.tseng@joslin.harvard.edu RI Schulz, Tim/F-4842-2013 OI Schulz, Tim/0000-0002-8413-3972 FU NIDDK NIH HHS [R01 DK077097, P30 DK036836] NR 35 TC 6 Z9 6 U1 2 U2 13 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2013 VL 1302 BP 35 EP 41 DI 10.1111/nyas.12277 PG 7 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA BHM40 UT WOS:000325920200005 PM 24111913 ER PT J AU Kar, HL O'Leary, KD AF Kar, Heidi Lary O'Leary, K. Daniel TI Emotional Intimacy Mediates the Relationship Between Posttraumatic Stress Disorder and Intimate Partner Violence Perpetration in OEF/OIF/OND Veterans SO VIOLENCE AND VICTIMS LA English DT Article DE aggression; path analysis; couples; mental health ID MALE VIETNAM VETERANS; MARITAL SATISFACTION; MILITARY SERVICE; FIT INDEXES; ADJUSTMENT; COMBAT; FAMILY; INTERVENTIONS; METAANALYSIS; AGGRESSION AB Veterans with posttraumatic stress disorder (PTSD) are at elevated risk for perpetrating intimate partner violence (IPV). Little research exists on the link between PTSD and physical IPV in Operational Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans. A sample of 110 male participants was recruited from the Northport Veterans Affairs Medical Center (VAMC). Three separate models were compared to determine which best explained the relationships between PTSD, IPV, emotional intimacy, and relationship satisfaction. Constructs were assessed via a battery of standardized, self-report instruments. Thirty-three percent of veterans had clinically elevated PTSD scores, and 31% of the men reported that they engaged in physical IPV in the past year. Poor emotional intimacy mediated the association between PTSD symptoms and perpetration of physical IPV. Past predeployment IPV perpetration was shown to be a predictor for current postdeployment physical IPV perpetration. C1 [Kar, Heidi Lary] San Francisco VA Med Ctr, San Francisco, CA USA. [O'Leary, K. Daniel] SUNY Stony Brook, Stony Brook, NY USA. RP Kar, HL (reprint author), Northport Vet Affairs Med Ctr, Psychol Serv, Northport, NY 11768 USA. EM Heidi.Kar@va.gov NR 44 TC 1 Z9 1 U1 1 U2 9 PU SPRINGER PUBLISHING CO PI NEW YORK PA 11 WEST 42ND STREET, NEW YORK, NY 10036 USA SN 0886-6708 EI 1945-7073 J9 VIOLENCE VICTIMS JI Violence Vict. PY 2013 VL 28 IS 5 BP 790 EP 803 DI 10.1891/0886-6708.VV-D-12-00080 PG 14 WC Criminology & Penology SC Criminology & Penology GA 237VM UT WOS:000325899000003 PM 24364123 ER PT S AU Weir, GC Bonner-Weir, S AF Weir, Gordon C. Bonner-Weir, Susan BE Powers, AC Ahima, RS TI Islet beta cell mass in diabetes and how it relates to function, birth, and death SO YEAR IN DIABETES AND OBESITY SE Annals of the New York Academy of Sciences LA English DT Article DE beta cell; islets; diabetes; neogenesis; insulin secretion ID THIOREDOXIN-INTERACTING PROTEIN; RAT PANCREATIC-ISLETS; INSULIN-SECRETION; IN-VIVO; CHRONIC HYPERGLYCEMIA; AMYLOID-POLYPEPTIDE; GLUCOSE-INFUSION; B-CELL; SUSTAINED OSCILLATIONS; COMPENSATORY GROWTH AB In type 1 diabetes (T1D) beta cell mass is markedly reduced by autoimmunity. Type 2 diabetes (T2D) results from inadequate beta cell mass and function that can no longer compensate for insulin resistance. The reduction of beta cell mass in T2D may result from increased cell death and/or inadequate birth through replication and neogenesis. Reduction in mass allows glucose levels to rise, which places beta cells in an unfamiliar hyperglycemic environment, leading to marked changes in their phenotype and a dramatic loss of glucose-stimulated insulin secretion (GSIS), which worsens as glucose levels climb. Toxic effects of glucose on beta cells (glucotoxicity) appear to be the culprit. This dysfunctional insulin secretion can be reversed when glucose levels are lowered by treatment, a finding with therapeutic significance. Restoration of beta cell mass in both types of diabetes could be accomplished by either beta cell regeneration or transplantation. Learning more about the relationships between beta cell mass, turnover, and function and finding ways to restore beta cell mass are among the most urgent priorities for diabetes research. C1 [Weir, Gordon C.; Bonner-Weir, Susan] Harvard Univ, Sch Med, Dept Med, Sect Islet Cell Biol & Regenerat Med,Res Div,Josl, Boston, MA USA. RP Weir, GC (reprint author), Joslin Diabet Ctr, Sect Islet Cell Biol & Regenerat Med, 1 Joslin Pl, Boston, MA 02215 USA. EM gordon.weir@joslin.harvard.edu FU National Institutes of Health [R01 DK 66056, DK 93909, P30 DK36836]; Juvenile Diabetes Research Foundation; American Diabetes Association; Diabetes Research and Wellness Foundation FX Our work has been supported by the National Institutes of Health [R01 DK 66056 and DK 93909 (S. B.-W.), P30 DK36836 (Joslin Diabetes Research Center)], the Juvenile Diabetes Research Foundation, the American Diabetes Association, and the Diabetes Research and Wellness Foundation. We thank the many collaborators, trainees, and laboratory workers who made our work in this area possible. NR 124 TC 100 Z9 107 U1 5 U2 28 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 BN 978-1-57331-882-2 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2013 VL 1281 BP 92 EP 105 DI 10.1111/nyas.12031 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BHL80 UT WOS:000325808500006 PM 23363033 ER PT J AU Yuan, HS Cho, H Chen, HH Panagia, M Sosnovik, DE Josephson, L AF Yuan, Hushan Cho, Hoonsung Chen, Howard H. Panagia, Marcelo Sosnovik, David E. Josephson, Lee TI Fluorescent and radiolabeled triphenylphosphonium probes for imaging mitochondria SO CHEMICAL COMMUNICATIONS LA English DT Article ID MOLECULES; CELLS AB Triphenylphosphonium-fluorochromes (TPP-fluorochromes) are a new class of spectrally variable, mitochondrially targeted probes, with an [F-18] labeling option which, when enabled, allows imaging of a cardiac perfusion deficit using PET/CT. C1 [Yuan, Hushan; Cho, Hoonsung; Josephson, Lee] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Charlestown, MA 02129 USA. [Chen, Howard H.; Panagia, Marcelo; Sosnovik, David E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Panagia, Marcelo; Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. RP Josephson, L (reprint author), Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, 149 13th St, Charlestown, MA 02129 USA. EM ljosephson@mgh.harvard.edu NR 15 TC 18 Z9 18 U1 0 U2 35 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1359-7345 EI 1364-548X J9 CHEM COMMUN JI Chem. Commun. PY 2013 VL 49 IS 88 BP 10361 EP 10363 DI 10.1039/c3cc45802d PG 3 WC Chemistry, Multidisciplinary SC Chemistry GA 235MT UT WOS:000325723900006 PM 24072060 ER PT S AU Gymrek, M Erlich, Y AF Gymrek, Melissa Erlich, Yaniv BE Shomron, N TI Profiling Short Tandem Repeats from Short Reads SO DEEP SEQUENCING DATA ANALYSIS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Short tandem repeats; Microsatellites; Whole-genome sequencing; Variant calling; Personal genomes; lobSTR ID DNA; GENOME; SEQUENCES; FORMAT; PERFORMANCE; ALGORITHMS; ALIGNMENT; DISEASE; SEARCH; FINDER AB Short tandem repeats (STRs), also known as microsatellites, have a wide range of applications, including medical genetics, forensics, and population genetics. High-throughput sequencing has the potential to profile large numbers of STRs, but cumbersome gapped alignment and STR-specific noise patterns hamper this task. We recently developed an algorithm, called lobSTR, to overcome these challenges and to accurately profile STRs from short reads. Here we describe how to use lobSTR to call STR variations from high-throughput sequencing datasets and to diagnose the quality of the calls. C1 [Gymrek, Melissa] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Gymrek, Melissa; Erlich, Yaniv] Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA. [Gymrek, Melissa] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Gymrek, Melissa] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Gymrek, Melissa] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. RP Gymrek, M (reprint author), MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. OI /0000-0002-6086-3903 NR 27 TC 1 Z9 1 U1 1 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-62703-514-9; 978-1-62703-513-2 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2013 VL 1038 BP 113 EP 135 DI 10.1007/978-1-62703-514-9_7 D2 10.1007/978-1-62703-514-9 PG 23 WC Genetics & Heredity; Medical Informatics SC Genetics & Heredity; Medical Informatics GA BHI02 UT WOS:000325474800008 PM 23872972 ER PT S AU Huang, L Wang, M Sharma, SK Sperandio, FF Maragani, S Nayka, S Chang, J Hamblin, MR Chiang, LY AF Huang, L. Wang, M. Sharma, S. K. Sperandio, F. F. Maragani, S. Nayka, S. Chang, J. Hamblin, M. R. Chiang, L. Y. BE Guldi, DM Fenton, JM Simonian, A TI Decacationic [70]Fullerene Approach for Efficient Photokilling of Infectious Bacteria and Cancer Cells SO FULLERENES, NANOTUBES, AND CARBON NANOSTRUCTURES - 221ST ECS MEETING SE ECS Transactions LA English DT Proceedings Paper CT 221st Meeting of the Electrochemical-Society (ECS) CY MAY 06-10, 2012 CL Seattle, WA SP Electrochem Soc, Fullerenes, Nanotubes, & Carbon Nanostructures, Energy Technol, Sensor ID GRAM-POSITIVE BACTERIA; PHOTODYNAMIC THERAPY; SINGLET OXYGEN; NEGATIVE BACTERIA; SURFACE-PROTEINS; INACTIVATION; C-60 AB Photodynamic inactivation of pathogenic bacteria and cancer cells by novel water-soluble decacationic fullerene monoadducts, C-60[>M(C3N6+C3)(2)] and C-70[>M(C3N6+C3)(2)], were investigated. In the presence of a high number of electron-donating iodide anions as parts of quaternary ammonium salts in the arm region, we found that C-70[>M(C3N6+C3)(2)] produced more highly reactive HO center dot radical than C-60[>M(C3N6+C3)(2)], in addition to singlet oxygen (O-1(2)). This finding offers an explanation of the preferential killing of Gram-positive and Gram-negative bacteria by C-60[>M(C3N6+C3)(2)] and C-70[>M(C3N6+C3)(2)], respectively. The hypothesis is that O-1(2) can diffuse more easily into porous cell walls of Gram-positive bacteria to reach sensitive sites, while the less permeable Gram-negative bacterial cell wall needs the more reactive HO center dot to cause real damage. C1 [Huang, L.; Sharma, S. K.; Sperandio, F. F.; Nayka, S.; Chang, J.; Hamblin, M. R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, L.; Sperandio, F. F.; Hamblin, M. R.; Chiang, L. Y.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA. [Wang, M.; Sperandio, F. F.; Maragani, S.; Chiang, L. Y.] Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA. [Sperandio, F. F.] Univ Sao Paulo, Sch Dent, BR-05508000 Sao Paulo, Brazil. [Sperandio, F. F.] Minist Educ Brazil, CAPES FDN, BR-7004002 Brasilia, DF, Brazil. [Chang, J.] Harvard Univ, Dept Chem, Cambridge, MA 02138 USA. [Hamblin, M. R.] Harvard Univ, MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Chiang, L. Y.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada. RP Huang, L (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. OI Hamblin, Michael/0000-0001-6431-4605 FU National Institute of Health (NIH) [R01CA137108] FX We thank the financial support of National Institute of Health (NIH) under the grant number R01CA137108. NR 19 TC 4 Z9 4 U1 1 U2 7 PU ELECTROCHEMICAL SOC INC PI PENNINGTON PA 65 S MAIN ST, PENNINGTON, NJ 08534-2839 USA SN 1938-5862 BN 978-1-60768-388-9; 978-1-62332-036-2 J9 ECS TRANSACTIONS PY 2013 VL 45 IS 20 BP 65 EP 73 DI 10.1149/04520.0065ecst PG 9 WC Electrochemistry; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Electrochemistry; Science & Technology - Other Topics; Materials Science GA BHH04 UT WOS:000325396600008 ER PT S AU Huynh, A Turka, LA AF Huynh, Alexandria Turka, Laurence A. BE Kerr, WG Fernandes, S TI Control of T cell tolerance by phosphatase and tensin homolog SO INOSITOL PHOSPHOLIPID SIGNALING IN PHYSIOLOGY AND DISEASE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Meeting on Inositol Phospholipid Signaling in Physiology and Disease CY JUN, 2012 CL New York Acad Sci, New York, NY HO New York Acad Sci DE T cells; tolerance; PI3K; PTEN; regulatory T cell ID PTEN; DIFFERENTIATION; MTOR; AKT AB The in vivo maintenance of immune tolerance is critically dependent on regulatory T (T-reg) cells, a lineage of CD4(+) T cells expressing the transcription factor Foxp3 that exerts immunoregulatory function. Because of the potential benefit of using T-reg cells for cellular immunotherapy in clinical settings, including autoimmune disease and transplantation, much attention has been directed at understanding the signals that govern T-reg cell development, function, and homeostasis. Studies with genetically modified mouse models have shown that the lipid phosphatase PTEN (phosphatase and tensin homolog), the predominant negative regulator of the PI3K/Akt pathway in T cells, has multiple functions in sustaining T cell-mediated immune tolerance in vivo. In addition to its role in maintaining T cell homeostasis, the PI3K/Akt pathway also has an essential role in T cell development and lineage commitment, contributing to the cell fate decision between conventional and regulatory T cells. C1 [Huynh, Alexandria; Turka, Laurence A.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr MGH East, Boston, MA 02129 USA. RP Turka, LA (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr MGH East, Bldg 149-9019,13th St, Boston, MA 02129 USA. EM lturka@partners.org NR 10 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 BN 978-1-57331-891-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2013 VL 1280 BP 27 EP 29 DI 10.1111/nyas.12015 PG 3 WC Oncology SC Oncology GA BHK09 UT WOS:000325690500008 PM 23551099 ER PT J AU Rodriguez, RA Hotchkiss, JR O'Hare, AM AF Rodriguez, Rudolph A. Hotchkiss, John R. O'Hare, Ann M. TI Geographic information systems and chronic kidney disease: racial disparities, rural residence and forecasting SO JOURNAL OF NEPHROLOGY LA English DT Article DE Chronic kidney disease; Geography; Geospatial analysis; Racial disparities; Rural health ID STAGE RENAL-DISEASE; UNITED-STATES; NEIGHBORHOOD POVERTY; HEALTH DISPARITIES; MYOCARDIAL-INFARCTION; PACIFIC-ISLANDERS; GEOCODING PROJECT; SOCIAL-CLASS; CARE; US AB The dynamics of health and health care provision in the United States vary substantially across regions, and there is substantial regional heterogeneity in population density, age distribution, disease prevalence, race and ethnicity, poverty and the ability to access care. Geocoding and geographic information systems (GIS) are important tools to link patient or population location to information regarding these characteristics. In this review, we provide an overview of basic GIS concepts and provide examples to illustrate how GIS techniques have been applied to the study of kidney disease, and in particular to understanding the interplay between race, poverty, rural residence and the planning of renal services for this population. The interplay of socioeconomic status and renal disease outcomes remains an important area for investigation and recent publications have explored this relationship utilizing GIS techniques to incorporate measures of socioeconomic status and racial composition of neighborhoods. In addition, there are many potential challenges in providing care to rural patients with chronic kidney disease including long travel times and sparse renal services such as transplant and dialysis centers. Geospatially fluent analytic approaches can also inform system level analyses of health care systems and these approaches can be applied to identify an optimal distribution of dialysis facilities. GIS analysis could help untangle the complex interplay between geography, socioeconomic status, and racial disparities in chronic kidney disease, and could inform policy decisions and resource allocation as the population ages and the prevalence of renal disease increases. C1 [Rodriguez, Rudolph A.; O'Hare, Ann M.] Univ Washington, Seattle, WA 98195 USA. [Rodriguez, Rudolph A.; O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [Hotchkiss, John R.] Univ Pittsburgh, Pittsburgh, PA USA. [Hotchkiss, John R.] Vet Engn Resource Ctr, Pittsburgh, PA USA. RP Rodriguez, RA (reprint author), Puget Sound Vet Affairs Med Ctr, Nephrol & Renal Dialysis Unit, Bldg 100 Room 5B113 1660 S Columbian Way, Seattle, WA 98108 USA. EM rudy.rodriguez@va.gov FU Chief Business Office, Veteran's Healthcare Administration; CDC; NIA [U01 AG006781]; UpToDate FX J.R. Hotchkiss: Chief Business Office, Veteran's Healthcare Administration. A.M. O'Hare: interagency agreement with the CDC and NIA (U01 AG006781 Larson) and receives Royalties from UpToDate. R.A. Rodriguez: none. NR 76 TC 7 Z9 7 U1 4 U2 17 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 1121-8428 EI 1724-6059 J9 J NEPHROL JI J. Nephrol. PD JAN-FEB PY 2013 VL 26 IS 1 BP 3 EP 15 DI 10.5301/jn.5000225 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA 235AI UT WOS:000325686000002 PM 23065915 ER PT J AU Kang, JX AF Kang, Jing X. TI Gut Microbiota and Personalized Nutrition SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Editorial Material ID DISEASE; HEALTH C1 [Kang, Jing X.] Massachusetts Gen Hosp, LLMT, Charlestown, MA 02129 USA. [Kang, Jing X.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Kang, JX (reprint author), Massachusetts Gen Hosp, LLMT, 149,13th St,Room 4001, Charlestown, MA 02129 USA. EM kang.jing@mgh.harvard.edu NR 6 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 EI 1661-6758 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2013 VL 6 IS 2 BP I EP II DI 10.1159/000353144 PG 2 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA 178RQ UT WOS:000321465500001 ER PT S AU Anstead, GM Cadena, J Javeri, H AF Anstead, Gregory M. Cadena, Jose Javeri, Heta BE Ji, Y TI Treatment of Infections Due to Resistant Staphylococcus aureus SO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PROTOCOLS, 2ND EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE MRSA; Vancomycin; Linezolid; Daptomycin; Oritavancin; Dalbavancin; Tigecycline; Telavancin; Ceftaroline; Clindamycin; Minocycline; Rifampin; Doxycycline; Trimethoprim-sulfamethoxazole; Fusidic acid; Fosfomycin; Pristinamycin; Dalbavancin; Oritavancin; Omadacycline; Delafl oxacin; Tidezolid; JNJ-Q2 ID SKIN-STRUCTURE INFECTIONS; SOFT-TISSUE INFECTIONS; GRAM-POSITIVE INFECTIONS; HIGH-DOSE DAPTOMYCIN; IN-VITRO ACTIVITY; INDUCIBLE CLINDAMYCIN RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; SIMULATED ENDOCARDIAL VEGETATIONS; VENTILATOR-ASSOCIATED PNEUMONIA; BROAD-SPECTRUM CEPHALOSPORIN AB This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin-dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or beta-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections. C1 [Anstead, Gregory M.; Cadena, Jose] South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA. [Anstead, Gregory M.; Cadena, Jose; Javeri, Heta] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. RP Anstead, GM (reprint author), South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA. NR 205 TC 0 Z9 0 U1 1 U2 7 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-62703-663-4; 978-1-62703-664-1 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2013 VL 185 BP 259 EP 309 DI 10.1007/978-1-62703-664-1_16 D2 10.1007/978-1-62703-664-1 PG 51 WC Microbiology SC Microbiology GA BHK36 UT WOS:000325709200017 ER PT S AU Dionne, KR Tyler, KL AF Dionne, Kalen R. Tyler, Kenneth L. BE Amini, S White, MK TI Slice Culture Modeling of Central Nervous System (CNS) Viral Infection SO NEURONAL CELL CULTURE: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Organotypic; Ex vivo; Brain slice; Spinal cord slice; Virus; Encephalitis; Myelitis; Cytokine; Apoptosis; Caspase ID ORGANOTYPIC HIPPOCAMPAL CULTURES; ACTIVATED PROTEIN-KINASE; NEURONAL CELL-DEATH; IN-VITRO; SYNAPTIC PLASTICITY; BRAIN; INJURY; DISEASE; TISSUE; FIBER AB The complexity of the central nervous system (CNS) is not recapitulated in cell culture models. Thin slicing and subsequent culture of CNS tissue has become a valued means to study neuronal and glial biology within the context of the physiologically relevant tissue milieu. Modern membrane-interface slice culturing methodology allows straightforward access to both CNS tissue and feeding medium, enabling experimental manipulations and analyses that would otherwise be impossible in vivo. CNS slices can be successfully maintained in culture for up to several weeks for investigation of evolving pathology and long-term intervention in models of chronic neurologic disease. Herein, membrane-interface slice culture models for studying viral encephalitis and myelitis are detailed, with emphasis on the use of these models for investigation of pathogenesis and evaluation of novel treatment strategies. We describe techniques to (1) generate brain and spinal cord slices from rodent donors, (2) virally infect slices, (3) assess virally induced injury/apoptosis, (4) characterize "CNS-specific" cytokine production, and (5) treat slices with cytokines/pharmaceuticals. Although our focus is on CNS viral infection, we anticipate that the described methods can be adapted to address a wide range of investigations within the fields of neuropathology, neuroimmunology, and neuropharmacology. C1 [Dionne, Kalen R.; Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Dept Neurol, Aurora, CO USA. RP Dionne, KR (reprint author), Denver Vet Affairs Med Ctr, Dept Neurol, Aurora, CO USA. OI Tyler, Kenneth/0000-0003-3294-5888 FU NIAID NIH HHS [R21AI01064]; NIGMS NIH HHS [T32GM008497]; NINDS NIH HHS [R01 NS050138, F30NS071630, R01NS076512, R01 NS051403] NR 46 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-62703-640-5; 978-1-62703-639-9 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2013 VL 1078 BP 97 EP 117 DI 10.1007/978-1-62703-640-5_9 D2 10.1007/978-1-62703-640-5 PG 21 WC Neurosciences SC Neurosciences & Neurology GA BHJ26 UT WOS:000325612600010 PM 23975824 ER PT S AU Choi, W Baumann, B Clermont, AC Feener, EP Boas, DA Fujimoto, JG AF Choi, WooJhon Baumann, Bernhard Clermont, Allen C. Feener, Edward P. Boas, David A. Fujimoto, James G. BE Manns, F Soderberg, PG Ho, A TI Functional imaging of hemodynamic stimulus response in the rat retina with ultrahigh-speed spectral/Fourier domain OCT SO OPHTHALMIC TECHNOLOGIES XXIII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Ophthalmic Technologies XXIII as a part of the SPIE Photonics West BiOS Meeting CY FEB 02-03, 2013 CL San Francisco, CA SP SPIE DE Optical coherence tomography; neurovascular coupling; hemodynamics; flicker stimulus; Doppler; blood flow; capillary; angiography ID OPTICAL COHERENCE TOMOGRAPHY; BLOOD-FLOW AB Measuring retinal hemodynamics in response to flicker stimulus is important for investigating pathophysiology in small animal models of diabetic retinopathy, because a reduction in the hyperemic response is thought to be one of the earliest changes in diabetic retinopathy. In this study, we investigated functional imaging of retinal hemodynamics in response to flicker stimulus in the rat retina using an ultrahigh speed spectral / Fourier domain OCT system at 840nm with an axial scan rate of 244kHz. At 244kHz the nominal axial velocity range that could be measured without phase wrapping was +/-37.7mm/s. Pulsatile total retinal arterial blood flow as a function of time was measured using an en face Doppler approach where a 200 mu m x 200 mu m area centered at the central retinal artery was repeatedly raster scanned at a volume acquisition rate of 55Hz. Three-dimensional capillary imaging was performed using speckle decorrelation which has minimal angle dependency compared to other angiography techniques based on OCT phase information. During OCT imaging, a flicker stimulus could be applied to the retina synchronously by inserting a dichroic mirror in the imaging interface. An acute transient increase in total retinal blood flow could be detected. At the capillary level, an increase in the degree of speckle decorrelation in capillary OCT angiography images could also be observed, which indicates an increase in the velocity of blood at the capillary level. This method promises to be useful for the investigation of small animal models of ocular diseases. C1 [Choi, WooJhon; Baumann, Bernhard; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Baumann, Bernhard] Tufts Univ, Tufts Med Ctr, New England Eye Ctr, Boston, MA 02116 USA. [Clermont, Allen C.; Feener, Edward P.] Joslin Diabetes Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Boas, David A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Choi, W (reprint author), MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. OI Baumann, Bernhard/0000-0001-6419-1932 FU National Institutes of Health (NIH) [R01-EY011289-26, R01-EY013516-09, R01-EY019029-04, R01-CA075289-15, R44-EY022864-01]; Air Force Office of Scientific Research [AFOSR FA9550-10-1-0551] FX This work was supported by the National Institutes of Health (NIH R01-EY011289-26, R01-EY013516-09, R01- EY019029-04, R01-EY013178-12, R01-NS057476-05, R01-HL095717-04, R01-CA075289-15, R44-EY022864-01), Air Force Office of Scientific Research (AFOSR FA9550-10-1-0551) and Samsung Scholarship. NR 11 TC 0 Z9 0 U1 0 U2 4 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9336-1 J9 PROC SPIE PY 2013 VL 8567 AR UNSP 85671C DI 10.1117/12.2004096 PG 6 WC Ophthalmology; Optics SC Ophthalmology; Optics GA BHH46 UT WOS:000325430800014 ER PT S AU Franco, W Gutierrez-Herrera, E Purschke, M Wang, Y Tam, J Anderson, RR Doukas, A AF Franco, Walfre Gutierrez-Herrera, Enoch Purschke, Martin Wang, Ying Tam, Josh Anderson, R. Rox Doukas, Apostolos BE Kollias, N Choi, B Zeng, H Kang, HW Knudsen, BE Wong, BJF Ilgner, JF Suter, MJ Lam, S Brenner, M Gregory, KW Tearney, GJ Marcu, L Hirschberg, H Madsen, SJ MahadevanJansen, A Jansen, ED Mandelis, A TI Development of a wide-field fluorescence imaging system for evaluation of wound re-epithelialization SO PHOTONIC THERAPEUTICS AND DIAGNOSTICS IX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Photonic Therapeutics and Diagnostics IX CY FEB 02-07, 2013 CL San Francisco, CA SP SPIE DE UV; fluorescence; skin; wound; imaging ID EPIDERMAL PROLIFERATION AB Normal skin barrier function depends on having a viable epidermis, an epithelial layer formed by keratinocytes. The transparent epidermis, which is less than a 100 mum thick, is nearly impossible to see. Thus, the clinical evaluation of re-epithelialization is difficult, which hinders selecting appropriate therapy for promoting wound healing. An imaging system was developed to evaluate epithelialization by detecting endogenous fluorescence emissions of cellular proliferation over a wide field of view. A custom-made 295 nm ultraviolet (UV) light source was used for excitation. Detection was done by integrating a near-UV camera with sensitivity down to 300 nm, a 12 mm quartz lens with iris and focus lock for the UV regime, and a fluorescence bandpass filter with 340 nm center wavelength. To demonstrate that changes in fluorescence are related to cellular processes, the epithelialization of a skin substitute was monitored in vitro. The skin substitute or construct was made by embedding microscopic live human skin tissue columns, 1 mm in diameter and spaced 1 mm apart, in acellular porcine dermis. Fluorescence emissions clearly delineate the extent of lateral surface migration of keratinocytes and the total surface covered by the new epithelium. The fluorescence image of new epidermis spatially correlates with the corresponding color image. A simple, user-friendly way of imaging the presence of skin epithelium would improve wound care in civilian burns, ulcers and surgeries. C1 [Franco, Walfre; Gutierrez-Herrera, Enoch; Purschke, Martin; Wang, Ying; Tam, Josh; Anderson, R. Rox; Doukas, Apostolos] Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Franco, W (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 3 TC 1 Z9 1 U1 0 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9334-7 J9 PROC SPIE PY 2013 VL 8565 AR 85650T DI 10.1117/12.2008476 PG 4 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BHA29 UT WOS:000324807200010 ER PT S AU Tan, KM Chee, A Shishkov, M Hariri, LP Applegate, MB Bouma, BE Suter, MJ AF Tan, K. M. Chee, A. Shishkov, M. Hariri, L. P. Applegate, M. B. Bouma, B. E. Suter, M. J. BE Kollias, N Choi, B Zeng, H Kang, HW Knudsen, BE Wong, BJF Ilgner, JF Suter, MJ Lam, S Brenner, M Gregory, KW Tearney, GJ Marcu, L Hirschberg, H Madsen, SJ MahadevanJansen, A Jansen, ED Mandelis, A TI Flexible transbronchial optical frequency domain imaging smart needle for biopsy guidance SO PHOTONIC THERAPEUTICS AND DIAGNOSTICS IX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Photonic Therapeutics and Diagnostics IX CY FEB 02-07, 2013 CL San Francisco, CA SP SPIE DE Peripheral pulmonary lesions; Optical coherence tomography; Optical frequency domain imaging; Endoscopic imaging; Medical optics instrumentation; Fiber optics imaging; Medical and biological imaging; Optical diagnostics for medicine ID COHERENCE TOMOGRAPHY; BRONCHIAL LESIONS; BRONCHOSCOPY; DIAGNOSIS AB Lung cancer is the leading cause of cancer related death. Macroscopic imaging techniques such as computed tomography are highly sensitivity at detecting small, <= 2cm, peripheral pulmonary lesions (PPLs) in the lung but lack the specificity necessary for diagnosis. Bronchoscopy is a procedure routinely performed to diagnose PPLs but is hindered with a low diagnostic yield due to challenging lesion localization. We have developed a flexible transbronchial optical frequency domain imaging (TB-OFDI) catheter that functions as a 'smart needle' to confirm the needle placement within the target lesion prior to biopsy. The TB-OFDI smart needle consists of a flexible and removable OFDI catheter that operates within a 21-gauge transbronchial needle aspiration (TBNA) needle. The OFDI catheter can be easily removed from the needle to facilitate subsequent aspiration or biopsy acquisition. The OFDI imaging core consists of an angled-polished ball lens with a spot size of 25 mu m at a working distance of 160 mu m from the catheter sheath. The ball-lens was designed to have an ellipsoid shape in order to compensate for the astigmatism caused by encasing the optics within a protective sheath. Transbronchial imaging of inflated excised swine lung parenchyma with the TB-OFDI smart needle yielded clear images of alveoli. In-vivo transbronchial imaging was also performed on three swine with artificial lesions injected transthoracially. Our results suggest that the TB-OFDI smart needle may be a useful tool for guiding biopsy acquisition to increase the diagnostic yield of PPLs. C1 [Tan, K. M.; Chee, A.; Applegate, M. B.; Suter, M. J.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, 40 Blossom St, Boston, MA 02114 USA. RP Tan, KM (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, 40 Blossom St, Boston, MA 02114 USA. EM msuter@partners.org FU American Lung Association Biomedical Research [RG-194681-N]; National Institutes of Health [R00CA134920, P41EB015903] FX This work was funded in part by the American Lung Association Biomedical Research Grant (RG-194681-N) and the National Institutes of Health (R00CA134920 and P41EB015903). NR 19 TC 0 Z9 0 U1 1 U2 3 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9334-7 J9 PROC SPIE PY 2013 VL 8565 AR 85652W DI 10.1117/12.2003022 PG 6 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BHA29 UT WOS:000324807200049 ER PT B AU Ingvar, M Petrovic, P Jensen, K AF Ingvar, Martin Petrovic, Predrag Jensen, Karin BE Colloca, L Flaten, MA Meissner, K TI Placing Placebo in Normal Brain Function with Neuroimaging SO PLACEBO AND PAIN: FROM BENCH TO BEDSIDE LA English DT Article; Book Chapter ID SPINAL-CORD; PAIN; RESPONSES; EXPECTATIONS; ANALGESIA; ACTIVATION; NETWORK; CORTEX; COGNITION; EMOTION C1 [Ingvar, Martin; Petrovic, Predrag] Karolinska Inst, Cognit Neurophysiol Res Grp, Stockholm Brain Inst, Osher Ctr Integrat Med, Stockholm, Sweden. [Jensen, Karin] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Charlestown, MA USA. RP Ingvar, M (reprint author), Karolinska Inst, Cognit Neurophysiol Res Grp, Stockholm Brain Inst, Osher Ctr Integrat Med, Stockholm, Sweden. NR 49 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-397931-5; 978-0-12-397928-5 PY 2013 BP 83 EP 88 DI 10.1016/B978-0-12-397928-5.00009-X PG 6 WC Anesthesiology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA BHG58 UT WOS:000325348000010 ER PT B AU Kong, J Gollub, RL AF Kong, Jian Gollub, Randy L. BE Colloca, L Flaten, MA Meissner, K TI Placebo Analgesia, Nocebo Hyperalgesia, and Acupuncture SO PLACEBO AND PAIN: FROM BENCH TO BEDSIDE LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; LOW-BACK-PAIN; CONNECTIVE-TISSUE; SHAM ACUPUNCTURE; ELECTROACUPUNCTURE STIMULATION; PATIENT EXPECTATIONS; FMRI; BRAIN; MECHANISMS; EXPECTANCY C1 [Kong, Jian; Gollub, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Kong, Jian; Gollub, Randy L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Kong, J (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. OI Gollub, Randy L./0000-0002-9434-4044 NR 94 TC 0 Z9 0 U1 1 U2 6 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-397931-5; 978-0-12-397928-5 PY 2013 BP 115 EP 126 DI 10.1016/B978-0-12-397928-5.00012-X PG 12 WC Anesthesiology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA BHG58 UT WOS:000325348000013 ER PT B AU DiLillo, V Hussong, A Kamholz, B Richardson, E AF DiLillo, Vicki Hussong, Andrea Kamholz, Barbara Richardson, Elizabeth BE Prinstein, MJ TI Psychologist and Parent: Advice from Professionals in Different Career Tracks SO PORTABLE MENTOR: EXPERT GUIDE TO A SUCCESSFUL CAREER IN PSYCHOLOGY, SECOND EDITION LA English DT Article; Book Chapter C1 [DiLillo, Vicki] Ohio Wesleyan Univ, Dept Psychol, Delaware, OH 43015 USA. [Hussong, Andrea] Univ N Carolina, Ctr Dev Sci, Chapel Hill, NC USA. [Hussong, Andrea] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [Kamholz, Barbara] VA Boston Healthcare Syst, Boston, MA USA. [Kamholz, Barbara] Boston Univ, Boston, MA 02215 USA. [Richardson, Elizabeth] Univ Massachusetts Dartmouth, Dept Psychol, N Dartmouth, MA USA. [Richardson, Elizabeth] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. RP DiLillo, V (reprint author), Ohio Wesleyan Univ, Dept Psychol, Delaware, OH 43015 USA. EM vgdilill@owu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4614-3993-6 PY 2013 BP 101 EP 116 DI 10.1007/978-1-4614-3994-3_7 D2 10.1007/978-1-4614-3994-3 PG 16 WC Education & Educational Research; Psychology, Multidisciplinary SC Education & Educational Research; Psychology GA BHB83 UT WOS:000324895600008 ER PT S AU Zhong, L Martinez-Pastor, B Silberman, DM Sebastian, C Mostoslavsky, R AF Zhong, Lei Martinez-Pastor, Barbara Silberman, Dafne M. Sebastian, Carlos Mostoslavsky, Raul BE Hirschey, MD TI Assaying Chromatin Sirtuins SO SIRTUINS: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Sirtuins; Chromatin; Chromatin immunoprecipitation (ChIP); Acid-extraction; Nucleosomal immunoprecipitation AB Most of the sirtuins' nuclear substrates identified so far are histones or other chromatin-associated proteins and, thus, it is of special relevance the development of good biochemical techniques to analyze the biology of these proteins in the context of chromatin. Here, we describe several of the chromatin-based techniques to identify sirtuins' substrates, including a chromatin immunoprecipitation (ChIP) protocol, an acid-extraction protocol, and a nucleosomal immunoprecipitation protocol to analyze putative sirtuin chromatin interactors. C1 [Zhong, Lei; Martinez-Pastor, Barbara; Silberman, Dafne M.; Sebastian, Carlos; Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. RP Zhong, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. FU NIDDK NIH HHS [DK088190-01A1, R01 DK088190]; NIGMS NIH HHS [R01 GM093072, GM093072-01] NR 4 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-62703-637-5; 978-1-62703-636-8 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2013 VL 1077 BP 149 EP 163 DI 10.1007/978-1-62703-637-5_10 D2 10.1007/978-1-62703-637-5 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA BHK08 UT WOS:000325690400011 PM 24014405 ER PT S AU Dominy, J Puigserver, P Canto, C AF Dominy, John Puigserver, Pere Canto, Carles BE Hirschey, MD TI In Vivo Measurement of the Acetylation State of Sirtuin Substrates as a Proxy for Sirtuin Activity SO SIRTUINS: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Acetylation; Sirtuins; PGC-1 alpha; Ndufa9; Immunoprecipitation; Western blot; Transfection; Homogenization ID METABOLISM; NAD(+); PGC-1-ALPHA; HOMEOSTASIS; PROTECTS; COMPLEX AB Evaluating the precise catalytic activity of sirtuin proteins in vivo is a challenging endeavor. Enzymological methods, including those employed in commercially available kits, require the isolation of immunopurified protein from cells or tissues, which can perturb regulatory protein-protein interactions as well as remove the enzyme from the reaction-altering effects of intracellular NAD(+), nicotinamide, and O-acetyl-ADP ribose concentrations. As such, the measurement of the steady state acetylation status of select sirtuin substrates in vivo remains an important tool for evaluating changes in sirtuin activity. Here, we describe how to perform the analysis of the acetylation status of key SIRT1 and SIRT3 targets in rodent tissues and cultured cells. C1 [Dominy, John; Puigserver, Pere] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Dominy, John; Puigserver, Pere] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. [Canto, Carles] Nestle Inst Hlth Sci, Lausanne, Switzerland. RP Dominy, J (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. OI Canto, Carles/0000-0002-5167-7922 FU NIDDK NIH HHS [R01 DK069966]; PHS HHS [R01 069966] NR 14 TC 2 Z9 2 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-62703-637-5; 978-1-62703-636-8 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2013 VL 1077 BP 217 EP 237 DI 10.1007/978-1-62703-637-5_15 D2 10.1007/978-1-62703-637-5 PG 21 WC Genetics & Heredity SC Genetics & Heredity GA BHK08 UT WOS:000325690400016 PM 24014410 ER PT J AU Johnson, JM Lev, MH AF Johnson, Jason M. Lev, Michael H. BE Torbey, MT Selim, MH TI Computed tomography in acute stroke SO STROKE BOOK, 2ND EDITION LA English DT Article; Book Chapter ID ANGIOGRAPHY SOURCE IMAGES; ACUTE CEREBRAL-ISCHEMIA; EARLY CT SCORE; 3-DIMENSIONAL FUNCTIONAL CT; INFARCT CORE; HYPERACUTE STROKE; BLOOD-FLOW; TECHNICAL IMPLEMENTATIONS; THROMBOLYTIC THERAPY; CAROTID ARTERIES C1 [Johnson, Jason M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Lev, Michael H.] Harvard Univ, Sch Med, Boston, MA USA. [Lev, Michael H.] Massachusetts Gen Hosp, Emergency Neuroradiol & Neurovasc Lab, Boston, MA 02114 USA. RP Johnson, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. NR 63 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-63472-5 PY 2013 BP 93 EP 123 D2 10.1017/CBO9781139344296 PG 31 WC Neurosciences SC Neurosciences & Neurology GA BHK31 UT WOS:000325706000009 ER PT J AU Chang, H Shih, LY Michelson, AD Dunn, P Frelinger, AL Wang, PN Kuo, MC Lin, TL Wu, JH Tang, TC AF Chang, Hung Shih, Lee-Yung Michelson, Alan D. Dunn, Po Frelinger, Andrew L. Wang, Po-Nan Kuo, Ming-Chung Lin, Tung-Liang Wu, Jin-Hou Tang, Tzung-Chih TI Clinical and Laboratory Significance of Defective P2Y(12) Pathway Function in Patients with Myeloproliferative Neoplasms: A Pilot Study SO ACTA HAEMATOLOGICA LA English DT Article DE Essential thrombocythemia; Myeloproliferative neoplasms; P2Y(12) receptors; Platelets; Polycythemia vera ID ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; PLATELET-FUNCTION; RISK-FACTOR; DISORDERS; THROMBOSIS; MUTATION; JAK2; LEUKOCYTOSIS; DISEASE AB Background: Patients with myeloproliferative neoplasms (MPN) have an increased risk for thrombosis and bleeding and show a defect in adenosine diphosphate (ADP)-induced platelet aggregation. This risk of thrombosis is further increased in MPN patients bearing the JAK2V617F mutation. Two ADP receptors, P2Y(1) and P2Y(12), are present on platelets. Although the pattern of defective ADP-induced platelet aggregation in MPN suggests an abnormality in the P2Y(12) pathway, no previous studies have specifically evaluated P2Y(12) function in MPN or the relationship between P2Y(12) function and the JAK2V617F mutation. Methods: Forty-one MPN patients were enrolled, including 24 with essential thrombocythemia (ET), 16 with polycythemia vera (PV) and 1 with primary myelofibrosis. Platelet P2Y(12) function in MPN was evaluated byflow-cytometric measurement of the phosphorylation of vasodilator-stimulated phosphoprotein (VASP). Clinical data were collected by review of medical records. JAK2V617F mutation was detected by allele-specific polymerase chain reaction. JAK2V617F allele burden was measured by the pyro-sequencing method. Results: In patients with MPN, platelet P2Y(12) function determined by VASP platelet reactivity index (PRI) was inversely correlated with platelet and white blood cell (WBC) counts. In subgroup analysis, PRI was inversely correlated with platelet and WBC counts in PV. PRI was also inversely correlated with platelet counts in ET, but the correlation of PRI and WBC counts did not reach statistical significance. Eight of the 41 patients had a history of thrombosis and only 2 had a bleeding history. Neither thrombosis nor bleeding patients were found to have significantly different PRIs. JAK2V617F mutation data were available in 35 cases. PRI was not different between JAK2V617F mutation and wild-type patients but PRI had a trend towards an inverse correlation with JAK2V617F allele burden for patients with mutations. Conclusions: The present study provides the first explicit demonstration of a defect in the P2Y(12) pathway in platelets of patients with MPN. Furthermore, platelet P2Y(12) function, assayed by VASP, is inversely correlated with platelet and WBC counts in patients with MPN. Platelet P2Y(12) function also appears to be inversely correlated with JAK2V617F allele burden. This compromised P2Y(12) function may be a novel mechanism for the bleeding tendency associated with extreme thrombocytosis in MPN. Copyright (C) 2013 S. Karger AG, Basel C1 [Chang, Hung; Shih, Lee-Yung; Dunn, Po; Wang, Po-Nan; Kuo, Ming-Chung; Lin, Tung-Liang; Wu, Jin-Hou; Tang, Tzung-Chih] Chang Gung Univ, Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Tao Yuan, Taiwan. [Chang, Hung; Shih, Lee-Yung; Dunn, Po] Chang Gung Univ, Sch Med, Tao Yuan, Taiwan. [Michelson, Alan D.; Frelinger, Andrew L.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Ctr Platelet Res Studies, Childrens Hosp Boston,Div Hematol Oncol, Boston, MA 02115 USA. RP Chang, H (reprint author), 199 Tung Hwa N Rd, Taipei, Taiwan. EM horng@adm.cgmh.org.tw FU Chang Gung Memorial Hospital [CMRP G380211]; Department of Health [DOH99-TD-C-111-006] FX This research was supported by grants from the Chang Gung Memorial Hospital (CMRP G380211) and the Department of Health (DOH99-TD-C-111-006) to H.C. and L.-Y.S. NR 35 TC 0 Z9 0 U1 1 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5792 J9 ACTA HAEMATOL-BASEL JI Acta Haematol. PY 2013 VL 130 IS 3 BP 181 EP 187 DI 10.1159/000348413 PG 7 WC Hematology SC Hematology GA 229BM UT WOS:000325236800012 PM 23751441 ER PT J AU Atri, A Molinuevo, JL Lemming, O Wirth, Y Pulte, I Wilkinson, D AF Atri, Alireza Molinuevo, Jose L. Lemming, Ole Wirth, Yvonne Pulte, Irena Wilkinson, David TI Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy SO ALZHEIMERS RESEARCH & THERAPY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CHOLINESTERASE INHIBITION; DEMENTED PATIENTS; CLINICAL-TRIALS; POOLED ANALYSIS; MODERATE; METAANALYSIS; 24-WEEK AB Introduction: Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine added to stable donepezil in patients with moderate to severe AD, and in a subset with moderate AD. Methods: Post hoc meta-analyses of data combined from two 24-week, randomised, double-blind, placebo-controlled trials of memantine 20 mg/day versus placebo, added to a stable cholinesterase inhibitor, were conducted. Data were included for all patients receiving donepezil 10 mg/day with Mini-Mental State Examination (MMSE) scores < 20 (n = 510). Efficacy was assessed using measures of cognition, function, and global status. Furthermore, marked clinical worsening, defined as concurrent deterioration from baseline in the three main efficacy domains, and safety, measured by treatment-emergent adverse events, were assessed. Analyses were performed for patients with moderate to severe AD (MMSE 5-19; MOD-SEV subgroup), and also for patients with moderate AD (MMSE 10-19; MOD subgroup; n = 367). Results: At week 24, in the MOD-SEV subgroup, patients receiving memantine added to donepezil significantly outperformed those receiving placebo added to donepezil in measures of cognition (P < 0.0001), function (P = 0.02), and global status (P = 0.010), with standardised mean differences (SMDs) of 0.36, 0.21, and 0.23, respectively (all last observation carried forward). Similarly, in the MOD subgroup, significant benefits were observed for cognition (P = 0.008), function (P = 0.04) and global status (P = 0.008), with SMDs of 0.28, 0.21, and 0.28, respectively. Significantly fewer patients receiving memantine added to donepezil showed marked clinical worsening than those receiving placebo added to donepezil, in both subgroups (MOD-SEV: 8.7% versus 20.4%, P = 0.0002; MOD: 5.9% versus 15.0%, P = 0.006). The incidence of adverse events was similar between treatment groups. Conclusions: These results support and extend previous evidence that combination treatment with memantine added to stable donepezil in patients with moderate AD, and in those with moderate to severe AD, is associated with significant benefits in reducing 24-week decline in cognition, function and global status. Combination treatment produces substantially reduced rates of marked clinical worsening, has good safety and tolerability, and generates effect sizes that are both statistically significant and clinically meaningful. C1 [Atri, Alireza] Massachusetts Gen Hosp, Dept Neurol, Memory Disorders Unit, Boston, MA 02114 USA. [Atri, Alireza] Edith Nourse Rogers Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA. [Atri, Alireza] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Molinuevo, Jose L.] Hosp Clin & Univ, Neurol Serv, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona 08036, Spain. [Lemming, Ole] H Lundbeck A S, Dept Biostat, DK-2500 Copenhagen, Denmark. [Wirth, Yvonne] Wirth Consulting, D-70193 Stuttgart, Germany. [Pulte, Irena] Merz Pharmaceut GmbH, Global Clin R&D CNS, D-60318 Frankfurt, Germany. [Wilkinson, David] Moorgreen Hosp, Memory Assessment & Res Ctr, Tom Rudd Unit, Southampton SO30 3JB, Hants, England. RP Atri, A (reprint author), Massachusetts Gen Hosp, Dept Neurol, Memory Disorders Unit, 15 Parkman St,WACC 715, Boston, MA 02114 USA. EM atri@nmr.mgh.harvard.edu OI Atri, Alireza/0000-0003-4405-6973; Molinuevo, Jose Luis/0000-0003-0485-6001 FU Forest Laboratories, Inc., New York; H. Lundbeck A/S, Denmark FX The reported analyses were made by H Lundbeck A/S, Denmark, in collaboration with Merz Pharmaceuticals GmbH, Germany. The original studies included in the present analysis were supported by funding from Forest Laboratories, Inc., New York. The authors would like to acknowledge the invaluable contribution of the principal investigators in the original trials as listed previously [16,17]. This manuscript was written with the assistance of Cambridge Medical Communication Ltd, and was funded by H. Lundbeck A/S, Denmark. While Dr Atri is the Associate Director, Clinical Operations, GRECC, ENRM Bedford VA Hospital, the contents of this study do not represent the views of the Department of Veterans Affairs or the United States Government. Finally, and most importantly, we express our deep gratitude for the commitment of the study participants and their caregivers, without whose generous contribution and dedication this research would not be possible. NR 41 TC 32 Z9 32 U1 1 U2 20 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-9193 J9 ALZHEIMERS RES THER JI Alzheimers Res. Ther. PY 2013 VL 5 IS 1 AR 6 DI 10.1186/alzrt160 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 229RP UT WOS:000325285300006 PM 23336974 ER PT J AU Mangale, D Kariuki, SN Chrabot, BS Kumabe, M Kelly, JA Harley, JB James, JA Sivils, KL Niewold, TB AF Mangale, Dorothy Kariuki, Silvia N. Chrabot, Beverly S. Kumabe, Marissa Kelly, Jennifer A. Harley, John B. James, Judith A. Sivils, Kathy L. Niewold, Timothy B. TI Familial Aggregation of High Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY LA English DT Article ID DISEASE RISK VARIANT; INTERFERON-ALPHA; AUTOIMMUNE-DISEASE; I INTERFERON; IFN-ALPHA; JUVENILE DERMATOMYOSITIS; INCREASED SENSITIVITY; ASSOCIATION; AUTOANTIBODIES; POLYMORPHISMS AB Systemic lupus erythematosus (SLE) patients frequently have high circulating tumor necrosis factor alpha (TNF-alpha) levels. We explored circulating TNF-alpha levels in SLE families to determine whether high levels of TNF-alpha were clustered in a heritable pattern. We measured TNF-alpha in 242 SLE patients, 361 unaffected family members, 23 unaffected spouses of SLE patients, and 62 unrelated healthy controls. Familial correlations and relative recurrence risk rates for the high TNF-alpha trait were assessed. SLE-affected individuals had the highest TNF-alpha levels, and TNF-alpha was significantly higher in unaffected first degree relatives than healthy unrelated subjects (P = 0.0025). No Mendelian patterns were observed, but 28.4% of unaffected first degree relatives of SLE patients had high TNF-alpha levels, resulting in a first degree relative recurrence risk of 4.48 (P = 2.9 x 10(-5)). Interestingly, the median TNF-alpha value in spouses was similar to that of the first degree relatives. Concordance of the TNF-alpha trait (high versus low) in SLE patients and their spouses was strikingly high at 78.2%. These data support a role for TNF-alpha in SLE pathogenesis, and TNF-alpha levels may relate with heritable factors. The high degree of concordance in SLE patients and their spouses suggests that environmental factors may also play a role in the observed familial aggregation. C1 [Mangale, Dorothy; Kariuki, Silvia N.; Chrabot, Beverly S.; Kumabe, Marissa] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA. [Mangale, Dorothy; Kariuki, Silvia N.; Chrabot, Beverly S.; Kumabe, Marissa] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA. [Kelly, Jennifer A.; James, Judith A.; Sivils, Kathy L.] Oklahoma Med Res Fdn, Arthritis & Clin Immunol Program, Oklahoma City, OK 73104 USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH 45229 USA. [Niewold, Timothy B.] Mayo Clin, Div Rheumatol, Rochester, MN 55905 USA. [Niewold, Timothy B.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA. RP Niewold, TB (reprint author), Mayo Clin, Div Rheumatol, 200 1st St SW,Guggenheim Bldg 3-42, Rochester, MN 55905 USA. EM niewold.timothy@mayo.edu OI Niewold, Timothy/0000-0003-3532-6660 FU Katen Scholarship at University of Chicago; US Department of Veterans Affairs; US Department of Defense [PR094002]; NIH [N01AR62277, R37AI024717, R01AR042460, P01AI083194, P20RR020143, P01AR049084, U01HG006828, P30AR053483, P30GM103510, U01AI101934, U19AI082714, R01AR04327, R01AR060861, K08AI083790, L30AI071651, UL1RR024999]; Lupus Research Institute Novel Research Grant; Alliance for Lupus Research Target Identification in Lupus Grant FX Dorothy Mangale received the Katen Scholarship at University of Chicago. John B. Harley Harley acknowledges the US Department of Veterans Affairs, the US Department of Defense (PR094002), NIH grants N01AR62277, R37AI024717, R01AR042460, P01AI083194, P20RR020143, P01AR049084, and U01HG006828. Judith A. James received the NIH grants P30AR053483, P30GM103510, U01AI101934, U19AI082714. Kathy L. Sivils received the NIH grants P01AI083194 and R01AR043274. Timothy B. Niewold received the NIH grants R01AR060861, K08AI083790, L30AI071651, and UL1RR024999, Lupus Research Institute Novel Research Grant, and an Alliance for Lupus Research Target Identification in Lupus Grant. NR 41 TC 5 Z9 5 U1 0 U2 1 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1740-2522 J9 CLIN DEV IMMUNOL JI Clin. Dev. Immunol. PY 2013 AR 267430 DI 10.1155/2013/267430 PG 6 WC Immunology SC Immunology GA 230WC UT WOS:000325373000001 ER PT J AU Thase, ME AF Thase, Michael E. BE Mann, JJ McGrath, PJ Roose, SP TI Cognitive behavior therapy SO CLINICAL HANDBOOK FOR THE MANAGEMENT OF MOOD DISORDERS LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE RESEARCH-PROGRAM; MENTAL-HEALTH TREATMENT; RECURRENT DEPRESSION; MAJOR DEPRESSION; UNIPOLAR DEPRESSION; NATIONAL-INSTITUTE; RELAPSE-PREVENTION; BIPOLAR DISORDERS; PRIMARY-CARE C1 Philadelphia VA Med Ctr, Dept Psychiat, Mood & Anxiety Disorders Treatment & Res Program, Philadelphia, PA USA. RP Thase, ME (reprint author), Philadelphia VA Med Ctr, Dept Psychiat, Mood & Anxiety Disorders Treatment & Res Program, Philadelphia, PA USA. NR 49 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-02463-2 PY 2013 BP 258 EP 269 D2 10.1017/CBO9781139175869 PG 12 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA BGN18 UT WOS:000323552500019 ER PT J AU Lisse, TS Adams, JS Hewison, M AF Lisse, Thomas S. Adams, John S. Hewison, Martin TI Vitamin D and MicroRNAs in Bone SO CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION LA English DT Article DE miRNA; vitamin D; VDR; osteoblasts; bone ID MESSENGER-RNA EXPRESSION; MESENCHYMAL STEM-CELLS; HUMAN ADIPOSE-TISSUE; BREAST-CANCER CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; D-RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; 1,25-DIHYDROXYVITAMIN D-3 AB MicroRNAs (miRNAs) are short noncoding RNAs that orchestrate complex posttranscriptional regulatory networks essential to the regulation of gene expression. Through complementarity with messenger RNA (mRNA) sequences, miRNAs act primarily to silence gene expression through either degradation or inhibited translation of target transcripts. In this way, miRNAs can act to fine-tune the transcriptional regulation of gene expression, but they may also play distinct roles in the proliferation, differentiation, and function of specific cell types. miRNA regulatory networks may be particularly important for signaling molecules such as vitamin D that exert pleiotropic effects on tissues throughout the body. The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)(2)D) functions as a steroid hormone that, when bound to its nuclear vitamin D receptor, is able to regulate target gene expression. However, recent studies have also implicated 1,25(OH)(2)D in epigenetic regulation of genes most notably as a modulator of miRNA function. The current review details our understanding of vitamin D and miRNAs with specific emphasis on the implications of this interaction for biological responses to vitamin D in one of its classical target tissues, i.e., bone. C1 [Lisse, Thomas S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Lisse, Thomas S.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Adams, John S.; Hewison, Martin] Univ Calif Los Angeles, Orthopaed Hosp, Res Ctr, Los Angeles, CA 90095 USA. [Adams, John S.; Hewison, Martin] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. RP Hewison, M (reprint author), Univ Calif Los Angeles, Orthopaed Hosp, Dept Orthopaed Surg, 615 Charles E Young Dr South,Room 410D, Los Angeles, CA 90095 USA. EM mhewison@mednet.ucla.edu FU NTH [2R01AR037399-21] FX This work was supported by NTH Grant No. 2R01AR037399-21. NR 145 TC 16 Z9 17 U1 1 U2 4 PU BEGELL HOUSE INC PI REDDING PA 50 CROSS HIGHWAY, REDDING, CT 06896 USA SN 1045-4403 J9 CRIT REV EUKAR GENE JI Crit. Rev. Eukaryot. Gene Expr. PY 2013 VL 23 IS 3 BP 195 EP 214 PG 20 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 228MB UT WOS:000325189800001 PM 23879537 ER PT J AU Rochman, DL Sheehan, MJ Kulich, RJ AF Rochman, Deborah L. Sheehan, Michael J. Kulich, Ronald J. TI Evaluation of a pain curriculum for occupational therapists: experiences from a master's-level graduate program over six years SO DISABILITY AND REHABILITATION LA English DT Article DE Curriculum; occupational therapy; pain attitudes; pain education; pain knowledge ID HEALTH-SCIENCE FACULTIES; MEDICAL-STUDENTS; NURSING-STUDENTS; NATIONAL-SURVEY; KNOWLEDGE; ATTITUDES; MANAGEMENT; EDUCATION; NURSES AB Purpose: Deficiencies in pain knowledge and attitudes among students and health practitioners are well documented. Occupational therapists (OTs) commonly care for patients who present with pain, and their knowledge of the field presumably impacts that care. This study presents the results of testing OT students' pain knowledge in order to assess the effects of embedding pain teaching in a generic master's-level OT course and to determine specific topics that should be addressed to improve upon existing OT curricula. Method: During the academic years 2004 through 2009, 194 OT students were administered a test of pain knowledge and attitudes on the first and last day of a required class which focused on procedural reasoning. Results: The results indicated significant (p<0.001) improvement in test scores after participation in the class. Whereas only 35% of students met the minimum "adequate" standard for pain knowledge at pre-test, 92% of students met this standard at post-test. Conclusions: The results demonstrate the effectiveness of a course taught by an instructor with pain expertise. In addition, analysis of individual items highlights the need for curricula to address theoretical versus practical understanding of pain, the ever-evolving science of pain, and pervasive biases about specific pain topics. C1 [Rochman, Deborah L.] Spaulding Rehabil Hosp, Dept Occupat Therapy, Medford, MA 02155 USA. [Sheehan, Michael J.] Quinnipiac Univ, Dept Psychol, Hamden, CT USA. [Kulich, Ronald J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Tufts Univ Dent Med, Boston, MA USA. RP Rochman, DL (reprint author), Spaulding Rehabil Hosp, 101 Main St, Medford, MA 02155 USA. EM DLRochman@partners.org NR 57 TC 1 Z9 1 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2013 VL 35 IS 22 BP 1933 EP 1940 DI 10.3109/09638288.2013.766273 PG 8 WC Rehabilitation SC Rehabilitation GA 230PW UT WOS:000325355400012 PM 23390881 ER PT J AU Hoge, EA Holzel, BK Marques, L Metcalf, CA Brach, N Lazar, SW Simon, NM AF Hoge, Elizabeth A. Hoelzel, Britta K. Marques, Luana Metcalf, Christina A. Brach, Narayan Lazar, Sara W. Simon, Naomi M. TI Mindfulness and Self-Compassion in Generalized Anxiety Disorder: Examining Predictors of Disability SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID STATE WORRY QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; CLINICAL ANXIETY; DEPRESSION; INVENTORY; SENSITIVITY; MEDITATORS; VALIDATION; BENEFITS; ADULTS AB Generalized anxiety disorder (GAD) is a condition characterized by worry and physiological arousal symptoms that causes significant disabilities in patients' lives. In order to improve psychotherapeutic interventions, a careful characterization of the deficiencies of this population as well as factors that ameliorate disability is crucial. Variables that have not traditionally been the focus of research should be considered, such as trait mindfulness and self-compassion. We investigated whether GAD patients would report lower mindfulness and self-compassion levels than healthy stressed individuals. Eighty-seven GAD patients and 49 healthy controls completed the Five Facet Mindfulness Questionnaire, the Self-Compassion Scale, and measures of anxiety. Patients with GAD also completed the Sheehan Disability Scale. Results showed that GAD patients had lower mindfulness and self-compassion than healthy stressed controls, and both were negatively correlated with levels of anxiety, worry, and anxiety sensitivity. In patients, mindfulness was a better predictor of disability than actual anxiety symptom scores. These findings highlight that in the presence of anxiety symptoms, mindfulness can be a factor that helps protect against feeling disabled by the disorder. The findings thereby add an important variable to the characterization of this disorder and should be taken into consideration for future treatment development. C1 [Hoge, Elizabeth A.; Marques, Luana; Metcalf, Christina A.; Brach, Narayan; Lazar, Sara W.; Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hoge, Elizabeth A.] Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA. [Hoelzel, Britta K.] Charite, Inst Med Psychol, D-13353 Berlin, Germany. RP Hoge, EA (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM ehoge@partners.org RI Hoge, Elizabeth/H-5879-2012; Lazar, Sara/G-3809-2012; OI Hoge, Elizabeth/0000-0002-5513-2292; Lazar, Sara/0000-0003-1126-8363; Brach, Narayan/0000-0002-1629-0626 FU NIH NCAAM [R21AT003425, K23AT004432]; Marie Curie International Outgoing Fellowship within the 7th European Community Framework Programme FX This research was supported in part by NIH NCAAM Grant R21AT003425 (P.I.: Lazar), in part by NIH NCCAM Grant K23AT004432 (P.I.: Hoge), and in part by a Marie Curie International Outgoing Fellowship within the 7th European Community Framework Programme (P.I.: Holzel). NR 48 TC 1 Z9 1 U1 3 U2 29 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X EI 1741-4288 J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 576258 DI 10.1155/2013/576258 PG 7 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 230KI UT WOS:000325337500001 ER PT J AU McCaffery, JM Papandonatos, GD Huggins, GS Peter, I Erar, B Kahn, SE Knowler, WC Lipkin, EW Kitabchi, AE Wagenknecht, LE Wing, RR AF McCaffery, Jeanne M. Papandonatos, George D. Huggins, Gordon S. Peter, Inga Erar, Bahar Kahn, Steven E. Knowler, William C. Lipkin, Edward W. Kitabchi, Abbas E. Wagenknecht, Lynne E. Wing, Rena R. CA Genetic Subgrp Look AHEAD Look AHEAD Res Grp TI Human Cardiovascular Disease IBC Chip-Wide Association with Weight Loss and Weight Regain in the Look AHEAD Trial SO HUMAN HEREDITY LA English DT Article DE Type 2 diabetes; Obesity; Weight loss; Diet; Genetics ID DIABETES PREVENTION PROGRAM; SALT EXPORT PUMP; BODY-MASS INDEX; FAMILIAL INTRAHEPATIC CHOLESTASIS; LIFE-STYLE INTERVENTION; OBESITY-RELATED TRAITS; ADIPOSE-TISSUE; CLINICAL-TRIAL; RISK-FACTORS; GENE AB Background/Aims:The present study identified genetic predictors of weight change during behavioral weight loss treatment. Methods: Participants were 3,899 overweight/obese individuals with type 2 diabetes from Look AHEAD, a randomized controlled trial to determine the effects of intensive lifestyle intervention (ILI), including weight loss and physical activity, relative to diabetes support and education, on cardiovascular outcomes. Analyses focused on associations of single nucleotide polymorphisms (SNPs) on the Illumina CARe iSelect (IBC) chip (minor allele frequency >5%; n = 31,959) with weight change at year 1 and year 4, and weight regain at year 4, among individuals who lost at year 1. Results: Two novel regions of significant chip-wide association with year-1 weight loss in ILI were identified (p < 2.96E-06). ABCB11 rs484066 was associated with 1.16 kg higher weight per minor allele at year 1, whereas TNFRSF11A, or RANK, rs17069904 was associated with 1.70 kg lower weight per allele at year 1. Conclusions: This study, the largest to date on genetic predictors of weight loss and regain, indicates that SNPs within ABCB11, related to bile salt transfer, and TNFRSF11A, implicated in adipose tissue physiology, predict the magnitude of weight loss during behavioral intervention. These results provide new insights into potential biological mechanisms and may ultimately inform weight loss treatment. (C) 2013 S. Karger AG, Basel C1 [McCaffery, Jeanne M.; Wing, Rena R.] Brown Univ, Miriam Hosp, Weight Control & Diabet Res Ctr, Dept Psychiat & Human Behav, Providence, RI USA. [McCaffery, Jeanne M.; Wing, Rena R.] Brown Univ, Brown Med Sch, Providence, RI 02912 USA. [Papandonatos, George D.; Erar, Bahar] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA. [Huggins, Gordon S.] Mol Cardiol Res Inst, MCRI Ctr Translat Genom, Tufts Med Ctr, Boston, MA USA. [Peter, Inga] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Lipkin, Edward W.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Knowler, William C.] Natl Inst Diabet & Digest & Kidney Dis, Phoenix, AZ USA. [Kitabchi, Abbas E.] Univ Tennessee, Ctr Hlth Sci, Div Endocrinol Diabet & Metab, Memphis, TN 38163 USA. [Wagenknecht, Lynne E.] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA. RP McCaffery, JM (reprint author), Miriam Hosp, Weight Control & Diabet Res Ctr, 196 Richmond St, Providence, RI 02903 USA. EM jeanne_mccaffery@brown.edu RI Papandonatos, George/J-2328-2014; OI Papandonatos, George/0000-0001-6770-932X; Kahn, Steven/0000-0001-7307-9002 FU Department of Health and Human Services through National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center (GCRC) [M01RR000056]; Clinical Translational Research Center (CTRC); Clinical and Translational Science Award [UL1 RR 024153]; NIH [DK 046204]; VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center [M01RR01346] FX This study was supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135 and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health, and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. The opinions expressed in this paper are those of the authors and do not necessarily reflect the views of the IHS or other funding sources.; Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (GCRC) (M01RR000056); the Clinical Translational Research Center (CTRC) funded by the Clinical and Translational Science Award (UL1 RR 024153) and NIH grant (DK 046204); the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs, and the Frederic C. Bartter General Clinical Research Center (M01RR01346). NR 67 TC 8 Z9 8 U1 0 U2 16 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 J9 HUM HERED JI Hum. Hered. PY 2013 VL 75 IS 2-4 BP 160 EP 174 DI 10.1159/000353181 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 229BE UT WOS:000325236000011 PM 24081232 ER PT J AU Jung, M AF Jung, Minsoo TI HEALTH DISPARITIES AMONG WAGE WORKERS DRIVEN BY EMPLOYMENT INSTABILITY IN THE REPUBLIC OF KOREA SO INTERNATIONAL JOURNAL OF HEALTH SERVICES LA English DT Article ID SELF-RATED HEALTH; TEMPORARY EMPLOYMENT; FLEXIBLE EMPLOYMENT; MORTALITY; EMPLOYEES; SECURITY; BACK; RISK; WELL AB Even though labor market flexibility continues to be a source of grave concern in terms of employment instability, as evidenced by temporary employment, only a few longitudinal studies have examined the effects of employment instability on the health status of wage workers. Against this backdrop, this study assesses the manner in which changes in employment type affect the health status of wage workers. The data originate from the Korean Labor and Income Panel Study's health-related surveys for the first through fourth years (n = 1,789; 1998 to 2001). This study estimates potential damage to self-rated health through the application of a generalized estimating equation, according to specific levels of employment instability. While controlling for age, socioeconomic position, marital status, health behavior, and access to health care, the study analysis confirms that changes in employment type exert significant and adverse effects on health status for a given year (OR = 1.47; 95% CI 1.10-1.96), to an extent comparable to the marked effects of smoking on human health (OR = 1.47; 95% CI 1.05-2.04). Given the global prevalence of labor flexibility, policy interventions must be implemented if employment instability triggers broad discrepancies not only in social standing, wage, and welfare benefits, but also in health status. C1 [Jung, Minsoo] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Ctr Community Based Res, Cambridge, MA 02138 USA. [Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea. [Jung, Minsoo] Korea Univ, Hlth Sci Res Inst, Seoul, South Korea. RP Jung, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Ctr Community Based Res, 450 Brookline Ave,LW 601, Boston, MA 02215 USA. EM minsoo_jung@dfci.harvard.edu OI Jung, Minsoo/0000-0003-3317-6507 NR 37 TC 1 Z9 1 U1 1 U2 4 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0020-7314 EI 1541-4469 J9 INT J HEALTH SERV JI Int. J. Health Serv. PY 2013 VL 43 IS 3 BP 483 EP 498 DI 10.2190/HS.43.3.g PG 16 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 224OK UT WOS:000324897600007 PM 24066417 ER PT J AU Ellis, C Focht, KL Grubaugh, AL AF Ellis, Charles Focht, Kendrea L. Grubaugh, Anouk L. TI Perceptions of stroke recovery: An exclusion of communication and cognition SO NEUROREHABILITATION LA English DT Article DE Stroke; recovery; cognition; communication ID PERSPECTIVES; HEALTH; APHASIA; CARE AB BACKGROUND: Perceptions of stroke recovery can differ substantially between stroke survivors and their healthcare providers. Concordance between the two is important for collaborative goal setting to facilitate optimal outcomes. OBJECTIVE: To explore stroke survivors' perceptions of their own recovery and residual impairments with specific emphasis on communication and cognition. METHODS AND PROCEDURES: A qualitative analytic approach was used in the study. Nine stroke survivors participated in a focus group discussion as part of a larger study designed to examine post-stroke outcomes. RESULTS: Early in the focus group proceedings, a discussion emphasizing how stroke survivors perceive their overall recovery emerged. Six of the nine participants (67%) perceived their overall stroke recovery to be greater than 90%, and only physical impairments were reported. Later in the course of the interview, eight of the nine participants (89%) reported either word retrieval or memory loss deficits which negatively influenced their daily functional activities. CONCLUSIONS: Stroke survivors in this sample did not include communication and cognitive deficits in their perception of their overall recovery despite later reporting these symptoms and related impairment. Failure of patients to include such persisting deficits in their reports of recovery can cause a mismatch between stroke survivor and healthcare provider goals. C1 [Ellis, Charles; Grubaugh, Anouk L.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Ellis, Charles; Focht, Kendrea L.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Grubaugh, Anouk L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Ellis, C (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,302, Charleston, SC 29425 USA. EM ellisc@musc.edu FU Veterans Health Administration Health Services Research and Development program FX The first author was supported by a career development award from the Veterans Health Administration Health Services Research and Development program. NR 28 TC 1 Z9 1 U1 3 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2013 VL 33 IS 2 BP 233 EP 239 DI 10.3233/NRE-130950 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 228IO UT WOS:000325179600007 PM 23949059 ER PT S AU Li, JX Yin, Q Wu, H AF Li, Jixi Yin, Qian Wu, Hao BE Alt, FW TI Structural Basis of Signal Transduction in the TNF Receptor Superfamily SO ADVANCES IN IMMUNOLOGY, VOL 119 SE Advances in Immunology LA English DT Review; Book Chapter ID KAPPA-B ACTIVATION; NECROSIS-FACTOR RECEPTOR; DEATH-EFFECTOR DOMAIN; MIXED LINEAGE KINASE; CELL-DEATH; PROGRAMMED NECROSIS; CRYSTAL-STRUCTURE; INTERACTING PROTEIN; IMMUNE-SYSTEM; NMR STRUCTURE AB Members of the tumor necrosis factor receptor superfamily play key roles in innate and adaptive immunity. Here, we review recent structural studies in the intracellular signal transduction of these receptors. A central theme revealed from these structural studies is that upon ligand binding, multiple intracellular proteins form higher-order signaling machines to transduce and amplify receptor activation information to different cellular fates, including NF-kappa B activation, apoptosis, and programmed necrosis. These studies open a new vista for understanding the biophysical principles in these signaling cascades. C1 [Wu, Hao] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Wu, H (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. EM hao.wu@childrens.harvard.edu FU NIAID NIH HHS [R01 AI045937, R37 AI050872] NR 102 TC 32 Z9 34 U1 3 U2 11 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-2776 BN 978-0-12-407707-2 J9 ADV IMMUNOL JI Adv.Immunol. PY 2013 VL 119 BP 135 EP 153 DI 10.1016/B978-0-12-407707-2.00005-9 PG 19 WC Immunology SC Immunology GA BGZ57 UT WOS:000324716600005 PM 23886067 ER PT S AU Tanzi, RE AF Tanzi, Rudolph E. BE Perry, G Zhu, X Smith, MA Sorensen, A Avila, J TI A Brief History of Alzheimer's Disease Gene Discovery SO ALZHEIMER'S DISEASE: ADVANCES FOR A NEW CENTURY SE Advances in Alzheimers Disease LA English DT Article; Book Chapter DE Amyloid-beta; amyloid-beta protein precursor; APOE; CD33; chromosome 21; down syndrome; genome-wide association study; presenilin ID AMYLOID BETA-PROTEIN; GENOME-WIDE ASSOCIATION; AMYOTROPHIC-LATERAL-SCLEROSIS; SYSTEMATIC METAANALYSES; IDENTIFIES VARIANTS; HUMAN CHROMOSOME-21; MISSENSE MUTATIONS; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; COMMON VARIANTS AB The rich and colorful history of gene discovery in Alzheimer's disease (AD) over the past three decades is as complex and heterogeneous as the disease, itself. Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases. The inheritance of AD exhibits a dichotomous pattern. On one hand, rare mutations in APP, PSEN1, and PSEN2 are fully penetrant for early-onset (<60 years) familial AD, which represents <5% of AD. On the other hand, common gene polymorphisms, such as the epsilon 4 and epsilon 2 variants of the APOE gene, influence susceptibility for common (>95%) late-onset AD. These four genes account for 30-50% of the inheritability of AD. Genome-wide association studies have recently led to the identification of additional highly confirmed AD candidate genes. Here, I review the past, present, and future of attempts to elucidate the complex and heterogeneous genetic underpinnings of AD along with some of the unique events that made these discoveries possible. C1 [Tanzi, Rudolph E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit,Dept Neurol,MassGen Inst N, Boston, MA USA. RP Tanzi, RE (reprint author), Harvard Univ, Sch Med, Genet & Aging Res Unit, Dept Neurol,MassGen Inst Neurodegenerat Dis,Massa, 114 16th St, Charlestown, MA 02129 USA. EM tanzi@helix.mgh.harvard.edu NR 47 TC 1 Z9 1 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 2210-5727 BN 978-1-61499-154-0 J9 ADV ALZH DIS PY 2013 VL 3 BP 5 EP 13 DI 10.3233/978-1-61499-154-0-5 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BGV89 UT WOS:000324325100002 ER PT S AU Hickman, SE El Khoury, J AF Hickman, Suzanne E. El Khoury, Joseph BE Perry, G Zhu, X Smith, MA Sorensen, A Avila, J TI The NeuroImmune System in Alzheimer's Disease: The Glass is Half Full SO ALZHEIMER'S DISEASE: ADVANCES FOR A NEW CENTURY SE Advances in Alzheimers Disease LA English DT Article; Book Chapter DE Alzheimer's disease; amyloid-beta; chemokines; microglia; mononuclear phagocytes; scavenger receptors ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MARROW-DERIVED MICROGLIA; BETA-AMYLOID FIBRILS; PERIVASCULAR MACROPHAGES; SCAVENGER RECEPTOR; INTERFERON-GAMMA; TRANSGENIC MICE; CRYPTOCOCCUS-NEOFORMANS; REACTIVE MICROGLIA; SENILE PLAQUES AB It is well established that microglia, the neuroimmune cells of the brain, are associated with amyloid-beta (A beta) deposits in Alzheimer's disease (AD). However, the roles of these cells and other mononuclear phagocytes such as monocytes and macrophages in AD pathogenesis and progression have been elusive. Clues to mononuclear phagocyte involvement came with the demonstration that A beta directly activates microglia and monocytes to produce neurotoxins, signifying that a receptor mediated interaction of A beta with these cells may be critical for neurodegeneration seen in AD. Also, in AD brain, mononuclear phagocyte distribution changes from a uniform pattern that covers the brain parenchyma to distinct clusters intimately associated with areas of A beta deposition, but the driving force behind this choreography was unclear. Here, we review our recent work identifying mononuclear phagocyte receptors for A beta and unraveling mechanisms of recruitment of these cells to areas of A beta deposition. While our findings and those of others have added significantly to our understanding of the role of the neuroimmune system in AD, the glass remains half full (or half empty) and a lot remains to be uncovered. C1 [Hickman, Suzanne E.; El Khoury, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA. [El Khoury, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Charlestown, MA 02129 USA. RP El Khoury, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, CNY 149,Room 8301,149 13th St, Charlestown, MA 02129 USA. EM jelkhoury@partners.org NR 54 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 2210-5727 BN 978-1-61499-154-0 J9 ADV ALZH DIS PY 2013 VL 3 BP 295 EP 302 DI 10.3233/978-1-61499-154-0-295 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BGV89 UT WOS:000324325100029 ER PT S AU Quinn, JF AF Quinn, Joseph F. BE Perry, G Zhu, X Smith, MA Sorensen, A Avila, J TI Biomarkers for Alzheimer's Disease: Showing the Way or Leading Us Astray? SO ALZHEIMER'S DISEASE: ADVANCES FOR A NEW CENTURY SE Advances in Alzheimers Disease LA English DT Article; Book Chapter DE Alzheimer's disease; biomarkers; clinical trials ID MILD COGNITIVE IMPAIRMENT; GAMMA-SECRETASE INHIBITOR; DECLINE; TRIAL; ACID AB The indolent nature of Alzheimer's disease, coupled with burgeoning interest in a "presymptomatic" stage of disease, has motivated efforts to identify, validate, and exploit surrogate disease markers for trials of disease-modifying or preventive strategies. Many of these efforts have been productive, and biomarkers are now routinely applied in selection of study subjects and evaluation of outcomes in clinical trials. On the other hand, biomarkers also have the capacity to lead to bad therapeutic outcomes when they determine "go-no go" decisions in early drug development. This paper reviews several reports of biomarker studies which illustrate the great potential, for both good and ill, of biomarkers of Alzheimer's disease. C1 [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. RP Quinn, JF (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Mail Code CR-131,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM quinnj@ohsu.edu NR 15 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 2210-5727 BN 978-1-61499-154-0 J9 ADV ALZH DIS PY 2013 VL 3 BP 371 EP 376 DI 10.3233/978-1-61499-154-0-371 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BGV89 UT WOS:000324325100035 ER PT J AU Kohnke, T Gomolka, B Bilal, S Zhou, XZ Sun, YP Rothe, M Baumgart, DC Weylandt, KH AF Koehnke, Thomas Gomolka, Beate Bilal, Sueleyman Zhou, Xiangzhi Sun, Yanping Rothe, Michael Baumgart, Daniel C. Weylandt, Karsten H. TI Acetylsalicylic Acid Reduces the Severity of Dextran Sodium Sulfate-Induced Colitis and Increases the Formation of Anti-Inflammatory Lipid Mediators SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; TRIGGERED RESOLVIN D1; COLORECTAL-CANCER; DOCOSAHEXAENOIC ACID; COX-2 INHIBITORS; ASPIRIN; MICE; PHAGOCYTOSIS; LIPOXINS; DRUGS AB The role of non-steroidal anti-inflammatory drugs in inflammatory bowel disease is controversial, as they have been implicated in disease aggravation. Different from other cyclooxygenase inhibitors, acetylsalicylic acid (ASA) enhances the formation of anti-inflammatory and proresolution lipoxins derived from arachidonic acid as well as resolvins from omega-3 polyunsaturated fatty acids such as docosahexaenoic acid (DHA). In this study, we examined the effect of ASA on murine dextran sodium sulfate colitis. A mouse magnetic resonance imaging (MRI) protocol and post mortem assessment were used to assess disease severity, and lipid metabolites were measured using liquid chromatography-coupled tandem mass spectrometry. Decreased colitis activity was demonstrated by phenotype and MRI assessment in mice treated with ASA, and confirmed in postmortem analysis. Analysis of lipid mediators showed sustained formation of lipoxin A4 and an increase of DHA-derived 17-hydroxydocosahexaenoic acid (17-HDHA) after treatment with ASA. Furthermore, in vitro experiments in RAW264.7 murine macrophages demonstrated significantly increased phagocytosis activity after incubation with 17-HDHA, supporting its proresolution effect. These results show a protective effect of ASA in a murine colitis model and could give a rationale for a careful reassessment of ASA therapy in patients with inflammatory bowel disease and particularly ulcerative colitis, possibly combined with DHA supplementation. C1 [Koehnke, Thomas; Gomolka, Beate; Bilal, Sueleyman; Baumgart, Daniel C.; Weylandt, Karsten H.] Free & Humboldt Univ Berlin, Charite Med Sch, Virchow Hosp, Dept Gastroenterol Hepatol & Endocrinol, D-13353 Berlin, Germany. [Koehnke, Thomas; Bilal, Sueleyman; Weylandt, Karsten H.] Massachusetts Gen Hosp, Lab Lipid Med & Technol, Boston, MA 02114 USA. [Koehnke, Thomas; Bilal, Sueleyman; Weylandt, Karsten H.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Zhou, Xiangzhi; Sun, Yanping] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Sun, Yanping] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA. [Sun, Yanping] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Rothe, Michael] Lipidomix GmbH, D-13125 Berlin, Germany. RP Weylandt, KH (reprint author), Free & Humboldt Univ Berlin, Charite Med Sch, Virchow Hosp, Dept Gastroenterol Hepatol & Endocrinol, D-13353 Berlin, Germany. EM karsten.weylandt@charite.de FU German Research Foundation (DFG) FX This work was supported by a grant from the German Research Foundation (DFG) to Karsten H. Weylandt. NR 56 TC 8 Z9 9 U1 1 U2 11 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 J9 BIOMED RES INT JI Biomed Res. Int. PY 2013 AR 748160 DI 10.1155/2013/748160 PG 10 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 222MS UT WOS:000324735800001 ER PT J AU Pullicino, PM Thompson, JLP Sacco, RL Sanford, AR Qian, M Teerlink, JR Haddad, H Diek, M Freudenberger, RS Labovitz, AJ Di Tullio, MR Lok, DJ Ponikowski, P Anker, SD Graham, S Mann, DL Mohr, JP Homma, S AF Pullicino, Patrick M. Thompson, John L. P. Sacco, Ralph L. Sanford, Alexandra R. Qian, Min Teerlink, John R. Haddad, Haissam Diek, Monika Freudenberger, Ronald S. Labovitz, Arthur J. Di Tullio, Marco R. Lok, Dirk J. Ponikowski, Piotr Anker, Stefan D. Graham, Susan Mann, Douglas L. Mohr, J. P. Homma, Shunichi CA WARCEF Investigators TI Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial SO CEREBROVASCULAR DISEASES LA English DT Article DE Aspirin; Cardiac embolism; Heart failure; Stroke prevention ID ACUTE ISCHEMIC-STROKE; ATRIAL-FIBRILLATION; CARDIOMYOPATHY; FREQUENCY; THERAPY AB Background: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths. Prespecified secondary analysis showed a 48% hazard ratio reduction (p = 0.005) for warfarin in IIS. Cardioembolism is likely the main pathogenesis of stroke in heart failure. We examined the IIS benefit for warfarin in more detail in post hoc secondary analyses. Methods: We subtyped IIS into definite, possible and noncardioembolic using the Stroke Prevention in Atrial Fibrillation method. Statistical tests, stratified by prior ischemic stroke or transient ischemic attack, were the conditional binomial for independent Poisson variables for rates, the Cochran-Mantel-Haenszel test for stroke subtype and the van Elteren test for modified Rankin Score (mRS) and National Institute of Health Stroke Scale (NIHSS) distributions, and an exact test for proportions. Results: Twenty-nine of 1,142 warfarin and 55 of 1,163 aspirin patients had IIS. The warfarin IIS rate (0.727/100 patient-years, PY) was lower than for aspirin (1.36/100 PY, p = 0.003). Definite cardioembolic IIS was less frequent on warfarin than aspirin (0.22 vs. 0.55/100 PY, p = 0.012). Possible cardioembolic IIS tended to be less frequent on warfarin than aspirin (0.37 vs. 0.67/100 PY, p = 0.063) but noncardioembolic IIS showed no difference: 5 (0.12/100 PY) versus 6 (0.15/100 PY, p = 0.768). Among patients experiencing IIS, there were no differences by treatment arm in fatal IIS, baseline mRS, mRS 90 days after IIS, and change from baseline to post-IIS mRS. The warfarin arm showed a trend to a lower proportion of severe nonfatal IIS [mRS 3-5; 3/23 (13.0%) vs. 16/48 (33.3%), p = 0.086]. There was no difference in NIHSS at the time of stroke (p = 0.825) or in post-IIS mRS (p = 0.948) between cardioembolic, possible cardioembolic and noncardioembolic stroke including both warfarin and aspirin groups. Conclusions: The observed benefits in the reduction of IIS for warfarin compared to aspirin are most significant for cardioembolic IIS among patients with low ejection fraction in sinus rhythm. This is supported by trends to lower frequencies of severe IIS and possible cardioembolic IIS in patients on warfarin compared to aspirin. Copyright (c) 2013 S. Karger AG, Basel C1 [Pullicino, Patrick M.] Univ Kent, Canterbury CT2 7NZ, Kent, England. [Thompson, John L. P.; Sanford, Alexandra R.; Qian, Min; Di Tullio, Marco R.; Mohr, J. P.; Homma, Shunichi] Columbia Univ, Med Ctr, New York, NY USA. [Graham, Susan] SUNY Buffalo, Buffalo, NY 14260 USA. [Sacco, Ralph L.] Univ Miami, Miami, FL USA. [Labovitz, Arthur J.] Univ S Florida, Tampa, FL USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Freudenberger, Ronald S.] Lehigh Valley Hosp, Allentown, PA USA. [Mann, Douglas L.] Washington Univ, St Louis, MO USA. [Haddad, Haissam] Univ Ottawa, Ottawa, ON K1N 6N5, Canada. [Diek, Monika; Anker, Stefan D.] Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany. [Lok, Dirk J.] Hosp Deventer, Deventer, Netherlands. [Ponikowski, Piotr] Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Anker, Stefan D.] IRCCS San Raffaele, Ctr Clin & Basic Res, Rome, Italy. RP Pullicino, PM (reprint author), Univ Kent, Canterbury CT2 7NZ, Kent, England. EM P.Pullicino@kent.ac.uk RI Ponikowski, Piotr/O-6454-2015; OI Ponikowski, Piotr/0000-0002-3391-7064; Mann, Douglas /0000-0002-2516-0145 FU National Institute of Neurological Diseases and Stroke [U01-NS-043975, U01-NS-039143] FX Funding was offered by U01-NS-043975 (S. Homma) and U01-NS-039143 (J.L.P. Thompson) from the National Institute of Neurological Diseases and Stroke. Warfarin and warfarin placebo were provided by Taro Pharmaceuticals USA Inc., Hawthorne, N.Y., USA, and aspirin and aspirin placebo by Bayer HealthCare LLC, Morristown, N.J., USA. NR 11 TC 4 Z9 5 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-9770 J9 CEREBROVASC DIS JI Cerebrovasc. Dis. PY 2013 VL 36 IS 1 BP 74 EP 78 DI 10.1159/000352058 PG 5 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 219WZ UT WOS:000324543600011 PM 23921215 ER PT J AU Liang, SH Collier, TL Rotstein, BH Lewis, R Steck, M Vasdev, N AF Liang, Steven H. Collier, Thomas Lee Rotstein, Benjamin H. Lewis, Rebecca Steck, Mia Vasdev, Neil TI Rapid microfluidic flow hydrogenation for reduction or deprotection of F-18-labeled compounds SO CHEMICAL COMMUNICATIONS LA English DT Article ID PET; KINASE AB We have combined the benefits of both microfluidics and flow hydrogenation to provide facile access to previously underutilized reduction and protecting group chemistries for PET imaging applications. The rapid removal of an O-benzyl protecting group to prepare 2-[F-18] fluoroquinolin-8-ol and the reduction of a nitro group in the synthesis of 4-[F-18] fluoroaniline were achieved within 3 minutes. C1 [Liang, Steven H.; Collier, Thomas Lee; Rotstein, Benjamin H.; Vasdev, Neil] Harvard Univ, Dept Radiol, Sch Med, Boston, MA 02114 USA. [Liang, Steven H.; Collier, Thomas Lee; Rotstein, Benjamin H.; Lewis, Rebecca; Steck, Mia; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Collier, Thomas Lee] Advion Inc, Ithaca, NY 14850 USA. [Lewis, Rebecca] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA. RP Vasdev, N (reprint author), Harvard Univ, Dept Radiol, Sch Med, 55 Fruit St, Boston, MA 02114 USA. EM vasdev.neil@mgh.harvard.edu OI Rotstein, Benjamin/0000-0001-9707-9357 FU Advion, Inc; ThalesNano Nanotechnology, Inc FX We thank Advion, Inc and ThalesNano Nanotechnology, Inc for generously providing equipment and/or funding for this research. We also thank Dr Jason P. Holland for helpful discussions and Hogger & Co. for the Journal cover design. NR 13 TC 13 Z9 13 U1 0 U2 15 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1359-7345 J9 CHEM COMMUN JI Chem. Commun. PY 2013 VL 49 IS 78 BP 8755 EP 8757 DI 10.1039/c3cc45166f PG 3 WC Chemistry, Multidisciplinary SC Chemistry GA 216EU UT WOS:000324265500003 PM 23948863 ER PT J AU Moazzami, K Roohi, A Moazzami, B AF Moazzami, Kasra Roohi, Aria Moazzami, Bobak TI Granulocyte colony stimulating factor therapy for acute myocardial infarction SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID STEM-CELL MOBILIZATION; CORONARY-ARTERY-DISEASE; ENDOTHELIAL PROGENITOR CELLS; RANDOMIZED CONTROLLED-TRIALS; CHRONIC HEART-FAILURE; BONE-MARROW-CELLS; G-CSF; CARDIAC-FUNCTION; INTRACORONARY INFUSION; VENTRICULAR-FUNCTION AB Background Acute myocardial infarction (AMI) is the leading cause of death in developed countries, and current treatment modalities have failed to regenerate the dead myocardium resulting from the ischemic damage. Stem cells have the potential to regenerate the damaged myocardium. These cells can be mobilized from the bone marrow by factors such as granulocyte colony stimulating factor (G-CSF). Objectives To assess the effects of stem cell mobilization following granulocyte colony stimulating factor therapy in patients with acute myocardial infarction. Search methods We searched CENTRAL (The Cochrane Library Issue 4, 2010), MEDLINE (1950 to November week 3, 2010), EMBASE (1980 to 2010 week 48), BIOSIS Previews (1969 to 30 November 2010), ISI Science Citation Index Expanded (1970 to 4 December 2010) and ISI Conference Proceedings Citation Index - Science (1990 to 4 December 2010). We also checked reference lists of articles. Selection criteria We included randomized controlled trials including participants with a clinical diagnosis of AMI who were randomly allocated to the subcutaneous administration of G-CSF through a daily dose of 2.5, 5 or 10 microgram/kg for four to six days or placebo. No age or other restrictions were applied for the selection of patients. Data collection and analysis Two authors independently selected trials, assessed trials for eligibility and methodological quality, and extracted data regarding the clinical efficacy and adverse outcomes. Disagreements were resolved by the third author. Main results We included seven trials reported in 30 references in the review (354 participants). In all trials, G-CSF was compared with placebo preparations. Dosage of G-CSF varied among studies, ranging from 2.5 to 10 microgram/kg/day. Regarding overall risk of bias, data regarding the generation of randomization sequence and incomplete outcome data were at a low risk of bias; however, data regarding binding of personnel were not conclusive. The rate of mortality was not different between the two groups (RR 0.64, 95% CI 0.15 to 2.80, P = 0.55). Regarding safety, the limited amount of evidence is inadequate to reach any conclusions regarding the safety of G-CSF therapy. Moreover, the results did not show any beneficial effects of G-CSF in patients with AMI regarding left ventricular function parameters, including left ventricular ejection fraction (RR 3.41, 95% CI - 0.61 to 7.44, P = 0.1), end systolic volume (RR - 1.35, 95% CI - 4.68 to 1.99, P = 0.43) and end diastolic volume (RR - 4.08, 95% CI - 8.28 to 0.12, P = 0.06). It should also be noted that the study was limited since the trials included lacked long enough follow up durations. Authors' conclusions Limited evidence from small trials suggested a lack of benefit of G-CSF therapy in patients with AMI. Since data of the risk of bias regarding blinding of personnel were not conclusive, larger RCTs with appropriate power calculations and longer follow up durations are required in order to address current uncertainties regarding the clinical efficacy and therapy-related adverse events of G-CSF treatment. C1 [Moazzami, Kasra] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr CVRC, Charlestown, MA USA. [Roohi, Aria; Moazzami, Bobak] Babol Univ Med Sci, Babol Sar, Iran. RP Moazzami, K (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr CVRC, 149 St, Charlestown, MA USA. EM moazzami.kasra@mgh.harvard.edu NR 55 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 5 AR CD008844 DI 10.1002/14651858.CD008844.pub2 PG 37 WC Medicine, General & Internal SC General & Internal Medicine GA 169DW UT WOS:000320758700017 PM 23728682 ER PT S AU Lei, HT Kazlauskas, A AF Lei, Hetian Kazlauskas, Andrius BE Cadenas, E Packer, L TI Detection of H2O2-Mediated Phosphorylation of Kinase-Inactive PDGFR alpha SO HYDROGEN PEROXIDE AND CELL SIGNALING, PT C SE Methods in Enzymology LA English DT Review; Book Chapter ID GROWTH-FACTORS; RECEPTOR; FAMILY; CELLS AB Platelet-derived growth factor (PDGF) receptor alpha (PDGFR alpha) belongs to the 58-member family of receptor tyrosine kinases and contributes to a variety of physiological and pathological settings. Activation of PDGFR alpha proceeds by at least two mechanisms. The traditional route involves PDGF-dependent dimerization and activation of the receptor's intrinsic kinase activity. The second mechanism proceeds intracellularly and involves reactive oxygen species and Src family kinases, which activate monomeric PDGFR alpha. Herein we describe an assay to investigate reactive oxygen species-mediated phosphorylation of PDGFR alpha that is independent of the receptor's intrinsic kinase activity. C1 [Lei, Hetian; Kazlauskas, Andrius] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02115 USA. RP Kazlauskas, A (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02115 USA. EM andrius_kazlauskas@meei.harvard.edu FU NEI NIH HHS [EY012509] NR 9 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-405881-1 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2013 VL 528 BP 189 EP 194 DI 10.1016/B978-0-12-405881-1.00011-2 PG 6 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BGW07 UT WOS:000324343900012 PM 23849866 ER PT J AU Goulidaki, N Polytarchou, C Spandidos, DA Sourvinos, G Iliopoulos, D AF Goulidaki, Nektaria Polytarchou, Christos Spandidos, Demetrios A. Sourvinos, George Iliopoulos, Demetrios TI MicroRNAs dramatically affect Human Cytomegalovirus (HCMV) lytic infection by interfering with molecular pathways of the host SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [Goulidaki, Nektaria; Spandidos, Demetrios A.; Sourvinos, George] Univ Crete, Sch Med, Dept Virol, Iraklion, Crete, Greece. [Goulidaki, Nektaria] Univ Crete, Sch Med, Grad Programme Mol Basis Human Dis, Iraklion, Crete, Greece. [Polytarchou, Christos; Iliopoulos, Demetrios] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Polytarchou, Christos; Iliopoulos, Demetrios] Univ Calif Los Angeles, David Geffen Sch Med, Ctr GI Syst Biol, Los Angeles, CA 90095 USA. [Polytarchou, Christos; Iliopoulos, Demetrios] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Med, Los Angeles, CA 90095 USA. [Polytarchou, Christos; Iliopoulos, Demetrios] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & Aids, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PY 2013 VL 32 SU 1 MA 362 BP S70 EP S70 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 219LC UT WOS:000324507400263 ER PT J AU Haddock, LJ Kim, DY Mukai, S AF Haddock, Luis J. Kim, David Y. Mukai, Shizuo TI Simple, Inexpensive Technique for High-Quality Smartphone Fundus Photography in Human and Animal Eyes SO JOURNAL OF OPHTHALMOLOGY LA English DT Article ID OPHTHALMOLOGY AB Purpose. We describe in detail a relatively simple technique of fundus photography in human and rabbit eyes using a smartphone, an inexpensive app for the smartphone, and instruments that are readily available in an ophthalmic practice. Methods. Fundus images were captured with a smartphone and a 20D lens with or without a Koeppe lens. By using the coaxial light source of the phone, this system works as an indirect ophthalmoscope that creates a digital image of the fundus. The application whose software allows for independent control of focus, exposure, and light intensity during video filming was used. With this app, we recorded high-definition videos of the fundus and subsequently extracted high-quality, still images from the video clip. Results. The described technique of smartphone fundus photography was able to capture excellent high-quality fundus images in both children under anesthesia and in awake adults. Excellent images were acquired with the 20D lens alone in the clinic, and the addition of the Koeppe lens in the operating room resulted in the best quality images. Successful photodocumentation of rabbit fundus was achieved in control and experimental eyes. Conclusion. The currently described system was able to take consistently high-quality fundus photographs in patients and in animals using readily available instruments that are portable with simple power sources. It is relatively simple to master, is relatively inexpensive, and can take advantage of the expanding mobile-telephone networks for telemedicine. C1 [Mukai, Shizuo] Harvard Univ, Sch Med, Retina Serv, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. RP Mukai, S (reprint author), Harvard Univ, Sch Med, Retina Serv, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM shizuo_mukai@meei.harvard.edu OI Haddock, Luis/0000-0003-4179-6992 NR 8 TC 26 Z9 26 U1 1 U2 13 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2090-004X J9 J OPHTHALMOL JI J. Ophthalmol. PY 2013 AR 518479 DI 10.1155/2013/518479 PG 5 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA 225IA UT WOS:000324954500001 ER PT J AU Ommaya, AK Adams, KM Allman, RM Collins, EG Cooper, RA Dixon, CE Fishman, PS Henry, JA Kardon, R Kerns, RD Kupersmith, J Lo, A Macko, R McArdle, R McGlinchey, RE McNeil, MR O'Toole, TP Peckham, PH Tuszynski, MH Waxman, SG Wittenberg, GF AF Ommaya, Alexander K. Adams, Kenneth M. Allman, Richard M. Collins, Eileen G. Cooper, Rory A. Dixon, C. Edward Fishman, Paul S. Henry, James A. Kardon, Randy Kerns, Robert D. Kupersmith, Joel Lo, Albert Macko, Richard McArdle, Rachel McGlinchey, Regina E. McNeil, Malcolm R. O'Toole, Thomas P. Peckham, P. Hunter Tuszynski, Mark H. Waxman, Stephen G. Wittenberg, George F. TI Opportunities in rehabilitation research SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material ID SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; TRANSCRANIAL MAGNETIC STIMULATION; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; 1ST MYOCARDIAL-INFARCTION; LOW-BACK-PAIN; PARKINSONS-DISEASE; OLDER-ADULTS C1 [Ommaya, Alexander K.] VA Off Res & Dev, Washington, DC USA. [Adams, Kenneth M.] VA Ann Arbor Healthcare Syst, Mental Hlth Serv, Ann Arbor, MI USA. [Allman, Richard M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Allman, Richard M.] Birmingham VA Med Ctr VAMC, GRECC, Birmingham, AL USA. [Allman, Richard M.] Birmingham VA Med Ctr VAMC, Div Gerontol & Geriatr, Birmingham, AL USA. [Allman, Richard M.] Univ Alabama Birmingham, Med Sch Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Med, Birmingham, AL USA. [Collins, Eileen G.] Jr VA Hosp, Edward Hines, Res & Dev Serv, Hines, IL USA. [Collins, Eileen G.] Univ Illinois, Coll Nursing, Chicago, IL USA. [Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Lab, Pittsburgh, PA USA. [Dixon, C. Edward] GRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dixon, C. Edward] Univ Pittsburgh, Pittsburgh, PA USA. [Fishman, Paul S.] Baltimore VAMC, Neurol Serv, Baltimore, MD USA. [Fishman, Paul S.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Henry, James A.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA. [Henry, James A.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Kerns, Robert D.] Iowa City VA Hlth Care Syst, Div Neuroophthalmol, Iowa City, IA USA. [Kerns, Robert D.] Iowa City VA Hlth Care Syst, VA Res Ctr Prevent & Treatment Visual, Iowa City, IA USA. [Kerns, Robert D.] Univ Iowa, Iowa City, IA USA. [Kupersmith, Joel] VA Connecticut Healthcare Syst, Pain Res Informat MultiMorbity & Educ Ctr, New Haven, CT USA. [Kupersmith, Joel] Yale Univ, Dept Psychiat, New Haven, CT USA. [Kupersmith, Joel] Yale Univ, Dept Neurol, New Haven, CT USA. [Kupersmith, Joel] Yale Univ, Dept Psychol, New Haven, CT USA. [Lo, Albert] Providence VAMC, Providence, RI USA. [Lo, Albert] Brown Univ, Div Biol & Med, Dept Neurol, Providence, RI 02912 USA. [Lo, Albert] Brown Univ, Div Biol & Med, Dept Publ Hlth, Providence, RI 02912 USA. [Macko, Richard] Baltimore VAMC, Ctr Excellence & GRECC, RR&D, Baltimore, MD USA. [Macko, Richard] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Macko, Richard] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Macko, Richard] Univ Maryland, Sch Med, Dept Phys Therapy, Baltimore, MD 21201 USA. [Macko, Richard] Univ Maryland, Sch Med, Dept Rehabil Sci, Baltimore, MD 21201 USA. [McArdle, Rachel] Bay Pines VA Healthcare Syst, Bay Pines, FL USA. [McArdle, Rachel] Univ S Florida, Dept Commun Sci & Disorders, Coll Behav & Community Disorders, Tampa, FL USA. [McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC & Translat Res Ctr TBI & Stress Dis, Boston, MA USA. [McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA USA. [McNeil, Malcolm R.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. [McNeil, Malcolm R.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [O'Toole, Thomas P.] Providence VAMC, Providence, RI USA. [O'Toole, Thomas P.] Brown Univ, Alpert Med Sch, Providence, RI USA. [Peckham, P. Hunter] Louis Stokes Cleveland VAMC, Cleveland Funct Elect Stimulat Ctr, Cleveland, OH USA. [Peckham, P. Hunter] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA. [Tuszynski, Mark H.] VA San Diego Healthcare Syst, San Diego, CA USA. [Tuszynski, Mark H.] Univ Calif, Dept Neurosci, La Jolla, CA USA. [Waxman, Stephen G.] VA Connecticut Healthcare Syst, Ctr Excellence Restorat Nervous Syst Funct, New Haven, CT USA. [Waxman, Stephen G.] Yale Univ, Sch Med, New Haven, CT USA. [Wittenberg, George F.] Baltimore VAMC, GRECC, Baltimore, MD USA. [Wittenberg, George F.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. RP Kupersmith, J (reprint author), VA Off Res & Dev, Washington, DC USA. EM jk@ku.persmith.com RI McGlinchey, Regina/R-1971-2016 FU Intramural VA [VA999999]; NIA NIH HHS [P30 AG028747] NR 154 TC 0 Z9 0 U1 1 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2013 VL 50 IS 6 BP VII EP XXXII DI 10.1682/JRRD.2012.09.0167 PG 26 WC Rehabilitation SC Rehabilitation GA 217HJ UT WOS:000324350200001 PM 24203548 ER PT J AU Goodrich, GL Martinsen, GL Flyg, HM Kirby, J Asch, SM Brahm, KD Brand, JM Cajamarca, D Cantrell, JL Chong, T Dziadul, JA Hetrick, BJ Huang, MA Ihrig, C Ingalla, SP Meltzer, BR Rakoczy, CM Rone, A Schwartz, E Shea, JE AF Goodrich, Gregory L. Martinsen, Gary L. Flyg, Heidi M. Kirby, Jennine Asch, Steven M. Brahm, Karen D. Brand, John M. Cajamarca, Diana Cantrell, Jenette L. Chong, Theresa Dziadul, John A. Hetrick, Barbara J. Huang, Michael A. Ihrig, Carolyn Ingalla, Shanida P. Meltzer, Bradley R. Rakoczy, Chrystyna M. Rone, Ashley Schwartz, Elliot Shea, Jane E. TI Development of a mild traumatic brain injury-specific vision screening protocol: A Delphi study SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accommodation; binocular vision; consensus; convergence insufficiency; Delphi method; mild traumatic brain injury; oculomotor; optometrist; traumatic brain injury; visual symptoms ID POST-CONCUSSION SYNDROME; POLYTRAUMA NETWORK SITE; CONVERGENCE INSUFFICIENCY; PHYSICAL-EXAMINATION; VISUAL FUNCTION; REHABILITATION; POPULATION; PREVALENCE; GUIDELINES; DIAGNOSIS AB Although traumatic brain injury (TBI) can happen to anyone at any time, the wars in Iraq and Afghanistan have brought it renewed attention. Fortunately, most cases of TBI from the recent conflicts are mild TBI (mTBI). Still, many physical, psychological, and social problems are associated with mTBI. Among the difficulties encountered are oculomotor and vision problems, many of which can impede daily activities such as reading. Therefore, correct diagnosis and treatment of these mTBI-related vision problems is an important part of patient recovery. Numerous eye care providers in the Department of Veterans Affairs, in military settings, and in civilian practices specialize and are proficient in examining patients who have a history of TBI. However, many do not have this level of experience working with and treating patients with mTBI. Recognizing this, we used a modified Delphi method to derive expert opinions from a panel of 16 optometrists concerning visual examination of the patient with mTBI. This process resulted in a clinical tool containing 17 history questions and 7 examination procedures. This tool provides a set of clinical guidelines that can be used as desired by any eye care provider either as a screening tool or adjunct to a full eye examination when seeing a patient with a history of mTBI. The 757 goal of this process was to provide optimal and uniform vision care for the patient with mTBI. C1 [Goodrich, Gregory L.; Martinsen, Gary L.; Flyg, Heidi M.; Kirby, Jennine; Asch, Steven M.; Ingalla, Shanida P.] Dept Vet Affairs VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Brahm, Karen D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Brand, John M.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Cajamarca, Diana] West Palm Beach VA Med Ctr VAMC, W Palm Beach, FL USA. [Cantrell, Jenette L.] Bay Pines VA Healthcare Syst, Bay Pines, FL USA. [Chong, Theresa] VA Southern Nevada Healthcare Syst, North Las Vegas, NV USA. [Dziadul, John A.] Viera VA Outpatient Clin, Viera, FL USA. [Hetrick, Barbara J.] Jonathan M Wainwright Mem VAMC, Walla Walla, WA USA. [Huang, Michael A.] VA Mission Valley Clin, San Diego, CA USA. [Ihrig, Carolyn] VA Western New York Healthcare Syst, Buffalo, NY USA. [Meltzer, Bradley R.] Northport VAMC, Northport, NY USA. [Rakoczy, Chrystyna M.] James A Haley Vet Hosp, Tampa, FL 33612 USA. [Rone, Ashley] Lexington VAMC, Lexington, KY USA. [Schwartz, Elliot] VA New York Harbor Healthcare Syst, New York, NY USA. [Shea, Jane E.] VA St Louis Hlth Care Syst, St Louis, MO USA. RP Goodrich, GL (reprint author), VA Palo Alto Hlth Care Syst, 795 Willow Rd,Bldg T-365, Menlo Pk, CA 94025 USA. EM Gregorv.Goodrich@va.gov FU VA Health Services Research & Development QUERI [RRP 11-008] FX This material was based on work supported by a VA Health Services Research & Development QUERI (grant RRP 11-008). NR 51 TC 8 Z9 8 U1 3 U2 18 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2013 VL 50 IS 6 BP 757 EP 768 DI 10.1682/JRRD.2012.10.0184 PG 12 WC Rehabilitation SC Rehabilitation GA 217HJ UT WOS:000324350200005 PM 24203539 ER PT S AU Vatansever, F Xuan, WJ Huang, YY Hamblin, MR AF Vatansever, Fatma Xuan, Weijun Huang, Ying-Ying Hamblin, Michael R. BE Hamblin, MR Arany, PR Carroll, JD TI Transcranial low-level light therapy produces neuroprotection, neurogenesis and BDNF after TBI in mice. SO MECHANISMS FOR LOW-LIGHT THERAPY VIII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Mechanisms for Low-Light Therapy VIII CY FEB 02, 2013 CL San Francisco, CA SP SPIE DE low-level laser therapy; traumatic brain injury; controlled cortical impact; neurological severity score; wire grip and motion test ID TRAUMATIC BRAIN-INJURY; BIPHASIC DOSE-RESPONSE; CENTRAL-NERVOUS-SYSTEM; LASER THERAPY; CELL-DEATH AB We have previously shown that transcranial low level light therapy (LLLT) can ameliorate brain damage in mice subjected to traumatic brain injury and improve neurological function. We used 810-nm laser and delivered 18 J/cm2 at an irradiance 25 mW/cm2. LLLT was either delivered once at 4 hours after controlled cortical impact TBI, once a day for 3 days, or once a day for 14 days. One and 3 applications of LLLT had beneficial effects on the mice, with 3 being better than 1, but 14 applications had no beneficial effect. We now report immunofluorescence studies in mouse brain sections that offer some explanation for this intriguing finding. Mice were injected for a week before sacrifice with a marker for proliferating cells (BrdU), and the neutrotrophin BDNF (brain derived neurotrophic factor) was stained for. We found increased BrdU incorporation indicating proliferating cells in the dentate gyrus of the hippocampus, the subventricular layer of the lateral ventricle, as well as the brain tissue surrounding the cortical lesion. Interestingly these cells were more abundant at 7 days than at 28 days post TBI. Co-labeling of BrdU with Neu-N was performed indicating that the proliferating cells were in fact neuronal in nature. Caspase-3 was used to study the neuronal death pathways activated after TBI and laser treatments. Mice with 3 laser treatments had much more BrdU incorporation than mice with 14. Upregulation of BDNF was seen at 7 days, a possible indication that neuroprogenitor cells may have migrated there from sites of neurogenesis. Taken together these data suggest that transcranial LLLT may have applications beyond TBI in areas such as neurodegenerative disease and psychiatric disorders. C1 [Vatansever, Fatma; Xuan, Weijun; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu OI Hamblin, Michael/0000-0001-6431-4605 NR 31 TC 1 Z9 1 U1 0 U2 3 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9338-5 J9 PROC SPIE PY 2013 VL 8569 AR UNSP 85690E DI 10.1117/12.2001900 PG 11 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BHA24 UT WOS:000324803700009 ER PT J AU Burdick, DJ Leverenz, JB AF Burdick, Daniel J. Leverenz, James B. BE Aarsland, D Cummings, J Weintraub, D Chaudhuri, KR TI Parkinson's disease: pathology, anatomy, and behavior SO NEUROPSYCHIATRIC AND COGNITIVE CHANGES IN PARKINSON'S DISEASE AND RELATED MOVEMENT DISORDERS: DIAGNOSIS AND MANAGEMENT LA English DT Article; Book Chapter ID IMPULSE CONTROL DISORDERS; CORTICAL LEWY BODIES; VISUAL HALLUCINATIONS; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; POSITRON EMISSION; BODY DISEASE; DEMENTIA; DEPRESSION C1 [Burdick, Daniel J.] Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Mental Illnes Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Burdick, DJ (reprint author), Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. NR 88 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-03922-3 PY 2013 BP 14 EP 24 D2 10.1017/CBO9781139856669 PG 11 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BGY95 UT WOS:000324630200003 ER PT J AU Weintraub, D Rektorova, I AF Weintraub, Daniel Rektorova, Irena BE Aarsland, D Cummings, J Weintraub, D Chaudhuri, KR TI Impulse control disorders and related behaviors SO NEUROPSYCHIATRIC AND COGNITIVE CHANGES IN PARKINSON'S DISEASE AND RELATED MOVEMENT DISORDERS: DIAGNOSIS AND MANAGEMENT LA English DT Article; Book Chapter ID HEDONISTIC HOMEOSTATIC DYSREGULATION; SUBTHALAMIC NUCLEUS STIMULATION; STRIATAL DOPAMINE RELEASE; DISEASE-RATING-SCALE; PARKINSONS-DISEASE; COMPULSIVE BEHAVIORS; CLINICAL-FEATURES; SEEKING BEHAVIOR; AGONIST THERAPY; FOLLOW-UP C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Rektorova, Irena] Masaryk Univ, Dept Neurol 1, Sch Med, Brno, Czech Republic. [Rektorova, Irena] Masaryk Univ, St Annes Hosp, Brno, Czech Republic. [Rektorova, Irena] CEITEC MU, Cent European Inst Technol, Brno, Czech Republic. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 105 TC 0 Z9 0 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-03922-3 PY 2013 BP 140 EP 152 D2 10.1017/CBO9781139856669 PG 13 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BGY95 UT WOS:000324630200014 ER PT J AU Barba, KA AF Barba, Kate A. BE Buttaro, TM Barba, KA TI Health Assessment SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID OLDER-ADULTS C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Barba, KA (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 24 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 9 EP 21 PG 13 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000003 ER PT J AU Evans, TE AF Evans, Theresa E. BE Buttaro, TM Barba, KA TI ATRIAL FIBRILLATION SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID OLDER C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Evans, TE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 86 EP 92 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000019 ER PT J AU Evans, TE AF Evans, Theresa E. BE Buttaro, TM Barba, KA TI HEART FAILURE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Evans, TE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 99 EP 105 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000021 ER PT J AU Cierpial, C Stengrevics, S AF Cierpial, Chelby Stengrevics, Susan BE Buttaro, TM Barba, KA TI HYPERTENSION SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID PREVENTION C1 [Cierpial, Chelby] Massachusetts Gen Hosp, Cardiac Intervent Unit, Boston, MA 02114 USA. [Stengrevics, Susan] Massachusetts Gen Hosp, Cardiac Arrhythmia Stepdown Unit, Boston, MA 02114 USA. RP Cierpial, C (reprint author), Massachusetts Gen Hosp, Cardiac Intervent Unit, Boston, MA 02114 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 105 EP 112 PG 8 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000022 ER PT J AU Evans, TE AF Evans, Theresa E. BE Buttaro, TM Barba, KA TI HEART VALVE DISEASE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID GUIDELINES C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Evans, TE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 117 EP 123 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000024 ER PT J AU Jeffries, M Marks, R AF Jeffries, Marian Marks, Rosemarie BE Buttaro, TM Barba, KA TI Respiratory Disorders SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 [Jeffries, Marian] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Marks, Rosemarie] Signature Healthcare, Brockton, MA USA. RP Jeffries, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 124 EP 128 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000025 ER PT J AU Jeffries, M Marks, R AF Jeffries, Marian Marks, Rosemarie BE Buttaro, TM Barba, KA TI CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 [Jeffries, Marian] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Marks, Rosemarie] Signature Healthcare, Brockton, MA USA. RP Jeffries, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 128 EP 134 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000026 ER PT J AU Jeffries, M Marks, R AF Jeffries, Marian Marks, Rosemarie BE Buttaro, TM Barba, KA TI INFLUENZA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 [Jeffries, Marian] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Marks, Rosemarie] Signature Healthcare, Brockton, MA USA. RP Jeffries, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 134 EP 138 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000027 ER PT J AU Jeffries, M Marks, R AF Jeffries, Marian Marks, Rosemarie BE Buttaro, TM Barba, KA TI PNEUMONIA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 [Jeffries, Marian] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Marks, Rosemarie] Signature Healthcare, Brockton, MA USA. RP Jeffries, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 138 EP 147 PG 10 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000028 ER PT J AU Fitzgerald, P AF Fitzgerald, Patricia BE Buttaro, TM Barba, KA TI Gastrointestinal Disorders SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID ACUTE ABDOMINAL-PAIN; OLDER C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fitzgerald, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 148 EP 152 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000029 ER PT J AU Fitzgerald, P AF Fitzgerald, Patricia BE Buttaro, TM Barba, KA TI DIVERTICULAR DISEASE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fitzgerald, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 152 EP 157 PG 6 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000030 ER PT J AU Fitzgerald, P AF Fitzgerald, Patricia BE Buttaro, TM Barba, KA TI ISCHEMIC BOWEL SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID COLITIS C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fitzgerald, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 158 EP 162 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000031 ER PT J AU Fitzgerald, P AF Fitzgerald, Patricia BE Buttaro, TM Barba, KA TI PANCREATITIS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fitzgerald, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 162 EP 167 PG 6 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000032 ER PT J AU Fitzgerald, P AF Fitzgerald, Patricia BE Buttaro, TM Barba, KA TI CONSTIPATION SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fitzgerald, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 167 EP 173 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000033 ER PT J AU Fitzgerald, P AF Fitzgerald, Patricia BE Buttaro, TM Barba, KA TI DIARRHEA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fitzgerald, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 173 EP 178 PG 6 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000034 ER PT J AU Fitzgerald, P AF Fitzgerald, Patricia BE Buttaro, TM Barba, KA TI GASTROESOPHAGEAL REFLUX DISEASE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fitzgerald, P (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 178 EP 182 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000035 ER PT J AU Tyksienski, CA AF Tyksienski, Carol A. BE Buttaro, TM Barba, KA TI Genitourinary Disorders SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; AGING KIDNEY C1 Massachusetts Gen Hosp, Hemodialysis Unit, Boston, MA 02114 USA. RP Tyksienski, CA (reprint author), Massachusetts Gen Hosp, Hemodialysis Unit, Boston, MA 02114 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 183 EP 191 PG 9 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000036 ER PT J AU Tyksienski, CA AF Tyksienski, Carol A. BE Buttaro, TM Barba, KA TI CHRONIC KIDNEY DISEASE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Hemodialysis Unit, Boston, MA 02114 USA. RP Tyksienski, CA (reprint author), Massachusetts Gen Hosp, Hemodialysis Unit, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 191 EP 197 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000037 ER PT J AU Cruz, C Fisher, SA Lussier-Cushing, M Repper-DeLisi, J AF Cruz, Constance Fisher, Sara A. Lussier-Cushing, Mary Repper-DeLisi, Jennifer BE Buttaro, TM Barba, KA TI Neurologic Disorders SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID DEMENTIA; DIAGNOSIS; CARE; TRY C1 [Cruz, Constance] Massachusetts Gen Hosp, Inpatient Psychiat Unit, Boston, MA 02114 USA. [Fisher, Sara A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lussier-Cushing, Mary; Repper-DeLisi, Jennifer] Massachusetts Gen Hosp, Psychiat Nursing Consultat Serv, Boston, MA 02114 USA. RP Cruz, C (reprint author), Massachusetts Gen Hosp, Inpatient Psychiat Unit, Boston, MA 02114 USA. NR 16 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 202 EP 209 PG 8 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000039 ER PT J AU Lussier-Cushing, M Repper-DeLisi, J Fisher, SA Cruz, C AF Lussier-Cushing, Mary Repper-DeLisi, Jennifer Fisher, Sara A. Cruz, Constance BE Buttaro, TM Barba, KA TI DELIRIUM IN THE OLDER HOSPITALIZED ADULT SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID CONFUSION ASSESSMENT METHOD; TRIAL; FALLS C1 [Lussier-Cushing, Mary; Repper-DeLisi, Jennifer] Massachusetts Gen Hosp, Psychiat Nursing Consultat Serv, Boston, MA 02114 USA. [Fisher, Sara A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cruz, Constance] Massachusetts Gen Hosp, Inpatient Psychiat Unit, Boston, MA 02114 USA. RP Lussier-Cushing, M (reprint author), Massachusetts Gen Hosp, Psychiat Nursing Consultat Serv, Boston, MA 02114 USA. NR 27 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 209 EP 221 PG 13 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000040 ER PT J AU Phipps, M AF Phipps, Marion BE Buttaro, TM Barba, KA TI ISCHEMIC STROKE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; ASSOCIATION; CARE; INCONTINENCE; STATEMENT; GUIDELINE C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Phipps, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 221 EP 230 PG 10 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000041 ER PT J AU Fahey, JB AF Fahey, Jean B. BE Buttaro, TM Barba, KA TI DIZZINESS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID VERTIGO C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fahey, JB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 230 EP 236 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000042 ER PT J AU Fahey, JB AF Fahey, Jean B. BE Buttaro, TM Barba, KA TI NORMAL PRESSURE HYDROCEPHALUS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID URINARY-INCONTINENCE; PREVALENCE; DIAGNOSIS; DISEASE C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fahey, JB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 236 EP 240 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000043 ER PT J AU Phipps, M AF Phipps, Marion BE Buttaro, TM Barba, KA TI PARKINSON'S DISEASE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Phipps, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 241 EP 248 PG 8 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000044 ER PT J AU Gavaghan, SR AF Gavaghan, Susan R. BE Buttaro, TM Barba, KA TI SEIZURES SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID EPILEPSY C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Gavaghan, SR (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 249 EP 254 PG 6 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000045 ER PT J AU Wood, SL AF Wood, Susan L. BE Buttaro, TM Barba, KA TI Endocrine SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID MANAGEMENT; PEOPLE C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wood, SL (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 255 EP 268 PG 14 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000046 ER PT J AU Wood, SL AF Wood, Susan L. BE Buttaro, TM Barba, KA TI HYPO/HYPERTHYROIDISM SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wood, SL (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 269 EP 275 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000047 ER PT J AU Wood, SL AF Wood, Susan L. BE Buttaro, TM Barba, KA TI HYPERPARATHYROIDISM/HYPOPARATHYROIDISM SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wood, SL (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 275 EP 283 PG 9 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000048 ER PT J AU Wood, SL AF Wood, Susan L. BE Buttaro, TM Barba, KA TI SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID HYPONATREMIA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wood, SL (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 283 EP 287 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000049 ER PT J AU Bardzik, S AF Bardzik, Susan BE Buttaro, TM Barba, KA TI Musculoskeletal SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID SEPTIC ARTHRITIS C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Bardzik, S (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 288 EP 292 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000050 ER PT J AU Caracci, L AF Caracci, Lesley BE Buttaro, TM Barba, KA TI OSTEOMYELITIS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID LONG BONES; MANAGEMENT C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Caracci, L (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 303 EP 308 PG 6 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000053 ER PT J AU Donovan, M AF Donovan, Melissa BE Buttaro, TM Barba, KA TI TUBERCULOSIS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Donovan, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 343 EP 350 PG 8 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000058 ER PT J AU Staples, MG AF Staples, Monica G. BE Buttaro, TM Barba, KA TI Multisystem Disorders SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID UNKNOWN ORIGIN; FEVER C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Staples, MG (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 18 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 351 EP 359 PG 9 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000059 ER PT J AU Staples, MG AF Staples, Monica G. BE Buttaro, TM Barba, KA TI POLYMYALGIA RHEUMATICA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID MANAGEMENT C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Staples, MG (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 359 EP 363 PG 5 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000060 ER PT J AU Staples, MG AF Staples, Monica G. BE Buttaro, TM Barba, KA TI RHEUMATOID ARTHRITIS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID THERAPY; STRATEGIES; DISEASE C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Staples, MG (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 14 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 364 EP 369 PG 6 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000061 ER PT J AU Roche, K AF Roche, Kate BE Buttaro, TM Barba, KA TI SYSTEMIC LUPUS ERYTHEMATOSUS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Roche, K (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 369 EP 376 PG 8 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000062 ER PT J AU Roche, K AF Roche, Kate BE Buttaro, TM Barba, KA TI TEMPORAL ARTERITIS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID POLYMYALGIA-RHEUMATICA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Roche, K (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 376 EP 379 PG 4 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000063 ER PT J AU Roche, K AF Roche, Kate BE Buttaro, TM Barba, KA TI VASCULITIS SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID DIAGNOSIS C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Roche, K (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 379 EP 385 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000064 ER PT J AU Kelly, NA AF Kelly, Nancy A. BE Buttaro, TM Barba, KA TI HYPERCALCEMIA AND HYPOCALCEMIA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Patient Care Serv, Boston, MA 02114 USA. RP Kelly, NA (reprint author), Massachusetts Gen Hosp, Patient Care Serv, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 408 EP 416 PG 9 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000067 ER PT J AU Good, GA AF Good, Grace A. BE Buttaro, TM Barba, KA TI HYPERKALEMIA AND HYPOKALEMIA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Good, GA (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 416 EP 423 PG 8 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000068 ER PT J AU Good, GA AF Good, Grace A. BE Buttaro, TM Barba, KA TI HYPONATREMIA AND HYPERNATREMIA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Good, GA (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 423 EP 432 PG 10 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000069 ER PT J AU Kelly, NA AF Kelly, Nancy A. BE Buttaro, TM Barba, KA TI HYPOMAGNESEMIA AND HYPERMAGNESEMIA SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Patient Care Serv, Boston, MA 02114 USA. RP Kelly, NA (reprint author), Massachusetts Gen Hosp, Patient Care Serv, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 432 EP 439 PG 8 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000070 ER PT J AU Cruz, C Fisher, SA Lussier-Cushing, M Repper-DeLisi, J AF Cruz, Constance Fisher, Sara A. Lussier-Cushing, Mary Repper-DeLisi, Jennifer BE Buttaro, TM Barba, KA TI Psychological Issues SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID GENERALIZED-ANXIETY-DISORDER; OLDER-ADULTS; LATER LIFE; DEPRESSION C1 [Cruz, Constance] Massachusetts Gen Hosp, Inpatient Psychiat Unit, Boston, MA 02114 USA. [Fisher, Sara A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lussier-Cushing, Mary; Repper-DeLisi, Jennifer] Massachusetts Gen Hosp, Psychiat Nursing Consultat Serv, Boston, MA 02114 USA. RP Cruz, C (reprint author), Massachusetts Gen Hosp, Inpatient Psychiat Unit, Boston, MA 02114 USA. NR 16 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 440 EP 445 PG 6 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000071 ER PT J AU Repper-DeLisi, J Cruz, C Fisher, SA Lussier-Cushing, M AF Repper-DeLisi, Jennifer Cruz, Constance Fisher, Sara A. Lussier-Cushing, Mary BE Buttaro, TM Barba, KA TI DEPRESSION SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter ID GERIATRIC DEPRESSION; OLDER-ADULTS; RISK-FACTOR; OUTCOMES; POPULATION; SCALE; CARE C1 [Repper-DeLisi, Jennifer; Lussier-Cushing, Mary] Massachusetts Gen Hosp, Psychiat Nursing Consultat Serv, Boston, MA 02114 USA. [Cruz, Constance] Massachusetts Gen Hosp, Inpatient Psychiat Unit, Boston, MA 02114 USA. [Fisher, Sara A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Repper-DeLisi, J (reprint author), Massachusetts Gen Hosp, Psychiat Nursing Consultat Serv, Boston, MA 02114 USA. NR 29 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 445 EP 453 PG 9 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000072 ER PT J AU McDonough, ML AF McDonough, Mary L. BE Buttaro, TM Barba, KA TI URINARY INCONTINENCE SO NURSING CARE OF THE HOSPITALIZED OLDER PATIENT LA English DT Article; Book Chapter C1 Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. RP McDonough, ML (reprint author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-0-8138-1046-1 PY 2013 BP 511 EP 517 PG 7 WC Geriatrics & Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA BGU98 UT WOS:000324235000082 ER PT S AU Wolchok, JD Hodi, FS Weber, JS Allison, JP Urba, WJ Robert, C O'Day, SJ Hoos, A Humphrey, R Berman, DM Lonberg, N Korman, AJ AF Wolchok, Jedd D. Hodi, F. Stephen Weber, Jeffrey S. Allison, James P. Urba, Walter J. Robert, Caroline O'Day, Steven J. Hoos, Axel Humphrey, Rachel Berman, David M. Lonberg, Nils Korman, Alan J. GP NYAS TI Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma SO PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE cytotoxic T-lymphocyte antigen-4; immuno-oncology; immunotherapy; ipilimumab; melanoma; monoclonal antibody ID T-LYMPHOCYTE ANTIGEN-4; CANCER-IMMUNOTHERAPY; CTLA-4 BLOCKADE; PHASE-II; METASTATIC MELANOMA; SOLID TUMORS; DOUBLE-BLIND; ADVERSE EVENTS; IMMUNE-SYSTEM; IV MELANOMA AB The immunotherapeutic agent ipilimumab has helped address a significant unmet need in the treatment of advanced melanoma. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte antigen-4 (CTLA-4), thereby augmenting antitumor immune responses. After decades in which a number of clinical trials were conducted, ipilimumab was the first therapy to improve overall survival in a randomized, controlled phase III trial of patients with advanced melanoma. These results led to the regulatory approval of ipilimumab at 3 mg/kg for the treatment of unresectable or metastatic melanoma. More than 17,000 patients worldwide have received ipilimumab, either as a commercial drug at 3 mg/kg or in clinical trials and expanded access programs at different doses. Consistent with its proposed mechanism of action, the most common toxicities associated with ipilimumab therapy are inflammatory in nature. These immune-related adverse events were mostly reversible when effective treatment guidelines were followed. Importantly, long-term follow-up of patients who received ipilimumab in a phase III trial showed that 24% survived at least two years, and in phase II studies, a proportion of patients survived at least five years. Evaluation of ipilimumab is ongoing in the adjuvant setting for melanoma, and for advanced disease in nonsmall cell lung, small cell lung, prostate, ovarian, and gastric cancers. C1 [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weber, Jeffrey S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Allison, James P.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Urba, Walter J.] Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA. Inst Gustave Roussy, Villejuif, France. [O'Day, Steven J.] Beverly Hills Canc Ctr, Beverly Hills, CA USA. [Hoos, Axel] GlaxoSmithKline, Collegeville, PA USA. [Humphrey, Rachel] MethylGene Inc, Montreal, PQ, Canada. [Berman, David M.] Bristol Myers Squibb Co, Princeton, NJ USA. [Lonberg, Nils; Korman, Alan J.] Bristol Myers Squibb, Redwood City, CA USA. RP Wolchok, JD (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, Ludwig Ctr Canc Immunotherapy, 1275 York Ave, New York, NY 10021 USA. EM wolchokj@mskcc.org NR 90 TC 90 Z9 92 U1 2 U2 31 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 BN 978-1-57331-916-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2013 VL 1291 BP 1 EP 13 DI 10.1111/nyas.12180 PG 13 WC Multidisciplinary Sciences; Pharmacology & Pharmacy SC Science & Technology - Other Topics; Pharmacology & Pharmacy GA BGZ96 UT WOS:000324771200001 PM 23772560 ER PT S AU Kam, LC Shen, K Dustin, ML AF Kam, L. C. Shen, K. Dustin, M. L. BE Yarmush, ML TI Micro- and Nanoscale Engineering of Cell Signaling SO ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 15 SE Annual Review of Biomedical Engineering LA English DT Review; Book Chapter DE micropatterning; epithelial; T lymphocyte; immune synapse ID SUPPORTED LIPID-BILAYERS; DIP-PEN NANOLITHOGRAPHY; EPITHELIAL-MESENCHYMAL TRANSITIONS; LASER-SCANNING LITHOGRAPHY; T-CELLS; IMMUNOLOGICAL SYNAPSE; SPINDLE ORIENTATION; ADHESION PROTEINS; RECEPTOR CLUSTER; ACTIVATION AB It is increasingly recognized that cell signaling, as a chemical process, must be considered at the local, micrometer scale. Micro- and nanofabrication techniques provide access to these dimensions, with the potential to capture and manipulate the spatial complexity of intracellular signaling in experimental models. This review focuses on recent advances in adapting surface engineering for use with biomolecular systems that interface with cell signaling, particularly with respect to surfaces that interact with multiple receptor systems on individual cells. The utility of this conceptual and experimental approach is demonstrated in the context of epithelial cells and T lymphocytes, two systems whose ability to perform their physiological function is dramatically impacted by the convergence and balance of multiple signaling pathways. C1 [Kam, L. C.] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA. [Shen, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA. [Dustin, M. L.] NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA. RP Kam, LC (reprint author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA. EM lk2141@columbia.edu OI Dustin, Michael/0000-0003-4983-6389 FU NEI NIH HHS [PN2 EY016586, PN2EY016586]; NIAID NIH HHS [R01 AI088377, R01AI088377]; NIBIB NIH HHS [R01 EB012521, R01EB012521]; NIDDK NIH HHS [K01 DK087770, K01DK087770] NR 102 TC 8 Z9 8 U1 0 U2 24 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1523-9829 BN 978-0-8243-3515-1 J9 ANNU REV BIOMED ENG JI Annu. Rev. Biomed. Eng. PY 2013 VL 15 BP 305 EP 326 DI 10.1146/annurev-bioeng-071811-150050 PG 22 WC Engineering, Biomedical SC Engineering GA BGR49 UT WOS:000323896000014 PM 23862677 ER PT S AU Homer, ML Nurmikko, AV Donoghue, JP Hochberg, LR AF Homer, Mark L. Nurmikko, Arto V. Donoghue, John P. Hochberg, Leigh R. BE Yarmush, ML TI Sensors and Decoding for Intracortical Brain Computer Interfaces SO ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 15 SE Annual Review of Biomedical Engineering LA English DT Review; Book Chapter DE brain machine interfaces; multielectrode arrays; signal processing; neural engineering ID LOCAL-FIELD POTENTIALS; PRIMARY MOTOR CORTEX; POSTERIOR PARIETAL CORTEX; NEURAL RECORDING-SYSTEM; SPIKING ACTIVITY; MICROELECTRODE ARRAYS; MACHINE INTERFACES; VOLUNTARY MOVEMENT; PROSTHETIC DEVICES; MULTIUNIT ACTIVITY AB Intracortical brain computer interfaces (iBCIs) are being developed to enable people to drive an output device, such as a computer cursor, directly from their neural activity. One goal of the technology is to help people with severe paralysis or limb loss. Key elements of an iBCI are the implanted sensor that records the neural signals and the software that decodes the user's intended movement from those signals. Here, we focus on recent advances in these two areas, placing special attention on contributions that are or may soon be adopted by the iBCI research community. We discuss how these innovations increase the technology's capability, accuracy, and longevity, all important steps that are expanding the range of possible future clinical applications. C1 [Homer, Mark L.] Brown Univ, Providence, RI 02912 USA. [Nurmikko, Arto V.; Hochberg, Leigh R.] Brown Univ, Sch Engn, Providence, RI 02912 USA. [Donoghue, John P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Donoghue, John P.; Hochberg, Leigh R.] Vet Affairs Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI 02908 USA. [Hochberg, Leigh R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. RP Homer, ML (reprint author), Brown Univ, Providence, RI 02912 USA. EM Leigh_Hochberg@brown.edu OI Hochberg, Leigh/0000-0003-0261-2273 FU NIBIB NIH HHS [R01 EB007401, R01EB007401-01]; NIDCD NIH HHS [R01DC009899, R01 DC009899] NR 118 TC 27 Z9 27 U1 6 U2 38 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1523-9829 BN 978-0-8243-3515-1 J9 ANNU REV BIOMED ENG JI Annu. Rev. Biomed. Eng. PY 2013 VL 15 BP 383 EP 405 DI 10.1146/annurev-bioeng-071910-124640 PG 23 WC Engineering, Biomedical SC Engineering GA BGR49 UT WOS:000323896000017 PM 23862678 ER PT J AU Smith, M Murphy, D Laxmisan, A Sittig, D Reis, B Esquivel, A Singh, H AF Smith, M. Murphy, D. Laxmisan, A. Sittig, D. Reis, B. Esquivel, A. Singh, H. TI Developing Software to "Track and Catch" Missed Follow-up of Abnormal Test Results in a Complex Sociotechnical Environment SO APPLIED CLINICAL INFORMATICS LA English DT Article DE Diagnostic errors; patient safety; test results; care delays; health information technology ID HEALTH INFORMATION-TECHNOLOGY; ELECTRONIC-MEDICAL-RECORDS; CANCER-DIAGNOSIS; TASK-ANALYSIS; ORDER ENTRY; CARE; SAFETY; SYSTEMS; DESIGN; ERRORS AB Background: Abnormal test results do not always receive timely follow-up, even when providers are notified through electronic health record (EHR)-based alerts. High workload, alert fatigue, and other demands on attention disrupt a provider's prospective memory for tasks required to initiate follow-up. Thus, EHR-based tracking and reminding functionalities are needed to improve follow-up. Objectives: The purpose of this study was to develop a decision-support software prototype enabling individual and system-wide tracking of abnormal test result alerts lacking follow-up, and to conduct formative evaluations, including usability testing. Methods: We developed a working prototype software system, the Alert Watch And Response Engine (AWARE), to detect abnormal test result alerts lacking documented follow-up, and to present context-specific reminders to providers. Development and testing took place within the VA's EHR and focused on four cancer-related abnormal test results. Design concepts emphasized mitigating the effects of high workload and alert fatigue while being minimally intrusive. We conducted a multifaceted formative evaluation of the software, addressing fit within the larger socio-technical system. Evaluations included usability testing with the prototype and interview questions about organizational and workflow factors. Participants included 23 physicians, 9 clinical information technology specialists, and 8 quality/safety managers. Results: Evaluation results indicated that our software prototype fit within the technical environment and clinical workflow, and physicians were able to use it successfully. Quality/safety managers reported that the tool would be useful in future quality assurance activities to detect patients who lack documented follow-up. Additionally, we successfully installed the software on the local facility's "test" EHR system, thus demonstrating technical compatibility. Conclusion: To address the factors involved in missed test results, we developed a software prototype to account for technical, usability, organizational, and workflow needs. Our evaluation has shown the feasibility of the prototype as a means of facilitating better follow-up for cancer-related abnormal test results. C1 [Smith, M.; Murphy, D.; Laxmisan, A.; Reis, B.; Singh, H.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA. [Smith, M.; Murphy, D.; Laxmisan, A.; Reis, B.; Singh, H.] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Smith, M.; Murphy, D.; Laxmisan, A.; Reis, B.; Singh, H.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Sittig, D.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA. [Sittig, D.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Esquivel, A.] St Lukes Episcopal Hlth Syst, Dept Clin Effectiveness & Performance Measurement, Houston, TX USA. RP Smith, M (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM ms6@bcm.edu FU VA Innovation Initiative [XNV 33-124]; VA National Center of Patient Safety; Houston VA HSR&D Center of Excellence [HFP90-020] FX The authors wish to acknowledge the expert contributions of: Dana Douglas, Mark Becker, and Dick Horst of UserWorks, Inc.; Bryan Campbell and Angela Schmeidel Randall of Normal Modes, LLC; and Ignacio Valdes and Fred Trotter of Astronaut Contracting, LLC. Additional thanks to Velma Payne, Varsha Modi, Kathy Taylor, Roxie Pierce, Pawan Gulati, and George Welch. Project supported by the VA Innovation Initiative (XNV 33-124), VA National Center of Patient Safety and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. There are no conflicts of interest for any authors. NR 59 TC 7 Z9 7 U1 3 U2 12 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 1869-0327 J9 APPL CLIN INFORM JI Appl. Clin. Inform. PY 2013 VL 4 IS 3 BP 359 EP 375 DI 10.4338/ACI-2013-04-RA-0019 PG 17 WC Medical Informatics SC Medical Informatics GA 215TZ UT WOS:000324234800004 PM 24155789 ER PT J AU Reisner, AT Khitrov, MY Chen, L Blood, A Wilkins, K Doyle, W Wilcox, S Denison, T Reifman, J AF Reisner, A. T. Khitrov, M. Y. Chen, L. Blood, A. Wilkins, K. Doyle, W. Wilcox, S. Denison, T. Reifman, J. TI Development and Validation of a Portable Platform for Deploying Decision-Support Algorithms in Prehospital Settings SO APPLIED CLINICAL INFORMATICS LA English DT Article DE Decision-support algorithms; prehospital care; device connectivity; vital-sign data; combat casualty care ID COMBAT CASUALTY CARE; TRAUMA PATIENTS; DEATH AB Background: Advanced decision-support capabilities for prehospital trauma care may prove effective at improving patient care. Such functionality would be possible if an analysis platform were connected to a transport vital-signs monitor. In practice, there are technical challenges to implementing such a system. Not only must each individual component be reliable, but, in addition, the connectivity between components must be reliable. Objective: We describe the development, validation, and deployment of the Automated Processing of Physiologic Registry for Assessment of Injury Severity (APPRAISE) platform, intended to serve as a test bed to help evaluate the performance of decision-support algorithms in a prehospital environment. Methods: We describe the hardware selected and the software implemented, and the procedures used for laboratory and field testing. Results: The APPRAISE platform met performance goals in both laboratory testing (using a vital-sign data simulator) and initial field testing. After its field testing, the platform has been in use on Boston MedFlight air ambulances since February of 2010. Conclusion: These experiences may prove informative to other technology developers and to healthcare stakeholders seeking to invest in connected electronic systems for prehospital as well as in-hospital use. Our experiences illustrate two sets of important questions: are the individual components reliable (e. g., physical integrity, power, core functionality, and end-user interaction) and is the connectivity between components reliable (e. g., communication protocols and the metadata necessary for data interpretation)? While all potential operational issues cannot be fully anticipated and eliminated during development, thoughtful design and phased testing steps can reduce, if not eliminate, technical surprises. C1 [Reisner, A. T.; Khitrov, M. Y.; Chen, L.; Reifman, J.] USAMRMC, TATRC, Biotechnol High Performance Comp Software Applica, Ft Detrick, MD 21702 USA. [Reisner, A. T.; Blood, A.; Wilcox, S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Wilkins, K.; Doyle, W.; Wilcox, S.; Denison, T.] Boston MedFlight, Bedford, MA USA. RP Reifman, J (reprint author), USAMRMC, TATRC, BHSAI, ATTN MCMR TT, 504 Scott St, Ft Detrick, MD 21702 USA. EM jaques.reifman.civ@mail.mil FU U.S. Department of Defense Medical Research and Development Program [D10_I_AR_JG_773]; Combat Casualty Care Research Area Directorate of the U.S. Army Medical Research and Materiel Command, Fort Detrick, MD FX This work was sponsored by the U.S. Department of Defense Medical Research and Development Program (Grant # D10_I_AR_JG_773) and by the Combat Casualty Care Research Area Directorate of the U.S. Army Medical Research and Materiel Command, Fort Detrick, MD. NR 15 TC 3 Z9 3 U1 1 U2 2 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 1869-0327 J9 APPL CLIN INFORM JI Appl. Clin. Inform. PY 2013 VL 4 IS 3 BP 392 EP 402 DI 10.4338/ACI-2013-04-RA-0023 PG 11 WC Medical Informatics SC Medical Informatics GA 215TZ UT WOS:000324234800006 PM 24155791 ER PT J AU Bilenca, A Bouma, B Tearney, G Marki, I Bocchio, N Geissbuehler, S Lasser, T AF Bilenca, Alberto Bouma, Brett Tearney, Guillermo Maerki, Iwan Bocchio, Noelia Geissbuehler, Stefan Lasser, Theo BE Shaked, NT Zalevsky, Z Satterwhite, LL TI Fluorescence Phase Microscopy (FPM) and Nanoscopy SO BIOMEDICAL OPTICAL PHASE MICROSCOPY AND NANOSCOPY LA English DT Article; Book Chapter ID OPTICAL COHERENCE TOMOGRAPHY; IN-VIVO; ILLUMINATION MICROSCOPY; SELF-INTERFERENCE; AXIAL RESOLUTION; LOCALIZATION; DYNAMICS; NM; RECONSTRUCTION; SCATTERING C1 [Bilenca, Alberto] Ben Gurion Univ Negev, Dept Biomed Engn, IL-84105 Beer Sheva, Israel. [Bouma, Brett; Tearney, Guillermo] Harvard Univ, Sch Med, Boston, MA USA. [Bouma, Brett; Tearney, Guillermo] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Bouma, Brett] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Tearney, Guillermo] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Maerki, Iwan; Bocchio, Noelia; Geissbuehler, Stefan; Lasser, Theo] Ecole Polytech Fed Lausanne, Lab Opt Biomed, Lausanne, Switzerland. RP Bilenca, A (reprint author), Ben Gurion Univ Negev, Dept Biomed Engn, IL-84105 Beer Sheva, Israel. NR 47 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-415886-3 PY 2013 BP 387 EP 404 PG 18 WC Engineering, Biomedical; Microscopy SC Engineering; Microscopy GA BGM79 UT WOS:000323522300019 ER PT J AU Chaparro, LE Furlan, AD Deshpande, A Mailis-Gagnon, A Atlas, S Turk, DC AF Enrique Chaparro, Luis Furlan, Andrea D. Deshpande, Amol Mailis-Gagnon, Angela Atlas, Steven Turk, Dennis C. TI Opioids compared to placebo or other treatments for chronic low-back pain SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Analgesics, Opioid [adverse effects; therapeutic use]; Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; Chronic Disease; Low Back Pain [drug therapy]; Morphine [therapeutic use]; Naproxen [therapeutic use]; Randomized Controlled Trials as Topic; Tramadol [adverse effects; therapeutic use]; Humans ID CHRONIC NONCANCER PAIN; OXYMORPHONE EXTENDED-RELEASE; BUPRENORPHINE TRANSDERMAL SYSTEM; TRAMADOL/ACETAMINOPHEN COMBINATION TABLETS; NONSTEROIDAL ANTIINFLAMMATORY DRUG; CHRONIC NONMALIGNANT PAIN; UPDATED METHOD GUIDELINES; CONTROLLED PHASE-III; DOUBLE-BLIND; CONTROLLED-TRIAL AB Background The use of opioids in the long-term management of chronic low-back pain (CLBP) has increased dramatically. Despite this trend, the benefits and risks of these medications remain unclear. This review is an update of a Cochrane review first published in 2007. Objectives To determine the efficacy of opioids in adults with CLBP. Search methods We electronically searched theCochrane Back ReviewGroup's SpecializedRegister, CENTRAL, CINAHL and PsycINFO, MEDLINE, and EMBASE from January 2006 to October 2012. We checked the reference lists of these trials and other relevant systematic reviews for potential trials for inclusion. Selection criteria We included randomized controlled trials (RCTs) that assessed the use of opioids (as monotherapy or in combination with other therapies) in adults with CLBP that were at least four weeks in duration. We included trials that compared non-injectable opioids to placebo or other treatments. We excluded trials that compared different opioids only. Data collection and analysis Two authors independently assessed the risk of bias and extracted data onto a pre-designed form. We pooled results using Review Manager (RevMan) 5.2. We reported on pain and function outcomes using standardized mean difference (SMD) or risk ratios with 95% confidence intervals (95% CI). We used absolute risk difference (RD) with 95% CI to report adverse effects. Main results We included 15 trials (5540 participants). Tramadol was examined in five trials (1378 participants); it was found to be better than placebo for pain (SMD-0.55, 95% CI -0.66 to -0.44; low quality evidence) and function (SMD -0.18, 95% CI -0.29 to -0.07; moderate quality evidence). Transdermal buprenorphine (two trials, 653 participants) may make little difference for pain (SMD -2.47, 95% CI 2.69 to -2.25; very low quality evidence), but no difference compared to placebo for function (SMD-0.14, 95% CI -0.53 to 0.25; very low quality evidence). Strong opioids (morphine, hydromorphone, oxycodone, oxymorphone, and tapentadol), examined in six trials (1887 participants), were better than placebo for pain (SMD -0.43, 95% CI -0.52 to -0.33; moderate quality evidence) and function (SMD -0.26, 95% CI -0.37 to -0.15; moderate quality evidence). One trial (1583 participants) demonstrated that tramadol may make little difference compared to celecoxib (RR 0.82, 95% CI 0.76 to 0.90; very low quality evidence) for pain relief. Two trials (272 participants) found no difference between opioids and antidepressants for either pain (SMD 0.21, 95% CI -0.03 to 0.45; very low quality evidence), or function (SMD -0.11, 95% -0.63 to 0.42; very low quality evidence). The included trials in this review had high drop-out rates, were of short duration, and had limited interpretability of functional improvement. They did not report any serious adverse effects, risks (addiction or overdose), or complications (sleep apnea, opioid-induced hyperalgesia, hypogonadism). In general, the effect sizes were medium for pain and small for function. Authors' conclusions There is some evidence (very low to moderate quality) for short-term efficacy (for both pain and function) of opioids to treat CLBP compared to placebo. The very few trials that compared opioids to non-steroidal anti-inflammatory drugs (NSAIDs) or antidepressants did not show any differences regarding pain and function. The initiation of a trial of opioids for long-term management should be done with extreme caution, especially after a comprehensive assessment of potential risks. There are no placebo-RCTs supporting the effectiveness and safety of long-term opioid therapy for treatment of CLBP. C1 [Enrique Chaparro, Luis] Hosp Pablo Tobon Uribe, Dept Anesthesiol, Medellin, Colombia. [Furlan, Andrea D.] Inst Work & Hlth, Toronto, ON, Canada. [Deshpande, Amol] Univ Hlth Network, TWH Comprehens Pain Unit, Toronto, ON, Canada. [Mailis-Gagnon, Angela] Toronto Western Hosp, Dept Med, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada. [Atlas, Steven] Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Boston, MA 02114 USA. [Turk, Dennis C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. RP Chaparro, LE (reprint author), Hosp Pablo Tobon Uribe, Dept Anesthesiol, Medellin, Colombia. EM luisdr74@yahoo.com FU Canadian Institutes for Health Research, Canada; CiHR [2012-2017] FX Internal sources; Canadian Institutes for Health Research, Canada.; Andrea Furlan received a New Investigator Award from CiHR (2012-2017) NR 98 TC 25 Z9 25 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 8 AR UNSP CD004959 DI 10.1002/14651858.CD004959.pub4 PG 102 WC Medicine, General & Internal SC General & Internal Medicine GA 211RT UT WOS:000323928600030 PM 23983011 ER PT J AU Wang, XL Chan, ST Fang, JL Nixon, EE Liu, J Kwong, KK Rosen, BR Hui, KKS AF Wang, Xiaoling Chan, Suk-Tak Fang, Jiliang Nixon, Erika E. Liu, Jing Kwong, Kenneth K. Rosen, Bruce R. Hui, Kathleen K. S. TI Neural Encoding of Acupuncture Needling Sensations: Evidence from a fMRI Study SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID HUMAN CORPUS-CALLOSUM; BRAINS DEFAULT NETWORK; AFFERENT NERVE-FIBERS; PARKINSONS-DISEASE; MANUAL ACUPUNCTURE; LIMBIC SYSTEM; WHITE-MATTER; 2ND PAIN; C-FIBERS; STIMULATION AB Deqi response, a psychophysical response characterized by a spectrum of different needling sensations, is essential for Chinese acupuncture clinical efficacy. Previous neuroimaging research works have investigated the neural correlates of an overall deqi response by summating the scores of different needling sensations. However, the roles of individual sensations in brain activity and how they interact with each other remain to be clarified. In this study, we applied fMRI to investigate the neural correlates of individual components of deqi during acupuncture on the right LV3 (Taichong) acupoint. We selected a subset of deqi responses, namely, pressure, heaviness, fullness, numbness, and tingling. Using the individual components of deqi of different subjects as covariates in the analysis of percentage change of bold signal, pressure was found to be a striking sensation, contributing to most of negative activation of a limbic-paralimbic-neocortical network (LPNN). The similar or opposite neural activity in the heavily overlapping regions is found to be responding to different needling sensations, including bilateral LPNN, right orbitofrontal cortex, and bilateral posterior parietal cortex. These findings provide the neuroimaging evidence of how the individual needle sensations interact in the brain, showing that the modulatory effects of different needling sensations contribute to acupuncture modulations of LPNN network. C1 [Wang, Xiaoling; Fang, Jiliang] China Acad Chinese Med Sci, Guang An Men Hosp, Dept Radiol, Beijing 100053, Peoples R China. [Wang, Xiaoling; Chan, Suk-Tak; Fang, Jiliang; Nixon, Erika E.; Liu, Jing; Kwong, Kenneth K.; Rosen, Bruce R.; Hui, Kathleen K. S.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Wang, Xiaoling; Chan, Suk-Tak; Fang, Jiliang; Nixon, Erika E.; Liu, Jing; Kwong, Kenneth K.; Rosen, Bruce R.; Hui, Kathleen K. S.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Chan, ST (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM phoebe@nmr.mgh.harvard.edu RI Chan, Suk-tak/G-5846-2015 FU National Institutes of Health, National Center for Complementary and Alternative Medicine [R21 AT00978, 1-PO1-002048-01, F05 AT003022]; National Center for Research Resources [P41 RR14075, U54 EB005149, 424 RR021382]; Human Brain Project Grant [NS34189]; Mental Illness and Neuroscience Discovery Institute (MIND); National Natural Science Foundation of China [81273674] FX This work was supported by funding from the National Institutes of Health, National Center for Complementary and Alternative Medicine (R21 AT00978, 1-PO1-002048-01, and F05 AT003022), the National Center for Research Resources (P41 RR14075, U54 EB005149, and 424 RR021382), the Human Brain Project Grant (NS34189), the Mental Illness and Neuroscience Discovery Institute (MIND), and the National Natural Science Foundation of China (2013-2016) (Grant no. 81273674). There is no conflict of interests for any author. NR 66 TC 0 Z9 0 U1 0 U2 8 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 483105 DI 10.1155/2013/483105 PG 15 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 215CF UT WOS:000324186100001 ER PT J AU Franciosa, M Triadafilopoulos, G Mashimo, H AF Franciosa, Mark Triadafilopoulos, George Mashimo, Hiroshi TI Stretta Radiofrequency Treatment for GERD: A Safe and Effective Modality SO GASTROENTEROLOGY RESEARCH AND PRACTICE LA English DT Review ID GASTROESOPHAGEAL-REFLUX DISEASE; LAPAROSCOPIC ANTIREFLUX SURGERY; RANDOMIZED CLINICAL-TRIAL; PROTON PUMP INHIBITORS; 4-YEAR FOLLOW-UP; ENERGY DELIVERY; ACID EXPOSURE; DRUG-USE; SYMPTOMS; JUNCTION AB Gastroesophageal reflux disease is one of the leading gastrointestinal disorders. Current treatments include lifestyle modifications, pharmacological therapies, surgical fundoplications, and, more recently, endoscopic procedures. The rising concern of long-term side effects of the popular proton-pump inhibitors and the more recent evidence raising doubts about the durability of fundoplication have spurred reinterest in endoscopic procedures to treat reflux disorders. In the aftermath of several innovative antireflux procedures that were introduced and failed clinically or financially over the past decade, there is lingering confusion regarding the merits of the presently available interventions. This paper focuses on one endoscopic procedure, Stretta, which now enjoys the longest experience, a recent meta-analysis, and robust data supporting its safety, efficacy, and durability. Stretta reduces esophageal acid exposure, decreases the frequency of transient lower esophageal relaxation, increases patient satisfaction, decreases medication use, and improves quality of life. As such, this procedure remains a valuable nonsurgical treatment option in the management of gastroesophageal reflux disease. C1 [Franciosa, Mark; Mashimo, Hiroshi] Harvard Univ, Sch Med, Ctr Swallowing & Motil Disorders, VA Boston Healthcare Syst, Boston, MA 02132 USA. [Triadafilopoulos, George] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94040 USA. RP Mashimo, H (reprint author), Harvard Univ, Sch Med, Ctr Swallowing & Motil Disorders, VA Boston Healthcare Syst, Boston, MA 02132 USA. EM hmashimo@hms.harvard.edu OI Triadafilopoulos, George/0000-0002-4233-3773 NR 34 TC 10 Z9 10 U1 0 U2 0 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-6121 J9 GASTROENT RES PRACT JI Gastroenterol. Res. Pract. PY 2013 AR 783815 DI 10.1155/2013/783815 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 218JM UT WOS:000324428700001 ER PT J AU Huber, BR Meabon, JS Martin, TJ Mourad, PD Bennett, R Kraemer, BC Cernak, I Petrie, EC Emery, MJ Swenson, ER Mayer, C Mehic, E Peskind, ER Cook, DG AF Huber, Bertrand R. Meabon, James S. Martin, Tobin J. Mourad, Pierre D. Bennett, Raymond Kraemer, Brian C. Cernak, Ibolja Petrie, Eric C. Emery, Michael J. Swenson, Erik R. Mayer, Cynthia Mehic, Edin Peskind, Elaine R. Cook, David G. TI Blast Exposure Causes Early and Persistent Aberrant Phospho- and Cleaved-Tau Expression in a Murine Model of Mild Blast-Induced Traumatic Brain Injury SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Blast-induced neurotrauma; brain trauma; cerebellum; mitochondrial oxidative stress; neurodegeneration; tauopathy ID HEAD-INJURY; CASPASE ACTIVATION; MOUSE MODEL; ENCEPHALOPATHY; DISEASE; STRESS; HYPERPHOSPHORYLATION; OVERPRESSURE; AFGHANISTAN; INVOLVEMENT AB Mild traumatic brain injury (mTBI) is considered the 'signature injury' of combat veterans that have served during the wars in Iraq and Afghanistan. This prevalence of mTBI is due in part to the common exposure to high explosive blasts in combat zones. In addition to the threats of blunt impact trauma caused by flying objects and the head itself being propelled against objects, the primary blast overpressure (BOP) generated by high explosives is capable of injuring the brain. Compared to other means of causing TBI, the pathophysiology of mild-to-moderate BOP is less well understood. To study the consequences of BOP exposure in mice, we employed a well-established approach using a compressed gas-driven shock tube that recapitulates battlefield-relevant open-field BOP. We found that 24 hours post-blast a single mild BOP provoked elevation of multiple phospho- and cleaved-tau species in neurons, as well as elevating manganese superoxide-dismutase (MnSOD or SOD2) levels, a cellular response to oxidative stress. In hippocampus, aberrant tau species persisted for at least 30 days post-exposure, while SOD2 levels returned to sham control levels. These findings suggest that elevated phospho- and cleaved-tau species may be among the initiating pathologic processes induced by mild blast exposure. These findings may have important implications for efforts to prevent blast-induced insults to the brain from progressing into long-term neurodegenerative disease processes. C1 [Huber, Bertrand R.; Petrie, Eric C.; Mayer, Cynthia; Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Northwest Network Mental Illness Res Educ & Clin, Seattle, WA USA. [Meabon, James S.; Petrie, Eric C.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Meabon, James S.; Martin, Tobin J.; Kraemer, Brian C.; Cook, David G.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Mourad, Pierre D.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Mourad, Pierre D.] Univ Washington, Appl Phys Lab, Seattle, WA 98105 USA. [Mourad, Pierre D.; Mehic, Edin] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA. [Bennett, Raymond] Baker Engn & Risk Consultants, San Antonio, TX USA. [Kraemer, Brian C.; Cook, David G.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2M7, Canada. [Emery, Michael J.; Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Swenson, Erik R.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA USA. [Cook, David G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. RP Cook, DG (reprint author), 1660 S Columbian Way, Seattle, WA 98108 USA. EM dgcook@u.washington.edu FU Department of Veterans Affairs Office of Research and Development Medical Research Service; University of Washington Friends of Alzheimer's Research; University of Washington Royalty Research Fund; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; NIH [T32 AG000258] FX This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (DGC, ERP, BCK), University of Washington Friends of Alzheimer's Research (DGC, ERP), University of Washington Royalty Research Fund (DGC); Northwest Network Mental Illness Research, Education and Clinical Center (ERP), Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (BRH); NIH T32 AG000258 (JSM); None of the authors have financial or other potential conflicts of interest regarding this report. NR 47 TC 35 Z9 35 U1 6 U2 23 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 37 IS 2 BP 309 EP 323 DI 10.3233/JAD-130182 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 217EA UT WOS:000324338400006 PM 23948882 ER PT J AU Thomas, RJ Bianchi, MT AF Thomas, Robert Joseph Bianchi, Matt Travis TI Changing the Direction of Sleep Medicine: Business can Boom, but it is Not as Usual SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Letter ID APNEA; HOME; DIAGNOSIS C1 [Thomas, Robert Joseph] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA. [Bianchi, Matt Travis] Massachusetts Gen Hosp, Dept Neurol, Div Sleep Med, Boston, MA 02114 USA. RP Thomas, RJ (reprint author), Beth Israel Deaconess Med Ctr, Pulm Off, KB 023,330 Brookline Ave, Boston, MA 02215 USA. EM rthomas1@bidmc.harvard.edu NR 15 TC 3 Z9 3 U1 0 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2013 VL 9 IS 9 BP 977 EP 979 DI 10.5664/jcsm.3014 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 217QQ UT WOS:000324375100021 PM 23997714 ER PT J AU Brundin, P Barker, RA Conn, PJ Dawson, TM Kieburtz, K Lees, AJ Schwarzschild, MA Tanner, CM Isaacs, T Duffen, J Matthews, H Wyse, RKH AF Brundin, Patrik Barker, Roger A. Conn, P. Jeffrey Dawson, Ted M. Kieburtz, Karl Lees, Andrew J. Schwarzschild, Michael A. Tanner, Caroline M. Isaacs, Tom Duffen, Joy Matthews, Helen Wyse, Richard K. H. TI Linked Clinical Trials - The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments SO JOURNAL OF PARKINSONS DISEASE LA English DT Review DE Drug repositioning; disease modification; neuroprotection ID DRUG DISCOVERY; DOPAMINERGIC-NEURONS; ANIMAL-MODEL; EXENDIN-4; FUTILITY; TARGETS; MINOCYCLINE; CREATINE; SEARCH; DAMAGE AB Finding new therapies for Parkinson's disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used, or being developed, in other therapeutic areas, as well as considering several natural, non-pharmaceutical compounds. The committee prioritized which of these putative treatments were most suited to move immediately into pilot clinical trials. Aspects considered included known modes of action, safety, blood-brain-barrier penetration, preclinical data in animal models of PD and the possibility to monitor target engagement in the brain. Of the 26 potential interventions, 10 were considered worth moving forward into small, parallel 'learning' clinical trials in PD patients. These trials could be funded in a multitude of ways through support from industry, research grants and directed philanthropic donations. The committee-based approach to select the candidate compounds might help rapidly identify new potential PD treatment strategies for use in clinical trials. C1 [Brundin, Patrik] Van Andel Inst, Ctr Neurodegenerat Sci, Grand Rapids, MI 49503 USA. [Barker, Roger A.] Cambridge Ctr Brain Repair, Cambridge, England. [Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN USA. [Dawson, Ted M.] Johns Hopkins Univ, Inst Cell Engn, Baltimore, MD USA. [Kieburtz, Karl] Univ Rochester, Med Ctr, Ctr Human Exp Therapeut, Rochester, NY 14642 USA. [Lees, Andrew J.] UCL, Reta Lila Weston Inst Neurol Studies, London, England. [Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Tanner, Caroline M.] Parkinsons Inst & Clin Ctr, Sunnyvale, CA USA. [Isaacs, Tom; Duffen, Joy; Matthews, Helen; Wyse, Richard K. H.] Cure Parkinsons Trust, Sarratt, Herts, England. RP Brundin, P (reprint author), Van Andel Res Inst, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA. EM Patrik.Brundin@vai.org RI Lees, Andrew/A-6605-2009 FU Bristol Myers Squibb; Astrazeneca; NIH/NINDS; NIH/NIDA; Maryland Stem Cell Research Foundation; Adrienne Helis Malvin Medical Research Foundation; JPB Foundation; Medivation; Michael J Fox Foundation; National Insitutes of Health (NEI); National Insitutes of Health (NINDS); National Insitutes of Health (NIA); National Insitutes of Health (NICHD); Neurosearch FX PB is a paid consultant for Neuronova AB, H Lundbeck A/S, TEVA Pharmaceuticals and Renovo Neural Inc. He is a cofounder of the biotechnology companies ParkCell AB and Acousort AB. His research team collaborates with Bioartic Neuroscience AB and has a funded collaboration with Metabolic Development Solutions Company. PJC receives research support from Bristol Myers Squibb and Astrazeneca. TMD is supported by grants from the NIH/NINDS, NIH/NIDA, Maryland Stem Cell Research Foundation, Adrienne Helis Malvin Medical Research Foundation and the JPB Foundation. He is also a paid consultant to Merck KGAA. KK is a consultant for the National Institute of Neurological Disorders and Stroke (NINDS), The US Food and Drug Administration, the US Veteran's Administration, Abbott, Acorda, Aptiv, AstraZeneca, Auspex, Biogen Idec, Biotie, Biovail, Boehringer Ingelheim, Celgene, Ceregene, CHDI, Civitas, Clintrex, Cynapsus, Endo, Impax, Intec, Ipsen, Isis, Knopp, Lilly, Link Medicine, Lundbeck, LZ Therapeutics, Medivation, Merck, Merz, Neotope/Elan Pharaceutical, Novartis, Orion, Otsuka, Pharm2B, Phytopharm, Schering-Plough, Roche, Siena Biotech, Soffinova, Synagile, Synosia, Teva, UCB Pharma, Upsher-Smith, Vaccinex, Vectura and Xenoport; he receives grants or research support from Medivation, Michael J Fox Foundation, National Insitutes of Health (NEI, NINDS, NIA, NICHD) and Neurosearch, and does legal consulting for Thompson Hine. AJL is a consultant for Britannia pharmaceuticals, and has received honoraria from Roche, Ipsen, Boehringer Ingelheim and Bial. CMT has consultancies with Impax, Abbvie and Adamas pharmaceuticals with all fees going to her institution. RAB, MAS, TI, JD, HM, and RKHW have no competing interests. NR 34 TC 7 Z9 7 U1 1 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2013 VL 3 IS 3 BP 231 EP 239 DI 10.3233/JPD-139000 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 218AN UT WOS:000324405000001 PM 24018336 ER PT J AU Spindler, M Gooneratne, NS Siderowf, A Duda, JE Cantor, C Dahodwala, N AF Spindler, Meredith Gooneratne, Nalaka S. Siderowf, Andrew Duda, John E. Cantor, Charles Dahodwala, Nabila TI Daytime Sleepiness is Associated with Falls in Parkinson's Disease SO JOURNAL OF PARKINSONS DISEASE LA English DT Article DE Parkinson's disease; falls; sleepiness; depression; cognitive impairment ID MINI-MENTAL-STATE; DOPAMINERGIC TREATMENT; OLDER-PEOPLE; FATIGUE; DISORDERS; DEPRESSION; FREQUENCY; DEMENTIA; INSOMNIA; QUALITY AB Falls are frequent in Parkinson's disease (PD), and may be influenced by daytime sleepiness. We reviewed the records of 120 men with PD. Mean Epworth Sleepiness Scale (ESS) values were significantly different between non-fallers and fallers (6.0 vs. 9.7, p < 0.01). In multivariate analysis, ESS remained significantly associated with falls (OR 1.2, 95% CI 1.1-1.4, p = 0.02), along with cognitive impairment (OR 4.4 95% CI 1.0-18.7, p = 0.04) and postural instability/gait dysfunction (OR 1.6 95% CI 1.0-2.4, p = 0.03) in non-depressed patients. In conclusion, non-depressed PD patients are 20% more likely to fall for every one unit increase in the ESS measure of sleepiness. C1 [Spindler, Meredith; Duda, John E.; Cantor, Charles; Dahodwala, Nabila] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19107 USA. [Spindler, Meredith; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Gooneratne, Nalaka S.] Univ Penn, Perelman Sch Med, Dept Med, Div Geriatr Med, Philadelphia, PA 19107 USA. [Gooneratne, Nalaka S.; Cantor, Charles] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19107 USA. [Gooneratne, Nalaka S.; Cantor, Charles] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19107 USA. [Siderowf, Andrew] Avid Radiopharmaceut Inc, Philadelphia, PA USA. RP Dahodwala, N (reprint author), Univ Penn, Sch Med, Parkinsons Dis & Movement Disorders Ctr, 330S 9th St, Philadelphia, PA 19107 USA. EM dahodwan@mail.med.upenn.edu FU Parkinson's Disease Research, Education and Clinical Center of the Philadelphia Veterans Affairs Medical Center; NIH [K23 AG034236] FX Funding for this project has been provided by the following: 1) Pilot Project Award from the Parkinson's Disease Research, Education and Clinical Center of the Philadelphia Veterans Affairs Medical Center; 2) NIH grant K23 AG034236 (Dahodwala). The information contained in this paper does not necessarily reflect the position or the policy of the United States Government, and no official endorsement should be inferred. NR 43 TC 0 Z9 1 U1 2 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2013 VL 3 IS 3 BP 387 EP 391 DI 10.3233/JPD-130184 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 218AN UT WOS:000324405000014 PM 23948992 ER PT J AU Zhang, J Da Zhang AF Zhang, Jie Da Zhang TI Image performance evaluation of a cone beam O-arm imaging system SO JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY LA English DT Article DE O-arm; cone-beam computed tomography (CT); modulation transfer function (MTF); noise power spectrum (NPS); performance; flat panel detector (FPD) ID NOISE POWER SPECTRUM; MODERN DIAGNOSTIC MDCT; X-RAY TARGETS; COMPUTED-TOMOGRAPHY; PART II; CT; TUBE AB Image performance of a cone beam O-arm system with the use of a Varian flat panel detector (PaxScan 4030CB) was evaluated. Modulation Transfer Function (MTF), Noise Power Spectrum (NPS), and tube output characteristics were measured. Image quality measurements were performed with a CATPHAN 424 phantom using a 120 kVp beam filtered with 1 mm Al and 0.1 mm Cu and three preset protocols at different exposure levels. The CPT445 Module was used to measure MTF. Water phantom images were used to calculate NPS. Then the NPS was normalized by dividing the square of the mean signal. The Photon fluence at each exposure (q) was estimated using the SpekCalc. The MTF indicates that the reconstruction filter of the O-arm is overenhancing, meaning that it yields values greater than unity. The system has a 10% MTF at 0.45 mm. The NPS shows the low frequency structured noise. The evaluation of image performance of the O-arm imaging system helps its future improvements and clinical applications. C1 [Zhang, Jie] Univ Kentucky, Dept Radiol, Div Med Phys, Lexington, KY 40536 USA. [Da Zhang] Massachusetts Gen Hosp, Div Diagnost Imaging Phys, Boston, MA 02114 USA. [Da Zhang] Massachusetts Gen Hosp, Dept Radiol, Webster Ctr Adv Res & Educ Radiat, Boston, MA 02114 USA. RP Zhang, J (reprint author), Univ Kentucky, Dept Radiol, Div Med Phys, 800 Rose St,HX311A, Lexington, KY 40536 USA. EM jnzh222@uky.edu NR 27 TC 0 Z9 0 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0895-3996 J9 J X-RAY SCI TECHNOL JI J. X-Ray Sci. Technol. PY 2013 VL 21 IS 3 BP 373 EP 380 DI 10.3233/XST-130385 PG 8 WC Instruments & Instrumentation; Optics; Physics, Applied SC Instruments & Instrumentation; Optics; Physics GA 216QE UT WOS:000324298000005 PM 24004867 ER PT J AU Metelev, V Zhang, SR Tabatadze, D Kumar, ATN Bogdanov, A AF Metelev, Valeri Zhang, Surong Tabatadze, David Kumar, Anand T. N. Bogdanov, Alexei, Jr. TI The three-dimensional context of a double helix determines the fluorescence of the internucleoside-tethered pair of fluorophores SO MOLECULAR BIOSYSTEMS LA English DT Article ID RESONANCE ENERGY-TRANSFER; DNA INTERACTIONS; MOLECULAR BEACONS; LIVING CELLS; BINDING; FRET; HYBRIDIZATION; ORIENTATION; RESOLUTION; PROBES AB We report a general phenomenon of the formation of either a fluorescent or an entirely quenched oligodeoxynucleotide (ODN) duplex system by hybridizing pairs of complementary ODNs with identical chemical composition. The ODNs carried internucleoside tether-linked cyanines, where the cyanines were chosen to form a Forster's resonance energy transfer (FRET) donor-acceptor pair. The fluorescent and quenched ODN duplex systems differed only in that the cyanines linked to the respective ODNs were linked either closer to the 5'- or 3'-ends of the molecule. In either case, however, the dyes were separated by an identical number (7 or 8) of base pairs. Characterization by molecular modeling and energy minimization using a conformational search algorithm in a molecular operating environment (MOE) revealed that linking of the dyes closer to the 5'-ends resulted in their reciprocal orientation across the major groove which allowed a closely interacting dye pair to be formed. This overlap between the donor and acceptor dye molecules resulted in changes in absorbance spectra consistent with the formation of H-aggregates. Conversely, dyes linked closer to 3'-ends exhibited emissive FRET and formed a pair of dyes that interacted with the DNA helix only weakly. Induced CD spectra analysis suggested that interaction with the double helix was weaker than in the case of the closely interacting cyanine dye pair. Linking the dyes such that the base pair separation was 10 or 0 favored energy transfer with subsequent acceptor emission. Our results suggest that when interpreting FRET measurements from nucleic acids, the use of a "spectroscopic ruler" principle which takes into account the 3D helical context of the double helix will allow more accurate interpretation of fluorescence emission. C1 [Metelev, Valeri; Zhang, Surong; Bogdanov, Alexei, Jr.] Univ Massachusetts, Sch Med, Dept Radiol, Lab Mol Imaging Probes, Worcester, MA 01655 USA. [Metelev, Valeri] Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119991, Russia. [Tabatadze, David] ZATA Pharmaceut Inc, Worcester, MA USA. [Kumar, Anand T. N.] Massachusetts Gen Hosp, A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Bogdanov, Alexei, Jr.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA. [Bogdanov, Alexei, Jr.] Moscow MV Lomonosov State Univ, Dept Bioengn & Bioinformat, Moscow 119991, Russia. RP Bogdanov, A (reprint author), Univ Massachusetts, Sch Med, Dept Radiol, Lab Mol Imaging Probes, Worcester, MA 01655 USA. EM alexei.bogdanov@umassmed.edu RI Metelev, Valeri/I-3238-2012; Bogdanov, Alexey/L-1407-2013 FU National Cancer Institute IMAT grant [R33CA134385, R01AG034901, R01EB015325] FX This work was supported in part by the National Cancer Institute IMAT grant R33CA134385 and R01AG034901 to A. B. and R01EB015325 to A.T.N.K. The authors are grateful to Dr Jeff Bacon (Department of Chemistry, Boston University) for his help with CD spectra acquisitions. The authors declare that they have no conflicts of interest. NR 29 TC 3 Z9 3 U1 0 U2 11 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1742-206X J9 MOL BIOSYST JI Mol. Biosyst. PY 2013 VL 9 IS 10 BP 2447 EP 2453 DI 10.1039/c3mb70108e PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 209MG UT WOS:000323761100007 PM 23925269 ER PT B AU Ruchelsman, DE Ring, DC AF Ruchelsman, David E. Ring, David C. BE Hak, DJ Ipaktchi, KR Morgan, SJ TI Adult Bicolumnar Distal Humerus Fractures SO ORTHOPEDIC TRAUMA CALL FOR THE ATTENDING SURGEON LA English DT Article; Book Chapter ID INTERNAL-FIXATION; OPEN REDUCTION; ELBOW ARTHROPLASTY; CAPITELLAR C1 [Ruchelsman, David E.] Tufts Univ, Sch Med, Dept Orthopaed Surg, Boston, MA 02111 USA. [Ruchelsman, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Ring, David C.] Harvard Univ, Sch Med, Boston, MA USA. [Ring, David C.] MGH Orthopaed Hand & Upper Extrem Serv, Boston, MA USA. RP Ruchelsman, DE (reprint author), Tufts Univ, Sch Med, Dept Orthopaed Surg, Boston, MA 02111 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-992-7 PY 2013 BP 113 EP 120 PG 8 WC Critical Care Medicine; Orthopedics SC General & Internal Medicine; Orthopedics GA BGT28 UT WOS:000324075400018 ER PT J AU Marak, CP Alappan, N Shim, C Guddati, AK AF Marak, Creticus P. Alappan, Narendrakumar Shim, Chang Guddati, Achuta K. TI Diffuse Alveolar Hemorrhage due to Ketorolac Tromethamine SO PHARMACOLOGY LA English DT Article DE Diffuse alveolar hemorrhage; Nonsteroidal anti-inflammatory drugs; Ketorolac; Hypersensitivity ID HEMOPTYSIS; DICLOFENAC AB Drug-induced lung disease (DILD) is a common but frequently missed diagnosis. Therefore, a high index of clinical suspicion and familiarity with the clinical syndromes associated with DILD are important in making the diagnosis. Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the mostly commonly used classes of medications. NSAIDs are safe when used at prescribed doses. Side effects from use of NSAIDs are not uncommon and can affect almost every organ system in the body. NSAIDs are notorious for causing pulmonary toxicity, the common ones being bronchospasm and hypersensitivity reactions. Diffuse alveolar hemorrhage (DAH) secondary to NSAIDs is uncommon. Here, we report a case of DAH secondary to the use of ketorolac tromethamine. Copyright (c) 2013 S. Karger AG, Basel C1 [Marak, Creticus P.; Alappan, Narendrakumar; Shim, Chang] Yeshiva Univ, Albert Einstein Coll Med, Montefiore Hosp, Div Pulm & Crit Care Med, New York, NY 10033 USA. [Guddati, Achuta K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Guddati, AK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 50 Fruit St, Boston, MA 02114 USA. EM aguddati@partners.org NR 12 TC 1 Z9 1 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0031-7012 J9 PHARMACOLOGY JI Pharmacology PY 2013 VL 92 IS 1-2 BP 11 EP 13 DI 10.1159/000351844 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 217KE UT WOS:000324357600003 PM 23867384 ER PT J AU Vatansever, F Hamblin, MR AF Vatansever, F. Hamblin, M. R. BE Laakso, EL Young, C TI Transcranial low-level laser (light) therapy: mechanisms and application to traumatic brain injury and beyond. SO PROCEEDINGS OF THE 9TH WORLD ASSOCIATION FOR LASER THERAPY CONGRESS (WALT) LA English DT Proceedings Paper CT 9th Biennial Congress of the World-Association-for-Laser-Therapy (WALT) CY SEP 28-30, 2012 CL Australian Med Laser Assoc (AMLA), Gold Coast, AUSTRALIA SP World Assoc Laser Therapy (WALT) HO Australian Med Laser Assoc (AMLA) DE low-level laser therapy; NIR laser; photobiomodulation; traumatic brain injury; neurogenesis; controlled cortical impact; neurological severity score ID CYTOCHROME-C-OXIDASE; TERM NEUROLOGICAL DEFICITS; NITRIC-OXIDE; UNITED-STATES; IR RADIATION; PHOTOBIOMODULATION; IRRADIATION; MICE; ANGIOGENESIS; APOPTOSIS AB Low-level laser (or light) therapy (LLLT) is attracting growing interest to treat both stroke and traumatic brain injury (TBI). The fact that near-infrared (NIR) light can penetrate through the scalp and skull into the brain, allows non-invasive treatment to be carried out with a low likelihood of treatment-related adverse events. It is proposed that red and NIR light is absorbed by chromophores in the mitochondria of cells (which are particularly abundant in cortical neurons) leading to changes in gene transcription and upregulation of proteins involved in cell survival, antioxidant production, collagen synthesis, reduction of chronic inflammation and cell migration and proliferation. We developed two different models of TBI in mice: a closed head weight drop and an open skull controlled cortical impact (CCI). Transcranial laser therapy consisting of a single exposure 4 hours post-TBI to 36 J/cm(2) of various lasers was delivered to the closed head model. 810 nm or 660 nm laser significantly improved neurological severity score in TBI up to 4-weeks post-TBI. Laser therapy at 730 nm or 980 nm was ineffective. We then examined the effect of 0, 1, 3, and 14 daily 810 nm laser treatments in the CCI model. A single laser exposure gave a significant improvement while 3 laser exposures were better still. Our data suggest that transcranial LLLT is a promising treatment for acute (and chronic) TBI and may have much wider applications to neurodegenerative and psychiatric diseases. The lack of side-effects and paucity of alternative treatments for brain diseases should encourage more early clinical trials. C1 [Vatansever, F.; Hamblin, M. R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Vatansever, F (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. EM fvatansever@partners.org; hamblin@helix.mgh.harvard.edu NR 44 TC 0 Z9 0 U1 3 U2 5 PU MEDIMOND S R L PI 40128 BOLOGNA PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY BN 978-88-7587-677-7 PY 2013 BP 73 EP 80 PG 8 WC Biophysics; Physics, Applied SC Biophysics; Physics GA BGW33 UT WOS:000324373900015 ER PT S AU Garcia-Bellmunt, L Sibila, O Restrepo, MI Anzueto, A AF Garcia-Bellmunt, Laia Sibila, Oriol Restrepo, Marcos I. Anzueto, Antonio BE Blasi, F Miravitlles, M Welte, T TI Chronic bronchitis: a risk factor for bronchial infection SO SPECTRUM OF BRONCHIAL INFECTION SE European Respiratory Monograph LA English DT Article; Book Chapter DE Acute exacerbation; airway inflammation; bronchial infection; chronic bronchitis; chronic obstructive pulmonary disease; host factors ID OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; QUALITY-OF-LIFE; NONTYPABLE HAEMOPHILUS-INFLUENZAE; CHRONIC MUCUS HYPERSECRETION; LOWER RESPIRATORY-TRACT; PSEUDOMONAS-AERUGINOSA; BACTERIAL-COLONIZATION; ACUTE EXACERBATIONS; COPD EXACERBATIONS AB Chronic bronchitis is a clinical entity characterised by chronic bronchial mucus hypersecretion. It is frequently associated with chronic obstructive pulmonary disease (COPD) and it is related to worse outcomes. COPD patients with chronic bronchitis experienced accelerated lung function decline and an increased risk of exacerbations. Chronic mucus hypersecretion is also associated with acute or chronic bacterial bronchial infection, and increased airway and systemic inflammation. In addition, different antibiotic and anti-inflammatory treatments have been tested in these patients, with conflicting results. Mechanisms to explain the relationship between chronic bronchitis and infection are not well established, although host factors have been identified as key factors in the pathogenesis of bronchial infection. This chapter discusses the association of chronic bronchitis and the risk of bronchial infection, and the infection mechanisms that are responsible for this association, potential antibiotic and anti-inflammatory treatment. C1 [Garcia-Bellmunt, Laia; Sibila, Oriol] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. RP Anzueto, A (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div San Antonio, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu NR 80 TC 0 Z9 0 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOCIETY PI SHEFFIELD PA 442 GLOSSOP ROAD, SHEFFIELD, S10 2PX, ENGLAND SN 2075-6674 BN 978-1-84984-035-4; 978-1-84984-034-7 J9 EUR RESPIR MONOGR PY 2013 IS 60 BP 18 EP 26 DI 10.1183/1025448x.10017012 PG 9 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA BGW46 UT WOS:000324380900004 ER PT J AU Roberts, JC Fischer, CM AF Roberts, Jonathan C. Fischer, Christopher M. BE Scalea, T Rogers, RL TI Cerebral venous sinus thrombosis SO VASCULAR EMERGENCIES: EXPERT MANAGEMENT FOR THE EMERGENCY PHYSICIAN LA English DT Article; Book Chapter ID RISK C1 [Roberts, Jonathan C.] Boston BIOMC, Dept Emergency Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Fischer, Christopher M.] Beth Israel Deaconess Med Ctr BIMOC, Dept Emergency Med, Boston, MA USA. RP Roberts, JC (reprint author), Boston BIOMC, Dept Emergency Med, Beth Israel Deaconess Med Ctr, Boston, MA USA. NR 22 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-03502-7 PY 2013 BP 1 EP 5 PG 5 WC Emergency Medicine; Surgery SC Emergency Medicine; Surgery GA BGO68 UT WOS:000323650700002 ER PT J AU Nentwich, LM Goldstein, JN AF Nentwich, Lauren M. Goldstein, Joshua N. BE Scalea, T Rogers, RL TI Intracerebral hemorrhage SO VASCULAR EMERGENCIES: EXPERT MANAGEMENT FOR THE EMERGENCY PHYSICIAN LA English DT Article; Book Chapter ID ASSOCIATION/AMERICAN-STROKE-ASSOCIATION; PREDICTS HEMATOMA EXPANSION; ACUTE CEREBRAL-HEMORRHAGE; ISCHEMIC-STROKE; BLOOD-PRESSURE; RISK-FACTORS; INTRAVENTRICULAR HEMORRHAGE; INTRACRANIAL HEMORRHAGE; COMPUTED-TOMOGRAPHY; AMYLOID ANGIOPATHY C1 [Nentwich, Lauren M.] Boston Univ, Sch Med, Boston Med Ctr, Dept Emergency Med, Boston, MA 02118 USA. [Nentwich, Lauren M.] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA. [Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. RP Nentwich, LM (reprint author), Boston Univ, Sch Med, Boston Med Ctr, Dept Emergency Med, Boston, MA 02118 USA. RI Goldstein, Joshua/H-8953-2016 NR 52 TC 1 Z9 1 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-03502-7 PY 2013 BP 18 EP 29 PG 12 WC Emergency Medicine; Surgery SC Emergency Medicine; Surgery GA BGO68 UT WOS:000323650700004 ER PT J AU Edlow, JA AF Edlow, Jonathan A. BE Scalea, T Rogers, RL TI Aneurysmal subarachnoid hemorrhage SO VASCULAR EMERGENCIES: EXPERT MANAGEMENT FOR THE EMERGENCY PHYSICIAN LA English DT Article; Book Chapter ID COMPUTED TOMOGRAPHIC ANGIOGRAPHY; TRAUMATIC LUMBAR PUNCTURE; INTRACRANIAL ANEURYSMS; EMERGENCY-DEPARTMENT; CEREBROSPINAL-FLUID; CEREBRAL ANEURYSMS; ACUTE HEADACHE; IN-PLACE; MANAGEMENT; DIAGNOSIS C1 [Edlow, Jonathan A.] Beth Israel Deaconess Med Ctr BIOMC, Dept Med, Boston, MA USA. [Edlow, Jonathan A.] Harvard Univ, Sch Med, Boston, MA USA. RP Edlow, JA (reprint author), Beth Israel Deaconess Med Ctr BIOMC, Dept Med, Boston, MA USA. NR 62 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-03502-7 PY 2013 BP 30 EP 42 PG 13 WC Emergency Medicine; Surgery SC Emergency Medicine; Surgery GA BGO68 UT WOS:000323650700005 ER PT J AU Madsen, BE Magdy, SH AF Madsen, Bo E. Magdy, Selim H. BE Scalea, T Rogers, RL TI Cervical artery dissection SO VASCULAR EMERGENCIES: EXPERT MANAGEMENT FOR THE EMERGENCY PHYSICIAN LA English DT Article; Book Chapter ID INTERNAL CAROTID-ARTERY; VERTEBRAL ARTERY; ISCHEMIC-STROKE; YOUNG-ADULTS; RISK-FACTORS; CHIROPRACTIC MANIPULATION; THROMBOLYSIS; METAANALYSIS; ASSOCIATION; COMMUNITY C1 [Madsen, Bo E.; Magdy, Selim H.] Beth Israel Deaconess Med Ctr BIDMC, Boston, MA USA. RP Madsen, BE (reprint author), Beth Israel Deaconess Med Ctr BIDMC, Boston, MA USA. NR 49 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-03502-7 PY 2013 BP 53 EP 62 PG 10 WC Emergency Medicine; Surgery SC Emergency Medicine; Surgery GA BGO68 UT WOS:000323650700007 ER PT J AU Holdnack, JA Drozdick, LW Weiss, LG Iverson, GL AF Holdnack, James A. Drozdick, Lisa Whipple Weiss, Larry G. Iverson, Grant L. BE Holdnack, JA Weiss, LG Iverson, GL TI WAIS-IV, WMS-IV, AND ACS Advanced Clinical Interpretation Preface SO WAIS-IV, WMS-IV, AND ACS: ADVANCED CLINICAL INTERPRETATION SE Practical Resources for the Mental Health Professional LA English DT Editorial Material; Book Chapter C1 [Holdnack, James A.; Drozdick, Lisa Whipple; Weiss, Larry G.] Pearson Assessment, San Antonio, TX USA. [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. RP Holdnack, JA (reprint author), Pearson Assessment, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-386953-1 J9 PRACT RESOUR MENT PY 2013 BP XI EP XIV PG 4 WC Psychology, Clinical SC Psychology GA BGQ37 UT WOS:000323772000001 ER PT J AU Goldstein, G Oakes, H Lovejoy, D Holdnack, JA AF Goldstein, Gerald Oakes, Howard Lovejoy, David Holdnack, James A. BE Holdnack, JA Weiss, LG Iverson, GL TI Assessing Individual's with Psychiatric and Developmental Disorders SO WAIS-IV, WMS-IV, AND ACS: ADVANCED CLINICAL INTERPRETATION SE Practical Resources for the Mental Health Professional LA English DT Article; Book Chapter ID HIGH-FUNCTIONING AUTISM; ASPERGER-SYNDROME; COGNITIVE FUNCTION; SOCIAL-PERCEPTION; SCHIZOPHRENIA; INTELLIGENCE; ADOLESCENTS; MEMORY; ADULTS; BRAIN C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Oakes, Howard; Lovejoy, David] Hartford Hosp, Hartford, CT USA. [Lovejoy, David] Univ Connecticut, Sch Med, Farmington, CT USA. [Holdnack, James A.] Pearson Assessment, San Antonio, TX USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 55 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-386953-1 J9 PRACT RESOUR MENT PY 2013 BP 545 EP 599 DI 10.1016/B978-0-12-386934-0.00011-0 PG 55 WC Psychology, Clinical SC Psychology GA BGQ37 UT WOS:000323772000012 ER PT B AU Chandler, L AF Chandler, Laura BE Dasgupta, A Sepulveda, JL TI Challenges in Clinical Microbiology Testing SO ACCURATE RESULTS IN THE CLINICAL LABORATORY: A GUIDE TO ERROR DETECTION AND CORRECTION LA English DT Article; Book Chapter ID BLOOD CULTURE CONTAMINATION; BRUCELLA-MELITENSIS; MISIDENTIFICATION; SUSCEPTIBILITY C1 [Chandler, Laura] Univ Penn, Dept Pathol & Lab Med, Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chandler, Laura] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Chandler, L (reprint author), Univ Penn, Dept Pathol & Lab Med, Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 29 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-415858-0 PY 2013 BP 315 EP 326 DI 10.1016/B978-0-12-415783-5.00020-7 PG 12 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA BGG75 UT WOS:000322877800022 ER PT B AU Chandler, L AF Chandler, Laura BE Dasgupta, A Sepulveda, JL TI Sources of Errors in Molecular Testing SO ACCURATE RESULTS IN THE CLINICAL LABORATORY: A GUIDE TO ERROR DETECTION AND CORRECTION LA English DT Article; Book Chapter ID POLYMERASE-CHAIN-REACTION; NUCLEIC-ACID AMPLIFICATION; PHENOL-CHLOROFORM EXTRACTION; THERMOSTABLE DNA-POLYMERASE; BOVINE SERUM-ALBUMIN; SINGLE-STEP METHOD; VIRUS TYPE-1 RNA; NEISSERIA-GONORRHOEAE; GENOMIC MEDICINE; DIAGNOSTIC PCR C1 [Chandler, Laura] Univ Penn, Dept Pathol & Lab Med, Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chandler, Laura] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Chandler, L (reprint author), Univ Penn, Dept Pathol & Lab Med, Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 57 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-415858-0 PY 2013 BP 327 EP 341 DI 10.1016/B978-0-12-415783-5.00021-9 PG 15 WC Medical Laboratory Technology; Pathology SC Medical Laboratory Technology; Pathology GA BGG75 UT WOS:000322877800023 ER PT S AU Findlay, VJ Larue, AC Turner, DP Watson, PM Watson, DK AF Findlay, Victoria J. LaRue, Amanda C. Turner, David P. Watson, Patricia M. Watson, Dennis K. BE Tew, KD Fisher, PB TI Understanding the Role of ETS-Mediated Gene Regulation in Complex Biological Processes SO ADVANCES IN CANCER RESEARCH, VOL 119 SE Advances in Cancer Research LA English DT Review; Book Chapter ID HUMAN BREAST-CANCER; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TRANSCRIPTION FACTOR FLI1; HUMAN DERMAL FIBROBLASTS; EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; PUTATIVE TUMOR-SUPPRESSOR; MAMMARY-GLAND DEVELOPMENT; PROTEIN-ASSOCIATED FACTOR; HEMATOPOIETIC STEM-CELLS AB Ets factors are members of one of the largest families of evolutionarily conserved transcription factors, regulating critical functions in normal cell homeostasis, which when perturbed contribute to tumor progression. The well-documented alterations in ETS factor expression and function during cancer progression result in pleiotropic effects manifested by the downstream effect on their target genes. Multiple ETS factors bind to the same regulatory sites present on target genes, suggesting redundant or competitive functions. The anti- and prometastatic signatures obtained by examining specific ETS regulatory networks will significantly improve our ability to accurately predict tumor progression and advance our understanding of gene regulation in cancer. Coordination of multiple ETS gene functions also mediates interactions between tumor and stromal cells and thus contributes to the cancer phenotype. As such, these new insights may provide a novel view of the ETS gene family as well as a focal point for studying the complex biological control involved in tumor progression. One of the goals of molecular biology is to elucidate the mechanisms that contribute to the development and progression of cancer. Such an understanding of the molecular basis of cancer will provide new possibilities for: (1) earlier detection, as well as better diagnosis and staging of disease; (2) detection of minimal residual disease recurrences and evaluation of response to therapy; (3) prevention; and (4) novel treatment strategies. Increased understanding of ETS-regulated biological pathways will directly impact these areas. C1 [Findlay, Victoria J.; LaRue, Amanda C.; Turner, David P.; Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Charleston, SC 29425 USA. [LaRue, Amanda C.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA. [Watson, Patricia M.] Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA. [Watson, Dennis K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, Charleston, SC 29425 USA. RP Watson, DK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Charleston, SC 29425 USA. EM watsondk@musc.edu NR 256 TC 13 Z9 14 U1 1 U2 13 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-230X BN 978-0-12-407190-2 J9 ADV CANCER RES JI Adv.Cancer Res. PY 2013 VL 119 BP 1 EP 61 DI 10.1016/B978-0-12-407190-2.00001-0 PG 61 WC Oncology SC Oncology GA BGK69 UT WOS:000323354400001 PM 23870508 ER PT J AU LaRusso, EM Freeman, MP AF LaRusso, Elizabeth M. Freeman, Marlene P. BE Mattison, DR TI Antidepressants in Pregnancy SO CLINICAL PHARMACOLOGY DURING PREGNANCY LA English DT Article; Book Chapter ID MAJOR DEPRESSION; UNITED-STATES; EXPOSURE; POSTPARTUM; OUTCOMES; IMPACT; WOMEN; RISK C1 [LaRusso, Elizabeth M.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Lebanon, NH 03766 USA. [Freeman, Marlene P.] Harvard Univ, Sch Med, Clin Serv, Boston, MA USA. [Freeman, Marlene P.] CTNI Massachusetts Gen Hosp, Boston, MA USA. RP LaRusso, EM (reprint author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Lebanon, NH 03766 USA. NR 20 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-386008-8 PY 2013 BP 295 EP 305 PG 11 WC Obstetrics & Gynecology; Pharmacology & Pharmacy SC Obstetrics & Gynecology; Pharmacology & Pharmacy GA BGG69 UT WOS:000322872400018 ER PT J AU Creaney, J Sneddon, S Dick, IM Dare, H Boudville, N Musk, AW Skates, SJ Robinson, BWS AF Creaney, Jenette Sneddon, Sophie Dick, Ian M. Dare, Hanne Boudville, Neil Musk, Arthur William Skates, Steven J. Robinson, Bruce W. S. TI Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum SO DISEASE MARKERS LA English DT Article ID SOLUBLE MESOTHELIN; MALIGNANT MESOTHELIOMA; TUMOR-MARKER; MOLECULAR-CLONING; N-ERC/MESOTHELIN; OVARIAN; OSTEOPONTIN; CANCER; CELLS AB The MSLN gene products, soluble mesothelin and megakaryocyte potentiating factor (MPF), are being investigated as biomarkers for the asbestos-related cancer malignant mesothelioma (MM). Pleural fluid biomarkers of MM can be elevated when serum levels remain normal. The aim of this study was to determine if this was true for MPF and to compare levels of mesothelin. Biomarker concentrations were compared in 66 MM patients, 39 patients with other malignancies, 37 with benign disease, 18 asbestos-exposed healthy individuals, and 53 patients with chronic kidney disease. In pleural effusions, MPF and soluble mesothelin concentrations were both significantly elevated in MM patients relative to controls. No significant difference between the area under the receiver operator curve (AUC) for MPF (0.945 +/- 0.02) and mesothelin (0.928 +/- 0.03) when distinguishing MM from all other causes of effusion was observed. MPF and mesothelin serum concentrations were highly correlated and of equivalent diagnostic accuracy with AUCs of 0.813 +/- 0.04 and 0.829 +/- 0.03, respectively. Serum levels of both markers increased with decreasing kidney function. In conclusion, MPF is elevated in the pleural effusions of MM patients similar to that of mesothelin. Mesothelin and MPF convey equivalent diagnostic information for distinguishing MM from other diseases in pleural effusions as well as serum. C1 [Creaney, Jenette; Sneddon, Sophie; Dick, Ian M.; Dare, Hanne; Robinson, Bruce W. S.] Univ Western Australia, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia. [Creaney, Jenette; Dare, Hanne] Sir Charles Gairdner Hosp, Australian Mesothelioma Tissue Bank, Perth, WA 6009, Australia. [Sneddon, Sophie; Dick, Ian M.] Sir Charles Gairdner Hosp, Perth, WA 6009, Australia. [Boudville, Neil] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia. [Boudville, Neil] Sir Charles Gairdner Hosp, Dept Renal Med, Nedlands, WA 6009, Australia. [Musk, Arthur William] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia. [Musk, Arthur William; Robinson, Bruce W. S.] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia. [Skates, Steven J.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Creaney, J (reprint author), Univ Western Australia, Sch Med & Pharmacol, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia. EM jenette.creaney@uwa.edu.au RI Robinson, Bruce/N-1900-2014 OI Sneddon, Sophie/0000-0003-4611-0822; FU Australian National Health and Medical Research Council (NHMRC) [310670, 628903, 1001020]; Insurance Commission of WA FX The samples used for this study form part of the Australian Mesothelioma Tissue Bank, a member bank of the Australasian Biospecimen Network, which is supported in part by the Australian National Health and Medical Research Council (NHMRC) (Grants 310670 and 628903). This study was supported in part by the NHMRC (Grant 1001020) and the Insurance Commission of WA. MPF standards and antibodies were kindly provided free of charge by Medical & Biological Laboratories Co., Ltd, Japan. The authors would like to acknowledge all the participants in this study. NR 35 TC 9 Z9 9 U1 0 U2 1 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2013 BP 119 EP 127 DI 10.1155/2013/874212 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 212MM UT WOS:000323987500001 PM 24167356 ER PT J AU Morasco, BJ AF Morasco, Benjamin J. BE Miller, PM TI Psychological Treatments for Pathological Gambling SO INTERVENTIONS FOR ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 3 LA English DT Article; Book Chapter ID COGNITIVE-BEHAVIORAL THERAPY; GAMBLERS; COMORBIDITY; ALCOHOL C1 [Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. NR 10 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-398363-3 PY 2013 BP 227 EP 233 DI 10.1016/B978-0-12-398338-1.00024-5 PG 7 WC Psychology, Clinical; Substance Abuse; Psychiatry; Psychology SC Psychology; Substance Abuse; Psychiatry GA BGI00 UT WOS:000323055000025 ER PT B AU Chakravorty, S AF Chakravorty, Subhajit BE Miller, PM TI The Treatment of Insomnia in Substance-Abusing Patients SO INTERVENTIONS FOR ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 3 LA English DT Article; Book Chapter C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Chakravorty, S (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-398363-3 PY 2013 BP 517 EP 525 DI 10.1016/B978-0-12-398338-1.00055-5 PG 9 WC Psychology, Clinical; Substance Abuse; Psychiatry; Psychology SC Psychology; Substance Abuse; Psychiatry GA BGI00 UT WOS:000323055000056 ER PT J AU Abramovitch, A Goldzweig, G Schweiger, A AF Abramovitch, Amitai Goldzweig, Gil Schweiger, Avraham TI Correlates of Physical Activity with Intrusive Thoughts, Worry and Impulsivity in Adults with Attention Deficit/Hyperactivity Disorder: A Cross-sectional Pilot Study SO ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES LA English DT Article ID DEFICIT-HYPERACTIVITY DISORDER; INDIVIDUAL-DIFFERENCES; WORRISOME THOUGHTS; UNITED-STATES; EXERCISE; METAANALYSIS; ADHD; CHILDREN; ANXIETY; METHYLPHENIDATE AB Background: Physical exercise is known to produce numerous psychological beneficial effects in healthy and clinical populations. Nevertheless, little is known about the relationship between exercise and ADHD symptoms, let alone among adults with ADHD. This study examines the association between exercise and three ADHD symptoms: (1) behavioral impulsivity; (2) intrusive unwanted thoughts and (3) worry. The latter two are cognitive facets of anxiety, a prominent symptom of ADHD. Methods: Physical activity was measured using a self-report questionnaire. Thirty participants with a diagnosis of ADHD were divided into two groups: Participants engaging in frequent aerobic activity ("high activity" group), and participants engaging in non-frequent physical activity ("low activity" group). Results: Adults with ADHD engaging in frequent aerobic physical activity report significantly less behavioral impulsivity and experience significantly less worrisome and intrusive thoughts. Conclusions: Our results reflect an association between physical activity and reduced symptoms of impulsivity and intrusive and worrisome thoughts in an adult ADHD sample. The results of this pilot study may encourage further investigations emphasizing the causal link between physical activity and ADHD symptoms. Suggested underlying neurobiological mechanisms, clinical implications and limitations are discussed. C1 [Abramovitch, Amitai] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Abramovitch, Amitai] Harvard Univ, Sch Med, Boston, MA USA. [Goldzweig, Gil; Schweiger, Avraham] Acad Coll Tel Aviv, Dept Behav Sci, Tel Aviv, Israel. RP Abramovitch, A (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 185 Cambridge St, Boston, MA 02114 USA. EM aabramovitch@partners.org RI Abramovitch, Amitai/I-3333-2012 OI Abramovitch, Amitai/0000-0001-9640-0970 NR 62 TC 6 Z9 6 U1 4 U2 24 PU MEDIAFARM GROUP PI TEL-AVIV PA 23 ZAMENHOFF ST, TEL-AVIV, 64373, ISRAEL SN 0333-7308 J9 ISR J PSYCHIATR REL JI Isr. J. Psychiatr. Relat. Sci. PY 2013 VL 50 IS 1 BP 47 EP 54 PG 8 WC Psychiatry SC Psychiatry GA 210KF UT WOS:000323830700009 PM 24029111 ER PT J AU Vecchio, D Acquaviva, A Arezzini, B Tenor, H Martorana, PA Gardi, C AF Vecchio, Daniela Acquaviva, Alessandra Arezzini, Beatrice Tenor, Hermann Martorana, Piero A. Gardi, Concetta TI Downregulation of NOX4 Expression by Roflumilast N-Oxide Reduces Markers of Fibrosis in Lung Fibroblasts SO MEDIATORS OF INFLAMMATION LA English DT Article ID IDIOPATHIC PULMONARY-FIBROSIS; HEPATIC STELLATE CELLS; PHOSPHODIESTERASE-4 INHIBITOR; COLLAGEN-SYNTHESIS; CIGARETTE-SMOKE; NADPH OXIDASE-4; IN-VITRO; MICE; PHARMACOKINETICS; PROTECTS AB The phosphodiesterase 4 inhibitor roflumilast prevents bleomycin-(BLM-) induced lung fibrosis in animal models. However, its mechanism of action remains unknown. We investigated whether roflumilast N-oxide (RNO), the active metabolite of roflumilast, can modulate in vitro the oxidative effects of BLM on human lung fibroblasts (HLF). In addition, since BLM increases the production of F-2-isoprostanes that have per se fibrogenic activity, the effect of RNO on oxidative stress and fibrogenesis induced by the F-2-isoprostane 8-epi-PGF(2 alpha). was investigated. HLF were preincubated either with the vehicle or with RNO and exposed to either BLM or 8-epi-PGF(2 alpha). Proliferation and collagen synthesis were assessed as [H-3]-thymidine and [H-3]-proline incorporation. Reactive oxygen species (ROS) and F-2-isoprostanes were measured. NADPH oxidase 4 (NOX4) protein and mRNA were also evaluated. BLM increased both cell proliferation and collagen synthesis and enhanced ROS and F-2-isoprostane production. These effects were significantly prevented by RNO. Also, RNO significantly reduced the increase in both NOX4 mRNA and protein, induced by BLM. Finally, 8-epi-PGF(2 alpha) per se stimulated HLF proliferation, collagen synthesis, and NOX4 expression and ROS generation, and RNO prevented these effects. Thus, the antifibrotic effect of RNO observed in vivo may be related to its ability to mitigate ROS generation via downregulation of NOX1. C1 [Vecchio, Daniela] Harvard Univ, Dept Dermatol, Sch Med, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02114 USA. [Acquaviva, Alessandra; Arezzini, Beatrice; Martorana, Piero A.; Gardi, Concetta] Univ Siena, Dept Physiopathol & Expt Med, I-53100 Siena, Italy. [Tenor, Hermann] Takeda Pharmaceut Int, CH-8152 Zurich, Switzerland. RP Gardi, C (reprint author), Univ Siena, Dept Physiopathol & Expt Med, Via A Moro 6, I-53100 Siena, Italy. EM concetta.gardi@unisi.it OI Gardi, Concetta/0000-0003-3748-809X FU Nycomed GmbH FX Concetta Gardi received a research grant from Nycomed GmbH. Hermann Tenor has been a full time employee of Nycomed GmbH. All other authors report no conflict of interests with this Paper. NR 25 TC 7 Z9 7 U1 2 U2 7 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0962-9351 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2013 AR 745984 DI 10.1155/2013/745984 PG 8 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 213BL UT WOS:000324028000001 ER PT S AU Anbil, S Rizvi, I Celli, JP Alagic, N Hasan, T AF Anbil, S. Rizvi, I. Celli, J. P. Alagic, N. Hasan, T. BE Kessel, DH Hasan, T TI A photobleaching- based PDT dose metric predicts PDT efficacy over certain BPD concentration ranges in a three-dimensional model of ovarian cancer SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXII CY FEB 02-04, 2013 CL San Francisco, CA SP SPIE DE Photodynamic Therapy; Implicit dosimetry; Three-dimensional model; Ovarian Cancer; photobleaching; PDT dose metric ID PHOTODYNAMIC THERAPY; MLL CELLS; IN-VITRO; DOSIMETRY; FLUORESCENCE; IMPLICIT; EXPLICIT AB Photodynamic therapy (PDT) dosimetry is an active area of study that is motivated by the need to reliably predict treatment outcomes. Implicit dosimetric parameters, such as photosensitizer (PS) photobleaching, may indicate PDT efficacy and could establish a framework to provide patient-customized PDT. Here, tumor destruction and benzoporphryin-derivative (BPD) photobleaching are characterized by systematically varying BPD-light combinations to achieve fixed PDT doses (M * J * cm(-2)) in a three-dimensional (3D) model of micrometastatic ovarian cancer (OvCa). It is observed that the BPD-light parameters used to construct a given PDT dose significantly impact nodule viability and BPD photobleaching. As a result, PDT dose, when measured by the product of BPD concentration and fluence, does not reliably predict overall efficacy. A PDT dose metric that incorporates a term for BPD photobleaching more robustly predicts PDT efficacy at low concentrations of BPD. These results suggest that PDT dose metrics that are informed by implicit approaches to dosimetry could improve the reliability of PDT-based regimens and provide opportunities for patient-specific treatment planning. C1 [Anbil, S.; Rizvi, I.; Alagic, N.; Hasan, T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA. RP Anbil, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, 40 Blossom St,BAR314C, Boston, MA 02114 USA. NR 13 TC 1 Z9 1 U1 1 U2 4 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9337-8 J9 PROC SPIE PY 2013 VL 8568 AR UNSP 85680S DI 10.1117/12.2010840 PG 5 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BGQ95 UT WOS:000323832500018 ER PT S AU Mallidi, S Huang, HC Liu, J Mai, ZM Hasan, T AF Mallidi, Srivalleesha Huang, Huang-Chiao Liu, Joyce Mai, Zhiming Hasan, Tayyaba BE Kessel, DH Hasan, T TI Towards Image-Guided Photodynamic Therapy of Glioblastoma SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXII CY FEB 02-04, 2013 CL San Francisco, CA SP SPIE DE Glioblastoma; Photodynamic therapy; Photosensitizer; Photoacoustic imaging; Dosimetry ID PHOTOACOUSTIC TOMOGRAPHY; MULTIFORME; DOSIMETRY; RESECTION; GLIOMA; AGENTS AB Glioblastoma (GBM) is an aggressive cancer with dismal survival rates and few new treatment options. Fluorescence guided resection of GBM followed by photodynamic therapy (PDT) has shown promise in several chemo- or radiotherapy non-responsive GBM treatments clinically. PDT is an emerging light and photosensitizer (PS) mediated cytotoxic method. However, as with other therapeutic modalities, the outcomes are variable largely due to the non-personalization of dose parameters. The variability can be attributed to the differences in heterogeneous photosensitizer accumulation in tumors. Building upon our previous findings on utilizing PS fluorescence for designing tumor-specific PDT dose, we explore the use of photoacoustic imaging, a technique that provides contrast based on the tissue optical absorption properties, to obtain 3D information on the tumoral photosensitizer accumulation. The findings of this study will form the basis for customized photodynamic therapy for glioblastoma and have the potential to serve as a platform for treatment of other cancers. C1 [Mallidi, Srivalleesha; Huang, Huang-Chiao; Liu, Joyce; Mai, Zhiming; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Sch Med, Boston, MA 02114 USA. RP Mallidi, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Sch Med, Boston, MA 02114 USA. NR 47 TC 0 Z9 0 U1 1 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9337-8 J9 PROC SPIE PY 2013 VL 8568 AR UNSP 85681C DI 10.1117/12.2010684 PG 7 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BGQ95 UT WOS:000323832500032 ER PT S AU Mensah, LB Mallidi, S Massodi, I Anbil, S Mai, ZM Hasan, T AF Mensah, Lawrence B. Mallidi, Srivalleesha Massodi, Iqbal Anbil, Sriram Mai, Zhiming Hasan, Tayyaba BE Kessel, DH Hasan, T TI Environmental Effects on Molecular Biomarkers Expression In Pancreatic and Brain Cancer SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXII CY FEB 02-04, 2013 CL San Francisco, CA SP SPIE DE Three-dimensional tumor models; (3D models); glioblastoma multiforme (GBM); pancreatic cancer; biomarkers; photodynamic therapy ID GLIOBLASTOMA-MULTIFORME; BREAST-CANCER; MULTIVARIATE-ANALYSIS; CLINICAL IMPORTANCE; XENOGRAFT MODEL; BCL-XL; EGFR; SURVIVAL; CELLS; PROGNOSIS AB A complete understanding of the biological mechanisms regulating devastating disease such as cancer remains elusive. Pancreatic and brain cancers are primary among the cancer types with poor prognosis. Molecular biomarkers have emerged as group of proteins that are preferentially overexpressed in cancers and with a key role in driving disease progression and resistance to chemotherapy. The epidermal growth factor receptor (EGFR), a cell proliferative biomarker is particularly highly expressed in most cancers including brain and pancreatic cancers. The ability of EGFR to sustain prolong cell proliferation is augmented by biomarkers such as Bax, Bcl-XL and Bcl-2, proteins regulating the apoptotic process. To better understand the role and effect of the microenvironment on these biomarkers in pancreatic cancer (PaCa); we analysed two pancreatic tumor lines (AsPc-1 and MiaPaCa-2) in 2D, 3D in-vitro cultures and in orthotopic tumors at different growth stages. We also investigated in patient derived glioblastoma (GBM) tumor cultures, the ability to utilize the EGFR expression to specifically deliver photosensitizer to the cells for photodynamic therapy. Overall, our results suggest that (1) microenvironment changes affect biomarker expression; thereby it is critical to understand these effects prior to designing combination therapies and (2) EGFR expression in tumor cells indeed could serve as a reliable and a robust biomarker that could be used to design targeted and image-guided photodynamic therapy. C1 [Mensah, Lawrence B.; Mallidi, Srivalleesha; Anbil, Sriram; Mai, Zhiming; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Mensah, LB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA. NR 51 TC 0 Z9 0 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9337-8 J9 PROC SPIE PY 2013 VL 8568 AR UNSP 856803 DI 10.1117/12.2010697 PG 8 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BGQ95 UT WOS:000323832500002 ER PT S AU Rizvi, I Anbil, S Celli, JP Alagic, N Massodi, I Hasan, T AF Rizvi, I. Anbil, S. Celli, J. P. Alagic, N. Massodi, I. Hasan, T. BE Kessel, DH Hasan, T TI Modeling Stromal Determinants of 3D Tumor Growth to Inform PDT-mediated Combination Treatments SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXII CY FEB 02-04, 2013 CL San Francisco, CA SP SPIE DE Ovarian Cancer; Tumor Endothelial Cells; Extracellular Matrix; Three-dimensional heterocellular model; tumor microenvironment ID EXTRACELLULAR-MATRIX; 3-DIMENSIONAL MODEL; ENDOTHELIAL-CELLS; OVARIAN-CANCER; MICROENVIRONMENT; CULTURES; THERAPY AB Advanced stage ovarian carcinoma is characterized by poor prognosis and peritoneal micronodules that exhibit treatment resistance. This is partially due to interactions between multifocal disease and the tumor microenvironment, which includes tumor endothelial cells (TECs) and extracellular matrix components (ECM). Here we describe the development of a three-dimensional model of ovarian cancer that incorporates TECs and ECM. A comparison of several methodologies to generate endothelialized ovarian micronodules along with a preliminary physical characterization is described. This model will allow for detailed investigation of tumor-stroma interactions and how they impact disease progression and treatment response. C1 [Rizvi, I.; Anbil, S.; Alagic, N.; Massodi, I.; Hasan, T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA. RP Rizvi, I (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed,Dept Dermatol, 40 Blossom St,BAR314C, Boston, MA 02114 USA. NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9337-8 J9 PROC SPIE PY 2013 VL 8568 AR UNSP 85680H DI 10.1117/12.2010678 PG 5 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BGQ95 UT WOS:000323832500010 ER PT S AU Cai, X Zhang, Y Li, L Choi, SW MacEwan, MR Yao, JJ Kim, C Xia, YN Wang, LHV AF Cai, Xin Zhang, Yu Li, Li Choi, Sung-Wook MacEwan, Matthew R. Yao, Junjie Kim, Chulhong Xia, Younan Wang, Lihong V. BE Oraevsky, AA Wang, LV TI Photoacoustic Microscopy of Neovascularization in Three-Dimensional Porous Scaffolds In Vivo SO PHOTONS PLUS ULTRASOUND: IMAGING AND SENSING 2013 SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Photons Plus Ultrasound - Imaging and Sensing CY FEB 03-05, 2013 CL San Francisco, CA SP SPIE DE Three-dimensional scaffold; photoacoustic microscopy; tissue engineering; neovascularization; biomedical; imaging AB It is a challenge to non-invasively visualize in vivo the neovascularization in a three-dimensional (3D) scaffold with high spatial resolution and deep penetration depth. Here we used photoacoustic microscopy (PAM) to chronically monitor neovascularization in an inverse opal scaffold implanted in a mouse model for up to six weeks. The neovasculature was observed to develop gradually in the same mouse. These blood vessels not only grew on top of the implanted scaffold but also penetrated into the scaffold. The PAM system offered a lateral resolution of similar to 45 mu m and a penetration depth of similar to 3 mm into the scaffold/tissue construct. By using the 3D PAM data, we further quantified the vessel area as a function of time. C1 [Cai, Xin; MacEwan, Matthew R.; Yao, Junjie; Wang, Lihong V.] Washington Univ, Dept Biomed Engn, Opt Imaging Lab, St Louis, MO 63130 USA. [Zhang, Yu; Xia, Younan] Emory Univ, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA. [Li, Li] Massachusetts Gen Hosp, Harvard Med Sch, Wellman Ctr Photomed, Boston, MA 02114 USA. [Choi, Sung-Wook] Catholic Univ Korea, Dept Biotechnol, Seoul, South Korea. [Kim, Chulhong] SUNY Buffalo, Dept Biomed Engn, Buffalo, NY 14260 USA. RP Wang, LHV (reprint author), Washington Univ, Dept Biomed Engn, Opt Imaging Lab, St Louis, MO 63130 USA. EM lhwang@biomed.wustl.edu FU NIH [R01 EB000712, R01 CA140220, R01 CA157277, R01 CA159959, U54 CA136398, DP1 EB016986] FX Our work was also sponsored by NIH grants R01 EB000712, R01 CA140220, R01 CA157277, R01 CA159959, U54 CA136398, and DP1 EB016986-NIH Director's Pioneer Award. L.V.W. has a financial interest in Microphotoacoustics, Inc. and Endra, Inc., which, however, did not support this work. Others claim no competing financial interests. NR 11 TC 0 Z9 0 U1 0 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9350-7 J9 PROC SPIE PY 2013 VL 8581 AR 858128 DI 10.1117/12.2005236 PG 6 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BGG45 UT WOS:000322832800047 ER PT J AU Schumm, JA O'Farrell, TJ AF Schumm, Jeremiah A. O'Farrell, Timothy J. BE Miller, PM Blume, AW Kavanagh, DJ Kampman, KM Bates, ME Larimer, ME Petry, NM DeWitte, P Ball, SA TI Families and Addiction SO PRINCIPLES OF ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 1 LA English DT Article; Book Chapter ID INTIMATE PARTNER VIOLENCE; ALCOHOL; DISORDERS; COUPLES C1 [Schumm, Jeremiah A.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Schumm, Jeremiah A.] Univ Cincinnati, Cincinnati, OH USA. [O'Farrell, Timothy J.] VA Boston Healthcare Syst, Brockton, MA USA. [O'Farrell, Timothy J.] Harvard Univ, Sch Med, Brockton, MA 02401 USA. RP Schumm, JA (reprint author), Cincinnati VA Med Ctr, Cincinnati, OH USA. NR 12 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-398361-9 PY 2013 BP 303 EP 312 DI 10.1016/B978-0-12-398336-7.00031-0 PG 10 WC Substance Abuse SC Substance Abuse GA BGG51 UT WOS:000322841800032 ER PT J AU Balsam, KF Molina, Y Lehavot, K AF Balsam, Kimberly F. Molina, Yamile Lehavot, Keren BE Miller, PM Blume, AW Kavanagh, DJ Kampman, KM Bates, ME Larimer, ME Petry, NM DeWitte, P Ball, SA TI Alcohol and Drug Use in Lesbian, Gay, Bisexual, and Transgender (LGBT) Youth and Young Adults SO PRINCIPLES OF ADDICTION: COMPREHENSIVE ADDICTIVE BEHAVIORS AND DISORDERS, VOL 1 LA English DT Article; Book Chapter ID SEXUAL ORIENTATION; SUBSTANCE USE; TRAJECTORIES; DEPENDENCE C1 [Balsam, Kimberly F.] Palo Alto Univ, Palo Alto, CA USA. [Molina, Yamile] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Lehavot, Keren] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Balsam, KF (reprint author), Palo Alto Univ, Palo Alto, CA USA. NR 10 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-398361-9 PY 2013 BP 563 EP 573 DI 10.1016/B978-0-12-398336-7.00058-9 PG 11 WC Substance Abuse SC Substance Abuse GA BGG51 UT WOS:000322841800059 ER PT J AU Mitra, B Jindal, R Lee, S Dong, DX Li, LL Sharma, N Maguire, T Schloss, R Yarmush, ML AF Mitra, Bhaskar Jindal, Rohit Lee, Serom Dong, Dave Xu Li, Lulu Sharma, Nripen Maguire, Tim Schloss, Rene Yarmush, Martin L. TI Microdevice integrating innate and adaptive immune responses associated with antigen presentation by dendritic cells SO RSC ADVANCES LA English DT Article ID CHEMICAL GRADIENTS; LINE MODEL; T-CELLS; MIGRATION; CHEMOTAXIS; STIMULATION; ACTIVATION; RECEPTOR; DISEASE; DEVICES AB Dendritic cells are the principal antigen presenting cells that are responsible for acquiring and transporting antigen from the peripheral tissue to the secondary lymphoid tissue. There they present it to T cells which ultimately initiate an antigen specific immune response. In vivo, the migration of dendritic cells (DCs) and T cell activation are intimately linked. However, ex vivo systems that facilitate integrated evaluation of DC chemotaxis and resulting T cell activation by migrated DCs are lacking. In this work, we have developed a microfabricated platform that integrates DC chemotaxis with T cell activation. The basic design of the microdevice includes two layers of PDMS, with the top layer comprising the chemotaxis compartment and the bottom layer containing a T cell compartment. In the chemotaxis compartment, the DCs are subjected to a chemokine gradient, and their migratory response is evaluated. In the T cell compartment, rapid DC-induced activation of T cells is evaluated by measuring the level of calcium in T cells. We demonstrate the efficacy of our approach by evaluating the integrated response of mature DCs, whereby the overall T cell activation response is governed both by the chemotaxis and the T cell activation potential of mature DCs relative to immature DCs. Our system provides a powerful platform for systematically probing various aspects of antigen induced immune responses - DC maturation, migration and T cell activation - in an integrated fashion. C1 [Mitra, Bhaskar; Jindal, Rohit; Lee, Serom; Dong, Dave Xu; Li, Lulu; Sharma, Nripen; Maguire, Tim; Schloss, Rene; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA. [Jindal, Rohit; Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. [Jindal, Rohit; Yarmush, Martin L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Jindal, Rohit; Yarmush, Martin L.] Shriners Burns Hosp, Boston, MA 02114 USA. RP Yarmush, ML (reprint author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA. EM yarmush@rci.rutgers.edu NR 31 TC 1 Z9 1 U1 1 U2 4 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2046-2069 J9 RSC ADV JI RSC Adv. PY 2013 VL 3 IS 36 BP 16002 EP 16010 DI 10.1039/c3ra41308j PG 9 WC Chemistry, Multidisciplinary SC Chemistry GA 203DW UT WOS:000323271700064 ER PT S AU Yenari, MA Han, HS AF Yenari, M. A. Han, H. S. BE Naritomi, H Krieger, DW TI Influence of Therapeutic Hypothermia on Regeneration after Cerebral Ischemia SO CLINICAL RECOVERY FROM CNS DAMAGE SE Frontiers of Neurology and Neuroscience LA English DT Article; Book Chapter ID TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC FACTOR; MILD HYPOTHERMIA; CARDIAC-ARREST; ADULT NEUROGENESIS; GLOBAL-ISCHEMIA; RAT HIPPOCAMPUS; ANGIOGENESIS; CELLS AB The protective effect of therapeutic hypothermia in cerebral ischemia is well accepted in experimental models, and some clinical studies show that there is benefit in humans as well. Long-term observations in animal and clinical studies have documented recovery of neurological function following hypothermia treatment. Diminished damage by hypothermic protection should contribute to the recovery in many ways, but hypothermia appears to enhance regeneration of brain tissue as well. Since regeneration of the brain after damage initiates within hours and is active days and weeks after stroke, prolonged hypothermia might affect regenerative processes which have been documented to occur in these time frames. As there is a lack of data at the basic and clinical levels, the mechanism of neuroregeneration by hypothermia is unclear. Yet, we speculate that hypothermia enhances regeneration by positively influencing neurogenesis, angiogenesis, gliogenesis and synapse/circuit formation after stroke. In this chapter, we will provide up-to-date data from experimental studies and clinical reports on the effect of therapeutic hypothermia on neuroregeneration, with perspectives on future research. Copyright (C) 2013 S. Karger AG, Basel C1 [Yenari, M. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yenari, M. A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Han, H. S.] Kyungpook Natl Univ, Sch Med, Dept Physiol, Taegu, South Korea. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu FU NINDS NIH HHS [R01 NS040516] NR 33 TC 6 Z9 6 U1 0 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-4431 BN 978-3-318-02309-1 J9 FRONT NEUROL NEUROSC JI Front. Neurol. Neurosci. PY 2013 VL 32 BP 122 EP 128 DI 10.1159/000346428 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA BGG55 UT WOS:000322844300015 PM 23859971 ER PT J AU Bouxsein, ML AF Bouxsein, Mary L. BE Thakker, RV Whyte, MP Eisman, JA Igarashi, T TI Overview of Bone Structure and Strength SO GENETICS OF BONE BIOLOGY AND SKELETAL DISEASE LA English DT Article; Book Chapter ID AGE-RELATED-CHANGES; VERTEBRAL TRABECULAR BONE; QUANTITATIVE COMPUTED-TOMOGRAPHY; X-RAY ABSORPTIOMETRY; PROXIMAL FEMUR; CORTICAL BONE; MECHANICAL-PROPERTIES; CANCELLOUS BONE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN C1 [Bouxsein, Mary L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Dept Orthoped Surg Med Ctr,Med Sch, Boston, MA 02215 USA. [Bouxsein, Mary L.] Harvard Univ, Sch Med, Endocrine Unit, Massachusetts Gen Hosp, Boston, MA USA. RP Bouxsein, ML (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Dept Orthoped Surg Med Ctr,Med Sch, Boston, MA 02215 USA. NR 117 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-387830-4 PY 2013 BP 25 EP 34 DI 10.1016/B978-0-12-387829-8.00002-0 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA BGF11 UT WOS:000322631800003 ER PT J AU Juppner, H Silve, C AF Jueppner, Harald Silve, Caroline BE Thakker, RV Whyte, MP Eisman, JA Igarashi, T TI Genetic Disorders Affecting PTH/PTHrP Receptor Function SO GENETICS OF BONE BIOLOGY AND SKELETAL DISEASE LA English DT Article; Book Chapter ID (PTH)/PTH-RELATED PEPTIDE RECEPTOR; HORMONE-RELATED PEPTIDE; JANSENS METAPHYSEAL CHONDRODYSPLASIA; FAMILIAL ISOLATED HYPOPARATHYROIDISM; BLOMSTRAND LETHAL OSTEOCHONDRODYSPLASIA; AUTOSOMAL RECESSIVE HYPOPARATHYROIDISM; EXTRACELLULAR CA2+-SENSING RECEPTOR; ADVANCED SKELETAL MATURATION; IDENTIFIES PDE4D MUTATIONS; MAMMARY-GLAND DEVELOPMENT C1 [Jueppner, Harald] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. [Jueppner, Harald] Massachusetts Gen Hosp, MassGen Hosp Children, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Silve, Caroline] INSERM, U986, F-94275 Le Kremlin Bicetre, France. [Silve, Caroline] Hop Bicetre, Ctr Reference Malad Rares Calcium & Phosphore, Le Kremlin Bicetre, France. [Silve, Caroline] Hop Bichat Claude Bernard, Lab Biochim Hormonale & Genet, F-75877 Paris 18, France. RP Juppner, H (reprint author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. NR 123 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-387830-4 PY 2013 BP 441 EP 457 DI 10.1016/B978-0-12-387829-8.00028-7 PG 17 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA BGF11 UT WOS:000322631800029 ER PT J AU Harte, CB Watts, TW Meston, CM AF Harte, Christopher B. Watts, Tyler W. Meston, Cindy M. TI Predictors of 1-, 6-and 12-month smoking cessation among a community-recruited sample of adult smokers in the United States SO JOURNAL OF SUBSTANCE USE LA English DT Article DE Smoking; smoking cessation; successful abstinence; predictors ID NICOTINE DEPENDENCE; METAANALYSIS; MORTALITY; VALIDITY; ALCOHOL; HEALTH; PATCH AB Baseline socio-demographics, substance use and smoking history characteristics, as well as intra-treatment indicators (i.e. nicotine patch adherence and tobacco use during patch treatment) of smoking cessation were examined among 65 community-based adult male smokers recruited from a metropolitan area within the United States. All participants were recruited between 2009 and 2010 and were enrolled in an 8-week smoking cessation programme involving nicotine patch treatment and adjunctive counselling. Stepwise multiple regression analyses were performed to examine unique predictors of smoking status at 1-, 6- and 12-month follow-up. Abstinence rates at 1-, 6- and 12-month follow-up periods were 34%, 18% and 17%, respectively. Results indicated that less smoking during patch treatment, and particularly during weeks 1 through 3, was the most robust predictor of successful abstinence, and this predicted smoking status at all follow-up periods. These results underscore the importance of total abstinence during the cessation process, especially at the outset of treatment, which is paramount to ultimate cessation success. Study limitations and clinical implications are discussed. C1 [Harte, Christopher B.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA. [Watts, Tyler W.; Meston, Cindy M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. RP Harte, CB (reprint author), VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, 150 S Huntington Ave 116-B4, Boston, MA 02130 USA. EM christopher.harte@va.gov OI Harte, Christopher/0000-0002-8097-7369 NR 31 TC 1 Z9 1 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1465-9891 J9 J SUBST USE JI J. Subst. Use PY 2013 VL 18 IS 5 BP 405 EP 416 DI 10.3109/14659891.2012.709913 PG 12 WC Substance Abuse SC Substance Abuse GA 206AC UT WOS:000323486300007 ER PT B AU Walker, RH AF Walker, Ruth H. BE Fernandez, HH Merello, M TI Chorea in a Man With Peripheral Neuropathy and Hepatomegaly: The Diagnosis Can Make a Difference! SO MOVEMENT DISORDERS: UNFORGETTABLE CASES AND LESSONS FROM THE BEDSIDE LA English DT Article; Book Chapter C1 James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-9362-8728-4 PY 2013 BP 155 EP 157 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BGI25 UT WOS:000323088600045 ER PT B AU Walker, RH AF Walker, Ruth H. BE Fernandez, HH Merello, M TI Speech and Gait Problems in a Patient Being Treated for Schizophrenia: A Lesson on Psychiatric Comorbidity From an Afro-Caribbean Man SO MOVEMENT DISORDERS: UNFORGETTABLE CASES AND LESSONS FROM THE BEDSIDE LA English DT Article; Book Chapter ID CEREBELLAR DEGENERATION C1 James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-9362-8728-4 PY 2013 BP 240 EP 242 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BGI25 UT WOS:000323088600072 ER PT J AU Haney, EM Calarge, C Bliziotes, MM AF Haney, Elizabeth M. Calarge, Chadi Bliziotes, M. Michael BE Karsenty, G TI Clinical Implications of Serotonin Regulation of Bone Mass SO TRANSLATIONAL ENDOCRINOLOGY OF BONE: REPRODUCTION, METABOLISM, AND THE CENTRAL NERVOUS SYSTEM LA English DT Article; Book Chapter ID SYSTEM-ACTIVE MEDICATIONS; NURSING-HOME RESIDENTS; REUPTAKE INHIBITOR USE; MINERAL DENSITY; DEPRESSIVE SYMPTOMS; FRACTURE RISK; OLDER WOMEN; HIP FRACTURE; POSTMENOPAUSAL WOMEN; PSYCHOTROPIC MEDICATIONS C1 [Haney, Elizabeth M.; Bliziotes, M. Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Calarge, Chadi] Univ Iowa, Iowa City, IA USA. [Bliziotes, M. Michael] Portland VA Med Ctr, Portland, OR USA. RP Haney, EM (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 94 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-415859-7 PY 2013 BP 189 EP 198 DI 10.1016/B978-0-12-415784-2.00016-6 PG 10 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA BGH26 UT WOS:000322959600017 ER PT S AU Wuu, CS Xu, Y Qian, X Adamovics, J Cascio, E Lu, HM AF Wuu, C-S Xu, Y. Qian, X. Adamovics, J. Cascio, E. Lu, H-M GP IOP TI Dosimetric assessment of the PRESAGE dosimeter for a proton pencil beam SO 7TH INTERNATIONAL CONFERENCE ON 3D RADIATION DOSIMETRY (IC3DDOSE) SE Journal of Physics Conference Series LA English DT Proceedings Paper CT 7th International Conference on 3D Radiation Dosimetry (IC3DDose) CY NOV 04-08, 2012 CL Sydney, AUSTRALIA SP Elekta, Scandidos, Varian Med Syst, NSW Govt, Minist Hlth, Macquarie Univ, Fac Sci, Univ Sydney, Inst Med Phys, Sun Nucl, CMS Alphatech, Nucletron, Univ Wollongong, Ctr Med Radiat Phys, NL TEC, MedTech Solut, Australasian Coll Phys Scientists & Engineers Med (ACPSEM), NSW ACT Branch ID POLYMER GEL DOSIMETRY; RADIOLOGICAL PROPERTIES; RADIATION-THERAPY; DOSE VERIFICATION; PHANTOM AB The objective of this study is to assess the feasibility of using PRESAGE dosimeters for proton pencil beam dosimetry. Two different formulations of phantom materials were tested for their suitability in characterizing a single proton pencil beam. The dosimetric response of PRESAGE was found to be linear up to 4Gy. First-generation optical CT scanner, OCTOPUS (TM) was used to implement dose distributions for proton pencil beams since it provides most accurate readout. Percentage depth dose curves and beam profiles for two proton energy, 110 MeV, and 93 MeV, were used to evaluate the dosimetric performance of two PRESAGE phantom formulas. The findings from this study show that the dosimetric properties of the phantom materials match with basic physics of proton beams. C1 [Wuu, C-S; Qian, X.] Columbia Univ, Dept Radiat Oncol, New York, NY 10027 USA. [Xu, Y.] Univ Pittsburgh Med Ctr, Dept Radiat Oncol, Pittsburgh, PA USA. [Adamovics, J.] Rider Univ, Dept Chem & Biol, Lawrenceville, NJ USA. [Cascio, E.; Lu, H-M] Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiat Oncol, Boston, MA USA. RP Wuu, CS (reprint author), Columbia Univ, Dept Radiat Oncol, New York, NY 10027 USA. EM csw6@columbia.edu RI Xu, Andy/C-7753-2016 OI Xu, Andy/0000-0002-0763-9953 NR 14 TC 0 Z9 0 U1 0 U2 0 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1742-6588 J9 J PHYS CONF SER PY 2013 VL 444 AR 012055 DI 10.1088/1742-6596/444/1/012055 PG 4 WC Physics, Multidisciplinary; Radiology, Nuclear Medicine & Medical Imaging SC Physics; Radiology, Nuclear Medicine & Medical Imaging GA BGH38 UT WOS:000322968600055 ER PT J AU Pusztaszeri, MP Sauder, KJ Cibas, ES Faquin, WC AF Pusztaszeri, Marc P. Sauder, Kenan J. Cibas, Edmund S. Faquin, William C. TI Fine-Needle Aspiration of Primary Langerhans Cell Histiocytosis of the Thyroid Gland, a Potential Mimic of Papillary Thyroid Carcinoma SO ACTA CYTOLOGICA LA English DT Article DE Thyroid; Langerhans cell histiocytosis; Eosinophilic granuloma; Fine-needle aspiration; Cytology; Langerhans cell; Dendritic cell; Immunochemistry; CD1a ID DENDRITIC CELLS; EOSINOPHILIC GRANULOMA; INVOLVEMENT; CYTOLOGY; PROGNOSIS; MOLECULE; ORIGIN; S-100; CD1A AB Background: The clinical presentation of Langerhans cell histiocytosis (LCH) as a primary solitary nodule in the thyroid gland is rare. As a result, there are few reports of its cytologic features in thyroid aspirates where it can pose a diagnostic pitfall. Case and Conclusion: To foster familiarity with its cytomorphology, we report the fine-needle aspiration biopsy (FNAB) findings of 3 specimens from 2 patients with LCH presenting as a solitary thyroid nodule. All aspirates contained numerous dispersed cells with prominent nuclear grooves, and the background showed a mixed pattern of chronic inflammation including scattered eosinophils. The aspirate from patient 1 raised a differential diagnosis that included chronic lymphocytic thyroiditis and a thyroglossal duct cyst, while the aspirate from patient 2 was interpreted as 'suspicious for papillary thyroid carcinoma'. The diagnosis of LCH was confirmed in both patients after lobectomy and immunohistochemical studies that revealed positive reactivity for CD1a and S-100. LCH of the thyroid gland is rare and can pose significant diagnostic challenges, but increased familiarity with its characteristic cytomorphology can help in avoiding diagnostic pitfalls. Copyright (C) 2013 S. Karger AG, Basel C1 [Pusztaszeri, Marc P.] Univ Hosp Geneva, Dept Pathol, Geneva, Switzerland. [Sauder, Kenan J.; Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Cibas, Edmund S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Sauder, Kenan J.; Cibas, Edmund S.; Faquin, William C.] Harvard Univ, Sch Med, Boston, MA USA. RP Faquin, WC (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 219 55 Fruit St, Boston, MA 02114 USA. EM wfaquin@partners.org NR 47 TC 4 Z9 6 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5547 J9 ACTA CYTOL JI Acta Cytol. PY 2013 VL 57 IS 4 BP 406 EP 412 DI 10.1159/000348801 PG 7 WC Pathology SC Pathology GA 201LC UT WOS:000323142100015 PM 23860349 ER PT J AU Gale, EM Kenton, N Caravan, P AF Gale, Eric M. Kenton, Nathaniel Caravan, Peter TI [Gd(CyPic3A)(H2O)(2)](-): a stable, bis(aquated) and high-relaxivity Gd(III) complex SO CHEMICAL COMMUNICATIONS LA English DT Article ID MRI CONTRAST AGENTS; MAGNETIC-RESONANCE PROBES; METAL-COMPLEXES; THERMODYNAMIC STABILITY; GADOLINIUM COMPLEX; KINETIC INERTNESS; WATER EXCHANGE; PYRIDINE; LIGANDS; DESIGN AB We report the synthesis and MR relevant properties of CyPic3A, a heptadentate chelator that forms ternary Gd(III) complexes of hydration state q = 2. [Gd(CyPic3A)(H2O)(2)](-) affords an r(1) value of 5.70 mM(-1) s(-1) at 1.41 T and 310 K and displays thermodynamic stability and kinetic inertness comparable to FDA approved MR imaging probes. C1 [Gale, Eric M.; Kenton, Nathaniel; Caravan, Peter] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Caravan, P (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Suite 2301,149 13th St, Charlestown, MA 02129 USA. EM caravan@nmr.mgh.harvard.edu FU National Institutes of Health [EB009062, CA009592] FX This work was supported by the National Institutes of Health (award EB009062 to P. C., and a post-doctoral fellowship, CA009592, to E.M.G.). NR 36 TC 13 Z9 13 U1 0 U2 14 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1359-7345 EI 1364-548X J9 CHEM COMMUN JI Chem. Commun. PY 2013 VL 49 IS 73 BP 8060 EP 8062 DI 10.1039/c3cc44116d PG 3 WC Chemistry, Multidisciplinary SC Chemistry GA 202EF UT WOS:000323195600023 PM 23903523 ER PT J AU Nott, A Fass, DM Haggarty, SJ Tsai, LH AF Nott, Alexi Fass, Daniel M. Haggarty, Stephen J. Tsai, Li-Huei BE Sweatt, JD Meaney, MJ Nestler, EJ Akbarian, S TI HDAC Inhibitors as Novel Therapeutics in Aging and Alzheimer's Disease SO EPIGENETIC REGULATION IN THE NERVOUS SYSTEM: BASIC MECHANISMS AND CLINICAL IMPACT LA English DT Article; Book Chapter ID HISTONE DEACETYLASE INHIBITORS; LONG-TERM-MEMORY; CONTEXTUAL FEAR EXTINCTION; AMYLOID PRECURSOR PROTEIN; APP/PS1 MOUSE MODEL; SYNAPTIC PLASTICITY; GENE-EXPRESSION; HUNTINGTONS-DISEASE; TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION C1 [Nott, Alexi; Tsai, Li-Huei] MIT, Howard Hughes Med Inst, Picower Inst Learning & Memory, Cambridge, MA 02139 USA. [Fass, Daniel M.; Haggarty, Stephen J.] Harvard Univ, Sch Med, Dept Neurol, Ctr Human Genet Res,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Fass, Daniel M.; Haggarty, Stephen J.] Harvard Univ, Sch Med, Dept Psychiat, Ctr Human Genet Res,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Fass, Daniel M.; Haggarty, Stephen J.; Tsai, Li-Huei] Broad Inst Harvard & MIT, Cambridge Ctr 7, Cambridge, MA USA. RP Nott, A (reprint author), MIT, Howard Hughes Med Inst, Picower Inst Learning & Memory, Cambridge, MA 02139 USA. OI /0000-0002-2029-7193 NR 115 TC 3 Z9 3 U1 0 U2 6 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-394405-4 PY 2013 BP 225 EP 248 DI 10.1016/B978-0-12-391494-1.00008-2 PG 24 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA BGD76 UT WOS:000322483000009 ER PT J AU Raven, EP Lu, PH Tishler, TA Heydari, P Bartzokis, G AF Raven, Erika P. Lu, Po H. Tishler, Todd A. Heydari, Panthea Bartzokis, George TI Increased Iron Levels and Decreased Tissue Integrity in Hippocampus of Alzheimer's Disease Detected in vivo with Magnetic Resonance Imaging SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; chelation; dementia; ferritin; field dependent relaxation rate increase (FDRI); iron; magnetic resonance imagining (MRI); myelin; prevention; treatment ID BRAIN FERRITIN IRON; MATTER STRUCTURAL INTEGRITY; OLIGODENDROCYTE CELL-DEATH; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; POPULATION-BASED COHORTS; NON-HAEMIN IRON; PARKINSONS-DISEASE; WHITE-MATTER; OXIDATIVE DAMAGE AB Background: Iron can catalyze damaging free radical reactions. With age, iron accumulates in brain gray matter regions and may contribute to the risk of developing age-related diseases such as Alzheimer's disease (AD). Prior MRI studies demonstrated increased iron deposits in basal ganglia regions; however, the hippocampus (Hipp), which is heavily damaged in AD, and comparator regions that are resistant to AD damage, such as thalamus (Th), have rarely been examined. Objective: To assess iron levels and evidence of tissue damage in Hipp and Th of AD subjects and healthy controls. Methods: Thirty-one AD and sixty-eight healthy control subjects participated in this study. High-and low-field strength MRI instruments were used in combination to quantify iron content of ferritin molecules (ferritin iron) using the field dependent relaxation rate increase (FDRI) method. Decreased transverse relaxation rate (R-2) was used as an index of tissue damage. Results: Compared with healthy controls, AD subjects had increased ferritin iron in Hipp (p = 0.019) but not Th (p = 0.637), and significantly decreased R-2 in Hipp (p < 0.001) but not Th (p = 0.37). In the entire sample, FDRI and R-2 were negatively correlated. Conclusion: The data shows that in AD, Hipp damage occurs in conjunction with ferritin iron accumulation. Prospective studies are needed to evaluate how increasing iron levels may influence the trajectory of tissue damage and cognitive and pathologic manifestations of AD. C1 [Raven, Erika P.; Tishler, Todd A.; Heydari, Panthea; Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Lu, Po H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, Dept Neurol, Div Brain Mapping, Lab Neuroimaging, Los Angeles, CA 90024 USA. [Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Dept Psychiat, West Los Angeles, CA USA. RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIH [MH 0266029, AG027342, T32 NS041231]; RCS Alzheimer's Foundation FX This work was supported in part by NIH grants (MH 0266029; AG027342; T32 NS041231) and the RCS Alzheimer's Foundation. NR 106 TC 43 Z9 44 U1 2 U2 21 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 37 IS 1 BP 127 EP 136 DI 10.3233/JAD-130209 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 206AJ UT WOS:000323487300013 PM 23792695 ER PT J AU Natunen, T Parrado, AR Helisalmi, S Pursiheimo, JP Sarajarvi, T Makinen, P Kurkinen, KMA Mullin, K Alafuzoff, I Haapasalo, A Bertram, L Soininen, H Tanzi, RE Hiltunen, M AF Natunen, Teemu Parrado, Antonio R. Helisalmi, Seppo Pursiheimo, Juha-Pekka Sarajarvi, Timo Makinen, Petra Kurkinen, Kaisa M. A. Mullin, Kristina Alafuzoff, Irina Haapasalo, Annakaisa Bertram, Lars Soininen, Hilkka Tanzi, Rudolph E. Hiltunen, Mikko TI Elucidation of the BACE1 Regulating Factor GGA3 in Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; beta-secretase; Braak staging; eukaryotic translation initiation factor 2 alpha; frozen brain tissue samples; Golgi-localized gamma-ear-containing ADP-ribosylation factor-binding protein; polymorphism; protein stability; tau protein ID BETA-SECRETASE ACTIVITY; FAMILY-BASED ASSOCIATION; TAU-HYPERPHOSPHORYLATION; NEURONAL DEGENERATION; CEREBRAL-ISCHEMIA; EXPRESSION; PROTEIN; PHOSPHORYLATION; EIF2-ALPHA; CORTEX AB Golgi-localized gamma-ear-containing ADP-ribosylation factor-binding protein (GGA3) is a central regulator of trafficking and degradation of BACE1 (beta-site A beta PP-cleaving enzyme), the rate-limiting enzyme in the production of amyloid-beta (A beta) in Alzheimer's disease (AD). Here, we assessed the potential role of GGA3 in AD pathogenesis using independent neuropathological, case-control, and family-based human sample cohorts. Increased BACE1 levels coincided with decreased GGA3 levels and with elevated phosphorylation status of eIF2 alpha-Ser51 in the temporal cortex of AD patients as compared to age-matched controls. Severity of the disease did not alter mRNA or protein levels of GGA3 in the inferior temporal cortex of AD patients, while a positive correlation between GGA3 and the levels of total, but not phosphorylated, tau was observed. Genetically, we did not observe consistent evidence for association between AD risk and common GGA3 polymorphisms across a number of independent sample cohorts. However, a nominally significant association was observed with rs2242230 (p < 0.05) among the Finnish case-control cohort. Accordingly, mRNA and protein levels of GGA3 in the inferior temporal cortex of AD patients did not significantly correlate with rs2242230 genotype status. While the present study indicates that GGA3 is involved in the cellular processes relevant for AD pathogenesis, the genetic data do not support the idea that common GGA3 polymorphisms would contribute to AD risk. C1 [Natunen, Teemu; Helisalmi, Seppo; Sarajarvi, Timo; Makinen, Petra; Kurkinen, Kaisa M. A.; Haapasalo, Annakaisa; Soininen, Hilkka; Hiltunen, Mikko] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio 70211, Finland. [Parrado, Antonio R.; Mullin, Kristina; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA USA. [Parrado, Antonio R.; Mullin, Kristina; Tanzi, Rudolph E.] Harvard Univ, Sch Med, Boston, MA USA. [Pursiheimo, Juha-Pekka] Univ Turku, Turku Ctr Biotechnol, Turku, Finland. [Alafuzoff, Irina] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden. [Bertram, Lars] Max Planck Inst Mol Genet, Dept Vertebrate Genom, Neuropsychiat Genet Grp, D-14195 Berlin, Germany. [Soininen, Hilkka] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland. RP Hiltunen, M (reprint author), Univ Eastern Finland, Inst Clin Med Neurol, POB 1627, Kuopio 70211, Finland. EM mikko.hiltunen@uef.fi RI Bertram, Lars/K-3889-2015 OI Bertram, Lars/0000-0002-0108-124X FU Academy of Finland; Finnish Funding Agency for Technology and Innovation [70048/09]; Sigrid Juselius Foundation; University of Eastern Finland (UEF-Brain); BIOMARKAPD project in the JPND programme; EVO grant of Kuopio University Hospital [5772708] FX This study was funded by Academy of Finland, EVO grant 5772708 of Kuopio University Hospital, the Finnish Funding Agency for Technology and Innovation grant 70048/09, Sigrid Juselius Foundation, the Strategic Funding of the University of Eastern Finland (UEF-Brain), and BIOMARKAPD project in the JPND programme. NR 34 TC 12 Z9 13 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 37 IS 1 BP 217 EP 232 DI 10.3233/JAD-130104 PG 16 WC Neurosciences SC Neurosciences & Neurology GA 206AJ UT WOS:000323487300019 PM 23970038 ER PT J AU Belter, JT Segil, JL Dollar, AM Weir, RF AF Belter, Joseph T. Segil, Jacob L. Dollar, Aaron M. Weir, Richard F. TI Mechanical design and performance specifications of anthropomorphic prosthetic hands: A review SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE amputee; grasping; grippers; hands; iLimb Hand; manipulation; Michelangelo Hand; rehabilitation; robotics; terminal devices AB In this article, we set forth a detailed analysis of the mechanical characteristics of anthropomorphic prosthetic hands. We report on an empirical study concerning the performance of several commercially available myoelectric prosthetic hands, including the Vincent, iLimb, iLimb Pulse, Bebionic, Bebionic v2, and Michelangelo hands. We investigated the finger design and kinematics, mechanical joint coupling, and actuation methods of these commercial prosthetic hands. The empirical findings are supplemented with a compilation of published data on both commercial and prototype research prosthetic hands. We discuss numerous mechanical design parameters by referencing examples in the literature. Crucial design trade-offs are highlighted, including number of actuators and hand complexity, hand weight, and grasp force. Finally, we offer a set of rules of thumb regarding the mechanical design of anthropomorphic prosthetic hands. C1 [Belter, Joseph T.; Dollar, Aaron M.] Yale Univ, Dept Mech Engn & Mat Sci, New Haven, CT 06511 USA. [Segil, Jacob L.] Univ Colorado, Dept Mech Engn, Boulder, CO 80309 USA. [Weir, Richard F.] Denver VA Med Ctr, Dept Vet Affairs VA Eastern Colorado Healthcare, Biomechatron Dev Lab, Denver, CO USA. [Weir, Richard F.] Univ Colorado Denver, Coll Engn & Appl Sci, Dept Bioengn, Denver, CO USA. RP Belter, JT (reprint author), Yale Univ, Dept Mech Engn & Mat Sci, 10 Hillhouse Ave, New Haven, CT 06511 USA. EM joseph.belter@yale.edu FU Gustavus and Louise Pfeiffer Research Foundation; Department of Veterans Affairs (VA) Rehabilitation Research and Development Service; U.S. Department of Defense [W81XWH-10-1-0921] FX This material was based on work supported by the Gustavus and Louise Pfeiffer Research Foundation; Department of Veterans Affairs (VA) Rehabilitation Research and Development Service, administered through the VA Colorado Eastern Healthcare System; and a U.S. Department of Defense award (grant W81XWH-10-1-0921). NR 47 TC 67 Z9 68 U1 13 U2 70 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2013 VL 50 IS 5 BP 599 EP 617 DI 10.1682/JRRD.2011.10.0188 PG 19 WC Rehabilitation SC Rehabilitation GA 202RO UT WOS:000323237500003 PM 24013909 ER PT S AU Lee, S Shima, A Singh, S Kalra, MK Kim, HJ Do, S AF Lee, Seungwan Shima, Aran Singh, Sarabjeet Kalra, Mannudeep K. Kim, Hee-Joung Do, Synho BE Nishikawa, RM Whiting, BR Hoeschen, C TI Co-registered image quality comparison in hybrid iterative reconstruction techniques: SAFIRE and SafeCT SO MEDICAL IMAGING 2013: PHYSICS OF MEDICAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Physics of Medical Imaging CY FEB 11-14, 2013 CL Lake Buena Vista, FL SP SPIE, Aeroflex Inc, Univ Cent Florida, CREOL Coll Opt & Photon, DQE Instruments Inc, Medtronic Inc, PIXELTEQ DE Iterative reconstruction; high-order statistics; SAFIRE; SafeCT; noise evaluation ID STATISTICS AB Iterative reconstruction techniques (IRTs) are used to reduce the radiation dose significantly and suppress the noise in computed tomography (CT) imaging. However, the image from IRTs is unacceptable to the human visual system due to the presence of outlier and non-Gaussian noise structure. The conventional noise measurements, such as mean and standard deviation, are limited to provide the information of noise characteristics of an image comprehensively when the undesirable noise structure happens on the image. In this study, the images reconstructed by using Weighted filtered back-projection (WFBP) and image-based IRTs (SAFIRE and SafeCT) were compared in terms of conventional noise statistics, high-order noise statistics, modulation transfer function (MTF), and slice sensitivity profile (SSP) with different levels of radiation dose. The results showed that the noise characteristics, which were considered with conventional and high-order noise statistics, and spatial resolution characteristics were different for the IRTs, reconstruction parameters, and levels of radiation dose. This study can contribute to the optimization of image quality from IRT with the reduction of radiation dose and development of IRT which overcomes the issue caused by undesirable noise structures. C1 [Lee, Seungwan; Shima, Aran; Singh, Sarabjeet; Kalra, Mannudeep K.; Do, Synho] Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St, Boston, MA 02114 USA. [Lee, Seungwan; Kim, Hee-Joung] Yonsei Univ, Coll Hlth Sci, Dept Radiol Sci, Seoul 120749, South Korea. RP Lee, S (reprint author), Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St, Boston, MA 02114 USA. NR 9 TC 1 Z9 1 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9442-9 J9 PROC SPIE PY 2013 VL 8668 AR 86683G DI 10.1117/12.2007525 PG 6 WC Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging GA BFZ77 UT WOS:000322002700117 ER PT S AU Zhang, D Li, XH Liu, B AF Zhang, Da Li, Xinhua Liu, Bob BE Nishikawa, RM Whiting, BR Hoeschen, C TI Multi-resolution Analysis of Scatter in Digital Breast Tomosynthesis Imaging SO MEDICAL IMAGING 2013: PHYSICS OF MEDICAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Physics of Medical Imaging CY FEB 11-14, 2013 CL Lake Buena Vista, FL SP SPIE, Aeroflex Inc, Univ Cent Florida, CREOL Coll Opt & Photon, DQE Instruments Inc, Medtronic Inc, PIXELTEQ DE Digital Breast Tomosynthesis; scatter estimation; multi-resolution analysis; wavelet; Monte Carlo simulation; experimental study ID MAMMOGRAPHY; CANCER AB The influence of large x-ray scatter components in projection images remains a problem for digital breast tomosynthesis, especially when anti-scatter grids may not be used because of dose limitation and possible source/detector geometric limitations. Monte-Carlo simulation of scatter fits better in this situation, but the heavy computational cost hinders its clinical application. To simplify scatter estimation, scatter is often assumed to be smooth. However, scatter is not spatial invariant across a projection image, and where and to what degree the smoothness could be claimed and utilized is unclear. In this study, we investigated this question via multi-resolution analysis based on two experiments: one with direct measurements of scatter profiles in the projection images of an anthropomorphic breast phantom; the other with scatter map obtained from Monte-Carlo simulation that used a voxelized breast model as input. We applied 1D and 2D wavelet-based multi-resolution analyses to the scatter profiles and maps. The first experiment indicated that a reduced number of scatter data points that matches the true data can be extracted from densely sampled but noisy scatter profiles: a data reduction rate of 64-128 was achieved at the inner region of the phantom, suggesting that the slowly changing scatter may be obtained at lower sampling distances of 9.0-17.9 mm. Near the edge of the phantom a data reduction rate of 8 was achieved, corresponding to a sampling distance of 2.2 mm. Similar observations were made from the second experiment. C1 [Zhang, Da; Li, Xinhua; Liu, Bob] Massachusetts Gen Hosp, Div Diagnost Imaging Phys, 55 Fruit St, Boston, MA 02114 USA. RP Liu, B (reprint author), Massachusetts Gen Hosp, Div Diagnost Imaging Phys, 55 Fruit St, Boston, MA 02114 USA. EM bliu7@bics.bwh.harvard.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9442-9 J9 PROC SPIE PY 2013 VL 8668 AR 86685L DI 10.1117/12.2007315 PG 7 WC Optics; Physics, Applied; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging GA BFZ77 UT WOS:000322002700187 ER PT J AU Thomas, RJ Chan, ST AF Thomas, Robert Joseph Chan, Suk-tak BE Nofzinger, E Maquet, P Thorpy, MJ TI Neuroimaging of cognitive effects in obstructive sleep apnea SO NEUROIMAGING OF SLEEP AND SLEEP DISORDERS LA English DT Article; Book Chapter ID MAGNETIC-RESONANCE-SPECTROSCOPY; ALZHEIMERS-DISEASE PATHOGENESIS; TERM INTERMITTENT HYPOXIA; NOCTURNAL BLOOD-PRESSURE; POSITIVE AIRWAY PRESSURE; BRAIN STRUCTURAL-CHANGES; SPATIAL WORKING-MEMORY; INTIMA-MEDIA THICKNESS; APOE EPSILON-4 ALLELE; CORTICAL SYNCHRONIZATION C1 [Thomas, Robert Joseph] Beth Israel Deaconess Med Ctr, Med Div Pulm Crit Care & Sleep, Boston, MA 02215 USA. [Chan, Suk-tak] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. RP Thomas, RJ (reprint author), Beth Israel Deaconess Med Ctr, Med Div Pulm Crit Care & Sleep, Boston, MA 02215 USA. RI Chan, Suk-tak/G-5846-2015 NR 105 TC 0 Z9 0 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-01863-1 PY 2013 BP 264 EP 274 D2 10.1017/CBO9781139088268 PG 11 WC Clinical Neurology; Neurosciences; Neuroimaging SC Neurosciences & Neurology GA BFZ47 UT WOS:000321971800036 ER PT J AU de Magistris, L Picardi, A Siniscalco, D Riccio, MP Sapone, A Cariello, R Abbadessa, S Medici, N Lammers, KM Schiraldi, C Iardino, P Marotta, R Tolone, C Fasano, A Pascotto, A Bravaccio, C AF de Magistris, Laura Picardi, Annarita Siniscalco, Dario Riccio, Maria Pia Sapone, Anna Cariello, Rita Abbadessa, Salvatore Medici, Nicola Lammers, Karen M. Schiraldi, Chiara Iardino, Patrizia Marotta, Rosa Tolone, Carlo Fasano, Alessio Pascotto, Antonio Bravaccio, Carmela TI Antibodies against Food Antigens in Patients with Autistic Spectrum Disorders SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID PRINCIPAL PATHOGENETIC COMPONENTS; COMMON DIETARY PROTEINS; GASTROINTESTINAL SYMPTOMS; CELIAC-DISEASE; INTESTINAL PERMEABILITY; CYTOKINE PRODUCTION; PERIPHERAL-BLOOD; CHILDREN; GLUTEN; INFLAMMATION AB Purpose. Immune system of some autistic patients could be abnormally triggered by gluten/casein assumption. The prevalence of antibodies to gliadin and milk proteins in autistic children with paired/impaired intestinal permeability and under dietary regimen either regular or restricted is reported. Methods. 162 ASDs and 44 healthy children were investigated for intestinal permeability, tissue-transglutaminase (tTG), anti-endomysium antibodies (EMA)-IgA, and total mucosal IgA to exclude celiac disease; HLA-DQ2/-DQ8 haplotypes; total systemic antibodies (IgA, IgG, and IgE); specific systemic antibodies: alpha-gliadin (AGA-IgA and IgG), deamidated-gliadin-peptide (DGP-IgA and IgG), total specific gliadin IgG (all fractions: alpha, beta, gamma, and omega), beta-lactoglobulin IgG, alpha-lactalbumin IgG, casein IgG; and milk IgE, casein IgE, gluten IgE, -lactoglobulin IgE, and alpha-lactalbumin IgE. Results. AGA-IgG and DPG-IgG titers resulted to be higher in ASDs compared to controls and are only partially influenced by diet regimen. Casein IgG titers resulted to be more frequently and significantly higher in ASDs than in controls. Intestinal permeability was increased in 25.6% of ASDs compared to 2.3% of healthy children. Systemic antibodies production was not influenced by paired/impaired intestinal permeability. Conclusions. Immune system of a subgroup of ASDs is triggered by gluten and casein; this could be related either to AGA, DPG, and Casein IgG elevated production or to impaired intestinal barrier function. C1 [de Magistris, Laura; Sapone, Anna; Cariello, Rita] Univ Naples 2, CIRANAD, I-80131 Naples, Italy. [Picardi, Annarita] Univ Naples 2, CIRANAD, Alimenti & Salute PhD Sch, I-80131 Naples, Italy. [Siniscalco, Dario; Schiraldi, Chiara] Univ Naples 2, Dept Expt Med, I-80138 Naples, Italy. [Siniscalco, Dario] Forza Silenzio, Ctr Autism, I-80138 Naples, Italy. [Riccio, Maria Pia; Pascotto, Antonio] Univ Naples 2, Dept Mental & Phys Hlth & Prevent Med, I-80138 Naples, Italy. [Abbadessa, Salvatore; Medici, Nicola] Univ Naples 2, Dept Gen Pathol, I-80138 Naples, Italy. [Lammers, Karen M.; Fasano, Alessio] Massachusetts Gen Hosp East, Ctr Celiac Res & Mucosal Immunol, Charlestown, MA 02129 USA. [Lammers, Karen M.; Fasano, Alessio] Massachusetts Gen Hosp East, Biol Res Ctr, Charlestown, MA 02129 USA. [Iardino, Patrizia] Univ Naples 2, UOC Clin & Mol Pathol, I-80138 Naples, Italy. [Marotta, Rosa] Univ Catanzaro Magna Graecia, Dept Psychiat, I-88100 Catanzaro, Italy. [Tolone, Carlo] Univ Naples 2, Dept Woman Children & Gen & Specialist Surg, I-80138 Naples, Italy. [Bravaccio, Carmela] Univ Naples Federico II, Dept Med Translat Sci, I-80131 Naples, Italy. RP de Magistris, L (reprint author), Univ Naples 2, CIRANAD, Via Pansini 5,Bldg 3, I-80131 Naples, Italy. EM laura.demagistris@unina2.it OI ABBADESSA, Salvatore/0000-0002-3607-2837; SCHIRALDI, Chiara/0000-0002-1066-843X; Siniscalco, Dario/0000-0002-3779-2596 FU Autism Research Institute (ARI); Centro Inter-universitario per Ricerche suAlimenti, Nutrizione e Apparato Digerente (CIRANAD) FX This study was approved by the Ethical Committee of the Second University of Naples (number 71, 11/02/2011), and it was supported by the Autism Research Institute (ARI) Grant 2010 (Siniscalco D) and Centro Inter-universitario per Ricerche suAlimenti, Nutrizione e Apparato Digerente (CIRANAD) Grant 2011. The authors are grateful to Miss. Elisabetta Carlino for technical advice on Dionex. A. Fasano has a financial interest in Alba Therapeutics. A. Sapone has a financial interest in Dr. Shar Institute. All other authors have no conflict of interests. NR 42 TC 5 Z9 5 U1 1 U2 7 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 J9 BIOMED RES INT JI Biomed Res. Int. PY 2013 AR 729349 DI 10.1155/2013/729349 PG 11 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 199GB UT WOS:000322981400001 ER PT J AU Barkai, U Weir, GC Colton, CK Ludwig, B Bornstein, SR Brendel, MD Neufeld, T Bremer, C Leon, A Evron, Y Yavriyants, K Azarov, D Zimermann, B Maimon, S Shabtay, N Balyura, M Rozenshtein, T Vardi, P Bloch, K de Vos, P Rotem, A AF Barkai, Uriel Weir, Gordon C. Colton, Clark K. Ludwig, Barbara Bornstein, Stefan R. Brendel, Mathias D. Neufeld, Tova Bremer, Chezi Leon, Assaf Evron, Yoav Yavriyants, Karina Azarov, Dimitri Zimermann, Baruch Maimon, Shiri Shabtay, Noa Balyura, Maria Rozenshtein, Tania Vardi, Pnina Bloch, Konstantin de Vos, Paul Rotem, Avi TI Enhanced Oxygen Supply Improves Islet Viability in a New Bioartificial Pancreas SO CELL TRANSPLANTATION LA English DT Article DE Diabetes; Bioartificial pancreas (BAP); Islets; Implantation; Immune barrier; Oxygen ID IMMUNOISOLATION DEVICE; INSULIN-SECRETION; TRANSPLANTATION; RAT; CELLS; ENCAPSULATION; SURVIVAL; MODEL; VASCULARIZATION; CONSUMPTION AB The current epidemic of diabetes with its overwhelming burden on our healthcare system requires better therapeutic strategies. Here we present a promising novel approach for a curative strategy that may be accessible for all insulin-dependent diabetes patients. We designed a subcutaneous implantable bioartificial pancreas (BAP)-the "beta-Air" that is able to overcome critical challenges in current clinical islet transplantation protocols: adequate oxygen supply to the graft and protection of donor islets against the host immune system. The system consists of islets of Langerhans immobilized in an alginate hydrogel, a gas chamber, a gas permeable membrane, an external membrane, and a mechanical support. The minimally invasive implantable device, refueled with oxygen via subdermally implanted access ports, completely normalized diabetic indicators of glycemic control (blood glucose intravenous glucose tolerance test and HbA1c) in streptozotocin-induced diabetic rats for periods up to 6 months. The functionality of the device was dependent on oxygen supply to the device as the grafts failed when oxygen supply was ceased. In addition, we showed that the device is immuno-protective as it allowed for survival of not only isografts but also of allografts. Histological examination of the explanted devices demonstrated morphologically and functionally intact islets; the surrounding tissue was without signs of inflammation and showed visual evidence of vasculature at the site of implantation. Further increase in islets loading density will justify the translation of the system to clinical trials, opening up the potential for a novel approach in diabetes therapy. C1 [Barkai, Uriel; Neufeld, Tova; Bremer, Chezi; Leon, Assaf; Evron, Yoav; Yavriyants, Karina; Azarov, Dimitri; Zimermann, Baruch; Maimon, Shiri; Shabtay, Noa; Balyura, Maria; Rozenshtein, Tania; Rotem, Avi] Beta O2 Technol, IL-49511 Kiryat Arie, Petach Tikva, Israel. [Weir, Gordon C.] Joslin Diabet Ctr, Div Res, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA. [Colton, Clark K.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Ludwig, Barbara; Bornstein, Stefan R.; Brendel, Mathias D.] Univ Hosp Carl Gustav Carus, Dept Med 3, Dresden, Germany. [Vardi, Pnina] Lin Med Ctr, Dept Diabet, Clalit Hlth Serv, Haifa, Israel. [Bloch, Konstantin] Tel Aviv Univ, Sackler Fac Med, Felsenstein Med Res Ctr, Diabet & Obes Res Lab, Petah Tiqwa, Israel. [de Vos, Paul] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Lab Med, Sect Immunoendocrinol, NL-9713 AV Groningen, Netherlands. RP Barkai, U (reprint author), Beta O2 Technol, 6 Efal St,POB 3226, IL-49511 Kiryat Arie, Petach Tikva, Israel. EM u.barkai@beta-o2.com RI de Vos, Paul/A-3170-2013 FU Beta-O2 Technologies, Israel; DFG; TRC [127]; Beta-O2 Technologies FX The study was funded by Beta-O2 Technologies, Israel. The study was partly supported by a DFG grant and TRC 127 to Stefan R. Bornstein, Barbara Ludwig, and Mathias D. Brendel. The authors gratefully acknowledge the technical assistance of Bart J. de Haan (Department of Pathology and Laboratory Medicine, University of Groningen, Groningen, The Netherlands) in the inmunohistochemistry analysis. Beta-O2 Technologies (the funder of this study) is the employer of Uriel Barkai, Tova Neufeld, Chezi Bremer, Assaf Leon, Yoav Evron, Karina Yavriyants, Dimitri Azarov, Baruch Zimermann, Shin Maimon, Noa Shabtay, Maria Balyura, Tania Rozenshtein, and Avi Rotem. Gordon C. Weir and Clark K Colton are on the Scientific Advisory Board for of Beta-O2 Technologies and are stock option holders. Paul de Vos is on the Scientific Advisory Board of Beta-O2 Technologies. Beta-O2 Technologies patented the design of the "beta-air" device and is pursuing its clinical development. NR 40 TC 32 Z9 32 U1 4 U2 33 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 J9 CELL TRANSPLANT JI Cell Transplant. PY 2013 VL 22 IS 8 BP 1463 EP 1476 DI 10.3727/096368912X657341 PG 14 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA 200SX UT WOS:000323092300012 PM 23043896 ER PT S AU Hoffmann, U Ayata, C AF Hoffmann, Ulrike Ayata, Cenk BE Zuccarello, M Clark, JF PyneGeithman, G Andaluz, N Hartings, JA Adeoye, OM TI Neurovascular Coupling During Spreading Depolarizations SO CEREBRAL VASOSPASM: NEUROVASCULAR EVENTS AFTER SUBARACHNOID HEMORRHAGE SE Acta Neurochirurgica Supplementum LA English DT Proceedings Paper CT 11th International Conference on Cerebral Vasospasm: Neurovascular Events after Subarachnoid Hemorrhage CY JUL 21-23, 2011 CL Cincinnati, OH DE Cortical spreading depolarizations; Neurovascular coupling; Cerebral perfusion; Electrocorticography ID CEREBRAL-CORTEX; SUBARACHNOID HEMORRHAGE; BLOOD-FLOW; DEPRESSION; ISCHEMIA; HYPOPERFUSION; PERFUSION; RAT AB Injury depolarizations akin to spreading depression of Leao are important in the progression of tissue damage in ischemic stroke, intracranial hemorrhage, and trauma. Much of the research on injury depolarizations has been focused on their origins, electrophysiological mechanisms, and metabolic impact. Recent studies showed that injury depolarizations cause vasoconstriction and diminish perfusion, which radically differs from the predominantly hyperemic response to spreading depression in otherwise-normal brain tissue. This adverse hemodynamic effect exacerbates metabolic supply-demand mismatch and worsens the tissue outcome. Although the mechanisms transforming the hemodynamic response from vasodilation into vasoconstriction are unclear, recent data suggest a role for elevated extracellular K+ and reduced intravascular perfusion pressure, among other factors. Clues from physiological and pharmacological studies in normal or injured brain in different species suggest that the intense pandepolarization evokes multiple opposing vasomotor mechanisms with variable magnitudes and timing, providing a conceptual framework to dissect the complex neurovascular coupling in brain injury. C1 [Hoffmann, Ulrike] Univ Munich, Klinikum Rechts Isar, Klin Anaesthesiol Tech, Munich, Germany. RP Hoffmann, U (reprint author), Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Neurovasc Res Lab, 149 13th St,Room 6408, Charlestown, MA 02129 USA. EM cayata@partners.org FU NINDS NIH HHS [NS055104, NS061505] NR 17 TC 5 Z9 6 U1 0 U2 1 PU SPRINGER-VERLAG WIEN PI VIENNA PA SACHSENPLATZ 4-6, A-1201 VIENNA, AUSTRIA SN 0065-1419 BN 978-3-7091-1191-8 J9 ACTA NEUROCHIR SUPPL JI Acta Neurochir. Suppl. PY 2013 VL 115 BP 161 EP 165 DI 10.1007/978-3-7091-1192-5_31 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA BGF56 UT WOS:000322747200031 PM 22890663 ER PT J AU David, SP Lancaster, T Stead, LF Evins, AE Prochaska, JJ AF David, Sean P. Lancaster, Tim Stead, Lindsay F. Evins, A. Eden Prochaska, Judith J. TI Opioid antagonists for smoking cessation SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Buprenorphine [therapeutic use]; Naloxone [therapeutic use]; Naltrexone [therapeutic use]; Narcotic Antagonists [therapeutic use]; Randomized Controlled Trials as Topic; Smoking [drug therapy]; Smoking Cessation [methods]; Humans ID RELATIVE REINFORCING VALUE; CIGARETTE-SMOKING; NALTREXONE TREATMENT; NICOTINE-DEPENDENCE; BEHAVIOR; NALOXONE; SMOKERS; WITHDRAWAL AB Background The reinforcing properties of nicotine may be mediated through release of various neurotransmitters both centrally and systemically. People who smoke report positive effects such as pleasure, arousal, and relaxation as well as relief of negative affect, tension, and anxiety. Opioid (narcotic) antagonists are of particular interest to investigators as potential agents to attenuate the rewarding effects of cigarette smoking. Objectives To evaluate the efficacy of opioid antagonists in promoting long-term smoking cessation. The drugs include naloxone and the longer-acting opioid antagonist naltrexone. Search methods We searched the Cochrane Tobacco Addiction Group Specialised Register for trials of naloxone, naltrexone and other opioid antagonists and conducted an additional search of MEDLINE using 'Narcotic antagonists' and smoking terms in April 2013. We also contacted investigators, when possible, for information on unpublished studies. Selection criteria We considered randomised controlled trials comparing opioid antagonists to placebo or an alternative therapeutic control for smoking cessation. We included in the meta-analysis only those trials which reported data on abstinence for a minimum of six months. We also reviewed, for descriptive purposes, results from short-term laboratory-based studies of opioid antagonists designed to evaluate psychobiological mediating variables associated with nicotine dependence. Data collection and analysis We extracted data in duplicate on the study population, the nature of the drug therapy, the outcome measures, method of randomisation, and completeness of follow-up. The main outcome measure was abstinence from smoking after at least six months follow-up in patients smoking at baseline. Abstinence at end of treatment was a secondary outcome. We extracted cotinine-or carbon monoxide-verified abstinence where available. Where appropriate, we performed meta-analysis, pooling risk ratios using a Mantel-Haenszel fixed-effect model. Main results Eight trials of naltrexone met inclusion criteria for meta-analysis of long-term cessation. One trial used a factorial design so five trials compared naltrexone versus placebo and four trials compared naltrexone plus nicotine replacement therapy (NRT) versus placebo plus NRT. Results from 250 participants in one long-term trial remain unpublished. No significant difference was detected between naltrexone and placebo (risk ratio (RR) 1.00; 95% confidence interval (CI) 0.66 to 1.51, 445 participants), or between naltrexone and placebo as an adjunct to NRT (RR 0.95; 95% CI 0.70 to 1.30, 768 participants). The estimate was similar when all eight trials were pooled (RR 0.97; 95% CI 0.76 to 1.24, 1213 participants). In a secondary analysis of abstinence at end of treatment, there was also no evidence of any early treatment effect, (RR 1.03; 95% CI 0.88 to 1.22, 1213 participants). No trials of naloxone or buprenorphine reported abstinence outcomes. Authors' conclusions Based on data from eight trials and over 1200 individuals, there was no evidence of an effect of naltrexone alone or as an adjunct to NRT on long-term smoking abstinence, with a point estimate strongly suggesting no effect and confidence intervals that make a clinically important effect of treatment unlikely. Although further trials might narrow the confidence intervals they are unlikely to be a good use of resources. C1 [David, Sean P.] Stanford Univ, Ctr Educ Family & Community Med, Stanford, CA 94304 USA. [Lancaster, Tim; Stead, Lindsay F.] Univ Oxford, Dept Primary Care Hlth Sci, Oxford, England. [Evins, A. Eden] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Prochaska, Judith J.] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94304 USA. RP David, SP (reprint author), Stanford Univ, Ctr Educ Family & Community Med, 1070 Arastradero Rd,Suite 300, Stanford, CA 94304 USA. EM spdavid@stanford.edu OI David, Sean/0000-0002-4922-2603 FU Brown University/Memorial Hospital of Rhode Island, USA; Department of Primary Care Health Sciences, University of Oxford, UK; National School for Health Research School for Primary Care Research, UK; National Institute for Health Research (NIHR), UK; National Institute of Mental Health (NIMH), USA [R01 MH083684]; National Institute on Drug Abuse, USA [P50 DA009253]; Tobacco-Related Disease Research Program (TRDRP), USA [17RT-0077] FX Internal sources; Brown University/Memorial Hospital of Rhode Island, USA.; Department of Primary Care Health Sciences, University of Oxford, UK.; National School for Health Research School for Primary Care Research, UK.; External sources; National Institute for Health Research (NIHR), UK.; National Institute of Mental Health (NIMH), USA.; R01 MH083684 (Dr Prochaska); National Institute on Drug Abuse, USA.; P50 DA009253 (Dr Prochaska); Tobacco-Related Disease Research Program (TRDRP), USA.; 17RT-0077 NR 28 TC 8 Z9 8 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 6 AR CD003086 DI 10.1002/14651858.CD003086.pub3 PG 38 WC Medicine, General & Internal SC General & Internal Medicine GA 174AC UT WOS:000321124000022 PM 23744347 ER PT J AU Iyengar, SR Hoyte, EG Loza, A Bonaccorso, S Chiang, D Umetsu, DT Nadeau, KC AF Iyengar, Shuba Rajashri Hoyte, Elizabeth G. Loza, Angelica Bonaccorso, Salvatore Chiang, David Umetsu, Dale T. Nadeau, Kari Christine TI Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY LA English DT Article DE Atopic dermatitis; Immunoglobulin E; Omalizumab; Cytokine expression ID THYMIC STROMAL LYMPHOPOIETIN; ANTI-IGE ANTIBODY; ALLERGIC-ASTHMA; RI EXPRESSION; INFLAMMATION; THERAPY; CELLS; DESENSITIZATION; ECZEMA; TSLP AB Background: Severe refractory atopic dermatitis (AD) is a chronic, debilitating condition that is associated with elevated serum immunoglobulin E (IgE) levels. Thymic stromal lymphopoietin (TSLP), thymus and activation-regulated chemokine (TARC) and OX40 ligand (OX40L) are important immunologic factors involved in the pathogenesis of AD. Omalizumab, an anti-IgE antibody indicated for use in allergic asthma, is implicated in regulating allergen presentation by dendritic cells and the T cell response during the effector phases of allergic disease. We investigated if anti-IgE therapy modulates the allergen-specific responses mediated by the TSLP pathway in young patients with severe refractory AD. Methods: This was a randomized, double-blind, placebo-controlled study of 8 patients between the ages of 4 and 22 years (mean = 11.6 years) with severe refractory AD (clinical trials.gov NCT01678092). Serum IgE ranged from 218 to 1,890 (mean = 1,068 IU/ml). Subjects received omalizumab (n = 4) or placebo (n = 4) every 2-4 weeks over 24 weeks using a regimen extrapolated from the package insert. TSLP, TARC, OX40L and other cytokines involved in AD were measured by using cytometric bead arrays. Results: All patients receiving omalizumab had strikingly decreased levels of TSLP, OX40L, TARC (involved in Th2 polarization) and interleukin (IL)-9 compared to placebo. In addition, there was a marked increase in IL-10, a tolerogenic cytokine, in the omalizumab-treated group. Patients on anti-IgE therapy had an improvement in clinical outcomes as measured by the SCORAD system; however, these effects were comparable to improvements in the control group. Conclusions: Anti-IgE therapy with omalizumab decreases levels of cytokines that are involved in Th2 polarization and allergic inflammation, including TSLP, TARC and OX40L. Copyright (c) 2013 S. Karger AG, Basel C1 [Iyengar, Shuba Rajashri] Massachusetts Gen Hosp, Div Pediat Allergy, Boston, MA 02114 USA. [Umetsu, Dale T.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA USA. [Hoyte, Elizabeth G.; Loza, Angelica; Bonaccorso, Salvatore; Chiang, David; Nadeau, Kari Christine] Stanford Univ, Sch Med, Div Pulm Allergy & Crit Care, Palo Alto, CA 94304 USA. RP Iyengar, SR (reprint author), Massachusetts Gen Hosp Children, Div Pediat Allergy & Immunol, 175 Cambridge St,Suite 559A,Charles River Pk Sout, Boston, MA 02114 USA. EM riyengar@partners.org FU Oxnard Foundation FX We would like to thank the Oxnard Foundation for supporting this study. NR 23 TC 39 Z9 41 U1 3 U2 12 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-2438 J9 INT ARCH ALLERGY IMM JI Int. Arch. Allergy Immunol. PY 2013 VL 162 IS 1 BP 89 EP 93 DI 10.1159/000350486 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA 196LK UT WOS:000322776600013 PM 23816920 ER PT J AU Cholerton, B Larson, EB Baker, LD Craft, S Crane, PK Millard, SP Sonnen, JA Montine, TJ AF Cholerton, Brenna Larson, Eric B. Baker, Laura D. Craft, Suzanne Crane, Paul K. Millard, Steven P. Sonnen, Joshua A. Montine, Thomas J. TI Neuropathologic Correlates of Cognition in a Population-Based Sample SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; brain; cerebrovascular disorders; cognition; dementia; Lewy bodies; pathologic processes ID ALZHEIMERS ASSOCIATION GUIDELINES; MINI-MENTAL-STATE; PARKINSONS-DISEASE; OLDER-ADULTS; NATIONAL INSTITUTE; DEMENTIA; IMPAIRMENT; COMMUNITY; PERFORMANCE; AUTOPSY AB Many cognitively normal older adults have underlying neuropathologic changes of Alzheimer's disease (AD), vascular brain injury (VBI), or Lewy body disease (LBD), which confer an increased risk of dementia. The current study focused on the association between multiple neuropathologic indices and performance on specific cognitive domains in a community sample of older adults. Of 438 participants in the Adult Changes in Thought population-based study of brain aging who were autopsied, 363 subjects had cognitive testing at their final study visit and were included. Associations were measured between performance on the Cognitive Abilities Screening Instrument prior to death and neuropathologic endpoints, including AD neuropathologic changes, LBD, cerebral amyloid angiopathy, and measures of VBI. Braak stage for neurofibrillary tangles, lower brain weight, and VBI as measured by cerebral cortical microvascular lesions (mu VBI) explained a significant proportion of the variance associated with global cognitive test performance (R-2 = 0.31, p < 0.0001) both in the entire sample and when analysis was restricted to non-demented subjects (R-2 = 0.23, p < 0.0001). Specific cognitive domains were differentially related to neuropathologic lesion type: memory and executive function with AD pathologic changes and cortical mu VBI, executive function with subcortical mu VBI, and visuospatial construction with LBD. Thus, neuropathologic lesions of LBD and mu VBI are associated with poorer cognitive performance over and above AD neuropathologic changes in subjects without dementia in this cohort. These findings underscore that cognitive impairment is a complex convergent trait that has important implications for clinical investigation and medical management of older adults. C1 [Cholerton, Brenna] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Millard, Steven P.] Vet Affairs Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA. [Cholerton, Brenna] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Larson, Eric B.; Crane, Paul K.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Sonnen, Joshua A.; Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Baker, Laura D.; Craft, Suzanne] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA. RP Cholerton, B (reprint author), VA Puget Sound Hlth Care Syst GRECC A 182, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM bchol@u.washington.edu RI Crane, Paul/C-8623-2014; Sonnen, 37382016/H-3738-2016; OI Sonnen, 37382016/0000-0001-9267-8705; Crane, Paul/0000-0003-4278-7465 FU Group Health Research Institute; Nancy and Buster Alvord Endowment; Department of Veterans Affairs; [NS062684]; [AG006781]; [AG024180] FX This research was supported by NS062684, AG006781, AG024180, the Group Health Research Institute, the Nancy and Buster Alvord Endowment, and the Department of Veterans Affairs. The funding sources did not provide scientific input for the study. NR 53 TC 13 Z9 13 U1 1 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 36 IS 4 BP 699 EP 709 DI 10.3233/JAD-130281 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 195XV UT WOS:000322738000008 PM 23666176 ER PT J AU Shaw, ND Goodwin, JL Silva, GE Hall, JE Quan, SF Malhotra, A AF Shaw, Natalie D. Goodwin, James L. Silva, Graciela E. Hall, Janet E. Quan, Stuart F. Malhotra, Atul TI Obstructive Sleep Apnea (OSA) in Preadolescent Girls is Associated with Delayed Breast Development Compared to Girls without OSA SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Obstructive sleep apnea; puberty; adolescence; sex steroids; lung ID LUTEINIZING-HORMONE SECRETION; PUBERTAL SELF-ASSESSMENT; PRESSURE TREATMENT; SEXUAL-MATURATION; TUCSON CHILDRENS; OBESE MEN; PATTERN; TESTOSTERONE; DYSFUNCTION; STAGE AB Study Objective: Adults with obstructive sleep apnea (OSA) have lower sex steroid levels than controls. We sought to determine whether OSA also interferes with reproductive hormones in adolescence by tracking the pace of pubertal development. Methods: One hundred seventy-two children in the Tucson Children's Assessment of Sleep Apnea study (TuCASA) underwent two home polysomnographic studies, spaced 4-5 years apart. Height and weight were measured at both visits, and Tanner staging of breasts/genitals and pubic hair were self-assessed by a pictorial questionnaire at follow-up. Results: Eighty-seven girls and 85 boys, age 8.9 +/- 1.6 years (mean +/- SD) at baseline and 13.4 +/- 1.6 years at follow-up, participated. Twenty-seven percent of participants were overweight or obese at baseline, and the majority remained so at follow-up. Twenty-six percent of girls and 28% of boys met criteria for OSA, defined as a respiratory disturbance index (RDI) >= 1/h associated with a 3% desaturation (RDI 3%), at baseline. There was an inverse relationship between baseline log RDI 3% and Tanner breast stage at follow-up (coefficient -1.3, p = 0.02) in girls after adjusting for age (p < 0.001), body mass index (p < 0.005), and ethnicity. Girls with OSA at baseline were more than 1 Tanner breast stage behind girls without OSA at follow-up. OSA did not affect genital development in boys or pubic hair development in either sex. Conclusions: OSA in preadolescent girls predicts delayed breast development relative to girls without OSA. Sleep fragmentation and/or hypoxia seen in OSA may interfere with reproductive development in girls. C1 [Shaw, Natalie D.; Hall, Janet E.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Shaw, Natalie D.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA. [Shaw, Natalie D.; Quan, Stuart F.; Malhotra, Atul] Harvard Univ, Sch Med, Div Sleep Med, Boston, MA USA. [Goodwin, James L.; Quan, Stuart F.] Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA. [Silva, Graciela E.] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA. [Quan, Stuart F.; Malhotra, Atul] Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA. RP Shaw, ND (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. OI Shaw, Natalie/0000-0002-0847-9170; Hall, Janet/0000-0003-4644-3061 FU National Heart, Lung, and Blood Institute [HL 62373]; NICHD National Institutes of Health [1K23HD073304-01] FX This work was supported by grant HL 62373 from the National Heart, Lung, and Blood Institute. Dr Shaw received fellowship support from the NICHD National Institutes of Health (1K23HD073304-01). NR 51 TC 3 Z9 3 U1 0 U2 4 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2013 VL 9 IS 8 BP 813 EP 818 DI 10.5664/jcsm.2928 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 201XX UT WOS:000323177500012 PM 23946712 ER PT J AU Nedjat-Haiem, FR Carrion, IV Lorenz, KA Ell, K Palinkas, L AF Nedjat-Haiem, Frances R. Carrion, Iraida V. Lorenz, Karl A. Ell, Kathleen Palinkas, Lawrence TI PSYCHOSOCIAL CONCERNS AMONG LATINAS WITH LIFE-LIMITING ADVANCED CANCERS SO OMEGA-JOURNAL OF DEATH AND DYING LA English DT Article ID BREAST-CANCER; HISPANIC PATIENTS AB Research has demonstrated that limited dialogue in end-of-life (EOL) care can negatively impact decision-making and place of death. Furthermore, when vulnerable populations are faced with EOL cancer care, they experience issues resulting from previous gaps in services attributed to sociocultural and economic issues that influence EOL care. These conditions place an additional burden on disadvantaged populations which can cause distress, especially as disparate conditions continue to persist. Little is known about Latinos' psychosocial concerns that lead to distress in EOL care. The objective of this study is to explore Latinas' experiences with life-limiting cancer conditions to identify the EOL care concerns that impact their dying experience. This study used a phenomenological approach to explore the EOL care concerns of 24 Latinas receiving treatment for metastatic cancers in a public sector healthcare system in Los Angeles, California. In-depth interviews were recorded and transcribed, and qualitative analysis was performed using Atlas.ti software. C1 [Nedjat-Haiem, Frances R.; Lorenz, Karl A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Nedjat-Haiem, Frances R.; Carrion, Iraida V.; Ell, Kathleen; Palinkas, Lawrence] Univ So Calif, Pacific Palisades, CA 90272 USA. RP Nedjat-Haiem, FR (reprint author), Univ So Calif, 17165 Ave Santa Ynez, Pacific Palisades, CA 90272 USA. EM nedjatha@usc.edu OI Carrion, Iraida/0000-0003-4076-6644 FU NCI NIH HHS [R25CA110454] NR 17 TC 3 Z9 3 U1 2 U2 5 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0030-2228 J9 OMEGA-J DEATH DYING JI Omega-J. Death Dying PY 2013 VL 67 IS 1-2 SI SI BP 167 EP 174 DI 10.2190/OM.67.1-2.t PG 8 WC Psychology, Multidisciplinary; Social Sciences, Biomedical SC Psychology; Biomedical Social Sciences GA 195CZ UT WOS:000322681200021 PM 23977793 ER PT J AU Garvey, KC Finkelstein, JA Laffel, LM Ochoa, V Wolfsdorf, JI Rhodes, ET AF Garvey, Katharine C. Finkelstein, Jonathan A. Laffel, Lori M. Ochoa, Victoria Wolfsdorf, Joseph I. Rhodes, Erinn T. TI Transition experiences and health care utilization among young adults with type 1 diabetes SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE type 1 diabetes mellitus; health care delivery; young adults; transition to adult care ID QUALITY-OF-LIFE; GLYCEMIC CONTROL; EMERGING ADULTS; FOLLOW-UP; ADOLESCENTS; MELLITUS; SYSTEMS; YOUTH; SERVICES; CHILDREN AB Background: The purpose of this study was to describe the current status of adult diabetes care in young adults with type 1 diabetes and examine associations between health care transition experiences and care utilization. Methods: We developed a survey to assess transition characteristics and current care in young adults with type 1 diabetes. We mailed the survey to the last known address of young adults who had previously received diabetes care at a tertiary pediatric center. Results: Of 291 surveys sent, 83 (29%) were undeliverable and three (1%) were ineligible. Of 205 surveys delivered, 65 were returned (response rate 32%). Respondents (mean age 26.6 +/- 3.0 years, 54% male, 91% Caucasian) transitioned to adult diabetes care at a mean age of 19.2 +/- 2.8 years. Although 71% felt mostly/completely prepared for transition, only half received recommendations for a specific adult provider. Twenty-six percent reported gaps exceeding six months between pediatric and adult diabetes care. Respondents who made fewer than three diabetes visits in the year prior to transition (odds ratio [OR] 4.5, 95% confidence interval [CI] 1.2-16.5) or cited moving/relocation as the most important reason for transition (OR 6.3, 95% CI 1.3-31.5) were more likely to report gaps in care exceeding six months. Patients receiving current care from an adult endocrinologist (79%) were more likely to report at least two diabetes visits in the past year (OR 6.0, 95% CI 1.5-24.0) compared with those receiving diabetes care from a general internist/adult primary care doctor (17%). Two-thirds (66%) reported receiving all recommended diabetes screening tests in the previous year, with no difference according to provider type. Conclusion: In this sample, transition preparation was variable and one quarter reported gaps in obtaining adult diabetes care. Nevertheless, the majority endorsed currently receiving regular diabetes care, although visit frequency differed by provider type. Because locating patients after transition was incomplete, our findings suggest the need for standardized methods to track transitioning patients. C1 [Garvey, Katharine C.; Laffel, Lori M.; Ochoa, Victoria; Wolfsdorf, Joseph I.; Rhodes, Erinn T.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Finkelstein, Jonathan A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. [Finkelstein, Jonathan A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Laffel, Lori M.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02215 USA. RP Garvey, KC (reprint author), Boston Childrens Hosp, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. EM katharine.garvey@childrens.harvard.edu FU Program for Patient Safety and Quality at Boston Children's Hospital; Agency for Healthcare Research and Quality [T32-HS000063]; National Institute of Diabetes and Digestive and Kidney Diseases [T32DK007699-30]; National Institute for Diabetes and Digestive and Kidney Diseases [K12-DK094721]; William Randolph Hearst Foundation; National Institute for Child Health and Human Development [K24-HD060786] FX This study was funded by a grant from the Program for Patient Safety and Quality at Boston Children's Hospital. KCG was supported by the Agency for Healthcare Research and Quality (T32-HS000063), the National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007699-30), the National Institute for Diabetes and Digestive and Kidney Diseases (K12-DK094721), and the William Randolph Hearst Foundation. JAF's work on this project was funded by a grant from the National Institute for Child Health and Human Development (K24-HD060786). LL's work on this project was funded by a grant from the National Institute for Diabetes and Digestive and Kidney Diseases (K12-DK094721). A portion of this study was presented in abstract form at the International Society for Pediatric and Adolescent Diabetes 37th Annual Meeting, October 19-22, 2011, Miami, Florida. NR 41 TC 8 Z9 9 U1 3 U2 10 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2013 VL 7 BP 761 EP 769 DI 10.2147/PPA.S45823 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 197UF UT WOS:000322876000001 PM 23990711 ER PT J AU Friedman, AN Yu, Z Denski, C Tamez, H Wenger, J Thadhani, R Li, Y Watkins, B AF Friedman, Allon N. Yu, Zhangsheng Denski, Cheryl Tamez, Hector Wenger, Julia Thadhani, Ravi Li, Yong Watkins, Bruce TI Fatty Acids and Other Risk Factors for Sudden Cardiac Death in Patients Starting Hemodialysis SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Omega-3; Fatty acids; Sudden cardiac death; Hemodialysis; Incident; Risk factors; Nutrition; Cardiovascular disease ID PLACEBO-CONTROLLED TRIAL; MYOCARDIAL-INFARCTION; HEART-FAILURE; UNITED-STATES; OMEGA-3-FATTY-ACIDS; DIALYSIS; DISEASE; OUTCOMES; ARREST; FISH AB Background: Little is known about risk factors for sudden cardiac death in hemodialysis patients during the high-risk first year of dialysis. We therefore undertook to identify such risk factors in a nationally representative cohort and were able to include baseline levels of blood fatty acids, some of which influence arrhythmogenicity and sudden cardiac death risk. Design: The study cohort included 100 patients who died of sudden cardiac death during the first year of hemodialysis and 300 frequency-matched controls. Using the elastic net statistical method, numerous demographic and clinical characteristics were included with baseline total serum levels for 11 major fatty acids (model 1) and with serum phospholipid fractions of these same fatty acids (model 2). Final models included only covariates that had a non-zero coefficient. Results: In model 1, serum albumin [odds ratio (95% CI): 0.55 (0.33-0.93); p = 0.03] and total serum long-chain n-3 docosapentaenoic acid [0.70 (0.51-0.97); p = 0.03] were inversely associated with the odds of sudden cardiac death, while the total serum saturated fatty acid level had a direct association [1.01 (1.00-1.02); p = 0.03]. In model 2, serum albumin and docosapentaenoic acid remained inversely associated with sudden cardiac death in a similar manner as in model 1. Pulse pressure also had an inverse association [0.96 (0.93-1.00); p < 0.05]. Conclusions: Several factors, including blood content of docosapentaenoic acid and saturated fatty acids, were associated with the odds of sudden cardiac death during year one of hemodialysis. These results raise the possibility that dietary modification may reduce sudden death risk. Copyright (c) 2013 S. Karger AG, Basel C1 [Friedman, Allon N.] Indiana Univ, Sch Med, Dept Med, Div Nephrol, Indianapolis, IN USA. [Yu, Zhangsheng; Denski, Cheryl] Indiana Univ, Sch Med, Dept Biostat, Indianapolis, IN USA. [Tamez, Hector; Wenger, Julia; Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. [Li, Yong; Watkins, Bruce] Univ Connecticut, Dept Nutr Sci, Lipid Chem & Mol Biol Lab, Storrs, CT USA. RP Friedman, AN (reprint author), 550 Univ Blvd Suite 6100, Indianapolis, IN 46202 USA. EM allfried@iupui.edu FU National Institutes of Health [DK084403, DK094872, HL112746]; National Kidney Foundation FX A.N.F. was supported by funding from the National Institutes of Health (DK084403) and the National Kidney Foundation. R.T. is supported by funding from the National Institutes of Health (DK094872, HL112746). NR 44 TC 3 Z9 4 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2013 VL 38 IS 1 BP 12 EP 18 DI 10.1159/000351764 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 191LI UT WOS:000322414100002 PM 23816975 ER PT S AU Gutierrez-Herrera, E Vacas-Jacques, P Anderson, R Zapol, W Franco, W AF Gutierrez-Herrera, Enoch Vacas-Jacques, Paulino Anderson, Rox Zapol, Warren Franco, Walfre BE Wax, AP Backman, V TI Oxygen saturation in free-diving whales: optical sensor development SO BIOMEDICAL APPLICATIONS OF LIGHT SCATTERING VII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Biomedical Applications of Light Scattering VII CY FEB 02-04, 2013 CL San Francisco, CA SP SPIE DE Avalanche Photodiode; Transimpedance Amplifier; Tissue Oxygenation Tag; Phase-modulated Frequency-domain Spectrophotometer ID BEAKED-WHALES; HEMOGLOBIN; MYOGLOBIN; SPECTROSCOPY; VALIDATION; MANAGEMENT; AUDIOGRAM; DOLPHINS; BUBBLES; MAMMALS AB Mass stranding of live whales has been explained by proposing many natural or human-related causes. Recent necropsy reports suggest a link between the mass stranding of beaked whales and the use of naval mid-frequency sonar. Surprisingly, whales have experienced symptoms similar to those caused by inert gas bubbles in human divers. Our goal is to develop a compact optical sensor to monitor the consumption of the oxygen stores in the muscle of freely diving whales. To this end we have proposed the use of a near-infrared phase-modulated frequency-domain spectrophotometer, in reflectance mode, to probe tissue oxygenation. Our probe consists of three main components: radiofrequency (RF) modulated light sources, a high-bandwidth avalanche photodiode with transimpedance amplifier, and a RF gain and phase detector. In this work, we concentrate on the design and performance of the light sensor, and its corresponding amplifier unit. We compare three state-of-the-art avalanche photodiodes: one through-hole device and two surface-mount detectors. We demonstrate that the gain due to the avalanche effect differs between sensors. The avalanche gain near maximum bias of the through-hole device exceeds by a factor of 2.5 and 8.3 that of the surface-mount detectors. We present the behavior of our assembled through-hole detector plus high-bandwidth transimpedance amplifier, and compare its performance to that of a commercially available module. The assembled unit enables variable gain, its phase noise is qualitatively lower, and the form factor is significantly smaller. Having a detecting unit that is compact, flexible, and functional is a milestone in the development of our tissue oxygenation tag. C1 [Gutierrez-Herrera, Enoch; Vacas-Jacques, Paulino; Anderson, Rox; Franco, Walfre] Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Gutierrez-Herrera, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, 55 Fruit St, Boston, MA 02114 USA. RI Backman, Vadim/B-6689-2009 NR 21 TC 0 Z9 0 U1 3 U2 9 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9361-3 J9 PROC SPIE PY 2013 VL 8592 AR 859201 DI 10.1117/12.2008547 PG 8 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BFX99 UT WOS:000321858000001 ER PT J AU Yoder, MS Lozano, B Center, KB Miller, A Acierno, R Tuerk, PW AF Yoder, Matthew S. Lozano, Brian Center, Kristy B. Miller, Aaron Acierno, Ron Tuerk, Peter W. TI EFFECTIVENESS OF PROLONGED EXPOSURE FOR PTSD IN OLDER VETERANS SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE PTSD; older adults; exposure therapy; veterans ID POSTTRAUMATIC-STRESS-DISORDER; COMBAT VETERANS; RAPE VICTIMS; THERAPY; SCALE; TRIAL AB Exposure-based therapy is an effective treatment for PTSD, including combat-related PTSD. However, questions remain within PTSD treatment literature and among front-line clinicians about the appropriateness of exposure-based therapies for older adults. The current study examined the effectiveness of Prolonged Exposure (PE) in reducing PTSD and depression symptoms in a sample of 65 Veterans age 60 and older who were diagnosed with PTSD via structured clinical interview. In addition to within-subject repeated measure analyses, the entire intent to treat sample was compared to treatment completers. Within group d-type effect sizes across both groups were large (1.13-1.90) and the retention rate was high (85%). Importantly, no adverse medical or psychiatric events were reported over the course of the study. Results are discussed and limitations, along with future directions, are presented. C1 Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC USA. RP Yoder, MS (reprint author), RHJ VAMC, Mental Hlth 116,109 Bee St, Charleston, SC 29401 USA. EM yoderm@musc.edu FU Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [CDA-2] FX Dr. Tuerk's contribution to this manuscript was partially supported by Career Development Award (CDA-2) from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI: Tuerk). NR 37 TC 6 Z9 6 U1 2 U2 8 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2013 VL 45 IS 2 BP 111 EP 124 DI 10.2190/PM.45.2.b PG 14 WC Psychiatry SC Psychiatry GA 195GA UT WOS:000322689100002 PM 23977816 ER PT J AU Tuerk, PW Hall, B Nagae, N McCauley, JL Yoder, M Rauch, SAM AF Tuerk, Peter W. Hall, Brian Nagae, Nobukazu McCauley, Jenna L. Yoder, Matthew Rauch, Sheila A. M. TI FORTY DAYS AFTER THE GREAT EAST JAPAN EARTHQUAKE: FIELD RESEARCH INVESTIGATING COMMUNITY ENGAGEMENT AND TRAUMATIC STRESS SCREENING IN A POST-DISASTER COMMUNITY MENTAL HEALTH TRAINING SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE PTSD; disaster; community mental health; Japan ID HANSHIN-AWAJI EARTHQUAKE; POSTTRAUMATIC-STRESS; PSYCHOLOGICAL DISTRESS; HURRICANE-ANDREW; SYMPTOMS; DISASTER; IMPACT; PTSD; RELIABILITY; MORBIDITY AB The current article describes the results of posttraumatic stress educational outreach and screening offered to 141 citizens of Japan who attended a public-service mental health training regarding post-disaster coping 40 days after a 6.8 Richter Scale earthquake, local and regional deaths, and an ongoing nuclear radiation threat. Attendees were given access to anonymous questionnaires that were integrated into the training as a tool to help enhance mental health literacy and bridge communication gaps. Questionnaires were turned in by a third of those in attendance. Among respondents, multiple exposures to potentially-traumatic events were common. More than a quarter of respondents met criteria for probable PTSD. Physical health and loss of sense of community were related to PTSD symptoms. Associations and diagnosis rates represented in these data are not generalizable to the population as a whole or intended for epidemiological purposes; rather, they are evidence of a potentially useful approach to post-disaster clinical screening, education, and engagement. Results are presented in the context of previous findings in Japan and ecologically-supportive post-disaster field research is discussed. C1 [Tuerk, Peter W.; Yoder, Matthew] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Tuerk, Peter W.; McCauley, Jenna L.; Yoder, Matthew] Med Univ S Carolina, Charleston, SC USA. [Hall, Brian] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Nagae, Nobukazu] Fukuoka Univ, Fukuoka, Japan. [Rauch, Sheila A. M.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Rauch, Sheila A. M.] Univ Michigan, Sch Med, Ann Arbor, MI USA. RP Tuerk, PW (reprint author), RHJ VAMC, Mental Hlth 116,109 Bee St, Charleston, SC 29401 USA. EM Tuerk@musc.edu RI Rauch, Sheila/K-4450-2015; OI Rauch, Sheila/0000-0001-9686-4011; Hall, Brian/0000-0001-9358-2377 FU Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [CDA-2]; NIMH [T32MH014592-35, T32MH018869-24] FX Drs. Tuerk's and Rauch's contribution to this article was partially supported by Career Development Awards (CDA-2) from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI: Tuerk, PI: Rauch). Dr. Hall's contribution to this work was supported by NIMH training grants T32MH014592-35 (PI: Zandi) and T32MH018869-24 (PI: Kilpatrick). NR 46 TC 5 Z9 6 U1 2 U2 10 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2013 VL 45 IS 2 BP 159 EP 174 DI 10.2190/PM.45.2.e PG 16 WC Psychiatry SC Psychiatry GA 195GA UT WOS:000322689100005 PM 23977819 ER PT J AU Thames, AD Arentoft, A Rivera-Mindt, M Hinkin, CH AF Thames, April D. Arentoft, Alyssa Rivera-Mindt, Monica Hinkin, Charles H. TI Functional disability in medication management and driving among individuals with HIV: A 1-year follow-up study SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE HIV; Instrumental activities of daily living; Cognitive function; Medication management; Driving ID PERFORMANCE-BASED MEASURES; NEUROPSYCHOLOGICAL IMPAIRMENT; NEUROCOGNITIVE DISORDERS; PHYSICAL PERFORMANCE; ALZHEIMER-DISEASE; OLDER ADULTS; INFECTION; ADHERENCE; HIV/AIDS; PREDICTORS AB Approximately 50% of individuals with HIV report cognitive deficits that can affect social or occupational functioning. The present study used a longitudinal design (1 year) to examine the relationship between cognitive factors and incidental functional deficits in medication management and driving ability among a cohort of 101 HIV+ participants. Participants were classified into groups of functionally stable and disabled for each laboratory-based functional task (i.e., Medication Management Task-Revised, MMT-R, and PC-based driving simulator). We hypothesized that participants who exhibited a functional deficit in either MMT-R or driving at follow-up assessment would demonstrate significantly poorer baseline cognitive performance at study entry than participants who remained functionally stable. As hypothesized, participants who demonstrated significantly lower baseline performance in learning/memory and executive functioning also demonstrated functional disability on the MMT-R at follow-up when compared to functionally stable participants. Poor baseline performance in speed of information processing was associated with a deficit in driving ability at follow-up assessment. Our results suggest that lower baseline cognitive functioning predicts downstream functional disability, and that deficits in learning/memory and information processing speed are particularly predictive of deficits in medication management and driving ability. C1 [Thames, April D.; Arentoft, Alyssa; Hinkin, Charles H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Sch Med, Los Angeles, CA 90095 USA. [Arentoft, Alyssa; Hinkin, Charles H.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Rivera-Mindt, Monica] Fordham Univ, Dept Psychol, New York, NY 10023 USA. [Rivera-Mindt, Monica] Mt Sinai Sch Med, Dept Neurol & Psychiat, New York, NY USA. RP Thames, AD (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza C8-746, Los Angeles, CA 90095 USA. EM athames@mednet.ucla.edu RI Thames, April/K-1964-2014; OI Thames, April/0000-0001-8414-7189; Arentoft, Alyssa/0000-0002-4235-4638 FU VA Merit Review; National Institute of Mental Health [T32 19535] FX We would like to acknowledge the following funding sources: VA Merit Review awarded to Charles Hinkin, PhD and National Institute of Mental Health training grant (T32 19535; PI: C. Hinkin). NR 45 TC 9 Z9 9 U1 3 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PD JAN 1 PY 2013 VL 35 IS 1 BP 49 EP 58 DI 10.1080/13803395.2012.747596 PG 10 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 189YL UT WOS:000322304100006 PM 23237014 ER PT S AU Cai, WL Zhang, D Lee, JG Yoshida, H AF Cai, Wenli Zhang, Da Lee, June-Goo Yoshida, Hiroyuki BE Novak, CL Aylward, S TI Low-dose dual-energy electronic cleansing for fecal-tagging CT colonography SO MEDICAL IMAGING 2013: COMPUTER-AIDED DIAGNOSIS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Computer-Aided Diagnosis CY FEB 12-14, 2013 CL Lake Buena Vista, FL SP SPIE, Aeroflex Inc, Univ Cent Florida, CREOL Coll Opt & Photon, DQE Instruments Inc, Medtronic Inc, PIXELTEQ DE Computer-aided diagnosis; x-ray and CT; abdominal; CT colonography; dual-energy CT; electronic cleansing; denoising ID COMPUTED-TOMOGRAPHY; CATHARTIC PREPARATION; FEASIBILITY AB Dual-energy electronic cleansing (DE-EC) provides a promising means for cleansing the tagged fecal materials in fecal-tagging CT colonography (CTC). However, the increased radiation dose due to the double exposures in dual-energy CTC (DE-CTC) scanning is a major limitation for the use of DE-EC in clinical practice. The purpose of this study was to develop and evaluate a low-dose DE-EC scheme in fecal-tagging DE-CTC. In this study, a custom-made anthropomorphic colon phantom, which was filled with simulated tagged materials by non-ionic iodinated contrast agent (Omnipaque iohexol, GE Healthcare), was scanned by a dual-source CT scanner (SOMATON Definition Flash, Siemens Healthcare) at two photon energies: 80 kVp and 140 kVp with nine different tube current settings ranging from 12 to 74 mAs for 140 kVp, and then reconstructed by soft-tissue reconstruction kernel (B30f). The DE-CTC images were subjected to a low-dose DE-EC scheme. First, our image-space DE-CTC denoising filter was applied for reduction of image noise. Then, the noise-reduced images were processed by a virtual lumen tagging method for reduction of partial volume effect and tagging inhomogeneity. The results were compared with the registered CTC images of native phantom without fillings. Preliminary results showed that our low-dose DE-EC scheme achieved the cleansing ratios, defined by the proportion of the cleansed voxels in the tagging mask, between 93.18% (12 mAs) and 96.62% (74 mAs). Also, the soft-tissue preservation ratios, defined by the proportion of the persevered voxels in the soft-tissue mask, were maintained in the range between 94.67% and 96.41%. C1 [Cai, Wenli; Zhang, Da; Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Cai, WL (reprint author), Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St 400C, Boston, MA 02114 USA. EM Cai.Wenli@mgh.harvard.edu NR 21 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9444-3 J9 PROC SPIE PY 2013 VL 8670 AR 86700W DI 10.1117/12.2008115 PG 9 WC Engineering, Electrical & Electronic; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BGC32 UT WOS:000322261500030 ER PT S AU Nappi, JJ Kim, SH Yoshida, H AF Naeppi, Janne J. Kim, Se Hyung Yoshida, Hiroyuki BE Novak, CL Aylward, S TI Volumetric detection of flat lesions for minimal-preparation dual-energy CT colonography SO MEDICAL IMAGING 2013: COMPUTER-AIDED DIAGNOSIS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Computer-Aided Diagnosis CY FEB 12-14, 2013 CL Lake Buena Vista, FL SP SPIE, Aeroflex Inc, Univ Cent Florida, CREOL Coll Opt & Photon, DQE Instruments Inc, Medtronic Inc, PIXELTEQ DE computer-aided detection; flat lesions; non-polypoid lesions; dual-energy CT; multi-energy CT; virtual colonoscopy; CT colonography ID COMPUTER-AIDED DETECTION; POLYPS AB Computer-aided detection (CAD) systems for computed tomographic colonography (CTC) tend to miss many flat lesions. We developed a volumetric method for automated detection of lesions with dual-energy CTC (DE-CTC). The target region for the detection is defined in terms of a distance transform of the colonic lumen. To detect lesions, volumetric shape features are calculated at the image scale defined by the thickness of the target region. False-positive (FP) detections are reduced by use of a random-forest classifier based on shape, texture, and dual-energy features of the detected lesion candidates. For pilot evaluation, 37 patients were examined by use of DE-CTC with a reduced one-day bowel preparation. The CAD scheme was trained with the DE-CTC data of 12 patients, and it was tested with the DE-CTC data of 25 patients. The detection sensitivity was assessed at multiple thicknesses of the target region. There were 39 lesions >= 6 mm in 15 patients, including 8 flat lesions >= 10 mm. The thickness of the target region had a statistically significant effect on the detection sensitivity. At the optimal thickness of the target region, the per-lesion and per-patient sensitivities for flat lesions were 100% at a median of 4 FPs per patient. C1 [Naeppi, Janne J.; Yoshida, Hiroyuki] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Nappi, JJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St,Suite 400C, Boston, MA 02114 USA. EM jnappi@partners.org; yoshida.hiro@mgh.harvard.edu OI Nappi, Janne/0000-0002-0108-0992 NR 24 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9444-3 J9 PROC SPIE PY 2013 VL 8670 AR 86702E DI 10.1117/12.2008127 PG 6 WC Engineering, Electrical & Electronic; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BGC32 UT WOS:000322261500082 ER PT J AU Long, FH AF Long, Frederick H. BE Issaq, HJ Veenstra, TD TI Multivariate Analysis for Metabolomics and Proteomics Data SO PROTEOMIC AND METABOLOMIC APPROACHES TO BIOMARKER DISCOVERY LA English DT Article; Book Chapter ID CORONARY-ARTERY-DISEASE; BREAST-CANCER; DIAGNOSIS C1 [Long, Frederick H.] Spect Solut LLC, Randolph, NJ USA. [Long, Frederick H.] Henry W Long Ctr Funct Canc Epigenet, Boston, MA USA. [Long, Frederick H.] Dana Faber Canc Inst, Boston, MA USA. [Long, Frederick H.] Harvard Univ, Sch Med, Boston, MA USA. RP Long, FH (reprint author), Spect Solut LLC, Randolph, NJ USA. NR 21 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-394795-6 PY 2013 BP 299 EP 311 DI 10.1016/B978-0-12-394446-7.00019-4 PG 13 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA BFQ63 UT WOS:000320992200020 ER PT J AU Allen, RS Guadagno, RE Parmelee, P Minney, JA Hilgeman, MM Tabb, KD McNeal, SF Houston, T Kertesz, S Davis, L AF Allen, R. S. Guadagno, R. E. Parmelee, P. Minney, J. A. Hilgeman, M. M. Tabb, K. D. McNeal, S. F. Houston, T. Kertesz, S. Davis, L. TI Internet connectivity among rural Alabama veterans: baseline findings from the Alabama Veterans Rural Health Initiative Project SO RURAL AND REMOTE HEALTH LA English DT Article DE aging; healthcare disparities; internet; rural population; USA; veterans' health ID OLDER-ADULTS; CARE; TECHNOLOGY; ACCESS; ATTITUDES; DISPARITIES; EDUCATION; MILITARY AB Introduction: The purpose of this secondary data analysis was to characterize the Internet usage of rural veterans (n=201) who had either never enrolled, or had previously enrolled but not accessed, Veterans Affairs (VA) health services in at least 2 years. The VA Office of Rural Health (ORH)(ie part of the United States Government Department of Veterans Affairs) is a government agency with the mission to improve access and quality of care for enrolled rural and highly rural US veterans. The ORH seeks to use evidence-based policies and innovative practices to support the unique needs of enrolled veterans residing in geographically remote areas. These individuals represent a population considered to experience health disparities secondary to reduced health care access. Methods: This study explored the role of the Internet in providing health information and information regarding VA services to rural Caucasian and African American veterans in the southeastern USA. African Americans were significantly younger (50.32 years, SD=13.50, range 22-85 years) than Caucasian rural veterans (58.50 years, SD=13.82, range 21-85 years). Results: A small majority of veterans (n=107; 53.23%) reported 'going on-line to use the Internet or World Wide Web, or to send and receive e-mail'. Among Internet users, multivariate logistic regression showed that neither age nor race/ethnicity predicted using the Internet to access health information or information regarding VA services. Conclusion: In comparison with population norms, rural veterans displayed lower usage of the Internet; however, there were few practical age differences between young, middle-aged and older rural veterans in use of the Internet for seeking health information. These results suggest a tremendous potential for online outreach efforts to rural veterans seeking health information and information regarding VA services and benefits. The US Federal Government's VA Office of Rural Health is investing in technology-based services and will need to disseminate information regarding the availability of these services to rural veterans. C1 [Allen, R. S.; Guadagno, R. E.; Parmelee, P.; Minney, J. A.] Univ Alabama, Tuscaloosa, AL 35487 USA. [Hilgeman, M. M.; Davis, L.] Tuscaloosa Vet Affairs Med Ctr, Tuscaloosa, AL USA. [Tabb, K. D.; McNeal, S. F.; Kertesz, S.] Birmingham Vet Affairs Med Ctr, Alabama Vet Rural Hlth Initiat, Birmingham, AL USA. [Houston, T.] Edith Nourse Rogers Mem Vet Hosp, EHlth Qual Enhancement Res Initiat, Bedford, MA USA. RP Allen, RS (reprint author), Univ Alabama, Tuscaloosa, AL 35487 USA. FU VA Health Services Research and Development Office (eHealth QUERI grant) [EHQ 10-190]; VA Office of Rural Health FX The authors acknowledge the support of the VA Health Services Research and Development Office (eHealth QUERI grant number EHQ 10-190) and the VA Office of Rural Health. NR 17 TC 1 Z9 1 U1 1 U2 7 PU AUSTRALIAN RURAL HEALTH EDUC NETWORK PI DEAKIN WEST PA PO BOX 242, DEAKIN WEST, ACT 2600, AUSTRALIA SN 1445-6354 J9 RURAL REMOTE HEALTH JI Rural Remote Health PD JAN-MAR PY 2013 VL 13 IS 1 AR 2138 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 190TY UT WOS:000322364800020 PM 23331256 ER PT S AU Rajewsky, K AF Rajewsky, Klaus BE Littman, DR Yokoyama, WM TI Years in Cologne SO ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 SE Annual Review of Immunology LA English DT Review; Book Chapter DE T-B collaboration; B cell development; germinal centers; memory B cells; B cell lymphomas; Hodgkin lymphoma; conditional gene targeting ID B-CELL DEVELOPMENT; REED-STERNBERG CELLS; CLASSICAL HODGKINS-DISEASE; HEAVY-CHAIN LOCUS; CHRONIC LYMPHOCYTIC-LEUKEMIA; CHRONIC IDIOTYPE SUPPRESSION; ANTIGEN-BINDING SPECIFICITY; CLASS SWITCH RECOMBINATION; VARIABLE REGION GENE; RECEPTOR-GAMMA-CHAIN AB This review describes the building and scientific activity of the Immunology Department at the Institute for Genetics in Cologne, co-founded by Max Delbruck in post-World War II Germany. The protagonist, a child of Russian emigrants, became interested in antibodies as a postdoc at the Pasteur Institute in Paris and a proponent of the antigen-bridge model of T-B cell collaboration during his early time in Cologne. He was challenged by the gap between cellular immunology and molecular genetics and profited from the advances of the latter as well as postwar economic growth in Germany. The Immunology Department became a place, and little universe in itself, where young scientists from all over the world came together to study cellular and molecular mechanisms of antibody formation. This included work on normal and malignant B cells in the human, particularly the origin of Hodgkin lymphoma, but the main focus was on B cell development and homeostasis, the germinal center reaction, and immunological memory, developing recombinase-assisted and conditional gene targeting in mice as a main technical tool. C1 [Rajewsky, Klaus] Harvard Univ, Sch Med, Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Rajewsky, Klaus] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. RP Rajewsky, K (reprint author), Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany. EM klaus.rajewsky@mdc-berlin.de FU DFG; University of Cologne; Land Nordrhein-Westfalen; Volkswagen Foundation; Fazit Foundation; Korber Foundation; Bayer AG; EMBO; European Union; Alexander von Humboldt Foundation; Human Frontier Science Program FX I express my sincere thanks to all collaborators, colleagues, and friends who have worked with me and supported me over the years. Some of them have kindly critically read parts of this article. I am grateful to each one of them and deeply apologize that I could neither mention everyone nor cover all the work that has been carried out in the Immunology Department in Cologne. A special word of thanks goes to our technical, animal, and administrative collaborators. Without their expert and dedicated support, our work would not have been possible. Some of their contributions are highlighted in the Supplemental Material to this article (follow the Supplemental Material link from the Annual Reviews home page at http://www.annualreviews.org). My thanks also go to the institutions that have generously funded our work, particularly the DFG, the University of Cologne, the Land Nordrhein-Westfalen, the Volkswagen Foundation, the Fazit Foundation, the Korber Foundation, Bayer AG, EMBO, the European Union, the Alexander von Humboldt Foundation, and the Human Frontier Science Program. NR 178 TC 2 Z9 2 U1 0 U2 6 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0732-0582 BN 978-0-8243-3031-6 J9 ANNU REV IMMUNOL JI Annu. Rev. Immunol. PY 2013 VL 31 BP 1 EP 29 DI 10.1146/annurev.immunol.021908.132646 PG 29 WC Immunology SC Immunology GA BFY00 UT WOS:000321861600001 PM 23140542 ER PT S AU Guillory, B Splenser, A Garcia, J AF Guillory, Bobby Splenser, Andres Garcia, Jose BE Litwack, G TI The Role of Ghrelin in Anorexia-Cachexia Syndromes SO ANOREXIA SE Vitamins and Hormones LA English DT Review; Book Chapter ID GROWTH-HORMONE SECRETAGOGUE; DES-ACYL GHRELIN; OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC HEART-FAILURE; LEAN BODY-MASS; UBIQUITIN-PROTEASOME PATHWAY; FOXO TRANSCRIPTION FACTORS; MUSCLE PROTEIN BREAKDOWN; PLACEBO-CONTROLLED TRIAL; O-ACYLTRANSFERASE GOAT AB Anorexia, sarcopenia, and cachexia are common complications of many chronic conditions including cancer, rheumatoid arthritis, HIV infection, aging, and chronic lung, heart, or kidney disease. Currently, there is no effective treatment for muscle atrophy or wasting conditions although they typically take a significant toll on the quality of life of patients and are associated with poor prognosis and decreased survival. Ghrelin affects multiple key pathways in the regulation of body weight, body composition, and appetite in the setting of cachexia that may lead to an increase in appetite and growth hormone secretion and a reduction in energy expenditure and inflammation. The net effect is increased lean body mass and fat mass preservation. In this chapter, we review the mechanisms of action of ghrelin and present the available data in animal models and human trials using ghrelin or ghrelin mimetics in different settings of cachexia. C1 [Guillory, Bobby; Splenser, Andres; Garcia, Jose] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Diabet Endocrinol & Metab, Houston, TX 77030 USA. [Garcia, Jose] Baylor Coll Med, Huffington Ctr Aging, Dept Mol & Cell Biol, Houston, TX 77030 USA. RP Garcia, J (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Diabet Endocrinol & Metab, Houston, TX 77030 USA. EM jgarcia1@bcm.edu FU NIA NIH HHS [AG040583, T32AG000183] NR 225 TC 7 Z9 8 U1 0 U2 11 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0083-6729 BN 978-0-12-410473-0 J9 VITAM HORM JI Vitam. Horm. PY 2013 VL 92 BP 61 EP 106 DI 10.1016/B978-0-12-410473-0.00003-9 PG 46 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Psychology SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Psychology GA BFP64 UT WOS:000320892700004 PM 23601421 ER PT J AU Iacono, MI Makris, N Mainardi, L Angelone, LM Bonmassar, G AF Iacono, Maria Ida Makris, Nikos Mainardi, Luca Angelone, Leonardo M. Bonmassar, Giorgio TI MRI-Based Multiscale Model for Electromagnetic Analysis in the Human Head with Implanted DBS SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE LA English DT Article ID DEEP BRAIN-STIMULATION; STEREOTACTIC FUNCTIONAL NEUROSURGERY; METALLIC IMPLANTS; DIELECTRIC-PROPERTIES; SUBTHALAMIC NUCLEUS; ATLAS; ABSORPTION; FIELD; REGISTRATION; EXPOSURE AB Deep brain stimulation (DBS) is an established procedure for the treatment of movement and affective disorders. Patients with DBS may benefit from magnetic resonance imaging (MRI) to evaluate injuries or comorbidities. However, the MRI radio-frequency (RF) energy may cause excessive tissue heating particularly near the electrode. This paper studies how the accuracy of numerical modeling of the RF field inside a DBS patient varies with spatial resolution and corresponding anatomical detail of the volume surrounding the electrodes. A multiscale model (MS) was created by an atlas-based segmentation using a 1 mm(3) head model (mRes) refined in the basal ganglia by a 200 mu m(2) ex-vivo dataset. Four DBS electrodes targeting the left globus pallidus internus were modeled. Electromagnetic simulations at 128 MHz showed that the peak of the electric field of the MS doubled (18.7 kV/m versus 9.33 kV/m) and shifted 6.4 mm compared to the mRes model. Additionally, the MS had a sixfold increase over the mRes model in peak-specific absorption rate (SAR of 43.9 kW/kg versus 7 kW/kg). The results suggest that submillimetric resolution and improved anatomical detail in the model may increase the accuracy of computed electric field and local SAR around the tip of the implant. C1 [Iacono, Maria Ida; Makris, Nikos; Angelone, Leonardo M.; Bonmassar, Giorgio] Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Med Sch, Charlestown, MA 02129 USA. [Iacono, Maria Ida; Angelone, Leonardo M.] US FDA, Div Phys, Off Sci & Engn Labs, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA. [Makris, Nikos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Morphometr Anal,Dept Psychiat & Neurol, Boston, MA 02129 USA. [Mainardi, Luca] Politecn Milan, Dept Bioengn, I-20133 Milan, Italy. RP Bonmassar, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Med Sch, Charlestown, MA 02129 USA. EM giorgio@nmr.mgh.harvard.edu OI Angelone, Leonardo/0000-0002-1105-021X FU National Institutes of Health [1R21EY020961-01, 1R43NS071988-01A, 15P41RR014075-13]; NIDA [1R01DA027804-01]; NIMH [1R21MH084041-01A1] FX Preparation of this paper was supported by Grants 1R21EY020961-01, 1R43NS071988-01A, and 15P41RR014075-13 from the National Institutes of Health and, in part, by Grants from NIDA 1R01DA027804-01 and NIMH 1R21MH084041-01A1. The authors give special thanks to A. Mareyam, J. R. Polimeni, L. L. Wald, and B. Fischl for providing them with the mu Res human brain dataset, to A. Van der Kouwe for his scientific support, and to Remcom's technical support. NR 71 TC 2 Z9 2 U1 0 U2 12 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1748-670X EI 1748-6718 J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PY 2013 AR UNSP 694171 DI 10.1155/2013/694171 PG 12 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 192HH UT WOS:000322474400001 ER PT S AU Mattei, PL Corey, KC Kimball, AB AF Mattei, Peter L. Corey, Kristen C. Kimball, Alexa B. BE Linder, MD Kimball, AB TI Cumulative Life Course Impairment: Evidence for Psoriasis SO DERMATOLOGICAL DISEASES AND CUMULATIVE LIFE COURSE IMPAIRMENT SE Current Problems in Dermatology LA English DT Article; Book Chapter ID QUALITY-OF-LIFE; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; TYPE-2 DIABETES-MELLITUS; SEVERE PLAQUE PSORIASIS; 1-YEAR FOLLOW-UP; METABOLIC SYNDROME; GASTRIC BYPASS; CROHNS-DISEASE; PSYCHOSOCIAL CONSEQUENCES; RHEUMATOID-ARTHRITIS AB Psoriasis is a disease state that may present significant cumulative life course impairment (CLCI). The impact of psoriasis on CLCI can be divided into social factors such as stigmatization, psychological factors such as depression, and physical factors such as pruritis, pain and arthritis. With a bimodal age range at first presentation, psoriasis tends to affect those in the second and fifth decades of life. In accordance with the CLCI model, the age of first presentation may substantially affect an individuals' life course, with younger patients more susceptible to CLCI. Social, psychological, and physical factors also provide protection from CLCI: personality, coping mechanisms, social support, and treatment or therapy may act as positive factors and mitigate these damaging effects. As the time course of most clinical trials encompasses a fraction of a patients' life, the true nature of this impact has not been easily captured. Longitudinal CLCI data in psoriasis is limited and continued life course data is needed. Copyright (C) 2013 S. Karger AG, Basel C1 [Mattei, Peter L.; Kimball, Alexa B.] Massachusetts Gen Hosp, Clin Unit Res Trials & Outcomes Skin CURTIS, Boston, MA 02114 USA. [Corey, Kristen C.] Univ Massachusetts, Sch Med, Boston, MA 02125 USA. [Kimball, Alexa B.] Harvard Univ, Sch Med, Boston, MA USA. [Kimball, Alexa B.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. RP Kimball, AB (reprint author), 50 Staniford St,Suite 240, Boston, MA 02114 USA. EM akimball@partners.org NR 94 TC 8 Z9 8 U1 1 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1421-5721 BN 978-3-318-02403-6 J9 CURR PROBL DERMATOL JI Curr.Probl.Dermatol. PY 2013 VL 44 BP 82 EP 90 DI 10.1159/000350008 PG 9 WC Dermatology SC Dermatology GA BFV83 UT WOS:000321591500009 PM 23796812 ER PT J AU Calderwood, SK Gong, JL Stevenson, MA Murshid, A AF Calderwood, Stuart K. Gong, Jianlin Stevenson, Mary Ann Murshid, Ayesha TI Cellular and molecular chaperone fusion vaccines: Targeting resistant cancer cell populations SO INTERNATIONAL JOURNAL OF HYPERTHERMIA LA English DT Review DE cellular molecular fusion; chaperone; resistant cells; vaccine ID HEAT-SHOCK PROTEINS; STEM-CELLS; INITIATING CELLS; ANTITUMOR IMMUNITY; CROSS-PRESENTATION; IMMUNOTHERAPY; RADIATION; METASTASIS; INHIBITORS; RESPONSES AB Molecular chaperone-based vaccines offer a number of advantages for cancer treatment. We have discussed the deployment of a vaccine prepared by gentle isolation of Hsp70 from tumour dendritic cell fusions (Hsp70 fusion vaccine). The vaccine was highly effective in triggering specific T cell immunity and in the treatment of tumour-bearing mice and the preparation was shown to retain an increased amount of tumour antigens compared to other chaperone-based isolates. This approach has the further advantage that tumour sub-populations could be used to prepare the Hsp70 fusion vaccine. Cellular fusion vaccines were made to specifically target drug-resistant cancer cells and tumour cell populations enriched in ovarian cancer stem cells (CSC). Such vaccines showed enhanced capacity to trigger T cell immunity to these resistant ovarian carcinoma populations. We have discussed the potential of using the cellular and Hsp70 fusion vaccine approaches in therapy of treatment-resistant cancer cells and its deployment in combination with ionising radiation or hyperthermia to enhance the effectiveness of both forms of therapy. C1 [Calderwood, Stuart K.; Stevenson, Mary Ann; Murshid, Ayesha] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiat Oncol, Boston, MA 02215 USA. [Gong, Jianlin] Boston Univ, Med Ctr, Dept Med, Boston, MA USA. RP Calderwood, SK (reprint author), BIDMC, 99 Brookline Ave, Boston, MA 02215 USA. EM scalderw@bidmc.harvard.edu FU US National Institutes of Health [RO-1CA047407, R01CA119045, RO-1CA094397] FX This work was supported by US National Institutes of Health research grants RO-1CA047407, R01CA119045 and RO-1CA094397. The authors alone are responsible for the content and writing of the paper. NR 53 TC 7 Z9 7 U1 0 U2 10 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 0265-6736 J9 INT J HYPERTHER JI Int. J. Hyperthermia PY 2013 VL 29 IS 5 BP 376 EP 379 DI 10.3109/02656736.2013.792126 PG 4 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 193AE UT WOS:000322528300004 PM 23682824 ER PT J AU Broyles, LM Gordon, AJ Rodriguez, KL Hanusa, BH Kengor, C Kraemer, KL AF Broyles, Lauren M. Gordon, Adam J. Rodriguez, Keri L. Hanusa, Barbara H. Kengor, Caroline Kraemer, Kevin L. TI Evaluation of a Pilot Training Program in Alcohol Screening, Brief Intervention, and Referral to Treatment for Nurses in Inpatient Settings SO JOURNAL OF ADDICTIONS NURSING LA English DT Article DE alcohol consumption; brief intervention; counseling; curriculum; education; inpatients; nurses; referral and consultation; screening ID PRIMARY-CARE; EMERGENCY-DEPARTMENT; IMPLEMENTATION-RESEARCH; MEDICAL-EDUCATION; TREATMENT SBIRT; ATTITUDES; EXPERIENCE; CURRICULUM; IMPACT; AAPPQ AB Alcohol screening, brief intervention, and referral to treatment (SBIRT) is a set of clinical strategies for reducing the burden of alcohol-related injury, disease, and disability. SBIRT is typically considered a physician responsibility but calls for interdisciplinary involvement requiring basic SBIRT knowledge and skills training for all healthcare disciplines. The purpose of this pilot study was to design, implement, and evaluate a theory-driven SBIRT training program for nurses in inpatient settings (RN-SBIRT) that was developed through an interdisciplinary collaboration of nursing, medical, and public health professionals and tailored for registered nurses in the inpatient setting. In this three-phase study, we evaluated (1) RN-SBIRT's effectiveness for changing nurses' alcohol-related knowledge, clinical practice, and attitudes and (2) the feasibility of implementing the inpatient curriculum. In a quasi-experimental design, two general medical units at our facility were randomized to receive RN-SBIRT or a self-directed Web site on alcohol-related care. We performed a formative evaluation of RN-SBIRT, guided by the RE-AIM implementation framework. After training, nurses in the experimental condition had significant increases in Role Adequacy for working with drinkers and reported increased performance and increased competence for a greater number of SBIRT care tasks. Despite some scheduling challenges for the nurses to attend RN-SBIRT, nurse stakeholders were highly satisfied with RN-SBIRT. Results suggest that with adequate training and ongoing role support, nurses in inpatient settings could play active roles in interdisciplinary initiatives to address unhealthy alcohol use among hospitalized patients. C1 [Broyles, Lauren M.; Gordon, Adam J.; Rodriguez, Keri L.; Hanusa, Barbara H.; Kengor, Caroline] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Broyles, Lauren M.; Gordon, Adam J.; Hanusa, Barbara H.] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network Mental Illness Res Ed, Pittsburgh, PA 15206 USA. [Broyles, Lauren M.; Gordon, Adam J.; Rodriguez, Keri L.; Kraemer, Kevin L.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Broyles, Lauren M.; Gordon, Adam J.; Rodriguez, Keri L.; Kraemer, Kevin L.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. RP Broyles, LM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,Bldg 2,Rm 4020W 151C-H, Pittsburgh, PA 15206 USA. EM lauren.broyles@va.gov FU Veterans Affairs Quality Enhancement Research Initiative Program [RRP 09-064]; Health Services Research and Development service of the U.S. Department of Veterans Affairs [CDA 10-014] FX Funding for this study was provided by Veterans Affairs Quality Enhancement Research Initiative Program (RRP 09-064, Principal Investigator, L. M. Broyles). The funding body played no role in the design; data collection, analysis, and interpretation of the data; the writing of the manuscript; nor the decision to submit the manuscript for publication. Dr. Broyles is currently supported by a Career Development Award (CDA 10-014) from the Health Services Research and Development service of the U.S. Department of Veterans Affairs. The material is the result of work supported with resources and the use of facilities at the Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U. S. government. NR 53 TC 7 Z9 8 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1088-4602 J9 J ADDICT NURS JI J. Addict. Nurs. PD JAN-MAR PY 2013 VL 24 IS 1 BP 8 EP 19 DI 10.1097/JAN.0b013e31828767ef PG 12 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA 185LZ UT WOS:000321970800004 PM 24622525 ER PT J AU Broyles, LM Conley, JW Harding, JD Gordon, AJ AF Broyles, Lauren M. Conley, James W. Harding, John D., Jr. Gordon, Adam J. TI A Scoping Review of Interdisciplinary Collaboration in Addictions Education and Training SO JOURNAL OF ADDICTIONS NURSING LA English DT Review DE Alcohol-related disorders; collaboration; cooperative behavior; curriculum; drug use disorders; education; interdisciplinary; interdisciplinary communication; interprofessional relations; substance abuse; substance addiction ID HEALTH-PROFESSIONAL STUDENTS; SUBSTANCE-ABUSE; BRIEF INTERVENTION; TREATMENT SBIRT; MODEL; MULTIDISCIPLINARITY; TRANSDISCIPLINARITY; CURRICULUM; PROVIDERS; SERVICES AB Developing a workforce of multidisciplinary healthcare professionals equipped with the knowledge and skills to collaboratively address the public health crisis of alcohol and other drug (AOD) use is critical for effectively identifying, preventing, and managing AOD conditions and their sequelae. Despite general enthusiasm for interdisciplinary education and training, little is known overall about the nature and outcomes of interdisciplinary collaboration in addictions education and training. We conducted a five-stage scoping review of the literature to provide an eight domain overview of the state of interdisciplinary collaboration in addictions education (ICAE). In our final review of 30 articles, we identified a lack of conceptual and terminological clarity around ICAE but a wide range of learners and professional collaborators in ICAE initiatives, which focused on a variety of AOD topics and used a constellation of didactic, interactive, and service-learning teaching strategies and formats. Although we found limited substantive educational or practice-oriented outcomes available for ICAE initiatives, learner and faculty feedback reflected high enthusiasm for ICAE and widespread perceptions of benefit for improved clinical care. Facilitators and barriers to the implementation of ICAE initiatives occurred at the level of the individual and the institution and ranged from pragmatic to conceptual. Emerging trends in ICAE initiatives included increased application of learning and implementation theory and extension of ICAE into research training. We conclude with recommendations to support ICAE as a new paradigm for addictions education for all health professionals. C1 [Broyles, Lauren M.; Harding, John D., Jr.; Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Broyles, Lauren M.; Conley, James W.; Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network Mental Illness Res Ed, Pittsburgh, PA 15206 USA. [Broyles, Lauren M.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Broyles, Lauren M.; Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. RP Broyles, LM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, 7180 Highland Dr,Bldg 2,Rm 4020W 151C-H, Pittsburgh, PA 15206 USA. EM Lauren.Broyles@va.gov FU Health Services Research & Development Service of the U.S. Department of Veterans Affairs [CDA 10-014] FX The authors have no conflicts of interest to declare. Dr. Broyles is currently supported by a Career Development Award (CDA 10-014) from the Health Services Research & Development Service of the U. S. Department of Veterans Affairs. The material is the result of work supported with resources and the use of facilities at the VAPHS, Pittsburgh, PA. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U. S. government. NR 40 TC 0 Z9 0 U1 2 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1088-4602 J9 J ADDICT NURS JI J. Addict. Nurs. PD JAN-MAR PY 2013 VL 24 IS 1 BP 29 EP 36 DI 10.1097/JAN.0b013e318282751e PG 8 WC Substance Abuse; Nursing SC Substance Abuse; Nursing GA 185LZ UT WOS:000321970800006 PM 24622527 ER PT J AU Farokhi, S Shamsuddin, SM Flusser, J Sheikh, UU Khansari, M Jafari-Khouzani, K AF Farokhi, Sajad Shamsuddin, Siti Mariyam Flusser, Jan Sheikh, Usman Ullah Khansari, Mohammad Jafari-Khouzani, Kourosh TI Rotation and noise invariant near-infrared face recognition by means of Zernike moments and spectral regression discriminant analysis SO JOURNAL OF ELECTRONIC IMAGING LA English DT Article ID FEATURE-EXTRACTION; IMAGE-ANALYSIS; TRANSFORMS; PATTERNS; RADON AB Face recognition is a rapidly growing research area, which is based heavily on the methods of machine learning, computer vision, and image processing. We propose a rotation and noise invariant near-infrared face-recognition system using an orthogonal invariant moment, namely, Zernike moments (ZMs) as a feature extractor in the near-infrared domain and spectral regression discriminant analysis (SRDA) as an efficient algorithm to decrease the computational complexity of the system, enhance the discrimination power of features, and solve the "small sample size" problem simultaneously. Experimental results based on the CASIA NIR database show the noise robustness and rotation invariance of the proposed approach. Further analysis shows that SRDA as a sophisticated technique, improves the accuracy and time complexity of the system compared with other data reduction methods such as linear discriminant analysis. (C) 2013 SPIE and IS&T C1 [Farokhi, Sajad; Shamsuddin, Siti Mariyam] Univ Teknol Malaysia, Fac Comp, Johor Baharu 81310, Malaysia. [Flusser, Jan] Acad Sci Czech Republic, Inst Informat Theory & Automat, CR-18208 Prague, Czech Republic. [Sheikh, Usman Ullah] Univ Teknol Malaysia, Fac Elect Engn, Johor Baharu 81310, Malaysia. [Khansari, Mohammad] Univ Tehran, Fac New Sci & Technol, Tehran 1439955941, Iran. [Jafari-Khouzani, Kourosh] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Boston, MA 02114 USA. RP Farokhi, S (reprint author), Univ Teknol Malaysia, Fac Comp, Johor Baharu 81310, Malaysia. EM fsajad2@live.utm.my RI Flusser, Jan /F-6209-2014; Sheikh, Usman/C-3596-2013 OI Sheikh, Usman/0000-0001-9054-093X FU Ministry of Higher Education under Long Term Research Grant Scheme [LRGS/TD/2011/UTM/ICT/03-4L805]; Czech Science Foundation [P103/11/1552]; Universiti Teknologi Malaysia FX The authors would like to thank Universiti Teknologi Malaysia for the support in Research and Development, and Soft Computing Research Group for the inspiration in making this study a success and Institute of Information Theory and Automation for providing MATLAB codes. This work is supported by The Ministry of Higher Education under Long Term Research Grant Scheme (LRGS/TD/2011/UTM/ICT/03-4L805) and by the Czech Science Foundation under Grant No. P103/11/1552. NR 34 TC 8 Z9 8 U1 0 U2 14 PU IS&T & SPIE PI BELLINGHAM PA 1000 20TH ST, BELLINGHAM, WA 98225 USA SN 1017-9909 EI 1560-229X J9 J ELECTRON IMAGING JI J. Electron. Imaging PD JAN-MAR PY 2013 VL 22 IS 1 AR 013030 DI 10.1117/1.JEI.22.1.013030 PG 11 WC Engineering, Electrical & Electronic; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA 186XJ UT WOS:000322079000003 ER PT J AU Zhang, HL Zhou, CK Wu, LM Ni, FM Zhu, J Jin, T AF Zhang, Hongliang Zhou, Chunkui Wu, Limin Ni, Fengming Zhu, Jie Jin, Tao TI Are Onconeural Antibodies a Clinical Phenomenology in Paraneoplastic Limbic Encephalitis? SO MEDIATORS OF INFLAMMATION LA English DT Review ID NMDA-RECEPTOR ENCEPHALITIS; ANTI-HU ANTIBODIES; CELL LUNG-CANCER; NEUROLOGICAL SYNDROMES; CEREBELLAR DEGENERATION; T-CELLS; GLUTAMATE-RECEPTOR; ADULT LIFE; ENCEPHALOMYELITIS; AUTOANTIBODIES AB Paraneoplastic neurological syndromes (PNSs) occur in patients with cancer and can cause clinical symptoms and signs of dysfunction of the nervous system that are not due to a local effect of the tumor or its metastases. Most of these clinical syndromes in adults are associated with lung cancer, especially small cell lung cancer (SCLC), lymphoma, and gynecological tumors. The finding of highly specific antibodies directed against onconeural antigens has revolutionized the diagnosis and promoted the understanding of these syndromes and led to the current hypothesis of an autoimmune pathophysiology. Accumulating data strongly suggested direct pathogenicity of these antibodies. The field of PNS has expanded rapidly in the past few years with the discovery of limbic encephalitis associated with glutamic acid decarboxylase (GAD) 65, the voltage (VGKC-gated potassium channel) complex, the methyl (N-NMDA-D-aspartate), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and gamma aminobutyric acid (GABA) (B) receptors, and so forth. Despite this, the clinical spectrum of these diseases has not yet been fully investigated. The clinical importance of these conditions lies in their frequent response to immunotherapies and, less commonly, their association with distinctive tumors. This review provides an overview on the pathogenesis and diagnosis of PNS, with emphasis on the role of antibodies in limbic encephalitis. C1 [Zhang, Hongliang; Zhou, Chunkui; Wu, Limin; Zhu, Jie; Jin, Tao] Jilin Univ, Bethune Hosp 1, Dept Neurol, Changchun 130021, Peoples R China. [Zhang, Hongliang; Zhu, Jie] Karolinska Inst, Novum, Dept Neurobiol Care Sci & Soc, S-14186 Huddinge, Sweden. [Zhou, Chunkui] Jilin Univ, Part Hosp 1 2, Dept Neurol, Changchun 130021, Peoples R China. [Wu, Limin] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA 02129 USA. [Ni, Fengming] Jilin Univ, Bethune Hosp 1, Dept Radiotherapy, Changchun 130021, Peoples R China. RP Jin, T (reprint author), Jilin Univ, Bethune Hosp 1, Dept Neurol, Xinmin St 71, Changchun 130021, Peoples R China. EM taotao_jin2004@yahoo.com.cn FU National Natural Science Foundation of China [81241147]; China Scholarship Council [2008102056] FX The work was supported by Grants from the National Natural Science Foundation of China (no. 81241147) and the China Scholarship Council (no. 2008102056). NR 62 TC 3 Z9 3 U1 1 U2 3 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0962-9351 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2013 AR 172986 DI 10.1155/2013/172986 PG 9 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 195LT UT WOS:000322704600001 ER PT J AU Gordon-Larsen, P Adair, LS Meigs, JB Mayer-Davis, E Herring, A Yan, SK Zhang, B Du, SF Popkin, BM AF Gordon-Larsen, Penny Adair, Linda S. Meigs, James B. Mayer-Davis, Elizabeth Herring, Amy Yan, Sheng-kai Zhang, Bing Du, Shufa Popkin, Barry M. TI Discordant Risk: Overweight and Cardiometabolic Risk in Chinese Adults SO OBESITY LA English DT Article ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; ABDOMINAL OBESITY; DIABETES-MELLITUS; HEALTH; PREVALENCE; NUTRITION; WOMEN AB Objective: Recent US work identified "metabolically healthy overweight" and "metabolically at risk normal weight" individuals. Less is known for modernizing countries with recent increased obesity. Design and Methods: Fasting blood samples, anthropometry and blood pressure from 8,233 adults aged 18-98 in the 2009 nationwide China Health and Nutrition Survey, were used to determine prevalence of overweight (Asian cut point, BMI >= 23 kg/m(2)) and five risk factors (prediabetes/diabetes (hemoglobin A1c >= 5.7%) inflammation (high-sensitivity C-reactive protein (hsCRP) >= 3 mg/l), prehypertension/hypertension (Systolic blood pressure/diastolic blood pressure >= 130/85 mm Hg), high triglycerides (>= 150 mg/dl), low high-density lipoprotein cholesterol (<40 (men)/ <50 mg/dl (women)). Sex-stratified, logistic, and multinomial logistic regression models estimated concurrent obesity and cardiometabolic risk, with and without abdominal obesity, adjusting for age, smoking, alcohol consumption, physical activity, urbanicity, and income. Results: Irrespective of urbanicity, 78.3% of the sample had >= 1 elevated cardiometabolic risk factor (normal weight: 33.2% had >= 1 elevated risk factor; overweight: 5.7% had none). At the age of 18-30 years, 47.4% had no elevated risk factors, which dropped to 6% by the age 70, largely due to age-related increase in hypertension risk (18-30 years: 11%; >70 years: 73%). Abdominal obesity was highly predictive of metabolic risk, irrespective of overweight (e. g., "metabolically at risk overweight" relative to "metabolically healthy normal weight" (men: relative risk ratio (RRR) = 39.06; 95% confidence interval (CI): 23.47, 65.00; women: RRR = 22.26; 95% CI: 17.49, 28.33)). Conclusion: A large proportion of Chinese adults have metabolic abnormalities. High hypertension risk with age, underlies the low prevalence of metabolically healthy overweight. Screening for cardiometabolic-related outcomes dependent upon overweight will likely miss a large portion of the Chinese at risk population. C1 [Gordon-Larsen, Penny; Adair, Linda S.; Mayer-Davis, Elizabeth; Du, Shufa; Popkin, Barry M.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27515 USA. [Gordon-Larsen, Penny; Adair, Linda S.; Du, Shufa; Popkin, Barry M.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC USA. [Meigs, James B.; Herring, Amy] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Meigs, James B.; Herring, Amy] Harvard Univ, Sch Med, Boston, MA USA. [Mayer-Davis, Elizabeth] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Herring, Amy] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Yan, Sheng-kai] Beijing Homa Biol Engn Co LTD, Beijing, Peoples R China. [Yan, Sheng-kai] China Japan Friendship Hosp, Dept Lab Med, Beijing, Peoples R China. [Zhang, Bing] China Ctr Dis Control, Natl Inst Nutr & Food Safety, Dept Publ Hlth Nutr, Beijing, Peoples R China. RP Gordon-Larsen, P (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27515 USA. EM pglarsen@unc.edu FU NIH: NIDDK [R21DK089306]; NHLBI [R01-HL108427]; NIH: NICHD [R01-HD30880]; National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) [K24DK080140] FX We thank Ms. Frances Dancy, BS and Ms Erica Brody, MPH, UNC Carolina Population Center for their helpful administrative assistance, Jim Terry, BA, Phil Bardsley PhD, and Dan Blanchette BA for programming and technical support. P.G.L. and L.S.A. contributed to study design, P.G.L. and L.S.A. contributed to data analysis, and all authors contributed to writing of the manuscript. P.G.L. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This work was supported by NIH: NIDDK (R21DK089306) and NHLBI (R01-HL108427). NIH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. This research uses data from the China Health and Nutrition Survey, funded by NIH: NICHD (R01-HD30880), although no direct support was received from grant for this analysis. Dr. Meigs is supported by National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) K24DK080140. NR 40 TC 20 Z9 20 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 J9 OBESITY JI Obesity PD JAN PY 2013 VL 21 IS 1 BP E166 EP E174 DI 10.1038/oby.2012.152 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 187AE UT WOS:000322086900025 PM 23505200 ER PT S AU McCullough, PA Bouchard, J Waikar, SS Siew, ED Endre, ZH Goldstein, SL Koyner, JL Macedo, E Doi, K Di Somma, S Lewington, A Thadhani, R Chakravarthi, R Ice, C Okusa, MD Duranteau, J Doran, P Yang, L Jaber, BL Meehan, S Kellum, JA Haase, M Murray, PT Cruz, D Maisel, A Bagshaw, SM Chawla, LS Mehta, RL Shaw, AD Ronco, C AF McCullough, Peter A. Bouchard, Josee Waikar, Sushrut S. Siew, Edward D. Endre, Zoltan H. Goldstein, Stuart L. Koyner, Jay L. Macedo, Etienne Doi, Kent Di Somma, Salvatore Lewington, Andrew Thadhani, Ravi Chakravarthi, Raj Ice, Can Okusa, Mark D. Duranteau, Jacques Doran, Peter Yang, Li Jaber, Bertrand L. Meehan, Shane Kellum, John A. Haase, Michael Murray, Patrick T. Cruz, Dinna Maisel, Alan Bagshaw, Sean M. Chawla, Lakhmir S. Mehta, Ravindra L. Shaw, Andrew D. Ronco, Claudio CA Acute Dialysis Quality Initiative BE McCullough, PA Kellum, JA Mehta, RL Murray, PT Ronco, C TI Implementation of Novel Biomarkers in the Diagnosis, Prognosis, and Management of Acute Kidney Injury: Executive Summary from the Tenth Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) SO ADQI CONSENSUS ON AKI BIOMARKERS AND CARDIORENAL SYNDROMES SE Contributions to Nephrology LA English DT Article; Proceedings Paper CT 10th Acute Dialysis Quality Initiative Consensus Conference CY AUG 30-SEP 01, 2011 CL Dublin, IRELAND ID FAILURE AB Detection of acute kidney injury is undergoing a dynamic revolution of biomarker technology allowing greater, earlier, and more accurate determination of diagnosis, prognosis, and with powerful implication for management. Biomarkers can be broadly considered as any measurable biologic entity or process that allows differentiation between normal function and injury or disease. The ADQI (Acute Dialysis Quality Initiative) had its Ninth Consensus Conference dedicated to synthesis and formulation of the existing literature on biomarkers for the detection of acute kidney injury in a variety of settings. In the papers that accompany this summary, ADQI workgroups fully develop key concepts from a summary of the literature in the domains of early diagnosis, differential diagnosis, prognosis and management, and concurrent physiologic and imaging measures. Copyright (C) 2013 S. Karger AG, Basel C1 [McCullough, Peter A.] St John Providence Hlth Syst, Warren, MI USA. [McCullough, Peter A.] Providence Hosp & Med Centers, Southfield, MI USA. [McCullough, Peter A.] Providence Hosp & Med Centers, Novi, MI USA. [McCullough, Peter A.] St John Macomb Oakland Ctr, Madison Hts, MI USA. [McCullough, Peter A.] St John Hosp & Med Ctr, Detroit, MI USA. [Bouchard, Josee] Univ Montreal, Div Nephrol, Div Nephrol & Hypertens, Montreal, PQ, Canada. [Waikar, Sushrut S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Renal Div, Boston, MA 02115 USA. [Siew, Edward D.] Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol & Hypertens, Nashville, TN 37212 USA. [Endre, Zoltan H.] Univ Otago, Dept Med, Christchurch Kidney Res Grp, Christchurch, New Zealand. [Goldstein, Stuart L.] Cincinnati Childrens Hosp, Med Ctr, Inst Heart, Div Nephrol & Hypertens,Ctr Acute Care Nephrol, Cincinnati, OH USA. [Koyner, Jay L.] Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA. [Macedo, Etienne] Univ Sao Paulo, Div Nephrol, Sao Paulo, Brazil. [Doi, Kent] Univ Tokyo, Dept Nephrol & Endocrinol, Tokyo, Japan. [Di Somma, Salvatore] Univ Roma La Sapienza, St Andreas Hosp, Fac Med Sch 2, I-00185 Rome, Italy. [Lewington, Andrew] Leeds Teaching Hosp, Leeds, W Yorkshire, England. [Thadhani, Ravi] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Chakravarthi, Raj] Albany Med Coll, Div Nephrol, Albany, NY 12208 USA. [Ice, Can] Erasmus MC Univ Med Ctr Rotterdam, Dept Intens Care Adults, Rotterdam, Netherlands. [Okusa, Mark D.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Duranteau, Jacques] Nephrol Unit, Le Kremlin Bicetre, Bicetre, France. [Doran, Peter] Univ Munich, Med Poliklin, D-80539 Munich, Germany. [Yang, Li] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Jaber, Bertrand L.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Meehan, Shane] Univ Chicago, Dept Pathol, Nephrol Sect, Chicago, IL 60637 USA. [Kellum, John A.] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA USA. [Haase, Michael] Otto von Guericke Univ, Dept Nephrol Hypertens Diabet & Endocrinol, Magdeburg, Germany. [Murray, Patrick T.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland. [Cruz, Dinna] San Bortolo Hosp, Dept Nephrol Dialysis & Transplantat, Vicenza, Italy. [Maisel, Alan] San Diego VA Med Ctr, Dept Med & Cardiol, San Diego, CA USA. [Maisel, Alan] Univ Calif San Diego, San Diego, CA 92103 USA. [Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada. [Chawla, Lakhmir S.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA. [Chawla, Lakhmir S.] George Washington Univ, Med Ctr, Dept Med, Div Renal Dis & Hypertens, Washington, DC 20037 USA. [Mehta, Ravindra L.] Univ Calif San Diego, Dept Med, Div Nephrol & Hypertens, San Diego, CA 92103 USA. [Shaw, Andrew D.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA. [Ronco, Claudio] San Bortolo Hosp, Int Renal Res Inst IRRIV, Dept Nephrol, Vicenza, Italy. RP McCullough, PA (reprint author), Providence Pk Hosp, Providence Pk Heart Inst, 47601 Grand River,B125, Novi, MI 48374 USA. EM peteramccullough@gmail.com OI Endre, Zoltan/0000-0002-4782-8695; Murray, Patrick/0000-0001-8516-1839; Meehan, Shane/0000-0001-9055-5576 FU Alere Inc.; Astute Medical Inc. FX The 9th International ADQI Consensus Conference was funded in part by generous support in form of unrestricted educational grants from Alere Inc., and Astute Medical Inc. The sponsors had no input on the content of this paper. NR 14 TC 38 Z9 45 U1 0 U2 3 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-318-02406-7 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2013 VL 182 BP 5 EP 12 DI 10.1159/000349962 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA BFX56 UT WOS:000321800100002 PM 23689652 ER PT S AU Cruz, DN Bagshaw, SM Maisel, A Lewington, A Thadhani, R Chakravarthi, R Murray, PT Mehta, RL Chawla, LS AF Cruz, Dinna N. Bagshaw, Sean M. Maisel, Alan Lewington, Andrew Thadhani, Ravi Chakravarthi, Rajasekara Murray, Patrick T. Mehta, Ravindra L. Chawla, Lakhmir S. CA ADQI 10 Workgrp BE McCullough, PA Kellum, JA Mehta, RL Murray, PT Ronco, C TI Use of Biomarkers to Assess Prognosis and Guide Management of Patients with Acute Kidney Injury SO ADQI CONSENSUS ON AKI BIOMARKERS AND CARDIORENAL SYNDROMES SE Contributions to Nephrology LA English DT Article; Proceedings Paper CT 10th Acute Dialysis Quality Initiative Consensus Conference CY AUG 30-SEP 01, 2011 CL Dublin, IRELAND ID GELATINASE-ASSOCIATED LIPOCALIN; CRITICALLY-ILL PATIENTS; ACUTE-RENAL-FAILURE; INTENSIVE-CARE-UNIT; ADULT CARDIAC-SURGERY; URINARY BIOMARKERS; REPLACEMENT THERAPY; POOR OUTCOMES; PROSPECTIVE COHORT; HEART-FAILURE AB Several new biomarkers of kidney damage have been characterized and are being validated in clinical studies. These damage biomarkers complement existing conventional biomarkers of kidney function (e.g. serum creatinine, serum urea, and urine output) that are currently utilized to diagnose and stage acute kidney injury (AKI). Both functional and damage biomarkers provide an opportunity to identify patients with AKI who are at risk for a less favorable prognosis in terms of worsening damage or further declines in kidney function and likelihood of need for renal replacement. We performed a systemic search and review of the available literature pre-conference. Our workgroup presented the findings in multiple rounds to the ADQI conference members and a final summary and review was refined in an iterative approach. The specific clinical situations of renal or liver transplantation, or cirrhosis/hepatorenal syndrome were not included. Overall, multiple AKI biomarkers have been well characterized for utilization for AKI prognosis. These functional and damage markers can be used to assist in decisions related to triage of patients with AKI and identifying patients with who are at risk for progression. Set cut-offs for various biomarkers and their bedside utility are forthcoming and will be in part determined by regulatory intended use guidelines, platform standardization, and inter-laboratory calibration. There remain many unresolved areas of AKI biomarker use in selected syndromes of AKI (e.g. cardiorenal syndrome, hepatorenal syndrome). As clinicians gain experience with AKI biomarkers, clinical care plans that incorporate them into routine care will shortly follow. Copyright (C) 2013 S. Karger AG, Basel C1 [Chawla, Lakhmir S.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, 900 23rd St,NW,G-105, Washington, DC 20037 USA. [Cruz, Dinna N.] San Bortolo Hosp, Dept Nephrol Dialysis & Transplantat, Vicenza, Italy. [Cruz, Dinna N.] Int Renal Res Inst IRRIV, Vicenza, Italy. [Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada. [Maisel, Alan] San Diego VA Med Ctr, Dept Med & Cardiol, San Diego, CA USA. [Lewington, Andrew] Univ Calif San Diego, San Diego, CA 92103 USA. [Chakravarthi, Rajasekara] St James Univ Hosp, Dept Renal Med, Leeds, W Yorkshire, England. Harvard Univ, Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02115 USA. [Thadhani, Ravi] Harvard Univ, Med Sch RT, Boston, MA 02115 USA. [Chakravarthi, Rajasekara] CARE Hosp, Inst Med Sci, Dept Nephrol, Hyderabad, Andhra Pradesh, India. [Murray, Patrick T.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland. [Mehta, Ravindra L.] Univ Calif San Diego, Dept Med & Nephrol, San Diego, CA 92103 USA. [Chawla, Lakhmir S.] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA. RP Chawla, LS (reprint author), George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, 900 23rd St,NW,G-105, Washington, DC 20037 USA. EM minkchawla@gmail.com OI Murray, Patrick/0000-0001-8516-1839 NR 54 TC 17 Z9 19 U1 0 U2 2 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-318-02406-7 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2013 VL 182 BP 45 EP + DI 10.1159/000349965 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA BFX56 UT WOS:000321800100005 PM 23689655 ER PT J AU Wang, XL Fang, JL Zhao, Q Fan, YY Liu, J Hong, Y Wang, HH Ma, YY Xu, CH Shi, S Kong, J Rong, PJ AF Wang, Xiaoling Fang, Jiliang Zhao, Qing Fan, Yangyang Liu, Jun Hong, Yang Wang, Honghong Ma, Yunyao Xu, Chunhua Shi, Shan Kong, Jian Rong, Peijing TI Deqi Sensations of Transcutaneous Electrical Nerve Stimulation on Auricular Points SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID ACUPUNCTURE; QI; HISTORY; BRAIN; FMRI AB Deqi sensation, a psychophysical response characterized by a spectrum of different needling sensations, is essential for Chinese acupuncture clinical efficacy. Previous research works have investigated the component of Deqi response upon acupuncture on acupoints on the trunk and limbs. However, the characteristics of Deqi sensations of transcutaneous electrical nerve stimulation (TENS) on auricular points are seldom reported. In this study, we investigated the individual components of Deqi during TENS on auricular concha area and the superior scapha using quantitative measurements in the healthy subjects and depression patients. The most striking characteristics of Deqi sensations upon TENS on auricular points were tingling, numbness, and fullness. The frequencies of pressure, warmness, heaviness, and soreness were relatively lower. The dull pain and coolness are rare. The characteristics of Deqi were similar for the TENS on concha and on the superior scapha. C1 [Wang, Xiaoling; Fang, Jiliang; Zhao, Qing; Fan, Yangyang; Liu, Jun; Hong, Yang; Wang, Honghong; Ma, Yunyao; Xu, Chunhua; Shi, Shan] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China. [Fang, Jiliang; Rong, Peijing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing 100700, Peoples R China. [Kong, Jian] Harvard Univ, Massachusetts Gen Hosp, Dept Psychiat, Sch Med, Boston, MA 02115 USA. RP Fang, JL (reprint author), China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China. EM fangmgh@163.com; drrongpj@163.com FU Beijing Natural Science Foundation [711117]; National Natural Science Foundation of China [81273674, 30973798]; Ministry of Science and Technology [2011EG152313]; National Science and Technology Support Program of China [2012BAF14B10] FX This work was supported by funding from the Beijing Natural Science Foundation (Grant no. 711117), the National Natural Science Foundation of China Research grants (no. 81273674, 30973798), the grant of the technology development research for institute from the Ministry of Science and Technology (2011EG152313), and the Twelfth Five-Year Plan of the National Science and Technology Support Program of China (2012BAF14B10). There is no conflict of interests for any author. NR 21 TC 0 Z9 0 U1 1 U2 7 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 371543 DI 10.1155/2013/371543 PG 5 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 188XB UT WOS:000322229900001 ER PT J AU Rahmani, A Rasmussen, AQ Honge, JL Ostli, B Levine, RA Hagege, A Nygaard, H Nielsen, SL Jensen, MO AF Rahmani, Azadeh Rasmussen, Ann Q. Honge, Jesper L. Ostli, Bjorn Levine, Robert A. Hagege, Albert Nygaard, Hans Nielsen, Sten L. Jensen, Morten O. TI Mitral Valve Mechanics Following Posterior Leaflet Patch Augmentation SO JOURNAL OF HEART VALVE DISEASE LA English DT Article ID IN-VITRO; REGURGITATION; REPAIR; MODEL; EXTENSION; INSIGHTS; PROLAPSE; DISEASE AB Background and aim of the study: Attention towards the optimization of mitral valve repair methods is increasing. Patch augmentation is one strategy used to treat functional ischemic mitral regurgitation (FIMR). The study aim was to investigate the force balance changes in specific chordae tendineae emanating from the posterior papillary muscle in a FIMR-simulated valve, following posterior leaflet patch augmentation. Methods: Mitral valves were obtained from 12 pigs (body weight 80 kg). An in vitro test set-up simulating the left ventricle was used to hold the valves. The left ventricular pressure was regulated with water to simulate different static pressures during valve closure. A standardized oval pericardial patch (17 x 29 mm) was introduced into the posterior leaflet from mid P2 to the end of the P3 scallop. Dedicated miniature transducers were used to record the forces exerted on the chordae tendineae. Data were acquired before and after 12 mm posterior and 5 mm apical posterior papillary muscle displacement to simulate the effect from one of the main contributors of FIMR, before and after patch augmentation. Results: The effect of displacing the posterior papillary muscle induced tethering on the intermediate chordae tendineae to the posterior leaflet, and resulted in a 39.8% force increase (p = 0.014). Posterior leaflet patch augmentation of the FIMR valve induced a 31.1% force decrease (p = 0.007). There was no difference in force between the healthy and the repaired valve simulations = 0.773). Conclusion: Posterior leaflet patch augmentation significantly reduced the forces exerted on the intermediate chordae tendineae from the posterior papillary muscle following FIMR simulation. As changes in chordal tension lead to a redistribution of the total stress exerted on the valve, patch augmentation may have an adverse long-term influence on mitral valve function and remodeling. C1 [Rahmani, Azadeh; Rasmussen, Ann Q.; Ostli, Bjorn] Univ Aarhus, Dept Engn, Aarhus, Denmark. [Honge, Jesper L.; Nygaard, Hans; Nielsen, Sten L.; Jensen, Morten O.] Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, Skejby, Denmark. [Levine, Robert A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Hagege, Albert] Univ Paris 05, Dept Cardiol, Hop Europeen Georges Pompidou, INSERM U633, Paris, France. RP Jensen, MO (reprint author), Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, DK-8200 Aarhus N, Denmark. EM dr.morten.jensen@gmail.com FU Danish Heart Foundation [07-4-B248-A1380-22362]; Central Denmark Region Health Science Research Fund; A.P. Moller Foundation for the Advancement of Medical Science; Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond; Horslev Fonden; Beckett Fonden; Henry og Astrid Mollers Fond; NHLBI [K24 HL67434]; Leducq Foundation, Paris, France [07CVD04] FX This research project was funded by the Danish Heart Foundation Grant #07-4-B248-A1380-22362, the Central Denmark Region Health Science Research Fund, the A.P. Moller Foundation for the Advancement of Medical Science, Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond, Horslev Fonden, Beckett Fonden, and Henry og Astrid Mollers Fond. Dr. Robert A. Levine's participation was supported by NHLBI grant # K24 HL67434, as well as grant 07CVD04 from the Leducq Foundation, Paris, France, for the Leducq MITRAL Transatlantic Network. The authors would also like to thank Jesper Brink Askov for data acquisitioning assistance, and Bjorn Ostli and Joakim Vester-Petersen for providing the left heart simulator. They also thank Mikael Norregaard Nielsen and Esben Skov Kragsnaes for providing modifications to the simulator. NR 29 TC 5 Z9 5 U1 0 U2 0 PU I C R PUBLISHERS PI NORTHWOOD PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET, ENGLAND SN 0966-8519 J9 J HEART VALVE DIS JI J. Heart Valve Dis. PD JAN PY 2013 VL 22 IS 1 BP 28 EP 35 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 182DL UT WOS:000321721800006 PM 23610985 ER PT J AU Vurro, M Ling, YZ Hurlbert, AC AF Vurro, Milena Ling, Yazhu Hurlbert, Anya C. TI Memory color of natural familiar objects: Effects of surface texture and 3-D shape SO JOURNAL OF VISION LA English DT Article DE color appearance; color vision; memory color; natural objects; three dimensionality ID DEPTH INFORMATION; VISUAL AGNOSIA; VENTRAL STREAM; RECOGNITION; PERCEPTION; REAL; FORM; REPRESENTATION; IDENTIFICATION; REPRODUCTION AB Natural objects typically possess characteristic contours, chromatic surface textures, and three-dimensional shapes. These diagnostic features aid object recognition, as does memory color, the color most associated in memory with a particular object. Here we aim to determine whether polychromatic surface texture, 3-D shape, and contour diagnosticity improve memory color for familiar objects, separately and in combination. We use solid three-dimensional familiar objects rendered with their natural texture, which participants adjust in real time to match their memory color for the object. We analyze mean, accuracy, and precision of the memory color settings relative to the natural color of the objects under the same conditions. We find that in all conditions, memory colors deviate slightly but significantly in the same direction from the natural color. Surface polychromaticity, shape diagnosticity, and three dimensionality each improve memory color accuracy, relative to uniformly colored, generic, or two-dimensional shapes, respectively. Shape diagnosticity improves the precision of memory color also, and there is a trend for polychromaticity to do so as well. Differently from other studies, we find that the object contour alone also improves memory color. Thus, enhancing the naturalness of the stimulus, in terms of either surface or shape properties, enhances the accuracy and precision of memory color. The results support the hypothesis that memory color representations are polychromatic and are synergistically linked with diagnostic shape representations. C1 [Vurro, Milena] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA. [Ling, Yazhu] Apple Comp Inc, Cupertino, CA 95014 USA. [Hurlbert, Anya C.] Newcastle Univ, Fac Med Sci, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. RP Vurro, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA. EM vurro.milena@mgh.harvard.edu FU EPSRC project grant [EP/D068738] FX Preliminary reports of these results were presented at VSS 2009 and appeared in its special issue (Vurro et al., 2009). Supported by EPSRC project grant (EP/D068738) to ACH. NR 59 TC 7 Z9 7 U1 1 U2 9 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 1534-7362 J9 J VISION JI J. Vision PY 2013 VL 13 IS 7 AR UNSP 20 DI 10.1167/13.7.20 PG 20 WC Ophthalmology SC Ophthalmology GA 173YX UT WOS:000321120800020 PM 23814075 ER PT S AU Akl, TJ Wilson, MA Ericson, MN Cote, GL AF Akl, Tony J. Wilson, Mark A. Ericson, M. Nance Cote, Gerard L. BE Cote, GL TI Optical Modeling toward Optimizing Monitoring of Intestinal Perfusion in Trauma Patients SO OPTICAL DIAGNOSTICS AND SENSING XIII: TOWARD POINT-OF-CARE DIAGNOSTICS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Diagnostics and Sensing XIII - Toward Point-of-Care Diagnostics CY FEB 06, 2013 CL San Francisco, CA SP SPIE DE Perfusion monitoring; Photoplethysmography; Trauma; Oximetry; Telemetry ID TISSUE; RESUSCITATION; PENETRATION; DEPTH; SHOCK AB Trauma is the number one cause of death for people between the ages 1 and 44 years in the United States. In addition, according to the Centers of Disease Control and Prevention, injury results in over 31 million emergency department visits annually. Minimizing the resuscitation period in major abdominal injuries increases survival rates by correcting impaired tissue oxygen delivery. Optimization of resuscitation requires a monitoring method to determine sufficient tissue oxygenation. Oxygenation can be assessed by determining the adequacy of tissue perfusion. In this work, we present the design of a wireless perfusion and oxygenation sensor based on photoplethysmography. Through optical modeling, the benefit of using the visible wavelengths 470, 525 and 590nm (around the 525nm hemoglobin isobestic point) for intestinal perfusion monitoring is compared to the typical near infrared (NIR) wavelengths (805nm isobestic point) used in such sensors. Specifically, NIR wavelengths penetrate through the thin intestinal wall (similar to 4mm) leading to high background signals. However, these visible wavelengths have two times shorter penetration depth that the NIR wavelengths. Monte-Carlo simulations show that the transmittance of the three selected wavelengths is lower by 5 orders of magnitude depending on the perfusion state. Due to the high absorbance of hemoglobin in the visible range, the perfusion signal carried by diffusely reflected light is also enhanced by an order of magnitude while oxygenation signal levels are maintained. In addition, short source-detector separations proved to be beneficial for limiting the probing depth to the thickness of the intestinal wall. C1 [Akl, Tony J.; Cote, Gerard L.] Texas A&M Univ, Dept Biomed Engn, College Stn, TX 77843 USA. [Wilson, Mark A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA. [Wilson, Mark A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Cote, Gerard L.] Oak Ridge Natl Lab, Oak Ridge, TN USA. RP Akl, TJ (reprint author), Texas A&M Univ, Dept Biomed Engn, College Stn, TX 77843 USA. RI Ericson, Milton/H-9880-2016 OI Ericson, Milton/0000-0002-6628-4865 FU NIH [5R01-GM077150] FX This research was funded by a bioengineering research partnership (BRP) grant from NIH, (#5R01-GM077150). NR 21 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9360-6 J9 PROC SPIE PY 2013 VL 8591 AR 859106 DI 10.1117/12.2003352 PG 6 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BFX14 UT WOS:000321740300006 ER PT S AU Sayegh, SI Taghian, A AF Sayegh, Samir I. Taghian, Alphonse BE Cote, GL TI Profilometry and subsurface imaging in pont of care diagnosis in ocular disease and lymphedema after breast cancer treatment SO OPTICAL DIAGNOSTICS AND SENSING XIII: TOWARD POINT-OF-CARE DIAGNOSTICS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Diagnostics and Sensing XIII - Toward Point-of-Care Diagnostics CY FEB 06, 2013 CL San Francisco, CA SP SPIE DE lymphedema; neoplastic disease; perometry; breast cancer; bioimpedance; structured light; topography; KINECT (TM) ID BIOELECTRICAL-IMPEDANCE SPECTROSCOPY; VOLUME AB Breast cancer-realted lymphedema (BCRL) can be irreversible with profound negative impact on patients' quality of life. Programs that provide screening and active surveillance for BCRL are essential to determine whether early detection and intervention influences the course of lymphedema development. Established methods of quantitatively assessing lymphedema at early stages include "volume" methods such as perometry and bioimpedance spectroscopy. Here we demonstrate 1) Use of topographical techniques analogous to those used in corneal toporgraphy 2) Development of point-of-care lymphedema detection and characterization based on off-the-shelf hardware 3) The role of subsurface imaging 4) Multimodal diagnostics and integration yielding higher sensitivity/specificity. C1 [Sayegh, Samir I.] Ctr Eye, Champaign, IL USA. [Taghian, Alphonse] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Sayegh, SI (reprint author), Ctr Eye, Champaign, IL USA. NR 36 TC 0 Z9 0 U1 0 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9360-6 J9 PROC SPIE PY 2013 VL 8591 AR 85910U DI 10.1117/12.2006601 PG 7 WC Engineering, Biomedical; Optics SC Engineering; Optics GA BFX14 UT WOS:000321740300020 ER PT S AU Ando, M Chikaura, Y Endo, T Gupta, R Huo, QK Hyodo, K Ichihara, S Mori, K Nakao, Y Ohura, N Sunaguchi, N Sugiyama, H Suzuki, Y Wu, YL Yuasa, T Zhang, XW AF Ando, Masami Chikaura, Yoshinori Endo, Tokiko Gupta, Rajiv Huo, Qingkai Hyodo, Kazuyuki Ichihara, Shu Mori, Kensaku Nakao, Yuki Ohura, Norihiko Sunaguchi, Naoki Sugiyama, Hiroshi Suzuki, Yoshifumi Wu, Yanlin Yuasa, Tetsuya Zhang Xiaowei BE Susini, J Dumas, P TI Tissue Visualization Using X-Ray Dark-Field Imaging towards Pathological Goal SO 11TH INTERNATIONAL CONFERENCE ON SYNCHROTRON RADIATION INSTRUMENTATION (SRI 2012) SE Journal of Physics Conference Series LA English DT Proceedings Paper CT 11th International Conference on Synchrotron Radiation Instrumentation (SRI) CY JUL 09-13, 2012 CL Lyon, FRANCE SP ESRF, SOLEIL ID COMPUTED-TOMOGRAPHY; PHASE-CONTRAST; RECONSTRUCTION AB In XDFI (x-ray dark-field imaging) LAA (Laue-case angle analyzer) simultaneously provides two x-ray images; one corresponds to a FD forward diffracted beam and a separate D diffracted beam. When this is applied to biomedical specimens x-ray images are very high contrast and very high spatial resolution. We constructed XDFI system at the vertical wiggler beamline BL-14C in KEK Photon Factory and performed imaging experiment of breast tissues and an excised human femoral artery. In this paper, we discuss a tissue visualization and pathological goal using 2D, 3D-CT and 2.5D image (tomosynthesis) with XDFI. C1 [Ando, Masami; Huo, Qingkai; Nakao, Yuki] Tokyo Univ Sci, Yamasaki 2461, Noda, Chiba 2788510, Japan. [Chikaura, Yoshinori] Kyushu Univ, Res Ctr Synchrotron Light Applicat, Kasuga, Fukuoka 8168580, Japan. [Endo, Tokiko; Ichihara, Shu] Nagoya Med Ctr, Dept Adv Diag, Naka Ku, Nagoya, Aichi 4600001, Japan. [Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 01778 USA. [Hyodo, Kazuyuki; Sunaguchi, Naoki; Sugiyama, Hiroshi] KEK, Photon Factory, Ibaraki 3050801, Japan. [Mori, Kensaku] Nagoya Univ, Grd Sch Informat Sci, Nagoya, Aichi 4648603, Japan. [Ohura, Norihiko] Kyorin Univ, Sch Med, Dept Plast Surg, Mitaka, Tokyo 1810001, Japan. [Suzuki, Yoshifumi] Kyushu Inst Technol, Grd Sch Engn, Kitakyushu, Fukuoka 8048550, Japan. [Wu, Yanlin] Grd Univ Sci, Sch Accelerator Sci, Tsukuba, Ibaraki 3050801, Japan. [Yuasa, Tetsuya] Yamagata Univ, Fac Engn, Yonezawa, Yamagata 9928510, Japan. RP Ando, M (reprint author), Tokyo Univ Sci, Yamasaki 2461, Noda, Chiba 2788510, Japan. EM msm-ando@rs.noda.tus.ac.jp FU MEXT in Japan [22591353, 23602002]; National Hospital Organization; PAB,KEK [2008S2-002, 2011G-672] FX This work is supported in part by a Grant-in-Aid for Scientific Research (No. 22591353, 23602002) from the MEXT in Japan, and in part by a Grant-in-Aid for Clinical Research from the National Hospital Organization. The experiment was performed under the approval of the PAB at KEK under No. 2008S2-002, 2011G-672 for use of the Photon Factory. NR 15 TC 0 Z9 0 U1 0 U2 2 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1742-6588 J9 J PHYS CONF SER PY 2013 VL 425 AR UNSP 192006 DI 10.1088/1742-6596/425/19/192006 PG 4 WC Instruments & Instrumentation; Physics, Applied; Physics, Multidisciplinary SC Instruments & Instrumentation; Physics GA BFL51 UT WOS:000320403700251 ER PT S AU Carr, CE Zuber, MT Ruvkun, G AF Carr, Christopher E. Zuber, Maria T. Ruvkun, Gary GP IEEE TI Life Detection with the Enceladus Orbiting Sequencer SO 2013 IEEE AEROSPACE CONFERENCE SE IEEE Aerospace Conference Proceedings LA English DT Proceedings Paper CT IEEE Aerospace Conference CY MAR 02-09, 2013 CL Big Sky, MT SP IEEE ID MURCHISON METEORITE; EARLY EARTH; ULTRAVIOLET PHOTOIRRADIATION; EXTRATERRESTRIAL NUCLEOBASES; CARBONACEOUS METEORITES; AMINO-ACIDS; SURFACE; SEARCH; PHOSPHORUS; PYRIMIDINE AB Widespread organic synthesis in the early solar nebula led to delivery of similar complex organics, probably including nucleobases or their precursors, to many potentially habitable locations such as Mars, Europa, and Enceladus. If life evolved beyond Earth, the presence of these organics could have biased life towards utilization of informational polymers (IPs) like RNA or DNA. Given this, searching for and sequencing any such IPs offers a definitive, information rich, approach to life detection that complements existing methods. Saturn's icy moon Enceladus offers possibly the best conditions in the solar system to find extant life beyond Earth. Recent discovery of a salt-water plume likely derived from sub-surface liquid reservoirs provides direct access to this potentially habitable environment. We describe an instrument concept, the Enceladus Orbiting Sequencer (EOS), specifically geared to search for life on Enceladus. As a payload on board an Enceladus flyby or orbiter mission, EOS would capture ice grains from the plume, then concentrate and characterize any long charged polymers using nanopore or semiconductor sequencing. Searching for life on Enceladus could give us our first glimpse of a second genesis and test whether biochemistry is varied or universal. C1 [Carr, Christopher E.; Zuber, Maria T.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA. [Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. [Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Carr, CE (reprint author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA. EM chrisc@mit.edu; zuber@mit.edu; ruvkun@molbio.mgh.harvard.edu FU NASA [NNX08AX15G] FX This work was funded under NASA award NNX08AX15G. NR 52 TC 0 Z9 0 U1 4 U2 20 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1095-323X BN 978-1-4673-1811-2 J9 AEROSP CONF PROC PY 2013 PG 11 WC Engineering, Aerospace; Engineering, Electrical & Electronic SC Engineering GA BFJ62 UT WOS:000320123901090 ER PT J AU Smith, GP AF Smith, Gideon P. BE Conn, PM TI Animal Models of Fibrosis in Human Disease SO ANIMAL MODELS FOR THE STUDY OF HUMAN DISEASE LA English DT Article; Book Chapter ID GROWTH-FACTOR-BETA; HEPATIC STELLATE CELLS; TUMOR-NECROSIS-FACTOR; C VIRUS-INFECTION; EXPERIMENTAL AUTOIMMUNE HEPATITIS; BLEOMYCIN-INDUCED SCLERODERMA; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN; SYSTEMIC-SCLEROSIS SCLERODERMA; ACTIVATED RECEPTOR-GAMMA; COLLAGEN GENE-EXPRESSION C1 Harvard Univ, Connect Tissue Dis Clin, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Smith, GP (reprint author), Harvard Univ, Connect Tissue Dis Clin, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 218 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-415912-9 PY 2013 BP 435 EP 458 DI 10.1016/B978-0-12-415894-8.00019-1 PG 24 WC Biology; Medical Ethics SC Life Sciences & Biomedicine - Other Topics; Medical Ethics GA BFR75 UT WOS:000321100200020 ER PT S AU Napetschnig, J Wu, H AF Napetschnig, Johanna Wu, Hao BE Dill, KA TI Molecular Basis of NF-kappa B Signaling SO ANNUAL REVIEW OF BIOPHYSICS, VOL 42 SE Annual Review of Biophysics LA English DT Review; Book Chapter DE TNF; Toll-like receptor; IKK; TRAF; ubiquitin; NEMO ID NUCLEAR EXPORT SIGNAL; TOLL/INTERLEUKIN-1 RECEPTOR DOMAIN; KINASE KINASE KINASE; TOLL-LIKE RECEPTORS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DEATH DOMAIN; INTERLEUKIN-1 RECEPTOR; POLYUBIQUITIN CHAINS; TRANSCRIPTION FACTOR AB NF-kappa B (nuclear factor kappa B) family transcription factors are master regulators of immune and inflammatory processes in response to both injury and infection. In the latent state, NF-kappa Bs are sequestered in the cytosol by their inhibitor I kappa B (inhibitor of NF-kappa B) proteins. Upon stimulations of innate immune receptors such as Toll-like receptors and cytokine receptors such as those in the TNF (tumor necrosis factor) receptor superfamily, a series of membrane proximal events lead to the activation of the IKK (I kappa B kinase). Phosphorylation of I kappa Bs results in their proteasomal degradation and the release of NF-kappa B for nuclear translocation and activation of gene transcription. Here, we review the plethora of structural studies in these NF-kappa B activation pathways, including the TRAF (TNF receptor-associated factor) proteins, IKK, NF-kappa B, ubiquitin ligases, and deubiquitinating enzymes. Although these structures only provide snapshots of isolated processes, an emerging picture is that these signaling cascades coalesce into large oligomeric signaling complexes, or signalosomes, for signal propagation. C1 [Napetschnig, Johanna; Wu, Hao] Weill Cornell Med Coll, Dept Biochem, New York, NY 10021 USA. [Wu, Hao] Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA 02115 USA. [Wu, Hao] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Napetschnig, J (reprint author), Weill Cornell Med Coll, Dept Biochem, New York, NY 10021 USA. EM hao.wu@childrens.harvard.edu FU NIAID NIH HHS [R01 AI045937, R01 AI050872, R01 AI079260, R01 AI089882, R01AI045937, R01AI079260, R01AI50872, R37 AI050872] NR 134 TC 178 Z9 197 U1 7 U2 61 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1936-122X BN 978-0-8243-1842-0 J9 ANNU REV BIOPHYS JI Annu. Rev. Biophys. PY 2013 VL 42 BP 443 EP 468 DI 10.1146/annurev-biophys-083012-130338 PG 26 WC Biophysics SC Biophysics GA BFW68 UT WOS:000321695700020 PM 23495970 ER PT J AU Parmigiani, G Trippa, L AF Parmigiani, G. Trippa, L. TI Bayesian Nonparametric Inference Why and How Comment SO BAYESIAN ANALYSIS LA English DT Editorial Material C1 [Parmigiani, G.; Trippa, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Parmigiani, G.; Trippa, L.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. RP Parmigiani, G (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU INT SOC BAYESIAN ANALYSIS PI PITTSBURGH PA CARNEGIE MELLON UNIV, DEPT STTISTICS, PITTSBURGH, PA 15213 USA SN 1931-6690 J9 BAYESIAN ANAL JI Bayesian Anal. PY 2013 VL 8 IS 2 BP 346 EP 347 PG 2 WC Mathematics, Interdisciplinary Applications; Statistics & Probability SC Mathematics GA 176VZ UT WOS:000321335600013 ER PT J AU Hussey, SE Liang, HY Costford, SR Klip, A DeFronzo, RA Sanchez-Avila, A Ely, B Musi, N AF Hussey, Sophie E. Liang, Hanyu Costford, Sheila R. Klip, Amira DeFronzo, Ralph A. Sanchez-Avila, Alicia Ely, Brian Musi, Nicolas TI TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipid-induced inflammation and insulin resistance in muscle cells SO BIOSCIENCE REPORTS LA English DT Article DE endotoxin; mitogen-activated protein kinase (MAPK); nuclear factor kappa B (NF-kappa B); saturated non-esterified fatty acid (NEFA); Toll-like receptor 4 (TLR4). ID SATURATED FATTY-ACIDS; NECROSIS-FACTOR-ALPHA; DIET-INDUCED OBESITY; KAPPA-B KINASE; SKELETAL-MUSCLE; PROTEIN-KINASE; GLUT4 TRANSLOCATION; 3-KINASE ACTIVITY; INNATE IMMUNITY; GLUCOSE-UPTAKE AB Emerging evidence suggests that TLR (Toll-like receptor) 4 and downstream pathways [MAPKs (mitogen-activated protein kinases) and NF-kappa B (nuclear factor kappa B)] play an important role in the pathogenesis of insulin resistance. LPS (lipopolysaccharide) and saturated NEFA (non-esterified fatty acids) activate TLR4, and plasma concentrations of these TLR4 ligands are elevated in obesity and Type 2 diabetes. Our goals were to define the role of TLR4 on the insulin resistance caused by LPS and saturated NEFA, and to dissect the independent contribution of LPS and NEFA to the activation of TLR4-driven pathways by employing TAK-242, a specific inhibitor of TLR4. LPS caused robust activation of the MAPK and NF-kappa B pathways in L6 myotubes, along with impaired insulin signalling and glucose transport. TAK-242 completely prevented the inflammatory response (MAPK and NF-kappa B activation) caused by LPS, and, in turn, improved LPS-induced insulin resistance. Similar to LPS, stearate strongly activated MAPKs, although stimulation of the NF-kappa B axis was modest. As seen with LPS, the inflammatory response caused by stearate was accompanied by impaired insulin action. TAK-242 also blunted stearate-induced inflammation; yet, the protective effect conferred by TAK-242 was partial and observed only on MAPKs. Consequently, the insulin resistance caused by stearate was only partially improved by TAK-242. In summary, TAK-242 provides complete and partial protection against LPS- and NEFA-induced inflammation and insulin resistance, respectively. Thus, LPS-induced insulin resistance depends entirely on TLR4, whereas NEFA works through TLR4-dependent and -independent mechanisms to impair insulin action. C1 [Hussey, Sophie E.; Liang, Hanyu; DeFronzo, Ralph A.; Ely, Brian; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA. [Hussey, Sophie E.; Liang, Hanyu; DeFronzo, Ralph A.; Sanchez-Avila, Alicia] Texas Diabet Inst, San Antonio, TX 78207 USA. [Costford, Sheila R.; Klip, Amira] Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada. [Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Ctr Hlth Aging, San Antonio, TX 78229 USA. [Musi, Nicolas] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Musi, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA. EM musi@uthscsa.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [RO1-DK80157, RO1-DK089229, RO1-DK24092]; Canadian Institutes of Health Research [MT12601] FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [grant numbers RO1-DK80157 and RO1-DK089229 (to N.M.), and RO1-DK24092 (to R.A.D.)] and the Canadian Institutes of Health Research [grant number MT12601 (to A.K.)]. NR 49 TC 14 Z9 19 U1 1 U2 13 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0144-8463 J9 BIOSCIENCE REP JI Biosci. Rep. PY 2013 VL 33 BP 37 EP U56 AR UNSP e00004 DI 10.1042/BSR20120098 PN 1 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 175PJ UT WOS:000321242600004 PM 23050932 ER PT J AU Eisen, A Kornowski, R Vaduganathan, M Lev, E Vaknin-Assa, H Bental, T Orvin, K Brosh, D Rechavia, E Battler, A Assali, A AF Eisen, Alon Kornowski, Ran Vaduganathan, Muthiah Lev, Eli Vaknin-Assa, Hana Bental, Tamir Orvin, Katia Brosh, David Rechavia, Eldad Battler, Alexander Assali, Abid TI Retroperitoneal Bleeding after Cardiac Catheterization: A 7-Year Descriptive Single-Center Experience SO CARDIOLOGY LA English DT Article DE Cardiac catheterization; Coronary angiography; Retroperitoneal bleeding; Retroperitoneal hematoma ID PERCUTANEOUS CORONARY INTERVENTION; ACCESS SITE COMPLICATIONS; RISK-FACTORS; BLOOD-TRANSFUSION; CLOSURE DEVICES; UNITED-STATES; HEMATOMA; PREDICTORS; TRIAL; METAANALYSIS AB Background: Retroperitoneal bleeding (RPB) is an unusual but potentially fatal vascular complication occurring after cardiac catheterization (CC). Contemporary data of RPB in the era of dual antiplatelet therapy and vascular closure devices are lacking. Methods: We retrospectively examined all RPB cases that occurred after CC in the Rabin Medical Center between the years 2005 and 2011. Results: Of 26,487 patients who underwent CC, a total of 48 patients (mean age 60.9 +/- 13.8 years, 52.1% female) with RPB were identified (0.18%). The indication for CC was acute coronary syndrome (43.7%), myocardial infarction (35.4%), stable angina pectoris (8.3%), hemodynamic studies for valvular heart disease (10.4%) and others (2.1%). Coronary intervention was performed in 34 patients (70.9%) and a vascular closure device (VCD) was used in 16 patients (33.3%). Seventy-seven percent of patients were treated with clopidogrel, 20.8% with glycoprotein IIb-IIIa inhibitors and 85.4% with anticoagulation during CC. Median time to diagnosis of bleeding was 9.0 h, while the median time to bleeding differed between patients with and without a VCD (12 vs. 5 h, respectively). The clinical presentation of RPB was hemorrhagic shock in 39.6% of patients and 50.0% required at least one blood transfusion. Patients were managed either with conservative treatment (79.2%), angiography stenting (14.6%) or vascular surgery (6.2%). A total of 3 patients died during hospitalization, of which RPB was the etiology in 2 (4.2%). Conclusions: RPB which is a rare complication of CC is associated with younger age and female gender, as compared to patients without RPB. Onset of bleeding can be delayed in patients with VCDs. With careful and early diagnosis, most patients with RPB after CC can be managed conservatively. Copyright (C) 2013 S. Karger AG, Basel C1 [Eisen, Alon; Kornowski, Ran; Lev, Eli; Vaknin-Assa, Hana; Bental, Tamir; Orvin, Katia; Brosh, David; Rechavia, Eldad; Battler, Alexander; Assali, Abid] Tel Aviv Univ, Dept Cardiol, Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel. [Vaduganathan, Muthiah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. RP Assali, A (reprint author), Tel Aviv Univ, Dept Cardiol, Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel. EM aassali@clalit.org.il NR 17 TC 3 Z9 3 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 2013 VL 125 IS 4 BP 217 EP 222 DI 10.1159/000351090 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 178KN UT WOS:000321446900004 PM 23797048 ER PT J AU Jankun, J Skrzypczak-Jankun, E Lipinski, B AF Jankun, Jerzy Skrzypczak-Jankun, Ewa Lipinski, Boguslaw TI Complex function of magnesium in blood clot formation and lysis SO CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE magnesium; anticoagulants ID ACTIVATOR INHIBITOR TYPE-1; INFLAMMATORY RESPONSE; COLLECTION TUBES; WHOLE-BLOOD; FACTOR XA; COAGULATION; PROTHROMBIN; SUPPLEMENTATION; TIME; THROMBOELASTOGRAPHY AB Magnesium salts alone or mixed with other minerals and vitamins are commonly used as dietary supplements. Also, magnesium is infused intra-operatively in a variety of surgeries. Magnesium is one of the most plentiful intracellular divalent cation and is a cofactor in approximately 300 enzymatic reactions. Magnesium is considered safe; however; there are some reports on its health risk when overdosed. It has been reported that Mg2+ ions play a role in blood clotting competing with Ca2+ ions. Moreover; magnesium has a different and conflicting role on proteins of coagulation cascade and its net action on coagulation is difficult to predict. For this reason we have investigated whether magnesium can change clotting characteristics of plasma and blood. We have found that magnesium increases the clotting time in plasma and in whole blood in a concentration-dependent fashion. Also, blood clotted in the presence of increased concentration of magnesium, has progressively shortened the lysis time of whole blood clots. We postulated that Mg2+ exerts its anticoagulant influence by acting at the stage of prothrombin activation in the blood coagulation cascade competing with calcium needed for thrombin activation. Shortening lysis of whole blood clots can utilize an alternative mechanism. PAI-1 in the presence of thrombin, vitronectin and Ca2+ or Mg2+ is inhibited, causing larger amounts of tPA to remain in the free form. Excessive amounts of tPA activate plasminogen that lyses clots faster. However, further investigations are required to determine the clinical relevance of these observations. C1 [Jankun, Jerzy; Skrzypczak-Jankun, Ewa] Univ Toledo, Dept Urol, Urol Res Ctr, Toledo, OH 43614 USA. [Jankun, Jerzy] Med Univ Gdansk, Gdansk, Poland. [Jankun, Jerzy] King Saud Univ, Coll Sci, Dept Biochem, Prot Res Chair, Riyadh 11451, Saudi Arabia. [Lipinski, Boguslaw] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Jankun, J (reprint author), Univ Toledo, Dept Urol, Urol Res Ctr, Mail Stop 1091,Hlth Sci Campus,3000 Arlington, Toledo, OH 43614 USA. EM Jerzy.Jankun@utoledo.edu NR 35 TC 4 Z9 4 U1 0 U2 1 PU TERMEDIA PUBLISHING HOUSE LTD PI POZNAN PA WENEDOW ST 9-1, POZNAN, 61-614, POLAND SN 1426-3912 J9 CENT EUR J IMMUNOL JI Central Eur. J. Immunol. PY 2013 VL 38 IS 2 BP 149 EP 153 DI 10.5114/ceji.2013.35203 PG 5 WC Immunology SC Immunology GA 182DC UT WOS:000321720900001 ER PT B AU Schuman, JS Epstein, DL AF Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI CHANDLER and GRANT'S GLAUCOMA FIFTH EDITION Introduction SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Editorial Material; Book Chapter ID NERVE-FIBER LAYER; SCANNING LASER OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OPEN-ANGLE GLAUCOMA; THICKNESS; REPRODUCIBILITY; PHOTOGRAPHY; POLARIMETRY; PROGRESSION; POPULATION C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 3 EP 6 PG 4 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900003 ER PT B AU Schuman, JS Kahook, MY Epstein, DL AF Schuman, Joel S. Kahook, Malik Y. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Practical Aqueous Humor Dynamics SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID ENUCLEATED HUMAN EYES; OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE; PROSTAGLANDIN-F2-ALPHA ANALOG; CERCOPITHECUS-ETHIOPS; RHESUS-MONKEY; MACACA-IRUS; OUTFLOW; FLOW; PILOCARPINE C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Kahook, Malik Y.] Univ Colorado, Dept Ophthalmol, Boulder, CO 80309 USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. NR 50 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 17 EP 23 PG 7 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900005 ER PT B AU Schuman, JS Epstein, DL AF Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI The Patient's History Symptoms of Glaucoma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE; LOXL1 GENE; PSEUDOEXFOLIATION GLAUCOMA; EXFOLIATION GLAUCOMA; SEQUENCE VARIANTS; ASSOCIATION; POPULATION; HYPOTHYROIDISM; EYE C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. NR 31 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 25 EP 31 PG 7 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900006 ER PT B AU Conner, IP Schuman, JS Kahook, MY Epstein, DL AF Conner, Ian P. Schuman, Joel S. Kahook, Malik Y. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Examination of the Eye SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Kahook, Malik Y.] Univ Colorado, Dept Ophthalmol, Boulder, CO 80309 USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 33 EP 40 PG 8 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900007 ER PT B AU Wingard, JB Schuman, JS AF Wingard, Jeremy B. Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI Tonometry and Tonography SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID GOLDMANN APPLANATION TONOMETRY; INTRAOCULAR-PRESSURE; TONO-PEN; AQUEOUS-HUMOR; EYES; RAT C1 [Wingard, Jeremy B.] Wheaton Eye Clin, Wheaton, IL 60187 USA. [Wingard, Jeremy B.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. RP Wingard, JB (reprint author), Wheaton Eye Clin, Wheaton, IL 60187 USA. NR 30 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 41 EP 50 PG 10 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900008 ER PT B AU Schuman, JS Joshi, D Gamell, LS AF Schuman, Joel S. Joshi, Deval Gamell, Lisa S. BE Kahook, MY Schuman, JS Epstein, DL TI The Angle of the Anterior Chamber SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID AQUEOUS OUTFLOW FACILITY; EXCISED HUMAN EYES; CLOSURE GLAUCOMA; LENS DEPRESSION C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Joshi, Deval] Univ Florida, Dept Ophthalmol, Gainesville, FL USA. [Gamell, Lisa S.] USF Eye Inst, Tampa, FL USA. [Gamell, Lisa S.] USF Hlth Morsani Coll Med, Tampa, FL USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. NR 13 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 51 EP 80 PG 30 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900009 ER PT B AU Conner, IP Schuman, JS Epstein, DL AF Conner, Ian P. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Examination of the Optic Nerve SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID BLOOD-PRESSURE; VISUAL FIELD; GLAUCOMA; PATHOGENESIS; HYPOTENSION; DISK C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 26 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 81 EP 94 PG 14 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900010 ER PT B AU Folio, LS Wollstein, G Schuman, JS AF Folio, Lindsey S. Wollstein, Gadi Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI Imaging of the Optic Nerve Head and Nerve Fiber Layer SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID SCANNING LASER POLARIMETRY; COHERENCE TOMOGRAPHY; GLAUCOMATOUS EYES; VISUAL-FIELD; THICKNESS MEASUREMENTS; DISC PHOTOGRAPHS; REPRODUCIBILITY; PROGRESSION; DISCRIMINATION; OPHTHALMOSCOPY C1 [Folio, Lindsey S.; Wollstein, Gadi] Univ Pittsburgh, Ophthalmol & Visual Sci Res Ctr, UPMC Eye Ctr, Dept Ophthalmol,Eye & Ear Inst,Sch Med, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. RP Folio, LS (reprint author), Univ Pittsburgh, Ophthalmol & Visual Sci Res Ctr, UPMC Eye Ctr, Dept Ophthalmol,Eye & Ear Inst,Sch Med, Pittsburgh, PA 15260 USA. NR 54 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 95 EP 109 PG 15 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900011 ER PT B AU Challa, P Schuman, JS AF Challa, Pratap Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI Topical Carbonic Anhydrase Inhibitors SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; CENTRAL CORNEAL THICKNESS; AQUEOUS-HUMOR FLOW; OPHTHALMIC SUSPENSION AZOPT(R); OCULAR HYPERTENSION; DOSE-RESPONSE; DORZOLAMIDE 2-PERCENT; INTRAOCULAR-PRESSURE; HUMAN-EYE; BRINZOLAMIDE 1-PERCENT C1 [Challa, Pratap] Residency Training Program, Durham, NC USA. [Challa, Pratap] Duke Univ, Ctr Eye, Durham, NC USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Harvard, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. RP Challa, P (reprint author), Residency Training Program, Durham, NC USA. NR 65 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 165 EP 169 PG 5 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900017 ER PT B AU Turalba, AV Rhee, DJ AF Turalba, Angela V. Rhee, Douglas J. BE Kahook, MY Schuman, JS Epstein, DL TI Prostaglandin Analogs SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID CYSTOID MACULAR EDEMA; AQUEOUS-HUMOR DYNAMICS; SMOOTH-MUSCLE-CELLS; OPEN-ANGLE GLAUCOMA; ELEVATED INTRAOCULAR-PRESSURE; RANDOMIZED CONTROLLED-TRIALS; HUMAN TRABECULAR MESHWORK; CYNOMOLGUS MONKEY EYES; HUMAN CILIARY BODY; OCULAR HYPERTENSION C1 [Turalba, Angela V.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston VA Healthcare Syst, Boston, MA 02115 USA. [Rhee, Douglas J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. RP Turalba, AV (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston VA Healthcare Syst, Boston, MA 02115 USA. NR 112 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 171 EP 176 PG 6 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900018 ER PT B AU Miller, KV Schuman, JS Epstein, DL AF Miller, Kimberly V. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Primary Open-Angle Glaucoma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OCULAR-HYPERTENSION-TREATMENT; PRESSURE-DEPENDENT CHANGES; AQUEOUS OUTFLOW PATHWAY; HUMAN LAMINA-CRIBROSA; BALTIMORE EYE SURVEY; TERM CLINICAL-TRIAL; INTRAOCULAR-PRESSURE; TRABECULAR MESHWORK; NONGLAUCOMATOUS NORMALS; ELDERLY POPULATION C1 [Miller, Kimberly V.] Univ Pittsburgh, Inst Eye & Ear, UPMC Eye Ctr, Dept Ophthalmol, Pittsburgh, PA 15213 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Harvard, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Miller, KV (reprint author), Univ Pittsburgh, Inst Eye & Ear, UPMC Eye Ctr, Dept Ophthalmol, Pittsburgh, PA 15213 USA. NR 50 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 185 EP 206 PG 22 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900020 ER PT B AU Conner, IP Miller, KV Schuman, JS Epstein, DL AF Conner, Ian P. Miller, Kimberly V. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Low-Tension Glaucoma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE REDUCTION; PERFUSION-PRESSURE; OPTIC NEUROPATHY; MIGRAINE; DAMAGE C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Miller, Kimberly V.] Univ Pittsburgh, Inst Eye & Ear, UPMC Eye Ctr, Dept Ophthalmol, Pittsburgh, PA 15213 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Harvard, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 24 TC 0 Z9 0 U1 1 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 207 EP 216 PG 10 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900021 ER PT B AU Conner, IP Miller, KV Schuman, JS Epstein, DL AF Conner, Ian P. Miller, Kimberly V. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Pigment Dispersion and Pigmentary Glaucomal SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; YAG LASER IRIDOTOMY; INTRAOCULAR-PRESSURE; MELANOMALYTIC GLAUCOMA; AQUEOUS OUTFLOW; LIVING MONKEYS; EYES; OBSTRUCTION; RESISTANCE; EXERCISE C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Miller, Kimberly V.] Univ Pittsburgh, Inst Eye & Ear, UPMC Eye Ctr, Dept Ophthalmol, Pittsburgh, PA 15213 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Harvard, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 227 EP 236 PG 10 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900023 ER PT B AU Ulrich, G Schuman, JS Epstein, DL Conner, IP AF Ulrich, George Schuman, Joel S. Epstein, David L. Conner, Ian P. BE Kahook, MY Schuman, JS Epstein, DL TI Acute Angle-Closure Glaucoma Diagnosis and Treatment SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID ARGON-LASER GONIOPLASTY; GONIOSYNECHIALYSIS C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Harvard, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 255 EP 268 PG 14 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900025 ER PT B AU Schuman, JS Kahook, MY Epstein, DL AF Schuman, Joel S. Kahook, Malik Y. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Plateau Iris SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID ANGLE-CLOSURE GLAUCOMA; LASER PERIPHERAL IRIDOPLASTY; GONIOPLASTY C1 [Schuman, Joel S.] Univ Pittsburgh, Eye & Ear Fdn, Sch Med, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Inst Eye & Ear, Sch Med, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Kahook, Malik Y.] Univ Colorado, Dept Ophthalmol, Boulder, CO 80309 USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Eye & Ear Fdn, Sch Med, Pittsburgh, PA 15260 USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 277 EP 280 PG 4 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900028 ER PT B AU Schuman, JS Epstein, DL AF Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI The Use of Special Tests in Narrow-Angled Eyes SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID CLOSURE GLAUCOMA; INTRAOCULAR-PRESSURE; PROVOCATIVE TEST; PRONE-POSITION; OUTFLOW C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 281 EP 284 PG 4 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900029 ER PT B AU Conner, IP Schuman, JS Epstein, DL AF Conner, Ian P. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI The Malignant Glaucoma Syndromes SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID ANGLE-CLOSURE GLAUCOMA; RETINAL-PIGMENT EPITHELIUM; ANTERIOR-CHAMBER; LASER IRIDOTOMY; PHENYLEPHRINE HYDROCHLORIDE; PSEUDOEXFOLIATION SYNDROME; INTRAOCULAR-PRESSURE; POSTERIOR SCLERITIS; SUBRETINAL FLUID; HYALOIDOTOMY C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 64 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 289 EP 304 PG 16 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900031 ER PT B AU Burgansky-Eliash, Z Simmons, RJ AF Burgansky-Eliash, Zvia Simmons, Richard J. BE Kahook, MY Schuman, JS Epstein, DL TI Nanophthalmos Diagnosis and Treatment SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID ANGLE-CLOSURE GLAUCOMA; UVEAL EFFUSION SYNDROME; CATARACT; SCLERA C1 [Burgansky-Eliash, Zvia] Edith Wolfson Med Ctr, Dept Ophthalmol, Holon, Israel. [Burgansky-Eliash, Zvia] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel. [Simmons, Richard J.] Simmons Eye Associates Boston, Boston, MA USA. [Simmons, Richard J.] Harvard Univ, Sch Med, Boston, MA USA. [Simmons, Richard J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Burgansky-Eliash, Z (reprint author), Edith Wolfson Med Ctr, Dept Ophthalmol, Holon, Israel. NR 28 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 305 EP 307 PG 3 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900032 ER PT B AU Conner, IP Schuman, JS Epstein, DL AF Conner, Ian P. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Angle-Closure Glaucoma Due to Multiple Cysts of the Iris and Ciliary Body SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Schuman, Joel S.] Amer Glaucoma Soc, New York, NY USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 337 EP 339 PG 3 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900036 ER PT B AU Pantcheva, MB Schuman, JS Kahook, MY Epstein, DL AF Pantcheva, Mina B. Schuman, Joel S. Kahook, Malik Y. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Glaucoma After Penetrating Keratoplasty SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID ANGLE-CLOSURE GLAUCOMA; ENDOTHELIAL KERATOPLASTY; POST-KERATOPLASTY; GONIOSYNECHIALYSIS; COMPLICATIONS; EYES; CYCLOPHOTOCOAGULATION; CYCLOCRYOTHERAPY; PRESSURE C1 [Pantcheva, Mina B.] Univ Colorado, Dept Ophthalmol, Sch Med, Aurora, CO USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Schuman, Joel S.] Amer Glaucoma Soc, New York, NY USA. [Kahook, Malik Y.] Univ Colorado, Dept Ophthalmol, Boulder, CO 80309 USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Pantcheva, MB (reprint author), Univ Colorado, Dept Ophthalmol, Sch Med, Aurora, CO USA. NR 28 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 347 EP 350 PG 4 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900039 ER PT B AU Schuman, JS Epstein, DL AF Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Combined Open-Angle and Angle-Closure Glaucoma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Schuman, Joel S.] Amer Glaucoma Soc, New York, NY USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 353 EP 355 PG 3 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900040 ER PT B AU Conner, IP Schuman, JS Epstein, DL AF Conner, Ian P. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Glaucoma in the Pseudophakic and Aphakic Eye SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID EXTRACAPSULAR CATARACT-EXTRACTION; PROPIONIBACTERIUM-ACNES ENDOPHTHALMITIS; INTRAOCULAR-LENS IMPLANTATION; SCANNING ELECTRON-MICROSCOPY; AQUEOUS-HUMOR OUTFLOW; ENUCLEATED HUMAN EYES; EPITHELIAL DOWNGROWTH; ANTERIOR-CHAMBER; ALPHA-CHYMOTRYPSIN; PUPILLARY BLOCK C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Schuman, Joel S.] Amer Glaucoma Soc, New York, NY USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 64 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 357 EP 366 PG 10 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900041 ER PT B AU Schuman, JS Kahook, MY Epstein, DL AF Schuman, Joel S. Kahook, Malik Y. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Characteristically Unilateral Glaucomas Differential Diagnosis SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter C1 [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Schuman, Joel S.] Amer Glaucoma Soc, New York, NY USA. [Kahook, Malik Y.] Univ Colorado, Dept Ophthalmol, Boulder, CO 80309 USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Schuman, JS (reprint author), Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 367 EP 368 PG 2 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900042 ER PT B AU Bourne, CI Shingleton, BJ AF Bourne, Carla I. Shingleton, Bradford J. BE Kahook, MY Schuman, JS Epstein, DL TI Glaucoma Due to Trauma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID YAG LASER TRABECULOPUNCTURE; ANGLE-RECESSION GLAUCOMA; RHEGMATOGENOUS RETINAL-DETACHMENT; TISSUE-PLASMINOGEN-ACTIVATOR; RANDOMIZED CLINICAL-TRIAL; EPSILON-AMINOCAPROIC ACID; SICKLE-CELL HYPHEMA; SEVERE EYE BURNS; TRANEXAMIC ACID; INTRAOCULAR-PRESSURE C1 [Bourne, Carla I.] Univ S Florida, Tampa, FL 33744 USA. [Shingleton, Bradford J.] Ophthalm Consultants Boston Inc, Boston, MA USA. [Shingleton, Bradford J.] Tufts Univ New England Med Ctr, Boston, MA USA. [Shingleton, Bradford J.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Shingleton, Bradford J.] Harvard Univ, Sch Med, Boston, MA USA. RP Bourne, CI (reprint author), Univ S Florida, Tampa, FL 33744 USA. NR 78 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 413 EP 422 PG 10 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900045 ER PT B AU Conner, IP Schuman, JS Epstein, DL AF Conner, Ian P. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Glaucoma Associated With Extraocular Venous Congestion (Increased Episcleral Venous Pressure) SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID STURGE-WEBER-SYNDROME; CAROTID-CAVERNOUS FISTULA; OPEN-ANGLE GLAUCOMA; DURAL SHUNT SYNDROME; MANAGEMENT; SECONDARY; SURGERY; VESSELS C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Schuman, Joel S.] Amer Glaucoma Soc, New York, NY USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 29 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 435 EP 439 PG 5 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900048 ER PT B AU Conner, IP Schuman, JS Epstein, DL AF Conner, Ian P. Schuman, Joel S. Epstein, David L. BE Kahook, MY Schuman, JS Epstein, DL TI Lens-Induced Glaucoma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID LASER POSTERIOR CAPSULOTOMY; NEODYMIUM-YAG LASER; OPEN-ANGLE GLAUCOMA; PHACOLYTIC GLAUCOMA; CONGENITAL CATARACTS; AQUEOUS OUTFLOW; DIAGNOSIS; COMPLICATIONS; OBSTRUCTION; VITRECTOMY C1 [Conner, Ian P.] UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Ctr Eye, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. [Schuman, Joel S.] New England Eye Ctr, Boston, MA USA. [Schuman, Joel S.] New England Eye Ctr, Glaucoma & Cataract Serv, Boston, MA USA. [Schuman, Joel S.] Amer Soc Clin Invest, New York, NY USA. [Schuman, Joel S.] Amer Ophthalmol Soc, New York, NY USA. [Schuman, Joel S.] Amer Glaucoma Soc, New York, NY USA. [Epstein, David L.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA. RP Conner, IP (reprint author), UPMC Eye Ctr, Pittsburgh, PA USA. NR 29 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 441 EP 447 PG 7 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900049 ER PT B AU Wiggs, JL AF Wiggs, Janey L. BE Kahook, MY Schuman, JS Epstein, DL TI Juvenile Open-Angle Glaucoma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID MYOCILIN GLN368STOP MUTATION; RISK-FACTORS; DIFFERENT POPULATIONS; TRABECULAR MESHWORK; CLINICAL-FEATURES; MUTANT MYOCILINS; ONSET; GENE; LOCUS; PHENOTYPE C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. RP Wiggs, JL (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. NR 43 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 465 EP 467 PG 3 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900052 ER PT B AU Wingard, JB Schuman, JS AF Wingard, Jeremy B. Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI Glaucoma Laser Surgery SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; RANDOMIZED CLINICAL-TRIAL; NEODYMIUM-YAG LASER; ENDOSCOPIC CYCLOPHOTOCOAGULATION; TRANSSCLERAL CYCLOPHOTOCOAGULATION; INTRAOCULAR-PRESSURE; HISTOPATHOLOGICAL CHANGES; TRABECULOPLASTY; ARGON; DIODE C1 [Wingard, Jeremy B.] Wheaton Eye Clin, Wheaton, IL USA. [Wingard, Jeremy B.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. RP Wingard, JB (reprint author), Wheaton Eye Clin, Wheaton, IL USA. NR 40 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 471 EP 475 PG 5 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900053 ER PT B AU Wingard, JB Schuman, JS AF Wingard, Jeremy B. Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI Laser Trabeculoplasty SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; RANDOMIZED CLINICAL-TRIAL; LONG-TERM EFFICACY; INTRAOCULAR-PRESSURE; THERAPY; GLT; BRIMONIDINE; SURGERY; DIODE; PILOT C1 [Wingard, Jeremy B.] Wheaton Eye Clin, Wheaton, IL USA. [Wingard, Jeremy B.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. RP Wingard, JB (reprint author), Wheaton Eye Clin, Wheaton, IL USA. NR 41 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 477 EP 485 PG 9 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900054 ER PT B AU Gamell, LS Saunders, T Schuman, JS AF Gamell, Lisa S. Saunders, Timothy Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI Laser Peripheral Iridotomy SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID NEODYMIUM-YAG; IRIDECTOMY; ARGON; GLAUCOMA C1 [Gamell, Lisa S.; Saunders, Timothy] USF Eye Inst, Tampa, FL USA. [Gamell, Lisa S.] USF Hlth Morsani Coll Med, Tampa, FL USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. RP Gamell, LS (reprint author), USF Eye Inst, Tampa, FL USA. NR 16 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 501 EP 510 PG 10 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900057 ER PT B AU Pantcheva, MB Schuman, JS AF Pantcheva, Mina B. Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI Cyclodestruction SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID SEMICONDUCTOR DIODE-LASER; CONTACT TRANSSCLERAL CYCLOPHOTOCOAGULATION; ND-YAG LASER; CONTINUOUS WAVE NEODYMIUM; YTTRIUM-ALUMINUM-GARNET; OPEN-ANGLE GLAUCOMA; HUMAN AUTOPSY EYES; RETINAL VASCULAR-DISEASE; RABBIT CILIARY BODY; SYMPATHETIC OPHTHALMIA C1 [Pantcheva, Mina B.] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. RP Pantcheva, MB (reprint author), Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA. NR 144 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 511 EP 522 PG 12 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900058 ER PT B AU Bourne, CI Shingleton, BJ Schuman, JS AF Bourne, Carla I. Shingleton, Bradford J. Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI The Management of Coexisting Cataract and Glaucoma SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID OPEN-ANGLE GLAUCOMA; INTRAOCULAR-LENS IMPLANTATION; CLEAR CORNEAL PHACOEMULSIFICATION; FLOPPY-IRIS SYNDROME; MICRO-BYPASS STENT; 2-SITE PHACOTRABECULECTOMY; ONE-SITE; DRAINAGE IMPLANT; CLOSURE GLAUCOMA; SCLERAL FLAP C1 [Bourne, Carla I.] Univ S Florida, Tampa, FL 33620 USA. [Shingleton, Bradford J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ophthalm Consultants Boston Inc,Tufts New England, Boston, MA USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Eye & Ear Fdn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. Univ Pittsburgh Med Ctr UPMC Eye Ctr, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] UPMC, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. RP Bourne, CI (reprint author), Univ S Florida, Tampa, FL 33620 USA. NR 72 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 567 EP 578 PG 12 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900063 ER PT B AU Chen, VM Walton, DS AF Chen, Vicki M. Walton, David S. BE Kahook, MY Schuman, JS Epstein, DL TI Unusual Pediatric Glaucomas SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Article; Book Chapter ID CONGENITAL-RUBELLA SYNDROME; STURGE-WEBER SYNDROME; MANIFESTATIONS; COMPLICATIONS; GONIOSURGERY; SECONDARY; ANIRIDIA; UVEITIS; GENE C1 [Chen, Vicki M.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA. [Walton, David S.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Chen, VM (reprint author), Tufts Med Ctr, New England Eye Ctr, Boston, MA USA. NR 29 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP 661 EP 679 PG 19 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900071 ER PT B AU Kahook, MY Schuman, JS AF Kahook, Malik Y. Schuman, Joel S. BE Kahook, MY Schuman, JS Epstein, DL TI CHANDLER and GRANT'S GLAUCOMA FIFTH EDITION INTRODUCTION SO CHANDLER AND GRANT'S GLAUCOMA, FIFTH EDITION LA English DT Editorial Material; Book Chapter C1 [Kahook, Malik Y.] Univ Colorado, Dept Ophthalmol, Boulder, CO 80309 USA. [Schuman, Joel S.] Univ Pittsburgh, Sch Med, Inst Eye & Ear, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Schuman, Joel S.] Massachusetts Eye & Ear Infirm, Boston, MA USA. [Schuman, Joel S.] Tufts Univ, New England Med Ctr, Medford, MA USA. RP Kahook, MY (reprint author), US FDA, Ophthalm Device Div, Rockville, MD 20857 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-954-5 PY 2013 BP XXIIII EP XXIIII PG 1 WC Ophthalmology SC Ophthalmology GA BFM72 UT WOS:000320564900002 ER PT J AU Haynes, RL van Leyen, K AF Haynes, Robin L. van Leyen, Klaus TI 12/15-Lipoxygenase Expression Is Increased in Oligodendrocytes and Microglia of Periventricular Leukomalacia SO DEVELOPMENTAL NEUROSCIENCE LA English DT Article DE Hypoxia-ischemia; Inflammation; Oxidative stress; Prematurity; Reactive oxygen species ID WHITE-MATTER INJURY; TRANSIENT FOCAL ISCHEMIA; CYTOSOLIC PHOSPHOLIPASE A(2); APOPTOSIS-INDUCING FACTOR; OXIDATIVE INJURY; BRAIN-INJURY; CELL-DEATH; GLUTATHIONE DEPLETION; RAT OLIGODENDROCYTES; PREMATURE-INFANTS AB Oxidative stress involving premyelinating oligodendrocytes (OLs) is a major factor in the pathogenesis of preterm white matter injury. In animal and cell culture studies, activation of the lipid-oxidizing enzyme 12/15-lipoxygenase (12/15-LOX) plays a central role as an inflammatory mediator in the pathology of oxidative stress and OL cell death, as well as ischemia and neuronal death. The role of 12/15-LOX, however, is unclear in the developing human brain. The mechanism of 12/15-LOX involves the production of reactive oxygen species through the metabolism of arachidonic acid, as well as direct detrimental effects on organelle membranes. Here we tested the hypothesis that the density of 12/15-LOX-expressing cells is increased in periventricular leukomalacia (PVL). Using immunocytochemistry (ICC) in human paraffin-embedded tissue, 12/15-LOX expression was seen in macrophages of the focally necrotic lesions in the periventricular white matter, as well as in glial cells throughout the surrounding white matter with reactive gliosis. Interestingly, no significant 12/15-LOX expression was detected in neurons in the cerebral cortex overlying the damaged white matter. Using a scoring system from 0 to 3, we assessed the density of 12/15-LOX-expressing cells in diffusely gliotic white matter from 20 to 43 postconceptional (PC) weeks in 19 PVL cases (median = 36 PC weeks) and 10 control (non-PVL) cases (median = 34 PC weeks). The density of 12/15-LOX-positive cells was significantly increased in the diffuse component of PVL (score = 1.17 +/- 0.15) compared to controls (score = 0.48 +/- 0.21; p = 0.014). Using double-label ICC, 12/15-LOX was observed in PVL in OLs of the O4 and O1 premyelinating stages, as well as in mature OLs as determined with the mature OL marker adenomatous polyposis coli (APC). In addition, 12/15-LOX expression was present in a population of CD68-positive activated microglia. There was no 12/15-LOX expression in reactive astrocytes. Finally we observed terminal deoxynucleotide transferase dUTP nick end-labeling-positive cells within the white matter of PVL that expressed 12/15-LOX and/or within close proximity of 12/15-LOX-positive cells. Our data support a role for 12/15-LOX activation as an inflammatory mediator of injury in PVL, with a contribution of 12/15-LOX to PVL-induced damage to or cell death of OLs, including those at the O1 and O4 stages. Copyright (C) 2013 S. Karger AG, Basel C1 [Haynes, Robin L.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Haynes, Robin L.] Harvard Univ, Sch Med, Boston, MA USA. [van Leyen, Klaus] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA USA. [van Leyen, Klaus] Harvard Univ, Sch Med, Charlestown, MA USA. RP Haynes, RL (reprint author), Boston Childrens Hosp, Dept Pathol, Enders Bldg,11th Floor,300 Longwood Ave, Boston, MA 02115 USA. EM Robin.haynes@childrens.harvard.edu RI Haynes, Robin/M-4401-2016 OI Haynes, Robin/0000-0003-4909-9585 FU National Institutes of Health [PO1-NS38475, R01 NS049430]; Cerebral Palsy International Research Foundation FX We would like to acknowledge the following people for their guidance and input during the course of this study: Dr. Hannah C. Kinney for assistance with pathological concerns and questions regarding tissue and database; Dr. Rebecca D. Folkerth for continual support in obtaining tissue through the autopsy services at Boston Children's Hospital and Brigham and Women's Hospital; Dr. Joseph J. Volpe for guidance on issues relating to neonatal brain injury and clinical implications of our research, and Dr. Paul A. Rosenberg for initial guidance into the lipoxygenase field in PVL. We would like to especially acknowledge Dr. Hannah C. Kinney for her critical review and thoughtful input into the writing of this paper. This work was supported by the National Institutes of Health (PO1-NS38475; to R. L. H.), Cerebral Palsy International Research Foundation (to R. L. H.), and the National Institutes of Health (R01 NS049430; to K.v.L.). NR 85 TC 11 Z9 12 U1 0 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0378-5866 J9 DEV NEUROSCI-BASEL JI Dev. Neurosci. PY 2013 VL 35 IS 2-3 BP 140 EP 154 DI 10.1159/000350230 PG 15 WC Developmental Biology; Neurosciences SC Developmental Biology; Neurosciences & Neurology GA 178JX UT WOS:000321445100005 PM 23838566 ER PT J AU Spaeth, RB Camhi, S Hashmi, JA Vangel, M Wasan, AD Edwards, RR Gollub, RL Kong, J AF Spaeth, Rosa B. Camhi, Stephanie Hashmi, Javeria A. Vangel, Mark Wasan, Ajay D. Edwards, Robert R. Gollub, Randy L. Kong, Jian TI A Longitudinal Study of the Reliability of Acupuncture Deqi Sensations in Knee Osteoarthritis SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID PLACEBO NEEDLE; RANDOMIZED-TRIAL; QI; VALIDATION; EFFICACY; PAIN; FMRI AB Deqi is one of the core concepts in acupuncture theory and encompasses a range of sensations. In this study, we used the MGH Acupuncture Sensation Scale (MASS) to measure and assess the reliability of the sensations evoked by acupuncture needle stimulation in a longitudinal clinical trial on knee osteoarthritis (OA) patients. The Knee injury and Osteoarthritis Outcome Score (KOOS) was used as the clinical outcome. Thirty OA patients were randomized into one of three groups (high dose, low dose, and sham acupuncture) for 4 weeks. We found that, compared with sham acupuncture, real acupuncture (combining high and low doses) produced significant improvement in knee pain (P = .025) and function in sport (P = .049). Intraclass correlation analysis showed that patients reliably rated 11 of the 12 acupuncture sensations listed on the MASS and that heaviness was rated most consistently. Overall perceived sensation (MASS Index) (P = .014), ratings of soreness (P = .002), and aching (P = .002) differed significantly across acupuncture groups. Compared to sham acupuncture, real acupuncture reliably evoked stronger deqi sensations and led to better clinical outcomes when measured in a chronic pain population. Our findings highlight the MASS as a useful tool for measuring deqi in acupuncture research. C1 [Spaeth, Rosa B.; Hashmi, Javeria A.; Gollub, Randy L.; Kong, Jian] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Camhi, Stephanie] Endicott Coll, Dept Psychol, Beverly, MA 01915 USA. [Vangel, Mark; Gollub, Randy L.; Kong, Jian] MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA. [Vangel, Mark] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA. [Wasan, Ajay D.; Edwards, Robert R.] Brigham & Womens Hosp, Dept Anesthesiol, Boston, MA 02115 USA. [Wasan, Ajay D.; Edwards, Robert R.] Brigham & Womens Hosp, Dept Perioperat & Pain Med, Boston, MA 02115 USA. [Wasan, Ajay D.; Edwards, Robert R.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Wasan, Ajay D.; Edwards, Robert R.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Kong, J (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. EM kongj@nmr.mgh.harvard.edu OI Gollub, Randy L./0000-0002-9434-4044 FU NCCAM [R21AT004497, R01AT006364, R01AT005280]; NIDA [R03AT218317]; [P01 AT006663] FX This work was supported by R21AT004497 (NCCAM), R03AT218317 (NIDA), and R01AT006364 (NCCAM) to Jian Kong, R01AT005280 (NCCAM) to Randy Gollub, and P01 AT006663 to Bruce Rosen. NR 41 TC 7 Z9 7 U1 0 U2 20 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 204259 DI 10.1155/2013/204259 PG 12 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 183PJ UT WOS:000321829100001 ER PT J AU Kepe, V Bordelon, Y Boxer, A Huang, SC Liu, J Thiede, FC Mazziotta, JC Mendez, MF Donoghue, N Small, G Barrio, JR AF Kepe, Vladimir Bordelon, Yvette Boxer, Adam Huang, Sung-Cheng Liu, Jie Thiede, Frederick C. Mazziotta, John C. Mendez, Mario F. Donoghue, Natacha Small, Garyw. Barrio, Jorge R. TI PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE FDDNP; neuropathology; Parkinson's disease; positron emission tomography; progressive supranuclear palsy; tauopathy ID ALZHEIMERS-DISEASE; NEURODEGENERATIVE TAUOPATHIES; LIVING BRAIN; TAU; PROTEIN; PATHOLOGY; FILAMENTS; DEPOSITS; CRITERIA AB Objective: Currently [F-18] FDDNP is the only PET imaging probe with the ability to visualize hyperphosphorylated tau fibrillar aggregates in living subjects. In this work, we evaluate in vivo [F-18] FDDNP labeling of brain neuropathology, primarily tau fibrillar aggregates, in patients with progressive supranuclear palsy (PSP), a human tauopathy usually lacking amyloid-beta deposits. Methods: Fifteen patients with PSP received [F-18] FDDNP PET scanning. [F-18] FDDNP distribution volume ratios, in reference to cerebellar gray matter, were determined for cortical and subcortical areas and compared with those of patients with Parkinson's disease with short disease duration, and age-matched control subjects without neurodegenerative disorders. Results: [F-18] FDDNP binding was present in subcortical areas (e.g., striatum, thalamus, subthalamic region, midbrain, and cerebellar white matter) regardless of disease severity, with progressive subcortical and cortical involvement as disease severity increased. Brain patterns of [F-18] FDDNP binding were entirely consistent with the known pathology distribution for PSP. High midbrain and subthalamic region [F-18] FDDNP binding was distinctive for PSP subjects and separated them from controls and patients with Parkinson's disease. Conclusions: These results provide evidence that [F-18] FDDNP is a sensitive in vivo PET imaging probe to map and quantify the dynamic regional localization of tau fibrillar aggregates in PSP. Furthermore, [F-18] FDDNP PET may provide a tool to detect changes in tau pathology distribution either associated with disease progression or as a treatment biomarker for future tau-specific therapies. Patterns of [F-18] FDDNP binding may also be useful in diagnosis early in disease presentation when clinical distinction among neurodegenerative disorders is often difficult. C1 [Kepe, Vladimir; Huang, Sung-Cheng; Liu, Jie; Barrio, Jorge R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Bordelon, Yvette; Thiede, Frederick C.; Mazziotta, John C.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.; Donoghue, Natacha; Small, Garyw.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Donoghue, Natacha] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Boxer, Adam] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. RP Barrio, JR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, CHS B2-086A,694817,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM jbarrio@mednet.ucla.edu FU National Institutes of Health [P01AG025831, R01AG038791, R01AG031278, R01AG034499, P50AG16570]; Tau Research Consortium; Elizabeth and Thomas Plott Endowment in Gerontology FX Supported by the National Institutes of Health (P01AG025831, R01AG038791, R01AG031278, R01AG034499, P50AG16570) and by the Tau Research Consortium. JRB gratefully acknowledges support from the Elizabeth and Thomas Plott Endowment in Gerontology. No company provided support of any kind for this study. Special thanks also to Dr. N. Satyamurthy and cyclotron staff and J. Williams and the Nuclear Medicine Clinic staff for their support with the scanning protocols. NR 35 TC 38 Z9 39 U1 1 U2 11 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 36 IS 1 BP 145 EP 153 DI 10.3233/JAD-130032 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 159FJ UT WOS:000320030200013 PM 23579330 ER PT J AU Macklin, EA Blacker, D Hyman, BT Betensky, RA AF Macklin, Eric A. Blacker, Deborah Hyman, Bradley T. Betensky, Rebecca A. TI Improved Design of Prodromal Alzheimer's Disease Trials through Cohort Enrichment and Surrogate Endpoints SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; clinical trials as topic; National Alzheimer's Coordinating Center Uniform Data Set; surrogate endpoint; survival analysis ID MILD COGNITIVE IMPAIRMENT; UNIFORM DATA SET; CLINICAL-TRIALS; DEMENTIA; RECOMMENDATIONS; INDIVIDUALS; PREDICTION; BIOMARKERS; TESTS AB Alzheimer's disease (AD) trials initiated during or before the prodrome are costly and lengthy because patients are enrolled long before clinical symptoms are apparent, when disease progression is slow. We hypothesized that design of such trials could be improved by: 1) selecting individuals at moderate near-term risk of progression to AD dementia (the current clinical standard) and 2) by using short-term surrogate endpoints that predict progression to AD dementia. We used a longitudinal cohort of older, initially non-demented, community-dwelling participants (n = 358) to derive selection criteria and surrogate endpoints and tested them in an independent national data set (n = 6,243). To identify a "mid-risk" subgroup, we applied conditional tree-based survival models to Clinical Dementia Rating (CDR) scale scores and common neuropsychological tests. In the validation cohort, a time-to-AD dementia trial applying these mid-risk selection criteria to a pool of all non-demented individuals could achieve equivalent power with 47% fewer participants than enrolling at random from that pool. We evaluated surrogate endpoints measureable over two years of follow-up based on cross-validated concordance between predictions from Cox models and observed time to AD dementia. The best performing surrogate, rate of change in CDR sum-of-boxes, did not reduce the trial duration required for equivalent power using estimates from the validation cohort, but alternative surrogates with better ability to predict time to AD dementia should be able to do so. The approach tested here might improve efficiency of prodromal AD trials using other potential measures and could be generalized to other diseases with long prodromal phases. C1 [Macklin, Eric A.; Betensky, Rebecca A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Macklin, Eric A.; Blacker, Deborah; Hyman, Bradley T.] Harvard Univ, Sch Med, Boston, MA USA. [Blacker, Deborah] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Blacker, Deborah] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Macklin, EA (reprint author), Massachusetts Gen Hosp, Ctr Biostat, 50 Staniford St,Suite 560, Boston, MA 02114 USA. EM emacklin@partners.org OI Macklin, Eric/0000-0003-1618-3502 FU National Institute on Aging [P01 AG004953, P50 AG005134-24S1, U01 AG016976]; National Cancer Institute [R01 CA075971]; Harvard NeuroDiscovery Center FX This work was supported by grants P01 AG004953, P50 AG005134-24S1, and U01 AG016976 from the National Institute on Aging, R01 CA075971 from the National Cancer Institute, and funds from the Harvard NeuroDiscovery Center. We thank the editor and reviewers for constructive suggestions for improvements to the manuscript. NR 40 TC 3 Z9 3 U1 1 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 36 IS 3 BP 475 EP 486 DI 10.3233/JAD-122212 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 180VV UT WOS:000321627900006 PM 23629586 ER PT J AU Amick, MM Kraft, M McGlinchey, R AF Amick, Melissa M. Kraft, Melissa McGlinchey, Regina TI Driving simulator performance of Veterans from the Iraq and Afghanistan wars SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accident; activity of daily living; deployment; military; motor vehicle; OIF/OEF; posttraumatic stress disorder; reintegration; safety; virtual reality ID PERSONNEL; CARE AB Driving simulator performance was examined in Operation Iraqi Freedom/Operation Enduring Freedom (Off/OEF) Veterans to objectively evaluate driving abilities among this cohort who self-report poorer driving safety postdeployment. OIF/OEF Veterans (n = 25) and age- and education-matched civilian controls (n = 25) participated in a 30 min driving simulator assessment that measured the frequency of minor, moderate, and severe driving errors. Frequency of errors in specific content domains (speed regulation, positioning, and signaling) was also calculated. All participants answered questions about number of lifetime traffic "warnings," moving violation tickets, and accidents. Veterans completed the Posttraumatic Stress Disorder (PTSD) Checklist Military Version. On the driving simulator assessment, Veterans committed more minor, moderate, severe, and speeding errors and reported poorer lifetime driving records than the civilian control group. Exploratory analyses revealed an association between increasing errors on the driving simulator with increasing symptoms of PTSD, although statistically this correlation did not reach significance. These findings suggest that Veterans perform more poorly on an objective evaluation of driving safety and that the presence of PTSD could be associated with worse performance on this standardized driving simulator assessment. C1 [Amick, Melissa M.; Kraft, Melissa; McGlinchey, Regina] Dept Vet Affairs VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders, Boston, MA USA. [Amick, Melissa M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [McGlinchey, Regina] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA. Harvard Univ, Sch Med, Dept Psychol, Boston, MA USA. RP Amick, MM (reprint author), VA Boston Healthcare Syst 182 JP, Translat Res Ctr TBI & Stress Disorders, 150 S Huntington Ave, Boston, MA 02130 USA. EM Melissa.Amick@va.gov FU VA Merit Review [B5009R] FX This material was based on work supported by VA Merit Review (grant B5009R). NR 19 TC 7 Z9 7 U1 0 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2013 VL 50 IS 4 BP 463 EP 470 DI 10.1682/JRRD.2012.06.0108 PG 8 WC Rehabilitation SC Rehabilitation GA 179RS UT WOS:000321539600005 PM 23934867 ER PT J AU Collins, MP Liu, CF Taylor, L Souza, PE Yueh, B AF Collins, Margaret P. Liu, Chuan-Fen Taylor, Leslie Souza, Pamela E. Yueh, Bevan TI Hearing aid effectiveness after aural rehabilitation: Individual versus group trial results SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE education; group visits; health resources; health services research; hearing aids; hearing loss; outcome assessment; patient satisfaction; rehabilitation of hearing impaired; Veterans ID HEALTH MAINTENANCE ORGANIZATION; BEHAVIORAL TREATMENT APPROACH; RANDOMIZED CONTROLLED-TRIAL; BASE-LINE CHARACTERISTICS; CHRONIC CARE CLINICS; 2-YEAR FOLLOW-UP; AUDIOLOGICAL REHABILITATION; COMMUNICATION COURSE; AUDITORY IMPAIRMENT; GROUP VISITS AB We designed this noninferiority randomized trial to determine (1) if group hearing aid fitting visits and group hearing aid follow-up visits were at least as effective as individual visits in terms of hearing-related function (measured with the Inner Effectiveness of Auditory Rehabilitation [EAR] scale) and adherence, and (2) if group visits were less costly over the 6 mo postfitting period. For 644 participants randomized to receive their hearing aid visits in an individual or group format at the Department of Veterans Affairs Puget Sound Health Care System, 6 mo outcomes showed no significant differences in Timer EAR scores between individual and group fitting (p = 0.53) or follow-up (p = 0.11), or in the number of hours per day hearing aids were worn between individual and group fitting (p = 0.90) or follow-up (p = 0.24). We found significantly higher cost for individual compared with group fitting (p < 0.001) and follow-up (p < 0.001). We conclude that outcomes for group hearing aid fitting and hearing aid follow-up visits were not inferior to individual hearing aid fitting and follow-up visits, with group fitting and follow-up visits yielding cost savings. C1 [Collins, Margaret P.; Liu, Chuan-Fen; Taylor, Leslie; Yueh, Bevan] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Collins, Margaret P.; Yueh, Bevan] Univ Washington, Dept Med Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. [Liu, Chuan-Fen; Yueh, Bevan] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Souza, Pamela E.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL USA. [Souza, Pamela E.] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN USA. [Yueh, Bevan] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA 98101 USA. RP Collins, MP (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM margaret.collins@va.gov RI Liu, Chang/B-7249-2009; OI Yueh, Bevan/0000-0003-1380-1053 FU VA, Office of Research and Development, Health Services Research and Development [SLI 04-265] FX This material was based on work supported by VA, Office of Research and Development, Health Services Research and Development (project SLI 04-265). NR 40 TC 6 Z9 7 U1 3 U2 17 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2013 VL 50 IS 4 BP 585 EP 598 DI 10.1682/JRRD.2012.03.0049 PG 14 WC Rehabilitation SC Rehabilitation GA 179RS UT WOS:000321539600015 PM 23934877 ER PT J AU Cheng, TF Li, HY Yang, XM Xia, W Sun, HZ AF Cheng, Tianfan Li, Hongyan Yang, Xinming Xia, Wei Sun, Hongzhe TI Interaction of SlyD with HypB of Helicobacter pylori facilitates nickel trafficking SO METALLOMICS LA English DT Article ID HISTIDINE-RICH PROTEIN; METAL-BINDING; METALLOCHAPERONE SLYD; HPN-LIKE; HYDROGENASE; UREASE; MATURATION; PATHWAY; SITES; NI2+ AB SlyD from Helicobacter pylori interacts with the [NiFe] hydrogenase accessory protein HypB through its IF domain. HpSlyD delivers Ni2+ to HpHypB, leading to the enhancement of GTPase activity of HpHypB and implying the facilitation of Ni2+ delivery from HpHypB to [NiFe] hydrogenase. C1 [Cheng, Tianfan; Li, Hongyan; Yang, Xinming; Xia, Wei; Sun, Hongzhe] Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China. [Xia, Wei] Harvard Univ, Sch Med, Childrens Hosp Boston, Immune Dis Inst, Boston, MA 02115 USA. RP Sun, HZ (reprint author), Univ Hong Kong, Dept Chem, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China. EM hsun@hku.hk OI xia, wei/0000-0001-6480-3265 FU Research Grants Council of Hong Kong [704909P, 704612P, N_HKU75209]; University of Hong Kong FX This research was supported by Research Grants Council of Hong Kong (704909P, 704612P and N_HKU75209) and the University of Hong Kong. NR 27 TC 12 Z9 12 U1 0 U2 10 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1756-5901 J9 METALLOMICS JI Metallomics PY 2013 VL 5 IS 7 BP 804 EP 807 DI 10.1039/c3mt00014a PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 171TI UT WOS:000320951600004 PM 23708681 ER PT S AU Luttrell, LM AF Luttrell, Louis M. BE Luttrell, LM TI PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE The Molecular Biology of Arrestins PREFACE SO MOLECULAR BIOLOGY OF ARRESTINS SE Progress in Molecular Biology and Translational Science LA English DT Editorial Material; Book Chapter C1 [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 1877-1173 BN 978-0-12-394440-5 J9 PROG MOL BIOL TRANSL JI Prog. Molec. Biol. Transl. Sci. PY 2013 VL 118 BP XV EP XV PG 1 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BFY19 UT WOS:000321874600001 PM 23764066 ER PT S AU Luttrell, LM Miller, WE AF Luttrell, Louis M. Miller, William E. BE Luttrell, LM TI Arrestins as Regulators of Kinases and Phosphatases SO MOLECULAR BIOLOGY OF ARRESTINS SE Progress in Molecular Biology and Translational Science LA English DT Review; Book Chapter ID PROTEIN-COUPLED RECEPTOR; G-BETA-GAMMA; ANGIOTENSIN-II RECEPTOR; NUCLEAR EXPORT SIGNAL; KAPPA-B ACTIVATION; BETA(2)-ADRENERGIC RECEPTOR; C-SRC; TYROSINE-KINASE; ERK ACTIVATION; CLATHRIN ADAPTER AB The discovery that, in addition to mediating G protein-coupled receptor (GPCR) desensitization and endocytosis, arrestins bind to diverse catalytically active nonreceptor proteins and act as ligand-regulated signaling scaffolds led to a paradigm shift in the study of GPCR signal transduction. Research over the past decade has solidified the concept that arrestins confer novel GPCR-signaling capacity by recruiting protein and lipid kinase, phosphatase, phosphodiesterase, and ubiquitin ligase activity into receptor-based multiprotein "signalsome" complexes. Signalsomes regulate downstream pathways controlled by Sic family nonreceptor tyrosine kinases, mitogen-activated protein kinases, protein kinase B (AKT), glycogen synthase kinase 3, protein phosphatase 2A, nuclear factor-kappa B, and several others, imposing spatial and temporal control on their function. While many arrestin-bound kinases and phosphatases are involved in the control of cytoskeletal rearrangement, vesicle endocytosis, exocytosis, and cell migration, other signals reach into the nucleus, affecting cell proliferation, apoptosis, and survival. Indeed, the kinase/phosphatase network regulated by arrestins may be fully as diverse as that regulated by heterotrimeric G proteins. C1 [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Miller, William E.] Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. FU NCATS NIH HHS [UL1 TR000077]; NIDDK NIH HHS [DK55524] NR 120 TC 20 Z9 20 U1 2 U2 5 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 1877-1173 BN 978-0-12-394440-5 J9 PROG MOL BIOL TRANSL JI Prog. Molec. Biol. Transl. Sci. PY 2013 VL 118 BP 115 EP 147 DI 10.1016/B978-0-12-394440-5.00005-X PG 33 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BFY19 UT WOS:000321874600006 PM 23764052 ER PT S AU Luttrell, LM AF Luttrell, Louis M. BE Luttrell, LM TI Arrestin Pathways as Drug Targets SO MOLECULAR BIOLOGY OF ARRESTINS SE Progress in Molecular Biology and Translational Science LA English DT Review; Book Chapter ID PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; PARATHYROID-HORMONE PTH; GROWTH-FACTOR RECEPTOR; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; BIASED-AGONISM; IN-VIVO; TYROSINE PHOSPHORYLATION; PHARMACOLOGICAL AGONISM AB Our growing appreciation of the pluridimensionality of G protein-coupled receptor (GPCR) efficacy, coupled with the phenomenon of orthosteric ligand "bias," offers the prospect of drugs that selectively modulate different aspects of GPCR function for therapeutic benefit. As the best-studied non-G protein effectors, arrestins have been shown to mediate a wide range of GPCR signals, and arrestin pathway-selective ligands have been identified for several receptors. When viewed from the perspective of short term in vitro assays, such "biased" agonists appear to activate a subset of the response profile produced by a conventional agonist. Yet, when examined in vivo, the limited data available suggest that biased ligand effects can diverge from their conventional counterparts in ways that cannot be predicted from their in vitro efficacy profile. While some widely conserved arrestin-regulated biological processes are becoming apparent, what is lacking at present is a rational framework for relating the in vitro efficacy of a "biased" agonist to its in vivo actions that will aid drug discovery programs in identifying "biased" ligands with the desired biological effects. C1 [Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. FU NIDDK NIH HHS [DK55524] NR 103 TC 11 Z9 11 U1 0 U2 7 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 1877-1173 BN 978-0-12-394440-5 J9 PROG MOL BIOL TRANSL JI Prog. Molec. Biol. Transl. Sci. PY 2013 VL 118 BP 469 EP 497 DI 10.1016/B978-0-12-394440-5.00018-8 PG 29 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BFY19 UT WOS:000321874600019 PM 23764065 ER PT J AU Ye, C Bhan, AK Deshpande, V Shankar, P Manjunath, N AF Ye, C. Bhan, A. K. Deshpande, V. Shankar, P. Manjunath, N. TI Silencing TNF-alpha in macrophages and dendritic cells for arthritis treatment SO SCANDINAVIAN JOURNAL OF RHEUMATOLOGY LA English DT Article ID RHEUMATOID-ARTHRITIS; ANTIINFLAMMATORY TREATMENT; COLLAGEN ANTIBODY; MURINE ARTHRITIS; MESSENGER-RNA; INFLAMMATION; INFLIXIMAB; JOINT AB Objectives: Tumour necrosis factor (TNF)-alpha secreted by macrophages and dendritic cells (DCs) plays a predominant role in arthritis. Our previous studies suggest that a small peptide, RVG-9R (29-aa peptide derived from the rabies virus glycoprotein, fused to 9R residues), can deliver small interfering RNA (siRNA) to macrophages and DCs. We therefore tested whether knockdown of TNF-alpha expression in macrophages and DCs by RVG-9R/bound siRNA targeting TNF-alpha reduces the severity of collagen antibody-induced arthritis (CAIA) in mice. Method: Arthritis was induced in mice by injecting a combination of antibodies to collagen followed by lipopolysaccharide (LPS) treatment. Mice were also injected with TNF-alpha siRNA complexed with RVG-9R peptide or an irrelevant peptide RVMAT-9R on days 1, 3, 5, and 7. As a positive control, dexamethasone was injected intravenously. Paw thickness was measured every 2 days and the mice were killed on day 10 for testing synovial TNF-alpha levels and histological analysis of joints. Results: In control mice, arthritis developed on day 4 and reached its peak between day 7 and day 9. Treatment with siTNF-alpha bound to RVG-9R, but not to RVMAT-9R, resulted in reducing paw thickness scores to the same level as dexamethasone treatment, associated with reduced TNF-alpha level in synovial fluid. Histological analysis of joints in the control RVMAT-9R/TNF-alpha siRNA-treated mice showed marked pannus formation and destruction of cartilage and subchondrial bone, as well as severe infiltration of inflammatory cells into the synovium. By contrast, the joint pathology was markedly reduced in RVG-9R/TNF-alpha siRNA-treated mice resembling the dexamethasone-treated mice. Conclusions: Suppression of TNF-alpha expression in macrophages and DCs by RVG-9R-mediated siRNA delivery could potentially be a clinically viable strategy for treatment of arthritis. C1 [Ye, C.; Shankar, P.; Manjunath, N.] Texas Tech Univ, Hlth Sci Ctr, Ctr Excellence Infect Dis, Paul L Foster Sch Med, El Paso, TX 79905 USA. [Bhan, A. K.; Deshpande, V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Ye, C (reprint author), Texas Tech Univ, Hlth Sci Ctr, Ctr Excellence Infect Dis, Paul L Foster Sch Med, El Paso, TX 79905 USA. EM chunting.ye@ttuhsc.edu FU National Institutes of Health (NIH) [U01AI075419] FX This work was supported by National Institutes of Health (NIH) grant U01AI075419 to N.M. NR 14 TC 3 Z9 3 U1 0 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0300-9742 J9 SCAND J RHEUMATOL JI Scand. J. Rheumatol. PY 2013 VL 42 IS 4 BP 266 EP 269 DI 10.3109/03009742.2013.777779 PG 4 WC Rheumatology SC Rheumatology GA 182KA UT WOS:000321739600003 PM 23582054 ER PT S AU Falvo, JV Jasenosky, LD Kruidenier, L Goldfeld, AE AF Falvo, James V. Jasenosky, Luke D. Kruidenier, Laurens Goldfeld, Anne E. BE Alt, FW TI Epigenetic Control of Cytokine Gene Expression: Regulation of the TNF/LT Locus and T Helper Cell Differentiation SO ADVANCES IN IMMUNOLOGY, VOL 118 SE Advances in Immunology LA English DT Review; Book Chapter ID TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA GENE; NF-KAPPA-B; SYSTEMIC-LUPUS-ERYTHEMATOSUS; IFN-GAMMA PROMOTER; RNA-POLYMERASE-II; HISTONE ACETYLTRANSFERASE ACTIVITY; CHROMOSOME CONFORMATION CAPTURE; BETA-GLOBIN LOCUS; RANGE INTRACHROMOSOMAL INTERACTIONS AB Epigenetics encompasses transient and heritable modifications to DNA and nucleosomes in the native chromatin context. For example, enzymatic addition of chemical moieties to the N-terminal "tails" of histones, particularly acetylation and methylation of lysine residues in the histone tails of H3 and H4, plays a key role in regulation of gene transcription. The modified histones, which are physically associated with gene regulatory regions that typically occur within conserved noncoding sequences, play a functional role in active, poised, or repressed gene transcription. The "histone code" defined by these modifications, along with the chromatin-binding acetylases, deacetylases, methylases, demethylases, and other enzymes that direct modifications resulting in specific patterns of histone modification, shows considerable evolutionary conservation from yeast to humans. Direct modifications at the DNA level, such as cytosine methylation at CpG motifs that represses promoter activity, are another highly conserved epigenetic mechanism of gene regulation. Furthermore, epigenetic modifications at the nucleosome or DNA level can also be coupled with higher-order intra- or interchromosomal interactions that influence the location of regulatory elements and that can place them in an environment of specific nucleoprotein complexes associated with transcription. In the mammalian immune system, epigenetic gene regulation is a crucial mechanism for a range of physiological processes, including the innate host immune response to pathogens and T cell differentiation driven by specific patterns of cytokine gene expression. Here, we will review current findings regarding epigenetic regulation of cytokine genes important in innate and/or adaptive immune responses, with a special focus upon the tumor necrosis factor/lymphotoxin locus and cytokine-driven CD4(+) T cell differentiation into the Th1, Th2, and Th17 lineages. C1 [Falvo, James V.; Jasenosky, Luke D.; Goldfeld, Anne E.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Falvo, James V.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Kruidenier, Laurens] GlaxoSmithKline R&D, Epinova Discovery Performance Unit, Immunoinflammat Therapy Area, Stevenage, Herts, England. [Goldfeld, Anne E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Goldfeld, Anne E.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Falvo, JV (reprint author), Childrens Hosp, Program Cellular & Mol Med, 300 Longwood Ave, Boston, MA 02115 USA. EM james.falvo@childrens.harvard.edu; anne.goldfeld@childrens.harvard.edu FU NHLBI NIH HHS [HL-059838, R01 HL059838]; NIGMS NIH HHS [GM076685, R01 GM076685] NR 481 TC 23 Z9 25 U1 2 U2 19 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-2776 BN 978-0-12-407708-9 J9 ADV IMMUNOL JI Adv.Immunol. PY 2013 VL 118 BP 37 EP 128 DI 10.1016/B978-0-12-407708-9.00002-9 PG 92 WC Immunology SC Immunology GA BFV91 UT WOS:000321592300002 PM 23683942 ER PT J AU Carlson, JCT Meimetis, LG Hilderbrand, SA Weissleder, R AF Carlson, Jonathan C. T. Meimetis, Labros G. Hilderbrand, Scott A. Weissleder, Ralph TI BODIPY-Tetrazine Derivatives as Superbright Bioorthogonal Turn-on Probes SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION LA English DT Article DE click chemistry; energy transfer; fluorescent probes; fluorogenic probes; tetrazines ID BOND ENERGY-TRANSFER; TRANSFER CASSETTES; LIVING CELLS; CYCLOADDITION; DIFFRACTION; MOLECULES; CHEMISTRY; LIGATION; PROTEINS; KINASE C1 [Carlson, Jonathan C. T.; Meimetis, Labros G.; Hilderbrand, Scott A.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Weissleder, Ralph] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu FU NHI [RO1EB010011, 2P50A086355]; DFCI-MGH Hematology Oncology Fellowship FX Part of this work was supported by NHI RO1EB010011 and 2P50A086355. J.C. was supported by a DFCI-MGH Hematology Oncology Fellowship. We thank Prof. Ralph Mazitschek for many insightful discussions, Dr. Katy Yang for cell culture assistance, Dr. Sarit Agasti for the gift of reagents, Alex Zaltsman for microscopy assistance, and Dr. Eszter Boros for her assistance with NMR spectroscopy. BODIPY=boron dipyrromethene. NR 44 TC 82 Z9 82 U1 10 U2 113 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 1433-7851 EI 1521-3773 J9 ANGEW CHEM INT EDIT JI Angew. Chem.-Int. Edit. PY 2013 VL 52 IS 27 BP 6917 EP 6920 DI 10.1002/anie.201301100 PG 4 WC Chemistry, Multidisciplinary SC Chemistry GA 169JS UT WOS:000320776900019 PM 23712730 ER PT J AU Jura, YH Lahey, S Eisner, BH Dretler, SP AF Jura, Ying H. Lahey, Susan Eisner, Brian H. Dretler, Stephen P. TI Ureteroscopic treatment of patients with small, painful, non-obstructing renal stones: the small stone syndrome SO CLINICAL NEPHROLOGY LA English DT Article DE nephrolithiasis; small; flank pain; kidney; renal colic; ureteroscopy ID SHOCK-WAVE LITHOTRIPSY; CALICEAL CALCULI; TREATMENT SELECTION; OUTCOMES AB Aims. Although it is thought that renal colic results from urinary tract obstruction, some patients evaluated for renal colic are found to have no source for their pain other than small, non-obstructing renal calyceal stones. We refer to this as "the small stone syndrome". We aim to determine if small non-obstructing calyceal stones may also cause pain and that treatment may relieve this pain. Method: A retrospective chart review was performed to identify patients with non-obstructing calyceal stones (<= 4 mm in diameter) evaluated for flank pain and treated by ureteroscopy. Patients completed a follow-up questionnaire regarding pre- and postoperative pain and quality of life (QOL). Results: 13 patients were included in the analysis. Mean stone diameter was 3 mm (range 1.5 - 4.0 mm). Following ureteroscopy, 11(85%) patients reported complete resolution of pain and 2 (15%) reported partial resolution. 12 patients were able to describe preoperative and postoperative QOL and of these, 8 (67%) had improved QOL, 4 (33%) had no change, and none reported worsening. Follow-up imaging was available in 10 patients: stone free in 6 (60%), reduction in stone size in 3 (30%), and stone unchanged in 1 (10%). Conclusions: Ureteroscopic treatment of painful small, non-obstructing renal calyceal stones achieved complete or partial resolution of pain in all patients and improvement in QOL in a majority of patients. C1 [Jura, Ying H.; Lahey, Susan; Eisner, Brian H.; Dretler, Stephen P.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Jura, Ying H.; Lahey, Susan; Eisner, Brian H.; Dretler, Stephen P.] Harvard Univ, Sch Med, Boston, MA USA. RP Jura, YH (reprint author), Massachusetts Gen Hosp, Dept Urol, GRB 1102,55 Fruit St, Boston, MA 02114 USA. EM ying.jura@gmail.com NR 16 TC 2 Z9 2 U1 0 U2 0 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD JAN PY 2013 VL 79 IS 1 BP 45 EP 49 DI 10.5414/CN107637 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 170HA UT WOS:000320839800007 PM 23006342 ER PT J AU Roche, MI Ramadas, RA Medoff, BD AF Roche, Marly I. Ramadas, Ravisankar A. Medoff, Benjamin D. TI The Role of CARMA1 in T Cells SO CRITICAL REVIEWS IN IMMUNOLOGY LA English DT Article DE CARMA1; T cell; T-cell receptor; NF-kappa B ID NF-KAPPA-B; KINASE-C-THETA; ANTIGEN-RECEPTOR; SIGNALING PATHWAYS; SCAFFOLD PROTEINS; COMPLEX-FORMATION; DIFFERENTIAL REQUIREMENT; LYMPHOCYTE-PROLIFERATION; IMMUNOLOGICAL SYNAPSE; TRANSCRIPTION FACTORS AB Caspase recruitment domain-containing membrane-associated guanylate kinase protein-1 (CARMA1), a member of the membrane associated guanylate kinase (MAGUK) family of kinases, is essential for T lymphocyte activation and proliferation via T-cell receptor (TCR) mediated NF-kappa B activation. Recent studies suggest a broader role for CARMA1 regulating other T-cell functions as well as a role in non-TCR-mediated signaling pathways important for lymphocyte development and functions. In addition, CARMA1 has been shown to be an important component in the pathogenesis of several human diseases. Thus, comprehensively defining its mechanisms of action and regulation could reveal novel therapeutic targets for T-cell mediated diseases and lymphoproliferative disorders. C1 [Roche, Marly I.; Medoff, Benjamin D.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Roche, Marly I.; Medoff, Benjamin D.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. [Roche, Marly I.; Medoff, Benjamin D.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Ramadas, Ravisankar A.] Merck Res Labs, Boston, MA 02115 USA. RP Medoff, BD (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, 55 Fruit St,Bulfinch 148, Boston, MA 02114 USA. EM bmedoff@partners.org FU NHLBI NIH HHS [T32 HL007874] NR 160 TC 5 Z9 6 U1 0 U2 4 PU BEGELL HOUSE INC PI REDDING PA 50 CROSS HIGHWAY, REDDING, CT 06896 USA SN 1040-8401 J9 CRIT REV IMMUNOL JI Crit. Rev. Immunol. PY 2013 VL 33 IS 3 BP 219 EP 243 PG 25 WC Immunology SC Immunology GA 171ZD UT WOS:000320968400003 PM 23756245 ER PT J AU Maeda, Y Kettner, N Lee, J Kim, J Cina, S Malatesta, C Gerber, J McManus, C Im, J Libby, A Mezzacappa, P Morse, LR Park, K Audette, J Napadow, V AF Maeda, Yumi Kettner, Norman Lee, Jeungchan Kim, Jieun Cina, Stephen Malatesta, Cristina Gerber, Jessica McManus, Claire Im, Jaehyun Libby, Alexandra Mezzacappa, Pia Morse, Leslie R. Park, Kyungmo Audette, Joseph Napadow, Vitaly TI Acupuncture-Evoked Response in Somatosensory and Prefrontal Cortices Predicts Immediate Pain Reduction in Carpal Tunnel Syndrome SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; HUMAN BRAIN; PLACEBO; STIMULATION; PLASTICITY; EXPERIENCE; CORTEX; STATE AB The linkage between brain response to acupuncture and subsequent analgesia remains poorly understood. Our aim was to evaluate this linkage in chronic pain patients with carpal tunnel syndrome (CTS). Brain response to electroacupuncture (EA) was evaluated with functional MRI. Subjects were randomized to 3 groups: (1) EA applied at local acupoints on the affected wrist (PC-7 to TW-5), (2) EA at distal acupoints (contralateral ankle, SP-6 to LV-4), and (3) sham EA at nonacupoint locations on the affected wrist. Symptom ratings were evaluated prior to and following the scan. Subjects in the local and distal groups reported reduced pain. Verum EA produced greater reduction of paresthesia compared to sham. Compared to sham EA, local EA produced greater activation in insula and S2 and greater deactivation in ipsilateral S1, while distal EA produced greater activation in S2 and deactivation in posterior cingulate cortex. Brain response to distal EA in prefrontal cortex (PFC) and brain response to verum EA in S1, SMA, and PFC were correlated with pain reduction following stimulation. Thus, while greater activation to verum acupuncture in these regions may predict subsequent analgesia, PFC activation may specifically mediate reduced pain when stimulating distal acupoints. C1 [Maeda, Yumi; Kim, Jieun; Cina, Stephen; Gerber, Jessica; Im, Jaehyun; Libby, Alexandra; Mezzacappa, Pia; Napadow, Vitaly] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Maeda, Yumi; Kettner, Norman; Napadow, Vitaly] Logan Coll Chiropract Univ Programs, Dept Radiol, Chesterfield, MO 63017 USA. [Lee, Jeungchan; Park, Kyungmo] Kyung Hee Univ, Dept Biomed Engn, Yongin 446701, Gyeonggido, South Korea. [Malatesta, Cristina; McManus, Claire] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Medford, MA 02155 USA. [Morse, Leslie R.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Audette, Joseph] Harvard Vanguard Med Associates, Dept Pain Med, Boston, MA 02215 USA. RP Maeda, Y (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, 2301 149 13th St, Charlestown, MA 02129 USA. EM ymaeda@nmr.mgh.harvard.edu RI Morse, Leslie/C-9442-2015 OI Morse, Leslie/0000-0002-7426-6341 FU NCCAM, National Institutes of Health [R01-AT004714, R01-AT004714-02S1, P01-AT002048] FX This work was supported by NCCAM, National Institutes of Health (R01-AT004714, R01-AT004714-02S1, P01-AT002048). NR 38 TC 9 Z9 9 U1 2 U2 13 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X EI 1741-4288 J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 795906 DI 10.1155/2013/795906 PG 13 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 178GB UT WOS:000321432100001 ER PT J AU Yeung, A Slipp, LE Jacquart, J Fava, M Denninger, JW Benson, H Fricchione, GL AF Yeung, Albert Slipp, Lauren E. Jacquart, Jolene Fava, Maurizio Denninger, John W. Benson, Herbert Fricchione, Gregory L. TI The Treatment of Depressed Chinese Americans Using Qigong in a Health Care Setting: A Pilot Study SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID CHRONIC PHYSICAL ILLNESSES; PERCEIVED SOCIAL SUPPORT; PSYCHOMETRIC CHARACTERISTICS; MULTIDIMENSIONAL SCALE; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; RATING-SCALE; OUTCOMES AB Background. This pilot study examined the feasibility and efficacy of providing Qigong treatment in a health center to Chinese Americans with major depressive disorder (MDD). Methods. Fourteen Chinese Americans with MDD were enrolled, and they received a 12-week Qigong intervention. The key outcome measurement was the 17-item Hamilton Rating Scale for Depression (HAM-D-17); the Clinical Global Impressions-Severity (CGI-S) and -Improvement (CGI-I), the Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF), and the Multidimensional Scale of Perceived Social Support (MSPSS) were also administered. Positive response was defined as a decrease of 50% or more on the HAM-D-17, and remission was defined as HAM-D-17 <= 7. Patients' outcome measurements were compared before and after the Qigong intervention. Results. Participants (N = 14) were 64% female, with a mean age of 53 (+/- 14). A 71% of participants completed the intervention. The Qigong intervention resulted in a positive treatment-response rate of 60% and a remission rate of 40% and statistically significant improvement, as measured by the HAM-D-17, CGI-S, CGI-I, Q-LES-Q-SF, and the family support subscale of the MSPSS. Conclusions. The Qigong intervention provided at a health care setting for the treatment of primary care patients with MDD is feasible. Further studies with larger sample sizes are warranted. C1 [Yeung, Albert; Slipp, Lauren E.; Jacquart, Jolene; Denninger, John W.; Benson, Herbert; Fricchione, Gregory L.] Massachusetts Gen Hosp, Benson Henry Inst, Boston, MA 02114 USA. [Yeung, Albert; Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Yeung, Albert] South Cove Community Hlth Ctr, Boston, MA 02111 USA. RP Yeung, A (reprint author), Massachusetts Gen Hosp, Benson Henry Inst, Boston, MA 02114 USA. EM ayeung@partners.org FU CDC [1R01DP003091] FX This research was supported by CDC Grant 1R01DP003091. The authors have no conflict of interests to report. NR 33 TC 0 Z9 0 U1 4 U2 8 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X EI 1741-4288 J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 168784 DI 10.1155/2013/168784 PG 5 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 177AZ UT WOS:000321349200001 ER PT J AU Osser, DN Roudsari, MJ Manschreck, T AF Osser, David N. Roudsari, Mohsen Jalali Manschreck, Theo TI The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Schizophrenia SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE algorithms; antipsychotics; psychopharmacology; schizophrenia ID TREATMENT-RESISTANT SCHIZOPHRENIA; PLACEBO-CONTROLLED-TRIAL; RANDOMIZED CONTROLLED-TRIAL; NEUROLEPTIC-INDUCED AKATHISIA; ADD-ON THERAPY; ATYPICAL ANTIPSYCHOTIC MEDICATION; NAIVE 1ST-EPISODE SCHIZOPHRENIA; LONG-ACTING INJECTIONS; DOUBLE-BLIND TRIAL; SCHIZOAFFECTIVE DISORDER AB This article is an update of the algorithm for schizophrenia from the Psychopharmacology Algorithm Project at the Harvard South Shore Program. A literature review was conducted focusing on new data since the last published version (1999-2001). The first-line treatment recommendation for new-onset schizophrenia is with amisulpride, aripiprazole, risperidone, or ziprasidone for four to six weeks. In some settings the trial could be shorter, considering that evidence of clear improvement with antipsychotics usually occurs within the first two weeks. If the trial of the first antipsychotic cannot be completed due to intolerance, try another until one of the four is tolerated and given an adequate trial. There should be evidence of bioavailability. If the response to this adequate trial is unsatisfactory, try a second monotherapy. If the response to this second adequate trial is also unsatisfactory, and if at least one of the first two trials was with risperidone, olanzapine, or a first-generation (typical) antipsychotic, then clozapine is recommended for the third trial. If neither trial was with any these three options, a third trial prior to clozapine should occur, using one of those three. If the response to monotherapy with clozapine (with dose adjusted by using plasma levels) is unsatisfactory, consider adding risperidone, lamotrigine, or ECT. Beyond that point, there is little solid evidence to support further psychopharmacological treatment choices, though we do review possible options. C1 [Osser, David N.; Manschreck, Theo] Harvard Univ, Sch Med, Brockton, MA 02401 USA. [Osser, David N.; Manschreck, Theo] VA Boston Healthcare Syst, Brockton Div, Brockton, MA 02301 USA. [Roudsari, Mohsen Jalali; Manschreck, Theo] Corrigan Mental Hlth Ctr, Lab Clin & Expt Psychopathol, Fall River, MA USA. [Roudsari, Mohsen Jalali; Manschreck, Theo] Beth Israel Deaconess Med Ctr, Harvard Commonwealth Ctr Excellence Clin Neurosci, Boston, MA 02215 USA. RP Osser, DN (reprint author), VA Boston Healthcare Syst, Brockton Div, 940 Belmont St, Brockton, MA 02301 USA. EM David.Osser@va.gov NR 222 TC 9 Z9 9 U1 6 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2013 VL 21 IS 1 BP 18 EP 40 DI 10.1097/HRP.0b013e31827fd915 PG 23 WC Psychiatry SC Psychiatry GA 173RW UT WOS:000321097600002 PM 23656760 ER PT J AU Miraldi, ER Sharfi, H Friedline, RH Johnson, H Zhang, T Lau, KS Ko, HJ Curran, TG Haigis, KM Yaffe, MB Bonneau, R Lauffenburger, DA Kahn, BB Kim, JK Neel, BG Saghatelian, A White, FM AF Miraldi, Emily R. Sharfi, Hadar Friedline, Randall H. Johnson, Hannah Zhang, Tejia Lau, Ken S. Ko, Hwi Jin Curran, Timothy G. Haigis, Kevin M. Yaffe, Michael B. Bonneau, Richard Lauffenburger, Douglas A. Kahn, Barbara B. Kim, Jason K. Neel, Benjamin G. Saghatelian, Alan White, Forest M. TI Molecular network analysis of phosphotyrosine and lipid metabolism in hepatic PTP1b deletion mice SO INTEGRATIVE BIOLOGY LA English DT Article ID ENDOPLASMIC-RETICULUM STRESS; LEAST-SQUARES REGRESSION; LIVER-SPECIFIC DELETION; TYROSINE PHOSPHORYLATION; MASS-SPECTROMETRY; INSULIN SENSITIVITY; BINDING-PROTEIN; LIGAND-BINDING; FATTY LIVER; OBESITY AB Metabolic syndrome describes a set of obesity-related disorders that increase diabetes, cardiovascular, and mortality risk. Studies of liver-specific protein-tyrosine phosphatase 1b (PTP1b) deletion mice (L-PTP1b(-/-)) suggest that hepatic PTP1b inhibition would mitigate metabolic-syndrome through amelioration of hepatic insulin resistance, endoplasmic-reticulum stress, and whole-body lipid metabolism. However, the altered molecular-network states underlying these phenotypes are poorly understood. We used mass spectrometry to quantify protein-phosphotyrosine network changes in L-PTP1b(-/-) mouse livers relative to control mice on normal and high-fat diets. We applied a phosphosite-set-enrichment analysis to identify known and novel pathways exhibiting PTP1b- and diet-dependent phosphotyrosine regulation. Detection of a PTP1b-dependent, but functionally uncharacterized, set of phosphosites on lipid-metabolic proteins motivated global lipidomic analyses that revealed altered polyunsaturated-fatty-acid (PUFA) and triglyceride metabolism in L-PTP1b(-/-) mice. To connect phosphosites and lipid measurements in a unified model, we developed a multivariate-regression framework, which accounts for measurement noise and systematically missing proteomics data. This analysis resulted in quantitative models that predict roles for phosphoproteins involved in oxidation-reduction in altered PUFA and triglyceride metabolism. C1 [Miraldi, Emily R.] MIT, Cambridge, MA 02138 USA. [Miraldi, Emily R.; Sharfi, Hadar; Johnson, Hannah; Lau, Ken S.; Curran, Timothy G.; Yaffe, Michael B.; White, Forest M.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Friedline, Randall H.; Ko, Hwi Jin; Kim, Jason K.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA. [Friedline, Randall H.; Ko, Hwi Jin; Kim, Jason K.] Univ Massachusetts, Sch Med, Dept Med, Div Endocrinol Metab & Diabet, Worcester, MA 01605 USA. [Johnson, Hannah; Lau, Ken S.; Curran, Timothy G.; Lauffenburger, Douglas A.; White, Forest M.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Zhang, Tejia; Saghatelian, Alan] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Lau, Ken S.; Haigis, Kevin M.] Massachusetts Gen Hosp, Ctr Canc Res, Mol Pathol Unit, Charlestown, MA 02129 USA. [Lau, Ken S.; Haigis, Kevin M.] Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA. [Haigis, Kevin M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Bonneau, Richard] NYU, Ctr Genom & Syst Biol, New York, NY 10003 USA. [Kahn, Barbara B.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab,Dept Med, Boston, MA 02215 USA. [Neel, Benjamin G.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada. [Neel, Benjamin G.] Univ Hlth Network, Ontario Canc Inst, Campbell Family Canc Res Inst, Toronto, ON M5G 1K7, Canada. [Neel, Benjamin G.] Univ Hlth Network, Princess Margaret Hosp, Toronto, ON M5G 1K7, Canada. RP Miraldi, ER (reprint author), MIT, Cambridge, MA 02138 USA. EM fwhite@mit.edu OI Lau, Ken/0000-0001-8438-0319 FU Pfizer Inc.; NIH [5R24DK090963, U54-CA112967, CA49152 R37, R01-DK080756]; UMass Mouse Metabolic Phenotyping Center Grant [U24-DK093000]; National Science Foundation; Ontario Ministry of Health and Long Term Care; Princess Margaret Hospital Foundation FX We thank Ms Angel Sing (OCI) for generating the mice for this study, Edwin Homan (Harvard) for help with fatty acid separation techniques, Robert Gerszten (Mass General Hospital) for helpful advice, and Kristen Naegle (Washington University) for assistance with phosphosite annotations in PTMScout. This work was supported by a grant from Pfizer Inc., NIH grants 5R24DK090963, U54-CA112967, CA49152 R37 (B.G.N.), and R01-DK080756 (J.K.K.), and the UMass Mouse Metabolic Phenotyping Center Grant (U24-DK093000) (J.K.K.). E. R. M. has been supported by a Graduate Research Fellowship from the National Science Foundation. Work in B.G.N.'s lab is partially supported by the Ontario Ministry of Health and Long Term Care and the Princess Margaret Hospital Foundation. NR 59 TC 5 Z9 5 U1 1 U2 11 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 EI 1757-9708 J9 INTEGR BIOL-UK JI Integr. Biol. PY 2013 VL 5 IS 7 BP 940 EP 963 DI 10.1039/c3ib40013a PG 24 WC Cell Biology SC Cell Biology GA 170TP UT WOS:000320877100003 PM 23685806 ER PT J AU Szostak, JW AF Szostak, Jack W. TI Towards non-enzymatic RNA replication SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS LA English DT Meeting Abstract C1 [Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. EM szostak@molbio.mgh.harvard.edu NR 2 TC 0 Z9 0 U1 3 U2 14 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0739-1102 J9 J BIOMOL STRUCT DYN JI J. Biomol. Struct. Dyn. PD JAN 1 PY 2013 VL 31 SU 1 SI SI MA 4 BP 2 EP 3 DI 10.1080/07391102.2013.786330 PG 2 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 160VU UT WOS:000320149400004 ER PT J AU Zhang, S Gryaznov, SM Szostak, JW AF Zhang, Shenglong Gryaznov, Sergei M. Szostak, Jack W. TI Efficient and high-fidelity copying of an RNA-like model prebiotic system SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS LA English DT Meeting Abstract C1 [Zhang, Shenglong; Szostak, Jack W.] Howard Hughes Med Inst, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zhang, Shenglong; Szostak, Jack W.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zhang, Shenglong; Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol & Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Gryaznov, Sergei M.] Geron Corp, Menlo Pk, CA 94025 USA. EM szostak@molbio.mgh.harvard.edu NR 2 TC 0 Z9 0 U1 2 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0739-1102 J9 J BIOMOL STRUCT DYN JI J. Biomol. Struct. Dyn. PD JAN 1 PY 2013 VL 31 SU 1 SI SI MA 5 BP 3 EP 3 DI 10.1080/07391102.2013.786331 PG 1 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 160VU UT WOS:000320149400006 ER PT J AU Engelhart, AE Powner, MW Szostak, JW AF Engelhart, Aaron E. Powner, Matthew W. Szostak, Jack W. TI Imperfect RNA synthesis via model prebiotic reactions and consequences for functional RNAs SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS LA English DT Meeting Abstract C1 [Engelhart, Aaron E.; Powner, Matthew W.; Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. EM szostak@molbio.mgh.harvard.edu NR 2 TC 0 Z9 0 U1 2 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0739-1102 J9 J BIOMOL STRUCT DYN JI J. Biomol. Struct. Dyn. PD JAN 1 PY 2013 VL 31 SU 1 SI SI MA 7 BP 4 EP 5 DI 10.1080/07391102.2013.786333 PG 2 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 160VU UT WOS:000320149400008 ER PT J AU Sheng, J Li, L Engelhart, AE Szostak, JW AF Sheng, Jia Li, Li Engelhart, Aaron E. Szostak, Jack W. TI Crystal structure studies of RNA molecules containing 2 '-5 '-linkages SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS LA English DT Meeting Abstract C1 [Sheng, Jia; Li, Li; Engelhart, Aaron E.; Szostak, Jack W.] Howard Hughes Med Inst, Harvard Med Sch, Massachusetts Gen Hosp, Dept Genet, Boston, MA 02114 USA. EM szostak@molbio.mgh.harvard.edu NR 0 TC 0 Z9 0 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0739-1102 J9 J BIOMOL STRUCT DYN JI J. Biomol. Struct. Dyn. PD JAN 1 PY 2013 VL 31 SU 1 SI SI MA 6 BP 4 EP 4 DI 10.1080/07391102.2013.786332 PG 1 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 160VU UT WOS:000320149400007 ER PT J AU Li, L Szostak, JW AF Li, Li Szostak, Jack W. TI Using pseudorotation as a reaction coordinate in free energy simulations of nucleic acids SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS LA English DT Meeting Abstract ID RELAXATION; RING C1 [Li, Li; Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. EM szostak@molbio.mgh.harvard.edu NR 5 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0739-1102 J9 J BIOMOL STRUCT DYN JI J. Biomol. Struct. Dyn. PD JAN 1 PY 2013 VL 31 SU 1 SI SI MA 8 BP 5 EP 5 DI 10.1080/07391102.2013.786334 PG 1 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 160VU UT WOS:000320149400010 ER PT J AU Paspulati, A Punjabi, OS Theodoropoulou, S Singh, RP AF Paspulati, Anirudh Punjabi, Omar S. Theodoropoulou, Sofia Singh, Rishi P. TI Triamcinolone Acetonide as an Adjuvant to Membrane Peeling Surgery: A Pilot Study SO OPHTHALMIC SURGERY LASERS & IMAGING LA English DT Article ID CYSTOID MACULAR EDEMA; INTRAVITREAL TRIAMCINOLONE; EPIRETINAL MEMBRANES; VITRECTOMY AB BACKGROUND AND OBJECTIVE: To evaluate the clinical outcome and complications of intravitreal injections of triamcinolone acetonide as adjuvant to reduce postoperative macular edema in patients undergoing pars plana vitrectomy for epiretinal membranes. PATIENTS AND METHODS: This retrospective comparative study included 22 patients (22 eyes) who underwent pars plana vitrectomy with membrane peeling for the treatment of idiopathic epiretinal membrane. Fifteen eyes (15 patients) received an intravitreal injection of 4 mg (0.1 cc) of triamcinolone acetonide at the end of surgery, and no injection was performed for 7 eyes (7 patients). Main outcome measures were visual acuity and intraocular pressure. Minimum follow-up was 3 months. RESULTS: Twenty-two eyes of 22 patients were included in the study. The follow-up ranged from 3 to 12 months. Visual acuity improved in both groups at 3 months: logarithm of the minimum angle of resolution -0.26 +/- 0.19 in the triamcinolone acetonide group (P = .001) and -0.26 +/- 0.13 in the control group (P = .002). However, there was no statistically significant difference in visual acuity improvement 1, 3, and 12 months postoperatively in the triamcinolone acetonide group compared with the control group (P = .79, = .94, and = .21, respectively). There was no significant difference in intraocular pressure change between the two groups during the follow-up period (P > .05). CONCLUSION: The current pilot study suggests that postoperative intravitreal injection of triamcinolone acetonide does not lead to better visual outcomes in patients undergoing pars plana vitrectomy for the treatment of idiopathic epiretinal membranes. C1 [Paspulati, Anirudh] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Punjabi, Omar S.; Singh, Rishi P.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA. [Theodoropoulou, Sofia] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Singh, RP (reprint author), Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,I-32, Cleveland, OH 44195 USA. EM drrishisingh@gmail.com NR 15 TC 1 Z9 1 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1542-8877 J9 OPHTHAL SURG LAS IM JI Ophthalmic Surg. Lasers Imaging PD JAN-FEB PY 2013 VL 44 IS 1 BP 41 EP 45 DI 10.3928/23258160-20121221-11 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 172PG UT WOS:000321016000008 PM 23418733 ER PT S AU Hartman, ML Groppo, F Ohnishi, M Goodson, JM Hasturk, H Tavares, M Yaskell, T Floros, C Behbehani, K Razzaque, MS AF Hartman, Mor-Li Groppo, Francisco Ohnishi, Mutsuko Goodson, J. Max Hasturk, Hatice Tavares, Mary Yaskell, Tina Floros, Constantino Behbehani, Kazem Razzaque, Mohammed S. BE Razzaque, MS TI Can Salivary Phosphate Levels Be an Early Biomarker to Monitor the Evolvement of Obesity? SO PHOSPHATE AND VITAMIN D IN CHRONIC KIDNEY DISEASE SE Contributions to Nephrology LA English DT Article; Book Chapter ID FIBROBLAST-GROWTH-FACTOR; SOFT-TISSUE CALCIFICATION; GENETIC-EVIDENCE; DEFICIENT MICE; KLOTHO; HOMEOSTASIS; METABOLISM; TOXICITY; LEPTIN; COTRANSPORTER AB Phosphate is an essential nutrient required for important biological reactions that maintain the normal homoeostatic control of the cell. The adverse effects of phosphate metabolism in obesity have not been studied in detail, chiefly because such an association is thought to be uncommon. However, in some animal models of obesity, serum phosphate levels were noted to be higher than the nonobese controls. For example, leptin-deficient (ob/ob) mice become severely obese and have high serum phosphate levels. In this study, we analyzed the phosphate content in saliva collected from children (n = 77; 10.5 +/- 1.8) to evaluate association with body mass index; there is a significant increase of salivary phosphate content in obese compared to normal-weight children (ANOVA p < 0.001). The correlation coefficient (r) between BMI and phosphate was 0.33 (p = 0.0032). Our results suggest that the human salivary phosphate level may be an early biomarker of the genesis of obesity in children. The diagnostic importance lies in the fact that the salivary phosphate level could provide a noninvasive predictive marker in the development of obesity. Further studies will be required to understand the underlying mechanism of increased salivary phosphate accumulation in obese and overweight children. Nevertheless, its occurrence without systemic changes could be of diagnostic value, particularly in monitoring evolvement of obesity. Copyright (C) 2013 S. Karger AG, Basel C1 [Hartman, Mor-Li; Goodson, J. Max; Hasturk, Hatice; Tavares, Mary; Yaskell, Tina; Floros, Constantino] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA 02142 USA. [Groppo, Francisco] Univ Estadual Campinas, Piracicaba Dent Sch, Piracicaba, SP, Brazil. [Ohnishi, Mutsuko; Razzaque, Mohammed S.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Behbehani, Kazem] Dasman Diabet Inst, Dasman, Kuwait. RP Goodson, JM (reprint author), Forsyth Inst, Dept Appl Oral Sci, 245 1st St, Cambridge, MA 02142 USA. EM Mgoodson@forsyth.org FU NIDDK NIH HHS [DK077276, R01 DK077276] NR 39 TC 5 Z9 5 U1 2 U2 15 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-318-02369-5 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2013 VL 180 BP 138 EP 148 DI 10.1159/000346793 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA BFV89 UT WOS:000321592100012 PM 23652556 ER PT J AU Rotstein, BH Liang, SH Holland, JP Collier, TL Hooker, JM Wilson, AA Vasdev, N AF Rotstein, Benjamin H. Liang, Steven H. Holland, Jason P. Collier, Thomas Lee Hooker, Jacob M. Wilson, Alan A. Vasdev, Neil TI (CO2)-C-11 fixation: a renaissance in PET radiochemistry SO CHEMICAL COMMUNICATIONS LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; ACID AMIDE HYDROLASE; ONE-POT SYNTHESIS; RAPID REDUCTIVE-CARBOXYLATION; C-11 CARBON-DIOXIDE; SECONDARY-AMINES; IN-VIVO; RECEPTOR RADIOLIGAND; CARBONYLATION; CARRIER AB Carbon-11 labelled carbon dioxide is the cyclotron-generated feedstock reagent for most positron emission tomography (PET) tracers using this radionuclide. Most carbon-11 labels, however, are installed using derivative reagents generated from [C-11]CO2. In recent years, [C-11]CO2 has seen a revival in applications for the direct incorporation of carbon-11 into functional groups such as ureas, carbamates, oxazolidinones, carboxylic acids, esters, and amides. This review summarizes classical [C-11]CO2 fixation strategies using organometallic reagents and then focuses on newly developed methods that employ strong organic bases to reversibly capture [C-11]CO2 into solution, thereby enabling highly functionalized labelled compounds to be prepared. Labelled compounds and radiopharmaceuticals that have been translated to the clinic are highlighted. C1 [Rotstein, Benjamin H.; Liang, Steven H.; Holland, Jason P.; Collier, Thomas Lee; Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Rotstein, Benjamin H.; Liang, Steven H.; Holland, Jason P.; Collier, Thomas Lee; Vasdev, Neil] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Collier, Thomas Lee] Advion Inc, Ithaca, NY 14850 USA. [Hooker, Jacob M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Wilson, Alan A.] Univ Toronto, Ctr Addict & Mental Hlth, Res Imaging Ctr, Toronto, ON M5T 1R8, Canada. [Wilson, Alan A.] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada. RP Vasdev, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA. EM vasdev.neil@mgh.harvard.edu RI Wilson, Alan/A-1788-2011; OI Hooker, Jacob/0000-0002-9394-7708; Holland, Jason/0000-0002-0066-219X; Rotstein, Benjamin/0000-0001-9707-9357 FU NCRR NIH HHS [S10 RR023385] NR 84 TC 22 Z9 22 U1 2 U2 24 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1359-7345 J9 CHEM COMMUN JI Chem. Commun. PY 2013 VL 49 IS 50 BP 5621 EP 5629 DI 10.1039/c3cc42236d PG 9 WC Chemistry, Multidisciplinary SC Chemistry GA 152DX UT WOS:000319511900002 PM 23673726 ER PT J AU Rio, DE Rawlings, RR Woltz, LA Gilman, J Hommer, DW AF Rio, Daniel E. Rawlings, Robert R. Woltz, Lawrence A. Gilman, Jodi Hommer, Daniel W. TI Development of the Complex General Linear Model in the Fourier Domain: Application to fMRI Multiple Input-Output Evoked Responses for Single Subjects SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE LA English DT Article ID TIME-SERIES ANALYSIS; STATISTICAL-ANALYSIS; SENSORY STIMULATION; FUNCTIONAL MRI; BRAIN; NOISE; IMAGE; ACTIVATION; INFERENCE AB A linear time-invariantmodel based on statistical time series analysis in the Fourier domain for single subjects is further developed and applied to functional MRI (fMRI) blood-oxygen level-dependent (BOLD) multivariate data. This methodology was originally developed to analyze multiple stimulus input evoked response BOLD data. However, to analyze clinical data generated using a repeated measures experimental design, the model has been extended to handle multivariate time series data and demonstrated on control and alcoholic subjects taken from data previously analyzed in the temporal domain. Analysis of BOLD data is typically carried out in the time domain where the data has a high temporal correlation. These analyses generally employ parametric models of the hemodynamic response function (HRF) where prewhitening of the data is attempted using autoregressive (AR) models for the noise. However, this data can be analyzed in the Fourier domain. Here, assumptions made on the noise structure are less restrictive, and hypothesis tests can be constructed based on voxel-specific nonparametric estimates of the hemodynamic transfer function (HRF in the Fourier domain). This is especially important for experimental designs involving multiple states (either stimulus or drug induced) that may alter the form of the response function. C1 [Rio, Daniel E.; Rawlings, Robert R.; Hommer, Daniel W.] NIAAA, Sect Brain Electrophysiol & Imaging, LCTS, NIH, Bethesda, MD 90034 USA. [Woltz, Lawrence A.] Synergy Res Inc, Monrovia, MD USA. [Gilman, Jodi] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Lab Neuroimaging & Genet, Charlestown, MA USA. RP Rio, DE (reprint author), NIAAA, Sect Brain Electrophysiol & Imaging, LCTS, NIH, 10 Ctr Dr,MSC 1540, Bethesda, MD 90034 USA. EM drio@nih.gov NR 44 TC 0 Z9 0 U1 0 U2 4 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1748-670X J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PY 2013 AR UNSP 645043 DI 10.1155/2013/645043 PG 16 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 169PE UT WOS:000320791500001 ER PT J AU Rosenberg, DE Turner, AP Littman, AJ Williams, RM Norvell, DC Hakimi, KM Czerniecki, JM AF Rosenberg, Dori E. Turner, Aaron P. Littman, Alyson J. Williams, Rhonda M. Norvell, Dan C. Hakimi, Kevin M. Czerniecki, Joseph M. TI Body mass index patterns following dysvascular lower extremity amputation SO DISABILITY AND REHABILITATION LA English DT Article DE Mobility disability; obesity; prosthesis ID LOWER-LIMB AMPUTATION; RISK-FACTORS; SELF-REPORT; OBESITY; AMPUTEES; ADULTS; PREVALENCE; OVERWEIGHT; WEIGHT; UNDERWEIGHT AB Purpose: Using preliminary data, we examined: (i) patterns of body mass index (BMI) over the year following amputation by amputation level and (ii) the association between BMI and mobility and prosthetic device use. Method: Patients from three medical centers undergoing dysvascular amputation (N = 87; M age = 62) participated in interviews pre-surgically and at 6 weeks, 4 months, and 12 months following amputation. The main outcome was self-reported BMI, adjusting for limb weight lost due to amputation. Additional outcomes were mobility and time spent using and walking in a prosthetic device. Results: Adjusted BMI slightly decreased at 6 weeks (pre-surgery M = 31.2; 6 weeks M = 30.3) and 4 months (M = 30.7) but exceeded baseline levels by 12 months (M = 31.7). There were no significant BMI differences by amputation level. In multivariable analyses, higher pre-surgical BMI was associated with fewer hours of prosthetic device walking at month 4 (beta = -0.49) and poorer overall mobility at month 12 (beta = -0.22). Conclusions: BMI increased at one year following amputation surgery. Higher pre-surgical BMI was associated with poorer mobility and prosthetic device use. Interventions are needed to prevent excess weight gain in the year following amputation. C1 [Rosenberg, Dori E.; Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin M.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Rosenberg, Dori E.] Grp Hlth Res Inst, Grp Hlth Cooperat, Seattle, WA USA. [Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin M.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Littman, Alyson J.] Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Norvell, Dan C.] Spectrum Res, Tacoma, WA USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM aaron.turner@med.va.gov OI Turner, Aaron/0000-0001-6897-8003 FU US Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Merit Review [A41241, CDA B4927W, CDA 6982]; NIH Kirschstein NRSA award [2T32HD007424-19] FX This material is based upon work supported by the US Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Merit Review A41241 (Joseph Czerniecki, PI), CDA B4927W (Aaron Turner, PI) CDA 6982 (Alyson Littman, PI) and NIH Kirschstein NRSA award (2T32HD007424-19) for Dori Rosenberg. NR 29 TC 7 Z9 7 U1 0 U2 14 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2013 VL 35 IS 15 BP 1269 EP 1275 DI 10.3109/09638288.2012.726690 PG 7 WC Rehabilitation SC Rehabilitation GA 169VM UT WOS:000320808700003 PM 23094934 ER PT J AU Lazaridou, A Philbrook, P Tzika, AA AF Lazaridou, Asimina Philbrook, Phaethon Tzika, Aria A. TI Yoga and Mindfulness as Therapeutic Interventions for Stroke Rehabilitation: A Systematic Review SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Review ID LONG-TERM MEDITATION; GRAY-MATTER DENSITY; STRESS-REDUCTION; PREFRONTAL CORTEX; COGNITIVE THERAPY; DEPRESSION; PRACTITIONERS; EXPERIENCE; MEDICINE; EXERCISE AB Aim. This paper reports a systematic review and critical appraisal of the evidence on the effectiveness of behavioral therapies such as yoga and mindfulness practices for stroke rehabilitation. Background. The experience of stroke can have a negative impact on both psychological and physical health and on quality of life. Yoga and relevant practices are promising therapies that have been used with patients with a variety of conditions. In order to draw conclusions on effectiveness for stroke patients, the evidence requires systematic assessment. Methods. A comprehensive search of major biomedical and complementary medicine databases was conducted. Relevant research was categorized by study type and appraised according to study design. Results. Five randomized controlled clinical trials and four single case studies were found. Additionally, one qualitative research study was identified. Studies reported positive results, including improvements in cognition, mood, and balance and reductions in stress. Modifications to different yoga practices make comparison between studies difficult, and a lack of controlled studies precludes any firm conclusions on efficacy. Conclusion. Yoga and mindfulness could be clinically valuable self-administered intervention options for stroke rehabilitation. Further research is needed to evaluate these specific practices and their suitability in stroke rehabilitation. C1 [Lazaridou, Asimina; Philbrook, Phaethon; Tzika, Aria A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, NMR Surg Lab,Dept Surg,Div Burns, Boston, MA 02114 USA. [Lazaridou, Asimina; Philbrook, Phaethon; Tzika, Aria A.] Harvard Univ, Shriners Burn Inst, Sch Med, Boston, MA 02114 USA. [Lazaridou, Asimina; Philbrook, Phaethon; Tzika, Aria A.] Harvard Univ, Athinoula A Martinos Ctr Biomed Imaging, Sch Med, Boston, MA 02114 USA. RP Tzika, AA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, NMR Surg Lab,Dept Surg,Div Burns, Boston, MA 02114 USA. EM aaria_tzika@hms.harvard.edu NR 63 TC 5 Z9 5 U1 3 U2 31 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 357108 DI 10.1155/2013/357108 PG 9 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 162CM UT WOS:000320242000001 ER PT J AU Faestel, PM Littell, CT Vitiello, MV Forsberg, CW Littman, AJ AF Faestel, Paul M. Littell, Christopher T. Vitiello, Michael V. Forsberg, Christopher W. Littman, Alyson J. TI Perceived Insufficient Rest or Sleep among Veterans: Behavioral Risk Factor Surveillance System 2009 SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Insufficient sleep; Veterans health; Behavior Risk Factor Surveillance System ID POSTTRAUMATIC-STRESS-DISORDER; UNITED-STATES; DURATION; DISTURBANCES; AFGHANISTAN; TRANSITION; DISABILITY; DEPLOYMENT; WORK; LIFE AB Study Objectives: Sleep problems are of particular concern among the active duty military population as factors such as inconsistent work hours and deployment may compromise adequate sleep and adversely impact performance. However, few prior studies have investigated whether the prevalence of sleep problems differ between Veterans and demographically similar non-Veterans. The purpose of this study is to investigate whether self-reported insufficient rest or sleep varies in relation to Veteran status and to identify high-risk groups of Veterans. Methods: This study used data from the 2009 Behavioral Risk Factor Surveillance System (analyzed in 2011), a state based national telephone survey of non-institutionalized US adults. Insufficient rest was assessed in 411,313 adults aged 21 and older, of whom 55,361 were Veterans. Sleep duration was assessed in 6 states (n = 4,936 Veterans and 30,983 non-Veterans). Model-based direct rate adjustment was used to estimate the prevalence of insufficient rest or sleep while controlling for confounding. Multivariable logistic regression was used to estimate odds ratios of insufficient sleep or rest in subgroups of Veterans. Results: After multivariable adjustment, insufficient rest or sleep (22.7% vs. 21.1%, p < 0.001) and short sleep duration (< 7 h/night, 34.9% vs. 31.3%, p = 0.026) were more common among Veterans than non-Veterans. When the Veteran group was further divided among newly transitioned (<= 12 months) and longer-term Veterans (> 12 months), the overall test for a difference was not statistically significant between groups, mainly because there was little difference in sleep between the two groups of Veterans. High-risk Veteran subgroups included those who were 21-44 years of age (vs. 65-74), women, non-whites, current smokers, obese, unable to work, and those in poor health. Conclusions: This study suggests that Veterans have a high burden of sleep problems and identifies subgroups that should be targeted to receive interventions and enhanced education regarding insufficient sleep. C1 [Faestel, Paul M.; Littell, Christopher T.] Madigan Healthcare Syst, Dept Prevent Med, Tacoma, WA USA. [Vitiello, Michael V.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Forsberg, Christopher W.; Littman, Alyson J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Faestel, PM (reprint author), MEDDAC, Dept Prevent Med, Mt Belvedere Dr,Bldg 10720, Ft Drum, NY 13602 USA. EM paul.faestel@us.army.mil OI Vitiello, Michael/0000-0002-9776-0473 FU Cooperative Studies Program, Department of Veterans Affairs; Puget Sound VA Medical Center; VA Rehabilitation Research and Development Career Development Award [6982] FX The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Defense or the Department of Veterans Affairs. This material is the result of work partly supported with resources and the use of facilities from the Cooperative Studies Program, Department of Veterans Affairs, and the Puget Sound VA Medical Center. Dr. Littman was supported by a VA Rehabilitation Research and Development Career Development Award (#6982). Institution at which work was performed: Madigan Healthcare System, Tacoma, WA. NR 35 TC 14 Z9 14 U1 0 U2 4 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2013 VL 9 IS 6 BP 577 EP 584 DI 10.5664/jcsm.2754 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 164UP UT WOS:000320436000009 PM 23772191 ER PT J AU Sasase, T Pezzolesi, MG Yokoi, N Yamada, T Matsumoto, K AF Sasase, Tomohiko Pezzolesi, Marcus G. Yokoi, Norihide Yamada, Takahisa Matsumoto, Kozo TI Animal Models of Diabetes and Metabolic Disease SO JOURNAL OF DIABETES RESEARCH LA English DT Editorial Material C1 [Sasase, Tomohiko] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Biol Pharmacol Res Labs, Osaka 5691125, Japan. [Pezzolesi, Marcus G.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02215 USA. [Yokoi, Norihide] Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Div Mol & Metab Med, Kobe, Hyogo 6500017, Japan. [Yamada, Takahisa] Niigata Univ, Grad Sch Sci & Technol, Div Life & Food Sci, Lab Anim Genet, Niigata 9502181, Japan. [Matsumoto, Kozo] Kyoto Sangyo Univ, Fac Life Sci, Dept Lab Anim Sci, Kyoto 6038555, Japan. RP Sasase, T (reprint author), Japan Tobacco Inc, Cent Pharmaceut Res Inst, Biol Pharmacol Res Labs, Osaka 5691125, Japan. EM tomohiko.sasase@jt.com NR 0 TC 2 Z9 2 U1 0 U2 1 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6745 J9 J DIABETES RES JI J. Diabetes Res. PY 2013 AR 281928 DI 10.1155/2013/281928 PG 2 WC Endocrinology & Metabolism; Medicine, Research & Experimental SC Endocrinology & Metabolism; Research & Experimental Medicine GA 181HE UT WOS:000321657800001 ER PT J AU Ge, RL Pejo, E Cotten, JF Raines, DE AF Ge, Rile Pejo, Ervin Cotten, Joseph F. Raines, Douglas E. TI Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate SO CRITICAL CARE LA English DT Article ID MULTIPLE TRAUMA PATIENTS; ADRENAL INSUFFICIENCY; MENINGOCOCCAL SEPSIS; MORTALITY; INHIBITION; METABOLITE; CORTISOL; ANIMALS; AGENTS AB Introduction: Etomidate is no longer administered as a continuous infusion for anesthetic maintenance or sedation, because it results in profound and persistent suppression of adrenocortical steroid synthesis with potentially lethal consequences in critically ill patients. We hypothesized that rapidly metabolized soft analogues of etomidate could be developed that do not produce persistent adrenocortical dysfunction even after prolonged continuous infusion. We hope that such agents might also provide more rapid and predictable anesthetic emergence. We have developed the soft etomidate analogue cyclopropyl-methoxycarbonyl etomidate (CPMM). Upon termination of 120-minute continuous infusions, hypnotic and encephalographic recoveries occur in four minutes. The aims of this study were to assess adrenocortical function during and following 120-minute continuous infusion of CPMM and to compare the results with those obtained using etomidate. Methods: Dexamethasone-suppressed rats were randomized into an etomidate group, CPMM group, or control group. Rats in the etomidate and CPMM groups received 120-minute continuous infusions of etomidate and CPMM, respectively. Rats in the control group received neither hypnotic. In the first study, adrenocortical function during hypnotic infusion was assessed by administering adrenocorticotropic hormone (ACTH) 90 minutes after the start of the hypnotic infusion and measuring plasma corticosterone concentrations at the end of the infusion 30 minutes later. In the second study, adrenocortical recovery following hypnotic infusion was assessed by administering ACTH every 30 minutes after infusion termination and measuring plasma corticosterone concentrations 30 minutes after each ACTH dose. Results: During hypnotic infusion, ACTH-stimulated serum corticosterone concentrations were significantly lower in the CPMM and etomidate groups than in the control group (100 +/- 64 ng/ml and 33 +/- 32 ng/ml versus 615 +/- 265 ng/ml, respectively). After hypnotic infusion, ACTH-stimulated serum corticosterone concentrations recovered to control values within 30 minutes in the CPMM group but remained suppressed relative to those in the control group for more than 3 hours in the etomidate group. Conclusions: Both CPMM and etomidate suppress adrenocortical function during continuous infusion. However, recovery occurs significantly more rapidly following infusion of CPMM. C1 [Ge, Rile; Pejo, Ervin; Cotten, Joseph F.; Raines, Douglas E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Raines, DE (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM draines@partners.org FU National Institutes of Health (Bethesda, MD, USA) [R01-GM087316, R21-DA029253]; Department of Anesthesia, Critical Care, and Pain Medicine of Massachusetts General Hospital (Boston, MA, USA) FX This work was funded by grants R01-GM087316 and R21-DA029253 from the National Institutes of Health (Bethesda, MD, USA) and by the Department of Anesthesia, Critical Care, and Pain Medicine of Massachusetts General Hospital (Boston, MA, USA). NR 33 TC 7 Z9 9 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X J9 CRIT CARE JI Crit. Care PY 2013 VL 17 IS 1 AR R20 DI 10.1186/cc12494 PG 7 WC Critical Care Medicine SC General & Internal Medicine GA 161AJ UT WOS:000320161900071 PM 23363638 ER PT J AU Zhu, D Gao, Y Chang, JL Kong, J AF Zhu, Dan Gao, Ying Chang, Jingling Kong, Jian TI Placebo Acupuncture Devices: Considerations for Acupuncture Research SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Review ID LOW-BACK-PAIN; RANDOMIZED-CONTROLLED-TRIAL; ELECTRICAL NERVE-STIMULATION; IRRITABLE-BOWEL-SYNDROME; PARK SHAM DEVICE; LASER ACUPUNCTURE; CLINICAL-TRIAL; ORAL-SURGERY; SINGLE-BLIND; CHRONIC NECK AB Determining an appropriate control for use in acupuncture research remains one of the largest methodological challenges acupuncture researchers face. In general, acupuncture controls fall under one of two categories: (1) sham acupuncture, in which the skin is punctured with real acupuncture needles either fully at nonacupoint locations or shallowly at acupoint locations or both and (2) placebo acupuncture, which utilizes nonpenetrating acupuncture devices. In this study, we will focus on non-penetrating placebo acupuncture devices (blunted-needle and nonneedle devices) that are currently available in acupuncture research. We will describe each device and discuss each device's validation and application in previous studies. In addition, we will outline the advantages and disadvantages of these devices and highlight how the differences among placebo devices can be used to isolate distinct components of acupuncture treatment and investigate their effects. We would like to emphasize that there is no single placebo device that can serve as the best control for all acupuncture studies; the choice of an acupuncture control should be determined by the specific aim of the study. C1 [Zhu, Dan; Gao, Ying; Chang, Jingling] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Neurol, Beijing 100700, Peoples R China. [Zhu, Dan; Kong, Jian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02129 USA. RP Gao, Y (reprint author), Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Neurol, 5 Haiyuncang, Beijing 100700, Peoples R China. EM gaoying973@126.com FU National Science Foundation of China [81072768]; New Century Excellent Talents in University of Ministry of Education of China [NCET-11-0603]; Chinese Medicine Clinical Evaluation Research Team in Brain Disease of Beijing University of Chinese Medicine [2011-CXTD-22, R01AT006364, R21AT004497, R03AT218317, P01AT006663] FX The authors thank the valuable suggestions, comments, and English editing form Sonya Freeman, Rosa Spaeth, and Lisette Roman in the Department of Psychiatry, Massachusetts General Hospital. This work was supported by the National Science Foundation of China (Grant no. 81072768), New Century Excellent Talents in University of Ministry of Education of China (Grant no. NCET-11-0603), Chinese Medicine Clinical Evaluation Research Team in Brain Disease of Beijing University of Chinese Medicine (Grant no. 2011-CXTD-22), R01AT006364, R21AT004497, and R03AT218317 to Jian Kong, and P01AT006663 to Bruce Rosen. NR 63 TC 12 Z9 12 U1 2 U2 17 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 628907 DI 10.1155/2013/628907 PG 9 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 166GG UT WOS:000320542100001 ER PT S AU Kobayashi, KS AF Kobayashi, Koichi S. BE Guarino, A Quigley, EMM Walker, WA TI Shaping Intestinal Bacterial Community by TLR and NLR Signaling SO PROBIOTIC BACTERIA AND THEIR EFFECT ON HUMAN HEALTH AND WELL-BEING SE World Review of Nutrition and Dietetics LA English DT Article; Book Chapter ID INFLAMMATORY-BOWEL-DISEASE; ILEAL CROHNS-DISEASE; TOLL-LIKE RECEPTOR-5; LECTIN REGIII-GAMMA; EPITHELIAL-CELLS; PEPTIDOGLYCAN RECOGNITION; MAINTAIN HOMEOSTASIS; TLR5-DEFICIENT MICE; INNATE IMMUNITY; KAPPA-B AB Human intestines harbor a diverse microbial community composed of a large number of bacteria and other microorganisms. These intestinal microbiota have evolved to achieve a symbiotic relationship with the host. In addition to aiding host metabolic pathways by breaking down foods and supplying nutrients to their host, microbiota play an important role in the development and maintenance of the host immune system. At the same time, the detection of microorganisms and their products by innate immune receptors such as TLRs (Toll-like receptors) and NLR (nucleotide-binding domain, leucine-rich repeats, or NOD-like receptor) proteins are critical for maintaining intestinal homeostasis by shaping microbial communities. This review summarizes recent progress about the role of TLRs and NLRs in the regulation of intestinal microbiota. Accumulating evidence suggest that intestinal microbiota have a large impact on both intestinal and systemic diseases. Therefore, understanding the mechanism of microbial regulation by TLRs and NLRs is important for the advancement of therapeutic interventions against digestive and other diseases. Copyright (c) 2013 S. Karger AG, Basel C1 [Kobayashi, Koichi S.] Texas A&M Hlth Sci Ctr, Dept Microbial & Mol Pathogenesis, Coll Med, College Stn, TX 77843 USA. [Kobayashi, Koichi S.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA USA. [Kobayashi, Koichi S.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Kobayashi, KS (reprint author), Texas A&M Hlth Sci Ctr, Dept Microbial & Mol Pathogenesis, Coll Med, 415A Reynolds Med Bldg, College Stn, TX 77843 USA. NR 55 TC 1 Z9 1 U1 2 U2 7 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0084-2230 BN 978-3-318-02324-4 J9 WORLD REV NUTR DIET JI World Rev.Nutr.Diet. PY 2013 VL 107 BP 32 EP 42 DI 10.1159/000346493 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA BFM65 UT WOS:000320562800006 ER PT J AU Hill, M Mor, MK Travis, L Ward, T Palevsky, PM Ramkumar, M Weisbord, SD AF Hill, Marlene Mor, Maria K. Travis, Lesli Ward, Tina Palevsky, Paul M. Ramkumar, Mohan Weisbord, Steven D. TI Renal function following fistulography in patients with advanced chronic kidney disease SO RENAL FAILURE LA English DT Article DE Acute kidney injury; contrast; dialysis access; fistulogram; glomerular filtration rate ID CONTRAST-INDUCED NEPHROPATHY; CORONARY-ANGIOGRAPHY; ARTERIOVENOUS-FISTULA; RISK; MORTALITY; RADIOCONTRAST; INTERVENTION; OUTCOMES; INJURY; HEMODIALYSIS AB Background/aims: Contrast-induced acute kidney injury (CIAKI) is associated with an accelerated progression of underlying chronic kidney disease (CKD). We sought to characterize the rate of loss of kidney function following fistulography in patients with advanced CKD. Materials/methods: We identified all patients with stage 4 or 5 non-dialysis-dependent CKD who underwent fistulography with iodinated contrast for non-maturing arteriovenous fistulae between 1 January 2010 and 30 November 2011. We recorded all eGFR values measured during the 6 months prior to and 6 months following the procedure, the volume and type of contrast, use of intravenous fluid and N-acetylcysteine (NAC), and timing of dialysis initiation following the procedure. We used mixed linear regression with random effects to compare the composite slope of decline in eGFR prior to and following fistulography. Results: Overall, 27 patients underwent a total of 44 fistulograms. The mean age of the patients was 66 years and mean baseline eGFR was 16.7 +/- 5 mL/min/1.73m(2). Patients received a median volume of contrast of 12 mL [IQR 10-20]. None of the patients initiated acute dialysis within weeks following the procedure. In unadjusted analyses, there was no statistically significant change in the rate of decline in eGFR following fistulography compared to pre-procedure (0.14 mL/min/month versus -0.14 mL/min/month, p = 0.11). In analyses that adjusted for procedural, demographic and clinical variables, the decline in eGFR following fistulography was not statistically different than before the procedure (0.15 mL/min/month versus -0.14 mL/min/month, p = 0.11). Conclusions: Fistulography with small volumes of iodinated contrast in patients with advanced CKD does not result in more rapid progression of underlying CKD. C1 [Hill, Marlene; Travis, Lesli; Ward, Tina; Palevsky, Paul M.; Ramkumar, Mohan; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Mor, Maria K.; Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.; Ramkumar, Mohan; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, 7E Room 120,111F-U, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 25 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0886-022X J9 RENAL FAILURE JI Ren. Fail. PY 2013 VL 35 IS 6 BP 791 EP 795 DI 10.3109/0886022X.2013.794432 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 161MS UT WOS:000320197800001 PM 23713575 ER PT J AU Hartmann, AS Wilhelm, S AF Hartmann, Andrea Sabrina Wilhelm, Sabine TI Obsessive-Compulsive and related disorders in the light of the new DSM-5 criteria SO ZEITSCHRIFT FUR PSYCHIATRIE PSYCHOLOGIE UND PSYCHOTHERAPIE LA German DT Article DE obsessive-compulsive and related disorders; body dysmorphic disorder; dermatillomania; trichotillomania; hoarding ID BODY DYSMORPHIC DISORDER; COGNITIVE-BEHAVIORAL THERAPY; EMOTION RECOGNITION DEFICITS; BASAL GANGLIA VOLUMES; ANOREXIA-NERVOSA; TOURETTE-SYNDROME; SPECTRUM DISORDERS; EATING-DISORDERS; ANXIETY DISORDERS; FUNCTIONAL NEUROANATOMY AB Various research groups have repeatedly linked different disorders with obsessive-compulsive disorder (OCD) and postulated an OC-spectrum that contains all these disorders. In the course of the development of the new diagnostic criteria for DSM-5, research has increased to verify the OC-spectrum concept and to develop a new grouping of disorders that are currently classified elsewhere. This review summarizes disorders currently considered as candidates for inclusion in the OC-spectrum category, whether there should be an OC-spectrum category at all, and where this category should be located in the DSM-5. The OC spectrum DSM-5 workgroup currently suggests the inclusion of a separate category OC- and related disorders into DSM-5. The category is proposed to consist of OCD, body dysmorphic disorder, dermatillomania, trichotillomania, and hoarding. C1 [Hartmann, Andrea Sabrina] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hartmann, Andrea Sabrina] Harvard Univ, Sch Med, Boston, MA USA. RP Hartmann, AS (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,185 Cambridge St,Suite 2200, Boston, MA 02114 USA. EM ahartmann1@partners.org NR 122 TC 5 Z9 5 U1 5 U2 30 PU VERLAG HANS HUBER PI BERN 9 PA LANGGASS-STRASSE 76, CH-3000 BERN 9, SWITZERLAND SN 1661-4747 J9 Z PSYCHIATR PSYCH PS JI Z. Psychiatr. Psychol. Psychother. PY 2013 VL 61 IS 3 BP 141 EP 153 DI 10.1024/1661-4747/a000153 PG 13 WC Psychology, Clinical SC Psychology GA 162ZV UT WOS:000320306000002 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI The Corneal Incision SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID TRAUMATIC WOUND DEHISCENCE; HYDROGEL OCULAR BANDAGE; CATARACT-SURGERY; CONSTRUCTION; ASTIGMATISM; MANAGEMENT; PATIENT C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Romano, Mario R.] ESCRS, Paris, France. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 20 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 11 EP 17 PG 7 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200002 ER PT J AU Ingmanson, EJ May-Benson, TA Braccini, S Porton, I Bauman, ML AF Ingmanson, Ellen J. May-Benson, Teresa A. Braccini, Stephanie Porton, Ingrid Bauman, Margaret L. TI Changes in social behavior following the application of sensory-integration based therapy in a young adult female chimpanzee (Pan troglodytes). SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY LA English DT Meeting Abstract CT 82nd Annual Meeting of the American-Association-of-Physical-Anthropologists CY APR 09-13, 2013 CL Knoxville, TN SP Amer Assoc Phys Anthropologists C1 [Ingmanson, Ellen J.] Bridgewater State Univ, Bridgewater, MA USA. [Braccini, Stephanie; Porton, Ingrid] St Louis Zoo, Great Apes, St Louis, MO USA. [Bauman, Margaret L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Bauman, Margaret L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-9483 J9 AM J PHYS ANTHROPOL JI Am. J. Phys. Anthropol. PY 2013 VL 150 SU 56 SI SI BP 157 EP 157 PG 1 WC Anthropology; Evolutionary Biology SC Anthropology; Evolutionary Biology GA 132BR UT WOS:000318043201398 ER PT S AU Vatansever, F Kawakubo, M Chung, H Hamblin, MR AF Vatansever, Fatma Kawakubo, Masayoshi Chung, Hoon Hamblin, Michael R. BE Chen, WR TI Photodynamic therapy stimulates anti-tumor immune response in mouse models: the role of regulatory T-cells, anti-tumor antibodies, and immune attack on brain metastases SO BIOPHOTONICS AND IMMUNE RESPONSES VIII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Biophotonics and Immune Responses VIII CY FEB 04, 2013 CL San Francisco, CA SP SPIE DE photodynamic therapy; tumor-associated antigen; benzoporphyrin derivative; regulatory T-cells; immune response ID COLON-CARCINOMA; CANCER; CYCLOPHOSPHAMIDE; MICE; IMMUNOTHERAPY; LYMPHOCYTES; COMBINATION; REGRESSION; INDUCTION; UPDATE AB We have previously shown that photodynamic therapy mediated by a vascular regimen of benzoporphyrin derivative and 690nm light is capable of inducing a robust immune response in the mouse CT26.CL25 tumor model that contains a tumor-rejection antigen, beta-galactosidase (beta-gal). For the first time we show that PDT can stimulate the production of serum IgG antibodies against the beta-gal antigen. It is known that a common cause of death from cancer, particularly lung cancer, is brain metastases; especially the inoperable ones that do not respond to traditional cytotoxic therapies either. We asked whether PDT of a primary tumor could stimulate immune response that could attack the distant brain metastases. We have developed a mouse model of generating brain metastases by injecting CT26.CL25 tumor cells into the brain as well as injecting the same cancer cells under the skin at the same time. When the subcutaneous tumor was treated with PDT, we observed a survival advantage compared to mice that had untreated brain metastases alone. C1 [Vatansever, Fatma; Kawakubo, Masayoshi; Chung, Hoon; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu NR 47 TC 0 Z9 0 U1 0 U2 6 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9351-4 J9 PROC SPIE PY 2013 VL 8582 AR UNSP 858203 DI 10.1117/12.2001902 PG 10 WC Nanoscience & Nanotechnology; Optics SC Science & Technology - Other Topics; Optics GA BFG31 UT WOS:000319763000001 ER PT B AU Hariri, S Malchau, H AF Hariri, Sanaz Malchau, Henrik BA Parvizi, J Klatt, BA BF Parvizi, J Klatt, BA TI OUTCOMES OF PRIMARY AND COMPLEX PRIMARY HIPS SO ESSENTIALS IN TOTAL HIP ARTHROPLASTY LA English DT Article; Book Chapter ID QUALITY-OF-LIFE; ACETABULAR COMPONENT ORIENTATION; PREOPERATIVE FUNCTIONAL STATUS; TOTAL JOINT ARTHROPLASTY; TOTAL KNEE ARTHROPLASTY; FEMORAL COMPONENTS; SURFACE FINISH; EARLY DISLOCATION; SURGICAL APPROACH; UNITED-STATES C1 [Hariri, Sanaz] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Malchau, Henrik] Harvard Univ, Sch Med, Boston, MA USA. [Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Malchau, Henrik] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Malchau, Henrik] Massachusetts Gen Hosp, Dept Orthoped, Adult Reconstruct Unit, Boston, MA 02114 USA. RP Hariri, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. NR 79 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-870-8 PY 2013 BP 181 EP 189 PG 9 WC Orthopedics SC Orthopedics GA BFF94 UT WOS:000319708000022 ER PT J AU Han, LP Zhang, XX Geng, LN Li, MM Zhang, Y Wu, MX AF Han, Liping Zhang, Xiaoxue Geng, Lina Li, Mengmeng Zhang, Yi Wu, Mei X. TI The expression of immediate early response gene X-1 in preeclampsia placenta and its pro-apoptotic role in preeclampsia SO HYPERTENSION IN PREGNANCY LA English DT Article DE Apoptosis; human umbilical vein endothelial cell; immediate early response gene X-1; placenta; preeclampsia ID IEX-1 EXPRESSION; CELL-DEATH; ACTIVATION; CANCER AB The stress-inducible immediate early response gene X-1 (IEX-1) regulates cell proliferation and apoptosis in a cell type and stimulus-dependent manner. The aim of this study was to investigate IEX-1 expression in preeclampsia placenta and human umbilical vein endothelial cells (HUVECs) cultured in the serum isolated from preeclampsia patients, to explore its relationship with the pathogenesis of preeclampsia. Thirty preeclampsia patients with 10 cases in the moderate group, 20 cases in the severe group (PE group) and 20 cases of normal pregnant women (control group) were randomly obtained. Reverse transcriptase-polymerase chain reaction and immunohistochemistry showed that IEX-1 expression was significantly higher in preeclampsia patients than in normal pregnant women (p<0.05). There was also a significant difference between moderate and severe preeclampsia (p<0.05). IEX-1 protein was mainly present in cytoplasm of placental trophoblast cells and decidual cells. Compared with the normal pregnancy group, IEX-1 in the preeclampsia group was colored more obviously, and the color was strengthened in correlation with the severity of the disease using immunocytochemial method. Flow cytometry and MTT revealed that the serum isolated from preeclampsia patients appeared to promote IEX-1 expression in cytoplasm of HUVECs, inhibited the proliferation and promoted the apoptosis of HUVECs when compared to the serum of normal pregnant women. Our study demonstrates a correlation of IEX-1 expression levels with the severity of preeclampsia. Given a well-known function of IEX-1 in regulation of apoptosis, IEX-1 may be important in the pathogenesis of preeclampsia by regulating placental villous trophoblast and decidual cell apoptosis as well as participation in endothelial cell injury process. C1 [Han, Liping; Zhang, Xiaoxue; Geng, Lina; Li, Mengmeng] Zhengzhou Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China. [Zhang, Xiaoxue] Zhengzhou Univ, Inst Clin Med, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China. [Zhang, Yi] Zhengzhou Univ, Dept Biotherapy Ctr, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China. [Wu, Mei X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. RP Han, LP (reprint author), Zhengzhou Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China. EM hanlp0825@yahoo.com.cn NR 20 TC 1 Z9 2 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1064-1955 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2013 VL 32 IS 2 BP 157 EP 168 DI 10.3109/10641955.2013.784785 PG 12 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 155NW UT WOS:000319756100006 PM 23725081 ER PT J AU Rana, S Schnettler, WT Powe, C Wenger, J Salahuddin, S Cerdeira, AS Verlohren, S Perschel, FH Arany, Z Lim, KH Thadhani, R Karumanchi, SA AF Rana, Sarosh Schnettler, William T. Powe, Camille Wenger, Julia Salahuddin, Saira Cerdeira, Ana Sofia Verlohren, Stefan Perschel, Frank H. Arany, Zoltan Lim, Kee-Hak Thadhani, Ravi Karumanchi, S. Ananth TI Clinical characterization and outcomes of preeclampsia with normal angiogenic profile SO HYPERTENSION IN PREGNANCY LA English DT Article DE Adverse outcomes; Angiogenic factors; Non-angiogenic preeclampsia ID PLACENTAL GROWTH-FACTOR; MATERNAL PLASMA-CONCENTRATIONS; SUSPECTED PREECLAMPSIA; DEVELOP PREECLAMPSIA; SOLUBLE ENDOGLIN; RENAL-DISEASE; PREGNANCY; HYPERTENSION; DIAGNOSIS; KIDNEY AB Objective: To compare the clinical characteristics and outcomes of preeclamptic women presenting with a normal plasma angiogenic profile with those subjects who are characterized by an abnormal angiogenic profile. Methods: This was a secondary analysis of a prospective cohort study in women presenting to obstetrical triage at <37 weeks of gestation and diagnosed with preeclampsia within 2 weeks of enrollment and in whom angiogenic factors (sFlt1 and PlGF) measurements were available. Patients were divided into two groups based on their circulating levels of these factors described as a ratio; the sFlt1/PlGF ratio, non-angiogenic preeclampsia (sFlt1/PlGF ratio <85) and angiogenic preeclampsia (sFlt1/PlGF ratio >= 85). The data are presented by sFlt1/PlGF category using median and quartile 1-quartile 3 for continuous variables and by frequency and sample sizes for categorical variables. Results: In our cohort, the patients with non-angiogenic preeclampsia (N=46) were more obese [BMI: 35.2 (31.6, 38.7) versus 31.1 (28.0, 39.0), p = 0.04], more likely to have preexisting diabetes (21.7% versus 2.0%, p = 0.002) and presented at a later gestational age [35 (32, 37) versus 32 (29, 34) weeks, p<0.0001] as compared with women with angiogenic preeclampsia (N=51). Women with non-angiogenic preeclampsia had no serious adverse outcomes (elevated liver function tests/low platelets: 0% versus 23.5%, abruption: 0% versus 9.8%, pulmonary edema: 0% versus 3.9%, eclampsia: 0% versus 2.0 %, small for gestational age: 0% versus 17.7% and fetal/neonatal death: 0% versus 5.9%) as compared with women with angiogenic preeclampsia. The rate of preterm delivery <34 weeks was 8.7% in non-angiogenic preeclampsia compared with 64.7% in angiogenic preeclampsia (p<0.0001). Interestingly, delivery between 34 and 37 weeks and resource utilization (hospital admission days) were similar in the two groups. Conclusion: In contrast to the angiogenic form, the non-angiogenic form of preeclampsia is characterized by little to no risk of preeclampsia-related adverse outcomes, other than iatrogenic prematurity. Incorporation of angiogenic biomarkers in the evaluation of preeclampsia may allow accurate and early identification of severe disease. C1 [Rana, Sarosh; Schnettler, William T.; Salahuddin, Saira; Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Div Maternal Fetal Med, Dept Obstet & Gynecol, Boston, MA 02215 USA. [Rana, Sarosh; Schnettler, William T.; Salahuddin, Saira; Cerdeira, Ana Sofia; Arany, Zoltan; Karumanchi, S. Ananth] Harvard Univ, Sch Med, Boston, MA USA. [Powe, Camille] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA. [Wenger, Julia; Thadhani, Ravi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol,Dept Med, Boston, MA USA. [Cerdeira, Ana Sofia; Arany, Zoltan; Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Div Nephrol, Dept Med, Boston, MA 02215 USA. [Cerdeira, Ana Sofia] Gulbenkian Programme Adv Med Educ, Lisbon, Portugal. [Verlohren, Stefan] Charite, Dept Obstet, Campus Virchow Clin, D-13353 Berlin, Germany. [Perschel, Frank H.] Charite, Dept Lab Med Clin Chem & Pathobiochem, D-13353 Berlin, Germany. [Lim, Kee-Hak] Boston Maternal Fetal Med, Boston, MA USA. [Karumanchi, S. Ananth] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Rana, S (reprint author), Beth Israel Deaconess Med Ctr, Div Maternal Fetal Med, Dept Obstet & Gynecol, 330 Brookline Ave,Kirstein 382, Boston, MA 02215 USA. EM srana1@bidmc.harvard.edu OI Verlohren, Stefan/0000-0003-3507-8636 FU NIH/NICHD [K08HD068398-01A1]; Harvard Diversity and Community Partnership Faculty Fellowship, NIH/NICHD; Howard Hughes Medical Institute; Harvard Diversity and Community Partnership Faculty Fellowship Award FX Dr Verlohren has served as a consultant to Roche Diagnostics. Dr Thadhani is a co-inventor on patents related to the prediction of preeclampsia that has been out licensed to diagnostic companies and has financial interest in Aggamin LLC. Dr Karumanchi is a co-inventor of multiple patents related to angiogenic proteins for the diagnosis and therapy of preeclampsia. These patents have been licensed to multiple companies. Dr Karumanchi reports having served as a consultant to Roche and Beckman Coulter and has financial interest in Aggamin LLC. The remaining authors report no conflicts. S. R. is supported by Harvard Diversity and Community Partnership Faculty Fellowship Award and K08HD068398-01A1 (NIH/NICHD). This study was funded by Harvard Diversity and Community Partnership Faculty Fellowship, NIH/NICHD and Howard Hughes Medical Institute. NR 33 TC 38 Z9 39 U1 1 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1064-1955 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2013 VL 32 IS 2 BP 189 EP 201 DI 10.3109/10641955.2013.784788 PG 13 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 155NW UT WOS:000319756100009 PM 23725084 ER PT J AU Bhattacharyya, S Xue, LQ Devkota, S Chang, EG Morris, S Tobacman, JK AF Bhattacharyya, Sumit Xue, Liquan Devkota, Suzanne Chang, Eugene Morris, Stephan Tobacman, Joanne K. TI Carrageenan-Induced Colonic Inflammation Is Reduced in Bcl10 Null Mice and Increased in IL-10-Deficient Mice SO MEDIATORS OF INFLAMMATION LA English DT Article ID NF-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; INSULIN-RESISTANCE; MALT LYMPHOMA; ACTIVATION; PROTEIN; TOLL-LIKE-RECEPTOR-4; PATHWAY; MACROPHAGES; MUTATIONS AB The common food additive carrageenan is a known activator of inflammation in mammalian tissues and stimulates both the canonical and noncanonical pathways of NF-kappa B activation. Exposure to low concentrations of carrageenan (10 mu g/mL in the water supply) has produced glucose intolerance, insulin resistance, and impaired insulin signaling in C57BL/6 mice. B-cell leukemia/lymphoma 10 (Bcl10) is a mediator of inflammatory signals from Toll-like receptor (TLR) 4 in myeloid and epithelial cells. Since the TLR4 signaling pathway is activated in diabetes and by carrageenan, we addressed systemic and intestinal inflammatory responses following carrageenan exposure in Bcl10 wild type, heterozygous, and null mice. Fecal calprotectin and circulating keratinocyte chemokine (KC), nuclear RelA and RelB, phospho(Thr559)-NF-kappa B-inducing kinase (NIK), and phospho(Ser36)-I kappa B alpha in the colonic epithelial cells were significantly less (P < 0.001) in the carrageenan-treated Bcl10 null mice than in controls. IL-10-deficient mice exposed to carrageenan in a germ-free environment showed an increase in activation of the canonical pathway of NF-kappa B (RelA) activation, but without increase in RelB or phospho-Bcl10, and exogenous IL-10 inhibited only the canonical pathway of NF-kappa B activation in cultured colonic cells. These findings demonstrate a Bcl10 requirement for maximum development of carrageenan-induced inflammation and lack of complete suppression by IL-10 of carrageenan-induced inflammation. C1 [Bhattacharyya, Sumit; Tobacman, Joanne K.] Univ Illinois, Dept Med, Chicago, IL 60612 USA. [Bhattacharyya, Sumit; Tobacman, Joanne K.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA. [Xue, Liquan; Morris, Stephan] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA. [Devkota, Suzanne] Univ Chicago, Dept Med, Chicago, IL USA. [Chang, Eugene] Joslin Diabet Ctr, Boston, MA 02115 USA. RP Tobacman, JK (reprint author), Univ Illinois, Dept Med, 840 S Wood St,CSN 440 M C 718, Chicago, IL 60612 USA. EM jkt@uic.edu FU Veteran's Administration; DDRCC [DK42086, UH3 DK083993] FX Funding was by Merit Review from the Veteran's Administration to J. K. Tobacman and DDRCC (DK42086) and UH3 DK083993 to E. Chang for the support of the gnotobiotic facility. The authors thank Dr. Susan Ball-Kell for her evaluation of the gastrointestinal pathology in the mice. NR 50 TC 5 Z9 5 U1 0 U2 3 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 0962-9351 EI 1466-1861 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2013 AR UNSP 397642 DI 10.1155/2013/397642 PG 13 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 162CI UT WOS:000320241600001 ER PT J AU Koziej, D Floryan, C Sperling, RA Ehrlicher, AJ Issadore, D Westervelt, R Weitz, DA AF Koziej, Dorota Floryan, Caspar Sperling, Ralph A. Ehrlicher, Allen J. Issadore, David Westervelt, Robert Weitz, David A. TI Microwave dielectric heating of non-aqueous droplets in a microfluidic device for nanoparticle synthesis SO NANOSCALE LA English DT Article ID NANOSTRUCTURED TUNGSTEN-OXIDE; TEMPERATURE-MEASUREMENT; BENZYL ALCOHOL; CHEMISTRY; FLUORESCENCE; SYSTEMS; NANOCRYSTALS; THERMOMETRY; CLUSTERS; SIZE AB We describe a microfluidic device with an integrated microwave heater specifically designed to dielectrically heat non-aqueous droplets using time-varying electrical fields with the frequency range between 700 and 900 MHz. The precise control of frequency, power, temperature and duration of the applied field opens up new vistas for experiments not attainable by conventional microwave heating. We use a non-contact temperature measurement system based on fluorescence to directly determine the temperature inside a single droplet. The maximum temperature achieved of the droplets is 50 degrees C in 15 ms which represents an increase of about 25 degrees C above the base temperature of the continuous phase. In addition we use an infrared camera to monitor the thermal characteristics of the device allowing us to ensure that heating is exclusively due to the dielectric heating and not due to other effects like non-dielectric losses due to electrode or contact imperfection. This is crucial for illustrating the potential of dielectric heating of benzyl alcohol droplets for the synthesis of metal oxides. We demonstrate the utility of this technology for metal oxide nanoparticle synthesis, achieving crystallization of tungsten oxide nanoparticles and remarkable microstructure, with a reaction time of 64 ms, a substantial improvement over conventional heating methods. C1 [Koziej, Dorota; Floryan, Caspar; Sperling, Ralph A.; Ehrlicher, Allen J.; Westervelt, Robert; Weitz, David A.] Harvard Univ, Dept Phys, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Koziej, Dorota] ETH, Dept Mat, Lab Multifunct Mat, CH-8093 Zurich, Switzerland. [Issadore, David] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Issadore, David] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. RP Koziej, D (reprint author), Harvard Univ, Dept Phys, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. EM koziejd@mat.ethz.ch RI Sperling, Ralph /I-7050-2013; Issadore, David/L-8451-2014; Koziej, Dorota/P-7957-2016; OI Sperling, Ralph /0000-0002-8027-0697; /0000-0002-9064-2642 FU NSF [DMR-1006546]; Harvard MRSEC [DMR-0820484]; Swiss National Foundation [PA00P2 129086, 2-77354-12]; Electron Microscopy of ETH Zurich (EMEZ) FX This work was supported by the NSF (DMR-1006546) the Harvard MRSEC (DMR-0820484), the Swiss National Foundation, projects: PA00P2 129086 and 2-77354-12 and by the Electron Microscopy of ETH Zurich (EMEZ). Martin Suess (EMEZ) help with HR-TEM and Rahel Boehlen support with the soft-litography are greatly acknowledged. DK thanks Prof. Markus Niederberger (ETH Zurich) for his enthusiastic support. NR 46 TC 10 Z9 10 U1 5 U2 57 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2040-3364 J9 NANOSCALE JI Nanoscale PY 2013 VL 5 IS 12 BP 5468 EP 5475 DI 10.1039/c3nr00500c PG 8 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA 155NX UT WOS:000319756200043 PM 23670701 ER PT J AU La Fountaine, MF Wecht, JM Cirnigliaro, CM Kirshblum, SC Spungen, AM Bauman, WA AF La Fountaine, Michael F. Wecht, Jill M. Cirnigliaro, Christopher M. Kirshblum, Steven C. Spungen, Ann M. Bauman, William A. TI Testosterone Replacement Therapy Improves QTaVI in Hypogonadal Men with Spinal Cord Injury SO NEUROENDOCRINOLOGY LA English DT Article DE Spinal cord injury; Hypogonadism; Testosterone; QT interval; Autonomic nervous system; QT variance ID AUTONOMIC NERVOUS-SYSTEM; QT INTERVAL VARIABILITY; VENTRICULAR REPOLARIZATION; HEART-RATE; CARDIOVASCULAR-DISEASE; HEALTHY-MEN; RISK; TETRAPLEGIA; EXPRESSION; MORTALITY AB Aim: To determine the effect of a 12-month intent-to-treat testosterone (T) replacement therapy (TRT) trial on QTa interval variability (QTaVI) in hypogonadal (HG) men with spinal cord injury (SCI). Method: A prospective, controlled 12-month TRT trial was completed in 22 healthy, chronic, nonambulatory men with SCI. Based on serum T concentration, subjects were designated as HG (<= 11.3 nmol/l) or eugonadal (EG >= 11.4 nmol/l). Digital 3-lead electrocardiograms were performed. Heart rate (RR), heart rate variability [including total power (TPRR), low frequency (LFRR) and high frequency (HFRR)], QTa, QTe, and RT intervals, QTC (Bazett formula), QTVN, and QTaVI were calculated and evaluated at baseline and at 12 months. Lipoprotein profiles (triglycerides, total cholesterol, low-density and high-density lipoproteins) were obtained at the respective time points. Results: Based on serum T concentration, 13 subjects were designated as HG and 11 as EG. During the trial, there were no group differences for RR, QTa, QTe or RT intervals, QTC, TPRR, HFRR, or lipoproteins. The HG group was older (p < 0.05) and their LFRR was lower (p < 0.05) at baseline. At baseline, QTaVI was significantly greater in the HG group compared to the EG group [-0.17 (0.92) vs. -1.07 (0.90); p < 0.05]. After TRT, this group difference was no longer present [-0.44 (0.87) vs. -0.65 (0.85)] and the change in the HG group was significant (p < 0.05). Conclusion: Hypogonadism in men with SCI was associated with elevated QTaVI at baseline. After 12 months of physiological TRT, the QTaVI improved in association with raising T into the normal range. These findings occurred independently of the prolongation of the QT interval. Copyright (C) 2013 S. Karger AG, Basel C1 [La Fountaine, Michael F.; Wecht, Jill M.; Cirnigliaro, Christopher M.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences Spinal Co, Bronx, NY 10468 USA. [La Fountaine, Michael F.; Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [La Fountaine, Michael F.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Hosp, Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Hosp, Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA. RP La Fountaine, MF (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Room 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM michael.lafountaine@va.gov NR 31 TC 1 Z9 1 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2013 VL 97 IS 4 BP 341 EP 346 DI 10.1159/000347070 PG 6 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 161BV UT WOS:000320166900007 PM 23343764 ER PT J AU Whelan, SP Zuckerbraun, BS AF Whelan, Sean P. Zuckerbraun, Brian S. TI Mitochondrial Signaling: Forwards, Backwards, and In Between SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY LA English DT Review ID UNFOLDED PROTEIN RESPONSE; INDUCED ROS RELEASE; RETROGRADE RESPONSE; SACCHAROMYCES-CEREVISIAE; STRESS RESPONSES; GENE-EXPRESSION; RNA-POLYMERASE; CELL-DEATH; ACTIVATION; YEAST AB Mitochondria are semiautonomous organelles that are a defining characteristic of almost all eukaryotic cells. They are vital for energy production, but increasing evidence shows that they play important roles in a wide range of cellular signaling and homeostasis. Our understanding of nuclear control of mitochondrial function has expanded over the past half century with the discovery of multiple transcription factors and cofactors governing mitochondrial biogenesis. More recently, nuclear changes in response to mitochondrial messaging have led to characterization of retrograde mitochondrial signaling, in which mitochondria have the ability to alter nuclear gene expression. Mitochondria are also integral to other components of stress response or quality control including ROS signaling, unfolded protein response, mitochondrial autophagy, and biogenesis. These avenues of mitochondrial signaling are discussed in this review. C1 [Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Gen Surg, Pittsburgh, PA 15206 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Dept Gen Surg, F1200 PUH,200 Lothrop St, Pittsburgh, PA 15206 USA. EM zuckerbraunbs@upmc.edu NR 85 TC 5 Z9 5 U1 0 U2 9 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1942-0900 EI 1942-0994 J9 OXID MED CELL LONGEV JI Oxidative Med. Cell. Longev. PY 2013 AR UNSP 351613 DI 10.1155/2013/351613 PG 10 WC Cell Biology SC Cell Biology GA 162FT UT WOS:000320251600001 ER PT J AU Simpson, KN Pei, PP Moller, J Baran, RW Dietz, B Woodward, W Migliaccio-Walle, K Caro, JJ AF Simpson, Kit N. Pei, Pamela P. Moeller, Joergen Baran, Robert W. Dietz, Birgitta Woodward, William Migliaccio-Walle, Kristen Caro, J. Jaime TI Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States SO PHARMACOECONOMICS LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; EXPERIENCED HIV-1-INFECTED PATIENTS; IMMUNODEFICIENCY-VIRUS-INFECTION; ONCE-DAILY DARUNAVIR/RITONAVIR; DISCRETE-EVENT SIMULATION; CARDIOVASCULAR-DISEASE; TREATMENT-NAIVE; VIROLOGICAL FAILURES; PROTEASE INHIBITORS; CONTROLLED-TRIAL AB Background The ARTEMIS trial compared first-line antiretroviral therapy (ART) with lopinavir/ritonavir (LPV/r) to darunavir plus ritonavir (DRV + RTV) for HIV-1-infected subjects. In order to fully assess the implications of this study, economic modelling extrapolating over a longer term is required. Objective The aim of this study was to simulate the course of HIV and its management, including the multiple factors known to be of importance in ART. Methods A comprehensive discrete event simulation was created to represent, as realistically as possible, ART management and HIV outcomes. The model was focused on patients for whom clinicians believed that LPV/r or DRV + RTV were good options as a first regimen. Prognosis was determined by the impact of initial treatment on baseline CD4+ T-cell count and viral load, adherence, virological suppression/failure/rebound, acquired resistance mutations, and ensuing treatment changes. Inputs were taken from trial data (ARTEMIS), literature and, where necessary, stated assumptions. Clinical measures included AIDS events, side effects, time on sequential therapies, cardiovascular events, and expected life-years lost as a result of HIV infection. The model underwent face, technical and partial predictive validation. Treatment-naive individuals similar to those in the ARTEMIS trial were modelled over a lifetime, and outcomes with first-line DRV + RTV were compared with those with LPV/r, both paired with tenofovir and emtricitabine. Up to three regimen changes were permitted. Drug prices were based on wholesale acquisition cost. Outcomes were lifetime healthcare costs (in 2011 US dollars) from the US healthcare system perspective and quality-adjusted life-years (QALYs) (discounted at 3 % per annum). Results Choice of LPV/r over DRV + RTV as initial ART resulted in nearly identical clinical outcomes, but distinctly different economic consequences. Starting with an LPV/r regimen potentially results in approximately US$25,000 discounted lifetime savings. Accumulated QALYs for LPV/r and DRV + RTV were 12.130 and 12.083, respectively (a 19-day difference). In sensitivity analyses, net monetary benefit ranged from US$12,000 to US$31,000, favouring LPV/r (base case US$27,762). Conclusions A comprehensive simulation of lifetime course of HIV in the USA indicated that using LPV/r as first-line therapy compared with DRV + RTV may result in cost savings, with similar clinical outcomes. C1 [Simpson, Kit N.] Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Leadership & Management, Charleston, SC 29425 USA. [Pei, Pamela P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Pei, Pamela P.; Migliaccio-Walle, Kristen; Caro, J. Jaime] United BioSource Corp, Lexington, MA USA. [Moeller, Joergen] United BioSource Corp, London, England. [Baran, Robert W.; Woodward, William] Abbott Labs, Abbott Pk, IL 60064 USA. [Dietz, Birgitta] Abbott GmbH & Co KG, Ludwigshafen, Germany. [Migliaccio-Walle, Kristen] Massachusetts Gen Hosp, Inst Clin & Econ Review, Boston, MA 02114 USA. [Caro, J. Jaime] McGill Univ, Fac Med, Montreal, PQ, Canada. RP Simpson, KN (reprint author), Med Univ S Carolina, Coll Hlth Profess, Dept Hlth Leadership & Management, 151B Rutledge Ave,Room 412, Charleston, SC 29425 USA. EM simpsonk@musc.edu OI Caro, Jaime/0000-0001-5470-3754 FU Abbott Laboratories FX This study was funded by Abbott Laboratories. K.N.S. was a paid consultant. P.P.P., J.M., K.M.-W. and J.J.C. were employees of a consultancy (United BioSource Corporation) that received funds for carrying out this work. R.W.B., B.D. and W.W. were all Abbott employees when this research was conducted. B.D., W.W. and R.W.B. hold stock in Abbott Laboratories. K.N.S., B.D., R.W.B. and J.J.C. conceived the original idea for the research. J.M., J.J.C., P.P.P. and K.N.S. developed the conceptual model. P.P.P., K.M.-W. and K.N.S. performed the data extraction for the evidence tables. W.W., B.D. and R.W.B. reviewed the conceptual model and evidence. J.M. and P.P.P. programmed the model and performed the analyses. P.P.P., J.M. and K.M.-W. drafted the manuscript. All authors reviewed, edited and made significant contributions to the final manuscript. K.N.S. acts as guarantor for the overall content. NR 74 TC 8 Z9 8 U1 1 U2 13 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-7690 J9 PHARMACOECONOMICS JI Pharmacoeconomics PY 2013 VL 31 IS 5 BP 427 EP 444 DI 10.1007/s40273-013-0048-3 PG 18 WC Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy GA 155AX UT WOS:000319718900009 PM 23620210 ER PT J AU Seah, DSE Cheong, TZ Anstey, MHR AF Seah, Davinia S. E. Cheong, Timothy Z. Anstey, Matthew H. R. TI The hidden cost of private health insurance in Australia SO AUSTRALIAN HEALTH REVIEW LA English DT Editorial Material AB The provision of health services in Australia currently is primarily financed by a unique interaction of public and private insurers. This commentary looks at a loophole in this framework, namely that private insurers have to date been able to avoid funding healthcare for some of their policy holders, as it is not a requirement to use private insurance when treatment occurs in Australian public hospitals. C1 [Seah, Davinia S. E.] Dana Farber Canc Inst, Boston, MA 02446 USA. [Cheong, Timothy Z.] Royal Victorian Eye & Ear Hosp, East Melbourne, Vic 3002, Australia. [Anstey, Matthew H. R.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. RP Anstey, MHR (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, W CC 470,1 Deaconess Rd, Boston, MA 02115 USA. EM Davinia_Seah@dfci.harvard.edu; timothy.cheong@eyeandear.org.au; manstey@bidmc.harvard.edu NR 29 TC 0 Z9 0 U1 0 U2 7 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 0156-5788 J9 AUST HEALTH REV JI Aust. Health Rev. PY 2013 VL 37 IS 1 BP 1 EP 3 DI 10.1071/AH11126 PG 3 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 146RS UT WOS:000319109100001 PM 23199697 ER PT J AU Claxton, A Baker, LD Wilkinson, CW Trittschuh, EH Chapman, D Watson, GS Cholerton, B Plymate, SR Arbuckle, M Craft, S AF Claxton, Amy Baker, Laura D. Wilkinson, Charles W. Trittschuh, Emily H. Chapman, Darla Watson, G. Stennis Cholerton, Brenna Plymate, Stephen R. Arbuckle, Matthew Craft, Suzanne TI Sex and ApoE Genotype Differences in Treatment Response to Two Doses of Intranasal Insulin in Adults with Mild Cognitive Impairment or Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; insulin; intranasal drug administration; mild cognitive impairment; randomized clinical trials ID APOLIPOPROTEIN-E GENOTYPE; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; GLUCOSE-METABOLISM; RATING-SCALE; OLDER-ADULTS; MEMORY; BRAIN; SENSITIVITY; DEMENTIA AB A previous clinical trial demonstrated that four months of treatment with intranasal insulin improves cognition and function for patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI), but prior studies suggest that response to insulin treatment may differ by sex and ApoE epsilon 4 carriage. Thus, responder analyses using repeated measures analysis of covariance were completed on the trial's 104 participants with MCI or AD who received either placebo or 20 or 40 IU of insulin for 4 months, administered by a nasal delivery device. Results indicate that men and women with memory impairment responded differently to intranasal insulin treatment. On delayed story memory, men and women showed cognitive improvement when taking 20 IU of intranasal insulin, but only men showed cognitive improvement for the 40 IU dose. The sex difference was most apparent for ApoE epsilon 4 negative individuals. For the 40 IU dose, ApoE epsilon 4 negative men improved while ApoE epsilon 4 negative women worsened. Their ApoE epsilon 4 positive counterparts remained cognitively stable. This sex effect was not detected in functional measures. However, functional abilities were relatively preserved for women on either dose of intranasal insulin compared with men. Unlike previous studies with young adults, neither men nor women taking intranasal insulin exhibited a significant change in weight over 4 months of treatment. C1 [Claxton, Amy; Wilkinson, Charles W.; Trittschuh, Emily H.; Chapman, Darla; Watson, G. Stennis; Cholerton, Brenna; Plymate, Stephen R.; Arbuckle, Matthew] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Claxton, Amy; Wilkinson, Charles W.; Trittschuh, Emily H.; Chapman, Darla; Watson, G. Stennis; Cholerton, Brenna; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Baker, Laura D.; Craft, Suzanne] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA. RP Craft, S (reprint author), Wake Forest Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM suzcraft@wakehealth.edu FU National Institute of Aging [AG027415, T32 AG000258]; Department of Veterans Affairs; Veterans Affairs Puget Sound Health Care System, Seattle, Washington FX This research was supported by National Institute of Aging grants AG027415 (to Dr. Craft) and T32 AG000258 (to Dr. Claxton), and the Department of Veterans Affairs. This material is the result of work supported in part by resources from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 43 TC 37 Z9 38 U1 2 U2 14 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 35 IS 4 BP 789 EP 797 DI 10.3233/JAD-122308 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 149TW UT WOS:000319345300012 PM 23507773 ER PT J AU Frohlich, EM Alonso, JL Borenstein, JT Zhang, X Arnaout, MA Charest, JL AF Frohlich, Else M. Alonso, Jose Luis Borenstein, Jeffrey T. Zhang, Xin Arnaout, M. Amin Charest, Joseph L. TI Topographically-patterned porous membranes in a microfluidic device as an in vitro model of renal reabsorptive barriers SO LAB ON A CHIP LA English DT Article ID TISSUE ENGINEERING APPLICATIONS; SCANNING-ELECTRON-MICROSCOPY; EPITHELIAL-CELLS; PRIMARY CILIUM; BASEMENT-MEMBRANES; BASAL LAMINA; SCAFFOLDS; FABRICATION; DIFFERENTIATION; NANOTOPOGRAPHY AB Models of reabsorptive barriers require both a means to provide realistic physiologic cues to and quantify transport across a layer of cells forming the barrier. Here we have topographically-patterned porous membranes with several user-defined pattern types. To demonstrate the utility of the patterned membranes, we selected one type of pattern and applied it to a membrane to serve as a cell culture support in a microfluidic model of a renal reabsorptive barrier. The topographic cues in the model resemble physiological cues found in vivo while the porous structure allows quantification of transport across the cell layer. Sub-micron surface topography generated via hot-embossing onto a track-etched polycarbonate membrane, fully replicated topographical features and preserved porous architecture. Pore size and shape were analyzed with SEM and image analysis to determine the effect of hot embossing on pore morphology. The membrane was assembled into a bilayer microfluidic device and a human kidney proximal tubule epithelial cell line (HK-2) and primary renal proximal tubule epithelial cells (RPTEC) were cultured to confluency on the membrane. Immunofluorescent staining of both cell types revealed protein expression indicative of the formation of a reabsorptive barrier responsive to mechanical stimulation: ZO-1 (tight junction), paxillin (focal adhesions) and acetylated a-tubulin (primary cilia). HK-2 and RPTEC aligned in the direction of ridge/groove topography of the membrane in the device, evidence that the device has mechanical control over cell response. This topographically-patterned porous membrane provides an in vitro platform on which to model reabsorptive barriers with meaningful applications for understanding biological transport phenomenon, underlying disease mechanisms, and drug toxicity. C1 [Frohlich, Else M.; Zhang, Xin] Boston Univ, Dept Mech Engn, Boston, MA 02215 USA. [Alonso, Jose Luis; Arnaout, M. Amin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol, Charlestown, MA 02129 USA. [Frohlich, Else M.; Borenstein, Jeffrey T.; Charest, Joseph L.] Charles Stark Draper Lab Inc, Biomed Engn Grp, Cambridge, MA 02139 USA. RP Charest, JL (reprint author), Charles Stark Draper Lab Inc, Biomed Engn Grp, 555 Technol Sq, Cambridge, MA 02139 USA. EM jcharest@draper.com RI Zhang, Xin/B-9244-2009 OI Zhang, Xin/0000-0002-4413-5084 FU Draper Laboratory; Draper University FX This work was funded by the Draper Laboratory Internal Research and Development program for Draper and a Draper University Research and Development program for MGH. NR 51 TC 13 Z9 13 U1 4 U2 50 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2013 VL 13 IS 12 BP 2311 EP 2319 DI 10.1039/c3lc50199j PG 9 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 148YS UT WOS:000319285500012 PM 23636129 ER PT B AU Dunphy, CH Hasserjian, RP George, TI AF Dunphy, Cherie H. Hasserjian, Robert P. George, Tracy I. BA Dunphy, CH BF Dunphy, CH TI Myeloproliferative Neoplasms SO NEOPLASTIC HEMATOPATHOLOGY: AN ATLAS AND CONCISE GUIDE LA English DT Article; Book Chapter ID CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; JAK2 V617F MUTATION; MAST-CELL SARCOMA; INTERNATIONAL WORKING GROUP; IMATINIB MESYLATE THERAPY; BONE-MARROW BIOPSIES; ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS; CLONAL CYTOGENETIC ABNORMALITIES C1 [Dunphy, Cherie H.] Lab Corp Amer, Ctr Mol Biol & Pathol, Res Triangle Pk, NC USA. [Dunphy, Cherie H.] Univ N Carolina, Chapel Hill, NC USA. [Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [George, Tracy I.] LPCH, Mary Johnson Pediat Ambulatory Care Ctr Lab, Stanford, CA USA. [George, Tracy I.] LPCH, Bass Ctr Lab, Stanford, CA USA. [George, Tracy I.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA. [George, Tracy I.] Stanford Univ, Med Ctr, RBC Special Studies Lab, Stanford, CA 94305 USA. RP Dunphy, CH (reprint author), Lab Corp Amer, Ctr Mol Biol & Pathol, Res Triangle Pk, NC USA. NR 146 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-63-5 PY 2013 BP 25 EP 72 PG 48 WC Hematology; Pathology SC Hematology; Pathology GA BFD79 UT WOS:000319299600002 ER PT J AU Lee, HW Lawton, C Na, YJ Yoon, S AF Lee, Hae Woo Lawton, Carl Na, Young Jeong Yoon, Seongkyu TI Robustness of chemometrics-based feature selection methods in early cancer detection and biomarker discovery SO STATISTICAL APPLICATIONS IN GENETICS AND MOLECULAR BIOLOGY LA English DT Article DE biomarker discovery; chemometrics; early detection; feature selection; omics; ovarian cancer; reproducibility; stability ID CARLO CROSS-VALIDATION; SELDI-TOF MS; VARIABLE SELECTION; OVARIAN-CANCER; BREAST-CANCER; WAVELENGTH SELECTION; MULTIVARIATE CALIBRATION; MASS-SPECTROMETRY; SERUM BIOMARKERS; STABILITY AB In omics studies aimed at the early detection and diagnosis of cancer, bioinformatics tools play a significant role when analyzing high dimensional, complex datasets, as well as when identifying a small set of biomarkers. However, in many cases, there are ambiguities in the robustness and the consistency of the discovered biomarker sets, since the feature selection methods often lead to irreproducible results. To address this, both the stability and the classification power of several chemometrics-based feature selection algorithms were evaluated using the Monte Carlo sampling technique, aiming at finding the most suitable feature selection methods for early cancer detection and biomarker discovery. To this end, two data sets were analyzed, which comprised of MALDI-TOF-MS and LC/TOF-MS spectra measured on serum samples in order to diagnose ovarian cancer. Using these datasets, the stability and the classification power of multiple feature subsets found by different feature selection methods were quantified by varying either the number of selected features, or the number of samples in the training set, with special emphasis placed on the property of stability. The results show that high consistency does not necessarily guarantee high predictive power. In addition, differences in the stability, as well as agreement in feature lists between several feature selection methods, depend on several factors, such as the number of available samples, feature sizes, quality of the information in the dataset, etc. Among the tested methods, only the variable importance in projection (VIP)-based method shows complementary properties, providing both highly consistent and accurate subsets of features. In addition, successive projection analysis (SPA) was excellent with regards to maintaining high stability over a wide range of experimental conditions. The stability of several feature selection methods is highly variable, stressing the importance of making the proper choice among feature selection methods. Therefore, rather than evaluating the selected features using only classification accuracy, stability measurements should be examined as well to improve the reliability of biomarker discovery. C1 [Lee, Hae Woo; Lawton, Carl; Yoon, Seongkyu] Univ Massachusetts, Dept Chem Engn, Lowell, MA 01854 USA. [Na, Young Jeong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Yoon, S (reprint author), Univ Massachusetts, Dept Chem Engn, Lowell, MA 01854 USA. EM Seongkyu_Yoon@uml.edu NR 68 TC 1 Z9 1 U1 1 U2 13 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-6302 J9 STAT APPL GENET MOL JI Stat. Appl. Genet. Mol. Biol. PY 2013 VL 12 IS 2 BP 207 EP 223 DI 10.1515/sagmb-2012-0067 PG 17 WC Biochemistry & Molecular Biology; Mathematical & Computational Biology; Statistics & Probability SC Biochemistry & Molecular Biology; Mathematical & Computational Biology; Mathematics GA 150MM UT WOS:000319394900005 PM 23502343 ER PT S AU Badalian-Very, G Vergilio, JA Fleming, M Rollins, BJ AF Badalian-Very, Gayane Vergilio, Jo-Anne Fleming, Mark Rollins, Barrett J. BE Abbas, AK Galli, SJ Howley, PM TI Pathogenesis of Langerhans Cell Histiocytosis SO ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8 SE Annual Review of Pathology-Mechanisms of Disease LA English DT Review; Book Chapter DE dendritic cells; BRAF ID CHEMOKINE RECEPTOR EXPRESSION; LA MICROSCOPIE ELECTRONIQUE; DENDRITIC CELLS; BONE-MARROW; MONOCLONAL-ANTIBODIES; EOSINOPHILIC GRANULOMA; SOLITARY GRANULOMA; ADHESION MOLECULES; MEMBRANOUS BONES; BRAF MUTATIONS AB Langerhans cell histiocytosis (LCH) combines in one nosological category a group of diseases that have widely disparate clinical manifestations but are all characterized by accumulation of proliferating cells with surface markers and ultrastructural features similar to cutaneous Langerhans cells (LCs). Despite this unified nosology, important questions about LCH remain unanswered. First, despite having phenotypic features of LCs, LCH cell gene-expression patterns differ from those in LCs. Although this observation suggests that LCH may arise from an earlier precursor, it is not necessarily inconsistent with the hypothesis that LCs are the cell of origin for LCH. Second, LCH's prominent inflammatory component and occasional benign clinical course suggest that LCH may not be a neoplasm. However, the demonstration that LCH cells are clonal, along with the recent discovery of activating BRAF mutations in LCH cells, strongly suggests that LCH is a neoplastic disease. These new observations point the way to rationally targeted therapies. C1 [Badalian-Very, Gayane; Rollins, Barrett J.] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA. [Badalian-Very, Gayane; Rollins, Barrett J.] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA 02215 USA. [Vergilio, Jo-Anne] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA. [Fleming, Mark] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Fleming, Mark] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Badalian-Very, G (reprint author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA. EM gayane_badalianvery@dfci.harvard.edu; jvergili@med.umich.edu; Mark.Fleming@childrens.harvard.edu; barrett_rollins@dfci.harvard.edu NR 119 TC 46 Z9 48 U1 1 U2 13 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1553-4006 BN 978-0-8243-4308-8 J9 ANNU REV PATHOL-MECH JI Annu. Rev. Pathol.-Mech Dis. PY 2013 VL 8 BP 1 EP 20 DI 10.1146/annurev-pathol-020712-163959 PG 20 WC Pathology SC Pathology GA BEX15 UT WOS:000318483400001 PM 22906202 ER PT S AU Lindsley, RC Ebert, BL AF Lindsley, R. Coleman Ebert, Benjamin L. BE Abbas, AK Galli, SJ Howley, PM TI Molecular Pathophysiology of Myelodysplastic Syndromes SO ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8 SE Annual Review of Pathology-Mechanisms of Disease LA English DT Review; Book Chapter DE RNA splicing; cytogenetic; epigenetic; mutation ID ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; HEMATOPOIETIC STEM-CELLS; THERAPY-RELATED MYELODYSPLASIA; METHYLTRANSFERASE GENE EZH2; FAMILIAL PLATELET DISORDER; ISOLATED ISOCHROMOSOME 17Q; PROGNOSTIC SCORING SYSTEM; HIGH-RISK; SOMATIC MUTATIONS AB The clinicopathologic heterogeneity of myelodysplastic syndromes (MDS) is driven by diverse, somatically acquired genetic abnormalities. Recent technological advances have enabled the identification of many new mutations, which have implicated novel pathways in MDS pathogenesis, including RNA splicing and epigenetic regulation of gene expression. Molecular abnormalities, either somatic point mutations or chromosomal lesions, can be identified in the vast majority of MDS cases and underlie specific disease phenotypes. As the full array of molecular abnormalities is characterized, genetic variables are likely to complement standard morphologic evaluation in future MDS classification schemes and risk models. C1 [Lindsley, R. Coleman; Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02215 USA. [Lindsley, R. Coleman; Ebert, Benjamin L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Lindsley, RC (reprint author), Brigham & Womens Hosp, Div Hematol, Boston, MA 02215 USA. EM bebert@partners.org; rlindsley@partners.org OI Lindsley, Coleman/0000-0001-9822-806X FU NCI NIH HHS [T32 CA009172]; NHLBI NIH HHS [R01 HL082945] NR 148 TC 23 Z9 25 U1 1 U2 5 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1553-4006 BN 978-0-8243-4308-8 J9 ANNU REV PATHOL-MECH JI Annu. Rev. Pathol.-Mech Dis. PY 2013 VL 8 BP 21 EP 47 DI 10.1146/annurev-pathol-011811-132436 PG 27 WC Pathology SC Pathology GA BEX15 UT WOS:000318483400002 PM 22934674 ER PT S AU Almendro, V Marusyk, A Polyak, K AF Almendro, Vanessa Marusyk, Andriy Polyak, Kornelia BE Abbas, AK Galli, SJ Howley, PM TI Cellular Heterogeneity and Molecular Evolution in Cancer SO ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8 SE Annual Review of Pathology-Mechanisms of Disease LA English DT Review; Book Chapter DE intratumor heterogeneity; clonal selection; cancer stem cells; Darwinian evolution; biomarkers ID IN-SITU HYBRIDIZATION; POLYMERASE-CHAIN-REACTION; GENE-EXPRESSION PROFILES; CHRONIC MYELOID-LEUKEMIA; PRIMARY BREAST-CANCER; SURROGATE END-POINTS; LUNG-CANCER; INTRATUMOR HETEROGENEITY; TUMOR HETEROGENEITY; CLONAL EVOLUTION AB Intratumor heterogeneity represents a major obstacle to effective cancer treatment and personalized medicine. However, investigators are now elucidating intratumor heterogeneity at the single-cell level due to improvements in technologies. Better understanding of the composition of tumors, and monitoring changes in cell populations during disease progression and treatment, will improve cancer diagnosis and therapeutic design. Measurements of intratumor heterogeneity may also be used as biomarkers to predict the risk of progression and therapeutic resistance. We summarize important considerations related to intratumor heterogeneity during tumor evolution. We also discuss experimental approaches that are commonly used to infer intratumor heterogeneity and describe how these methodologies can be translated into clinical practice. C1 [Almendro, Vanessa; Marusyk, Andriy; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA. [Almendro, Vanessa; Marusyk, Andriy; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. [Almendro, Vanessa] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Med Oncol, E-08036 Barcelona, Spain. RP Almendro, V (reprint author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA. EM Vanessa_Almendro@dfci.harvard.edu; Andriy_Marusyk@dfci.harvard.edu; Kornelia_Polyak@dfci.harvard.edu FU NCI NIH HHS [P01 CA80111] NR 153 TC 142 Z9 147 U1 14 U2 82 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1553-4006 BN 978-0-8243-4308-8 J9 ANNU REV PATHOL-MECH JI Annu. Rev. Pathol.-Mech Dis. PY 2013 VL 8 BP 277 EP 302 DI 10.1146/annurev-pathol-020712-163923 PG 26 WC Pathology SC Pathology GA BEX15 UT WOS:000318483400011 PM 23092187 ER PT J AU Cholerton, BA Zabetian, CP Quinn, JF Chung, KA Peterson, A Espay, AJ Revilla, FJ Devoto, J Watson, GS Hu, SC Edwards, KL Montine, TJ Leverenz, JB AF Cholerton, Brenna A. Zabetian, Cyrus P. Quinn, Joseph F. Chung, Kathryn A. Peterson, Amie Espay, Alberto J. Revilla, Fredy J. Devoto, Johnna Watson, G. Stennis Hu, Shu-Ching Edwards, Karen L. Montine, Thomas J. Leverenz, James B. TI Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics SO JOURNAL OF PARKINSONS DISEASE LA English DT Article DE Cognition; cohort studies; dementia; mild cognitive impairment; movement disorders; Parkinson disease ID MILD COGNITIVE IMPAIRMENT; PARKINSONS-DISEASE; DIAGNOSTIC-CRITERIA; NORWEGIAN PARKWEST; ALZHEIMERS-DISEASE; GENDER-DIFFERENCES; DEMENTIA; PREVALENCE; INCIDENT; PROFILE AB Background: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. Objective: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. Methods: Six hundred nineteen participants with idiopathic PD (68.0 +/- 9.1 years, 7.1 +/- 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. Results: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. Conclusions: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD. C1 [Cholerton, Brenna A.; Zabetian, Cyrus P.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Cholerton, Brenna A.; Watson, G. Stennis; Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Edwards, Karen L.] Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA USA. [Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson, Amie] Portland VA Med Ctr, Portland, OR USA. [Quinn, Joseph F.; Chung, Kathryn A.; Peterson, Amie] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Espay, Alberto J.; Revilla, Fredy J.; Devoto, Johnna] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA. RP Cholerton, BA (reprint author), VA Puget Sound Hlth Care Syst, GRECC A-182,9600 Vet Dr SW, Tacoma, WA 98493 USA. EM bchol@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306; Espay, Alberto/0000-0002-3389-136X FU Nancy and Buster Alvord Endowment; Department of Veterans Affairs; [NS062684]; [NS065070] FX This research was supported by NS062684 and NS065070, the Nancy and Buster Alvord Endowment, and the Department of Veterans Affairs. The funding sources did not provide scientific input for the study. NR 50 TC 16 Z9 16 U1 4 U2 15 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2013 VL 3 IS 2 BP 205 EP 214 DI 10.3233/JPD-130189 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 149SE UT WOS:000319340700011 PM 23938350 ER PT B AU Nguyen, RT Nguyen, ET Rao, S AF Nguyen, Rosalyn T. Nguyen, Elizabeth T. Rao, Smita BE Wyss, JF Patel, AD TI Other Ankle Disorders SO THERAPEUTIC PROGRAMS FOR MUSCULOSKELETAL DISORDERS LA English DT Article; Book Chapter ID SYNDESMOSIS INJURIES; PERONEAL TENDONS; MEDIAL HEAD; TENNIS LEG; SPRAINS; GASTROCNEMIUS; MANAGEMENT; REHABILITATION; TENDINOPATHY; FOOT C1 [Nguyen, Rosalyn T.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Nguyen, Rosalyn T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nguyen, Rosalyn T.] Harvard Univ, Sch Med, Boston, MA USA. [Nguyen, Elizabeth T.] New York Presbyterian Hosp Columbia Cornell, Dept Phys Med & Rehabil, New York, NY USA. [Rao, Smita] NYU, Dept Phys Therapy, New York, NY USA. RP Nguyen, RT (reprint author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-40-6 PY 2013 BP 253 EP 261 PG 9 WC Orthopedics; Rehabilitation; Sport Sciences SC Orthopedics; Rehabilitation; Sport Sciences GA BEY34 UT WOS:000318661200036 ER PT S AU Bastepe, M AF Bastepe, Murat BE Maghnie, M Loche, S Cappa, M Ghizzoni, L Lorini, R TI Genetics and Epigenetics of Parathyroid Hormone Resistance SO HORMONE RESISTANCE AND HYPERSENSITIVITY: FROM GENETICS TO CLINICAL MANAGEMENT SE Endocrine Development LA English DT Proceedings Paper CT Meeting on Hormone Resistance and Hypersensitivity from Genetics to Clinical Management CY MAY 13-15, 2012 CL Genoa, ITALY ID PSEUDOHYPOPARATHYROIDISM-TYPE-IB; ALBRIGHT HEREDITARY OSTEODYSTROPHY; STIMULATORY-G-PROTEIN; GS-ALPHA GENE; CYCLASE COUPLING PROTEIN; NUCLEOTIDE REGULATORY PROTEIN; GRADIENT GEL-ELECTROPHORESIS; IDENTIFIES PDE4D MUTATIONS; IMPRINTING CONTROL ELEMENT; MOUSE GNAS LOCUS AB End-organ resistance to the actions of parathyroid hormone (PTH) is defined as pseudohypoparathyroidism (PHP). Described originally by Fuller Albright and his colleagues in early 1940s, this rare genetic disease is subclassified into two types according to the nephrogenous response to the administration of biologically active PTH. In type I, the PTH-induced urinary excretion of both phosphate and cyclic AMP (cAMP) is blunted. In type II, only the PTH-induced urinary excretion of phosphate is blunted, while the cAMP response is unimpaired. Different subtypes of PHP type I have been described based on the existence of additional clinical features, such as resistance to other hormones and Albright's hereditary osteodystrophy, and underlying molecular defects. Genetic mutations responsible for the different subtypes of PHP type I involve the GNAS complex locus, an imprinted gene encoding the a-subunit of the stimulatory G protein (Gs alpha) and several other transcripts that are expressed in a parent-of-origin specific manner. Mutations in Gs alpha-coding GNAS exons cause PHP-Ia and, in some cases, PHP-Ic, while mutations that disrupt the imprinting of GNAS lead to PHP-Ib. PHP type II is less well characterized with respect to its molecular cause. Recently, however, mutations in PRKAR1A, a regulatory subunit of the cAMP-dependent protein kinase, have been identified in several cases of PTH and other hormone resistance and skeletal dysplasia that are considered to be affected by PHP type II due to unimpaired urinary excretion of cAMP following PTH administration. Copyright (C) 2013 S. Karger AG, Basel C1 Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Bastepe, M (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St Thier 10, Boston, MA 02114 USA. EM bastepe@helix.mgh.harvard.edu NR 100 TC 10 Z9 10 U1 0 U2 5 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1421-7082 BN 978-3-318-02267-4 J9 ENDOCR DEV JI Endocr. Dev. PY 2013 VL 24 BP 11 EP 24 DI 10.1159/000342494 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BFA76 UT WOS:000319026400002 PM 23392091 ER PT J AU Staton, LJ Estrada, C Panda, M Ortiz, D Roddy, D AF Staton, Lisa J. Estrada, Carlos Panda, Mukta Ortiz, David Roddy, Donna TI A multimethod approach for cross-cultural training in an internal medicine residency program SO MEDICAL EDUCATION ONLINE LA English DT Article DE cultural competence; residency education; community resources; web-based curriculum; racial disparities; internal medicine ID ETHNIC DISPARITIES; HEALTH-CARE; PREPAREDNESS; COMPETENCE; EDUCATION AB Background: Cultural competence training in residency is important to improve learners' confidence in cross-cultural encounters. Recognition of cultural diversity and avoidance of cultural stereotypes are essential for health care providers. Methods: We developed a multimethod approach for cross-cultural training of Internal Medicine residents and evaluated participants' preparedness for cultural encounters. The multimethod approach included (1) a conference series, (2) a webinar with a national expert, (3) small group sessions, (4) a multicultural social gathering, (5) a Grand Rounds presentation on cross-cultural training, and (6) an interactive, online case-based program. Results: The program had 35 participants, 28 of whom responded to the survey. Of those, 16 were white (62%), and residents comprised 71% of respondents (n = 25). Following training, 89% of participants were more comfortable obtaining a social history. However, prior to the course only 27% were comfortable caring for patients who distrust the US system and 35% could identify religious beliefs and customs which impact care. Most (71%) believed that the training would help them give better care for patients from different cultures, and 63% felt more comfortable negotiating a treatment plan following the course. Conclusions: Multimethod training may improve learners' confidence and comfort with cross-cultural encounters, as well as lay the foundation for ongoing learning. Follow-up is needed to assess whether residents' perceived comfort will translate into improved patient outcomes. C1 [Staton, Lisa J.; Panda, Mukta] Univ Tennessee, Coll Med Chattanooga, Dept Internal Med, Chattanooga, TN 37403 USA. [Estrada, Carlos] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL USA. [Ortiz, David; Roddy, Donna] BlueCross BlueShield Tennessee, Chattanooga, TN USA. RP Staton, LJ (reprint author), Univ Tennessee, Coll Med Chattanooga, Dept Internal Med, 975 East 3rd,Box 94, Chattanooga, TN 37403 USA. EM lisa.staton@erlanger.org NR 12 TC 0 Z9 0 U1 2 U2 9 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2013 VL 18 BP 1 EP 6 AR 20352 DI 10.3402/meo.v18i0.20352 PG 6 WC Education & Educational Research SC Education & Educational Research GA 147WA UT WOS:000319198700001 PM 23683845 ER PT J AU Vianna, VF Bonfim, DC Cavalcanti, AD Fernandes, MC Kahn, SA Casado, PL Lima, IC Murray, SS Murray, EJB Duarte, MEL AF Vianna, Veronica Fernandes Bonfim, Danielle Cabral Cavalcanti, Amanda dos Santos Fernandes, Marco Cury Kahn, Suzana Assad Casado, Priscila Ladeira Lima, Inaya Correa Murray, Samuel S. Murray, Elsa J. Brochmann Leite Duarte, Maria Eugenia TI Late Adherent Human Bone Marrow Stromal Cells Form Bone and Restore the Hematopoietic Microenvironment In Vivo SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID MESENCHYMAL STEM-CELLS; OSTEOGENESIS; FIBROBLASTS; ASSAYS; NICHE AB Bone marrow stromal cells (BMSCs) are a valuable resource for skeletal regenerative medicine because of their osteogenic potential. In spite of the very general term "stem cell," this population of cells is far from homogeneous, and different BMSCs clones have greatly different phenotypic properties and, therefore, potentially different therapeutic potential. Adherence to a culture flask surface is a primary defining characteristic of BMSCs. We hypothesized that based on the adherence time we could obtain an enriched population of cells with a greater therapeutic potential. We characterized two populations of bone marrow-derived cells, those that adhered by three days (R-cells) and those that did not adhere by three days but did by six days (L-cells). Clones derived from L-cells could be induced into adipogenic, chondrogenic, and osteogenic differentiation in vitro. L-cells appeared to have greater proliferative capacity, as manifested by larger colony diameter and clones with higher CD146 expression. Only clones from L-cells developed bone marrow stroma in vivo. We conclude that the use of late adherence of BMSCs is one parameter that can be used to enrich for cells that will constitute a superior final product for cell therapy in orthopedics. C1 [Vianna, Veronica Fernandes; Bonfim, Danielle Cabral; Cavalcanti, Amanda dos Santos; Fernandes, Marco Cury; Kahn, Suzana Assad; Casado, Priscila Ladeira; Leite Duarte, Maria Eugenia] Natl Inst Traumatol & Orthopaed, Clin & Basic Res Div, BR-20940070 Rio De Janeiro, RJ, Brazil. [Vianna, Veronica Fernandes; Bonfim, Danielle Cabral; Leite Duarte, Maria Eugenia] Univ Fed Rio de Janeiro, Inst Biomed Sci, BR-21941970 Rio De Janeiro, RJ, Brazil. [Lima, Inaya Correa] Univ Fed Rio de Janeiro, COPPE, Lab Nucl Instrumentat, BR-21941970 Rio De Janeiro, RJ, Brazil. [Murray, Samuel S.; Murray, Elsa J. Brochmann] VA Greater Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. [Murray, Samuel S.; Murray, Elsa J. Brochmann] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. RP Vianna, VF (reprint author), Natl Inst Traumatol & Orthopaed, Clin & Basic Res Div, Ave Brasil 500, BR-20940070 Rio De Janeiro, RJ, Brazil. EM vvianna@into.saude.gov.br NR 29 TC 1 Z9 1 U1 2 U2 4 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 J9 BIOMED RES INT JI Biomed Res. Int. PY 2013 AR 790842 DI 10.1155/2013/790842 PG 11 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 141KW UT WOS:000318725100001 ER PT J AU Scheff, SW Price, DA Schmitt, FA Roberts, KN Ikonomovic, MD Mufson, EJ AF Scheff, Stephen W. Price, Douglas A. Schmitt, Frederick A. Roberts, Kelly N. Ikonomovic, Milos D. Mufson, Elliott J. TI Synapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; early onset; episodic memory; synapses; synaptic plasticity ID MILD COGNITIVE IMPAIRMENT; POSTERIOR PARIETAL CORTEX; VOXEL-BASED MORPHOMETRY; PITTSBURGH-COMPOUND-B; DEFAULT-MODE NETWORK; RHESUS-MONKEY; EPISODIC MEMORY; EMISSION-TOMOGRAPHY; FRONTAL-CORTEX; AMYLOID BURDEN AB Amnestic mild cognitive impairment (aMCI) is considered to be one of the early stages in the progression from no cognitive impairment (NCI) to Alzheimer's disease (AD). Individuals with aMCI have increased levels of AD-type neuropathology in multiple regions of the neocortex and hippocampus and demonstrate a loss of synaptic connectivity. Recent neuroimaging studies have reported increased levels of C-11-PiB (Pittsburgh, compound B) in regions of the neocortex including the precuneus region of the medial parietal lobe. This cortical region has been implicated in episodic memory, which is disrupted early in the progression of AD. In this study, unbiased stereology coupled with electron microscopy was used to quantify total synaptic numbers in lamina 3 of the precuneus from short postmortem autopsy tissue harvested from subjects who died at different cognitive stages during the progression of AD. Individuals with aMCI did not reveal a statistically significant decline in total synapses compared to the NCI cohort while the AD group did show a modest but significant decline. Synaptic numbers failed to correlate with several different cognitive tasks including the Mini-Mental State Examination scores and episodic memory scores. Although levels of [H-3] PiB binding were elevated in both the aMCI and AD groups, it did not strongly correlate with synaptic counts. These results support the idea that despite increased amyloid load, the precuneus region does not show early changes in synaptic decline during the progression of AD. C1 [Scheff, Stephen W.; Price, Douglas A.; Schmitt, Frederick A.; Roberts, Kelly N.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ikonomovic, Milos D.] Ctr Geriatr Res Educ & Clin, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Mufson, Elliott J.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. RP Scheff, SW (reprint author), Univ Kentucky, Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA. EM sscheff@email.uky.edu FU National Institute of Health [P01 AG14449, P30 AG0283883, P01 AG025204R01, AG027219, AG025204]; Mansbach Chair in Alzheimer's Disease FX This work was supported by the National Institute of Health grants: P01 AG14449; P30 AG0283883; P01 AG025204R01; AG027219, AG025204 and the Mansbach Chair in Alzheimer's Disease. We are indebted to the altruism of the participants in the SBCOA and the Religious Orders Study. The pathological diagnosis was performed by M. R. Markesbery and P. T. Nelson (SBCOA) and J. A. Schneider (Rush University Medical Center). NR 91 TC 18 Z9 18 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 35 IS 3 BP 599 EP 609 DI 10.3233/JAD-122353 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 140AY UT WOS:000318627800016 PM 23478309 ER PT J AU Atwood, CW AF Atwood, Charles W., Jr. TI Progress Toward a Clearer Understanding of the Role of Bilevel Positive Airway Pressure Therapy for Obstructive Sleep Apnea SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material C1 [Atwood, Charles W., Jr.] VA Pittsburgh Healthcare Syst, Sleep Disorders Program, Pittsburgh, PA USA. [Atwood, Charles W., Jr.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, UPMC Sleep Med Ctr, Pittsburgh, PA 15213 USA. [Atwood, Charles W., Jr.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Atwood, CW (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, 3459 5th Ave,NW628 MUH, Pittsburgh, PA 15213 USA. EM atwoodcw@upmc.edu NR 7 TC 4 Z9 4 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2013 VL 9 IS 4 BP 337 EP 338 DI 10.5664/jcsm.2582 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 139SI UT WOS:000318604100007 PM 23585748 ER PT J AU Grutters, JPC Sculpher, M Briggs, AH Severens, JL Candel, MJ Stahl, JE De Ruysscher, D Boer, A Ramaekers, BLT Joore, MA AF Grutters, Janneke P. C. Sculpher, Mark Briggs, Andrew H. Severens, Johan L. Candel, Math J. Stahl, James E. De Ruysscher, Dirk Boer, Albert Ramaekers, Bram L. T. Joore, Manuela A. TI Acknowledging Patient Heterogeneity in Economic Evaluation A Systematic Literature Review SO PHARMACOECONOMICS LA English DT Review ID COST-EFFECTIVENESS ANALYSIS; PREFERENCE SUB-GROUPS; SUBGROUP ANALYSIS; CLINICAL-TRIALS; RECOGNIZING DIVERSITY; COVARIATE ADJUSTMENT; INDIVIDUALIZED CARE; PUBLIC PREFERENCES; HEALTH-CARE; DECISION-MAKING AB Background and Objective Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic evaluations pay only limited attention to patient heterogeneity. The objective of the present paper is to provide a comprehensive overview of the current knowledge regarding patient heterogeneity within economic evaluation of healthcare programmes. Methods A systematic literature review was performed to identify methodological papers on the topic of patient heterogeneity in economic evaluation. Data were obtained using a keyword search of the PubMed database and manual searches. Handbooks were also included. Relevant data were extracted regarding potential sources of patient heterogeneity, in which of the input parameters of an economic evaluation these occur, methods to acknowledge patient heterogeneity and specific concerns associated with this acknowledgement. Results A total of 20 articles and five handbooks were included. The relevant sources of patient heterogeneity (demographics, preferences and clinical characteristics) and the input parameters where they occurred (baseline risk, treatment effect, health state utility and resource utilization) were combined in a framework. Methods were derived for the design, analysis and presentation phases of an economic evaluation. Concerns related mainly to the danger of false-positive results and equity issues. Conclusion By systematically reviewing current knowledge regarding patient heterogeneity within economic evaluations of healthcare programmes, we provide guidance for future economic evaluations. Guidance is provided on which sources of patient heterogeneity to consider, how to acknowledge them in economic evaluation and potential concerns. The improved acknowledgement of patient heterogeneity in future economic evaluations may well improve the efficiency of healthcare. C1 [Grutters, Janneke P. C.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6500 Nijmegen, Netherlands. [Sculpher, Mark] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. [Briggs, Andrew H.] Univ Glasgow, Ctr Populat Hlth Sci, Glasgow, Lanark, Scotland. [Severens, Johan L.] Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, Netherlands. [Candel, Math J.] Maastricht Univ, Sch Publ Hlth & Primary Care CAPHRI, Dept Methodol & Stat, Maastricht, Netherlands. [Stahl, James E.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [De Ruysscher, Dirk] Maastricht Univ, Med Ctr, Maastro Clin, Dept Radiat Oncol, Maastricht, Netherlands. [Boer, Albert] Dutch Hlth Care Insurance Board CvZ, Diemen, Netherlands. [Ramaekers, Bram L. T.; Joore, Manuela A.] Maastricht Univ, Sch Publ Hlth & Primary Care CAPHRI, Dept Hlth Serv Res, Maastricht, Netherlands. [Joore, Manuela A.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands. RP Grutters, JPC (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, POB 9101, NL-6500 Nijmegen, Netherlands. EM J.Grutters@ebh.umcn.nl RI Grutters, Janneke/G-1499-2013 FU Dutch Organisation for Health Research and Development (ZonMw) [152002021]; Pfizer FX This study was financially supported by a research grant (number 152002021) from the Dutch Organisation for Health Research and Development (ZonMw). Janneke Grutters received an unrestricted HTAcademy scholarship prize from Pfizer for this work. The funding organization had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. The authors have no conflicts of interest. NR 49 TC 19 Z9 19 U1 1 U2 11 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-7690 EI 1179-2027 J9 PHARMACOECONOMICS JI Pharmacoeconomics PY 2013 VL 31 IS 2 BP 111 EP 123 DI 10.1007/s40273-012-0015-4 PG 13 WC Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy GA 138TV UT WOS:000318533800003 PM 23329430 ER PT J AU Yan, X Shen, H Jiang, HJ Hu, D Wang, J Wu, XQ AF Yan, Xin Shen, Hua Jiang, Hongjian Hu, Dan Wang, Jun Wu, Xinqi TI External Qi of Yan Xin Qigong Inhibits Activation of Akt, Erk1/2 and NF-kappa B and Induces Cell Cycle Arrest and Apoptosis in Colorectal Cancer Cells SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY LA English DT Article DE Colorectal cancer; Akt; Erk1/2; NF-kappa B; External qi of Yan Xin qigong; Apoptosis ID COLON-CANCER; SIGNALING PATHWAYS; MUTATIONS; RADIOSENSITIVITY; PROGRESSION; RESISTANCE; GROWTH; P53; CARCINOMA; BREAST AB Background/Aims: Colorectal cancer (CRC) is the second leading cause of cancer death in the Western countries. Novel approaches of treatment are needed for CRC. The purpose of the present study was to investigate cytotoxic effect of external Qi of Yan Xin Qigong (YXQ-EQ) on human colorectal cancer cells. Methods: The effect of YXQ-EQ on viability, cell cycle progression and apoptosis in colorectal cancer HT-29 cells was investigated. Phosphorylation of Akt and Erk1/2, activation of NF-kappa B and the expression of proteins involved in regulation of cell cycle and apoptosis were examined by Western blot analysis. Results: YXQ-EQ markedly decreased viability and blocked colony formation of HT-29 cells. YXQ-EQ downregulated cyclin D1 expression and increased accumulation of cyclin-dependent kinase inhibitors p21(ciP1) and p27(KiP1), resulting in G1 cell cycle arrest. YXQ-EQ induced apoptosis in HT-29 cells in association with decreased expression of antiapoptotic proteins Bcl-xL, XIAP, survivin and Mcl-1 and elevated expression of proapoptotic protein Bax. YXQ-EQ significantly repressed phosphorylation of Akt and Erk1/2 and NF-kappa B activation in HT-29 cells, suggesting that YXQ-EQ may exert cytotoxic effect through regulating signaling pathways critical for cell proliferation and survival. Furthermore, YXQ-EQ treated PBS and an YXQ-EQ treated plant extract induced apoptosis in HT-29 cells. Conclusion: These findings show that YXQ-EQ has potent cytotoxic effect on HT-29 cells and suggest that YXQ-EQ could be potentially used for colorectal cancer treatment either directly or indirectly via carriers. Copyright (C) 2013 S. Karger AG, Basel C1 [Yan, Xin] Hongqing Inst Tradit Chinese Med, Chongqing, Peoples R China. [Yan, Xin; Shen, Hua; Wang, Jun] New Med Sci Res Inst, New York, NY USA. [Jiang, Hongjian; Hu, Dan; Wu, Xinqi] Brigham & Womens Hosp, Boston, MA 02115 USA. [Jiang, Hongjian; Hu, Dan; Wu, Xinqi] Harvard Univ, Sch Med, Boston, MA USA. [Wu, Xinqi] Dana Farber Canc Inst, Boston, MA 02215 USA. RP Wu, XQ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM xwu1@partners.org RI Hu, Dan/D-9642-2015 FU Yan Xin Foundation FX This work was supported in part by Yan Xin Foundation. NR 56 TC 9 Z9 10 U1 4 U2 59 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-8987 J9 CELL PHYSIOL BIOCHEM JI Cell. Physiol. Biochem. PY 2013 VL 31 IS 1 BP 113 EP 122 DI 10.1159/000343354 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 137BB UT WOS:000318408600012 PM 23363659 ER PT J AU Brouwers, HB Greenberg, SM AF Brouwers, H. Bart Greenberg, Steven M. TI Hematoma Expansion following Acute Intracerebral Hemorrhage SO CEREBROVASCULAR DISEASES LA English DT Review DE Intracerebral hemorrhage; Hematoma expansion; CT angiography spot sign; Clinical trials; Functional outcome ID ANGIOGRAPHY SPOT SIGN; BLOOD-PRESSURE REDUCTION; ACTIVATED FACTOR-VII; CEREBRAL AMYLOID ANGIOPATHY; APOLIPOPROTEIN-E EPSILON-2; COMPUTED-TOMOGRAPHY; CONTRAST EXTRAVASATION; IDENTIFIES PATIENTS; HEMOSTATIC THERAPY; SURGICAL TRIAL AB Intracerebral hemorrhage (ICH), the most devastating form of stroke, has no specific therapy proven to improve outcome by randomized controlled trial. Location and baseline hematoma volume are strong predictors of mortality, but are nonmodifiable by the time of diagnosis. Expansion of the initial hematoma is a further marker of poor prognosis that may be at least partly preventable. Several risk factors for hematoma expansion have been identified, including baseline ICH volume, early presentation after symptom onset, anticoagulation, and the CT angiography spot sign. Although the biological mechanisms of hematoma expansion remain unclear, accumulating evidence supports a model of ongoing secondary bleeding from ruptured adjacent vessels surrounding the initial bleeding site. Several large clinical trials testing therapies aimed at preventing hematoma expansion are in progress, including aggressive blood pressure reduction, treatment with recombinant factor VIIa guided by CT angiography findings, and surgical intervention for superficial hematomas without intraventricular extension. Hematoma expansion is so far the only marker of outcome that is amenable to treatment and thus a potentially important therapeutic target. Copyright (c) 2013 S. Karger AG, Basel C1 [Brouwers, H. Bart] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA 02114 USA. [Brouwers, H. Bart; Greenberg, Steven M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Hemorrhag Stroke Res Grp, Boston, MA 02114 USA. [Brouwers, H. Bart; Greenberg, Steven M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA. RP Brouwers, HB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res,Rosand Lab, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA. EM brouwers@chgr.mgh.harvard.edu FU National Institutes of Health (NIH) [R01AG026484]; NIH - National Institute of Neurological Disorders and Stroke (NINDS) SPOTRIAS [P50NS051343] FX All funding entities had no involvement in the study design, data collection, analysis, and interpretation, writing of the manuscript and in the decision to submit for publication. The project described was supported by grant No. R01AG026484 from the National Institutes of Health (NIH). H.B. Brouwers was supported by the NIH - National Institute of Neurological Disorders and Stroke (NINDS) SPOTRIAS fellowship grant P50NS051343. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NINDS. NR 54 TC 45 Z9 48 U1 0 U2 7 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-9770 J9 CEREBROVASC DIS JI Cerebrovasc. Dis. PY 2013 VL 35 IS 3 BP 195 EP 201 DI 10.1159/000346599 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 137ER UT WOS:000318418800001 PM 23466430 ER PT S AU Drummond, I Austin-Tse, C AF Drummond, Iain Austin-Tse, Christina BE Marshall, WF TI Zebrafish Cilia SO CILIA, PT B SE Methods in Enzymology LA English DT Review; Book Chapter ID MUTATIONS AFFECTING DEVELOPMENT; POLYCYSTIC KIDNEY-DISEASE; ZINC-FINGER NUCLEASES; INTRAFLAGELLAR TRANSPORT; KUPFFERS VESICLE; JOUBERT SYNDROME; CYST FORMATION; DYNEIN ARMS; FLUID-FLOW; CILIOGENESIS AB Zebrafish are ideally suited for analysis of genes required for ciliogenesis and cilia function. Combining genetic manipulation with high quality in vivo imaging, zebrafish embryos provide a high-throughput system for annotation of the cilia proteome. The specific advantages of the system are the availability of cilia mutants, the ability to target genes of unknown function using antisense methods, the feasibility of observing cilia in living embryos, and the ability to image fixed cilia in wholemount at high resolution. Techniques are described for analysis of mutants, gene knockdown using antisense morpholino oligos, visualizing cilia and cilia orientation in wholemount zebrafish embryos, live imaging cilia, and electron microscopy of zebrafish cilia. C1 [Drummond, Iain] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. [Drummond, Iain; Austin-Tse, Christina] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. RP Drummond, I (reprint author), Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. EM idrummon@receptor.mgh.harvard.edu OI Austin-Tse, Christina/0000-0001-6492-6716 FU NIDDK NIH HHS [DK053093, DK070263] NR 62 TC 2 Z9 2 U1 0 U2 6 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-397944-5 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2013 VL 525 BP 219 EP 244 DI 10.1016/B978-0-12-397944-5.00011-0 PG 26 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BEY63 UT WOS:000318737400012 PM 23522472 ER PT J AU Smith, KL Meah, Y Reininger, B Farr, M Zeidman, J Thomas, DC AF Smith, Kirk L. Meah, Yasmin Reininger, Belinda Farr, Miles Zeidman, Jessica Thomas, David C. TI Integrating service learning into the curriculum: Lessons from the field SO MEDICAL TEACHER LA English DT Article ID COMMUNITY-BASED EDUCATION; MEDICAL-EDUCATION; HEALTH PERSPECTIVE; TOMORROWS DOCTORS; PARTNERSHIPS; INVOLVEMENT; OUTCOMES AB The authors, representing two of the "signature" community service learning (CSL) programs in the 2010 Flexner Centenary volume of Academic Medicine, provide details of their programs - Frontera de Salud, a community-based program at the University of Texas Medical Branch, and the East Harlem Health Outreach Partnership, a clinic-based program at the Mount Sinai School of Medicine - specific to the task of integrating CSL into the medical school curriculum. They explain the nature and purpose of CSL, note gaps in the present curriculum which CSL aims to fill and highlight elements of CSL that are highly pertinent to Association of American Medical Colleges, Accreditation Council for Graduate Medical Education and Liaison Committee on Medical Education guidelines for undergraduate and graduate medical education. They also discuss barriers to the integration of CSL into the medical school curriculum and detail ways to overcome the logistic and fiscal challenges involved in making this highly effective and rewarding educational experience available to students of medicine. C1 [Smith, Kirk L.] Univ Texas Med Branch, Galveston, TX 77555 USA. [Meah, Yasmin; Thomas, David C.] Mt Sinai Sch Med, New York, NY USA. [Reininger, Belinda] Univ Texas Hlth Sci Ctr, Houston, TX USA. [Farr, Miles; Zeidman, Jessica] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Smith, KL (reprint author), Univ Texas Med Branch, Dept Internal Med, Rebecca Sealy Hosp 2 500, Galveston, TX 77555 USA. EM klsmith@utmb.edu FU DSHS; Center for Disease Control's Community Diabetes Program FX A program so attuned to preventive measures and public health would not have been possible without the support, expertise and active involvement of the University of Texas Health Science Center Houston School of Public Health; indeed, the comprehensive system of healthcare delivery adumbrated above was designed and implemented in close collaboration with faculty at UT-SPH who were also instrumental in bringing the community-based care model to the attention of the Texas Department of State Health Services (DSHS). Denominated Socios para su Salud (Partners in Health), Cameron Park's disease prevention and control program came under the auspices of DSHS in 2006 with funding provided by the Center for Disease Control's Community Diabetes Program. Of greater consequence, the program also came to the attention of the Texas Legislature which perceived in the low cost, grass-roots prevention strategy a means to curtail the state's ruinous Medicaid expenditures. In 2009, the Texas Legislature provided $6 million to disseminate the Partners in Health model of community-based diabetes prevention and control throughout the state, beginning with the south Texas and Texas Gulf Coast regions (Cameron, Webb, Nueces, and Galveston Counties) originally identified, and served, by the Frontera de Salud service chapters at UTMB, UTHSCH, and UTHSCSA. NR 37 TC 4 Z9 4 U1 0 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0142-159X J9 MED TEACH JI Med. Teach. PY 2013 VL 35 IS 5 BP E1139 EP E1148 DI 10.3109/0142159X.2012.735383 PG 10 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 136KO UT WOS:000318361000004 PM 23316888 ER PT J AU Wagner, DC Scheibe, J Glocke, I Weise, G Deten, A Boltze, J Kranz, A AF Wagner, Daniel-Christoph Scheibe, Johanna Glocke, Isabelle Weise, Gesa Deten, Alexander Boltze, Johannes Kranz, Alexander TI Object-based analysis of astroglial reaction and astrocyte subtype morphology after ischemic brain injury SO ACTA NEUROBIOLOGIAE EXPERIMENTALIS LA English DT Article DE astrocytes; reactive astrogliosis; immunohistochemistry; brain ischemia; confocal microscopy ID SPINAL-CORD-INJURY; FIBRILLARY ACIDIC PROTEIN; GLUTAMINE-SYNTHETASE; PERIINFARCT AREA; RAT-BRAIN; COLOCALIZATION; MICROSCOPY; CELLS; MICE; REGENERATION AB The astrocytic response to ischemic brain injury is characterized by specific alterations of glial cell morphology and function. Various studies described both beneficial and detrimental aspects of activated astrocytes, suggesting the existence of different subtypes. We investigated this issue using a novel object-based approach to study characteristics of astrogliosis after stroke. Spontaneously hypertensive rats received permanent middle cerebral artery occlusion. After 96 h, brain specimens were removed, fixed and stained for GFAP, glutamine synthetase (GS), S 100 beta and Musashil (Msh1). Three regions of interest were defined (contralateral hemisphere, ipsilateral remote zone and infarct border zone), and confocal stacks were acquired (n=5 biological with each n=4 technical replicates). The stacks were background-corrected and colocalization between the selected markers and GFAP was determined using an automated thresholding algorithm. The fluorescence and colocalization channels were then converted into 3D-objects using both intensity and volume as filters to ultimately determine the final volumes of marker expression and colocalization, as well as the morphological changes of astrocyte process arborisation. We found that both S100 beta and Msh1 determined the same GFAP-positive astroglial cell population albeit the cellular compartments differed. GFAP stained most of the astrocyte processes and is hence suitable for the analysis of qualitative characteristics of astrogliosis. Due to its pen-nuclear localization, Msh1 is appropriate to estimate the total number of astrocytes even in regions with severe reactive astrogliosis. GS expression in GFAP-positive astrocytes was high in the remote zone and low at the infarct border, indicating the existence of astrocyte subclasses. C1 [Wagner, Daniel-Christoph; Scheibe, Johanna; Glocke, Isabelle; Weise, Gesa; Deten, Alexander; Boltze, Johannes; Kranz, Alexander] Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany. [Wagner, Daniel-Christoph; Weise, Gesa; Deten, Alexander; Boltze, Johannes; Kranz, Alexander] Translat Ctr Regenerat Med, Leipzig, Germany. [Boltze, Johannes] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Boltze, Johannes] Harvard Univ, Sch Med, Boston, MA USA. RP Wagner, DC (reprint author), Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany. EM daniel-christoph.wagner@izi.fraunhofer.de NR 34 TC 12 Z9 13 U1 0 U2 3 PU NENCKI INST EXPERIMENTAL BIOLOGY PI WARSAW PA UL PASTEURA 3, 02-093 WARSAW, POLAND SN 0065-1400 J9 ACTA NEUROBIOL EXP JI Acta Neurobiol. Exp. PY 2013 VL 73 IS 1 BP 79 EP 87 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 134GH UT WOS:000318197900006 PM 23595285 ER PT J AU Lu, PH Mendez, MF Lee, GJ Leow, AD Lee, HW Shapira, J Jimenez, E Boeve, BB Caselli, RJ Graff-Radford, NR Jack, CR Kramer, JH Miller, BL Bartzokis, G Thompson, PM Knopman, DS AF Lu, Po H. Mendez, Mario F. Lee, Grace J. Leow, Alex D. Lee, Hyun-Woo Shapira, Jill Jimenez, Elvira Boeve, Bradley B. Caselli, Richard J. Graff-Radford, Neill R. Jack, Clifford R. Kramer, Joel H. Miller, Bruce L. Bartzokis, George Thompson, Paul M. Knopman, David S. TI Patterns of Brain Atrophy in Clinical Variants of Frontotemporal Lobar Degeneration SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Frontotemporal dementia; Primary progressive aphasia; Longitudinal study; Magnetic resonance imaging; Tensor-based morphometry; White matter ID TENSOR-BASED MORPHOMETRY; PRIMARY-PROGRESSIVE-APHASIA; VOXEL-BASED MORPHOMETRY; WHITE-MATTER CHANGES; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; SEMANTIC DEMENTIA; DIFFUSION; MRI; PATHOLOGY AB Background/Aims: The clinical syndromes of frontotemporal lobar degeneration include behavioral variant frontotemporal dementia (bvFTD) and semantic (SV-PPA) and nonfluent variants (NF-PPA) of primary progressive aphasia. Using magnetic resonance imaging (MRI), tensor-based morphometry (TBM) was used to determine distinct patterns of atrophy between these three clinical groups. Methods: Twenty-seven participants diagnosed with bvFTD, 16 with SV-PPA, and 19 with NF-PPA received baseline and follow-up MRI scans approximately 1 year apart. TBM was used to create three-dimensional Jacobian maps of local brain atrophy rates for individual subjects. Results: Regional analyses were performed on the three-dimensional maps and direct comparisons between groups (corrected for multiple comparisons using permutation tests) revealed significantly greater frontal lobe and frontal white matter atrophy in the bvFTD relative to the SV-PPA group (p < 0.005). The SV-PPA subjects exhibited significantly greater atrophy than the bvFTD in the fusiform gyrus (p = 0.007). The NF-PPA group showed significantly more atrophy in the parietal lobes relative to both bvFTD and SV-PPA groups (p < 0.05). Percent volume change in ventromedial prefrontal cortex was significantly associated with baseline behavioral symptomatology. Conclusion: The bvFTD, SV-PPA, and NF-PPA groups displayed distinct patterns of progressive atrophy over a 1-year period that correspond well to the behavioral disturbances characteristic of the clinical syndromes. More specifically, the bvFTD group showed significant white matter contraction and presence of behavioral symptoms at baseline predicted significant volume loss of the ventromedial prefrontal cortex. Copyright (C) 2013 S. Karger AG, Basel C1 [Lu, Po H.; Mendez, Mario F.; Lee, Grace J.; Shapira, Jill; Jimenez, Elvira; Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Leow, Alex D.; Bartzokis, George; Thompson, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Lab Neuroimaging, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Mendez, Mario F.; Jimenez, Elvira] Greater Los Angeles VA Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Leow, Alex D.] Community Psychiat Associates, Sacramento, CA USA. [Kramer, Joel H.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Leow, Alex D.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Leow, Alex D.] Univ Illinois, Dept Bioengn, Chicago, IL USA. [Boeve, Bradley B.; Jack, Clifford R.; Knopman, David S.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Caselli, Richard J.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA. [Graff-Radford, Neill R.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Lee, Hyun-Woo] McGill Univ, Dept Phys, Montreal, PQ, Canada. RP Lu, PH (reprint author), Mary S Easton Ctr Alzheimers Dis Res, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA. EM plu@mednet.ucla.edu RI Bartzokis, George/K-2409-2013; Leow, Alex/K-3236-2014; Jack, Clifford/F-2508-2010 OI Leow, Alex/0000-0002-5660-8651; Jack, Clifford/0000-0001-7916-622X FU National Institute of Health/National Institute of Aging (NIH/NIA) [K23-AG028727, R01-AG034499]; Alzheimer's Association [NIRG-07-60424]; NIH [P50 AG-16570, R01-AG023195, R01-AG11378, P50 AG-16574, P30-AG19610, R01-AG022983, P50-AG023501, U01 AG016976]; California Alzheimer's Disease Center; NIA, NIBIB; National Library of Medicine; National Center for Research Resources [AG016570, EB01651, LM05639, RR019771] FX This work was supported by grants K23-AG028727 and R01-AG034499 from the National Institute of Health/National Institute of Aging (NIH/NIA) and a grant from the Alzheimer's Association (NIRG-07-60424). Further support for this study came from NIH grants P50 AG-16570 (UCLA Alzheimer's Disease Research Center), R01-AG023195, R01-AG11378, P50 AG-16574 (Mayo Alzheimer's Disease Research Center), P30-AG19610 (Arizona Alzheimer Disease Center), R01-AG022983, P50-AG023501 (UCSF Alzheimer Disease Research Center) U01 AG016976 (National Alzheimer's Coordinating Center), and the California Alzheimer's Disease Center. Algorithm development for this study was also funded by the NIA, NIBIB, the National Library of Medicine, and the National Center for Research Resources (AG016570, EB01651, LM05639, RR019771 to PT). NR 68 TC 8 Z9 9 U1 2 U2 10 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2013 VL 35 IS 1-2 BP 34 EP 50 DI 10.1159/000345523 PG 17 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 130GB UT WOS:000317900400003 PM 23306166 ER PT J AU Kelley, JM Malouf, RA AF Kelley, John M. Malouf, Rebecca A. TI Blind Dates and Mate Preferences: An Analysis of Newspaper Matchmaking Columns SO EVOLUTIONARY PSYCHOLOGY LA English DT Article DE human mate selection; parental investment theory; sexual strategies theory; gender selectivity effect; age differential effect ID GENDER-DIFFERENCES; SEX-DIFFERENCES; SELECTION AB Parental investment theory and sexual strategies theory predict that women and men should differ on many of the criteria by which they choose mates. These theories posit a gender selectivity effect, such that women should be more selective than men in their mating choices. The theories also posit an age differential effect, such that women should seek older mates, and men should seek younger mates. These two hypotheses have been supported by self-report surveys, speed-dating studies, analysis of on-line and newspaper personal ads, and laboratory analog studies. However, each of these data sources has limitations. Therefore, a new source of data may provide a valuable additional test of the robustness of these effects. The current study examined two independent sources of data involving blind dates arranged and paid for by newspapers. Consistent with the first hypothesis, we found women to be more selective than men. We also found that matchmakers tended to pair older men with younger women, consistent with the second hypothesis. However, contrary to the second hypothesis, we found no evidence that the age differential between members of a couple influenced their ratings of the date. The implications of these findings are discussed. C1 [Kelley, John M.; Malouf, Rebecca A.] Endicott Coll, Dept Psychol, Beverly, MA 01915 USA. [Kelley, John M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. RP Kelley, JM (reprint author), Endicott Coll, Dept Psychol, Beverly, MA 01915 USA. EM JohnKelley@Post.Harvard.Edu NR 15 TC 0 Z9 0 U1 7 U2 45 PU EVOLUTIONARY PSYCHOL PI DAVIE PA C/O TOOD K SHACKELFORD, DIR, FLORIDA ATLANTIC UNIV, DEPT PSYCHOL, 2912 COLLEGE AVE, DAVIE, FL 33314 USA SN 1474-7049 J9 EVOL PSYCHOL-US JI Evol. Psychol. PY 2013 VL 11 IS 1 BP 1 EP 8 PG 8 WC Psychology, Experimental SC Psychology GA 130FC UT WOS:000317897300001 PM 23282582 ER PT J AU Knapp, H Anaya, HD AF Knapp, H. Anaya, H. D. TI Implementation science in the real world: a case study of HIV rapid testing SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE implementation science; quality improvement; organizational change; process design/re-design/re-engineering; performance improvement models; HIV; diagnostic testing; rapid test ID NEEDLE PHOBIA; DIAGNOSIS; FRAMEWORK; RISK AB Implementation science theories offer technical principles for carrying out activities designed to create or improve systems; however, such theories tend not to provide pragmatic or streamlined guidance when it comes to executing the actual implementation. We assembled a streamlined and comprehensive six-step theory-based implementation science model (ADAPTS - Assessment, Deliverables, Activate, Pretraining, Training, Sustainability) derived from the methods we have used to successfully execute multiple self-sustaining implementation efforts within the Veteran's Affairs Healthcare System. This paper provides a case study of our ADAPTS implementation science model, using a complex multisite HIV rapid testing implementation project as an exemplar. C1 [Knapp, H.; Anaya, H. D.] VA Greater Los Angeles Healthcare Syst, Vet Affairs VA Qual Enhancement Res Initiat HIV &, Los Angeles, CA USA. [Knapp, H.; Anaya, H. D.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, VA Greater Los Angeles Hlth Serv Res & Dev HRS&D, Los Angeles, CA USA. [Anaya, H. D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. RP Knapp, H (reprint author), 11301 Wilshire Blvd 111G,Bldg 500,Off 4681, Los Angeles, CA 90073 USA. EM Herschel.Knapp@va.gov NR 18 TC 2 Z9 2 U1 1 U2 7 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD JAN PY 2013 VL 24 IS 1 BP 5 EP 11 DI 10.1258/ijsa.2012.012140 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 134IJ UT WOS:000318203300001 PM 23427213 ER PT J AU Lei-Rivera, L Sutera, J Galatioto, JA Hujsak, BD Gurley, JM AF Lei-Rivera, Laura Sutera, John Galatioto, Jessica A. Hujsak, Bryan D. Gurley, James M. TI Special tools for the assessment of balance and dizziness in individuals with mild traumatic brain injury SO NEUROREHABILITATION LA English DT Article DE Vestibular rehabilitation; traumatic brain injury; concussion; outcomes measures ID ERROR SCORING SYSTEM; DWELLING OLDER-ADULTS; PAROXYSMAL POSITIONAL VERTIGO; FUNCTIONAL GAIT ASSESSMENT; SENSORY INTERACTION; POSTURAL STABILITY; FALL RISK; CLINICAL-TEST; FOLLOW-UP; CONCUSSION AB INTRODUCTION: Although a majority of patients following minor traumatic brain injury recover to their pre-morbid functional level, persistent activity and participation limitations can occur in the refractory patient. These long-term consequences of brain injury may only become apparent months to years after the injury. In order to quantify these long-term sequella, laboratory, clinical and functional outcome measures may not only identify needed areas of treatment, but may also assist in determining the impact of the treatment on the individuals function. PURPOSE: The aim of this manuscript is to review the clinical utility of vestibular laboratory testing and the bedside vestibular examination in patients following mild traumatic brain injury. In addition, the validity and inter-observer reliability of functional outcome measures commonly used in individuals with mTBI will also be reviewed. SUMMARY: Because of the diffuse pathology seen with mTBI, multiple tests are needed to determine the resultant impairment and their impact on the patient's activity level and participation level. Laboratory test and bedside tests of vestibular impairment are reviewed. Functional outcome measures including the Dynamic Gait Index, the Functional Gait Assessment, the Balance Error Scoring System, and Dual Task Performance are reviewed for their appropriateness in quantifying the effect of mTBI at activity level and participation level of the individual. CONCLUSION: TBI rehabilitation services are increasingly exemplified by the needs of patients, rather than by the underlying pathology or diagnosis. Basing treatment decisions and treatment timing on laboratory, clinical, and functional testing can optimize the rehabilitation outcome. C1 [Lei-Rivera, Laura; Sutera, John; Hujsak, Bryan D.] New York Eye & Ear Infirm, Vestibular Rehabil Dept, New York, NY USA. [Galatioto, Jessica A.] New York Eye & Ear Infirm, Ctr Hearing & Balance Disorders, New York, NY USA. [Gurley, James M.] Mercy Coll, Phys Therapy Program, Dobbs Ferry, NY 10522 USA. [Gurley, James M.] James J Peters VAMC, Dept Otololaryngol, Bronx, NY USA. RP Gurley, JM (reprint author), Mercy Coll, Phys Therapy Program, 555 Broadway, Dobbs Ferry, NY 10522 USA. EM jgurley@mercy.edu NR 61 TC 3 Z9 4 U1 2 U2 22 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2013 VL 32 IS 3 BP 463 EP 472 DI 10.3233/NRE-130869 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 135DM UT WOS:000318266200005 PM 23648601 ER PT J AU Gurley, JM Hujsak, BD Kelly, JL AF Gurley, James M. Hujsak, Bryan D. Kelly, Jennifer L. TI Vestibular rehabilitation following mild traumatic brain injury SO NEUROREHABILITATION LA English DT Article DE Vestibular rehabilitation; traumatic brain injury; concussion ID PAROXYSMAL POSITIONAL VERTIGO; STABILITY FOLLOWING CONCUSSION; DIZZINESS HANDICAP INVENTORY; PREDICT PROTRACTED RECOVERY; SPORTS-RELATED CONCUSSION; HEART-RATE-VARIABILITY; VESTIBULOOCULAR REFLEX; POSTURAL-CONTROL; SMOOTH-PURSUIT; FOOTBALL PLAYERS AB INTRODUCTION: Vertigo, dizziness, and imbalance are a symptom complex that is commonly found following concussion. Early metabolic changes following concussion may lead to worsening of the injury and symptoms in individuals not properly managed from the outset. When symptoms do not recover spontaneously, skilled vestibular rehabilitation can be an effective modality in an attempt to normalize the individual's vestibular responses. PURPOSE: The purpose of this review is to appraise the current and accepted methods available to the skilled clinician in quantifying and treating vestibular dysfunction following concussion. Incidence and prognostic indicators will be reviewed along with common barriers to recovery. SUMMARY: Vestibular Rehabilitation following concussion utilizes similar tools and techniques employed when treating those solely with peripheral pathology. The clinician must not only have a solid understanding of when and why certain exercises are required, but also be willing to accept that less exercise may be indicated in this population. As injury to the system following mild traumatic brain injury can include both peripheral and central structures, the duration of therapy and the time to recovery may be prolonged. Co-morbidities including cognitive and behavioral issues, visual-perceptual dysfunction, metabolic dysfunction, and autonomic dysfunction may hamper the effectiveness of the traditional Vestibular Rehabilitation approach. As successful treatment does not occur in a vacuum, working closely with other disciplines well versed in treating these co-morbid issues will help the individual to obtain optimal recovery. CONCLUSION: Vestibular Rehabilitation is an effective modality for managing dizziness, vertigo, and imbalance following concussion. Careful consideration of the acuity of the injury, along with effective management of co-morbid conditions will optimize the result. C1 [Gurley, James M.] Mercy Coll, Phys Therapy Program, Dobbs Ferry, NY 10522 USA. [Gurley, James M.] James J Peters VAMC, Dept Otololaryngol, Bronx, NY USA. [Hujsak, Bryan D.; Kelly, Jennifer L.] New York Eye & Ear Infirm, Vestibular Rehabil Dept, New York, NY USA. RP Gurley, JM (reprint author), Mercy Coll, Phys Therapy Program, 555 Broadway, Dobbs Ferry, NY 10522 USA. EM jgurley@mercy.edu NR 79 TC 11 Z9 11 U1 2 U2 34 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2013 VL 32 IS 3 BP 519 EP 528 DI 10.3233/NRE-130874 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 135DM UT WOS:000318266200010 PM 23648606 ER PT J AU Shore, J Chu, CJ Bianchi, MT AF Shore, Jesse Chu, Catherine J. Bianchi, Matt T. TI Power laws and fragility in flow networks SO SOCIAL NETWORKS LA English DT Article DE Network dynamics; Power law; Degree distribution; Flow networks; Network collapse; Resource networks; Network evolution ID SCALE-FREE NETWORKS; EVOLVING NETWORKS; COMPLEX NETWORKS; CENTRALITY; DISTRIBUTIONS; CONGESTION; EMERGENCE; TOPOLOGY; SYSTEMS; WEB AB What makes economic and ecological networks so unlike other highly skewed networks in their tendency toward turbulence and collapse? Here, we explore the consequences of a defining feature of these networks: their nodes are tied together by flow. We show that flow networks tend to the power law degree distribution (PLDD) due to a self-reinforcing process involving position within the global network structure, and thus present the first random graph model for PLDDs that does not depend on a rich-get-richer function of nodal degree. We also show that in contrast to non-flow networks, PLDD flow networks are dramatically more vulnerable to catastrophic failure than non-PLDD flow networks, a finding with potential explanatory power in our age of resource- and financial-interdependence and turbulence. (c) 2013 Elsevier B.V. All rights reserved. C1 [Shore, Jesse] Boston Univ, Sch Management, Dept Informat Syst, Boston, MA 02215 USA. [Chu, Catherine J.; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Chu, Catherine J.; Bianchi, Matt T.] Harvard Univ, Sch Med, Boston, MA USA. RP Shore, J (reprint author), Boston Univ, Sch Management, Dept Informat Syst, Boston, MA 02215 USA. EM jccs@bu.edu OI Shore, Jesse/0000-0003-3812-0262 FU NINDS NIH HHS [K12 NS066225] NR 40 TC 1 Z9 1 U1 3 U2 25 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-8733 J9 SOC NETWORKS JI Soc. Networks PD JAN PY 2013 VL 35 IS 1 BP 116 EP 123 DI 10.1016/j.socnet.2013.01.005 PG 8 WC Anthropology; Sociology SC Anthropology; Sociology GA 130TN UT WOS:000317943100010 PM 26082568 ER PT J AU Nigwekar, SU Bhan, I Turchin, A Skentzos, SC Hajhosseiny, R Steele, D Nazarian, RM Wenger, J Parikh, S Karumanchi, A Thadhani, R AF Nigwekar, Sagar U. Bhan, Ishir Turchin, Alexander Skentzos, Stephen C. Hajhosseiny, Reza Steele, David Nazarian, Rosalynn M. Wenger, Julia Parikh, Samir Karumanchi, Ananth Thadhani, Ravi TI Statin Use and Calcific Uremic Arteriolopathy: A Matched Case-Control Study SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Calcific uremic arteriolopathy; Calciphylaxis; Case control; Statin; Vitamin D ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; VASCULAR CALCIFICATION; RISK-FACTORS; CALCIPHYLAXIS; HEMODIALYSIS; SIMVASTATIN; SURVIVAL; PARICALCITOL; INFLAMMATION AB Background: Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is characterized by vascular calcification, thrombosis and intense inflammation. Prior research has shown that statins have anticalcification, antithrombotic and antiinflammatory properties; however, the association between statin use and CUA has not been investigated. Methods: This matched case-control study included 62 adult maintenance hemodialysis (HD) patients with biopsy-confirmed CUA diagnosed between the years 2002 and 2011 (cases). All cases were hospitalized at the time of diagnosis. Controls (n = 124) were hospitalized maintenance HD patients without CUA (matched to cases by gender and timing of hospitalization). Univariate and multivariable logistic regression models were applied to compute odds ratio (OR) and 95% confidence intervals (CI) for CUA in statin users, and also to examine previously described associations. Results: The mean age of cases was 58 years. Most were females (68%), and of white race (64%). Statin use was more common in controls than in cases (39 vs. 19%, p < 0.01). Statin use was associated with lower odds of CUA in unadjusted (OR 0.38, 95% CI 0.18-0.79) and adjusted (OR 0.20, 95% CI 0.05-0.88) analyses. Hypercalcemia (OR 2.25, 95% CI 1.14-4.43), hypoalbuminemia (OR 5.73, 95% CI 2.79-11.77), calcitriol use (OR 5.69, 95% CI 1.02-31.77) and warfarin use (OR 4.30, 95% CI 1.57-11.74) were positively associated with CUA in adjusted analyses whereas paricalcitol and doxercalciferol were not (OR 1.33, 95% CI 0.54-3.27). Conclusion: Statin use may be negatively associated with odds of CUA. Further large prospective studies with attention to potential confounders are needed to confirm these findings. Copyright (C) 2013 S. Karger AG, Basel C1 [Nigwekar, Sagar U.; Bhan, Ishir; Hajhosseiny, Reza; Steele, David; Wenger, Julia; Thadhani, Ravi] Harvard Univ, Sch Med, Div Nephrol, Boston, MA USA. [Nazarian, Rosalynn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Serv,Dermatopathol Unit, Boston, MA USA. [Nigwekar, Sagar U.] Harvard Univ, Sch Med, Scholars Clin Sci Program, Boston, MA USA. [Turchin, Alexander; Skentzos, Stephen C.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Parikh, Samir; Karumanchi, Ananth] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA. RP Nigwekar, SU (reprint author), Massachusetts Gen Hosp, Bulfinch 127,55 Fruit St, Boston, MA 02114 USA. EM sagarnigs@gmail.com OI Nazarian, Rosalynn/0000-0003-4003-7193 FU Clinical Scientist in Nephrology (CSN) Fellowship from the American Kidney Fund; Abbott Laboratories FX Sagar U. Nigwekar is supported by the Clinical Scientist in Nephrology (CSN) Fellowship from the American Kidney Fund.; Ravi Thadhani is a consultant to Fresenius Medical Care North America and has received a research grant from Abbott Laboratories. Other authors report no disclosures. NR 36 TC 20 Z9 20 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2013 VL 37 IS 4 BP 325 EP 332 DI 10.1159/000348806 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 130HC UT WOS:000317903200005 PM 23548843 ER PT J AU Turner, TH Hinson, V AF Turner, Travis H. Hinson, Vanessa TI Mattis Dementia Rating Scale Cutoffs Are Inadequate for Detecting Dementia in Parkinson's Disease SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE cognition; diagnosis; geriatric; measurement; statistics; tests ID MILD COGNITIVE IMPAIRMENT; SCREENING DEMENTIA; DISORDER AB The Mattis Dementia Rating Scale (DRS) is widely used to assess cognition and screen for dementia in Parkinson's disease (PD). In 2008, Llebaria and colleagues reported excellent sensitivity and specificity detecting dementia in PD using a DRS total score cutoff of 123. However, this study used a sample with rather low mean educational achievement (8.9 years). The 123 cutoff score was cross-validated in a sample of 51 PD patients with a rather high mean educational achievement (14.84 years). A total score cutoff of 123 correctly classified 60.7% of the sample, with 20% sensitivity and 100% specificity. Use of age- and education-corrected scaled scores improved classification accuracy, but these cutoffs corresponded to the 25th percentile. Optimal classification of 82.4% accuracy was achieved using a raw total score cutoff of 133, corresponding roughly to the 16th percentile. Neither age nor education evinced a strong correlation to DRS total score in our sample. Results suggest caution in applying the DRS-2 total score cutoff of 123 and highlight the importance of comprehensive neuropsychological evaluations for clinical diagnosis of dementia in PD. C1 [Turner, Travis H.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. Ralph H Johnson VAMC, Mental Hlth Serv, Charleston, SC 29401 USA. RP Turner, TH (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM turnertr@musc.edu NR 28 TC 3 Z9 4 U1 1 U2 2 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0908-4282 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PD JAN 1 PY 2013 VL 20 IS 1 BP 61 EP 65 DI 10.1080/09084282.2012.670168 PG 5 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA 109PH UT WOS:000316380000009 PM 23373686 ER PT J AU Carter, JB Johnson, MM Chua, TL Karia, PS Schmults, CD AF Carter, Joi B. Johnson, Matthew M. Chua, Tiffany L. Karia, Pritesh S. Schmults, Chrysalyne D. TI Outcomes of Primary Cutaneous Squamous Cell Carcinoma With Perineural Invasion An 11-Year Cohort Study SO JAMA DERMATOLOGY LA English DT Article ID SKIN-CANCER; HEAD; NECK; RISK AB Objective: To identify factors associated with poor outcomes in perineurally invasive squamous cell carcinoma. Design: Retrospective cohort study. Setting: Two academic hospitals in Boston, Massachusetts. Patients: Adults with perineural SCC diagnosed from 1998 to 2008. Main Outcome Measures: Hazard ratios (HRs) for local recurrence, nodal metastasis, death from disease, and overall death, adjusted for known prognostic factors. Results: A total of 114 cases were included, all but 2 involving unnamed nerves. Only a single local recurrence occurred in cases with no risk factors other than nerve invasion. Tumors with large nerve (>= 0.1 mm in caliber) invasion were significantly more likely to have other risk factors, including diameters of 2 cm or greater (P < .001), invasion beyond the subcutaneous fat (P < .003), multiple nerve involvement (P < .001), infiltrative growth (P =. 01), or lymphovascular invasion (P =. 01). On univariate analysis, large nerve invasion was associated with increased risk of nodal metastasis (HR, 5.6 [95% CI, 1.1-27.9]) and death from disease (HR, 4.5 [95% CI, 1.2-17.0]). On multivariate analysis, tumor diameter of 2 cm or greater predicted local recurrence (HR, 4.8 [95% CI, 1.8-12.7]), >1 risk factor predicted nodal metastasis (2 factors: HR, 4.1 [95% CI, 1.0-16.6]), lymphovascular invasion predicted death from disease (HR, 15.3 [95% CI, 3.7-62.8]), and overall death (HR, 1.1 [95% CI, 1.0-1.1]). Invasion beyond subcutaneous fat also predicted overall death (HR, 2.1 [95% CI, 1.0-4.3]). Conclusions: Squamous cell carcinoma involving unnamed small nerves (<0.1 mm in caliber) may have a low risk of poor outcomes in the absence of other risk factors. Large-caliber nerve invasion is associated with an elevated risk of nodal metastasis and death, but this is due in part to multiple other risk factors associated with large-caliber nerve invasion. A larger study is needed to estimate the specific prognostic impact of nerve caliber. JAMA Dermatol. 2013;149(1):35-41 C1 [Carter, Joi B.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Johnson, Matthew M.] Miraca Life Sci, Newton, MA USA. [Chua, Tiffany L.; Karia, Pritesh S.; Schmults, Chrysalyne D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA. RP Schmults, CD (reprint author), Brigham & Womens Hosp, Mohs & Dermatol Surg Ctr, Dept Dermatol, 1153 Ctr St,Ste 4349, Jamaica Plain, MA 02130 USA. EM cschmults@partners.org NR 15 TC 32 Z9 32 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6068 J9 JAMA DERMATOL JI JAMA Dermatol. PD JAN PY 2013 VL 149 IS 1 BP 35 EP 41 PG 7 WC Dermatology SC Dermatology GA 127BB UT WOS:000317668000005 PM 23324754 ER PT J AU Chang, AY Ghazi, E Okawa, J Werth, VP AF Chang, Aileen Y. Ghazi, Elizabeth Okawa, Joyce Werth, Victoria P. TI Quality of Life Differences Between Responders and Nonresponders in the Treatment of Cutaneous Lupus Erythematosus SO JAMA DERMATOLOGY LA English DT Letter ID INSTRUMENT; SEVERITY; CLASI C1 [Chang, Aileen Y.; Ghazi, Elizabeth; Okawa, Joyce; Werth, Victoria P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chang, Aileen Y.; Ghazi, Elizabeth; Okawa, Joyce; Werth, Victoria P.] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Ghazi, Elizabeth] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, 3400 Civ Ctr Blvd,Ste 1-330S, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Intramural NIH HHS; NIAMS NIH HHS [K24-AR 18 02207, K24 AR002207] NR 6 TC 8 Z9 8 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6068 J9 JAMA DERMATOL JI JAMA Dermatol. PD JAN PY 2013 VL 149 IS 1 BP 104 EP 106 DI 10.1001/2013.jamadermatol.467 PG 4 WC Dermatology SC Dermatology GA 127BB UT WOS:000317668000024 PM 23324773 ER PT J AU Simopoulos, AP Kang, JX AF Simopoulos, Artemis P. Kang, Jing X. TI In Honor of Dr. Alexander Leaf SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Biographical-Item C1 [Kang, Jing X.] Massachusetts Gen Hosp, Lab Lipid Med & Technol, Charlestown, MA 02129 USA. RP Kang, JX (reprint author), Massachusetts Gen Hosp, Lab Lipid Med & Technol, 149,13th St,Room 4001, Charlestown, MA 02129 USA. EM kang.jing@mgh.harvard.edu NR 0 TC 1 Z9 1 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2013 VL 6 IS 1 BP 33 EP 33 DI 10.1159/000348536 PG 1 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA 125PQ UT WOS:000317553900004 ER PT J AU Baethge, C Assall, OP Baldessarini, RJ AF Baethge, Christopher Assall, Oliver P. Baldessarini, Ross J. TI Systematic Review of Blinding Assessment in Randomized Controlled Trials in Schizophrenia and Affective Disorders 2000-2010 SO PSYCHOTHERAPY AND PSYCHOSOMATICS LA English DT Review DE Blinding assessment; Controlled trials; Mood disorders; Quality of reports; Schizophrenia; Therapeutics ID CONTROLLED CLINICAL-TRIALS; EMPIRICAL-EVIDENCE; PLACEBO; SUCCESS; DEPRESSION; STATEMENT; QUALITY; DESIGN; DRUGS; BIAS AB Background: Blinding is an integral part of many randomized controlled trials (RCTs). However, both blinding and blinding assessment seem to be rarely documented in trial reports. Method: Systematic review of articles on RCTs in schizophrenia and affective disorders research during 2000 2010. Results: Among 2,467 publications, 61(2.5%; 95% confidence interval: 1.9-3.1%) reported assessing participant, rater, or clinician blinding: 5/672 reports on schizophrenia (0.7%; 0.3-1.6%) and 33/1,079 (3.1%; 2.1-4.2%) on affective disorders, without significant trends across the decade. Rarely was blinding assessed at the beginning, in most studies assessment was at the end. Proportion of patients' and raters' correct guesses of study arm averaged 54.4 and 62.0% per study, with slightly more correct guesses in treatment arms than in placebo arms. Three fourths of responders correctly guessed that they received the active agent. Blinding assessment was more frequently reported in papers on psychotherapy and brain stimulation than on drug trials (5.1%, 1.7-11.9%, vs. 8.3%, 4.3-14.4%, vs. 2.1%, 1.5-2.8%). Lack of assessment of blinding was associated with: (a) positive findings, (b) full industrial sponsorship, and (c) diagnosis of schizophrenia. There was a moderate association of treatment success and blinding status of both trial participants (r = 0.51, p = 0.002) and raters (r = 0.55, p = 0.067). Many RCT reports did not meet CONSORT standards regarding documentation of persons blinded (60%) or of efforts to match interventions (50%). Conclusions: Recent treatment trials in major psychiatric disorders rarely reported on or evaluated blinding. We recommend routine documentation of blinding strategies in reports. Copyright (C) 2013 S. Karger AG, Basel C1 [Baethge, Christopher; Assall, Oliver P.] Univ Cologne, Dept Psychiat & Psychotherapy, Sch Med, DE-50937 Cologne, Germany. [Baldessarini, Ross J.] Harvard Univ, Sch Med, Dept Psychiat, McLean Div,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Baethge, C (reprint author), Univ Cologne, Klin Psychiat & Psychotherapie, Kerpener Str 62, DE-50937 Cologne, Germany. EM cbaethge@uni-koeln.de FU Bruce J. Anderson Foundation; McLean Private Donors Psychiatric Research Fund FX This work is part of the doctoral thesis of Oliver Paul Assall for the University of Koln. It was supported in part by a grant from the Bruce J. Anderson Foundation and by the McLean Private Donors Psychiatric Research Fund (to R.J.B.). NR 35 TC 8 Z9 8 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0033-3190 J9 PSYCHOTHER PSYCHOSOM JI Psychother. Psychosom. PY 2013 VL 82 IS 3 BP 152 EP 160 DI 10.1159/000346144 PG 9 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 129AK UT WOS:000317810600004 PM 23548796 ER PT J AU Saavedra, AP Warth, JA Burke, JF Norton, KJ Gelfand, JA AF Saavedra, Arturo P. Warth, James A. Burke, John F. Norton, Kathryn J. Gelfand, Jeffrey A. TI Increased dense erythrocytes in flame-burned patients SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION LA English DT Article ID IRREVERSIBLY SICKLED CELLS; FLOW BEHAVIOR; MICROCIRCULATION; ATP AB OBJECTIVE: We have studied dense erythrocytes separated on Arabinogalactan (Stractan) ultracentrifuged gradients in flame-burned patients and in normal individuals. In each case, the percentage of erythrocytes in the densest layers was increased when compared to age and sex matched controls. METHODS AND RESULTS: Using an in vitro system, we showed that as human whole blood is warmed to 48.6 degrees C, the number of dense erythrocytes increases. In addition, the reduced glutathionine (GSH) content of the densest red blood cells is decreased compared to those in lighter fractions on the same gradient or to dense erythrocytes separated from blood incubated at room temperature. These dense red cells were largely composed of spherocytes and spheroechynocytes, two forms of erythrocytes which have been shown by others to have markedly abnormal flow characteristics in vitro. CONCLUSIONS: We have demonstrated that in vivo dense erythrocytes can be generated in the setting of flame burns. Thus, the underlying reason may be oxidant injury as represented by the reduced level of GSH that we found in association with the generation of dense erythrocytes. C1 [Saavedra, Arturo P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Saavedra, Arturo P.] Dana Farber Canc Inst, Dept Cutaneous Oncol, Boston, MA 02115 USA. [Warth, James A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Warth, James A.] Harvard Univ, Sch Med, Dept Med, Faulkner Hosp, Boston, MA USA. [Burke, John F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA. [Norton, Kathryn J.] Tufts Univ New England Med Ctr, Dept Med, Boston, MA USA. [Gelfand, Jeffrey A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. RP Saavedra, AP (reprint author), Brigham & Womens Hosp, Dept Dermatol, 221 Longwood Ave, Boston, MA 02115 USA. EM asoavedra@partners.org FU Dermatology Foundation FX Dr. Arturo Saavedra was partially supported by a grant from the Dermatology Foundation. NR 20 TC 1 Z9 1 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1386-0291 J9 CLIN HEMORHEOL MICRO JI Clin. Hemorheol. Microcirc. PY 2013 VL 53 IS 4 BP 349 EP 356 DI 10.3233/CH-2012-1556 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 124JP UT WOS:000317459900006 PM 22596230 ER PT J AU Lui, JK LaPrad, AS Parameswaran, H Sun, Y Albert, MS Lutchen, KR AF Lui, J. K. LaPrad, A. S. Parameswaran, H. Sun, Y. Albert, M. S. Lutchen, K. R. TI Semiautomatic Segmentation of Ventilated Airspaces in Healthy and Asthmatic Subjects Using Hyperpolarized He-3 MRI SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE LA English DT Article ID AIR-FLOW OBSTRUCTION; MAGNETIC-RESONANCE; CYSTIC-FIBROSIS; LUNG; SPIROMETRY; CONTOURS; BRAIN AB A segmentation algorithm to isolate areas of ventilation from hyperpolarized helium-3 magnetic resonance imaging ((HPHe)-He-3 MRI) is described. The algorithm was tested with (HPHe)-He-3 MRI data from four healthy and six asthmatic subjects. Ventilated lung volume (VLV) measured using our semiautomated technique was compared to that obtained from manual outlining of ventilated lung regions and to standard spirometric measurements. VLVs from both approaches were highly correlated (R = 0.99; P < 0.0001) with a mean difference of 3.8mL and 95% agreement indices of -30.8mL and 38.4 mL. There was no significant difference between the VLVs obtained through the semiautomatic approach and the manual approach. A Dice coefficient which quantified the intersection of the two datasets was calculated and ranged from 0.95 to 0.97 with a mean of 0.96 +/- 0.01 (mean +/- SD). VLVs obtained through the semiautomatic algorithm were also highly correlated with measurements of forced expiratory volume in one second (FEV1) (R = 0.82; P = 0.0035) and forced vital capacity (FVC) (R = 0.95; P < 0.0001). The technique may open new pathways toward advancing more quantitative characterization of ventilation for routine clinical assessment for asthma severity as well as a number of other respiratory diseases. C1 [Lui, J. K.] Boston Univ, Sch Med, Boston, MA 02118 USA. [LaPrad, A. S.; Parameswaran, H.; Lutchen, K. R.] Boston Univ, Dept Biomed Engn, Coll Engn, Boston, MA 02115 USA. [Sun, Y.; Albert, M. S.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Sun, Y.; Albert, M. S.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA. [Sun, Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Albert, M. S.] Lakehead Univ, Dept Chem, Thunder Bay, ON P7A 5E1, Canada. [Albert, M. S.] Thunder Bay Reg Res Inst, Thunder Bay, ON P7B 6V4, Canada. RP Lutchen, KR (reprint author), Boston Univ, Dept Biomed Engn, Coll Engn, Boston, MA 02115 USA. EM klutch@bu.edu FU National Institutes of Health FX The authors would like to thank W. C. Karl, J. Konrad, Y-S. Tzeng, and J. P. Roche for their helpful advice and knowledge in image processing. The authors have been supported by the National Institutes of Health. NR 26 TC 2 Z9 2 U1 0 U2 4 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1748-670X J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PY 2013 AR 624683 DI 10.1155/2013/624683 PG 9 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 125EN UT WOS:000317521900001 ER PT J AU Holsinger, JW Scutchfield, FD AF Holsinger, James W., Jr. Scutchfield, F. Douglas BE Holsinger, JW TI History and Context of Public Health Care Introduction SO CONTEMPORARY PUBLIC HEALTH: PRINCIPLES, PRACTICE, AND POLICY LA English DT Editorial Material; Book Chapter ID EMERGENCY PREPAREDNESS; DISPARITIES C1 [Holsinger, James W., Jr.; Scutchfield, F. Douglas] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. [Holsinger, James W., Jr.] US Dept Vet Affairs, Washington, DC USA. [Holsinger, James W., Jr.] Univ Kentucky, Med Ctr, Lexington, KY 40506 USA. [Scutchfield, F. Douglas] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Scutchfield, F. Douglas] Univ Kentucky, Sch Publ Hlth, Lexington, KY 40506 USA. RP Holsinger, JW (reprint author), Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. NR 47 TC 1 Z9 1 U1 0 U2 0 PU UNIV PRESS KENTUCKY PI LEXINGTON PA 102 LAFFERTY HALL, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40506 USA BN 978-0-8131-4124-4 PY 2013 BP 1 EP 23 PG 23 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BDZ13 UT WOS:000315694300003 ER PT B AU Holsinger, JW AF Holsinger, James W., Jr. BE Holsinger, JW TI CONTEMPORARY PUBLIC HEALTH Principles, Practice, and Policy Preface SO CONTEMPORARY PUBLIC HEALTH: PRINCIPLES, PRACTICE, AND POLICY LA English DT Editorial Material; Book Chapter C1 [Holsinger, James W., Jr.] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. [Holsinger, James W., Jr.] US Dept Vet Affairs, Washington, DC USA. [Holsinger, James W., Jr.] Univ Kentucky, Med Ctr, Lexington, KY 40506 USA. RP Holsinger, JW (reprint author), Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU UNIV PRESS KENTUCKY PI LEXINGTON PA 102 LAFFERTY HALL, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40506 USA BN 978-0-8131-4124-4 PY 2013 BP XIII EP XIV PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BDZ13 UT WOS:000315694300002 ER PT B AU Keck, CW Scutchfield, FD Holsinger, JW AF Keck, C. William Scutchfield, F. Douglas Holsinger, James W., Jr. BE Holsinger, JW TI Future of Public Health Conclusion SO CONTEMPORARY PUBLIC HEALTH: PRINCIPLES, PRACTICE, AND POLICY LA English DT Editorial Material; Book Chapter ID SOCIAL DETERMINANTS; IMPACT ASSESSMENT; IMPROVING HEALTH; CARE C1 [Scutchfield, F. Douglas; Holsinger, James W., Jr.] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. [Scutchfield, F. Douglas] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Scutchfield, F. Douglas] Univ Kentucky, Sch Publ Hlth, Lexington, KY 40506 USA. [Holsinger, James W., Jr.] US Dept Vet Affairs, Washington, DC USA. [Holsinger, James W., Jr.] Univ Kentucky, Med Ctr, Lexington, KY 40506 USA. NR 49 TC 0 Z9 0 U1 0 U2 0 PU UNIV PRESS KENTUCKY PI LEXINGTON PA 102 LAFFERTY HALL, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40506 USA BN 978-0-8131-4124-4 PY 2013 BP 251 EP 276 PG 26 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BDZ13 UT WOS:000315694300015 ER PT J AU Malhotra, D Fletcher, AL Turley, SJ AF Malhotra, Deepali Fletcher, Anne L. Turley, Shannon J. TI Stromal and hematopoietic cells in secondary lymphoid organs: partners in immunity SO IMMUNOLOGICAL REVIEWS LA English DT Review DE fibroblastic reticular cell; lymphatic endothelial cell; blood endothelial cell; integrin alpha(+)(7) pericyte; T cell; dendritic cell; tolerance/suppression ID FIBROBLASTIC RETICULAR CELLS; HIGH ENDOTHELIAL VENULES; REGULATORY T-CELLS; MESENCHYMAL STEM-CELLS; NITRIC-OXIDE SYNTHASE; DENDRITIC CELLS; SELF-TOLERANCE; NODE CORTEX; PERIPHERAL TOLERANCE; POSITIVE SELECTION AB Secondary lymphoid organs (SLOs), including lymph nodes, Peyer's patches, and the spleen, have evolved to bring cells of the immune system together. In these collaborative environments, lymphocytes scan the surfaces of antigen-presenting cells for cognate antigens, while moving along stromal networks. The cell-cell interactions between stromal and hematopoietic cells in SLOs are therefore integral to the normal functioning of these tissues. Not only do stromal cells physically construct SLO architecture but they are essential for regulating hematopoietic populations within these domains. Stromal cells interact closely with lymphocytes and dendritic cells, providing scaffolds on which these cells migrate, and recruiting them into niches by secreting chemokines. Within lymph nodes, stromal cell-ensheathed conduit networks transport small antigens deep into the SLO parenchyma. More recently, stromal cells have been found to induce peripheral CD8(+) T-cell tolerance and control the extent to which newly activated T cells proliferate within lymph nodes. Thus, stromal-hematopoietic crosstalk has important consequences for regulating immune cell function within SLOs. In addition, stromal cell interactions with hematopoietic cells, other stroma, and the inflammatory milieu have profound effects on key stromal functions. Here, we examine ways in which these interactions within the lymph node environment influence the adaptive immune response. C1 [Malhotra, Deepali; Fletcher, Anne L.; Turley, Shannon J.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Malhotra, Deepali] Harvard Univ, Sch Med, Div Med Sci, Boston, MA USA. [Turley, Shannon J.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA. [Fletcher, Anne L.] Monash Univ, Immunol & Stem Cell Labs, Clayton, Vic, Australia. RP Turley, SJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM shannon_turley@dfci.harvard.edu OI Malhotra, Deepali/0000-0002-8215-7639 FU National Institutes of Health [R01 DK074500, P01 AI045757] FX This work was supported by National Institutes of Health grants R01 DK074500 and P01 AI045757 (to Shannon J. Turley). The authors have no conflicts of interest to declare. NR 121 TC 59 Z9 59 U1 1 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-2896 J9 IMMUNOL REV JI Immunol. Rev. PD JAN PY 2013 VL 251 SI SI BP 160 EP 176 DI 10.1111/imr.12023 PG 17 WC Immunology SC Immunology GA 119DK UT WOS:000317077400013 PM 23278748 ER PT J AU Kuperberg, G AF Kuperberg, Gina TI WHERE MEMORY MEETS LANGUAGE: A DYNAMIC NEURAL ARCHITECTURE OF LANGUAGE COMPREHENSION SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Kuperberg, Gina] Tufts Univ, Medford, MA USA. [Kuperberg, Gina] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 28 EP 28 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500040 ER PT J AU Kleckner, IR Avery, JA Quigley, KS Simmons, WK Barrett, LF AF Kleckner, Ian R. Avery, Jason A. Quigley, Karen S. Simmons, W. Kyle Barrett, Lisa Feldman TI NEURAL CORRELATES OF INTEROCEPTIVE ATTENTION AND INTEROCEPTIVE ACCURACY SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Kleckner, Ian R.; Quigley, Karen S.; Barrett, Lisa Feldman] Northeastern Univ, Interdisciplinary Affect Sci Lab, Boston, MA 02115 USA. [Kleckner, Ian R.; Avery, Jason A.; Simmons, W. Kyle] Laureate Inst Brain Res, Tulsa, OK USA. [Simmons, W. Kyle] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA. [Barrett, Lisa Feldman] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 40 EP 40 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500087 ER PT J AU Ahveninen, J Huang, S Nummenmaa, A Belliveau, JW Hung, AY Jaaskelainen, IP Rauschecker, JP Rossi, S Tiitinen, H Raij, T AF Ahveninen, Jyrki Huang, Samantha Nummenmaa, Aapo Belliveau, John W. Hung, An-Yi Jaaskelainen, Iiro P. Rauschecker, Josef P. Rossi, Stephanie Tiitinen, Hannu Raij, Tommi TI TRANSCRANIAL MAGNETIC STIMULATION PROVIDES CAUSAL EVIDENCE FOR "WHAT" AND "WHERE" PATHWAYS IN HUMAN AUDITORY CORTEX SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Ahveninen, Jyrki; Huang, Samantha; Nummenmaa, Aapo; Belliveau, John W.; Hung, An-Yi; Rossi, Stephanie; Raij, Tommi] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Jaaskelainen, Iiro P.; Tiitinen, Hannu] Aalto Univ, Dept Biomed Engn & Computat Sci BECS, Espoo, Finland. [Rauschecker, Josef P.] Georgetown Univ, Med Ctr, Dept Neurosci, Lab Integrat Neurosci & Cognit, Washington, DC 20057 USA. RI Jaaskelainen, Iiro/C-7392-2012 OI Jaaskelainen, Iiro/0000-0001-6001-6950 NR 0 TC 0 Z9 0 U1 0 U2 4 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 55 EP 55 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500156 ER PT J AU Bernhard, R Chaponis, J Siburian, R Gallagher, P Perlis, R Greene, J AF Bernhard, Regan Chaponis, Jonathan Siburian, Richie Gallagher, Patience Perlis, Roy Greene, Joshua TI THE GENETICS OF MORAL JUDGMENT: INFLUENCES OF THE OXYTOCIN RECEPTOR AND ARGININE VASOPRESSIN RECEPTOR 1A GENES SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Bernhard, Regan; Greene, Joshua] Harvard Univ, Cambridge, MA 02138 USA. [Chaponis, Jonathan; Siburian, Richie; Gallagher, Patience; Perlis, Roy] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 58 EP 58 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500173 ER PT J AU Kuperberg, G Fanucci, K AF Kuperberg, Gina Fanucci, Kristina TI EVENTS ALONG THE GARDEN PATH: NO N400 EFFECT AND A P600 EFFECT TO SEMANTICALLY REVERSIBLE EVENTS IN DIS-COURSE SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Kuperberg, Gina; Fanucci, Kristina] Tufts Univ, Medford, MA USA. [Kuperberg, Gina; Fanucci, Kristina] Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 138 EP 138 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500547 ER PT J AU Lau, E Weber, K Delaney-Busch, N Ustine, C Fanucci, K Hamalainen, M Kuperberg, G AF Lau, Ellen Weber, Kirsten Delaney-Busch, Nate Ustine, Candida Fanucci, Kristina Hamalainen, Matti Kuperberg, Gina TI PREDICTIVE SEMANTIC FACILITATION IN SCHIZOPHRENIA: A MULTIMODAL IMAGING INVESTIGATION SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Lau, Ellen] Univ Maryland, College Pk, MD 20742 USA. [Lau, Ellen; Weber, Kirsten; Delaney-Busch, Nate; Ustine, Candida; Fanucci, Kristina; Kuperberg, Gina] Tufts Univ, Medford, MA USA. [Lau, Ellen; Weber, Kirsten; Delaney-Busch, Nate; Ustine, Candida; Fanucci, Kristina; Hamalainen, Matti; Kuperberg, Gina] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 138 EP 138 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500548 ER PT J AU Lynn, S Hoge, E Fischer, L Barrett, LF Simon, N AF Lynn, Spencer Hoge, Elizabeth Fischer, Laura Barrett, Lisa Feldman Simon, Naomi TI GENDER DIFFERENCES IN OXYTOCIN-ASSOCIATED DISRUPTION OF DECISION BIAS DURING EMOTION PERCEPTION SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Lynn, Spencer; Barrett, Lisa Feldman] Northeastern Univ, Boston, MA USA. [Hoge, Elizabeth; Fischer, Laura; Barrett, Lisa Feldman; Simon, Naomi] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 148 EP 148 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500596 ER PT J AU Manning, J Hedden, T Prelec, D Gabrieli, J AF Manning, Joshua Hedden, Trey Prelec, Drazen Gabrieli, John TI PERSONALITY INFLUENCES INTERTEMPORAL CHOICE: BEHAVIORAL AND BRAIN EVIDENCE SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Manning, Joshua; Prelec, Drazen; Gabrieli, John] MIT, Cambridge, MA 02139 USA. [Hedden, Trey] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 6 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 148 EP 148 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500597 ER PT J AU Paczynski, M Jackendoff, R Holcomb, P Kuperberg, G AF Paczynski, Martin Jackendoff, Ray Holcomb, Phillip Kuperberg, Gina TI INDIVIDUAL DIFFERENCES IN ASPECTUAL COERCION SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Paczynski, Martin; Jackendoff, Ray; Holcomb, Phillip; Kuperberg, Gina] Tufts Univ, Medford, MA USA. [Paczynski, Martin] Univ Miami, Coral Gables, FL 33124 USA. [Kuperberg, Gina] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 8 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 165 EP 165 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030500677 ER PT J AU Patel, S Sheth, S Mian, M Bourne, S Flaherty, A Eskandar, E AF Patel, Shaun Sheth, Sameer Mian, Matt Bourne, Sarah Flaherty, Alice Eskandar, Emad TI CORRELATION AND CAUSATION: A SYSTEMS APPROACH TO UNDERSTANDING DECISION-MAKING AT THE SINGLE-NEURONAL LEVEL IN THE HUMAN BRAIN SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Patel, Shaun; Sheth, Sameer; Mian, Matt; Flaherty, Alice; Eskandar, Emad] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Patel, Shaun] Boston Univ, Sch Med, Boston, MA 02215 USA. [Bourne, Sarah] Vanderbilt Univ Sch Med, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 179 EP 179 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030501031 ER PT J AU List, A Rosenberg, M Sherman, A Grabowecky, M Suzuki, S Esterman, M AF List, Alexandra Rosenberg, Monica Sherman, Aleksandra Grabowecky, Marcia Suzuki, Satoru Esterman, Michael TI NEURAL CORRELATES OF LOCAL VS. GLOBAL ATTENTIONAL SCOPE REVEALED VIA EEG PATTERN CLASSIFICATION SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [List, Alexandra; Sherman, Aleksandra; Grabowecky, Marcia; Suzuki, Satoru] Northwestern Univ, Evanston, IL 60208 USA. [Rosenberg, Monica] Yale Univ, New Haven, CT 06520 USA. [Esterman, Michael] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 182 EP 182 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030501042 ER PT J AU Sheynin, J Shikari, S Ostovich, J Ekeh, B Beck, KD Pang, KCH Servatius, RJ Gilbertson, MW Orr, SP Myers, CE AF Sheynin, Jony Shikari, Saima Ostovich, Jackie Ekeh, Barbara Beck, Kevin D. Pang, Kevin C. H. Servatius, Richard J. Gilbertson, Mark W. Orr, Scott P. Myers, Catherine E. TI CONTRIBUTION OF SAFETY SIGNALS TO ESCAPE/AVOIDANCE LEARNING IN HEALTHY INDIVIDUALS SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Sheynin, Jony; Beck, Kevin D.; Pang, Kevin C. H.; Servatius, Richard J.; Myers, Catherine E.] Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA. [Shikari, Saima; Ostovich, Jackie; Ekeh, Barbara] Rutgers State Univ, Honors Coll, Newark, NJ 07102 USA. [Beck, Kevin D.; Pang, Kevin C. H.; Servatius, Richard J.; Myers, Catherine E.] Univ Med & Dent New Jersey, New Jersey Med Sch, Stress & Motivated Behav Inst, Newark, NJ 07103 USA. [Beck, Kevin D.; Pang, Kevin C. H.; Servatius, Richard J.; Myers, Catherine E.] New Jersey Hlth Care Syst, Dept Vet Affairs, E Orange, NJ USA. [Gilbertson, Mark W.] Manchester VA Med Ctr, Dept Vet Affairs, Manchester, NH USA. [Orr, Scott P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Orr, Scott P.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 213 EP 214 PG 2 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030501191 ER PT J AU Wilson-Mendenhall, C Barrett, LF Bartoshuk, L Clark, D Colquhoun, T AF Wilson-Mendenhall, Christy Barrett, Lisa Feldman Bartoshuk, Linda Clark, David Colquhoun, Thomas TI DELECTABLE DESSERTS & BEAUTIFUL BLOOMS: THE AFFECTIVE SALIENCE OF NATURAL CATEGORIES SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Meeting Abstract CT 20th Annual Meeting of the Cognitive-Neuroscience-Society CY APR 13-16, 2013 CL San Francisco, CA SP Cognit Neuroscience Soc C1 [Wilson-Mendenhall, Christy; Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA. [Wilson-Mendenhall, Christy; Barrett, Lisa Feldman] Massachusetts Gen Hosp, Martinos Ctr Biomedial Imaging, Boston, MA 02114 USA. [Bartoshuk, Linda] Univ Florida, Ctr Taste & Smell, Gainesville, FL 32611 USA. [Clark, David; Colquhoun, Thomas] Univ Florida, Dept Environm Hort, Gainesville, FL 32611 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PY 2013 SU S BP 243 EP 243 PG 1 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 118MV UT WOS:000317030501333 ER PT J AU Gu, CX Qiao, JP Zhu, ML Du, JL Shang, WH Yin, W Wang, W Han, M Lu, WD AF Gu, Chenxin Qiao, Jinping Zhu, Meilin Du, Jinglei Shang, Weihu Yin, Wei Wang, Wei Han, Mei Lu, Weidong TI Preliminary Evaluation of the Interactions of Panax ginseng and Salvia miltiorrhiza Bunge with 5-Fluorouracil on Pharmacokinetics in Rats and Pharmacodynamics in Human Cells SO AMERICAN JOURNAL OF CHINESE MEDICINE LA English DT Article DE Panax ginseng (PGS); Salvia miltiorrhiza Bunge (SMB); 5-Fluorouracil; Pharmacokinetics; Pharmacodynamics; Cytotoxicity ID NF-KAPPA-B; ALTERNATIVE MEDICINE; BREAST-CANCER; IN-VITRO; HERBAL INTERACTIONS; TANSHINONE-IIA; ASIAN GINSENG; GROWTH; VIVO; COMPLEMENTARY AB An increasing number of cancer patients are using herbs in combination with conventional chemotherapeutic treatment. It is therefore important to study the potential consequences of the interactions between herbs and anticancer drugs. The effects of extracts from Panax ginseng (PGS) and Salvia miltiorrhiza Bunge (SMB) on the pharmacokinetics of 5-fluorouracil (5-FU) were performed in vivo and detected by high performance liquid chromatography (HPLC), while, an ATP assay was used to study the pharmacodynamic interactions in vitro. The results of the pharmacokinetic experiments showed a significant increase in the elimination half-life (t1/2(k(e))) of 5-FU in the PGS-pretreated group and in the area under the curve (AUC) in the SMB-pretreated group compared with the control group. However, after SMB pretreatment, weight loss was observed in rats. The results of pharmacodynamic experiments showed that neither PGS nor SMB, when used alone, directly inhibited cancer cell growth at 0.1-100 mu g/ml. Moreover, PGS had a synergistic cytotoxic effect with 5-FU on human gastric cancer cells but not on normal gastric cells. The results imply that when combined with 5-FU, PGS may be a better candidate for further study. This study might provide insights for the selection of herbal-chemotherapy agent interactions. C1 [Gu, Chenxin; Qiao, Jinping; Zhu, Meilin; Du, Jinglei; Shang, Weihu; Yin, Wei; Wang, Wei; Han, Mei] Beijing Normal Univ, Minist Educ, Coll Chem, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China. [Han, Mei] Beijing Normal Univ, Coll Nat Resources & Technol, Beijing 100875, Peoples R China. [Lu, Weidong] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA. RP Han, M (reprint author), Beijing Normal Univ, Coll Nat Resources & Technol, Coll Chem, Key Lab Radiopharmaceut,Minist Educ, 19 XinJieKouWai St, Beijing 100875, Peoples R China. EM hanmei@bnu.edu.cn RI Lu, Weidong/C-3844-2008 OI Lu, Weidong/0000-0003-2838-6307 FU National Key Technology RD Program [2008BAI49B04]; China National Science Foundation [81173139] FX This work was supported by the National Key Technology R&D Program (2008BAI49B04) and the China National Science Foundation (81173139). We are grateful to Mr. Yongyan Wang and Mr. Jianqiang Zou for program suggestions. NR 46 TC 14 Z9 14 U1 1 U2 20 PU WORLD SCIENTIFIC PUBL CO PTE LTD PI SINGAPORE PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE SN 0192-415X EI 1793-6853 J9 AM J CHINESE MED JI Am. J. Chin. Med. PY 2013 VL 41 IS 2 BP 443 EP 458 DI 10.1142/S0192415X13500328 PG 16 WC Integrative & Complementary Medicine; Medicine, General & Internal SC Integrative & Complementary Medicine; General & Internal Medicine GA 119XX UT WOS:000317134200016 PM 23548131 ER PT S AU Appleton, KM Lee, MH Alele, C Alele, C Luttrell, DK Peterson, YK Morinelli, TA Luttrell, LM AF Appleton, Kathryn M. Lee, Mi-Hye Alele, Christian Alele, Christine Luttrell, Deirdre K. Peterson, Yuri K. Morinelli, Thomas A. Luttrell, Louis M. BE Conn, PM TI Biasing the Parathyroid Hormone Receptor: Relating In Vitro Ligand Efficacy to In Vivo Biological Activity SO G PROTEIN COUPLED RECEPTORS: MODELING, ACTIVATION, INTERACTIONS AND VIRTUAL SCREENING SE Methods in Enzymology LA English DT Review; Book Chapter ID HUMAN PTH/PTHRP RECEPTOR; C ACTIVATION DOMAIN; BONE-FORMATION; 7-TRANSMEMBRANE RECEPTORS; AGONIST ACTIVITY; PHOSPHOLIPASE-C; PTH RECEPTOR; PROTEIN; PEPTIDE; CELLS AB Recent advances in our understanding of the pluridimensional nature of GPCR signaling have provided new insights into how orthosteric ligands regulate receptors, and how the phenomenon of functional selectivity or ligand "bias" might be exploited in pharmaceutical design. In contrast to the predictions of simple two-state models of GPCR function, where ligands affect all aspects of GPCR signaling proportionally, current models assume that receptors exist in multiple "active" conformations that differ in their ability to couple to different downstream effectors, and that structurally distinct ligands can bias signaling by preferentially stabilizing different active states. The type 1 parathyroid hormone receptor (PTH1R) offers unique insight into both the opportunities and challenges of exploiting ligand bias in pharmaceutical design, not only because numerous "biased" PTH analogs have been described but also because many of them have been characterized for biological activity in vivo. The PTH1R has pleiotropic signaling capacity, coupling to G(s), G(q/11), and G(i/o) family heterotrimeric G proteins, and binding arrestins, which mediate receptor desensitization and arrestin-dependent signaling. Here, we compare the activity of six different PTH1R ligands in a common HEK293 cell background using three readouts of receptor activation, cAMP production, intracellular calcium influx, and ERK1/2 activation, demonstrating the range of signal bias that can be experimentally observed in a "typical" screening program. When the in vitro activity profiles of these ligands are compared to their reported effects on bone mass in murine models, it is apparent that ligands activating cAMP production produce an anabolic response that does not correlate with the ability to also elicit calcium signaling. Paradoxically, one ligand that exhibits inverse agonism for cAMP production and arrestin-dependent ERK1/2 activation in vitro, (D-Trp(12), Tyr(34))-bPTH(7-34), reportedly produces an anabolic bone response in vivo despite an activity profile that is dramatically different from that of other active ligands. This underscores a major challenge facing efforts to rationally design "biased" GPCR ligands for therapeutic application. While it is clearly plausible to identify functionally selective ligands, the ability to predict how bias will affect drug response in vivo, is often lacking, especially in complex disorders. C1 [Appleton, Kathryn M.; Lee, Mi-Hye; Alele, Christian; Alele, Christine; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Luttrell, Deirdre K.; Morinelli, Thomas A.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Appleton, Kathryn M.; Peterson, Yuri K.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Morinelli, Thomas A.; Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. EM luttrell@musc.edu FU NCRR NIH HHS [S10 RR027777]; NIDDK NIH HHS [R01 DK55524] NR 56 TC 12 Z9 12 U1 0 U2 9 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-407865-9 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2013 VL 522 BP 229 EP 262 DI 10.1016/B978-0-12-407865-9.00013-3 PG 34 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BEL04 UT WOS:000317147300013 PM 23374189 ER PT J AU Hu, YP Wehrly, R Gorrindo, T Hezel, DM Gironda, C Jenike, MA Stewart, SE AF Hu, Yu-Pei Wehrly, Rebecca Gorrindo, Tristan Hezel, Dianne M. Gironda, Christina Jenike, Michael A. Stewart, S. Evelyn TI Gender specific short stature in male adolescents with obsessive-compulsive disorder SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS LA English DT Article DE Obsessive-compulsive disorder; Adolescent; Gender; Growth; Height; Short stature; Serotonin reuptake inhibitor ID GROWTH-HORMONE; TOURETTE-SYNDROME; PREVALENCE; HEIGHT; PREDICTORS; WEIGHT; OCD; EPIDEMIOLOGY; ASSOCIATION; HYPOTHESIS AB Background: Obsessive-compulsive disorder (OCD) is a neuropsychiatric illness with frequent childhood onset and notable gender differences. Anecdotally, male OCD-affected youth frequently report concerns about short stature, resulting in endocrinology consultation. Initial reports have described this phenomenon, yet none have systematically analyzed potential confounders for this observation or examined for this in adults. Determining whether short stature is truly associated with OCD among adolescent males is important given its emotional impacts and costs of potentially unnecessary medical evaluations. This may also inform future studies of the potential complex etiologic overlaps between OCD, neuroendocrine pathophysiology and genetic risk variants. Methods: A total of 42 adolescents (9-20 years old) were recruited from a tertiary Pediatric OCD clinic between 2008 and 2010. Subjects with a DSM-IV OCD diagnosis who provided voluntary informed consent/assent were included; those with comorbid eating disorders were excluded. Height and weight were measured and transformed into percentiles using the US CDC growth census database (NHANES 2000). Clinical variables were compared by gender via the Fisher's exact test using a significance threshold of p<0.05. A multiple regression model predicting short stature was built to control for potential confounders. For secondary analyses, height and weight were collected from a random sample of OCD-affected adults (20-33 years old) at an OCD treatment program to examine for short stature among OCD-affected men. Results: The mean height percentile was 33.9% (SD 29.6) for male and 51.5% (SD 31.1) for female adolescents, with significantly more cases of short stature (<20%ile for age) among males (p=0.004). Comparative analyses demonstrated no significant confounding gender differences accounting for observed height differences (p>0.05). After adjusting for important clinical covariates, including serotonin reuptake inhibitor (SRI) use, psychostimulant use, and Tourette history, short stature remained strongly associated with male gender (OR=7A; 95% Cl: 1.5-36.6; p=0.01). This gender difference was not found in a comparable adult Sample (p=0.45), which had no elevated incidence of short stature. Conclusions: Short stature is common among adolescent OCD-affected males but not females, and appears to normalize by adulthood. This feature does not appear to be attributable to confounding clinical factors such as medication use. (C) 2012 Published by Elsevier Inc. C1 [Hu, Yu-Pei; Gironda, Christina; Jenike, Michael A.; Stewart, S. Evelyn] McLean Hosp, Belmont, MA 02178 USA. [Gorrindo, Tristan; Hezel, Dianne M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wehrly, Rebecca; Jenike, Michael A.] Harvard Univ, Sch Med, Boston, MA USA. [Stewart, S. Evelyn] Univ British Columbia, Vancouver, BC V5Z 4H4, Canada. [Stewart, S. Evelyn] British Columbia Mental Hlth & Addict Res Inst, Vancouver, BC, Canada. RP Stewart, SE (reprint author), Univ British Columbia, Dept Psychiat, A3-118,West 28th Ave, Vancouver, BC V5Z 4H4, Canada. EM stewart@pngu.mgh.harvard.edu RI Stewart, Evelyn/K-6961-2014; OI Stewart, S. Evelyn/0000-0002-0994-6383 NR 52 TC 1 Z9 1 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2211-3649 J9 J OBSESS-COMPULS REL JI J. Obsessive-Compuls. Relat. Disord. PD JAN PY 2013 VL 2 IS 1 BP 30 EP 36 DI 10.1016/j.jocrd.2012.07.009 PG 7 WC Psychiatry SC Psychiatry GA 120BV UT WOS:000317145400005 ER PT J AU Abramovitch, A Dar, R Mittelman, A Schweiger, A AF Abramovitch, Amitai Dar, Reuven Mittelman, Andrew Schweiger, Avraham TI Don't judge a book by its cover: ADHD-like symptoms in obsessive compulsive disorder SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS LA English DT Article DE OCD; ADHD; Comorbidity; DSM; Symptoms; Attention ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; CEREBRAL-BLOOD-FLOW; BEHAVIORAL-INHIBITION; NONVERBAL MEMORY; NEUROPSYCHOLOGICAL PERFORMANCE; FUNCTIONAL CONNECTIVITY; PERSONALITY-DISORDER; CLINICAL-VARIABLES; HOARDING SYMPTOMS AB Reported OCD-ADHD comorbidity rates are highly variable and the two disorders are characterized by opposite symptomatology and antithetical pathophysiology. We hypothesized that OCD-related attentional impairment could be misdiagnosed as ADHD symptoms. Thirty adults with OCD, thirty with ADHD, and thirty matched healthy controls (HC) completed disorder-specific measures and an ADHD DSM-IV based questionnaire examining childhood and current symptoms. The ADHD group met significantly more current and childhood ADHD criteria than the other groups. Within the HC and ADHD groups, but not the OCD group, significant positive correlations were found between childhood and current ADHD symptoms. Only within the OCD group, obsessive-compulsive symptoms and ADHD criteria correlated positively. These findings support the predictions of the executive overload model of OCD, suggesting that ADHD-like symptoms in OCD may be a consequence of OCD symptomatology. Clinical implications of a potential misdiagnosis should be considered in light of the probability that stimulant medication exacerbates OCD symptoms. This is particularly important in children, where ADHD diagnosis is based primarily on informant reports. (C) 2012 Elsevier Inc. All rights reserved. C1 [Abramovitch, Amitai] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Abramovitch, Amitai; Mittelman, Andrew] Massachusetts Gen Hosp, Dept Psychiat, OCD, Boston, MA 02114 USA. [Abramovitch, Amitai; Mittelman, Andrew] Massachusetts Gen Hosp, Related Disorders Program, Boston, MA 02114 USA. [Dar, Reuven] Tel Aviv Univ, Sch Psychol Sci, Dept Psychol, IL-69978 Tel Aviv, Israel. [Schweiger, Avraham] Acad Coll Tel Aviv, Sch Behav Sci, IL-61083 Tel Aviv, Israel. RP Abramovitch, A (reprint author), Massachusetts Gen Hosp, Dept Psychiat, OCD, 185 Cambridge St,Suite 2000, Boston, MA 02114 USA. EM aabramovitch@partners.org; ruvidar@post.tau.ac.il; amittelman@partners.org; schweige@mta.ac.il RI Abramovitch, Amitai/I-3333-2012 OI Abramovitch, Amitai/0000-0001-9640-0970 NR 103 TC 4 Z9 4 U1 5 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2211-3649 J9 J OBSESS-COMPULS REL JI J. Obsessive-Compuls. Relat. Disord. PD JAN PY 2013 VL 2 IS 1 BP 53 EP 61 DI 10.1016/j.jocrd.2012.09.001 PG 9 WC Psychiatry SC Psychiatry GA 120BV UT WOS:000317145400009 ER PT J AU Lai, PS Matteau, A Iddriss, A Hawes, CL Ranieri, VM Thompson, BT AF Lai, P. S. Matteau, A. Iddriss, A. Hawes, C. L. Ranieri, V. M. Thompson, B. T. TI An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock SO MINERVA ANESTESIOLOGICA LA English DT Article DE Sepsis; Shock, septic; Drotrecogin alfa activated; Meta-analysis as topic ID GOAL-DIRECTED THERAPY; PROTEIN-C; SURVIVING SEPSIS; SAFETY; CARE; CAMPAIGN; EPIDEMIOLOGY; COAGULOPATHY; GUIDELINES; PROGRAM AB Background. Significant debate continues over the efficacy of drotrecogin alpha activated (DAA) in sepsis. This updated meta-analysis provides an updated summary effect estimate and explores the reasons for outcome heterogeneity in placebo-controlled randomized clinical trials of DAA on 28-day all-cause mortality in patients with severe sepsis or septic shock. Methods. Computer searches of MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, published abstracts from major intensive care meetings and examination of reference lists were used to identify five placebo-controlled randomized clinical trials with 7260 patients. The primary endpoint was 28-day all-cause mortality. Secondary outcomes were 28-day incidence of severe bleeding and intracranial hemorrhage. Results. DAA was not associated with improved 28-day all-cause mortality in patients with severe sepsis or septic shock (pooled relative risk (RR) of 0.97 [95% CI 0.83-1.14]), and is associated with an increase in serious bleeding. The significant heterogeneity in the pooled RR for 28-day mortality (I-2 value of 59.4%, chi(2) P-value 0.043) is no longer present with exclusion of the post-study amendment portion of PROWESS (I-2 value of 0%, chi(2) P-value 0.44 without PROWESS post-amendment). Using meta-regression, the best ranked predictor of outcome heterogeneity was baseline mortality in the placebo arm, which was among the highest in PROWESS. Conclusion. DAA is not associated with improved survival in patients with severe sepsis or septic shock. Further studies should be done to determine whether changes in supportive therapy for sepsis explain the variable efficacy of DAA in randomized controlled clinical trials observed over time. (Minerva Anestesiol 2013;79:33-43) C1 [Lai, P. S.; Thompson, B. T.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Matteau, A.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Iddriss, A.; Hawes, C. L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Ranieri, V. M.] Univ Turin, S Giovanni Battista Molinette Hosp, Turin, Italy. RP Lai, PS (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Bulfinch 148,55 Fruit St, Boston, MA 02114 USA. EM plai@partners.org FU NIEHS NIH HHS [F32 ES020082] NR 38 TC 5 Z9 5 U1 0 U2 7 PU EDIZIONI MINERVA MEDICA PI TURIN PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY SN 0375-9393 J9 MINERVA ANESTESIOL JI Minerva Anestesiol. PD JAN PY 2013 VL 79 IS 1 BP 33 EP 43 PG 11 WC Anesthesiology; Critical Care Medicine SC Anesthesiology; General & Internal Medicine GA 122LK UT WOS:000317319400007 PM 23174922 ER PT J AU Verzi, MP Shin, HJ San Roman, AK Liu, XS Shivdasani, RA AF Verzi, Michael P. Shin, Hyunjin San Roman, Adrianna K. Liu, X. Shirley Shivdasani, Ramesh A. TI Intestinal Master Transcription Factor CDX2 Controls Chromatin Access for Partner Transcription Factor Binding SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID GENE-EXPRESSION; TRANSGENIC MICE; PHO5 PROMOTER; HUMAN GENOME; CHIP-SEQ; DIFFERENTIATION; ENHANCERS; CELLS; MAINTENANCE; DISRUPTION AB Tissue-specific gene expression requires modulation of nucleosomes, allowing transcription factors to occupy cis elements that are accessible only in selected tissues. Master transcription factors control cell-specific genes and define cellular identities, but it is unclear if they possess special abilities to regulate cell-specific chromatin and if such abilities might underlie lineage determination and maintenance. One prevailing view is that several transcription factors enable chromatin access in combination. The homeodomain protein CDX2 specifies the embryonic intestinal epithelium, through unknown mechanisms, and partners with transcription factors such as HNF4A in the adult intestine. We examined enhancer chromatin and gene expression following Cdx2 or Hnf4a excision in mouse intestines. HNF4A loss did not affect CDX2 binding or chromatin, whereas CDX2 depletion modified chromatin significantly at CDX2-bound enhancers, disrupted HNF4A occupancy, and abrogated expression of neighboring genes. Thus, CDX2 maintains transcription-permissive chromatin, illustrating a powerful and dominant effect on enhancer configuration in an adult tissue. Similar, hierarchical control of cell-specific chromatin states is probably a general property of master transcription factors. C1 [Verzi, Michael P.; San Roman, Adrianna K.; Shivdasani, Ramesh A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Shin, Hyunjin; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Verzi, Michael P.; Shivdasani, Ramesh A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Verzi, Michael P.; Shivdasani, Ramesh A.] Harvard Univ, Sch Med, Boston, MA USA. [Verzi, Michael P.] Rutgers State Univ, Dept Genet, New Brunswick, NJ 08903 USA. [San Roman, Adrianna K.] Harvard Univ, Sch Med, Grad Program Biol & Biomed Sci, Boston, MA USA. RP Shivdasani, RA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM xsliu@jimmy.harvard.edu; ramesh_shivdasani@dfci.harvard.edu FU National Institutes of Health [R01DK082889, R01HG4069, K01DK088868, P50CA127003]; Crohn's and Colitis Foundation of America [1987] FX This work was supported by National Institutes of Health grants R01DK082889 (R.A.S.), R01HG4069 (X.S.L.), K01DK088868 (M.P.V.), and P50CA127003 and fellowship number 1987 from the Crohn's and Colitis Foundation of America (M.P.V.). NR 51 TC 20 Z9 20 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD JAN PY 2013 VL 33 IS 2 BP 281 EP 292 DI 10.1128/MCB.01185-12 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 120QM UT WOS:000317186300008 PM 23129810 ER PT J AU Yu, ZY Poppe, JL Wang, XY AF Yu, Zhanyang Poppe, Jessica L. Wang, Xiaoying TI Mitochondrial Mechanisms of Neuroglobin's Neuroprotection SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY LA English DT Review ID FOCAL CEREBRAL-ISCHEMIA; FREE-RADICAL SCAVENGER; N-TERMINAL KINASE; NITRIC-OXIDE; OXIDATIVE STRESS; CELL-DEATH; CYTOCHROME-C; ARTERY OCCLUSION; BRAIN-INJURY; AXONAL-TRANSPORT AB Neuroglobin (Ngb) is an oxygen-binding globin protein that has been demonstrated to be neuroprotective against stroke and related neurological disorders. However, the underlying mechanisms of Ngb's neuroprotection remain largely undefined. Mitochondria play critical roles in multiple physiological pathways including cell respiration, energy production, free radical generation, and cellular homeostasis and apoptosis. Mitochondrial dysfunction is widely involved in the pathogenesis of stroke and neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's diseases. Accumulating evidence showed that elevated Ngb level is associated with preserved mitochondrial function, suggesting that Ngb may play neuroprotective roles through mitochondria-mediated pathways. In this paper we briefly discuss the mitochondria-related mechanisms in Ngb's neuroprotection, especially those involved in ATP production, ROS generation and scavenging, and mitochondria-mediated cell death signaling pathways. C1 [Yu, Zhanyang] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Charlestown, MA 02129 USA. RP Yu, ZY (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Charlestown, MA 02129 USA. EM zyu@partners.org FU NIH [R01-NS049476, RO1-NS065998]; American Heart Association [12POST9720007] FX This work was supported in part by NIH Grants R01-NS049476 and RO1-NS065998 (to X. Wang) and Postdoctoral Fellowship (12POST9720007) from the American Heart Association (to Z. Yu). The authors thank Dr. Eng H. Lo for his very helpful discussion. they declare no conflict of interests. NR 122 TC 16 Z9 17 U1 1 U2 11 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1942-0900 J9 OXID MED CELL LONGEV JI Oxidative Med. Cell. Longev. PY 2013 AR 756989 DI 10.1155/2013/756989 PG 11 WC Cell Biology SC Cell Biology GA 120VE UT WOS:000317200400001 ER PT S AU Cherry, ABC Daley, GQ AF Cherry, Anne B. C. Daley, George Q. BE Caskey, CT TI Reprogrammed Cells for Disease Modeling and Regenerative Medicine SO ANNUAL REVIEW OF MEDICINE, VOL 64 SE Annual Review of Medicine LA English DT Review; Book Chapter DE induced pluripotent stem (iPS) cells; history of reprogramming; cellular therapy; gene correction; hematology ID PLURIPOTENT STEM-CELLS; TAL EFFECTOR NUCLEASES; ZINC-FINGER NUCLEASES; HUMAN SOMATIC-CELLS; HUMAN IPS CELLS; HEMATOPOIETIC DIFFERENTIATION; APLASTIC-ANEMIA; MARROW TRANSPLANTATION; AORTIC ENDOTHELIUM; DEFINED FACTORS AB The conversion of somatic cells into pluripotent cells is transforming the way diseases are researched and treated. Induced pluripotent stem (iPS) cells' promise may soon be realized in the field of hematology, as hematopoietic stem cell transplants are already commonplace in clinics around the world. We provide a current comparison between induced pluripotent and embryonic stem cells, describe progress toward modeling hematological disorders using iPS cells, and illustrate the hurdles that must be overcome before iPS cell therapies will be available in clinics. C1 [Cherry, Anne B. C.; Daley, George Q.] Childrens Hosp, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA. [Cherry, Anne B. C.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Cherry, Anne B. C.; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Daley, George Q.] Broad Inst, Boston, MA 02115 USA. [Cherry, Anne B. C.; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA. RP Cherry, ABC (reprint author), Childrens Hosp, Howard Hughes Med Inst, Stem Cell Transplantat Program, Div Pediat Hematol Oncol,Manton Ctr Orphan Dis Re, Boston, MA 02115 USA. EM george.daley@childrens.harvard.edu FU Howard Hughes Medical Institute; NHLBI NIH HHS [RC2 HL102815, RC2-HL102815, U01 HL100001, U01-HL100001]; NIDDK NIH HHS [RC4 DK090913, R24 DK092760, R24DK092760, RC4DK090913] NR 67 TC 66 Z9 68 U1 3 U2 33 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4219 BN 978-0-8243-0564-2 J9 ANNU REV MED JI Annu. Rev. Med. PY 2013 VL 64 BP 277 EP 290 DI 10.1146/annurev-med-050311-163324 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BEF31 UT WOS:000316384400020 PM 23327523 ER PT S AU Reiser, J Sever, S AF Reiser, Jochen Sever, Sanja BE Caskey, CT TI Podocyte Biology and Pathogenesis of Kidney Disease SO ANNUAL REVIEW OF MEDICINE, VOL 64 SE Annual Review of Medicine LA English DT Review; Book Chapter DE CKD; actin cytoskeleton; dynamin; suPAR; novel therapeutics ID ACTIN POLYMERIZATION; MEDIATED ENDOCYTOSIS; UROKINASE RECEPTOR; CELL BIOLOGY; RHO-GTPASES; CATHEPSIN-L; DYNAMIN; PROTEINURIA; GLOMERULOSCLEROSIS; CYTOSKELETON AB Proteinuric chronic kidney disease (CKD), once a rare affliction believed to be mainly caused by genetic mutations, has become a global pandemic that severely diminishes the quality of life for millions. Despite the changing face of CKD, treatment options and resources remain woefully antiquated and have failed to arrest or reverse the effects of kidney-related diseases. Histological and genetic data strongly implicate one promising target: the podocyte. Podocytes are terminally differentiated cells of the kidney glomerulus that are essential for the integrity of the kidney filter. Their function is primarily based on their intricate structure, which includes foot processes. Loss of these actin-driven membrane extensions is tightly connected to the presence of protein in the urine, podocyte loss, development of CKD, and ultimately renal failure. C1 [Reiser, Jochen] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. [Sever, Sanja] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. [Sever, Sanja] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Reiser, J (reprint author), Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. EM jochen_reiser@rush.edu FU NIDDK NIH HHS [R01 DK087985] NR 36 TC 43 Z9 46 U1 1 U2 12 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4219 BN 978-0-8243-0564-2 J9 ANNU REV MED JI Annu. Rev. Med. PY 2013 VL 64 BP 357 EP 366 DI 10.1146/annurev-med-050311-163340 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA BEF31 UT WOS:000316384400025 PM 23190150 ER PT S AU Pietrobon, D Moskowitz, MA AF Pietrobon, Daniela Moskowitz, Michael A. BE Julius, D TI Pathophysiology of Migraine SO ANNUAL REVIEW OF PHYSIOLOGY, VOL 75 SE Annual Review of Physiology LA English DT Review; Book Chapter DE spreading depression; trigeminovascular system; neurogenic inflammation; excitatory/inhibitory balance ID GENE-RELATED PEPTIDE; FAMILIAL HEMIPLEGIC MIGRAINE; CORTICAL SPREADING DEPRESSION; TRANSCRANIAL MAGNETIC STIMULATION; GENOME-WIDE ASSOCIATION; ACTIVITY-MODIFYING PROTEIN-1; TRIGEMINAL NUCLEUS CAUDALIS; NOCICEPTIVE DURAL INPUT; MAST-CELL DEGRANULATION; DELAYED CEREBRAL EDEMA AB Migraine is a collection of perplexing neurological conditions in which the brain and its associated tissues have been implicated as major players during an attack. Once considered exclusively a disorder of blood vessels, compelling evidence has led to the realization that migraine represents a highly choreographed interaction between major inputs from both the peripheral and central nervous systems, with the trigeminovascular system and the cerebral cortex among the main players. Advances in in vivo and in vitro technologies have informed us about the significance to migraine of events such as cortical spreading depression and activation of the trigeminovascular system and its constituent neuropeptides, as well as about the importance of neuronal and glial ion channels and transporters that contribute to the putative cortical excitatory/inhibitory imbalance that renders migraineurs susceptible to an attack. This review focuses on emerging concepts that drive the science of migraine in both a mechanistic direction and a therapeutic direction. C1 [Pietrobon, Daniela] Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy. [Pietrobon, Daniela] Univ Padua, CNR Inst Neurosci, I-35121 Padua, Italy. [Moskowitz, Michael A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Neurosci Ctr, Boston, MA 02129 USA. [Moskowitz, Michael A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Neurosci Ctr, Boston, MA 02129 USA. RP Pietrobon, D (reprint author), Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy. EM daniela.pietrobon@unipd.it; moskowitz@helix.mgh.harvard.edu NR 171 TC 131 Z9 135 U1 16 U2 64 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4278 BN 978-0-8243-0375-4 J9 ANNU REV PHYSIOL JI Annu. Rev. Physiol. PY 2013 VL 75 BP 365 EP 391 DI 10.1146/annurev-physiol-030212-183717 PG 27 WC Physiology SC Physiology GA BEF28 UT WOS:000316381400017 PM 23190076 ER PT J AU Brandacher, G Sachs, DH Thomson, AW AF Brandacher, Gerald Sachs, David H. Thomson, Angus W. TI Immunology of Vascularized Composite Allografts SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY LA English DT Editorial Material C1 [Brandacher, Gerald] Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD 21205 USA. [Sachs, David H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA. [Thomson, Angus W.] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA. RP Brandacher, G (reprint author), Johns Hopkins Univ, Sch Med, Dept Plast & Reconstruct Surg, Baltimore, MD 21205 USA. EM brandacher@jhmi.edu RI Brandacher, Gerald/L-7540-2016 NR 0 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1740-2522 J9 CLIN DEV IMMUNOL JI Clin. Dev. Immunol. PY 2013 AR 689071 DI 10.1155/2013/689071 PG 2 WC Immunology SC Immunology GA 116PU UT WOS:000316895500001 ER PT J AU Agnew-Blais, J Seidman, LJ AF Agnew-Blais, Jessica Seidman, Larry J. TI Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: A quantitative and qualitative review SO COGNITIVE NEUROPSYCHIATRY LA English DT Article DE Familial high risk; Meta-analysis; Neurocognition; Psychosis; Schizophrenia ID JERUSALEM INFANT-DEVELOPMENT; EDINBURGH HIGH-RISK; CONTINUOUS PERFORMANCE-TEST; GENETIC-RISK; 1ST-DEGREE RELATIVES; COGNITIVE DEFICITS; SUSTAINED ATTENTION; NEUROPSYCHOLOGICAL ASSESSMENT; LANGUAGE LATERALIZATION; NONPSYCHOTIC RELATIVES AB Introduction. Neurocognitive dysfunction is a central feature of schizophrenia and is observed during all phases of the illness. Because schizophrenia is known to run in families, studying neurocognitive function in first-degree, nonpsychotic relatives has been a widely utilised strategy for almost 50 years for understanding presumed genetic risk. Studying nonpsychotic relatives (familial high-risk, or FHR) allows for identification of cognitive vulnerability markers independent of confounds associated with psychosis. Methods. Prior meta-analyses have elucidated the level and pattern of cognitive deficits in the premorbid, prodromal, and postonset periods of psychosis, and in relatives regardless of age. However, no prior quantitative analyses have specifically focused on studies of young first-degree relatives of individuals with schizophrenia who have not passed through the peak age illness risk (70 individual tests and 250 variables. Conclusions. In general, young FHR individuals demonstrated deficits with a moderate level of severity compared with healthy controls. The largest average effect sizes (ESs), based on tests given in at least three independent studies, were on estimates of Full Scale IQ (d= 0.777), followed by Vocabulary (d= 0.749) and single word reading tests (d= 0.698) (often used as estimates of IQ). Measures of declarative memory, sustained attention, working memory and others had more modest ESs. Deficits were milder than in established schizophrenia, but often as severe as in clinical high-risk or putatively prodromal participants and in older relatives examined in prior meta-analyses. Additionally, while assessed from a more limited literature, youth at FHR for schizophrenia tended to show worse neurocognitive functioning than those at FHR for affective psychosis. This suggests that genetic risk for schizophrenia as reflected in a positive FHR carries an especially heavy impact on cognitive ability. C1 [Agnew-Blais, Jessica] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr,Dept Psychiat, Publ Psychiat Div,Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Seidman, LJ (reprint author), Massachusetts Mental Hlth Ctr, Dept Psychiat, Beth Israel Deaconess Med Ctr, Commonwealth Res Ctr, 5th Floor,75 Fenwood Rd, Boston, MA 02115 USA. EM lseidman@bidmc.harvard.edu RI Agnew-Blais, Jessica/L-9236-2015 OI Agnew-Blais, Jessica/0000-0002-0755-6867 FU NIMH [T32MH017119, U01 MH081928, P50MH080272, SCDMH82101008006] FX This research was supported, in part, by NIMH Grants (T32MH017119, JA-B) U01 MH081928, P50MH080272 and SCDMH82101008006 (LJS). NR 110 TC 43 Z9 44 U1 1 U2 21 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 1354-6805 J9 COGN NEUROPSYCHIATRY JI Cogn. Neuropsychiatry PD JAN 1 PY 2013 VL 18 IS 1-2 SI SI BP 44 EP 82 DI 10.1080/13546805.2012.676309 PG 39 WC Psychiatry SC Psychiatry GA 110LQ UT WOS:000316444200004 PM 22998599 ER PT J AU Hochholzer, W Giugliano, RP AF Hochholzer, Willibald Giugliano, Robert P. TI Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD? SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Article DE Lipids; Cholesterol; Cardiovascular risk; Lipid lowering therapy; Statins; Niacin; Fibrate; Ezetimibe; Omega-3 fatty acids; Cholesterol ester transfer protein inhibitors; Proprotein convertase subtilisin kexin type 9 inhibitors ID CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; PLACEBO-CONTROLLED TRIAL; TYPE-2 DIABETES-MELLITUS; RANDOMIZED CLINICAL-TRIAL; LOWERING LDL CHOLESTEROL; PANEL-III GUIDELINES; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; HIGH-RISK AB Hypercholesterolemia is one of the main risk factors for the development of atherosclerotic diseases. Multiple clinical trials of lipid-lowering agents have demonstrated that lowering cholesterol effectively reduces the risk of cardiovascular events and death. Currently, treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") is the most commonly used approach, given their superior efficacy relative to other cholesterol lowering agents. However, not all patients on statin monotherapy achieve target cholesterol levels, and even when cholesterol lowering is successful, significant residual cardiovascular risk remains. There is increasing interest in developing combination cholesterol-modifying therapies that may augment the treatment effect and minimize the side effects of statins. Although there is currently no evidence that any of the potential therapy combinations can improve clinical outcome compared to statin monotherapy alone, results of several large ongoing trials will help to clarify this important field. C1 [Hochholzer, Willibald] Univ Herzzentrum Freiburg Bad Krozingen, D-79189 Bad Krozingen, Germany. [Giugliano, Robert P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA. RP Giugliano, RP (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, 350 Longwood Ave,1st Floor, Boston, MA 02115 USA. EM willibald.hochholzer@herzzentrum.de; rgiugliano@partners.org FU Amgen; Merck FX W. Hochholzer: Consultancy for Sanofi-Aventis; R. Giugliano: Consultancy for Amgen, Merck and Sanofi, travel/accommodations expenses covered or reimbursed from Amgen and Merck. NR 95 TC 2 Z9 2 U1 0 U2 3 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 J9 CURR ATHEROSCLER REP JI Curr. Atheroscleros. Rep. PD JAN PY 2013 VL 15 IS 1 AR 290 DI 10.1007/s11883-012-0290-8 PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 112DS UT WOS:000316573000001 PM 23242605 ER PT J AU Pretorius, E Bester, J Vermeulen, N Lipinski, B AF Pretorius, Etheresia Bester, Janette Vermeulen, Natasha Lipinski, Boguslaw TI Oxidation Inhibits Iron-Induced Blood Coagulation SO CURRENT DRUG TARGETS LA English DT Article DE Fibrinogen; blood coagulation; iron; hydroxyl radical; oxidation ID HYDROGEN-PEROXIDE; SELENITE; ANTIOXIDANTS; CANCER; DEATH; CELLS AB Blood coagulation under physiological conditions is activated by thrombin, which converts soluble plasma fibrinogen (FBG) into an insoluble clot. The structure of the enzymatically-generated clot is very characteristic being composed of thick fibrin fibers susceptible to the fibrinolytic degradation. However, in chronic degenerative diseases, such as atherosclerosis, diabetes mellitus, cancer, and neurological disorders, fibrin clots are very different forming dense matted deposits (DMD) that are not effectively removed and thus create a condition known as thrombosis. We have recently shown that trivalent iron (ferric ions) generates hydroxyl radicals, which subsequently convert FBG into abnormal fibrin clots in the form of DMDs. A characteristic feature of DMDs is their remarkable and permanent resistance to the enzymatic degradation. Therefore, in order to prevent thrombotic incidences in the degenerative diseases it is essential to inhibit the iron-induced generation of hydroxyl radicals. This can be achieved by the pretreatment with a direct free radical scavenger (e.g. salicylate), and as shown in this paper by the treatment with oxidizing agents such as hydrogen peroxide, methylene blue, and sodium selenite. Although the actual mechanism of this phenomenon is not yet known, it is possible that hydroxyl radicals are neutralized by their conversion to the molecular oxygen and water, thus inhibiting the formation of dense matted fibrin deposits in human blood. C1 [Pretorius, Etheresia; Bester, Janette; Vermeulen, Natasha] Univ Pretoria, Dept Physiol, Fac Hlth Sci, ZA-0007 Arcadia, South Africa. [Lipinski, Boguslaw] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. RP Pretorius, E (reprint author), Univ Pretoria, Dept Physiol, Fac Hlth Sci, Private Bag X323, ZA-0007 Arcadia, South Africa. EM resia.pretorius@up.ac.za NR 30 TC 20 Z9 20 U1 0 U2 5 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-4501 J9 CURR DRUG TARGETS JI Curr. Drug Targets PD JAN PY 2013 VL 14 IS 1 BP 13 EP 19 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 116GO UT WOS:000316871200003 PM 23170793 ER PT J AU Ananthakrishnan, AN Korzenik, JR Hur, C AF Ananthakrishnan, Ashwin N. Korzenik, Joshua R. Hur, Chin TI Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE Crohn's disease; mucosal healing; infliximab; cost-effectiveness ID SCHEDULED MAINTENANCE TREATMENT; INFLAMMATORY-BOWEL-DISEASE; LONG-TERM; CLINICAL-RESPONSE; DOSE-ESCALATION; INFLIXIMAB; ADALIMUMAB; ADULTS; TRIAL; HOSPITALIZATION AB Background: Observational studies have demonstrated that mucosal healing (MH) may be associated with reductions in hospitalizations and surgeries for moderate to severe Crohn's disease (CD). Whether treatment to achieve MH is a cost-effective endpoint has not been established previously. Methods: We constructed a decision analytic model comparing two treatment strategies. In the clinical response (CR) arm, patients not in clinical remission at year 1 are dose-escalated. In the MH arm, patients with persistence of mucosal ulcerations at year 1 are escalated irrespective of clinical symptoms. Patients remain at risk for hospitalization and surgeries while they have active disease. We examined a 2-year time horizon. Results: In the base case the MH strategy was more effective at 2 years (quality-adjusted life year [QALY] 0.71) compared to the CR strategy (QALY 0.69) but was also more expensive with an incremental cost-effectiveness ratio (ICER) of $49,278/QALY gained. In a hypothetical cohort of 100,000 patients assigned to each treatment arm, the MH strategy resulted in lower rates of hospitalization and surgery with a number needed to treat of 27 and 106, respectively. The results were sensitive to the ability of infliximab to achieve MH and the incremental benefit of MH over clinical remission. Conclusions: We demonstrate that MH as an endpoint is a cost-effective strategy in CD patients initiating IFX therapy. Further prospective studies on durability of MH and its incremental benefit as well as the ability of other available biologic agents to achieve MH are necessary to validate our findings. (Inflamm Bowel Dis 2013;19:37-44) C1 [Ananthakrishnan, Ashwin N.; Korzenik, Joshua R.; Hur, Chin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.; Korzenik, Joshua R.; Hur, Chin] Harvard Univ, Sch Med, Boston, MA USA. [Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Fl, Boston, MA 02114 USA. EM aananthakrishnan@partners.org OI Hur, Chin/0000-0002-2819-7576 NR 39 TC 16 Z9 17 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2013 VL 19 IS 1 BP 37 EP 44 DI 10.1002/ibd.22951 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 109VL UT WOS:000316397200013 PM 22416019 ER PT J AU Moran, CJ Walters, TD Guo, CH Kugathasan, S Klein, C Turner, D Wolters, VM Bandsma, RH Mouzaki, M Zachos, M Langer, JC Cutz, E Benseler, SM Roifman, CM Silverberg, MS Griffiths, AM Snapper, SB Muise, AM AF Moran, Christopher J. Walters, Thomas D. Guo, Cong-Hui Kugathasan, Subra Klein, Christoph Turner, Dan Wolters, Victorien M. Bandsma, Robert H. Mouzaki, Marialena Zachos, Mary Langer, Jacob C. Cutz, Ernest Benseler, Susanne M. Roifman, Chaim M. Silverberg, Mark S. Griffiths, Anne M. Snapper, Scott B. Muise, Aleixo M. TI IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE IL-10; IL-10 receptor; inflammatory bowel disease; immunodeficiency ID INFLAMMATORY-BOWEL-DISEASE; REGULATORY T-CELLS; INTERLEUKIN-10 RECEPTOR; CROHNS-DISEASE; SUSCEPTIBILITY LOCI; MUTATIONS; VARIANTS; SIGNALS; NUMBER; IL10 AB Background: Interleukin-10 (IL-10) signaling genes are attractive inflammatory bowel disease (IBD) candidate genes as IL-10 restricts intestinal inflammation, IL-10 polymorphisms have been associated with IBD in genome-wide association studies, and mutations in IL-10 and IL-10 receptor (IL-10R) genes have been reported in immunodeficient children with severe infantile-onset IBD. Our objective was to determine if IL-10R polymorphisms were associated with early-onset IBD (EO-IBD) and very-early-onset IBD (VEO-IBD). Methods: Candidate-gene analysis of IL10RA and IL10RB was performed after initial sequencing of an infantile onset-IBD patient identified a novel homozygous mutation. The discovery cohort included 188 EO-IBD subjects and 188 healthy subjects. Polymorphisms associated with IBD in the discovery cohort were genotyped in an independent validation cohort of 422 EO-IBD subjects and 480 healthy subjects. Results: We identified a homozygous, splice-site point mutation in IL10RA in an infantile-onset IBD patient causing a premature stop codon (P206X) and IL-10 insensitivity. IL10RA and IL10RB sequencing in the discovery cohort identified five IL10RA polymorphisms associated with ulcerative colitis (UC) and two IL10RB polymorphisms associated with Crohn's disease (CD). Of these polymorphisms, two IL10RA single nucleotide polymorphisms, rs2228054 and rs2228055, were associated with VEO-UC in the discovery cohort and replicated in an independent validation cohort (odds ratio [OR] 3.08, combined P = 2 x 10(-4); and OR = 2.93, P = 6 x 10(-4), respectively). Conclusions: We identified IL10RA polymorphisms that confer risk for developing VEO-UC. Additionally, we identified the first splice site mutation in IL10RA resulting in infantile-onset IBD. This study expands the phenotype of IL10RA polymorphisms to include both severe arthritis and VEO-UC. (Inflamm Bowel Dis 2013;19:115-123) C1 [Moran, Christopher J.] MassGen Hosp Children, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, Boston, MA USA. [Moran, Christopher J.; Snapper, Scott B.] Childrens Hosp Boston, Dept Med, Div Pediat Gastroenterol Hepatol & Nutr, Boston, MA 02115 USA. [Moran, Christopher J.; Snapper, Scott B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Walters, Thomas D.; Wolters, Victorien M.; Bandsma, Robert H.; Mouzaki, Marialena; Zachos, Mary; Griffiths, Anne M.; Muise, Aleixo M.] Hosp Sick Children, Dept Paediat, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada. [Guo, Cong-Hui; Wolters, Victorien M.; Muise, Aleixo M.] Univ Toronto, Cell Biol Program, Toronto, ON, Canada. [Kugathasan, Subra] Emory Univ, Sch Med, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, Atlanta, GA USA. [Klein, Christoph] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat, Munich, Germany. [Turner, Dan] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Pediat Gastroenterol Unit, Jerusalem, Israel. [Langer, Jacob C.] Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada. [Cutz, Ernest] Hosp Sick Children, Dept Pathol, Toronto, ON M5G 1X8, Canada. [Benseler, Susanne M.] Hosp Sick Children, Div Rheumatol, Toronto, ON M5G 1X8, Canada. [Roifman, Chaim M.] Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada. [Silverberg, Mark S.] Mt Sinai Hosp, Div Gastroenterol, Toronto, ON M5G 1X5, Canada. [Snapper, Scott B.] Brigham & Womens Hosp, Div Gastroenterol & Hepatol, Boston, MA 02115 USA. [Snapper, Scott B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Snapper, SB (reprint author), Childrens Hosp Boston, Div Gastroenterol & Nutr, Ctr Inflammatory Bowel Dis Treatment & Res, 300 Longwood Ave, Boston, MA 02115 USA. EM scott.snapper@childrens.harvard.edu; aleixo.muise@sickkids.ca RI Silverberg, Mark/B-4183-2008 FU Crohn's and Colitis Foundation of America (CCFA); Crohn's and Colitis Foundation of Canada (CCFC) / Canadian Association of Gastroenterology (CAG) / Canadian Institute for Health Research (CIHR); Canadian Child Health Clinician Scientist Program (Strategic Training Initiatives in Health Research Program - CIHR) award; Ontario Ministry of Research and Innovation; CDHNF/NASPGHAN George Ferry Young Investigator Development Award; Canadian Institute of Health Research [MOP119457]; Gale and Graham Wright Research Chair in Digestive Diseases; NIDDK; Wolpow Chair in IBD Research and Treatment; Harvard Digestive Disease Center [P30 DK034854] FX C.J.M. is supported by an award from the Crohn's and Colitis Foundation of America (CCFA). A. M. M. is supported by a transition award from the Crohn's and Colitis Foundation of Canada (CCFC) / Canadian Association of Gastroenterology (CAG) / Canadian Institute for Health Research (CIHR), a Canadian Child Health Clinician Scientist Program (Strategic Training Initiatives in Health Research Program - CIHR) award, and an Early Researcher Award from the Ontario Ministry of Research and Innovation and a CDHNF/NASPGHAN George Ferry Young Investigator Development Award and funded by a Canadian Institute of Health Research - Operating Grant (MOP119457). M. S. S. is supported in part by the Gale and Graham Wright Research Chair in Digestive Diseases. Partial funding to recruit subjects and collect samples was provided by M. S. S. through NIDDK grant DK. This work was funded in part by funding to Dr. Snapper through the Wolpow Chair in IBD Research and Treatment as well as through funding made possible from the Harvard Digestive Disease Center P30 DK034854. NR 26 TC 77 Z9 81 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2013 VL 19 IS 1 BP 115 EP 123 DI 10.1002/ibd.22974 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 109VL UT WOS:000316397200023 PM 22550014 ER PT S AU Blower, MD AF Blower, Michael D. BE Jeon, KW TI Molecular Insights into Intracellular RNA Localization SO INTERNATIONAL REVIEW OF CELL AND MOLECULA BIOLOGY, VOL 302 SE International Review of Cell and Molecular Biology LA English DT Review; Book Chapter ID BICOID MESSENGER-RNA; SIGNAL RECOGNITION PARTICLE; SYNTHESIZING SECRETORY PROTEIN; DNA MICROARRAY ANALYSIS; GERMLINE P GRANULES; CELL-FREE FORMATION; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; XENOPUS-OOCYTES AB Localization of mRNAs to specific destinations within a cell or an embryo is important for local control of protein synthesis. mRNA localization is well known to function in very large and polarized cells such as neurons, and to facilitate embryonic patterning during early development. However, recent genome-wide studies have revealed that mRNA localization is more widely utilized than previously thought to control gene expression. Not only can transcripts be localized asymmetrically within the cytoplasm, they are often also localized to symmetrically distributed organelles. Recent genetic, cytological, and biochemical studies have begun to provide molecular insight into how cells select RNAs for transport, move them to specific destinations, and control their translation. This chapter will summarize recent insights into the mechanisms and function of RNA localization with a specific emphasis on molecular insights into each step in the mRNA localization process. C1 [Blower, Michael D.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Blower, Michael D.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. RP Blower, MD (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. EM blower@molbio.mgh.harvard.edu FU NIGMS NIH HHS [5 R01 GM086434-05, R01 GM086434] NR 138 TC 12 Z9 12 U1 1 U2 17 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 1937-6448 BN 978-0-12-407699-0 J9 INT REV CEL MOL BIO JI Int. Rev. Cell Mol. Biol. PY 2013 VL 302 BP 1 EP 39 DI 10.1016/B978-0-12-407699-0.00001-7 PG 39 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BDZ25 UT WOS:000315698500001 PM 23351709 ER PT J AU Kieburtz, K Landwehrmeyer, GB Cudkowicz, M Dorsey, ER Feigin, A Hunt, V Kayson, E McDermott, M Noonberg, S Seitz, W Soliveri, P Walker, F Burgunder, JM Romero, I Magara, A Stebler, Y Rickards, H Wright, J De Souza, J Barker, RA Mason, S Di Pietro, A Goodman, A O'Keeffe, D Langlois, M Ferland, G Verret, L Chouinard, S Paris, S LePage, C Nemeth, AH Merritt, C Cox, C Astbury, T Murphy, S Ahmed, A St Marie, P Berila, RA Kubu, C Segro, V Kumar, R Erickson, D Schneiders, J Frucht, S Wasserman, P Moskowitz, C Scott, B Perry-Trice, P Wyne, S Soliveri, P Parida, D Redaelli, V Soltan, W Robowski, P Nowak, M Schinwelski, M Dziadkiewicz, A Andrews, T Ruddy, D Dougherty, A Boelmans, K Schmalfeld, J Munchau, A Zittel, S Mallonee, W Suter, G Tan, J Seeberger, L Harris, J Champion, J Wojcieszek, J Belden, J Price, K Hughes-Gay, M Sprehn, G Squitieri, F Martino, T De Gregorio, F De Nicola, A Elifani, F Rosenblatt, A Yoritomo, N Margolis, R Nichols, P Palhagen, SE Hoglund, AV Paucar, M Reza-Soltani, TW Beister, A Raab, T Kieni, J Schrenk, C Banaszkiewicz, K Misztela, J Wojcik, M Szczygiel, E Golosz, M Rudzinska, M Roos, RAC van den Bogaard, SJA Bos, R Booij, SJ Hyson, C Megens, J Makaji, E Jenkins, M Hersch, S Maya, S Dresser, C Rosas, D Blindauer, K Schindler, C Hung, S McNees, AA Tabrizi, S Novak, M Say, M Patel, A Panegyres, P Lewis, N Jukich, S Faull, C Hjermind, LE Jakobsen, O Vogel, A Nielsen, TR Nielsen, JE Kostyk, S Seward, A Agrawal, P Kraakevik, J Hogarth, P Wilson, A Lear, J Kraus, PH Saft, C Steiner, T Hoffmann, R Stamm, C Schollhammer, J Uhl, I Kaminski, B O'Donovan, K Quarrell, O Nevitt, L Kipps, C Hare, A Gunner, K Hayward, E Nance, M Hamerlinck, J Wielinski, C Yastrubetskaya, O Chiu, E Chua, P Mannaa, B de Tommaso, M Serpino, C Cormio, C Sciruicchio, V De Michele, G Di Maio, L Russo, CV Sacca, F Salvatore, E Tucci, T Wolz, M Klingelhofer, L Wolz, A Schmidt, S Storch, A Spruth, E Thiel, S Neumann, B Gelderblom, H Priller, J Sass, C Probst, D Werner, C Leavitt, BR Coleman, A Raymond, L Wheelock, V Tempkin, T Baynes, K Hermanowicz, N Niswonger, S Haske-Palomino, M Bordelon, Y Gratiano, A Johnson, A Corey-Bloom, J Goldstein, J Peavy, G Geschwind, M Gooblar, J Barton, C Fernandez, H Rodriguez, R Suelter, M Daniels, M Romrell, J Swartz, C Beglinger, L Epping, E Waterman, E Smith, MM Dubinsky, R Dubinsky, H Gray, C Craufurd, D Howard, E Jones, M Murphy, H Anderson, K Nickerson, C De Santo, J Rigaud, T Zappala, N Robottom, B Singer, C Quesada, M Rodriguez-Spengler, K Cardenache, RH Reilmann, R Bohlen, S Hoelzner, EM Colcher, A Maccarone, H Altin, L Siderowf, A Greenamyre, TJ Lucarelli, N Ivanco, L Marshall, F Hickey, C Deuel, L Biglan, K Sussmuth, SD Orth, M Trautmann, S Eschenbach, C Samii, A Macaraeg, A Zielonka, D Ciesielska, A Marcinkowski, JT Sempolowicz, J Karaskiewicz, H Walker, F O'Neill, C Haq, I Witkowski, G Antczak, J Rola, R Richter, P Rakowicz, M Jachinska, K Criswell, S Deppen, P Wharton, K Mahant, N McCusker, E Griffith, J Loy, C Stewart, L Fisher, D Holt, D Orme, C Watts, A Weber, J White, K Hauser, RA Albin, R Coffey, C Fischer, W Miyasaki, J AF Kieburtz, Karl Landwehrmeyer, Georg B. Cudkowicz, Merit Dorsey, E. Ray Feigin, Andrew Hunt, Victoria Kayson, Elise McDermott, Michael Noonberg, Sarah Seitz, Wendy Soliveri, Paola Walker, Francis Burgunder, Jean-Marc Romero, Irene Magara, Anouk Stebler, Yanik Rickards, Hugh Wright, Jan De Souza, Jenny Barker, Roger A. Mason, Sarah Di Pietro, Anna Goodman, Anna O'Keeffe, Deidre Langlois, Melanie Ferland, Germain Verret, Louis Chouinard, Sylvain Paris, Suzanne LePage, Christiane Nemeth, Andrea H. Merritt, Claire Cox, Caroline Astbury, Therese Murphy, Sarah Ahmed, Anwar St Marie, Patricia Berila, Rose Anne Kubu, Cynthia Segro, Vicki Kumar, Rajeev Erickson, Diane Schneiders, Jay Frucht, Steven Wasserman, Paula Moskowitz, Carol Scott, Burton Perry-Trice, Peggy Wyne, Sarah Soliveri, Paola Parida, Dominga Redaelli, Veronica Soltan, Witold Robowski, Piotr Nowak, Malgorzata Schinwelski, Michal Dziadkiewicz, Artur Andrews, Thomasin Ruddy, Deborah Dougherty, Andrew Boelmans, Kai Schmalfeld, Jenny Muenchau, Alexander Zittel, Simone Mallonee, William Suter, Greg Tan, Jeremy Seeberger, Lauren Harris, Jane Champion, Jamie Wojcieszek, Joanne Belden, Joann Price, Katie Hughes-Gay, Marsha Sprehn, Gwen Squitieri, Ferdinando Martino, Tiziana De Gregorio, Francesca De Nicola, Annunziata Elifani, Francesca Rosenblatt, Adam Yoritomo, Nadine Margolis, Russell Nichols, Paige Palhagen, Sven E. Hoglund, Arja Vehkala Paucar, Martin Reza-Soltani, Tina Wallden Beister, Antonie Raab, Tina Kieni, Janina Schrenk, Caroline Banaszkiewicz, Krzysztof Misztela, Jakub Wojcik, Magdalena Szczygiel, Elzbieta Golosz, Marta Rudzinska, Monika Roos, Raymund A. C. van den Bogaard, Simon J. A. Bos, Reineke Booij, Suzanne J. Hyson, Christopher Megens, Julie Makaji, Emilija Jenkins, Mary Hersch, Steven Maya, Susan Dresser, Caleb Rosas, Diana Blindauer, Karen Schindler, Clara Hung, Serena McNees, Alexander Aaron Tabrizi, Sarah Novak, Marianne Say, Miranda Patel, Aakta Panegyres, Peter Lewis, Nicola Jukich, Samantha Faull, Catherine Hjermind, Lena Elisabeth Jakobsen, Oda Vogel, Asmus Nielsen, T. Rune Nielsen, Jorgen E. Kostyk, Sandra Seward, Allison Agrawal, Punit Kraakevik, Jeff Hogarth, Penelope Wilson, April Lear, Joyce Kraus, Peter H. Saft, Carsten Steiner, Tanja Hoffmann, Rainer Stamm, Christiane Schollhammer, Joanna Uhl, Idun Kaminski, Barbara O'Donovan, Kirsty Quarrell, Oliver Nevitt, Louise Kipps, Christopher Hare, Angela Gunner, Kerry Hayward, Elaine Nance, Martha Hamerlinck, Judy Wielinski, Catherine Yastrubetskaya, Olga Chiu, Edmond Chua, Phyllis Mannaa, Bernadette de Tommaso, Marina Serpino, Claudia Cormio, Claudia Sciruicchio, Vittorio De Michele, Giuseppe Di Maio, Luigi Russo, Cinzia Valeria Sacca, Francesco Salvatore, Elena Tucci, Tecla Wolz, Martin Klingelhoefer, Lisa Wolz, Annett Schmidt, Simone Storch, Alexander Spruth, Eike Thiel, Silvia Neumann, Britta Gelderblom, Harald Priller, Josef Sass, Christian Probst, Daniela Werner, Cornelius Leavitt, Blair R. Coleman, Allison Raymond, Lynn Wheelock, Vicki Tempkin, Teresa Baynes, Kathleen Hermanowicz, Neal Niswonger, Shari Haske-Palomino, Maureen Bordelon, Yvette Gratiano, Angelina Johnson, Arik Corey-Bloom, Jody Goldstein, Jody Peavy, Guerry Geschwind, Michael Gooblar, Jonathan Barton, Cindy Fernandez, Hubert Rodriguez, Ramon Suelter, Michele Daniels, Marie Romrell, Janet Swartz, Camille Beglinger, Leigh Epping, Eric Waterman, Elijah Smith, Megan M. Dubinsky, Richard Dubinsky, Hilary Gray, Carolyn Craufurd, David Howard, Elizabeth Jones, Mary Murphy, Helen Anderson, Karen Nickerson, Constance De Santo, Jennifer Rigaud, Tamara Zappala, Nancy Robottom, Bradley Singer, Carlos Quesada, Monica Rodriguez-Spengler, Kenia Cardenache, Rene Hernandez Reilmann, Ralf Bohlen, Stefan Hoelzner, Eva-Maria Colcher, Amy Maccarone, Heather Altin, Lisa Siderowf, Andrew Greenamyre, Timothy John Lucarelli, Nancy Ivanco, Larry Marshall, Frederick Hickey, Charlyne Deuel, Lisa Biglan, Kevin Sussmuth, Sigurd D. Orth, Michael Trautmann, Sonja Eschenbach, Carolin Samii, Ali Macaraeg, Alma Zielonka, Daniel Ciesielska, Anna Marcinkowski, Jerzy T. Sempolowicz, Justyna Karaskiewicz, Hanna Walker, Francis O'Neill, Christine Haq, Ihtsham Witkowski, Grezegorz Antczak, Jakub Rola, Rafal Richter, Przemyslaw Rakowicz, Maria Jachinska, Katarzyna Criswell, Susan Deppen, Patricia Wharton, Kathleen Mahant, Neil McCusker, Elizabeth Griffith, Jane Loy, Clement Stewart, Linda Fisher, Danielle Holt, Dustina Orme, Constance Watts, Arthur Weber, Joseph White, Kathy Hauser, Robert A. Albin, Roger Coffey, Christopher Fischer, Wilhelm Miyasaki, Janis CA HORIZON Investigators TI A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease SO JAMA NEUROLOGY LA English DT Article ID MINI-MENTAL-STATE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; DEMENTIA; DONEPEZIL; DIMEBON; RIVASTIGMINE; DYSFUNCTION; INVENTORY AB Background: Latrepirdine is an orally administered experimental small molecule that was initially developed as an antihistamine and subsequently was shown to stabilize mitochondrial membranes and function, which might be impaired in Huntington disease. Objective: To determine the effect of latrepirdine on cognition and global function in patients with mild to moderate Huntington disease. Design: Randomized, double-blind, placebo-controlled study. Setting: Sixty-four research centers in Australia, Europe, and North America. Patients: Four hundred three patients with mild to moderate Huntington disease and baseline cognitive impairment (Mini-Mental State Examination score, 10-26). Intervention: Latrepirdine (20 mg) vs matching placebo administered orally 3 times daily for 26 weeks. Main Outcome Measures: The co-primary outcome measures were cognition as measured by the change in Mini-Mental State Examination score from baseline to week 26 and global function at week 26 as measured by the Clinician Interview-Based Impression of Change, plus carer interview, which ranges from 1 (marked improvement) to 7 (marked worsening). Secondary efficacy outcome measures included behavior, daily function, motor function, and safety. Results: The mean change in Mini-Mental State Examination score among participants randomized to latrepirdine (1.5-point improvement) did not differ significantly from that among participants randomized to placebo (1.3-point improvement) (P=.39). Similarly, the distribution of the Clinician Interview-Based Impression of Change, plus carer interview did not differ significantly among those randomized to latrepirdine compared with placebo (P=.84). No significant treatment effects were detected on the secondary efficacy outcome measures. The incidence of adverse events was similar between those randomized to latrepirdine (68.5%) and placebo (68.0%). Conclusion: In patients with mild to moderate Huntington disease and cognitive impairment, treatment with latrepirdine for 6 months was safe and well tolerated but did not improve cognition or global function relative to placebo. Trial Registration: clinicaltrials.gov Identifier: NCT00920946 JAMA Neurol. 2013;70(1):25-33. Published online October 29, 2012. doi:10.1001/2013.jamaneurol.382 C1 [Rickards, Hugh; Wright, Jan; De Souza, Jenny] Birmingham & Solihull Mental Hlth Fdn, Birmingham, W Midlands, England. [Rickards, Hugh; Wright, Jan; De Souza, Jenny] Birmingham & Solihull Mental Hlth Fdn, Solihull, W Midlands, England. [Barker, Roger A.; Mason, Sarah; Di Pietro, Anna; Goodman, Anna; O'Keeffe, Deidre] Cambridge Ctr Brain Repair, Cambridge, England. [Langlois, Melanie; Ferland, Germain; Verret, Louis] CHU Quebec, Hop Enfants Jesus, Quebec City, PQ, Canada. [Chouinard, Sylvain; Paris, Suzanne; LePage, Christiane] CHUM Hosp Notre Dame, Montreal, PQ, Canada. [Nemeth, Andrea H.; Merritt, Claire; Cox, Caroline; Astbury, Therese; Murphy, Sarah] Oxford Univ Hosp NHS Trust, Churchill Hosp, Oxford, England. [Ahmed, Anwar; St Marie, Patricia; Berila, Rose Anne; Kubu, Cynthia] Cleveland Clin, Cleveland, OH 44106 USA. [Segro, Vicki; Kumar, Rajeev; Erickson, Diane; Schneiders, Jay] Colorado Neurol Inst, Englewood, CO USA. [Frucht, Steven; Wasserman, Paula; Moskowitz, Carol] Columbia Univ, Med Ctr, New York, NY USA. [Scott, Burton; Perry-Trice, Peggy; Wyne, Sarah] Duke Univ, Durham, NC USA. [Soliveri, Paola; Parida, Dominga; Redaelli, Veronica] Fdn IRCCS Ist Neurol C Besta, Milan, Italy. [Soltan, Witold; Robowski, Piotr; Nowak, Malgorzata; Schinwelski, Michal; Dziadkiewicz, Artur] Gabinet Zabiegowy Gdansk, Gdansk, Poland. [Andrews, Thomasin; Ruddy, Deborah; Dougherty, Andrew] Guys Hosp, London SE1 9RT, England. [Boelmans, Kai; Schmalfeld, Jenny; Muenchau, Alexander; Zittel, Simone] Univ Hamburg Hosp, Hamburg, Germany. [Mallonee, William; Suter, Greg; Tan, Jeremy] Hereditary Neurol Dis Ctr, Wichita, KS USA. [Seeberger, Lauren; Harris, Jane; Champion, Jamie] Idaho Elks Rehabil Ctr, Boise, ID USA. [Wojcieszek, Joanne; Belden, Joann; Price, Katie; Hughes-Gay, Marsha; Sprehn, Gwen] Indiana Univ Sch Med, Indianapolis, IN USA. [Squitieri, Ferdinando; Martino, Tiziana; De Gregorio, Francesca; De Nicola, Annunziata; Elifani, Francesca] IRCCS Neuromed Unita Neurogenet, Pozzilli, Italy. [Rosenblatt, Adam; Yoritomo, Nadine; Margolis, Russell; Nichols, Paige] Johns Hopkins Univ, Baltimore, MD USA. [Palhagen, Sven E.; Hoglund, Arja Vehkala; Paucar, Martin; Reza-Soltani, Tina Wallden] Karolinska Hosp, S-10401 Stockholm, Sweden. [Beister, Antonie; Raab, Tina; Kieni, Janina; Schrenk, Caroline] Klin Taufkirchin, Munich, Germany. [Banaszkiewicz, Krzysztof; Misztela, Jakub; Wojcik, Magdalena; Szczygiel, Elzbieta; Golosz, Marta; Rudzinska, Monika] Krakow Inst, Krakow, Poland. [Roos, Raymund A. C.; van den Bogaard, Simon J. A.; Bos, Reineke; Booij, Suzanne J.] Leiden Univ, Med Ctr, Leiden, Netherlands. [Hyson, Christopher; Megens, Julie; Makaji, Emilija; Jenkins, Mary] London Hlth Sci Ctr, London, England. [Hersch, Steven; Maya, Susan; Dresser, Caleb; Rosas, Diana] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Blindauer, Karen; Schindler, Clara; Hung, Serena] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [McNees, Alexander Aaron] Medivat, San Francisco, CA USA. [Tabrizi, Sarah; Novak, Marianne; Say, Miranda; Patel, Aakta] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. [Panegyres, Peter; Lewis, Nicola; Jukich, Samantha; Faull, Catherine] Disorders Res, Subiaco, WA, Australia. [Hjermind, Lena Elisabeth; Jakobsen, Oda; Vogel, Asmus; Nielsen, T. Rune; Nielsen, Jorgen E.] Neurogenet Clin, Copenhagen, Denmark. [Kostyk, Sandra; Seward, Allison; Agrawal, Punit] Ohio State Univ, Columbus, OH 43210 USA. [Kraakevik, Jeff; Hogarth, Penelope; Wilson, April; Lear, Joyce] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kraus, Peter H.; Saft, Carsten; Steiner, Tanja; Hoffmann, Rainer; Stamm, Christiane; Schollhammer, Joanna; Uhl, Idun; Kaminski, Barbara] Ruhruniv Bochum, Copenhagen Univ Hosp, Memory Disorders Res Unit, Copenhagen, Denmark. [O'Donovan, Kirsty; Quarrell, Oliver; Nevitt, Louise] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England. [Kipps, Christopher; Hare, Angela; Gunner, Kerry; Hayward, Elaine] Southampton Gen Hosp, Southampton, Hants, England. [Nance, Martha; Hamerlinck, Judy; Wielinski, Catherine] Struthers Parkinsons Ctr, Golden Valley, MN USA. [Yastrubetskaya, Olga; Chiu, Edmond; Chua, Phyllis; Mannaa, Bernadette] St Vincents Aged Psychiat Serv, Melbourne, Vic, Australia. [de Tommaso, Marina; Serpino, Claudia; Cormio, Claudia; Sciruicchio, Vittorio] Univ Bari, Bari, Italy. [De Michele, Giuseppe; Di Maio, Luigi; Russo, Cinzia Valeria; Sacca, Francesco; Salvatore, Elena; Tucci, Tecla] Univ Naples Federico II, Naples, Italy. [Wolz, Martin; Klingelhoefer, Lisa; Wolz, Annett; Schmidt, Simone; Storch, Alexander] Univ Klinikum Carl Gustav Carus, Dresden, Germany. [Spruth, Eike; Thiel, Silvia; Neumann, Britta; Gelderblom, Harald; Priller, Josef] Univ Klinikum Charite, Berlin, Germany. [Sass, Christian; Probst, Daniela; Werner, Cornelius] Univ Aachen, Aachen, Germany. [Leavitt, Blair R.; Coleman, Allison; Raymond, Lynn] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Wheelock, Vicki; Tempkin, Teresa; Baynes, Kathleen] Univ Calif Davis, Davis Med Ctr, Davis, CA USA. [Hermanowicz, Neal; Niswonger, Shari; Haske-Palomino, Maureen] Univ Calif Irvine, Irvine, CA USA. [Bordelon, Yvette; Gratiano, Angelina; Johnson, Arik] Univ Calif Los Angeles, Los Angeles, CA USA. [Corey-Bloom, Jody; Goldstein, Jody; Peavy, Guerry] Univ Calif San Diego, San Diego, CA 92103 USA. [Geschwind, Michael; Gooblar, Jonathan; Barton, Cindy] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fernandez, Hubert; Rodriguez, Ramon; Suelter, Michele; Daniels, Marie; Romrell, Janet; Swartz, Camille] Univ Florida, Gainesville, FL USA. [Beglinger, Leigh; Epping, Eric; Waterman, Elijah; Smith, Megan M.] Univ Iowa, Iowa City, IA USA. [Dubinsky, Richard; Dubinsky, Hilary; Gray, Carolyn] Univ Kansas, Med Ctr, Lawrence, KS 66045 USA. [Craufurd, David; Howard, Elizabeth; Jones, Mary; Murphy, Helen] Univ Manchester, Manchester Acad, Hlth Sci Ctr, Manchester, Lancs, England. [Craufurd, David; Howard, Elizabeth; Jones, Mary; Murphy, Helen] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England. [Anderson, Karen; Nickerson, Constance; De Santo, Jennifer; Rigaud, Tamara; Zappala, Nancy; Robottom, Bradley] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Singer, Carlos; Quesada, Monica; Rodriguez-Spengler, Kenia; Cardenache, Rene Hernandez] Univ Miami, Miami, FL USA. [Reilmann, Ralf; Bohlen, Stefan; Hoelzner, Eva-Maria] Univ Munster, D-48149 Munster, Germany. [Colcher, Amy; Maccarone, Heather; Altin, Lisa; Siderowf, Andrew] Univ Penn, Philadelphia, PA 19104 USA. [Greenamyre, Timothy John; Lucarelli, Nancy] Univ Pittsburgh, Pittsburgh, PA USA. [Marshall, Frederick; Hickey, Charlyne; Deuel, Lisa; Biglan, Kevin] Univ Rochester, Rochester, NY USA. [Sussmuth, Sigurd D.; Orth, Michael; Trautmann, Sonja; Eschenbach, Carolin] Univ Ulm, D-89069 Ulm, Germany. [Samii, Ali; Macaraeg, Alma] Univ Washington, Seattle, WA 98195 USA. [Zielonka, Daniel; Ciesielska, Anna; Marcinkowski, Jerzy T.; Sempolowicz, Justyna; Karaskiewicz, Hanna] USI MED Poznan, Poznan, Poland. [Walker, Francis; O'Neill, Christine; Haq, Ihtsham] Wake Forest Univ, Winston Salem, NC 27109 USA. [Witkowski, Grezegorz; Antczak, Jakub; Rola, Rafal; Richter, Przemyslaw; Rakowicz, Maria; Jachinska, Katarzyna] Warsaw IPIN Inst Psychiat & Neurol, Warsaw, Poland. [Criswell, Susan; Deppen, Patricia; Wharton, Kathleen] Washington Univ, St Louis, MO USA. [Mahant, Neil; McCusker, Elizabeth; Griffith, Jane; Loy, Clement; Stewart, Linda] Westmead Hosp, Sydney, NSW, Australia. RP Dorsey, ER (reprint author), 600 N Wolfe St,Meyer 6-181D, Baltimore, MD 21287 USA. EM ray.dorsey@jhmi.edu RI Craufurd, David/G-5277-2013; Raymond, Lynn/A-6664-2010; OI Raymond, Lynn/0000-0002-8610-1042; Sacca, Francesco/0000-0002-1323-6317; Elifani, Francesca/0000-0002-0824-9543; Landwehrmeyer, Georg Bernhard/0000-0003-3375-790X; Nielsen, Jorgen Erik/0000-0003-0453-5582 FU Elan; Medivation; SIENA; Teva; Huntington Study Group; CHDI Foundation; Alzheimer's Disease Cooperative Study Group; Boehringer Ingelheim Pharmaceuticals, Inc; Teva Neuroscience; Impax Pharmaceuticals; UCB, Inc; GE Healthcare; IPSEN Pharmaceuticals; Novartis; Parkinson Study Group; Solvay; Quintiles; Biogen Idec; California Institute for Regenerative Medicine; Huntington Study Group, Lundbeck; University of California, Irvine; Michael J. Fox Foundation; National Institutes of Health (National Eye Institute); National Institutes of Health (National Institute of Neurological Disorders and Stroke); National Institutes of Health (National Institute on Aging); National Institutes of Health (Eunice Kennedy Shriver National Institute of Child Health and Human Development); NeuroSearch; Pfizer; Siena Biotech; AOP Orphan; GlaxoSmithKline; European Commission; Medesia; Amarin; European Huntington's Disease Network; Novartis Pharmaceuticals Switzerland; Teva Pharma GmbH FX Dr Corey-Bloom is a principal investigator on multiple clinical trials for the treatment of cognitive dysfunction and dementia sponsored by pharmaceutical companies such as Elan, Medivation, SIENA, and Teva, in addition to the Huntington Study Group, CHDI Foundation, and Alzheimer's Disease Cooperative Study Group. Dr Hauser has received honoraria or payments for consulting, advisory services, speaking services, or research over the past 12 months for the following: advisory boards (Boehringer Ingelheim Pharmaceuticals, Inc, Teva Neuroscience, Impax Pharmaceuticals, UCB, Inc, GE Healthcare, IPSEN Pharmaceuticals, Novartis, Parkinson Study Group, Solvay, Quintiles, and Biogen Idec), speakers' bureau (Allergan Neuroscience, GlaxoSmithKline, Teva Neuroscience, Boehringer Ingelheim Pharmaceuticals, Inc, Novartis Pharmaceuticals, and IPSEN Pharmaceuticals), consulting (Bial, Lundbeck, Biogen Idec, Boehringer Ingelheim, Chelsea Therapeutics, GE Healthcare, Impax, Santhera Pharmaceuticals, Merck Serono/EMD Serono, Solvay Pharmaceuticals, Synosis Therapeutics, Schering-Plough, Shire Pharmaceuticals, Inc, XenoPort, Inc, Medivation, Addex, Adamas Pharmaceuticals, and Noven Pharmaceuticals), research (PICO-Tesla, Schwartz Pharma, Genzyme, Acadia, Solvay Pharmaceuticals, Impax, Teva Neuroscience, [Merck] Serono, Schering-Plough, Novartis Pharmaceuticals, IPSEN Pharmaceuticals, XenoPort Pharmaceuticals, Chelsea Therapeutics, Allergan Neuroscience, Molecular Biometrics, The Michael J. Fox Foundation for Parkinson's Research, and the National Parkinson Foundation), and royalties (University of South Florida). In addition, Dr Hauser has consulted in litigation with lawyers representing various current and former manufacturers of welding consumables. Dr Hermanowicz reports research, clinical trial, speaking honoraria, and salary support from the California Institute for Regenerative Medicine, Huntington Study Group, Lundbeck, and University of California, Irvine. Dr Kieburtz reports serving as a consultant to the National Institutes of Health (National Institute of Neurological Disorders and Stroke), US Food and Drug Administration, US Veterans Administration, Abbott, Acorda, Aptiv, Biogen Idec, Biotie, Biovail, Boehringer Ingelheim, Ceregene, Civitas, Clintrex, Cynapsus, EMD Merck Serono, Genzyme, Impax, Intec, Ipsen, Isis, Knopp, Eli Lilly, Link Medicine, Lundbeck, LZ Therapeutics, Merz, Novartis, Orion, Otsuka, Pharm2B, Phytopharm, Schering-Plough, Siena Biotech, Synosia, Solvay, Synagile, Teva, UCB Pharma, Vaccinex, Vectura, and XenoPort; he also reports grants and research support from Medivation, The Michael J. Fox Foundation, the National Institutes of Health (National Eye Institute, National Institute of Neurological Disorders and Stroke, National Institute on Aging, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development), NeuroSearch, and Pfizer, as well as legal consulting for Pfizer, Thompson Hine, and welding rod litigation defendants. Dr Landwehrmeyer reports receiving consultancy fees from Siena Biotech, AOP Orphan, Teva, and GlaxoSmithKline, as well as grants for Huntington disease-related studies for the Institution University of Ulm from the European Commission, CHDI Foundation, Medivation, NeuroSearch, Novartis, Medesia, and Amarin. Dr McNees has served as a clinical project manager for Medivation from 2007 to the present. Dr Margolis disclosed funding for this project from Medivation and Pfizer. Dr Noonberg works for Medivation and holds stock in the company.; Dr Saft has received honoraria from Temmler Pharma Gmbh & Co KG and payment from the European Huntington's Disease Network for the REGISTRY study, from Novartis Pharmaceuticals Switzerland for the AFQ056 study, from NeuroSearch for the ACR16 Study, and from Siena Biotech for Selisistat studies, as well as research support from Teva Pharma GmbH; no financial interests are related to the material in the manuscript. None of the HORIZON investigators of the Huntington Study Group or the European Huntington's Disease Network has had equity interest or received any personal remuneration from the sponsoring companies since the initiation of the study. All authors completed and submitted the International Committee of Medical Journal Editors form for financial disclosure. NR 37 TC 11 Z9 12 U1 3 U2 34 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 J9 JAMA NEUROL JI JAMA Neurol. PD JAN PY 2013 VL 70 IS 1 BP 25 EP 33 DI 10.1001/2013.jamaneurol.382 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 115GJ UT WOS:000316800300004 ER PT J AU Ji, RJ Schwamm, LH Pervez, MA Singhal, AB AF Ji, Ruijun Schwamm, Lee H. Pervez, Muhammad A. Singhal, Aneesh B. TI Ischemic Stroke and Transient Ischemic Attack in Young Adults Risk Factors, Diagnostic Yield, Neuroimaging, and Thrombolysis SO JAMA NEUROLOGY LA English DT Article ID PATENT FORAMEN OVALE; CEREBRAL INFARCTION; CAUSATIVE CLASSIFICATION; CRYPTOGENIC STROKE; ANGIOGRAPHY; REGISTRY; SYSTEM; TERM AB Background: Approximately 10% to 14% of ischemic strokes occur in young adults. Objective: To investigate the yield of diagnostic tests, neuroimaging findings, and treatment of ischemic strokes in young adults. Design: We retrospectively reviewed data from our Get with the Guidelines-Stroke database from 2005 through 2010. Setting: University hospital tertiary stroke center. Patients: A total of 215 consecutive inpatients aged 18 to 45 years with ischemic stroke/transient ischemic attack. The mean (SD) age was 37.5 (7) years; 51% were male. Results: There were high incidence rates of hypertension (20%), diabetes mellitus (11%), dyslipidemia (38%), and smoking (34%). Relevant abnormalities were shown on cerebral angiography in 136 of 203 patients, on cardiac ultrasonography in 100 of 195, on Holter monitoring in 2 of 192; and on hypercoagulable panel in 30 of 189 patients. Multiple infarcts were observed in 31% and were more prevalent in individuals younger than age 35 years. Relevant arterial lesions were frequently detected in the middle cerebral artery (23%), internal carotid artery (13%), and vertebrobasilar arteries (13%). Cardioembolic stroke occurred in 47% (including 17% with isolated patent foramen ovale), and 11% had undetermined stroke etiology. The median National Institutes of Health Stroke Scale score was 3 (interquartile range, 0-9) and 81% had good outcome at hospital discharge. Of the 29 patients receiving thrombolysis (median National Institutes of Health Stroke Scale score, 14; interquartile range, 9-17), 55% had good outcome at hospital discharge and none developed symptomatic brain hemorrhage. Conclusions: This study shows the contemporary profile of ischemic stroke in young adults admitted to a tertiary stroke center. Stroke etiology can be determined in nearly 90% of patients with modern diagnostic tests. The causes are heterogeneous; however, young adults have a high rate of traditional vascular risk factors. Thrombolysis appears safe and short-term outcomes are favorable. JAMA Neurol. 2013;70(1):51-57. Published online October 29, 2012. doi:10.1001/jamaneurol.2013.575 C1 [Ji, Ruijun; Schwamm, Lee H.; Pervez, Muhammad A.; Singhal, Aneesh B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Ji, Ruijun] Capital Med Univ, Dept Neurol, Beijing, Peoples R China. RP Singhal, AB (reprint author), Massachusetts Gen Hosp, Dept Neurol, ACC 729C, Boston, MA 02114 USA. EM asinghal@partners.org OI Schwamm, Lee/0000-0003-0592-9145 FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01NS051412, R21NS077442]; National Nature Science Foundation of China [30700240]; Nova Program, Beijing Science and Technology Commission [2008B30] FX This study was funded by grants R01NS051412 and R21NS077442 from the National Institutes of Health/National Institute of Neurological Disorders and Stroke; grant 30700240 from the National Nature Science Foundation of China; and grant 2008B30 from the Nova Program, Beijing Science and Technology Commission. NR 24 TC 37 Z9 40 U1 2 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 J9 JAMA NEUROL JI JAMA Neurol. PD JAN PY 2013 VL 70 IS 1 BP 51 EP 57 DI 10.1001/jamaneurol.2013.575 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 115GJ UT WOS:000316800300007 PM 23108720 ER PT J AU Faez, S Loewenstein, J Sobrin, L AF Faez, Sepideh Loewenstein, John Sobrin, Lucia TI Concordance of Antiretinal Antibody Testing Results Between Laboratories in Autoimmune Retinopathy SO JAMA OPHTHALMOLOGY LA English DT Letter C1 [Faez, Sepideh; Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Uveitis Serv, Boston, MA USA. [Loewenstein, John; Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Retina Serv, Boston, MA USA. RP Sobrin, L (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM lucia_sobrin@meei.harvard.edu FU NEI NIH HHS [EY16335-02] NR 4 TC 13 Z9 13 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6165 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD JAN PY 2013 VL 131 IS 1 BP 113 EP 115 PG 4 WC Ophthalmology SC Ophthalmology GA 113QP UT WOS:000316683000028 PM 23307224 ER PT J AU Bhama, PK Davis, GE Bhrany, AD Lam, DJ Futran, ND AF Bhama, Prabhat K. Davis, Greg E. Bhrany, Amit D. Lam, Derek J. Futran, Neal D. TI The Effects of Intensive Care Unit Staffing on Patient Outcomes Following Microvascular Free Flap Reconstruction of the Head and Neck A Pilot Study SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID RESECTION AB Objective: To determine if the implementation of the closed intensive care unit (ICU) at our institution altered clinical outcomes in patients who had undergone microvascular free flap reconstruction of the head and neck by the Otolaryngology-Head and Neck Surgery Service. Design: Retrospective medical chart review. Setting: A single tertiary medical center. Patients: The open ICU cohort had 52 flaps performed on 50 patients, and the closed ICU cohort had 52 flaps performed on 52 patients. Main Outcome Measures: Fifty-two free flap reconstructions of head and neck defects were performed on 50 patients who were admitted to an open ICU. The length of stay (LOS) in the ICU and hospital and incidence of complications were compared with those of 52 patients who underwent 52 free flap reconstructions and were admitted to a closed ICU over a separate period. Results: The mean length of stay in the ICU was 44 and 45 hours in the open and closed ICU cohorts, respectively (P=.90). The incidence of surgical and medical complications was similar in the open and closed ICU cohorts (P>.05). Conclusions: There does not appear to be a significant difference in patient outcome between open and closed ICU care in our study. JAMA Otolaryngol Head Neck Surg. 2013;139(1):37-42 C1 [Bhama, Prabhat K.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Div Facial Plast Surg,Dept Otolaryngol, Boston, MA 02108 USA. [Davis, Greg E.; Bhrany, Amit D.; Futran, Neal D.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Sch Med, Seattle, WA 98195 USA. [Lam, Derek J.] Univ Cincinnati, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA. RP Bhama, PK (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Div Facial Plast Surg,Dept Otolaryngol, Boston, MA 02108 USA. EM pbhama@gmail.com FU National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [KL2 RR025015]; Stryker Corporation FX This publication was made possible by grant KL2 RR025015 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH).; Dr Futran is a consultant for Stryker Corporation and received payment for technical advice on medical device design and presentation regarding Stryker medical devices. There is no direct conflict with the subject of this article, and the information within as it does not pertain to any of Dr Futran's consultant activities with Stryker Corporation. NR 14 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6181 J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD JAN PY 2013 VL 139 IS 1 BP 37 EP 42 DI 10.1001/jamaoto.2013.1132 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 114HM UT WOS:000316731700006 PM 23329089 ER PT J AU Profit, J Zupancic, JAF Gould, JB Pietz, K Kowalkowski, MA Draper, D Hysong, SJ Petersen, LA AF Profit, Jochen Zupancic, John A. F. Gould, Jeffrey B. Pietz, Kenneth Kowalkowski, Marc A. Draper, David Hysong, Sylvia J. Petersen, Laura A. TI Correlation of Neonatal Intensive Care Unit Performance Across Multiple Measures of Quality of Care SO JAMA PEDIATRICS LA English DT Article ID HOSPITAL QUALITY; MORTALITY-RATES; SAFETY CULTURE; HEALTH-CARE; INFECTIONS; INDICATORS; OUTCOMES; NETWORK; STATES; NICU AB Objectives: To examine whether high performance on one measure of quality is associated with high performance on others and to develop a data-driven explanatory model of neonatal intensive care unit (NICU) performance. Design: We conducted a cross-sectional data analysis of a statewide perinatal care database. Risk-adjusted NICU ranks were computed for each of 8 measures of quality selected based on expert input. Correlations across measures were tested using the Pearson correlation coefficient. Exploratory factor analysis was used to determine whether underlying factors were driving the correlations. Setting: Twenty-two regional NICUs in California. Patients: In total, 5445 very low-birth-weight infants cared for between January 1, 2004, and December 31, 2007. Main Outcomes Measures: Pneumothorax, growth velocity, health care-associated infection, antenatal corticosteroid use, hypothermia during the first hour of life, chronic lung disease, mortality in the NICU, and discharge on any human breast milk. Results: The NICUs varied substantially in their clinical performance across measures of quality. Of 28 unitlevel correlations, 6 were significant (rho < .05). Correlations between pairs of measures of quality of care were strong (rho >= .5) for 1 pair, moderate (range, rho >= .3 to rho < .5) for 8 pairs, weak (range, rho >= .1 to rho < .3) for 5 pairs, and negligible (rho < .1) for 14 pairs. Exploratory factor analysis revealed 4 underlying factors of quality in this sample. Pneumothorax, mortality in the NICU, and antenatal corticosteroid use loaded on factor 1; growth velocity and health care-associated infection loaded on factor 2; chronic lung disease loaded on factor 3; and discharge on any human breast milk loaded on factor 4. Conclusion: In this sample, the ability of individual measures of quality to explain overall quality of neonatal intensive care was modest. JAMA Pediatr. 2013;167(1):47-54. Published online November 12, 2012. doi:10.1001/jamapediatrics.2013.418 C1 [Profit, Jochen] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Profit, Jochen; Pietz, Kenneth; Kowalkowski, Marc A.; Hysong, Sylvia J.; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Profit, Jochen] Texas Childrens Hosp, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA. [Profit, Jochen; Pietz, Kenneth; Kowalkowski, Marc A.; Hysong, Sylvia J.; Petersen, Laura A.] Michael E DeBakey VA Med Ctr, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Hlth Policy & Qual Program, Houston, TX 77030 USA. [Zupancic, John A. F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA. [Zupancic, John A. F.] Harvard Univ, Sch Med, Div Newborn Med, Boston, MA 02215 USA. [Gould, Jeffrey B.] Stanford Univ, Sch Med, Div Neonatol, Perinatal Epidemiol & Hlth Outcomes Res Unit, Palo Alto, CA 94304 USA. [Gould, Jeffrey B.] Lucile Packard Childrens Hosp, Palo Alto, CA USA. [Gould, Jeffrey B.] Calif Perinatal Qual Care Collaborat, Palo Alto, CA USA. [Draper, David] Univ Calif Santa Cruz, Dept Appl Math & Stat, Baskin Sch Engn, Santa Cruz, CA 95064 USA. RP Profit, J (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Vet Affairs Hlth Serv Res & Dev Ctr Excel, Hlth Policy & Qual Program, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM profit@bcm.edu RI Hysong, Sylvia/B-8420-2008; OI Hysong, Sylvia/0000-0002-9063-5207; Kowalkowski, Marc/0000-0003-2624-4209; Zupancic, John/0000-0003-1734-7193 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [1 K23 HD056298]; Department of Veterans Affairs Health Services Research and Development Program [CD2-07-0181]; Veterans Affairs Health Services Research and Development Center of Excellence grant [HFP90-20]; American Heart Association [0540043N] FX This study is supported in part by grants 1 K23 HD056298 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Dr Profit), CD2-07-0181 from the Department of Veterans Affairs Health Services Research and Development Program (Dr Hysong), Veterans Affairs Health Services Research and Development Center of Excellence grant HFP90-20 (Drs Hysong and Petersen), and American Heart Association Established Investigator Award 0540043N (Dr Petersen). NR 30 TC 9 Z9 9 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6203 J9 JAMA PEDIATR JI JAMA Pediatr. PD JAN PY 2013 VL 167 IS 1 BP 47 EP 54 DI 10.1001/jamapediatrics.2013.418 PG 8 WC Pediatrics SC Pediatrics GA 115FH UT WOS:000316797500010 PM 23403539 ER PT J AU Doehrmann, O Ghosh, SS Polli, FE Reynolds, GO Horn, F Keshavan, A Triantafyllou, C Saygin, ZM Whitfield-Gabrieli, S Hofmann, SG Pollack, M Gabrieli, JD AF Doehrmann, Oliver Ghosh, Satrajit S. Polli, Frida E. Reynolds, Gretchen O. Horn, Franziska Keshavan, Anisha Triantafyllou, Christina Saygin, Zeynep M. Whitfield-Gabrieli, Susan Hofmann, Stefan G. Pollack, Mark Gabrieli, John D. TI Predicting Treatment Response in Social Anxiety Disorder From Functional Magnetic Resonance Imaging SO JAMA PSYCHIATRY LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; NATIONAL COMORBIDITY SURVEY; FACIAL EXPRESSIONS; MAJOR DEPRESSION; EMOTIONAL FACES; ANTIDEPRESSANT TREATMENT; AMYGDALA REACTIVITY; ANTERIOR CINGULATE; NEURAL RESPONSES; CONTROLLED-TRIAL AB Context: Current behavioral measures poorly predict treatment outcome in social anxiety disorder (SAD). To our knowledge, this is the first study to examine neuro-imaging- based treatment prediction in SAD. Objective: To measure brain activation in patients with SAD as a biomarker to predict subsequent response to cognitive behavioral therapy (CBT). Design: Functional magnetic resonance imaging (fMRI) data were collected prior to CBT intervention. Changes in clinical status were regressed on brain responses and tested for selectivity for social stimuli. Setting: Patients were treated with protocol-based CBT at anxiety disorder programs at Boston University or Massachusetts General Hospital and underwent neuroimaging data collection at Massachusetts Institute of Technology. Patients: Thirty-nine medication-free patients meeting DSM-IV criteria for the generalized subtype of SAD. Interventions: Brain responses to angry vs neutral faces or emotional vs neutral scenes were examined with fMRI prior to initiation of CBT. Main Outcome Measures: Whole-brain regression analyses with differential fMRI responses for angry vs neutral faces and changes in Liebowitz Social Anxiety Scale score as the treatment outcome measure. Results: Pretreatment responses significantly predicted subsequent treatment outcome of patients selectively for social stimuli and particularly in regions of higher-order visual cortex. Combining the brain measures with information on clinical severity accounted for more than 40% of the variance in treatment response and substantially exceeded predictions based on clinical measures at baseline. Prediction success was unaffected by testing for potential confounding factors such as depression severity at baseline. Conclusions: The results suggest that brain imaging can provide biomarkers that substantially improve predictions for the success of cognitive behavioral interventions and more generally suggest that such biomarkers may offer evidence-based, personalized medicine approaches for optimally selecting among treatment options for a patient. C1 [Doehrmann, Oliver; Ghosh, Satrajit S.; Polli, Frida E.; Reynolds, Gretchen O.; Horn, Franziska; Keshavan, Anisha; Triantafyllou, Christina; Saygin, Zeynep M.; Gabrieli, John D.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA. [Doehrmann, Oliver; Ghosh, Satrajit S.; Polli, Frida E.; Reynolds, Gretchen O.; Horn, Franziska; Keshavan, Anisha; Triantafyllou, Christina; Saygin, Zeynep M.; Gabrieli, John D.] MIT, Poitras Ctr Affect Disorders Res, Cambridge, MA 02139 USA. [Doehrmann, Oliver; Whitfield-Gabrieli, Susan; Gabrieli, John D.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Triantafyllou, Christina] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Athinoula A Martinos Ctr, Boston, MA 02115 USA. [Doehrmann, Oliver; Hofmann, Stefan G.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Pollack, Mark] Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA. RP Doehrmann, O (reprint author), MIT, McGovern Inst Brain Res, 43 Vassar St,Room 46-4033D, Cambridge, MA 02139 USA. EM oldoe@mit.edu RI Hofmann, Stefan/B-8769-2014; OI Hofmann, Stefan/0000-0002-3548-9681; Doehrmann, Oliver/0000-0002-4614-4144; Ghosh, Satrajit/0000-0002-5312-6729 FU Deutsche Forschungsgemeinschaft [DO-1469/1-1]; Poitras Center for Affective Disorders Research; National Institutes of Mental Health [MH078308, MH075889]; Bristol-Myers Squibb; Euthymics; Forest Laboratories; GlaxoSmithKline; Eli Lilly; National Center for Complementary; Alternative Medicine, National Institute on Drug Abuse, and National Institutes of Mental Health FX Dr Doehrmann was supported by postdoctoral fellowship DO-1469/1-1 from the Deutsche Forschungsgemeinschaft. Neuroimaging was supported by the Poitras Center for Affective Disorders Research. Dr Hofmann is a paid consultant for Merck/Schering-Plough and is supported by National Institutes of Mental Health grant MH078308. Dr Pollack is supported by National Institutes of Mental Health grant MH075889. He additionally is a member of the advisory boards or a consultant for BrainCells, Eli Lilly, Johnson & Johnson, MedAvante, Labopharm, Mindsite, Otsuka, Targia Pharmaceuticals, and Pfizer. He has received research grants from Bristol-Myers Squibb, Euthymics, Forest Laboratories, GlaxoSmithKline, Eli Lilly, National Center for Complementary and Alternative Medicine, National Institute on Drug Abuse, and National Institutes of Mental Health. Continuing Medical Education-supported activities of Dr Pollack were sponsored by AstraZeneca, Sepracor, and Pfizer. He holds equity in MedAvante, Mensante Corporation, Mindsite, and Targia Pharmaceuticals and receives royalties for SIGH-A, SAFER interviews. NR 64 TC 70 Z9 71 U1 0 U2 30 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-622X J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JAN PY 2013 VL 70 IS 1 BP 87 EP 97 DI 10.1001/2013.jamapsychiatry.5 PG 11 WC Psychiatry SC Psychiatry GA 114GM UT WOS:000316729100012 PM 22945462 ER PT J AU Fusar-Poli, P Borgwardt, S Bechdolf, A Addington, J Riecher-Rossler, A Schultze-Lutter, F Keshavan, M Wood, S Ruhrmann, S Seidman, LJ Valmaggia, L Cannon, T Velthorst, E De Haan, L Cornblatt, B Bonoldi, I Birchwood, M McGlashan, T Carpenter, W McGorry, P Klosterkotter, J McGuire, P Yung, A AF Fusar-Poli, Paolo Borgwardt, Stefan Bechdolf, Andreas Addington, Jean Riecher-Rossler, Anita Schultze-Lutter, Frauke Keshavan, Matcheri Wood, Stephen Ruhrmann, Stephan Seidman, Larry J. Valmaggia, Lucia Cannon, Tyrone Velthorst, Eva De Haan, Lieuwe Cornblatt, Barbara Bonoldi, Ilaria Birchwood, Max McGlashan, Thomas Carpenter, William McGorry, Patrick Klosterkotter, Joachim McGuire, Philip Yung, Alison TI The Psychosis High-Risk State A Comprehensive State-of-the-Art Review SO JAMA PSYCHIATRY LA English DT Review ID ULTRA-HIGH-RISK; RANDOMIZED CONTROLLED-TRIAL; CLINICAL HIGH-RISK; MAGNETIC-RESONANCE SPECTROSCOPY; BASE-LINE CHARACTERISTICS; INITIAL PRODROMAL PHASE; 1ST EPISODE PSYCHOSIS; AT-RISK; 1ST-EPISODE PSYCHOSIS; MENTAL STATE AB Context: During the past 2 decades, a major transition in the clinical characterization of psychotic disorders has occurred. The construct of a clinical high-risk (HR) state for psychosis has evolved to capture the prepsychotic phase, describing people presenting with potentially prodromal symptoms. The importance of this HR state has been increasingly recognized to such an extent that a new syndrome is being considered as a diagnostic category in the DSM-5. Objective: To reframe the HR state in a comprehensive state-of-the-art review on the progress that has been made while also recognizing the challenges that remain. Data Sources: Available HR research of the past 20 years from PubMed, books, meetings, abstracts, and international conferences. Study Selection and Data Extraction: Critical review of HR studies addressing historical development, inclusion criteria, epidemiologic research, transition criteria, outcomes, clinical and functional characteristics, neurocognition, neuroimaging, predictors of psychosis development, treatment trials, socioeconomic aspects, nosography, and future challenges in the field. Data Synthesis: Relevant articles retrieved in the literature search were discussed by a large group of leading worldwide experts in the field. The core results are presented after consensus and are summarized in illustrative tables and figures. Conclusions: The relatively new field of HR research in psychosis is exciting. It has the potential to shed light on the development of major psychotic disorders and to alter their course. It also provides a rationale for service provision to those in need of help who could not previously access it and the possibility of changing trajectories for those with vulnerability to psychotic illnesses. C1 [Fusar-Poli, Paolo; Valmaggia, Lucia; Bonoldi, Ilaria; McGuire, Philip] Kings Coll London, Dept Psychosis Studies, London WC2R 2LS, England. [Valmaggia, Lucia] Kings Coll London, Dept Psychol, London WC2R 2LS, England. [Fusar-Poli, Paolo; Valmaggia, Lucia; Bonoldi, Ilaria; McGuire, Philip] NHSSLAM Fdn Trust, OASIS Team Prodromal Psychosis, London, England. [Borgwardt, Stefan; Riecher-Rossler, Anita] Univ Basel, Dept Psychiat, Basel, Switzerland. [Bechdolf, Andreas; Ruhrmann, Stephan; Klosterkotter, Joachim] Univ Cologne, Dept Psychiat & Psychotherapy, D-50931 Cologne, Germany. [Addington, Jean] Univ Calgary, Dept Psychiat, Calgary, AB, Canada. [Schultze-Lutter, Frauke] Univ Bern, Univ Hosp Child & Adolescent Psychiat, Bern, Switzerland. [Keshavan, Matcheri; Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Keshavan, Matcheri; Seidman, Larry J.] Harvard Univ, Sch Med, Boston, MA USA. [Wood, Stephen] Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia. [Wood, Stephen] Melbourne Hlth, Melbourne, Vic, Australia. [Wood, Stephen; Birchwood, Max] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England. [Seidman, Larry J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA. [Cannon, Tyrone] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Velthorst, Eva; De Haan, Lieuwe] Univ Amsterdam, Acad Med Ctr, Dept Early Psychosis, NL-1105 AZ Amsterdam, Netherlands. [Cornblatt, Barbara] Zucker Hillside Hosp, Dept Psychiat Res, New York, NY USA. [McGlashan, Thomas] Yale Univ, Sch Med, New Haven, CT USA. [Carpenter, William] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21201 USA. [McGorry, Patrick; Yung, Alison] Univ Melbourne, Orygen Youth Hlth Res Ctr, Melbourne, Vic 3010, Australia. RP Fusar-Poli, P (reprint author), Inst Psychiat, Dept Psychosis Studies, PO63,De Crespigny Pk, London SE5 8AF, England. EM p.fusar@libero.it RI Ruhrmann, Stephan/F-1461-2013; Wood, Stephen/M-8652-2014; Valmaggia, Lucia/E-9653-2012; Borgwardt, Stefan/A-6366-2008; Riecher-Rossler, Anita/I-5551-2015; Birchwood, Max/E-3474-2017; OI Ruhrmann, Stephan/0000-0002-6022-2364; Wood, Stephen/0000-0003-4186-5919; Valmaggia, Lucia/0000-0001-6099-8464; Riecher-Rossler, Anita/0000-0001-6361-8789; Birchwood, Max/0000-0002-7476-0171; Yung, Alison/0000-0002-0401-9791; Borgwardt, Stefan/0000-0002-5792-3987 FU NIMH NIH HHS [U01 MH081984] NR 159 TC 289 Z9 299 U1 12 U2 73 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-622X J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JAN PY 2013 VL 70 IS 1 BP 107 EP 120 DI 10.1001/jamapsychiatry.2013.269 PG 14 WC Psychiatry SC Psychiatry GA 114GM UT WOS:000316729100015 PM 23165428 ER PT J AU Sundt, TM AF Sundt, Thoralf M. TI How Good Is "Good Enough"? SO JAMA SURGERY LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA. RP Sundt, TM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 55 Fruit St, Boston, MA 02114 USA. EM tsundt@partners.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6254 J9 JAMA SURG JI JAMA Surg. PD JAN PY 2013 VL 148 IS 1 BP 10 EP 11 PG 2 WC Surgery SC Surgery GA 113NS UT WOS:000316675300002 PM 23324832 ER PT J AU Wisneski, AD Beyer, AT Shunk, KA AF Wisneski, Andrew D. Beyer, Anna T. Shunk, Kendrick A. TI An Unusual Case of Bilateral Subclavian-Carotid Artery Graft Occlusion With Coronary Steal Syndrome Managed in the Cath Lab SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Article DE carotid artery; chronic total occlusion ID STENOSIS AB A 65-year-old man, s/p coronary bypass surgery (CABG) with left internal mammary artery (LIMA) to the left anterior descending (LAD) artery 12 years previously, presented to his local hospital with left upper extremity pain, dizziness, falls, and chest pain. At the outside hospital, a proximal total left subclavian occlusion was found and the patient underwent left subclavian artery to common carotid artery (SCA-CCA) bypass surgery. Shortly thereafter, the patient developed right subclavian thrombosis, and underwent right SCA-CCA bypass surgery. Twenty days later, coronary steal symptoms recurred; troponin levels were elevated and ultrasound exam revealed bilateral SCA-CCA graft occlusion. The patient was then transferred to a tertiary care facility with a diagnosis of non-ST elevation myocardial infarct (NSTEMI). A successful endovascular procedure was performed in the cardiac catheterization laboratory with the use of coronary chronic total occlusion (CTO) devices, to treat the coronary steal syndrome. J INVASIVE CARDIOL 2013;25(1):E14-E16 C1 Univ Calif San Francisco, Dept Cardiol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Shunk, KA (reprint author), San Francisco VA Med Ctr, Dept Cardiol, 111C,4150 Clement St, San Francisco, CA 94121 USA. EM Kendrick.Shunk@va.gov FU Gilead; InfraredX; Abbott Vascular; Siemens Medical Systems FX The authors have completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Shunk holds grants from Gilead, InfraredX, Abbott Vascular, and Siemens Medical Systems, and discloses stock ownership (divested) in Revascular Therapeutics, Inc. NR 8 TC 2 Z9 2 U1 0 U2 2 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD JAN PY 2013 VL 25 IS 1 BP E14 EP E16 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 110AQ UT WOS:000316414600005 PM 23293182 ER PT J AU Sharma, SK Krayer, M Sperandio, FF Huang, LY Huang, YY Holten, D Lindsey, JS Hamblin, MR AF Sharma, Sulbha K. Krayer, Michael Sperandio, Felipe F. Huang, Liyi Huang, Ying-Ying Holten, Dewey Lindsey, Jonathan S. Hamblin, Michael R. TI Synthesis and evaluation of cationic bacteriochlorin amphiphiles with effective in vitro photodynamic activity against cancer cells at low nanomolar concentration SO JOURNAL OF PORPHYRINS AND PHTHALOCYANINES LA English DT Article DE photodynamic therapy; HeLa cancer cells; bacteriochlorins; confocal microscopy; subcellular localization; apoptosis ID SUBCELLULAR-LOCALIZATION; PHOTOPHYSICAL PROPERTIES; ENDOPLASMIC-RETICULUM; DEATH PATHWAYS; THERAPY; PHOTOSENSITIZERS; EFFICACY; CHLORIN; MITOCHONDRIA; DERIVATIVES AB Bacteriochlorins are attractive candidates as photosensitizers for photodynamic therapy (PDT) due to their intense absorption in the near-infrared (NIR) region of the spectrum where light transmission through tissue is maximal. Many naturally occurring bacteriochlorins are inherently unstable due to adventitious atmospheric oxidation. A de novo synthesis affords bacteriochlorins that contain a geminal dimethyl group in each reduced pyrrole ring to increase stability against oxidation. Here, three new synthetic bacteriochlorins, each bearing a single side-chain containing one or two positive charges, were investigated for their in vitro PDT activity against HeLa human cancer cells. All bacteriochlorins were active at low nanomolar concentration when activated with NIR light; those bearing a single positive charge exhibited faster uptake and higher activity. The bacteriochlorins were localized in mitochondria, lysosomes and endoplasmic reticulum as shown by organelle specific fluorescent probes. Cell death was via apoptosis as shown by cell morphology and nuclear condensation. Taken together, the results show the importance of appropriate peripheral groups about a photosensitizer for effective PDT applications. C1 [Sharma, Sulbha K.; Sperandio, Felipe F.; Huang, Liyi; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Krayer, Michael; Lindsey, Jonathan S.] N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA. [Sperandio, Felipe F.; Huang, Liyi; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Sperandio, Felipe F.] Univ Sao Paulo, Sch Dent, Dept Oral Pathol, BR-05508000 Sao Paulo, Brazil. [Sperandio, Felipe F.] Minist Educ Brazil, CAPES Fdn, BR-70040020 Brasilia, DF, Brazil. [Huang, Liyi] Guangxi Med Univ, Dept Infect Dis, Affiliated Coll & Hosp 1, Nanning 530021, Peoples R China. [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning 530021, Peoples R China. [Holten, Dewey] Washington Univ, Dept Chem, St Louis, MO 63130 USA. [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Lindsey, JS (reprint author), N Carolina State Univ, Dept Chem, Box 8204, Raleigh, NC 27695 USA. EM jlindsey@ncsu.edu RI Lindsey, Jonathan/J-7761-2012; Huang, Ying-ying/G-3153-2011; OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin, Michael/0000-0001-6431-4605 FU NIH [R01AI050875]; Jimmy V NCSU Cancer Therapeutics Training Program; National Institute of Allergy and Infectious Diseases [R41AI072854]; North Carolina Biotechnology Center; NCSU Department of Chemistry FX This work was supported by a grant from the NIH (R01AI050875 to M. R. H.). M. K. was supported by the Jimmy V NCSU Cancer Therapeutics Training Program. L. H. was supported by a grant (R41AI072854) from the National Institute of Allergy and Infectious Diseases to NIRvana Pharmaceuticals, Inc. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or the NIH. Mass spectra were obtained at the NCSU Department of Chemistry Mass Spectrometry Facility. Funding for the facility was obtained from the North Carolina Biotechnology Center and the NCSU Department of Chemistry. NR 60 TC 9 Z9 9 U1 0 U2 18 PU WORLD SCI PUBL CO INC PI HACKENSACK PA 27 WARREN ST, STE 401-402, HACKENSACK, NJ 07601 USA SN 1088-4246 J9 J PORPHYR PHTHALOCYA JI J. Porphyr. Phthalocyanines PD JAN-FEB PY 2013 VL 17 IS 1-2 BP 73 EP 85 DI 10.1142/S108842461250126X PG 13 WC Chemistry, Multidisciplinary SC Chemistry GA 117JO UT WOS:000316949700008 PM 23956614 ER PT J AU Kang, D Martinez, RV Whitesides, GM Tearney, GJ AF Kang, Dongkyun Martinez, Ramses V. Whitesides, George M. Tearney, Guillermo J. TI Miniature grating for spectrally-encoded endoscopy SO LAB ON A CHIP LA English DT Article ID CORONARY ANGIOPLASTY; FIBER ENDOSCOPY; LITHOGRAPHY AB Spectrally-encoded endoscopy (SEE) is an ultraminiature endoscopy technology that acquires high-definition images of internal organs through a sub-mm endoscopic probe. In SEE, a grating at the tip of the imaging optics diffracts the broadband light into multiple beams, where each beam with a distinctive wavelength is illuminated on a unique transverse location of the tissue. By encoding one transverse coordinate with the wavelength, SEE can image a line of the tissue at a time without using any beam scanning devices. This feature of the SEE technology allows the SEE probe to be miniaturized to sub-mm dimensions. While previous studies have shown that SEE has the potential to be utilized for various clinical imaging applications, the translation of SEE for medicine has been hampered by challenges in fabricating the miniature grating inherent to SEE probes. This paper describes a new fabrication method for SEE probes. The new method uses a soft lithographic approach to pattern a high-aspect-ratio grating at the tip of the miniature imaging optics. Using this technique, we have constructed a 500 mm-diameter SEE probe. The miniature grating at the tip of the probe had a measured diffraction efficiency of 75%. The new SEE probe was used to image a human finger and formalin fixed mouse embryos, demonstrating the capability of this device to visualize key anatomic features of tissues with high image contrast. In addition to providing high quality imaging SEE optics, the soft lithography method allows cost-effective and reliable fabrication of these miniature endoscopes, which will facilitate the clinical translation of SEE technology. C1 [Kang, Dongkyun; Tearney, Guillermo J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Kang, Dongkyun; Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Martinez, Ramses V.; Whitesides, George M.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Whitesides, George M.] Harvard Univ, Wyss Inst Biol Inspired Engn, Cambridge, MA 02138 USA. [Tearney, Guillermo J.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Tearney, Guillermo J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Tearney, GJ (reprint author), Harvard Univ, Sch Med, 55 Fruit St, Boston, MA 02114 USA. EM tearney@helix.mgh.harvard.edu RI Martinez, Ramses/C-5219-2009; Kang, Dongkyun/C-1085-2013 OI Martinez, Ramses/0000-0002-0234-7732; Kang, Dongkyun/0000-0001-5063-5387 FU National Institute of Health/National Institute of Biomedical Imaging and Bioengineering [R21EB007718]; Office of Naval Research [N0014-10-1-0942]; FP7 People program under the project Marie Curie [IOF-275148]; Canon FX The authors thank Drs. Daniel Irimia and Salil Desai at BioMEMS resource center, Massachusetts General Hospital for their help on the elastomeric stamp fabrication during early stage of the research. This research was sponsored by National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (Grant# R21EB007718) and by the Office of Naval Research under award N0014-10-1-0942. R.V.M. acknowledges funding by the FP7 People program under the project Marie Curie IOF-275148. G. J. T is currently receiving research sponsorship from Canon related to the subject matter of this paper. The authors have submitted a provisional US patent application for the fabrication method described in this paper. NR 23 TC 4 Z9 4 U1 1 U2 25 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 EI 1473-0189 J9 LAB CHIP JI Lab Chip PY 2013 VL 13 IS 9 BP 1810 EP 1816 DI 10.1039/c3lc50076d PG 7 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 117OL UT WOS:000316962700019 PM 23503940 ER PT J AU Smeekens, SP Ng, A Kumar, V Johnson, MD Plantinga, TS van Diemen, C Arts, P Verwiel, ETP Gresnigt, MS Fransen, K van Sommeren, S Oosting, M Cheng, SC Joosten, LAB Hoischen, A Kullberg, BJ Scott, WK Perfect, JR van der Meer, JWM Wijmenga, C Netea, MG Xavier, RJ AF Smeekens, Sanne P. Ng, Aylwin Kumar, Vinod Johnson, Melissa D. Plantinga, Theo S. van Diemen, Cleo Arts, Peer Verwiel, Eugene T. P. Gresnigt, Mark S. Fransen, Karin van Sommeren, Suzanne Oosting, Marije Cheng, Shih-Chin Joosten, Leo A. B. Hoischen, Alexander Kullberg, Bart-Jan Scott, William K. Perfect, John R. van der Meer, Jos W. M. Wijmenga, Cisca Netea, Mihai G. Xavier, Ramnik J. TI Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans SO NATURE COMMUNICATIONS LA English DT Article ID BLOOD-STREAM INFECTIONS; LISTERIA-MONOCYTOGENES; GENE-EXPRESSION; UNITED-STATES; RNA-SEQ; EPIDEMIOLOGY; RECOGNITION; MACROPHAGES; HOSPITALS; CLASSIFICATION AB Candida albicans is the most common human fungal pathogen causing mucosal and systemic infections. However, human antifungal immunity remains poorly defined. Here by integrating transcriptional analysis and functional genomics, we identified Candida-specific host defence mechanisms in humans. Candida induced significant expression of genes from the type I interferon pathway in human peripheral blood mononuclear cells. This unexpectedly prominent role of type I interferon pathway in anti-Candida host defence was supported by additional evidence. Polymorphisms in type I interferon genes modulated Candida-induced cytokine production and were correlated with susceptibility to systemic candidiasis. In in vitro experiments, type I interferons skewed Candida-induced inflammation from a Th17 response towards a Th1 response. Patients with chronic mucocutaneous candidiasis displayed defective expression of genes in the type I interferon pathway. These findings indicate that the type I interferon pathway is a main signature of Candida-induced inflammation and has a crucial role in anti-Candida host defence in humans. C1 [Smeekens, Sanne P.; Plantinga, Theo S.; Gresnigt, Mark S.; Oosting, Marije; Cheng, Shih-Chin; Joosten, Leo A. B.; Kullberg, Bart-Jan; van der Meer, Jos W. M.; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Med 463, NL-6525 GA Nijmegen, Netherlands. [Smeekens, Sanne P.; Plantinga, Theo S.; Gresnigt, Mark S.; Oosting, Marije; Cheng, Shih-Chin; Joosten, Leo A. B.; Kullberg, Bart-Jan; van der Meer, Jos W. M.; Netea, Mihai G.] Nijmegen Inst Infect Inflammat & Immun N4i 463, NL-6500 HB Nijmegen, Netherlands. [Ng, Aylwin; Xavier, Ramnik J.] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge Ctr 7, Cambridge, MA 02142 USA. [Ng, Aylwin; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Ng, Aylwin; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA. [Kumar, Vinod; van Diemen, Cleo; Fransen, Karin; van Sommeren, Suzanne; Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9700 RB Groningen, Netherlands. [Johnson, Melissa D.; Perfect, John R.] Duke Univ, Med Ctr, Durham, NC 27710 USA. [Johnson, Melissa D.; Perfect, John R.] Campbell Univ, Sch Pharm, Dept Clin Res, Buies Creek, NC 27506 USA. [Arts, Peer; Verwiel, Eugene T. P.; Hoischen, Alexander] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet 855, NL-6500 HB Nijmegen, Netherlands. [Scott, William K.] Univ Miami, Miller Sch Med, Dept Human Genet, Dr John T Macdonald Fdn, Miami, FL 33136 USA. [Scott, William K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA. RP Netea, MG (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Med 463, Geert Grootepl Zuid 8, NL-6525 GA Nijmegen, Netherlands. EM m.netea@aig.umcn.nl RI van der Meer, Jos/C-8521-2013; Hoischen, Alexander/D-1282-2013; Smeekens, Sanne/G-8307-2011; Netea, Mihai/N-5155-2014; Kullberg, Bart Jan/C-8520-2013; Wijmenga, Cisca/D-2173-2009; Plantinga, Theo/A-6895-2015; Cheng, Shih-Chin/H-4567-2015; Oosting, Marije/H-7437-2015; Joosten, Leo/H-3138-2015; Gresnigt, Mark/H-3530-2015 OI Johnson, Melissa/0000-0002-6606-9460; Wijmenga, Cisca/0000-0002-5635-1614; van der Meer, Jos/0000-0001-5120-3690; Hoischen, Alexander/0000-0002-8072-4476; Smeekens, Sanne/0000-0002-7835-914X; Cheng, Shih-Chin/0000-0003-1251-8774; Gresnigt, Mark/0000-0002-9514-4634 FU National Institutes of Health [AI062773, DK043351, DK83756]; Helmsley Trust; ERC Consolidator grant [ERC-310372]; Coeliac Disease Consortium; Dutch Government [BSIK03009]; Netherlands Organization for Scientific Research (NWO VICI) [918.66.620] FX R.J.X. was supported by National Institutes of Health grants AI062773, DK043351 and DK83756 and the Helmsley Trust. M.G.N. was supported by an ERC Consolidator grant (ERC-310372). The work in the group of CW is financially supported by the Coeliac Disease Consortium, an Innovative Cluster approved by the Netherlands Genomics Initiative and funded by the Dutch Government (BSIK03009), and by the Netherlands Organization for Scientific Research (NWO VICI grant 918.66.620). We thank Fadi Towfic for helpful discussions, Mathieu Platteel, Astrid Maatman, Soesma Medema-Jankipersadsing, Rutger Modderman, Judith Land and Gosia Trynka for assisting in the stimulation experiments, RNA and DNA analysis, and microarray experiments (immunochip and gene expression). Furthermore, we thank Kornelia Neveling and Petra de Vries for technical assistance with the RNA sequencing experiments. NR 48 TC 48 Z9 49 U1 1 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JAN PY 2013 VL 4 AR 1342 DI 10.1038/ncomms2343 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 112SV UT WOS:000316614600012 PM 23299892 ER PT J AU Mendez, MF Owens, EM Berenji, GR Peppers, DC Liang, LJ Licht, EA AF Mendez, Mario F. Owens, Emily M. Berenji, Gholam Reza Peppers, Dominique C. Liang, Li-Jung Licht, Eliot A. TI Mild traumatic brain injury from primary blast vs. blunt forces: Post-concussion consequences and functional neuroimaging SO NEUROREHABILITATION LA English DT Article DE Mild traumatic brain injury; blast forces; post-concussion; positron emission tomography imaging ID PERSISTENT POSTCONCUSSIVE SYMPTOMS; POSITRON EMISSION TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; OIF/OEF SERVICE MEMBERS; IRAQ WAR VETERANS; HEAD-INJURY; POSTTRAUMATIC-STRESS; NEUROPSYCHOLOGICAL DEFICITS; MILITARY PERSONNEL; FDG-PET AB INTRODUCTION: Primary blast forces may cause dysfunction from mild traumatic brain injury (mTBI). OBJECTIVE: To investigate the effects of primary blast forces, independent of associated blunt trauma and post-traumatic stress disorder, on sensitive post-concussive measures. METHODS: This study investigated post-concussive symptoms, functional health and well-being, cognition, and positron emission tomography (PET) neuroimaging among 12 Iraq or Afghanistanwar veterans who sustained pure blast-force mTBI, compared to 12 who sustained pure blunt-force mTBI. RESULTS: Both groups had significantly lower scores than published norms on the Rivermead Post-Concussion Questionnaire (RPQ) and the SF36-V Health Survey. Compared to the Blunt Group, the Blast Group had poorer scores on the Paced Auditory Serial Addition Test (PASAT) and greater PET hypometabolism in the right superior parietal region. Only the Blast Group had significant correlations of their RPQ, SF36-V Mental Composite Score, and PASAT scores with specific regional metabolic changes. CONCLUSION: This pilot study suggests that pure blast force mTBI may have greater post-concussive sequelae including deficits in attentional control and regional brain metabolism, compared to blunt mTBI. A disturbance of a right parietal-frontal attentional network is one potential explanation for these findings. C1 [Mendez, Mario F.; Owens, Emily M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Mendez, Mario F.; Licht, Eliot A.] VA Greater Los Angeles Healthcare Ctr, Neurol Sect, Los Angeles, CA 90073 USA. [Berenji, Gholam Reza; Peppers, Dominique C.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. [Liang, Li-Jung] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU Veterans Affairs Administration FX No conflicts of interest. This research was made possible by a grant from the Veterans Affairs Administration. NR 70 TC 16 Z9 16 U1 5 U2 27 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2013 VL 32 IS 2 BP 397 EP 407 DI 10.3233/NRE-130861 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 115ZT UT WOS:000316851900025 PM 23535805 ER PT J AU O'Donovan, A Slavich, GM Epel, ES Neylan, TC AF O'Donovan, Aoife Slavich, George M. Epel, Elissa S. Neylan, Thomas C. TI Exaggerated neurobiological sensitivity to threat as a mechanism linking anxiety with increased risk for diseases of aging SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Anxiety; Attentional bias; Cellular aging; Diseases of aging; Hypothalamic-pituitary-adrenal axis; Inflammation; Information processing; Neurobiological; Parasympathetic nervous system; Psychoneuroimmunology; Sympathetic nervous system; Threat ID POSTTRAUMATIC-STRESS-DISORDER; C-REACTIVE PROTEIN; HEART-RATE-VARIABILITY; PREFRONTAL CORTICAL PROJECTIONS; URINARY CORTISOL EXCRETION; MENTAL-HEALTH DISORDERS; EXPLICIT MEMORY BIAS; QUALITY-OF-LIFE; GENERALIZED-ANXIETY; ATTENTIONAL BIAS AB Anxiety disorders increase risk for the early development of several diseases of aging. Elevated inflammation, a common risk factor across diseases of aging, may play a key role in the relationship between anxiety and physical disease. However, the neurobiological mechanisms linking anxiety with elevated inflammation remain unclear. In this review, we present a neurobiological model of the mechanisms by which anxiety promotes inflammation. Specifically we propose that exaggerated neurobiological sensitivity to threat in anxious individuals may lead to sustained threat perception, which is accompanied by prolonged activation of threat-related neural circuitry and threat-responsive biological systems including the hypothalamic-pituitary-adrenal (HPA) axis, autonomic nervous system (ANS), and inflammatory response. Over time, this pattern of responding can promote chronic inflammation through structural and functional brain changes, altered sensitivity of immune cell receptors, dysregulation of the HPA axis and ANS, and accelerated cellular aging. Chronic inflammation, in turn, increases risk for diseases of aging. Exaggerated neurobiological sensitivity to threat may thus be a treatment target for reducing disease risk in anxious individuals. (c) 2012 Elsevier Ltd. All rights reserved. C1 [O'Donovan, Aoife; Epel, Elissa S.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [O'Donovan, Aoife; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [O'Donovan, Aoife; Neylan, Thomas C.] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Slavich, George M.] Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. [Slavich, George M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP O'Donovan, A (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116H, 4150 Clement St, San Francisco, CA 94121 USA. EM aoife.odonovan@ucsf.edu FU Society in Science - The Branco Weiss Fellowship FX Aoife O'Donovan and George M. Slavich were supported by Society in Science - The Branco Weiss Fellowship during the preparation of this review. We thank Joshua Woolley, Keely Muscatell, Kristen Nishimi, and Annika Rose for their helpful feedback on a previous version of this manuscript. NR 235 TC 30 Z9 30 U1 13 U2 37 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD JAN PY 2013 VL 37 IS 1 BP 96 EP 108 DI 10.1016/j.neubiorev.2012.10.013 PG 13 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 112IU UT WOS:000316586700007 PM 23127296 ER PT J AU Vassy, JL AF Vassy, Jason L. TI Can genetic information change patient behavior to reduce Type 2 diabetes risk? SO PERSONALIZED MEDICINE LA English DT Editorial Material DE genetic testing; health behavior; personalized medicine; prevention; Type 2 diabetes ID MELLITUS; PREDICTION; POPULATION; PREVENTION; DESIGN C1 [Vassy, Jason L.] VA Boston HealthCare Syst, Gen Internal Med Sect, Boston, MA USA. [Vassy, Jason L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Res Program G2P, Boston, MA 02115 USA. [Vassy, Jason L.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02130 USA. RP Vassy, JL (reprint author), VA Boston HealthCare Syst, Gen Internal Med Sect, Boston, MA USA. EM jvassy@partners.org NR 17 TC 3 Z9 4 U1 3 U2 7 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1741-0541 J9 PERS MED JI Pers. Med. PD JAN PY 2013 VL 10 IS 1 BP 9 EP 12 DI 10.2217/PME.12.116 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 115FG UT WOS:000316797400003 ER PT J AU McGuire, AL Robinson, JO Ramoni, RB Morley, DS Joffe, S Plon, SE AF McGuire, Amy L. Robinson, Jill Oliver Ramoni, Rachel B. Morley, Debra S. Joffe, Steven Plon, Sharon E. TI Returning genetic research results: study type matters SO PERSONALIZED MEDICINE LA English DT Article DE ethics; genome-wide association; genomics; policy; return of results; whole-genome sequencing ID INFORMED-CONSENT; CLINICAL-RESEARCH; WORKING GROUP; PARTICIPANTS; MEDICINE; GENOMICS; DUTY AB Aim: The return of individual genetic research results has been identified as one of the most pressing ethical challenges warranting immediate policy attention. We explored the practices and perspectives of genome-wide association studies (GWAS) investigators on this topic. Materials & methods: Corresponding authors of published GWAS were invited to participate in a semistructured interview. Interviews (n = 35) were transcribed and analyzed using conventional content analysis. Results: Most investigators had not returned GWAS results. Several had experience returning results in the context of linkage/family studies, and many felt that it will become a larger issue in whole-genome/-exome sequencing. Conclusions: Research context and nature of the study are important considerations in the decision to return results. More nuanced ethical guidelines should take these contextual factors into account. C1 [McGuire, Amy L.; Robinson, Jill Oliver] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA. [Ramoni, Rachel B.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA. [Morley, Debra S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Joffe, Steven] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Joffe, Steven] Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA. [Plon, Sharon E.] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA. RP McGuire, AL (reprint author), Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA. EM amcguire@bcm.edu OI Joffe, Steven/0000-0002-0667-7384 FU Baylor College of Medicine Clinical and Translational Research Program; Baylor Annual Fund [NIDCR K08 DE016956, NHGRI HG006485-01] FX This research was funded by the Baylor College of Medicine Clinical and Translational Research Program and the Baylor Annual Fund; NIDCR K08 DE016956; and NHGRI HG006485-01. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 26 TC 14 Z9 14 U1 2 U2 8 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1741-0541 J9 PERS MED JI Pers. Med. PD JAN PY 2013 VL 10 IS 1 BP 27 EP 34 DI 10.2217/PME.12.109 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 115FG UT WOS:000316797400009 PM 24077424 ER PT J AU Arar, N Delgado, E Lee, S Abboud, HE AF Arar, Nedal Delgado, Elizabeth Lee, Shuko Abboud, Hanna E. TI Improving learning about familial risks using a multicomponent approach: the GRACE program SO PERSONALIZED MEDICINE LA English DT Article DE familial risks assessment; family health history tool; genomics; learning; online Surgeon General ID PRIMARY-CARE; PUBLIC-HEALTH; HISTORY INFORMATION; COLORECTAL-CANCER; TOOL; HERITABILITY; DISEASES; SUPPORT; RECORD; BREAST AB Aim: To enhance learning (knowledge, attitudes and practices) about the importance of family health history (FHH) information and familial risks. Methods: A pre-post design with one group was employed in this study. Five learning sessions were conducted with a community-based sample (n = 75) recruited from five counties in Texas, USA. Each learning session included: a short online video; enactive instructions on how to use the online Surgeon General FHH tool; and a presentation on how to assess familial risks. Participants completed the pre-post knowledge, attitudes and practices questionnaires and the study's satisfaction survey, and participated in a short focus group interview. Results: Participants' average age was 48.1 +/- 13.3 years. Over half of the participants (79%) were female, and 55% described themselves as non-Hispanic White. Our findings showed significant changes (p < 0.05) in participants' specific knowledge about factors that affect their familial risks. Similarly, significant changes (p < 0.05) in participants' attitudes toward familial risks assessment for common disease complications and confidence in controlling these risks have been documented. Participants' reported a high level of satisfaction in using online FHH tools, yet no significant change (p > 0.05) was detected in their reported practices regarding sharing FHH information with their providers or relatives. Focus group interviews revealed that participants were uncertain about providers' or relatives' reactions to sharing FHH information. Conclusion: Using different learning styles may have a significant impact on improving knowledge and attitudes about familial risks. C1 [Arar, Nedal; Delgado, Elizabeth; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Arar, Nedal; Lee, Shuko; Abboud, Hanna E.] Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care System, San Antonio, TX 78284 USA. RP Arar, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM ararn@uthscsa.edu FU NIH [CTSA: UL1RR025767]; VHA-HSRD [DNA 08-129, PPO 09-241]; Area Health Education Center at South Texas FX This work was supported by NIH grant (CTSA: UL1RR025767) and the VHA-HSR&D (DNA 08-129 and PPO 09-241, principal investigator: N Arar) and Area Health Education Center at South Texas. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 40 TC 2 Z9 2 U1 0 U2 1 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1741-0541 J9 PERS MED JI Pers. Med. PD JAN PY 2013 VL 10 IS 1 BP 35 EP 44 DI 10.2217/PME.12.107 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 115FG UT WOS:000316797400010 PM 23682294 ER PT J AU Shan, GB Weissleder, R Hilderbrand, SA AF Shan, Guobin Weissleder, Ralph Hilderbrand, Scott A. TI Upconverting Organic Dye Doped Core-Shell Nano-Composites for Dual-Modality NIR Imaging and Photo-Thermal Therapy SO THERANOSTICS LA English DT Article DE Cell imaging; Core-shell; Dye; Nano-composites; Photo-thermal therapy; Up-conversion ID 808-NM DIODE-LASER; CANCER-THERAPY; GOLD NANORODS; PHOTODYNAMIC THERAPY; CARBON NANOTUBES; INDOCYANINE-GREEN; CELL DESTRUCTION; DRUG-DELIVERY; QUANTUM DOTS; NANOPARTICLES AB Nanotechnology approaches offer the potential for creating new optical imaging agents with unique properties that enable uses such as combined molecular imaging and photo-thermal therapy. Ideal preparations should fluoresce in the near-infrared (NIR) region to ensure maximal tissue penetration depth along with minimal scattering and light absorption. Due to their unique photophysical properties, upconverting ceramics such as NaYF4:Er3+,Yb3+ nanoparticles have become promising optical materials for biological imaging. In this work, the design and synthesis of NaYF4:Er3+,Yb3+@SiO2 core-shell nano-composites, which contain highly absorbing NIR carbocyanine dyes in their outer silica shell, are described. These materials combine optical emission (from the upconverting core nanoparticle) with strong NIR absorption (from the carbocyanine dyes incorporated into the shell) to enable both optical imaging and photo-thermal treatment, respectively. Ultimately, this hybrid composite nanomaterial approach imparts the ability to both visualize, via upconversion imaging, and treat, via photo-thermal heating, using two distinct optical channels. Proof-of-principle in vitro experiments are presented to demonstrate the combined imaging and photo-thermal properties of this new functional nano-composite. C1 [Hilderbrand, Scott A.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Hilderbrand, Scott A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Hilderbrand, SA (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5210, Boston, MA 02114 USA. EM Scott_Hilderbrand@hms.harvard.edu FU NHLBI [HHSN268201000044C] FX This research is supported in part by NHLBI contract HHSN268201000044C. NR 41 TC 44 Z9 44 U1 18 U2 203 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2013 VL 3 IS 4 BP 267 EP 274 DI 10.7150/thno.5226 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 118BE UT WOS:000316996600004 PM 23606913 ER PT J AU Nordenstedt, H Graham, DY Kramer, JR Rugge, M Verstovsek, G Fitzgerald, S Alsarraj, A Shaib, Y Velez, ME Abraham, N Anand, B Md, RC El-Serag, HB AF Nordenstedt, Helena Graham, David Y. Kramer, Jennifer R. Rugge, Massimo Verstovsek, Gordana Fitzgerald, Stephanie Alsarraj, Abeer Shaib, Yasser Velez, Maria E. Abraham, Neena Anand, Bhupinderjit Cole, Rhonda El-Serag, Hashem B. TI Helicobacter pylori-Negative Gastritis: Prevalence and Risk Factors SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID EROSIVE ESOPHAGITIS; ERADICATION; INFECTION AB OBJECTIVES: Recent studies using histology alone in select patients have suggested that Helicobacter pylori negative gastritis may be common. The objective of this study was to investigate the prevalence of H. pylori among individuals with histologic gastritis. METHODS: Subjects between 40 and 80 years underwent elective esophagogastroduodenoscopy at a VA Medical Center. Gastric biopsies were mapped from seven prespecified sites (two antrum, four corpus, and one cardia) and graded by two gastrointestinal pathologists, using the Updated Sydney System. H. pylori-negative required four criteria: negative triple staining at all seven gastric sites, negative H. pylori culture, negative IgG H. pylori serology, and no previous treatment for H. pylori. Data regarding tobacco smoking, alcohol drinking, nonsteroidal anti-inflammatory drug, and proton pump inhibitor (PPI) use were obtained by questionnaire. RESULTS: Of the 491 individuals enrolled, 40.7 % (200) had gastritis of at least grade 2 in at least one biopsy site or grade 1 in at least two sites. Forty-one (20.5 %) had H. pylori-negative gastritis; most (30 or 73.2 %) had chronic gastritis, five (12.2 %) had active gastritis, and six (14.6 %) had both. H. pylori negative gastritis was approximately equally distributed in the antrum, corpus, and both antrum and corpus. Past and current PPI use was more frequent in H. pylori-negative vs. H. pylori-positive gastritis (68.2 % and 53.8 %; P = 0.06). CONCLUSIONS: We used multiple methods to define non-H. pylori gastritis and found it in 21 % of patients with histologic gastritis. While PPI use is a potential risk factor, the cause or implications of this entity are not known. Am J Gastroenterol 2013; 108:65-71; doi:10.1038/ajg.2012.372; published online 13 November 2012 C1 [Nordenstedt, Helena; Kramer, Jennifer R.; Fitzgerald, Stephanie; Alsarraj, Abeer; Abraham, Neena; El-Serag, Hashem B.] Houston VA HSR&D Ctr Excellence, Houston, TX USA. [Nordenstedt, Helena; Graham, David Y.; Rugge, Massimo; Shaib, Yasser; Velez, Maria E.; Abraham, Neena; Anand, Bhupinderjit; Cole, Rhonda; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Graham, David Y.; Shaib, Yasser; Velez, Maria E.; Abraham, Neena; Anand, Bhupinderjit; Cole, Rhonda; El-Serag, Hashem B.] Dept Med, Houston, TX USA. [Kramer, Jennifer R.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Rugge, Massimo] Univ Padua, Dept Diagnost Med Sci & Special Therapies, Surg Pathol & Cytopathol Unit, Padua, Italy. [Verstovsek, Gordana] Michael E DeBakey VA Med Ctr, Dept Pathol, Houston, TX USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.edu RI Rugge, Massimo/K-7525-2016 FU VA HSR&D Houston Center of Excellence [HFP90-020]; NCI [R01 116845]; NIDDK [K24-04-107] FX This work was partly supported by the VA HSR&D Houston Center of Excellence (HFP90-020), Grant support : NCI R01 116845 and NIDDK K24-04-107. NR 11 TC 22 Z9 22 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2013 VL 108 IS 1 BP 65 EP 71 DI 10.1038/ajg.2012.372 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 107AI UT WOS:000316186600009 PM 23147524 ER PT J AU Fricker, Z Levy, E Kleiner, D Taylor, JG Koh, C Holland, SM Heller, T AF Fricker, Zachary Levy, Elliot Kleiner, David Taylor, James G. Koh, Christopher Holland, Steven M. Heller, Theo TI Case Series: Biliary Leak After Transjugular Liver Biopsy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID COMPLICATIONS; NEEDLE C1 [Fricker, Zachary] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Levy, Elliot] NIH, Radiol & Imaging Sci Dept, Ctr Clin, Bethesda, MD 20892 USA. [Kleiner, David] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA. [Taylor, James G.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA. [Koh, Christopher; Heller, Theo] NIDDK, Liver Dis Branch, NIH, Bethesda, MD USA. [Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA. RP Fricker, Z (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM zfricker@gmail.com; theoh@intra.niddk.nih.gov OI Kleiner, David/0000-0003-3442-4453; Taylor, James/0000-0002-4421-1809 FU Intramural NIH HHS NR 12 TC 2 Z9 2 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2013 VL 108 IS 1 BP 145 EP 147 DI 10.1038/ajg.2012.352 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 107AI UT WOS:000316186600024 PM 23287950 ER PT J AU Bao, J Fisher, JE Lillegard, JB Wang, W Amiot, B Yu, Y Dietz, AB Nahmias, Y Nyberg, SL AF Bao, Ji Fisher, James E. Lillegard, Joseph B. Wang, William Amiot, Bruce Yu, Yue Dietz, Allan B. Nahmias, Yaakov Nyberg, Scott L. TI Serum-Free Medium and Mesenchymal Stromal Cells Enhance Functionality and Stabilize Integrity of Rat Hepatocyte Spheroids SO CELL TRANSPLANTATION LA English DT Article DE Bioartificial liver; Spheroid; Hepatocyte; Medium; Ureagenesis ID ACUTE LIVER-FAILURE; UREA CYCLE ENZYMES; BIOARTIFICIAL LIVER; GENE-EXPRESSION; AMINO-ACIDS; AMMONIA; METABOLISM; ARTERIAL AB Long-term culture of hepatocyte spheroids with high ammonia clearance is valuable for therapeutic applications, especially the bioartificial liver. However, the optimal conditions are not well studied. We hypothesized that liver urea cycle enzymes can be induced by high protein diet and maintain on a higher expression level in rat hepatocyte spheroids by serum-free medium (SFM) culture and coculture with mesenchymal stromal cells (MSCs). Rats were feed normal protein diet (NPD) or high protein diet (HPD) for 7 days before liver digestion and isolation of hepatocytes. Hepatocyte spheroids were formed and maintained in a rocked suspension culture with or without MSCs in SFM or 10% serum-containing medium (SCM). Spheroid viability, kinetics of spheroid formation, hepatic functions, gene expression, and biochemical activities of rat hepatocyte spheroids were tested over 14 days of culture. We observed that urea cycle enzymes of hepatocyte spheroids can be induced by high protein diet. SFM and MSCs enhanced ammonia clearance and ureagenesis and stabilized integrity of hepatocyte spheroids compared to control conditions over 14 days. Hepatocytes from high protein diet-fed rats formed spheroids and maintained a high level of ammonia detoxification for over 14 days in a novel SFM. Hepatic functionality and spheroid integrity were further stabilized by coculture of hepatocytes with MSCs in the spheroid microenvironment. These findings have direct application to development of the spheroid reservoir bioartificial liver. C1 [Bao, Ji] West China Hosp, Dept Pathol, Chengdu, Sichuan, Peoples R China. [Bao, Ji; Fisher, James E.; Lillegard, Joseph B.; Wang, William; Yu, Yue; Nyberg, Scott L.] Mayo Clin, Dept Surg, Div Expt Surg, Rochester, MN 55905 USA. [Amiot, Bruce] Brami Biomed Inc, Minneapolis, MN USA. [Dietz, Allan B.] Mayo Clin, Div Transfus Med, Rochester, MN 55905 USA. [Nahmias, Yaakov] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA USA. RP Nyberg, SL (reprint author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA. EM Nyberg.scott@mayo.edu RI Nahmias, Yaakov/H-4725-2013; Dietz, Allan/H-7414-2015; OI Dietz, Allan/0000-0003-3410-9621; Nahmias, Yaakov/0000-0002-6051-616X FU Marriott Foundation; NIH; China Scholarship Council FX This work was funded by the Marriott Foundation, NIH, and China Scholarship Council. The authors declare no conflicts of interest. NR 27 TC 13 Z9 14 U1 0 U2 6 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2013 VL 22 IS 2 BP 299 EP 308 DI 10.3727/096368912X656054 PG 10 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA 106PV UT WOS:000316158100009 PM 23006214 ER PT J AU Sankaran, VG Orkin, SH AF Sankaran, Vijay G. Orkin, Stuart H. TI The Switch from Fetal to Adult Hemoglobin SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE LA English DT Article ID SICKLE-CELL-DISEASE; GLOBIN GENE-EXPRESSION; FACTOR KLF1 CAUSES; GAMMA-GLOBIN; BETA-THALASSEMIA; DNA METHYLATION; RISK-FACTORS; C-MYB; NUCLEAR RECEPTORS; DIABETIC MOTHERS AB The fetal-to-adult hemoglobin switch and silencing of fetal hemoglobin (HbF) have been areas of long-standing interest among hematologists, given the fact that clinical induction of HbF production holds tremendous promise to ameliorate the clinical symptoms of sickle cell disease (SCD) and beta-thalassemia. In this article, we discuss historic attempts to induce HbF that have resulted in some therapeutic approaches to manage SCD and beta-thalassemia. We then go on to discuss how more recent molecular studies that have identified regulators, including BCL11A, MYB, and KLF1, hold great promise to develop targeted and more effective approaches for HbF induction. We go on to discuss strategies by which such approaches may be developed. Older studies in this field can provide important lessons for future studies aimed at developing more effective strategies for HbF induction, and we therefore chronologically cover the work accomplished as this field has evolved over the course of the past four decades. C1 [Sankaran, Vijay G.; Orkin, Stuart H.] Harvard Univ, Sch Med, Div Hematol Oncol, Childrens Hosp Boston, Boston, MA 02115 USA. [Sankaran, Vijay G.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Sankaran, Vijay G.] Broad Inst, Cambridge, MA 02142 USA. [Orkin, Stuart H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Sankaran, VG (reprint author), Harvard Univ, Sch Med, Div Hematol Oncol, Childrens Hosp Boston, Boston, MA 02115 USA. EM sankaran@broadinstitute.org; stuart_orkin@dfci.harvard.edu FU National Institutes of Health [T32 HL007574-30]; Boston Children's Hospital FX We thank T. DiCesare for assistance in preparing illustrations. V. G. S. received support from National Institutes of Health grant T32 HL007574-30 and from funding provided by Boston Children's Hospital. S.H.O. is an investigator of the Howard Hughes Medical Institute. NR 98 TC 51 Z9 53 U1 4 U2 19 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 2157-1422 J9 CSH PERSPECT MED JI Cold Spring Harb. Perspect. Med. PD JAN PY 2013 VL 3 IS 1 AR a011643 DI 10.1101/cshperspect.a011643 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 111ZD UT WOS:000316559900005 PM 23209159 ER PT S AU Lam, A Holbrook, E AF Lam, Allen Holbrook, Eric BE Bleier, BS TI Skull Base Anatomy and CSF Rhinorrhea SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID CEREBROSPINAL-FLUID LEAKS; HIGH-RESOLUTION CT; BENIGN INTRACRANIAL HYPERTENSION; BETA-TRACE PROTEIN; DIAGNOSIS; CISTERNOGRAPHY; MANAGEMENT; FLUORESCEIN; IDENTIFICATION; TRANSFERRIN AB The skull base is an intricate interface between the cranium and face allowing the passageway of vital structures. Anatomic conceptualization forms the platform for surgical approaches and solutions to skull base pathology. Understanding embryogenesis provides further depth into the pathophysiology of congenital defects. This chapter aims to highlight skull base anatomy and embryology along with cerebrospinal fluid physiology and diagnostic evaluation of cerebrospinal fluid leaks. Copyright (C) 2013 S. Karger AG, Basel C1 [Lam, Allen; Holbrook, Eric] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Lam, A (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM allen_lam@meei.harvard.edu NR 45 TC 1 Z9 2 U1 0 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5; 978-3-8055-9952-8 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP 1 EP 11 DI 10.1159/000342263 PG 11 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300002 PM 23257547 ER PT S AU Bleier, BS AF Bleier, Benjamin S. BE Bleier, BS TI Comprehensive Techniques in CSF Leak Repair and Skull Base Reconstruction Preface SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Editorial Material; Book Chapter C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. RP Bleier, BS (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP IX EP IX PG 1 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300001 ER PT S AU Gray, ST Wu, AW AF Gray, Stacey T. Wu, Arthur W. BE Bleier, BS TI Pathophysiology of latrogenic and Traumatic Skull Base Injury SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID CEREBROSPINAL-FLUID LEAKS; ENDOSCOPIC SINUS SURGERY; COMPLICATIONS; MANAGEMENT; EXPERIENCE; REPAIR; RHINORRHEA; FISTULAS; RECONSTRUCTION; METAANALYSIS AB Traumatic skull base injuries can be divided into iatrogenic injuries from surgery and accidental traumatic injuries. The most common cause of iatrogenic skull base injury is endoscopic sinus surgery. The reported rate of cerebrospinal fluid (CSF) leak as a complication of endoscopic sinus surgery is less than 1%. Intraoperative injury most commonly occurs at the ethmoid roof and the lateral lamella of the cribiform plate. Case complexity, such as revision surgery, as well as surgical experience has been shown to be a contributing factor to iatrogenic CSF leaks during endoscopic sinus surgery. Other causes of iatrogenic CSF leaks include endoscopic skull base and open neurosurgical procedures. CSF leak occurs in 2.6% of all closed head traumas and is more likely in the case of a definitive skull base fracture. The majority of accidental trauma CSF leaks can be managed conservatively, but those that persist beyond a week are typically managed surgically to avoid the risk of meningitis. Copyright (C) 2013 S. Karger AG, Basel C1 [Gray, Stacey T.; Wu, Arthur W.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Gray, ST (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM stacey_gray@meei.harvard.edu NR 35 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP 12 EP 23 DI 10.1159/000342264 PG 12 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300003 PM 23257548 ER PT S AU Ting, JY Metson, R AF Ting, Jonathan Y. Metson, Ralph BE Bleier, BS TI Free Graft Techniques in Skull Base Reconstruction SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID CEREBROSPINAL-FLUID LEAKS; TRANSNASAL ENDOSCOPIC REPAIR; LONG-TERM; RHINORRHEA; MANAGEMENT; SURGERY; ENCEPHALOCELES; SINUS; EXPERIENCE AB Over the last 20-30 years, the management of anterior skull base defects, CSF leaks and encephaloceles has shifted towards endoscopic, minimally invasive approaches. Whether their etiology is spontaneous or traumatic, the large majority of these lesions can be repaired with free mucosal grafts. Such grafts may be readily harvested from the nasal septum or turbinates and applied as either a single layer reconstruction for small leaks or as a multilayer reconstruction for larger defects. The accessibility, ease of placement, and high take rate associated with free mucosal grafts makes them a wise and popular choice for reconstruction of many skull base defects. Copyright (C) 2013 S. Karger AG, Basel C1 [Ting, Jonathan Y.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Ting, Jonathan Y.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Ting, JY (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM jonathan_ting@meei.harvard.edu NR 27 TC 1 Z9 1 U1 0 U2 2 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP 33 EP 41 DI 10.1159/000342266 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300005 PM 23257550 ER PT S AU Meier, JC Bleier, BS AF Meier, Joshua C. Bleier, Benjamin S. BE Bleier, BS TI Anteriorly Based Pedicled Flaps for Skull Base Reconstruction SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID INFERIOR TURBINATE FLAP; NASOSEPTAL FLAP AB The expansion of endoscopic skull base surgery has resulted in the creation of large defects that must be repaired to ensure separation of the cranial vault from the nasal cavity. The workhorse of anterior skull base reconstruction remains the nasoseptal or Hadad-Bassagasteguy flap. Despite its success, the nasoseptal flap is limited in its ability to reach extremely anterior defects including those involving the frontal break, posterior frontal table, and anterior cribiform plate. Alternative approaches utilizing anteriorly pedicled flaps have been described which exploit the vascular supply to the anterior septum and lateral nasal wall. The diminutive nature of the anterior septal blood supply has led to the elaboration of a bipedicled anterior septal flap which is capable of reliable reconstruction of both the frontal beak as well as posterior frontal table defects. Similarly anteriorly based inferior turbinate flaps pedicled largely on anterior ethmoid arborizations have been used successfully to reconstruct anterior defects. In light of the limitations of the nasoseptal flap, the addition of anteriorly pedicled flaps to the clinical armamentarium offers the opportunity to provide vascularized mucosal coverage of virtually any region of the skull base which can be reached endoscopically. Copyright (C) 2013 S. Karger AG, Basel C1 [Meier, Joshua C.; Bleier, Benjamin S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Bleier, BS (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM bleierb@gmail.com NR 11 TC 6 Z9 6 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP 64 EP 70 DI 10.1159/000342281 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300008 PM 23257553 ER PT S AU Herr, MW Lin, DT AF Herr, Marc W. Lin, Derrick T. BE Bleier, BS TI Microvascular Free Flaps On Skull Base Reconstruction SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID FREE-TISSUE TRANSFER; ANTERIOR CRANIOFACIAL RESECTION; ANTEROLATERAL THIGH FLAP; DEFECTS; COMPLICATIONS; SURGERY; TUMORS; HEAD AB The anatomical challenges of skull base surgery are well known. Furthermore, ablative and traumatic defects in this region produce complex reconstructive problems with a high risk of significant postoperative morbidity and mortality. Over the past two decades, microvascular free tissue reconstruction following open resection has been shown to improve outcomes and reduce complication rates when compared to the traditional use of pedicled flaps. The increasing use of free tissue transfer has been further strengthened by improved technical expertise and high flap success rates. Since the size and type of free tissue to be utilized must be individualized to each defect, the accomplished reconstructive surgeon should be extremely versatile and, by extension, facile with a several types of free flaps. Thus, four of the most commonly used flaps - the rectus abdominis, radial forearm, latissimus dorsi and anterolateral thigh flaps - are discussed. Copyright (C) 2013 S. Karger AG, Basel C1 [Herr, Marc W.; Lin, Derrick T.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. RP Lin, DT (reprint author), Massachusetts Eye & Ear Infirm, Skull Base Ctr, 243 Charles St, Boston, MA 02114 USA. EM derrick_lin@meei.harvard.edu NR 32 TC 3 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP 81 EP 91 DI 10.1159/000342283 PG 11 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300010 PM 23257555 ER PT S AU Jang, JW Chan, AW AF Jang, Joanne W. Chan, Annie W. BE Bleier, BS TI Prevention and Management of Complications after Radiotherapy for Skull Base Tumors: A Multidisciplinary Approach SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID VESSEL-DEPLETED NECK; TEMPORAL-LOBE NECROSIS; MICROVASCULAR RECONSTRUCTION; NASOPHARYNGEAL CARCINOMA; FLAP RECONSTRUCTION; RADIATION-THERAPY; RECIPIENT VESSELS; NASOSEPTAL FLAP; CANCER-PATIENTS; HEAD AB Radiotherapy is an important treatment approach for a variety of benign and malignant skull base tumors. For patients with malignant skull base tumors, radiation therapy is usually given with surgery and chemotherapy. While patient- and tumor-specific factors can affect the risk of radiation-related complications, surgery and chemotherapy also play a large causal role. As surgery and chemotherapy can lower the radiation dose tolerance of the normal tissues in the skull base, a multidisciplinary team approach is necessary in the initial treatment decision-making process. Radiation can delay wound healing and increase complications after reconstructive surgery, and so surgical planning between surgeons and radiation oncologists is critical to ensure the successful repair. In this article, we will discuss the etiology, risk factors and management of osteonecrosis and sinonasal-cutaneous fistula, the two major complications after multimodality treatment of skull base tumors. Careful consideration of specific tumor-, patient- and treatment-related factors in a multidisciplinary manner is vital in minimizing these complications. Copyright (C) 2013 S. Karger AG, Basel C1 [Jang, Joanne W.; Chan, Annie W.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Chan, AW (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Cox 337, Boston, MA 02114 USA. EM awchan@partners.org NR 27 TC 4 Z9 4 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP 163 EP 173 DI 10.1159/000342293 PG 11 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300017 PM 23257562 ER PT S AU Meier, JC Bleier, BS AF Meier, Joshua C. Bleier, Benjamin S. BE Bleier, BS TI Novel Techniques and the Future of Skull Base Reconstruction SO COMPREHENSIVE TECHNIQUES IN CSF LEAK REPAIR AND SKULL BASE RECONSTRUCTION SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID ARGON-LASER; IN-VIVO; DURAL RECONSTRUCTION; HUMAN-EXPERIENCE; ANIMAL-MODEL; DIODE-LASER; TISSUE; REPAIR; MECHANISM; CLOSURE AB The field of endoscopic skull base surgery has evolved considerably in recent years fueled largely by advances in both imaging and instrumentation. While the indications for these approaches continue to be extended, the ability to reconstruct the resultant defects has emerged as a rate-limiting obstacle. Postoperative failures with current multilayer grafting techniques remain significant and may increase as the indications for endoscopic resections continue to expand. Laser tissue welding represents a novel method of wound repair in which laser energy is applied to a chromophore doped biologic solder at the wound edge to create a laser weld (fig. 1). These repairs are capable of withstanding forces far exceeding those exerted by intracranial pressure with negligible collateral thermal tissue injury. Recent clinical trials have demonstrated the safety and feasibility of endoscopic laser welding while exposing the limitations of first generation hyaluronic acid based solders. Novel supersaturated gel based solders are currently being tested in clinical trials and appear to possess significantly improved viscoelastic properties. While laser tissue welding remains an experimental technique, continued success with these novel solder formulations may catalyze the widespread adoption of this technique for skull base repair in the near future. Copyright (C) 2013 S. Karger AG, Basel C1 [Meier, Joshua C.; Bleier, Benjamin S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Bleier, BS (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, 243 Charles St, Boston, MA 02114 USA. EM bleierb@gmail.com NR 29 TC 2 Z9 2 U1 0 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-8055-9953-5 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2013 VL 74 BP 174 EP 183 DI 10.1159/000342294 PG 10 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA BDY61 UT WOS:000315658300018 PM 23257563 ER PT J AU Oh, B Choi, S Inamori, A Rosenthal, D Yeung, A AF Oh, Byeongsang Choi, Sunmi Inamori, Aya Rosenthal, David Yeung, Albert TI Effects of Qigong on Depression: A Systemic Review SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC PHYSICAL ILLNESSES; QUALITY-OF-LIFE; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; EXERCISE; DISORDER; THERAPY; INTERVENTION; EPIDEMIOLOGY AB Physical exercises and relaxation have been found to be beneficial for depression. However, there is little evidence on the use of Qigong, a mind-body practice integrating gentle exercise and relaxation, in the management of depression. The aim of this paper is to evaluate the effects of Qigong on depression. The paper examined clinical trials measuring the effect of Qigong on depression within six large-scale medical research databases (PubMed, Medline, ProQuest, Science Direct, EMBASE, and PsycInfo) till October 2011. Key words "Qigong," "depression," and "mood" were used. Ten studies were identified as original randomized controlled trial (RCT) studies investigating the effect of Qigong on depression as primary (n = 2) or secondary outcome (n = 8). Four studies reported positive results of the Qigong treatment on depression; two reported that Qigong effect on depression was as effective as physical exercise. One study reported that Qigong was comparable to a conventional rehabilitation program, but the remaining three studies found no benefits of Qigong on depression. While the evidence suggests the potential effects of Qigong in the treatment of depression, the review of the literature shows inconclusive results. Further research using rigorous study designs is necessary to investigate the effectiveness of Qigong in depression. C1 [Oh, Byeongsang; Rosenthal, David] Dana Farber Canc Inst, Boston, MA 02215 USA. [Oh, Byeongsang; Rosenthal, David] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Oh, Byeongsang] Univ Sydney, Sydney Med Sch, Camperdown, NSW 2006, Australia. [Choi, Sunmi] Korea Inst Oriental Med, Acupuncture Moxibust & Meridian Res Ctr, Taejon 305811, South Korea. [Inamori, Aya; Yeung, Albert] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Inamori, Aya; Yeung, Albert] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Oh, B (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM boh1@partners.org FU Development of Acupuncture, Moxibustion and Meridian Standard Health Technology, Korea Institute of Oriental Medicine (KIOM) [K13010] FX This work was supported by the Development of Acupuncture, Moxibustion and Meridian Standard Health Technology (K13010), Korea Institute of Oriental Medicine (KIOM). NR 39 TC 5 Z9 5 U1 2 U2 17 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 134737 DI 10.1155/2013/134737 PG 8 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 106UB UT WOS:000316169100001 ER PT J AU Karagiannis, AKA Ziogas, DC Gras-Miralles, B Geiger, BM Nagel, J Trebicka, E Najarian, R Cherayil, BJ Kokkotou, E AF Karagiannis, Apostolos K. A. Ziogas, Dimitrios C. Gras-Miralles, Beatriz Geiger, Brenda M. Nagel, Jutta Trebicka, Estela Najarian, Robert Cherayil, Bobby J. Kokkotou, Efi TI Increased Susceptibility of Melanin-Concentrating Hormone-Deficient Mice to Infection with Salmonella enterica Serovar Typhimurium SO INFECTION AND IMMUNITY LA English DT Article ID NEUROPEPTIDE-Y NPY; DENDRITIC CELLS; SUBSTANCE-P; RECEPTOR; MCH; PHAGOCYTOSIS; EXPRESSION; COLITIS; PEPTIDE; MODEL AB Melanin-concentrating hormone (MCH) was initially identified in mammals as a hypothalamic neuropeptide regulating appetite and energy balance. However, the wide distribution of MCH receptors in peripheral tissues suggests additional functions for MCH which remain largely unknown. We have previously reported that mice lacking MCH develop attenuated intestinal inflammation when exposed to Clostridium difficile toxin A. To further characterize the role of MCH in host defense mechanisms against intestinal pathogens, Salmonella enterocolitis (using Salmonella enterica serovar Typhimurium) was induced in MCH-deficient mice and their wild-type littermates. In the absence of MCH, infected mice had increased mortality associated with higher bacterial loads in blood, liver, and spleen. Moreover, the knockout mice developed more-severe intestinal inflammation, based on epithelial damage, immune cell infiltrates, and local and systemic cytokine levels. Paradoxically, these enhanced inflammatory responses in the MCH knockout mice were associated with disproportionally lower levels of macrophages infiltrating the intestine. Hence, we investigated potential direct effects of MCH on monocyte/macrophage functions critical for defense against intestinal pathogens. Using RAW 264.7 mouse monocytic cells, which express endogenous MCH receptor, we found that treatment with MCH enhanced the phagocytic capacity of these cells. Taken together, these findings reveal a previously unappreciated role for MCH in host-bacterial interactions. C1 [Karagiannis, Apostolos K. A.; Ziogas, Dimitrios C.; Gras-Miralles, Beatriz; Geiger, Brenda M.; Nagel, Jutta; Najarian, Robert; Kokkotou, Efi] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Trebicka, Estela; Cherayil, Bobby J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Kokkotou, E (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. EM ekokkoto@bidmc.harvard.edu OI Gras-Miralles, Beatriz/0000-0002-5943-7755 FU National Institutes of Health [R01 DK080058, R01 AI08900]; American Gastroenterological Association; Broad Medical Research Program of The Broad Foundation [IBD-0165] FX This study was supported by National Institutes of Health grants R01 DK080058 (E.K.) and R01 AI08900 (B.J.C.), a bridging grant from the American Gastroenterological Association (E.K.), and grant IBD-0165 from the Broad Medical Research Program of The Broad Foundation (E.K.). NR 29 TC 2 Z9 2 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD JAN PY 2013 VL 81 IS 1 BP 166 EP 172 DI 10.1128/IAI.00572-12 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 108MQ UT WOS:000316298000016 PM 23115043 ER PT J AU Garakani, A Martinez, JM Yehuda, R Gorman, JM AF Garakani, Amir Martinez, Jose M. Yehuda, Rachel Gorman, Jack M. TI Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Glutamine; Corticotropin releasing factor (CRF); Major depressive disorder (MDD); Venlafaxine; Antidepressant; Stress ID CSF; CITALOPRAM; SPECTROSCOPY; FLUOXETINE; DISORDERS; MOOD AB Background: Glutamate and corticotropin releasing hormone (CRH) are pro-stress neurotransmitters and may be altered in the plasma and cerebrospinal fluid (CSF) of persons with major depressive disorder (MDD). The goal of this study was to compare the CSF levels of glutamate, glutamine and CRH between patients with depression and healthy controls. Methods: Eighteen patients with MDD and 25 healthy controls underwent a lumbar puncture (LP); CSF samples were withdrawn and assays were done for glutamine, glutamate, and CRH. Patients with MDD underwent 8 weeks of treatment with the antidepressant venlafaxine and then had a repeat LP post treatment. Results: Patients had higher baseline scores on depression and suicide rating scales and those scales improved significantly post-treatment. Higher suicidal ratings at baseline were correlated with higher glutamate levels (p=0.016). There were no significant differences between the control and patient group in any baseline CSF measures of glutamate (p=0.761), glutamine (p=0.226) or CRH (p=0.675). Despite no significant change in glutamate (p=0.358) and CRH (p=0.331) in the treatment group, there was a post-treatment decrease in glutamine (p=0.045) in patients. Limitations: There was a small sample size, age discordance between patients and controls, lack of a follow-up LP in controls, absence of dexamethasone suppression testing, and fluctuating sample sizes among various measures. Conclusion: Although no significant differences were noted between patients and controls at baseline there was an association of high CSF glutamate and suicidal ideation and lower glutamine post-treatment which may be correlated with attenuation of dysfunction in the glutamatergic system after antidepressant treatment. (c) 2012 Elsevier B.V. All rights reserved. C1 [Garakani, Amir; Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Martinez, Jose M.] NYU, Med Ctr, New York, NY 10016 USA. [Yehuda, Rachel] James J Peters Vet Affairs, Bronx, NY USA. [Gorman, Jack M.] Franklin Behav Hlth Consultants, Bronx, NY USA. [Garakani, Amir] Silver Hill Hosp, New Canaan, CT USA. RP Garakani, A (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM amir.garakani@mssm.edu RI Garakani, Amir/A-3936-2013 FU National Institutes of Health (NIH) Grant [R01-MH58808, K08-MH6701] FX This work was supported by the National Institutes of Health (NIH) Grant nos. R01-MH58808 and K08-MH6701. NR 24 TC 8 Z9 8 U1 2 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PY 2013 VL 146 IS 2 BP 262 EP 265 DI 10.1016/j.jad.2012.06.037 PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 106PC UT WOS:000316156000015 PM 22840611 ER PT J AU Chen, Q Sun, XQ Zhou, XH Liu, JH Wu, JN Zhang, Y Wang, JH AF Chen, Qiang Sun, Xiaqin Zhou, Xiao-hong Liu, Jin-huan Wu, Jane Zhang, Yan Wang, Jia-huai TI N-terminal horseshoe conformation of DCC is functionally required for axon guidance and might be shared by other neural receptors SO JOURNAL OF CELL SCIENCE LA English DT Article DE Axon guidance cue; Crystal structure; Genome-wide search; Immunoglobulin superfamily; Neural receptor ID CELL-ADHESION MOLECULES; NETRIN RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; STRUCTURAL BASIS; HOMOPHILIC ADHESION; COLORECTAL-CANCER; CRYSTAL-STRUCTURE; DSCAM; PROTEIN; FAMILY AB Deleted in colorectal cancer (DCC) is a receptor for the axon guidance cues netrin-1 and draxin. The interactions between these guidance cues and DCC play a key role in the development of the nervous system. In the present study, we reveal the crystal structure of the N-terminal four Ig-like domains of DCC. The molecule folds into a horseshoe-like configuration. We demonstrate that this horseshoe conformation of DCC is required for guidance-cue-mediated axonal attraction. Structure-based mutations that disrupt the DCC horseshoe indeed impair its function. A comparison of the DCC horseshoe with previously described horseshoe structures has revealed striking conserved structural features and important sequence signatures. Using these signatures, a genome-wide search allows us to predict the N-terminal horseshoe arrangement in a number of other cell surface receptors, nearly all of which function in the nervous system. The N-terminal horseshoe appears to be evolutionally selected as a platform for neural receptors. C1 [Chen, Qiang; Liu, Jin-huan; Wang, Jia-huai] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Oncol, Boston, MA 02215 USA. [Sun, Xiaqin; Zhang, Yan] Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China. [Zhou, Xiao-hong; Wu, Jane] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Zhou, Xiao-hong; Wu, Jane] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Ctr Genet Med, Chicago, IL 60611 USA. [Wang, Jia-huai] Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China. RP Zhang, Y (reprint author), Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China. EM yanzhang@pku.edu.cn; jwang@red.dfci.harvard.edu OI Chen, Qiang/0000-0002-2398-4482; zhou, xiaohong/0000-0003-0519-2550 FU National Institutes of Health (NIH) [HL48675, CA107193]; National Program of Basic Research; Ministry of Science and Technology of China [2009CB941301]; National Science Foundation of China (NSFC) [91132718]; Peking University; Ministry of Education of China; National Center for Research Resources at the NIH [RR-15301]; U.S. Department of Energy, Office of Basic Energy Sciences [DE-AC02-06CH11357] FX This work was supported by the National Institutes of Health (NIH) [grant numbers HL48675 to J.-h.W. and CA107193 to J.W.]. The work was also supported by the National Program of Basic Research sponsored by the Ministry of Science and Technology of China [grant number 2009CB941301]; a National Science Foundation of China (NSFC) Major Research Grant [grant number 91132718]; a Peking University President Research Grant to Y.Z. and the Ministry of Education of China (to J.-h.W. and Y.Z.). In addition, this work is partly based upon research conducted at the Advanced Photon Source on the Northeastern Collaborative Access Team beamlines, which are supported by the National Center for Research Resources at the NIH [award number RR-15301]. Use of the Advanced Photon Source is supported by the U.S. Department of Energy, Office of Basic Energy Sciences [contract number DE-AC02-06CH11357]. Deposited in PMC for release after 12 months. NR 45 TC 12 Z9 12 U1 0 U2 6 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 J9 J CELL SCI JI J. Cell Sci. PD JAN 1 PY 2013 VL 126 IS 1 BP 186 EP 195 DI 10.1242/jcs.111278 PG 10 WC Cell Biology SC Cell Biology GA 110QT UT WOS:000316460800019 PM 23038776 ER PT J AU Trikudanathan, S Pedley, A Massaro, JM Hoffmann, U Seely, EW Murabito, JM Fox, CS AF Trikudanathan, Subbulaxmi Pedley, Alison Massaro, Joseph M. Hoffmann, Udo Seely, Ellen W. Murabito, Joanne M. Fox, Caroline S. TI Association of Female Reproductive Factors with Body Composition: The Framingham Heart Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GESTATIONAL DIABETES-MELLITUS; ADIPOSE-TISSUE VOLUMES; METABOLIC RISK-FACTORS; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; FAT DISTRIBUTION; MENOPAUSAL TRANSITION; WAIST CIRCUMFERENCE; PHYSICAL-ACTIVITY; RELATIVE WEIGHT AB Background: Identifying reproductive risk factors in women offers a life course approach to obesity and cardiovascular disease prevention. The association of female reproductive factors with measures of regional body fat distribution has not been comprehensively studied. Methods: We examined the association of female reproductive factors (age at menarche, parity, age at natural menopause, menopausal status) in association with body composition data from women who participated in the Offspring and the Third Generation Framingham Heart Study cohorts. Visceral adipose tissue (VAT) and sc adipose tissue (SAT) were measured volumetrically by multidetector computerized tomography. We modeled the relationship between each fat depot and female reproductive factors after adjusting for various factors such as age, smoking status, alcohol intake, physical activity index, hormone replacement therapy, and menopausal status. Results: Earlier age at menarche was associated with increased body mass index (BMI), waist circumference (WC), VAT, and SAT (P < 0.0001). This association of earlier menarche with adiposity measures was attenuated after adjusting for BMI (all P > 0.70). We observed no association between parity and all parameters of adiposity measurements (all P > 0.24). Similarly, age at natural menopause was not associated with measures of body composition. Despite higher mean BMI among the post-(BMI 27.3 kg/m(2)) compared with the premenopausal women(BMI 25.9 kg/m(2)) in an age-matched analysis, mean VAT was not different between the two groups (P = 0.30). Conclusions: Earlier menarche is associated with overall obesity but not with VAT or SAT after accounting for measures of generalized adiposity. Parity and menopausal age were not associated with adiposity measures. Although postmenopausal women had increased BMI, VAT, and SAT, the association was predominantly due to age. (J Clin Endocrinol Metab 98: 236-244, 2013) C1 [Trikudanathan, Subbulaxmi; Seely, Ellen W.; Fox, Caroline S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol Metab & Diabet,Dept Med, Boston, MA 02115 USA. [Hoffmann, Udo] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA. [Pedley, Alison] NIH, Bethesda, MD 20892 USA. [Massaro, Joseph M.; Murabito, Joanne M.; Fox, Caroline S.] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA. [Massaro, Joseph M.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Murabito, Joanne M.] Boston Univ, Sch Med, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA. [Fox, Caroline S.] NHLBI, Ctr Populat Studies, Bethesda, MD 20824 USA. RP Fox, CS (reprint author), 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. EM foxca@nhlbi.nih.gov OI Murabito, Joanne/0000-0002-0192-7516; Massaro, Joseph/0000-0002-2682-4812 FU National Heart, Lung, and Blood Institute's Framingham Heart Study [N01-HC-25195, T32 HL 007609-26] FX This work was partially supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract N01-HC-25195) and Grant T32 HL 007609-26. This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health and Boston University School of Medicine. NR 43 TC 17 Z9 18 U1 4 U2 14 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2013 VL 98 IS 1 BP 236 EP 244 DI 10.1210/jc.2012-1785 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 107IT UT WOS:000316210300057 PM 23093491 ER PT J AU Kizer, JR Benkeser, D Arnold, AM Djousse, L Zieman, SJ Mukamal, KJ Tracy, RP Mantzoros, CS Siscovick, DS Gottdiener, JS Ix, JH AF Kizer, Jorge R. Benkeser, David Arnold, Alice M. Djousse, Luc Zieman, Susan J. Mukamal, Kenneth J. Tracy, Russell P. Mantzoros, Christos S. Siscovick, David S. Gottdiener, John S. Ix, Joachim H. TI Total and High-Molecular-Weight Adiponectin and Risk of Coronary Heart Disease and Ischemic Stroke in Older Adults SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID FASTING PLASMA-GLUCOSE; CARDIOVASCULAR HEALTH; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; WOMEN; MEN; PARTICIPANTS; INFLAMMATION; MORTALITY; FAILURE AB Context: Adiponectin is atheroprotective in the laboratory, but prospective studies have shown opposite associations with cardiovascular disease (CVD) in healthy middle-aged populations (protective) and older cohorts (adverse). Whether this relates to different proportions of high-molecular-weight (HMW) adiponectin is unknown. Objective: The aim of the study was to test the hypothesis that total adiponectin is directly associated, but HMW adiponectin is inversely related, with CVD in older adults. Design, Setting, and Participants: We evaluated 3290 participants free of prevalent CVD in a longitudinal cohort study of U. S. adults aged 65 yr and older. Main Outcome Measures: We measured incident CVD (n = 1291), comprising coronary heart disease and ischemic stroke. Results: Total and HMW adiponectin were tightly correlated (r = 0.94). Cubic splines adjusted for potential confounders revealed that the associations of total and HMW adiponectin with CVD were U-shaped, with inflection points of 20 and 10 mg/liter, respectively. After controlling for potential confounding, levels of total and HMW adiponectin below these cutpoints tended to be inversely associated with incident CVD, driven by their significant or near-significant relations with coronary heart disease [hazard ratio (HR), 0.85 per SD increase; 95% confidence interval (CI), 0.75-96; and HR, 0.87; 95% CI, 0.75-1.01, respectively]. These associations were abrogated by additional inclusion of putative metabolic intermediates. Above these cutpoints, however, both total and HMW adiponectin were significantly directly associated with CVD after adjustment for confounders and, particularly, mediators (HR, 1.20 per SD increase; 95% CI, 1.06-1.35; and HR, 1.12; 95% CI, 1.02-1.24, respectively). Conclusion: In community-living elders, total and HMW adiponectin showed similar U-shaped relationships with CVD. The inverse relation in the lower range, but not the direct association at the higher end, disappeared after inclusion of putative intermediates, suggesting that high levels may reflect adverse processes separate from adiponectin's beneficial glycometabolic properties. (J Clin Endocrinol Metab 98: 255-263, 2013) C1 [Kizer, Jorge R.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA. [Kizer, Jorge R.] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA. [Benkeser, David; Arnold, Alice M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Djousse, Luc] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02130 USA. [Djousse, Luc; Mantzoros, Christos S.] Harvard Univ, Sch Med, Boston, MA 02130 USA. [Djousse, Luc] Boston Vet Affairs Med Ctr, Boston, MA 02130 USA. [Zieman, Susan J.] NIA, Div Geriatr & Clin Gerontol, Bethesda, MD 20814 USA. [Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Mukamal, Kenneth J.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Tracy, Russell P.] Univ Vermont, Dept Pathol, Colchester, VT 05401 USA. [Tracy, Russell P.] Univ Vermont, Dept Biochem, Colchester, VT 05401 USA. [Mantzoros, Christos S.] Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02130 USA. [Mantzoros, Christos S.] Boston VA Healthcare Syst, Endocrinol Sect, Boston, MA 02130 USA. [Siscovick, David S.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Gottdiener, John S.] Univ Maryland, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21201 USA. [Ix, Joachim H.] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA 92093 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, Dept Med, San Diego, CA 92093 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Prevent Med, Dept Family & Prevent Med, San Diego, CA 92093 USA. RP Kizer, JR (reprint author), Albert Einstein Coll Med, Cardiovasc Clin Res Unit, Mazer Bldg,Room 114,1300 Morris Pk Ave, Bronx, NY 10461 USA. EM jorge.kizer@einstein.yu.edu RI Djousse, Luc/F-5033-2017 OI Djousse, Luc/0000-0002-9902-3047 FU National Heart, Lung and Blood Institute (NHLBI) [R01 HL-094555, HHSN268201200036C, N01-HC-85239, N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC55222, N01-HC-75150, N01-HC-45133, HL080295]; National Institute on Aging [AG-023629, AG-15928, AG-20098, AG-027058] FX This work was supported by Grant R01 HL-094555 from the National Heart, Lung and Blood Institute (NHLBI). The Cardiovascular Health Study was supported by NHLBI contracts HHSN268201200036C, N01-HC-85239, N01-HC-85079 through N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC55222, N01-HC-75150, N01-HC-45133, and NHLBI Grant HL080295, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through Grants AG-023629, AG-15928, AG-20098, and AG-027058 from the National Institute on Aging. See also http://www.chs-nhlbi.org/pi.htm. NR 40 TC 18 Z9 19 U1 1 U2 6 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2013 VL 98 IS 1 BP 255 EP 263 DI 10.1210/jc.2012-2103 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 107IT UT WOS:000316210300059 PM 23162097 ER PT J AU Bergman, BC Howard, D Schauer, IE Maahs, DM Snell-Bergeon, JK Clement, TW Eckel, RH Perreault, L Rewers, M AF Bergman, Bryan C. Howard, David Schauer, Irene E. Maahs, David M. Snell-Bergeon, Janet K. Clement, Timothy W. Eckel, Robert H. Perreault, Leigh Rewers, Marian TI The Importance of Palmitoleic Acid to Adipocyte Insulin Resistance and Whole-Body Insulin Sensitivity in Type 1 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CORONARY-ARTERY CALCIFICATION; SKELETAL-MUSCLE; ADIPOSE-TISSUE; GLUCOSE-METABOLISM; IMPAIRED BASAL; FATTY-ACIDS; IN-VIVO; MELLITUS; LIPOLYSIS; HUMANS AB Context: Type 1 diabetes is an insulin-resistant state, but it is less clear which tissues are affected. Our previous report implicated skeletal muscle and liver insulin resistance in people with type 1 diabetes, but this occurred independently of generalized, visceral, or ectopic fat. Objective: The aim of the study was to measure adipose tissue insulin sensitivity and plasma triglyceride composition in individuals with type 1 diabetes after overnight insulin infusion to lower fasting glucose. Design, Patients, and Methods: Fifty subjects (25 individuals with type 1 diabetes and 25 controls without) were studied. After 3 d of dietary control and overnight insulin infusion, we performed a three-stage hyperinsulinemic/euglycemic clamp infusing insulin at 4, 8, and 40 mU/m(2) . min. Infusions of [1,1,2,3,3-H-2(2)]glycerol and [1-C-13]palmitate were used to quantify lipid metabolism. Results: Basal glycerol and palmitate rates of appearance were similar between groups, decreased more in control subjects during the first two stages of the clamp, and similarly suppressed during the highest insulin dose. The concentration of insulin required for 50% inhibition of lipolysis was twice as high in individuals with type 1 diabetes. Plasma triglyceride saturation was similar between groups, but palmitoleic acid in plasma triglyceride was inversely related to adipocyte insulin sensitivity. Unesterified palmitoleic acid in plasma was positively related to insulin sensitivity in controls, but not in individuals with type 1 diabetes. Conclusions: Adipose tissue insulin resistance is a significant feature of type 1 diabetes. Palmitoleic acid is not related to insulin sensitivity in type 1 diabetes, as it was in controls, suggesting a novel mechanism for insulin resistance in this population. (J Clin Endocrinol Metab 98: E40-E50, 2013) C1 [Bergman, Bryan C.; Howard, David; Schauer, Irene E.; Clement, Timothy W.; Eckel, Robert H.; Perreault, Leigh] Univ Colorado Anschutz Med Campus, Div Endocrinol Metab & Diabet, Dept Med, Aurora, CO 80045 USA. [Maahs, David M.; Snell-Bergeon, Janet K.; Rewers, Marian] Univ Colorado Anschutz Med Campus, Sch Med, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80045 USA. [Schauer, Irene E.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Bergman, BC (reprint author), Univ Colorado Anschutz Med Campus, Div Endocrinol Metab & Diabet, POB 6511,MS 8106, Aurora, CO 80045 USA. EM Bryan.Bergman@ucdenver.edu OI Bergman, Bryan/0000-0002-9561-1052 FU National Institutes of Health (NIH) National Heart, Lung, and Blood Institute [R01 HL-61753, R01 HL-079611]; Clinical Translational Research Center at the University of Colorado Denver [M01 RR000051, RR-00036]; Barbara Davis Center for Childhood Diabetes in Denver; NIH Diabetes Endocrinology Research Center Clinical Investigation Core [P30 DK57516]; National Institute for Diabetes and Digestive and Kidney Diseases [K01 DK066219]; NIH Building Interdisciplinary Research Careers in Women's Health [K12, K23 DK075360]; American Diabetes Association junior faculty award [1-10-JF-50] FX This work was supported by the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (Grants R01 HL-61753 and R01 HL-079611); the Clinical Translational Research Center at the University of Colorado Denver (Grants M01 RR000051 and RR-00036); as well as the Barbara Davis Center for Childhood Diabetes in Denver. Support was also provided by the NIH Diabetes Endocrinology Research Center Clinical Investigation Core (P30 DK57516), National Institute for Diabetes and Digestive and Kidney Diseases (K01 DK066219; to B. C. B.), NIH Building Interdisciplinary Research Careers in Women's Health (K12; to I. E. S.), K23 DK075360 (to D. M. M.), and the American Diabetes Association junior faculty award 1-10-JF-50 (to J.K.S.-B.). NR 41 TC 12 Z9 13 U1 0 U2 9 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2013 VL 98 IS 1 BP E40 EP E50 DI 10.1210/jc.2012-2892 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 107IT UT WOS:000316210300006 PM 23150678 ER PT J AU Boyce, AM Glover, M Kelly, MH Brillante, BA Butman, JA Fitzgibbon, EJ Brewer, CC Zalewski, CK Peck, CMC Kim, HJ Collins, MT AF Boyce, Alison M. Glover, McKinley Kelly, Marilyn H. Brillante, Beth A. Butman, John A. Fitzgibbon, Edmond J. Brewer, Carmen C. Zalewski, Christopher K. Peck, Carolee M. Cutler Kim, H. Jeffrey Collins, Michael T. TI Optic Neuropathy in McCune-Albright Syndrome: Effects of Early Diagnosis and Treatment of Growth Hormone Excess SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID STIMULATORY G-PROTEIN; FIBROUS DYSPLASIA; SOMATOSTATIN ANALOG; PEGVISOMANT; THERAPY; GH; HYPERSECRETION; DYSFUNCTION; MUTATION; STATURE AB Context: GH excess is a serious complication of McCune-Albright syndrome (MAS) and has been associated with craniofacial morbidity. Objective: The aim of the study was to determine whether early diagnosis and treatment of MAS-associated GH excess prevents optic neuropathy and hearing impairment, the major morbidities associated with GH excess. Design and Setting: A retrospective cross-sectional analysis was conducted at a clinical research center. Patients: Twenty-two subjects with MAS-associated GH excess and 21 control MAS subjects without GH excess were included in the study. Intervention: Biochemical testing included random GH, nadir GH after glucose load, nadir GH on frequent sampling, and IGF-I Z-score. Subjects underwent imaging, ophthalmological, audiological, and otolaryngological assessment. Treatment included octreotide, pegvisomant, transphenoidal surgery, and/or radiotherapy as indicated. Main Outcome Measure: Association of optic neuropathy and hearing impairment to age at GH excess diagnosis/treatment was measured. Results: Of 129 MAS subjects, 26 (20%) were diagnosed with GH excess based on elevation of two measures of GH function. Of these, 22 subjects were candidates for pharmacological intervention. Optic neuropathy was significantly correlated with intervention status, with no cases in the early intervention group (diagnosed/treated before age 18) or the control group, and four of seven (57%) in the late intervention group (diagnosed/treated after age 18) (Fisher's exact test; odds ratio, 0.027; P = 0.0058). Early diagnosis/intervention was not associated with reduction in hearing deficits (odds ratio, 1.25; P = 1.00). Mean head circumference SD score was significantly higher in the late (6.08; range, 2.70 to 22.56) than the early intervention (2.67; range, -0.65 to 6.72) or control groups (2.13; range, -2.06 to 7.79) (P = 0.003). Conclusions: Early diagnosis/treatment of GH excess in MAS is important to prevent optic neuropathy and craniofacial expansion. The relationship between hearing deficits and GH excess remains less clear and requires further study. (J Clin Endocrinol Metab 98: E126-E134, 2013) C1 [Boyce, Alison M.; Glover, McKinley; Kelly, Marilyn H.; Brillante, Beth A.; Peck, Carolee M. Cutler; Collins, Michael T.] Natl Inst Dent & Craniofacial Res, Skeletal Clin Studies Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA. [Boyce, Alison M.] NICHHD, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA. [Boyce, Alison M.] Childrens Natl Med Ctr, Bone Hlth Program, Div Orthopaed & Sports Med, Washington, DC 20010 USA. [Glover, McKinley] Duke Univ, Sch Med, Durham, NC 27710 USA. [Glover, McKinley] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Butman, John A.] NIH, Dept Diagnost Radiol, Mark O Hatfield Clin Res Ctr, Bethesda, MD 20892 USA. [Fitzgibbon, Edmond J.] NEI, NIH, Bethesda, MD 20892 USA. [Brewer, Carmen C.; Zalewski, Christopher K.] Natl Inst Deafness & Other Commun Disorders, Audiol Unit, Otolaryngol Branch, NIH, Bethesda, MD 20892 USA. [Peck, Carolee M. Cutler] Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Memphis, TN 38163 USA. [Kim, H. Jeffrey] Natl Inst Deafness & Other Commun Disorders, Off Clin Director, NIH, Bethesda, MD 20892 USA. [Kim, H. Jeffrey] Georgetown Univ Hosp, Dept Otolaryngol, Washington, DC 20007 USA. RP Boyce, AM (reprint author), Childrens Natl Med Ctr, Bone Hlth Program, Div Orthopaed & Sports Med, 111 Michigan Ave NW, Washington, DC 20010 USA. EM aboyce@childrensnational.org; mcollins@mail.nih.gov RI Butman, John/J-2780-2013 OI Butman, John/0000-0002-1547-9195 FU Division of Intramural Research, National Institute of Dental and Craniofacial Research; National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Disorders; National Eye Institute, National Institutes of Health, Department of Health and Human Services; Clinical Research Training Program; NIH; Pfizer Pharmaceutical Group FX This work was supported by the Division of Intramural Research, National Institute of Dental and Craniofacial Research, National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, and the National Eye Institute, National Institutes of Health, Department of Health and Human Services, and in part by the Clinical Research Training Program, a public-private partnership supported by the NIH, and a grant to the Foundation for the NIH from Pfizer Pharmaceutical Group (to M.G.). NR 33 TC 17 Z9 19 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2013 VL 98 IS 1 BP E126 EP E134 DI 10.1210/jc.2012-2111 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 107IT UT WOS:000316210300020 PM 23093488 ER PT J AU Tomer, Y Hasham, A Davies, TF Stefan, M Concepcion, E Keddache, M Greenberg, DA AF Tomer, Yaron Hasham, Alia Davies, Terry F. Stefan, Mihaela Concepcion, Erlinda Keddache, Mehdi Greenberg, David A. TI Fine Mapping of Loci Linked to Autoimmune Thyroid Disease Identifies Novel Susceptibility Genes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID LINKAGE ANALYSIS; GRAVES-DISEASE; THYROGLOBULIN GENE; TSH RECEPTOR; ASSOCIATION; POLYMORPHISM; POPULATION; MECHANISMS; FAMILIES; JAPANESE AB Context: Genetic factors play a major role in the etiology of autoimmune thyroid disease (AITD) including Graves' disease (GD) and Hashimoto's thyroiditis (HT). We have previously identified three loci on chromosomes 10q, 12q, and 14q that showed strong linkage with AITD, HT, and GD, respectively. Objectives: The objective of the study was to identify the AITD susceptibility genes at the 10q, 12q, and 14q loci. Design and Participants: Three hundred forty North American Caucasian AITD patients and 183 healthy controls were studied. The 10q, 12q, and 14q loci were fine mapped by genotyping densely spaced single-nucleotide polymorphisms (SNPs) using the Illumina GoldenGate genotyping platform. Case control association analyses were performed using the UNPHASED computer package. Associated SNPs were reanalyzed in a replication set consisting of 238 AITD patients and 276 controls. Results: Fine mapping of the AITD locus, 10q, showed replicated association of the AITD phenotype (both GD and HT) with SNP rs6479778. This SNP was located within the ARID5B gene recently reported to be associated with rheumatoid arthritis and GD in Japanese. Fine mapping of the GD locus, 14q, revealed replicated association of the GD phenotype with two markers, rs12147587 and rs2284720, located within the NRXN3 and TSHR genes, respectively. Conclusions: Fine mapping of three linked loci identified novel susceptibility genes for AITD. The discoveries of new AITD susceptibility genes will engender a new understanding of AITD etiology. (J Clin Endocrinol Metab 98: E144-E152, 2013) C1 [Tomer, Yaron; Hasham, Alia; Davies, Terry F.; Stefan, Mihaela; Concepcion, Erlinda] Mt Sinai Sch Med, Div Endocrinol, Dept Med, New York, NY 10029 USA. [Keddache, Mehdi] Cincinnati Childrens Hosp Med Ctr, Genome Ctr, Cincinnati, OH 45229 USA. [Greenberg, David A.] Columbia Univ, Div Stat Genet, New York, NY 10032 USA. [Tomer, Yaron; Hasham, Alia; Davies, Terry F.; Stefan, Mihaela] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA. EM yaron.tomer@mssm.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK061659, DK067555, DK073681, DK069713, DK052464, DK080459]; MADGC grant National Institutes of Health/National Institute of Allergy and Infectious Diseases [RO1-AI-68759]; Veterans Affairs Merit Award Program; [NS27941]; [NA61829]; [MH48858] FX This work was supported in part by Grants DK061659, DK067555, and DK073681 from the National Institute of Diabetes and Digestive and Kidney Diseases (to Y.T.); Grants DK069713, DK052464, and DK080459 from the National Institute of Diabetes and Digestive and Kidney Diseases (to T.F.D.); Grants NS27941, NA61829, and MH48858 (to D.A.G.); MADGC grant National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant RO1-AI-68759 (to Peter Gregersen); and the Veterans Affairs Merit Award Program (to Y.T. and T.F.D.). NR 39 TC 18 Z9 18 U1 0 U2 8 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2013 VL 98 IS 1 BP E144 EP E152 DI 10.1210/jc.2012-2408 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 107IT UT WOS:000316210300022 PM 23118423 ER PT J AU Virella, G Colglazier, J Chassereau, C Hunt, KJ Baker, NL Lopes-Virella, MF AF Virella, Gabriel Colglazier, Joan Chassereau, Charlyne Hunt, Kelly J. Baker, Nathaniel L. Lopes-Virella, Maria F. TI IMMUNOASSAY OF MODIFIED FORMS OF HUMAN LOW DENSITY LIPOPROTEIN IN ISOLATED CIRCULATING IMMUNE COMPLEXES SO JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY LA English DT Article DE diabetic complications; immune complexes; modified LDL capture assays; modified lipoproteins; oxidized LDL; risk factors ID CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; OXIDIZED LDL; DIABETES-MELLITUS; ATHEROSCLEROSIS; ANTIBODIES; AUTOANTIBODIES; MACROPHAGES; PROGRESSION; CELLS AB Modified lipoproteins are able to induce inflammatory reactions through innate immunity pathways and are immunogenic, leading to an autoimmune response that results in the formation of proinflammatory immune complexes. The measurement of circulating oxidized lipoproteins and corresponding antibodies has, therefore, been proposed as an approach to assess the risk for complications in patients with diabetes and for the risk of cardiovascular disease in the general population. However, the majority of modified low density lipoprotein (LDL) in the peripheral circulation exists in the form of immune complexes, and this is a significant obstacle for the measurement of modified LDL and the corresponding antibodies. In this manuscript, we describe in detail the methodology developed by our group for isolation and fractionation of circulating immune complexes (IC), allowing the accurate assay of different LDL modifications. This approach has resulted in several studies showing that the levels of modified LDL are risk factors with a stronger association to diabetic retinopathy, nephropathy, and macrovascular disease. Ongoing research is focused on evaluating the predictive power of modified LDL levels for the development or progression of atherosclerotic cardiovascular disease in other patient populations and on the simplification of the assay to make it more applicable to diagnostic laboratories. C1 [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Colglazier, Joan; Chassereau, Charlyne; Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Colglazier, Joan; Chassereau, Charlyne] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Hunt, Kelly J.; Baker, Nathaniel L.] Med Univ S Carolina, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Ralph H Johnson VA Med Ctr, Dept Lab Serv, Charleston, SC USA. RP Virella, G (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29425 USA. EM virellag@musc.edu NR 40 TC 3 Z9 3 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1532-1819 J9 J IMMUNOASS IMMUNOCH JI J. Immunoass. Immunoch. PD JAN 1 PY 2013 VL 34 IS 1 BP 61 EP 74 DI 10.1080/15321819.2012.683500 PG 14 WC Biochemical Research Methods; Immunology; Medical Laboratory Technology SC Biochemistry & Molecular Biology; Immunology; Medical Laboratory Technology GA 105HH UT WOS:000316056800006 PM 23323982 ER PT J AU Syme, ML Delaney, E Wachen, JS Gosian, J Moye, J AF Syme, Maggie L. Delaney, Eileen Wachen, Jennifer Schuster Gosian, Jeffrey Moye, Jennifer TI Sexual Self-Esteem and Psychosocial Functioning in Military Veterans After Cancer SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article DE veteran; sexual self-esteem; cancer; survivorship; psychological distress ID QUALITY-OF-LIFE; BREAST-CANCER; LONG-TERM; PROSTATE-CANCER; SURVIVORS; CARE; AFFAIRS; HEALTH; MORBIDITY; INVENTORY AB Little is known about the sexual well-being of male Veteran cancer survivors, or the relationship of sexual concerns to psychosocial adaptation postcancer. This study examined the association between sexual self-esteem and psychosocial concerns in male Veteran cancer survivors. Forty-one male survivors were recruited from a Veterans Affairs (VA) hospital to participate in a pilot study addressing cancer survivorship care for Veterans. Sixty- to 90-minute interviews were conducted, assessing sociodemographic, medical, stress/burden (cancer-related posttraumatic stress disorder [PTSD], depression), and resource (social support, post-traumatic growth) variables. Twenty-one (51.2%) Veteran cancer survivors reported lowered sexual self-esteem as a result of cancer, which corresponded to significantly higher levels of depression and cancer-related PTSD. The lowered sexual self-esteem group also indicated significantly lower social support. Veteran cancer survivors with lowered sexual self-esteem tend to have higher levels of stress and lower levels of resources, putting them at risk for lowered quality of life. This increased risk highlights the importance of addressing sexual well-being in the survivorship care of Veterans. C1 [Syme, Maggie L.] San Diego State Univ, Dept Psychol, SDSU UCSD Canc Ctr Comprehens Partnership, San Diego, CA 92120 USA. [Delaney, Eileen] USN, Ctr Combat & Operat Stress Control, San Diego, CA 92152 USA. [Wachen, Jennifer Schuster] Boston Univ, Sch Med, Natl Ctr PTSD, VA Boston Healthcare Syst, Boston, MA 02118 USA. [Gosian, Jeffrey] VA Boston Healthcare Syst, Boston, MA USA. [Moye, Jennifer] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Boston, MA 02115 USA. RP Syme, ML (reprint author), San Diego State Univ, Dept Psychol, 6363 Alvarado Ct,Suite 250, San Diego, CA 92120 USA. EM maggie.mai.29@gmail.com RI Moye, Jennifer/F-2240-2017; OI Moye, Jennifer/0000-0002-3434-347X; Syme, Maggie/0000-0003-3260-5568 FU RRD VA [I01 RX000104] NR 31 TC 1 Z9 1 U1 2 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0734-7332 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PD JAN 1 PY 2013 VL 31 IS 1 BP 1 EP 12 DI 10.1080/07347332.2012.741096 PG 12 WC Psychology, Social SC Psychology GA 104HS UT WOS:000315983500001 PM 23311968 ER PT J AU Gandhi, L Drappatz, J Ramaiya, NH Otterson, GA AF Gandhi, Leena Drappatz, Jan Ramaiya, Nikhil H. Otterson, Gregory A. TI High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non-Small-Cell Lung Cancer SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article ID LYMPHOMA C1 [Gandhi, Leena] Harvard Univ, Dana Farber Canc Inst, Sch Med, Dept Med Oncol, Boston, MA 02215 USA. [Gandhi, Leena] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02215 USA. [Gandhi, Leena; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02215 USA. [Otterson, Gregory A.] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA. [Drappatz, Jan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Drappatz, Jan] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Gandhi, L (reprint author), Harvard Univ, Dana Farber Canc Inst, Sch Med, 450 Brookline Ave, Boston, MA 02215 USA. EM Leena_Gandhi@dfci.harvard.edu OI Gandhi, Leena/0000-0002-2398-9179 FU Pfizer; Genentech; GSK; Celgene FX Grants were received by Pfizer, Genentech, GSK and Celgene. NR 8 TC 18 Z9 20 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD JAN PY 2013 VL 8 IS 1 BP E3 EP E5 DI 10.1097/JTO.0b013e3182762d20 PG 3 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 107GY UT WOS:000316204500002 PM 23242445 ER PT J AU Coverdale, JH Roberts, LW Balon, R Beresin, EV AF Coverdale, John H. Roberts, Laura Weiss Balon, Richard Beresin, Eugene V. TI Writing for academia: Getting your research into print: AMEE Guide No. 74 SO MEDICAL TEACHER LA English DT Article ID EVIDENCE MEDICAL-EDUCATION; QUALITATIVE RESEARCH; USERS GUIDES; HEALTH-CARE; PART 1; BEME; DESIGN; PUBLICATION; MANUSCRIPT; XXIII AB The authors identify and describe strategies for success in writing for publication, including how to choose an educational research topic, define the question and choose the correct design, know the anatomy of a research paper, write each of the sections, optimize the writing before publication, choose a journal, and respond to editors and reviewers. The research question should be focused, modest, and achievable given the constraints of the setting, significant, and appropriately imbedded in the available literature. The choice of methods is determined by the nature of the educational research question and should conform to ethical standards. Specific strategies for writing include starting where it is easiest to do so, spontaneously and uncritically writing the first paragraphs through, minimizing external impediments to the work, and knowing how each section of a manuscript is routinely structured. All papers require a number of revisions with careful attention to accuracy and detail as well as to specific requirements of the target journal before submission. Authors should respond positively, not defensively, and in detail to all of the editor's and reviewers' suggestions for revision. Writing for success is therefore a disciplined and systematic process following prescribed steps, which, although hard work, is rewarding. C1 [Coverdale, John H.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA. [Roberts, Laura Weiss] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Balon, Richard] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [Balon, Richard] Wayne State Univ, Sch Med, Dept Anesthesiol, Detroit, MI USA. [Beresin, Eugene V.] Harvard Univ, Dept Psychiat, Boston, MA 02115 USA. [Beresin, Eugene V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Beresin, Eugene V.] McLean Hosp, Boston, MA USA. RP Roberts, LW (reprint author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd,Room 3215, Stanford, CA 94305 USA. EM RobertsL@Stanford.edu OI Roberts, Laura Weiss/0000-0003-4270-253X NR 39 TC 6 Z9 7 U1 2 U2 12 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0142-159X J9 MED TEACH JI Med. Teach. PY 2013 VL 35 IS 2 BP E926 EP E934 DI 10.3109/0142159X.2012.742494 PG 9 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 111ZL UT WOS:000316560800001 PM 23228107 ER PT J AU Paly, JJ Efstathiou, JA Hedgire, SS Chung, PWM O'Malley, M Shah, A Bekelman, JE Harisinghani, M Shipley, WU Zietman, AL Beard, C AF Paly, Jonathan J. Efstathiou, Jason A. Hedgire, Sandeep S. Chung, Peter W. M. O'Malley, Martin Shah, Anand Bekelman, Justin E. Harisinghani, Mukesh Shipley, William U. Zietman, Anthony L. Beard, Clair TI Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields SO RADIOTHERAPY AND ONCOLOGY LA English DT Article DE Seminoma; Lymph node metastases; Adjuvant therapy ID I TESTICULAR SEMINOMA; 2ND CANCER-RISK; VOLUME; REDUCTION; TESTIS; TUMORS; TRIAL AB Background and purpose: To analyze the location of metastatic lymph nodes in seminoma patients relative to vascular and bony anatomy and conventional radiation fields. Materials and methods: Cross-sectional scans of 90 seminoma patients with infradiaphragmatic adenopathy were analyzed. The position of each node respective to vascular anatomy was transferred to a standardized template. Conventional radiation fields were overlaid on the template and locations of metastatic nodes were assessed. Results: One hundred and forty-five nodes were radiographically positive. Eighty-four percent, 9%, and 7% of nodes were located in the para-aortic, common iliac, and pelvic regions, respectively. Ninety-nine percent of nodes were within a 2.5 cm lateral and 2.1 cm anterior expansion of the aorta inferior to T12/L1. No radiographically positive nodes were identified within the renal hilum or superior to L1 in left-sided seminomas. For right-sided seminomas, no radiographically positive nodes were superior to L2. Three percent of all radiographically positive nodes would have been located outside of conventional and modified fields. Conclusions: Infradiaphragmatic nodal metastases from a contemporary cohort of seminoma patients localized to a smaller area than is targeted by conventional radiation fields. Modified treatment fields based on vascular, rather than bony, anatomy are smaller and may allow for a significant decrease in normal tissue irradiation and toxicity. (C) 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 106 (2013) 64-68 C1 [Paly, Jonathan J.; Efstathiou, Jason A.; Shipley, William U.; Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Hedgire, Sandeep S.; Harisinghani, Mukesh] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Chung, Peter W. M.] Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON, Canada. [Chung, Peter W. M.; O'Malley, Martin] Univ Toronto, Toronto, ON M5S 1A1, Canada. [O'Malley, Martin] Princess Margaret Hosp, Dept Med Imaging, Toronto, ON, Canada. [Shah, Anand; Bekelman, Justin E.] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Beard, Clair] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Efstathiou, JA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02114 USA. EM jefstathiou@partners.org NR 22 TC 6 Z9 6 U1 1 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-8140 J9 RADIOTHER ONCOL JI Radiother. Oncol. PD JAN PY 2013 VL 106 IS 1 BP 64 EP 68 DI 10.1016/j.radonc.2012.12.002 PG 5 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 108NY UT WOS:000316303800010 PM 23321493 ER PT J AU Brown, TJ Pittman, AL Monaco, GN Benscoter, BJ Mantravadi, AV Akst, LM Jones, KJ Foecking, EM AF Brown, Todd J. Pittman, Amy L. Monaco, Gina N. Benscoter, Brent J. Mantravadi, Avinash V. Akst, Lee M. Jones, Kathryn J. Foecking, Eileen M. TI Androgen treatment and recovery of function following recurrent laryngeal nerve injury in the rat SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE LA English DT Article DE Testosterone propionate; recurrent laryngeal nerve; vocal fold mobility; crush injury ID HAMSTER FACIAL MOTONEURONS; HUMAN VOCAL FOLD; GONADAL-STEROIDS; ELECTRICAL-STIMULATION; MESSENGER-RNA; SCIATIC-NERVE; REGENERATIVE PROPERTIES; INDUCED ACCELERATION; AXONAL REGENERATION; HORMONE-RECEPTORS AB Purpose: To investigate the effects of the androgen testosterone propionate (TP), on regeneration of the recurrent laryngeal nerve (RLN) after unilateral crush injury using assessment of vocal fold mobility (VFM) as a measure of behavioral recovery. Methods: 48 adult male rats underwent standardized crush injury of left RLN and received treatment in the form of 2 silastic capsules containing TP or controls receiving a blank capsule (untreated). Direct laryngoscopic assessment of vocal cord mobility was performed before, immediately following and 1, 2, 3, 4, 5 or 6 weeks post injury. Results: Treatment with TP enhanced the recovery of full VFM following crush injury of the RLN compared to controls. There was statistically significant improvement in VFM seen at the 1 and 2 week time points (p < 0.05). By 4 weeks TP-treated rats displayed a 100% recovery of VFM function, compared to only 50% by the control group. Conclusions: TP enhances RLN functional recovery following a crush injury, which further supports its potential general applicability as a therapeutic agent in peripheral nerve injury. C1 [Brown, Todd J.; Jones, Kathryn J.] Richard L Roudebush VA Med Ctr, R&D Serv, Indianapolis, IN USA. [Brown, Todd J.; Jones, Kathryn J.] Indiana Sch Med, Dept Cell Biol & Anat, Indianapolis, IN USA. [Pittman, Amy L.; Benscoter, Brent J.; Mantravadi, Avinash V.; Foecking, Eileen M.] Loyola Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Proviso, IL USA. [Akst, Lee M.] Johns Hopkins Univ Hosp, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA. [Monaco, Gina N.] Loyola Univ Chicago, Stritch Sch Med, Cell Biol Neurobiol & Anat Program, Maywood, IL USA. [Foecking, Eileen M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, R&D Serv, Hines, IL 60141 USA. RP Brown, TJ (reprint author), Richard L Roudebush VAMC, 1481W 10th St,Mail Code 151,Rm C-3074, Indianapolis, IN 46202 USA. EM tojobrow@iupui.edu FU Loyola RFC Grant [201299] FX The authors of this paper would like to acknowledge Keith Fargo, Ph.D. and Rena Meadows, B.S. for their invaluable help with statistical analysis and would also like to thank Piotr Tekiela for the technical work he contributed to this study. This work was supported by funds from Loyola RFC Grant #201299 and was performed in the labs of Dr. Kathryn Jones at Edward Hines, Jr. VA Hospital, Hines, IL. NR 44 TC 6 Z9 6 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0922-6028 J9 RESTOR NEUROL NEUROS JI Restor. Neurol. Neurosci. PY 2013 VL 31 IS 2 BP 169 EP 176 DI 10.3233/RNN-120287 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 112SN UT WOS:000316613700006 PM 23247060 ER PT J AU Fu, XJ Fang, Y Yao, M AF Fu, Xiu-jun Fang, Yong Yao, Min TI Antimicrobial Photodynamic Therapy for Methicillin-Resistant Staphylococcus aureus Infection SO BIOMED RESEARCH INTERNATIONAL LA English DT Review ID GRAM-POSITIVE BACTERIA; MURINE MRSA ARTHRITIS; ESCHERICHIA-COLI; IN-VITRO; LETHAL PHOTOSENSITIZATION; POLYMERIC MICELLES; ACRIDINE-ORANGE; METHYLENE-BLUE; SINGLET OXYGEN; GROWTH-PHASE AB Nowadays methicillin-resistant Staphylococcus aureus (MRSA) is one of the most common multidrug resistant bacteria both in hospitals and in the community. In the last two decades, there has been growing concern about the increasing resistance to MRSA of the most potent antibiotic glycopeptides. MRSA infection poses a serious problem for physicians and their patients. Photosensitizer-mediated antimicrobial photodynamic therapy (PDT) appears to be a promising and innovative approach for treating multidrug resistant infection. In spite of encouraging reports of the use of antimicrobial PDT to inactivate MRSA in large in vitro studies, there are only few in vivo studies. Therefore, applying PDT in the clinic for MRSA infection is still a long way off. C1 [Fu, Xiu-jun; Fang, Yong; Yao, Min] Shanghai Jiao Tong Univ, Dept Burns & Plast Surg, Peoples Hosp 3, Shanghai 201900, Peoples R China. [Fu, Xiu-jun; Fang, Yong; Yao, Min] Shanghai Jiao Tong Univ, Inst Traumat Med, Sch Med, Shanghai 201900, Peoples R China. [Yao, Min] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA. RP Yao, M (reprint author), Shanghai Jiao Tong Univ, Dept Burns & Plast Surg, Peoples Hosp 3, 280 Mohe Rd, Shanghai 201900, Peoples R China. EM yaomin1688@yahoo.com FU Ph.D. Programs Foundation of the Ministry of Education of China [20120073110088]; Doctoral Innovative Fund at the School of Medicine, Shanghai Jiao Tong University [BXJ201238]; project of Shanghai "PU JIANG REN CAI" [10PJ1407000] FX This study was supported partially by a grant from Ph.D. Programs Foundation of the Ministry of Education of China (20120073110088), a grant from the Doctoral Innovative Fund at the School of Medicine, Shanghai Jiao Tong University (BXJ201238), and the project of Shanghai "PU JIANG REN CAI" (10PJ1407000). NR 77 TC 18 Z9 18 U1 3 U2 40 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 J9 BIOMED RES INT JI Biomed Res. Int. PY 2013 AR 159157 DI 10.1155/2013/159157 PG 9 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 102YM UT WOS:000315880600001 ER PT J AU Pandey, GS Tseng, SC Howard, TE Sauna, ZE AF Pandey, Gouri Shankar Tseng, Sandra C. Howard, Tom E. Sauna, Zuben E. TI Detection of Intracellular Factor VIII Protein in Peripheral Blood Mononuclear Cells by Flow Cytometry SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID HEMOPHILIA-A; MONOCLONAL-ANTIBODIES; GENE; INHIBITORS; EXPRESSION; COAGULATION AB Flow cytometry is widely used in cancer research for diagnosis, detection of minimal residual disease, as well as immune monitoring and profiling following immunotherapy. Detection of specific host proteins for diagnosis predominantly uses quantitative PCR and western blotting assays. In this study, we optimized a flow cytometry-based detection assay for Factor VIII protein in peripheral blood mononuclear cells (PBMCs). An indirect intracellular staining (ICS) method was standardized using monoclonal antibodies to different domains of human Factor VIII protein. The FVIII protein expression level was estimated by calculating the mean and median fluorescence intensities (MFI) values for each monoclonal antibody. ICS staining of transiently transfected cell lines supported the method's specificity. Intracellular FVIII protein expression was also detected by the monoclonal antibodies used in the study in PBMCs of five blood donors. In summary, our data suggest that intracellular FVIII detection in PBMCs of hemophilia A patients can be a rapid and reliable method to detect intracellular FVIII levels. C1 [Pandey, Gouri Shankar; Tseng, Sandra C.; Sauna, Zuben E.] US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA 90073 USA. RP Pandey, GS (reprint author), US FDA, Lab Hemostasis, Div Hematol, Ctr Biol Evaluat & Res, 29 Lincoln Dr, Bethesda, MD 20892 USA. EM gouri.pandey@fda.hhs.gov; zuben.sauna@fda.hhs.gov FU National Heart, Lung and Blood Institute; NIH [1RC2-HL101851, HL-71130, HL-72533]; Bayer Healthcare Corporation; Bayer Haemophilia Awards Program; Baxter Healthcare Corporation; Clinical Translational Science Institute at the University of Southern California's Keck School of Medicine FX The research conducted in the laboratory of Z. E. Sauna is funded by the Modernization of Science Program of the Center for Biologics Evaluation and Research, Food and Drug Administration. Research conducted in the laboratory of T. E. Howard is funded by Grants from the National Heart, Lung and Blood Institute, NIH, (1RC2-HL101851, HL-71130, and HL-72533) as well as from Bayer Healthcare Corporation, Bayer Haemophilia Awards Program, Baxter Healthcare Corporation, and the Clinical Translational Science Institute at the University of Southern California's Keck School of Medicine. NR 26 TC 2 Z9 2 U1 0 U2 4 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 J9 BIOMED RES INT JI Biomed Res. Int. PY 2013 AR 793502 DI 10.1155/2013/793502 PG 8 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 102YR UT WOS:000315881100001 ER PT J AU Ghazi, E Sontheimer, RD Werth, VP AF Ghazi, E. Sontheimer, R. D. Werth, V. P. TI The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Review DE amyopathic dermatomyositis; interstitial lung diseases; connective tissue disease ID INTERSTITIAL LUNG-DISEASE; SINE MYOSITIS; JAPANESE PATIENTS; GENE 5; POLYMYOSITIS; MYOPATHIES; AUTOANTIBODIES; MANIFESTATION; ASSOCIATION; DERMATOLOGY AB The objective of this review is to summarise the published evidence that supports the existence of amyopathic dermatomyositis (ADM) and its clinical significance including risk for rapidly progressive, fatal interstitial lung disease (ILD) and possible risk for internal malignancy. By establishing such inherent risks, we hope to establish the importance of formally recognising ADM as a subset of dermatomyositis (DM). Population-based epidemiologic studies have suggested that amyopathic DM might account for 20% of the total population of dermatomyositis (DM) patients (1). Patients presenting with ADM have been reported by investigators of multiple nationalities to be at risk for rapidly progressive, potentially fatal ILD (2-5). In addition, a new autoantibody, anti-CADM-140, has been reported to be a risk factor for the development of interstitial lung disease in CADM patients (6-9). It has been argued that ADM patients may be at increased risk of developing internal malignancy compared to the general population, though its rate in comparison to classic DM (CDM) needs further study (1, 10-12). In our population, 41% of CADM patients were previously classified as LE or UCTD. We conclude that ADM is a real entity that makes up a significant portion of the DM disease. It is important to formally recognise amyopathic DM as a subset of DM as it carries increased risk of ILD and possibly malignancy. Without appropriate disease classification, the opportunity for ILD and malignancy screening may be missed. C1 [Ghazi, E.; Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Ghazi, E.; Werth, V. P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Ghazi, E.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Sontheimer, R. D.] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIAMS NIH HHS [K24 AR002207] NR 55 TC 10 Z9 12 U1 0 U2 1 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD JAN-FEB PY 2013 VL 31 IS 1 BP 128 EP 134 PG 7 WC Rheumatology SC Rheumatology GA 101ER UT WOS:000315758500020 PM 23190767 ER PT J AU Neuringer, IP AF Neuringer, Isabel P. TI Posttransplant Lymphoproliferative Disease after Lung Transplantation SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY LA English DT Review ID EPSTEIN-BARR-VIRUS; SOLID-ORGAN TRANSPLANTATION; VIRAL LOAD ASSAYS; CD8(+) T-CELLS; REAL-TIME PCR; DNA LOAD; FDG-PET; DISORDER; RECIPIENTS; RITUXIMAB AB Posttransplant lymphoproliferative disease (PTLD) after lung transplantation occurs due to immunosuppressant therapy which limits antiviral host immunity and permits Epstein-Barr viral (EBV) replication and transformation of B cells. Mechanistically, EBV survives due to latency, escape from cytotoxic T cell responses, and downregulation of host immunity to EBV. Clinical presentation of EBV may occur within the lung allograft early posttransplantation or later onset which is more likely to be disseminated. Improvements in monitoring through EBV viral load have provided a means of earlier detection; yet, sensitivity and specificity of EBV load monitoring after lung transplantation may require further optimization. Once PTLD develops, staging and tissue diagnosis are essential to appropriate histopathological classification, prognosis, and guidance for therapy. The overall paradigm to treat PTLD has evolved over the past several years and depends upon assessment of risk such as EBV-naive status, clinical presentation, and stage and sites of disease. In general, clinical practice involves reduction in immunosuppression, anti-CD20 biologic therapy, and/or use of plasma cell inhibition, followed by chemotherapy for refractory PTLD. This paper focuses upon the immunobiology of EBV and PTLD, as well as the clinical presentation, diagnosis, prognosis, and emerging treatments for PTLD after lung transplantation. C1 Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. RP Neuringer, IP (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Bullfinch 148,55 Fruit St, Boston, MA 02114 USA. EM ineuringer@partners.org NR 73 TC 8 Z9 8 U1 0 U2 1 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1740-2522 J9 CLIN DEV IMMUNOL JI Clin. Dev. Immunol. PY 2013 AR 430209 DI 10.1155/2013/430209 PG 11 WC Immunology SC Immunology GA 106IH UT WOS:000316136200001 ER PT J AU Sena, DF Lindsley, K AF Sena, Dayse F. Lindsley, Kristina TI Neuroprotection for treatment of glaucoma in adults SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Administration, Oral; Administration, Topical; Cell Death; Disease Progression; Glaucoma, Open-Angle [drug therapy]; Neuroprotective Agents [administration & dosage]; Optic Nerve; Optic Nerve Diseases [etiology; prevention & control]; Retinal Ganglion Cells [physiology]; Adult; Humans ID NORMAL-TENSION GLAUCOMA; OPEN-ANGLE GLAUCOMA; LOW-PRESSURE GLAUCOMA; RETINAL GANGLION-CELLS; OCULAR PERFUSION-PRESSURE; VISUAL-FIELD LOSS; INTRAOCULAR-PRESSURE; CLINICAL-TRIAL; FIXED-COMBINATION; RANDOMIZED-TRIAL AB Background Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the commonest form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death. Objectives The objective of this review was to systematically examine the evidence regarding the effectiveness of neuroprotective agents for slowing the progression of OAG in adults. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 9), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE, (January 1950 to October 2012), EMBASE (January 1980 to October 2012), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to October 2012), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 16 October 2012. Selection criteria We included randomized controlled trials (RCTs) in which topical or oral treatments were used for neuroprotection in adults with OAG. Minimum follow up time was four years. Data collection and analysis Two review authors independently reviewed titles and abstracts from the literature searches. Full-text copies of potentially relevant studies were obtained and re-evaluated for inclusion. Two review authors independently extracted data related study characteristics, risk of bias, and outcome data. One trial was identified for this review, thus we performed no meta-analysis. Two studies comparing memantine to placebo are currently awaiting classification until additional study details are provided. We documented reasons for excluding studies from the review. Main results We included one multi-center RCT of adults with low-pressure glaucoma (Low-pressure Glaucoma Treatment Study, LoGTS) conducted in the USA. The primary outcome was visual field progression after four years of treatment with either brimonidine or timolol. Of the 190 adults enrolled in the study, 12 (6.3%) were excluded after randomization and 77 (40.5%) did not complete four years of follow up. The rate of attrition was unbalanced between groups with more participants dropping out of the brimonidine group (55%) than the timolol group (29%). Of those remaining in the study at four years, participants assigned to brimonidine showed less visual field progression than participants assigned to timolol (5/45 participants in the brimonidine group compared with 18/56 participants in the timolol group). Since no information was available for the 12 participants excluded from the study, or the 77 participants who dropped out of the study, we cannot draw any conclusions from these results as the participants for whom data are missing may or may not have progressed. The mean IOP was similar in both groups at the four-year follow up among those for whom data were available: 14.2 mmHg (standard deviation (SD) = 1.9) among the 43 participants in the brimonidine group and 14.0 mmHg (SD = 2.6) among the 48 participants in the timolol group. Among the participants who developed progressive visual field loss, IOP reduction of 20% or greater was not significantly different between groups: 4/9 participants in the brimonidine group and 12/31 participants in the timolol group. The study authors did not report data for visual acuity or vertical cup-disc ratio. The most frequent adverse event was ocular allergy to study drug, which occurred more frequently in the brimonidine group (20/99 participants) than the timolol group (3/79 participants). Authors' conclusions Although neuroprotective agents are intended to act as pharmacological antagonists to prevent cell death, this trial did not provide evidence that they are effective in preventing retinal ganglion cell death, and thus preserving vision in people with OAG. Further clinical research is needed to determine whether neuroprotective agents may be beneficial for individuals with OAG. Such research should focus outcomes important to patients, such as preservation of vision, and how these outcomes relate to cell death and optic nerve damage. Since OAG is a chronic, progressive disease with variability in symptoms, RCTs designed to measure the effectiveness of neuroprotective agents would require long-term follow up (more than four years) in order to detect clinically meaningful effects. C1 [Sena, Dayse F.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Lindsley, Kristina] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Sena, DF (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St,Connecting Bldg 703, Boston, MA 02114 USA. EM sena.dayse@gmail.com FU National Eye Institute, National Institutes of Health, USA [N-01-EY-2-1003, 1 U01 EY020522-01] FX External sources; Contract N-01-EY-2-1003, National Eye Institute, National Institutes of Health, USA. 2010 first publication of review; Grant 1 U01 EY020522-01, National Eye Institute, National Institutes of Health, USA. 2012 update of review NR 104 TC 5 Z9 5 U1 3 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 2 AR CD006539 DI 10.1002/14651858.CD006539.pub3 PG 32 WC Medicine, General & Internal SC General & Internal Medicine GA 097GK UT WOS:000315461800015 PM 23450569 ER PT J AU Yeh, CH Chien, LC Balaban, D Sponberg, R Primavera, J Morone, NE Glick, R Albers, KM Cohen, SM Ren, DX Huang, LC Suen, LKP AF Yeh, Chao Hsing Chien, Lung Chang Balaban, Devora Sponberg, Rebecca Primavera, Jaclyn Morone, Natalia E. Glick, Ronald Albers, Kathryn M. Cohen, Susan M. Ren, Dianxu Huang, Li Chun Suen, Lorna Kwai-Ping TI A Randomized Clinical Trial of Auricular Point Acupressure for Chronic Low Back Pain: A Feasibility Study SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article ID EVIDENCE-INFORMED MANAGEMENT; MORRIS DISABILITY QUESTIONNAIRE; PRIMARY DYSMENORRHEA; ACUPUNCTURE POINTS; AURICULOTHERAPY; PREVALENCE; SCALE; CARE AB Objectives. This prospective, randomized clinical trial (RCT) was designed to investigate the feasibility and effects of a 4-week auricular point acupressure (APA) for chronic low back pain (CLBP). Methods. Participants were randomized to either true APA (true acupoints with taped seeds on the designated ear points for CLBP) or sham APA (sham acupoints with taped seeds but on different locations than those designated for CLBP). The duration of treatment was four weeks. Participants were assessed before treatment, weekly during treatment, and 1 month following treatment. Results. Participants in the true APA group who completed the 4-week APA treatment had a 70% reduction in worst pain intensity, a 75% reduction in overall pain intensity, and a 42% improvement in disability due to back pain from baseline assessment. The reductions of worst pain and overall pain intensity in the true APA group were statistically greater than participants in the sham group (P < 0.01) at the completion of a 4-week APA and 1 month followup. Discussion. The preliminary findings of this feasibility study showed a reduction in pain intensity and improvement in physical function suggesting that APA may be a promising treatment for patients with CLBP. C1 [Yeh, Chao Hsing; Balaban, Devora; Sponberg, Rebecca; Primavera, Jaclyn; Cohen, Susan M.; Ren, Dianxu] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Chien, Lung Chang] Washington Univ, Dept Internal Med, St Louis, MO USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Dept Med, VA Pittsburgh Healthcare Syst,Geriatr Res Educ &, Pittsburgh, PA 15213 USA. [Glick, Ronald] Univ Pittsburgh, Sch Med, Med Ctr, Dept Psychiat Phys Med & Rehabil, Pittsburgh, PA USA. [Glick, Ronald] Univ Pittsburgh, Sch Med, Med Ctr, Dept Family Med, Pittsburgh, PA USA. [Albers, Kathryn M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Huang, Li Chun] World Acad Auricular Med, Hoover, AL USA. [Suen, Lorna Kwai-Ping] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Hong Kong, Peoples R China. RP Yeh, CH (reprint author), Univ Pittsburgh, Sch Nursing, 3500 Victoria St,440 Victoria Bldg, Pittsburgh, PA 15261 USA. EM yehc@pitt.edu RI Suen, Lorna/F-5077-2014; OI Suen, Lorna/0000-0002-0126-6674; Albers, Kathryn/0000-0003-4597-9323 FU Center for Research and Evaluation Pilot/Feasibility Study Program, School of Nursing, University of Pittsburgh FX This study was supported by a grant to Dr. Yeh from Center for Research and Evaluation Pilot/Feasibility Study Program, School of Nursing, University of Pittsburgh. NR 51 TC 6 Z9 6 U1 1 U2 23 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1741-427X EI 1741-4288 J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2013 AR 196978 DI 10.1155/2013/196978 PG 9 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 103EJ UT WOS:000315897200001 ER PT J AU Melcher, JR Knudson, IM Levine, RA AF Melcher, Jennifer R. Knudson, Inge M. Levine, Robert A. TI Subcallosal brain structure: Correlation with hearing threshold at supra-clinical frequencies (> 8 kHz), but not with tinnitus SO HEARING RESEARCH LA English DT Article ID PSYCHOMETRIC PROPERTIES; INVENTORY; AGE AB This study tested for differences in brain structure between tinnitus and control subjects, focusing on a subcallosal brain region where striking differences have been inconsistently found previously. Voxel-based morphometry (VBM) was used to compare structural MRIs of tinnitus subjects and non-tinnitus controls. Audiograms of all subjects were normal or near-normal at standard clinical frequencies (<= 8 kHz). Mean threshold through 14 kHz, age, sex and handedness were matched between groups. There were no definitive differences between tinnitus and control groups in modulated or unmodulated maps of gray matter (GM) probability (i.e., GM volume and concentration, respectively). However, when the image data were tested for correlations with parameters that were either not measured or not matched between the tinnitus and control groups of previous studies, a notable correlation was found: Threshold at supra-clinical frequencies (above 8 kHz) was negatively correlated with modulated GM probability in ventral posterior cingulate cortex, dorsomedial prefrontal cortex, and a subcallosal region that included ventromedial prefrontal cortex and coincided with previously-reported differences between tinnitus and control subjects. The results suggest an explanation for the discrepant findings in subcallosal brain: threshold at supra-clinical frequencies may have differed systematically between tinnitus and control groups in some studies but not others. The observed correlation between (1) brain structure in regions engaged in cognitive and attentional processes and (2) hearing sensitivity at frequencies generally considered unnecessary for normal human auditory behavior is surprising and worthy of follow up. (c) 2012 Elsevier B.V. All rights reserved. C1 [Melcher, Jennifer R.; Knudson, Inge M.; Levine, Robert A.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Melcher, Jennifer R.; Knudson, Inge M.; Levine, Robert A.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Melcher, Jennifer R.] Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Boston, MA USA. RP Melcher, JR (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM jennifer_melcher@meei.harvard.edu FU Tinnitus Research Consortium; NIH/NIDCD [P30DC005209] FX The authors wish to thank Barbara Norris and Wendy Gu for assistance with data-taking and Barbara Norris for assistance with the figures. Support was provided by the Tinnitus Research Consortium and NIH/NIDCD P30DC005209. NR 19 TC 27 Z9 27 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5955 J9 HEARING RES JI Hear. Res. PD JAN PY 2013 VL 295 BP 79 EP 86 DI 10.1016/j.heares.2012.03.013 PG 8 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA 098NX UT WOS:000315557100010 PM 22504034 ER PT J AU Doba, N Tokuda, Y Tomiyama, H Goldstein, NE Kushiro, T Hinohara, S AF Doba, Nobutaka Tokuda, Yasuharu Tomiyama, Hirofumi Goldstein, Nathan E. Kushiro, Toshio Hinohara, Shigeaki TI Changes in Ankle Brachial Pulse Wave Velocity during a Five-Year Follow-up Period in Older Japanese Adults: Sub-analysis Results of the Health Research Volunteer Study in Japan SO INTERNAL MEDICINE LA English DT Article DE aging; arterial stiffness; antihypertensive medication; older adults; low hemoglobin ID ALL-CAUSE MORTALITY; ARTERIAL STIFFNESS; BLOOD-PRESSURE; BASE-LINE; CARDIOVASCULAR EVENTS; HYPERTENSION; FRAILTY; AGE; METAANALYSIS; TRIAL AB Objective Brachial-ankle pulse wave velocity (baPWV) is a measure of arterial stiffness. However, precisely how aging, hypertension and other factors influence this in progressively stiffening large arteries, especially in older adults, remains uncertain. We examined changes in arterial stiffness in a population of active older Japanese adults using a five-year follow-up cohort study. Methods Comprehensive geriatric assessments were performed in socially active adults over the age of 70 years at The Life Planning Center Clinic in Tokyo. Clinically acceptable baPWV measurements at baseline and at the end of the study were obtained in 257 individuals (115 men, baseline mean age of 78 +/- 4 years; 142 women, baseline mean age of 77 +/- 4 years) classified into four groups based on the use of antihypertensive interventions at the end of the study: Group 1 (112 normotensives), Group 2 (49 hypertensives without medication use), Group 3 (39 hypertensives with medication use initiated during the follow-up period) and Group 4 (57 hypertensives receiving medications throughout the follow-up period). Results During the follow-up period, Group 1 exhibited no changes in blood pressure with increases in baPWV. Group 2 exhibited increases in blood pressure and baPWV. Both Groups 3 and 4 exhibited decreases in blood pressure without any changes in baPWV. Other factors such as age, gender and the hemoglobin level could also have influenced baPWV. Conclusion Arterial stiffness increases with aging; however, antihypertensive medications were found to provide protective effects against the development of arterial stiffness during a five-year follow-up period. Other factors that modify baPWV were also identified. C1 [Doba, Nobutaka] Life Planning Ctr Fdn, Div Res & Educ, Tokyo, Japan. [Tokuda, Yasuharu] Univ Tsukuba, Inst Clin Med, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 305, Japan. [Tomiyama, Hirofumi] Tokyo Med Univ, Dept Internal Med 2, Tokyo 1608402, Japan. [Goldstein, Nathan E.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Bronx, NY USA. [Kushiro, Toshio] Nihon Univ, Sch Med, Ctr Hlth Evaluat & Promot, Tokyo 102, Japan. RP Doba, N (reprint author), Life Planning Ctr Fdn, Div Res & Educ, Tokyo, Japan. EM doba@krd.biglobe.ne.jp FU Life Planning Center FX This work was supported by an institutional research fund from the Life Planning Center (a non-profit organization). We thank all the Healthy Research Volunteers who participated in this study, and we also express our gratitude to the other research members at the LPC for their professional and technical assistance with the study. NR 26 TC 3 Z9 5 U1 1 U2 1 PU JAPAN SOC INTERNAL MEDICINE PI TOKYO PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN SN 0918-2918 J9 INTERNAL MED JI Intern. Med. PY 2013 VL 52 IS 1 BP 21 EP 27 DI 10.2169/internalmedicine.52.8671 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 103YD UT WOS:000315954500005 PM 23291670 ER PT J AU Won, JS Kim, J Annamalai, B Shunmugavel, A Singh, I Singh, AK AF Won, Je-Seong Kim, Jinsu Annamalai, Balasubramaniam Shunmugavel, Anandakumar Singh, Inderjit Singh, Avtar K. TI Protective Role of S-Nitrosoglutathione (GSNO) Against Cognitive Impairment in Rat Model of Chronic Cerebral Hypoperfusion SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; bilateral common carotid artery occlusion; cerebral hypoperfusion; inflammation; S-nitrosylation; S-nitrosoglutathione ID NITRIC-OXIDE SYNTHASE; CHRONIC BRAIN HYPOPERFUSION; CAROTID-ARTERY OCCLUSION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; LEARNING DYSFUNCTION; ENDOTHELIAL FUNCTION; NITROSO-GLUTATHIONE; EXPERIMENTAL STROKE; DOPAMINE NEURONS AB Chronic cerebral hypoperfusion (CCH), featuring in most of the Alzheimer's disease spectrum, plays a detrimental role in brain amyloid-beta (A beta) homeostasis, cerebrovascular morbidity, and cognitive decline; therefore, early management of cerebrovascular pathology is considered to be important for intervention in the impending cognitive decline. S-nitrosoglutathione (GSNO) is an endogenous nitric oxide carrier modulating endothelial function, inflammation, and neurotransmission. Therefore, the effect ofGSNOtreatment on CCH-associated neurocognitive pathologieswas determined in vivo by using rats with permanent bilateral common carotid artery occlusion (BCCAO), a rat model of chronic cerebral hypoperfusion. We observed that rats subjected to permanent BCCAO showed a significant decrease in learning/memory performance and increases in brain levels of A beta and vascular inflammatory markers. GSNO treatment (50 mu g/kg/day for 2 months) significantly improved learning and memory performance of BCCAO rats and reduced the A beta levels and ICAM-1/VCAM-1 expression in the brain. Further, in in vitro cell culture studies, GSNO treatment also decreased the cytokine-induced proinflammatory responses, such as activations of NF kappa B and STAT3 and expression of ICAM-1 and VCAM-1 in endothelial cells. In addition, GSNO treatment increased the endothelial and microglial A beta uptake. Additionally, GSNO treatment inhibited the beta-secretase activity in primary rat neuron cell culture, thus reducing secretion of A beta, suggesting GSNO mediated mechanisms in anti-inflammatory and anti-amyloidogenic activities. Taken together, these data document that systemic GSNO treatment is beneficial for improvement of cognitive decline under the conditions of chronic cerebral hypoperfusion and suggests a potential therapeutic use of GSNO for cerebral hypoperfusion associated mild cognitive impairment in Alzheimer's disease. C1 [Won, Je-Seong; Annamalai, Balasubramaniam; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Kim, Jinsu; Shunmugavel, Anandakumar; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Pathol & Lab Med Serv, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Charles P Darby Children Res Inst, Dept Pathol & Lab Med, 504D,173 Ashley Ave, Charleston, SC 29425 USA. EM avtar.singh@va.gov FU NIH; VA [NS072511, BX001062, NS037766, NS022576, BX001072] FX This work was supported by grants from NIH and VA (NS072511, BX001062, NS037766, NS022576 and BX001072). We also acknowledge Ms. Joyce Bryan and Ms. Chara Williams for their help in procurement of animals and supplies. NR 63 TC 16 Z9 19 U1 0 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 34 IS 3 BP 621 EP 635 DI 10.3233/JAD-121786 PG 15 WC Neurosciences SC Neurosciences & Neurology GA 104KK UT WOS:000315991500006 PM 23254638 ER PT J AU Zhang, X Eggert, US AF Zhang, Xin Eggert, Ulrike S. TI Non-traditional roles of G protein-coupled receptors in basic cell biology SO MOLECULAR BIOSYSTEMS LA English DT Review ID HETEROTRIMERIC G-PROTEINS; DELTA-OPIOID RECEPTORS; CAENORHABDITIS-ELEGANS EMBRYOS; OLFACTORY RECEPTOR; BETA-ARRESTINS; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; SPINDLE POSITION; GENE-EXPRESSION; NERVOUS-SYSTEM AB G protein-coupled receptors (GPCRs) are key signaling proteins that regulate how cells interact with their environment. Traditional signaling cascades involving GPCRs have been well described and are well established and very important clinical targets. With the development of more recent technologies, hints about the involvement of GPCRs in fundamental cell biological processes are beginning to emerge. In this review, we give a basic introduction to GPCR signaling and highlight some less well described roles of GPCRs, including in cell division and membrane trafficking, which may occur through canonical and non-canonical signaling pathways. C1 [Zhang, Xin] Chinese Acad Sci, High Field Magnet Lab, Hefei, Peoples R China. [Zhang, Xin; Eggert, Ulrike S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zhang, Xin; Eggert, Ulrike S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Eggert, Ulrike S.] Kings Coll London, Dept Chem, London WC2R 2LS, England. [Eggert, Ulrike S.] Kings Coll London, Randall Div Cell & Mol Biophys, London WC2R 2LS, England. [Zhang, Xin] Harvard Univ, Sch Med, Ulrike Eggerts Lab, Boston, MA USA. [Eggert, Ulrike S.] Harvard Univ, Sch Med, Lab Tim Mitchison, Boston, MA USA. [Eggert, Ulrike S.] Kings Coll London, Randall Div, London WC2R 2LS, England. RP Eggert, US (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM ulrike.eggert@kcl.ac.uk FU NIH [R01 GM082834]; Human Frontier Science Program Young Investigator Award; Marie Curie CIG grant [304137]; ERC [306659] FX Research in the Eggert lab is funded by NIH grant R01 GM082834, a Human Frontier Science Program Young Investigator Award, Marie Curie CIG grant 304137 and ERC Starting Grant 306659. NR 116 TC 5 Z9 5 U1 3 U2 40 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1742-206X J9 MOL BIOSYST JI Mol. Biosyst. PY 2013 VL 9 IS 4 BP 586 EP 595 DI 10.1039/c2mb25429h PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 103IG UT WOS:000315908800007 PM 23247090 ER PT J AU Quesnel, AM Moonis, G Appel, J O'Malley, JT McKenna, MJ Curtin, HD Merchant, SN AF Quesnel, Alicia M. Moonis, Gul Appel, Jason O'Malley, Jennifer T. McKenna, Michael J. Curtin, Hugh D. Merchant, Saumil N. TI Correlation of Computed Tomography With Histopathology in Otosclerosis SO OTOLOGY & NEUROTOLOGY LA English DT Article DE Computed tomography; Histopathology; Otosclerosis; Radiology; Temporal bone ID SENSORINEURAL HEARING-LOSS; COCHLEAR OTOSCLEROSIS; CT; DENSITOMETRY; DIAGNOSIS; CAPSULE AB Objective: Until now, the use of computed tomography (CT) in the diagnosis and evaluation of otosclerosis has been based on correlation of radiologic findings to patient histories, intraoperative examinations, and audiologic data. The purpose of this study was to compare CT findings in otosclerosis to histopathology. Study Design: Prospective blinded. Setting: Radiology department in a tertiary referral hospital and otopathology laboratory. Patients: Temporal bones from patients with otosclerosis and other otologic diseases (used as controls). Intervention(s): Blinded review of specimen CT scans by radiologists and comparison of CT findings to histopathology of the same bones. Main Outcome Measure(s): Ability of CT to diagnose otosclerosis, identify otosclerotic foci in defined zones of the otic capsule, determine endosteal layer involvement, oval window (OW) obliteration, and round window (RW) obliteration. Results: In a randomized blinded evaluation, radiologists identified 8 of 10 bones with otosclerosis and made 3 false-positive diagnoses from the 36 control bones. Radiologic examination correctly identified otosclerosis anterior to the oval window, in the pericochlear area, and in the round window niche in 17 of 17, 9 of 11, and 3 of 6 bones, respectively. CT correctly determined involvement of the endosteal layer, OW obliteration, and RW obliteration in 5 of 8, 2 of 2, and 2 of 2 temporal bones. Conclusion: High-resolution CT is highly sensitive and specific for the diagnosis of otosclerosis when compared with histopathology. Very small and subtle otosclerotic foci seen on pathology may be missed on CT. Although CT was able to positively identify cochlear endosteal margin involvement, the false-negative rate on CT was significant. C1 [Quesnel, Alicia M.; O'Malley, Jennifer T.; McKenna, Michael J.; Merchant, Saumil N.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Quesnel, Alicia M.; O'Malley, Jennifer T.; McKenna, Michael J.; Merchant, Saumil N.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Moonis, Gul; Appel, Jason; Curtin, Hugh D.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Moonis, Gul] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA. RP Quesnel, AM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM alicia_quesnel@meei.harvard.edu FU National Institutes of Health grant [U24DC011943] FX This work was supported by National Institutes of Health grant U24DC011943 (to S. N. M.). NR 16 TC 6 Z9 6 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1531-7129 J9 OTOL NEUROTOL JI Otol. Neurotol. PD JAN PY 2013 VL 34 IS 1 BP 22 EP 28 DI 10.1097/MAO.0b013e318277a1f7 PG 7 WC Clinical Neurology; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 055DG UT WOS:000312394800008 PM 23235550 ER PT J AU Wang, LX Stengel, A Goebel-Stengel, M Shaikh, A Yuan, PQ Tache, Y AF Wang, Lixin Stengel, Andreas Goebel-Stengel, Miriam Shaikh, Almaas Yuan, Pu-Qing Tache, Yvette TI Intravenous injection of urocortin 1 induces a CRF2 mediated increase in circulating ghrelin and glucose levels through distinct mechanisms in rats SO PEPTIDES LA English DT Article DE Acyl ghrelin; Astressin(2)-B; CRF; Des-acyl ghrelin; Radioimmunoassay; Rat; Urocortin ID CORTICOTROPIN-RELEASING-FACTOR; ACYL GHRELIN; FOOD-INTAKE; FUNCTIONAL IMPLICATIONS; PERIPHERAL UROCORTIN; INTERNATIONAL-UNION; DESACYL GHRELIN; RECEPTORS; STOMACH; HORMONE AB Urocortins (Ucns) injected peripherally decrease food intake and gastric emptying through peripheral CRF2 receptors in rodents. However, whether Ucns influence circulating levels of the orexigenic and prokinetic hormone, ghrelin has been little investigated. We examined plasma levels of ghrelin and blood glucose after intravenous (iv) injection of Ucn 1, the CRF receptor subtype involved and underlying mechanisms in ad libitum fed rats equipped with a chronic iv cannula. Ucn 1 (10 mu g/kg, iv) induced a rapid onset and long lasting increase in ghrelin levels reaching 68% and 219% at 0.5 and 3 h post injection respectively and a 5-h hyperglycemic response. The selective CRF2 agonist, Ucn 2 (3 mu g/kg, iv) increased fasting acyl (3 h: 49%) and des-acyl ghrelin levels (3 h: 30%) compared to vehicle while the preferential agonist, CRF (3 mu g/kg, iv) had no effect. Ucn l's stimulatory actions were blocked by the selective CRF2 antagonist, astressin(2)-B (100 mu g/kg, iv). Hexamethonium (10 mg/kg, sc) prevented Ucn 1-induced rise in total ghrelin levels while not altering the hyperglycemic response. These data indicate that systemic injection of Ucns induces a CRF2-mediated increase in circulating ghrelin levels likely via indirect actions on gastric ghrelin cells that involves a nicotinic pathway independently from the hyperglycemic response. (C) 2012 Elsevier Inc. All rights reserved. C1 [Wang, Lixin; Stengel, Andreas; Goebel-Stengel, Miriam; Shaikh, Almaas; Yuan, Pu-Qing; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Wang, Lixin; Stengel, Andreas; Goebel-Stengel, Miriam; Shaikh, Almaas; Yuan, Pu-Qing; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA 90024 USA. [Wang, Lixin; Stengel, Andreas; Goebel-Stengel, Miriam; Shaikh, Almaas; Yuan, Pu-Qing; Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Wang, LX (reprint author), 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lixinw@ucla.edu FU Veterans Administration Research Career Scientist Award; VA Merit Award; German Research Foundation [STE 1765/3-1]; Charite University Funding [UFF 89-441-176]; [NIH DK-41301]; [R01 NIH DX 33061] FX This work was supported by the Veterans Administration Research Career Scientist Award, VA Merit Award, Center Grant NIH DK-41301 (Animal Core) and R01 NIH DX 33061 (Y.T.), German Research Foundation STE 1765/3-1 (A.S.) and Charite University Funding UFF 89-441-176 (A.S.). We thank Dr. Jean Rivier (Clayton Foundation Laboratories, Salk Institute, La Jolla, CA) for the generous supply of peptides. We are grateful to Mrs. Honghui Liang for the excellent technical support and Ms. Eugenia Hu for her review of the manuscript. NR 55 TC 9 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD JAN PY 2013 VL 39 BP 164 EP 170 DI 10.1016/j.peptides.2012.11.009 PG 7 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 102IW UT WOS:000315839300025 PM 23183626 ER PT J AU Sweeney, BJ Wilbur, DC AF Sweeney, Brenda J. Wilbur, David C. TI Effects on Cervical Cytology Screening Productivity Associated with Implementation of the BD FocalPoint (TM) Guided Screener Imaging System SO ACTA CYTOLOGICA LA English DT Article DE Cervical cytology; Workload; Automation; Pap test ID CLINICAL-TRIALS; INTENDED-USE; CANCER; ABNORMALITIES; SENSITIVITY; RATES AB Objectives: Automated screening will become important due to an aging workforce, declining numbers of new cytotechnologists, and the need for increased screening sensitivity in the vaccine era, where high-grade abnormalities will decline. This study documents workload in gynecologic cytology throughput before and after the implementation of the BD FocalPoint (TM) Guided Screener (GS) System. Study Design: We collected daily screening data from 3 time periods: the 12 months prior to GS implementation, the 6 months immediately after implementation, and the ensuing 7-18 months after implementation. Data was tabulated at the individual and total laboratory levels. Results: In the 6-month period immediately following implementation, productivity increased in 3 of 5 cytotechnologists, as compared to the figures 12 months before implementation. The laboratory increased productivity slightly (+2.4%), with individual changes ranging from -6.9 to +14.7%. In the 7- to 18-month 'mature' period after implementation, productivity increased in all 5 cytotechnologists with an average of +15.4%. Individual increases ranged from +6.1 to +26.9%. Conclusions: Overall productivity increased in the period beyond 6 months, and this increase was eventually noted in all personnel. Increased productivity was associated with a short period of learning in which the magnitude of the effect was less than in the mature period. Copyright (C) 2013 S. Karger AG, Basel C1 [Sweeney, Brenda J.; Wilbur, David C.] Massachusetts Gen Hosp, James Homer Wright Lab Pathol, Cytopathol Unit, Boston, MA 02114 USA. [Wilbur, David C.] Harvard Univ, Sch Med, Boston, MA USA. RP Wilbur, DC (reprint author), Massachusetts Gen Hosp, James Homer Wright Lab Pathol, 55 Fruit St, Boston, MA 02114 USA. EM dwilbur@partners.org NR 19 TC 2 Z9 2 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5547 J9 ACTA CYTOL JI Acta Cytol. PY 2013 VL 57 IS 2 BP 147 EP 152 DI 10.1159/000345569 PG 6 WC Pathology SC Pathology GA 098IV UT WOS:000315543700005 PM 23406848 ER PT J AU Cohen-Adad, J El Mendili, MM Morizot-Koutlidis, R Lehericy, S Meininger, V Blancho, S Rossignol, S Benali, H Pradat, PF AF Cohen-Adad, Julien El Mendili, Mohamed-Mounir Morizot-Koutlidis, Regine Lehericy, Stephane Meininger, Vincent Blancho, Sophie Rossignol, Serge Benali, Habib Pradat, Pierre-Francois TI Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE ALS; spinal cord; diffusion tensor imaging; magnetization transfer; atrophy ID AMYOTROPHIC-LATERAL-SCLEROSIS; SOMATOSENSORY EVOKED-POTENTIALS; DIFFUSION TENSOR MRI; CORTICOSPINAL TRACT; MULTIPLE-SCLEROSIS; WHITE-MATTER; DISEASE PROGRESSION; MOUSE MODEL; STIMULATION; BRAIN AB Our objective was to demonstrate that ALS patients have sensory pathway involvement and that local cord atrophy reflects segmental lower motor neuron involvement. Twenty-nine ALS patients with spinal onset and twenty-one healthy controls were recruited. Diffusion tensor imaging (DTI), magnetization transfer and atrophy index were measured in the spinal cord, complemented with transcranial magnetic stimulations. Metrics were quantified within the lateral corticospinal and the dorsal segments of the cervical cord. Significant differences were detected between patients and controls for DTI and magnetization transfer metrics in the lateral and dorsal segments of the spinal cord. Fractional anisotropy correlated with ALSFRS-R (p = 0.04) and motor threshold (p = 0.02). Stepwise linear regression detected local spinal cord atrophy associated with weakness in the corresponding muscle territory, i.e. C4 level for deltoid and C7 level for hand muscles. In conclusion, impairment of spinal sensory pathways was detected at an early stage of the disease. Our data also demonstrate an association between muscle deficits and local spinal cord atrophy, suggesting that atrophy is a sensitive biomarker for lower motor neurons degeneration. C1 [Cohen-Adad, Julien; El Mendili, Mohamed-Mounir; Benali, Habib; Pradat, Pierre-Francois] Grp Hosp Pitie Salpetriere, INSERM, UPMC, UMR 678, F-75651 Paris, France. [Cohen-Adad, Julien] Harvard Univ, Sch Med, Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Morizot-Koutlidis, Regine] Grp Hosp Pitie Salpetriere, AP HP, Dept Explorat Fonct Neurol, F-75651 Paris, France. [Lehericy, Stephane] Ctr Neuroimagerie Rech CENIR, Paris, France. [Lehericy, Stephane; Meininger, Vincent] Univ Paris 06, Paris, France. [Lehericy, Stephane] ICM Inst Cerveau & Moelle Epiniere, Paris, France. [Meininger, Vincent; Pradat, Pierre-Francois] Grp Hosp Pitie Salpetriere, AP HP, Dept Malad Syst Nerveux, F-75651 Paris, France. [Blancho, Sophie] Inst Rech Moelle Epiniere & Encephale, Paris, France. [Rossignol, Serge] Univ Montreal, Fac Med, GRSNC, Montreal, PQ H3C 3J7, Canada. [Cohen-Adad, Julien] Ecole Polytech Montreal, Dept Elect Engn, Montreal, PQ, Canada. RP Pradat, PF (reprint author), Grp Hosp Pitie Salpetriere, Dept Malad Syst Nerveux, 47-83 Blvd Hop, F-75651 Paris, France. EM pierre-francois.pradat@psl.aphp.fr FU Association Francaise contre les Myopathies (AFM); Institut pour la Recherche sur la Moelle epiniere et l'Encephale (IRME); National MS Society; Sensori-Motor Rehabilitation Research Team (SMRRT) of the Canadian Institute of Health Research FX We thank Kevin Nigaud, Alexandre Vignaud and Eric Bardinet for helping with the acquisition and Henrik Lundell for providing the code to measure the cord area. We are grateful for the contribution of the patients and their relatives. We thank the clinicians of the Paris ALS Centre, Gaelle Bruneteau, Lucette Lacomblez, Marie-Violaine Lebouteux, Timothee Lenglet and Francois Salachas. We thank the reviewers for their very insightful comments. This study was supported by the Association Francaise contre les Myopathies (AFM), the Institut pour la Recherche sur la Moelle epiniere et l'Encephale (IRME), the National MS Society and the Sensori-Motor Rehabilitation Research Team (SMRRT) of the Canadian Institute of Health Research. NR 53 TC 34 Z9 34 U1 1 U2 14 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 2167-8421 J9 AMYOTROPH LAT SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD JAN PY 2013 VL 14 IS 1 BP 30 EP 38 DI 10.3109/17482968.2012.701308 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 096OZ UT WOS:000315415400007 PM 22881412 ER PT J AU Rudnicki, SA Berry, JD Ingersoll, E Archibald, D Cudkowicz, ME Kerr, DA Dong, YW AF Rudnicki, Stacy A. Berry, James D. Ingersoll, Evan Archibald, Don Cudkowicz, Merit E. Kerr, Douglas A. Dong, Yingwen TI Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE Amyotrophic lateral sclerosis; dexpramipexole; ALSFRS-R; CAFS; Phase II ID ALSFRS-R; RANDOMIZED-TRIAL; RATING-SCALE; PROGRESSION; POPULATION; RILUZOLE; MORTALITY; TIME AB Our objective was to explore treatment effects in patient subgroups using post hoc analyses of data from part 2 of the dexpramipexole Phase II study. Subjects with amyotrophic lateral sclerosis (ALS) received dexpramipexole 300 mg/day or 50 mg/day for 24 weeks. Treatment effects on the slope of the revised ALS Functional Rating Score (ALSFRS-R) and Combined Assessment of Function and Survival (CAFS) were evaluated in dichotomized subgroups: riluzole use, gender, site of symptom onset. Other subgroups were dichotomized using median baseline values for age, ALSFRS-R, slow vital capacity, symptom duration, diagnostic delay, and progression rate. Results showed that there was a 21% reduction in ALSFRS-R decline favoring the 300-mg vs. 50-mg arm (p = 0.177); mean CAFS ranking was significantly higher in the 300-mg vs. 50-mg arm (52.4 vs. 41.1; p = 0.046). Trends were recapitulated in virtually all subgroups. Generally, ALSFRS-R decline was reduced and CAFS rankings were higher in the 300-mg vs. 50-mg arm across subgroups. CAFS rankings were significantly higher in the 300-mg vs. 50-mg arm among subjects with ALSFRS-R scores <= 35, symptom duration < 18.7 months, or progression rate >= 0.7 points/month (p < 0.03). In conclusion, the observed benefit of 300-vs. 50-mg dexpramipexole on functional decline and survival was generally consistent among subjects regardless of baseline characteristics. C1 [Rudnicki, Stacy A.] Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA. [Berry, James D.; Cudkowicz, Merit E.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Ingersoll, Evan; Archibald, Don] Knopp Biosci, Pittsburgh, PA USA. [Kerr, Douglas A.; Dong, Yingwen] Biogen Idec Inc, Cambridge, MA USA. RP Rudnicki, SA (reprint author), Univ Arkansas Med Sci, Dept Neurol, 501 Jackson Stephens Dr,Room 761, Little Rock, AR 72205 USA. EM sarudnicki@uams.edu FU MDA; ALS Therapy Alliances; AAN Clinical Research Training Fellowship; Biogen Idec FX S. A. Rudnicki has served as a consultant and study investigator for Knopp Biosciences LLC. J. D. Berry has served as a consultant for Biogen Idec and receives funding from the MDA and ALS Therapy Alliances. E. Ingersoll and D. Archibald are employees of Knopp Biosciences LLC. M. E. Cudkowicz served on an advisory board for Biogen Idec, is a DSMB member for Trophos and consultant for GSK and Shire; she was also the recipient of the 1996 AAN Clinical Research Training Fellowship. D. A. Kerr and Y. Dong are employees of Biogen Idec. The authors alone are responsible for the content and writing of the paper.; The Phase II study was sponsored and conducted by Knopp Biosciences LLC. This report was sponsored by Biogen Idec. Medical writing assistance funded by Biogen Idec was provided by Linda Goldstein of UBC Scientific Solutions. NR 23 TC 17 Z9 17 U1 0 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 2167-8421 J9 AMYOTROPH LAT SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD JAN PY 2013 VL 14 IS 1 BP 44 EP 51 DI 10.3109/17482968.2012.723723 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 096OZ UT WOS:000315415400009 PM 22985432 ER PT J AU Kamran, SC Howard, SA Shinagare, AB Krajewski, KM Jagannathan, JP Hornick, JL Ramaiya, NH AF Kamran, S. C. Howard, S. A. Shinagare, A. B. Krajewski, K. M. Jagannathan, J. P. Hornick, J. L. Ramaiya, N. H. TI Malignant peripheral nerve sheath tumors: Prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location SO EJSO LA English DT Article DE Malignant triton tumor; Malignant peripheral nerve sheath tumor; Neurofibromatosis; Rhabdomyoblastic differentiation ID RHABDOMYOSARCOMATOUS DIFFERENTIATION; SURVIVAL; SCHWANNOMA AB Purpose: The purpose of this study was to assess the impact of rhabdomyoblastic differentiation [malignant triton tumors (MTT)], neurofibromatosis 1 (NF1) status and location on the outcome of malignant peripheral nerve sheath tumors. Methods: In this IRB-approved, HIPAA-compliant retrospective study medical records of 84 patients with pathologically confirmed MPNST from 1999 to 2011 were retrospectively reviewed. Patient and tumor characteristics including size, location, NF1 status, absence or presence of rhabdomyoblastic differentiation (MPNST versus MTT, respectively), recurrence and metastatic patterns and outcomes were evaluated. Results: Of 84 patients, 62 were MPNST and 22 were MTT. MTT occurred in older patients than MPNST (50 years versus 40.7 years, p = 0.04) and were larger (12.3 cm versus 8.1 cm, p = 0.01). While there was no difference between the location, rate of recurrent or metastasis disease, and metastatic pattern between MTT and MPNST groups, MTT had shorter metastasis-free interval (median, 1 month versus 9 months, p = 0.02) and shorter survival (median, 10 months versus 43 months, p < 0.0001). NF1 status, while associated with earlier diagnosis (mean age, 35.1 years versus 46.5 years, p = 0.008), had no impact on rate of MTT or on prognosis. Patients with primary in the torso had shorter survival than those with extremity primary (median, 15 months versus 47 months, p = 0.0004). Multivariate analysis using the Cox proportional hazard regression model yielded age (p = 0.029), size (p = 0.0001), presence of rhabdomyoblastic differentiation (MTT) (p = 0.001), and location in the torso (p = 0.01) as independent predictors of survival. Conclusions: Among patients with malignant peripheral nerve sheath tumors, rhabdomyoblastic differentiation (MTT) and location in the torso are associated with poor prognosis. NF1 status has no impact on the prognosis. (c) 2012 Elsevier Ltd. All rights reserved. C1 [Kamran, S. C.; Howard, S. A.; Shinagare, A. B.; Krajewski, K. M.; Jagannathan, J. P.; Hornick, J. L.; Ramaiya, N. H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. [Kamran, S. C.; Howard, S. A.; Shinagare, A. B.; Krajewski, K. M.; Jagannathan, J. P.; Hornick, J. L.; Ramaiya, N. H.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Kamran, S. C.; Howard, S. A.; Shinagare, A. B.; Krajewski, K. M.; Jagannathan, J. P.; Hornick, J. L.; Ramaiya, N. H.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Shinagare, AB (reprint author), Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA. EM ashinagare@partners.org OI Kamran, Sophia/0000-0001-9283-6515 NR 20 TC 5 Z9 6 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0748-7983 J9 EJSO-EUR J SURG ONC JI EJSO PD JAN PY 2013 VL 39 IS 1 BP 46 EP 52 DI 10.1016/j.ejso.2012.09.001 PG 7 WC Oncology; Surgery SC Oncology; Surgery GA 096RJ UT WOS:000315421700008 PM 23084090 ER PT J AU Zhao, W Ho, L Varghese, M Yemul, S Dams-O'Connor, K Gordon, W Knable, L Freire, D Haroutunian, V Pasinetti, GM AF Zhao, Wei Ho, Lap Varghese, Merina Yemul, Shrishailam Dams-O'Connor, Kristen Gordon, Wayne Knable, Lindsay Freire, Daniel Haroutunian, Vahram Pasinetti, Giulio Maria TI Decreased Level of Olfactory Receptors in Blood Cells Following Traumatic Brain Injury and Potential Association with Tauopathy SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Biomarker; olfactory receptor; peripheral blood mononuclear cell; tauopathy; traumatic brain injury ID MILD ALZHEIMER-DISEASE; LOBE MEMORY SYSTEM; MOUSE MODEL; IN-VITRO; EXPRESSION; PROTEIN; TAU; PLASTICITY; DISCOVERY; SCLEROSIS AB Traumatic brain injury (TBI) is a leading cause of death and disability among children and young adults in the United States. In this study, we explored whether changes in the gene expression profile of peripheral blood mononuclear cells (PBMC) may provide a clinically assessable "window" into the brain, reflecting molecular alterations following TBI that might contribute to the onset and progression of TBI clinical complications. We identified three olfactory receptor (OR) TBI biomarkers that are aberrantly down-regulated in PBMC specimens from TBI subjects. Down-regulation of these OR biomarkers in PBMC was correlated with the severity of brain injury and TBI-specific symptoms. A two-biomarker panel comprised of OR11H1 and OR4M1 provided the best criterion for segregating the TBI and control cases with 90% accuracy, 83.3% sensitivity, and 100% specificity. We found that the OR biomarkers are ectopically expressed in multiple brain regions, including the entorhinal-hippocampus system known to play an important role in memory formation and consolidation. Activation of OR4M1 led to attenuation of abnormal tau phosphorylation, possibly through JNK signaling pathway. Our results suggested that addition of the two-OR biomarker model to current diagnostic criteria may lead to improved TBI detection for clinical trials, and decreased expression of OR TBI biomarkers might be associated with TBI-induced tauopathy. Future studies exploring the physiological relevance of OR TBI biomarkers in the normal brain and in the brain following TBI will provide a better understanding of the biological mechanisms underlying TBI and insights into novel therapeutic targets for TBI. C1 [Zhao, Wei; Ho, Lap; Varghese, Merina; Yemul, Shrishailam; Knable, Lindsay; Freire, Daniel; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil, New York, NY 10029 USA. [Haroutunian, Vahram; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Yemul, Shrishailam; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA. EM Giulio.Pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 FU National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1RR029887] FX This study was supported in part by discretionary funding to GMP and in part from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (UL1RR029887). NR 50 TC 11 Z9 11 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 34 IS 2 BP 417 EP 429 DI 10.3233/JAD-121894 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 095MF UT WOS:000315337900008 PM 23241557 ER PT J AU Lovering, ME Proctor, SP Heaton, KJ AF Lovering, Meghan E. Proctor, Susan P. Heaton, Kristin J. TI A retrospective study of anxiety disorder diagnoses in the military from 2000 to 2009 SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Anxiety disorders; Military; PTSD; Rates; DMED ID NATIONAL-COMORBIDITY-SURVEY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; DSM-IV DISORDERS; SURVEY REPLICATION; US MILITARY; COMBAT; PREVALENCE; DEPLOYMENT; WOMEN AB The objective of this study was to describe trends in the diagnostic rates for anxiety disorders (ADs) types in the U.S. military from 2000 to 2009. Data for the numbers of diagnosed cases for the first documented occurrence of ADs during ambulatory visits while serving in the military were obtained from the Defense Medical Epidemiology Database for all active duty service members and examined across branch of service and by gender. Results indicate that Anxiety Not Otherwise Specified (ANOS) was the most frequently diagnosed AD type in each of the 10 years between 2000 and 2009, with an average rate of 0.8 per 100 service members for first service occurrence, followed by PTSD at a rate of 0.5 out of every 100. Starting in 2002, the yearly first occurrence rates of ANDS and PTSD were significantly higher (p < 0.001) compared to each proceeding year, with the same pattern present among males and females separately. The majority of first occurrence AD diagnoses were diagnosed in the Army (47% of Anxiety NOS and 60% of PTSD cases) compared to the other service branches (i.e., Navy, Air Force, and Marines). (C) 2012 Elsevier Ltd. All rights reserved. C1 [Lovering, Meghan E.; Proctor, Susan P.; Heaton, Kristin J.] USA, Environm Med Res Inst, Natick, MA 01760 USA. [Proctor, Susan P.; Heaton, Kristin J.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Proctor, Susan P.] VA Boston Healthcare Syst, Res Serv, Boston, MA USA. RP Lovering, ME (reprint author), USA, Environm Med Res Inst, 15 Kansas St,Bldg 42, Natick, MA 01760 USA. EM meghan.lovering@us.army.mil RI Heaton, Kristin/E-3660-2013 NR 33 TC 1 Z9 1 U1 1 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD JAN PY 2013 VL 27 IS 1 BP 25 EP 32 DI 10.1016/j.janxdis.2012.10.003 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 096US UT WOS:000315430700004 PM 23299116 ER PT J AU Perez-Johnston, R Narin, O Mino-Kenudson, M Ingkakul, T Warshaw, AL Fernandez-del Castillo, C Sahani, VD AF Perez-Johnston, R. Narin, O. Mino-Kenudson, M. Ingkakul, T. Warshaw, A. L. Fernandez-del Castillo, C. Sahani, V. D. TI Frequency and significance of calcification in IPMN SO PANCREATOLOGY LA English DT Article DE Calcification; IPMN; CT ID PAPILLARY MUCINOUS NEOPLASM; CALCIFIED GASTRIC-CANCER; PANCREATIC CALCIFICATION; COLORECTAL-CARCINOMA; CT; METASTASES; TUMORS AB The frequency and significance of calcification in intraductal papillary mucinous neoplasms (IPMN) are unknown. We examined calcifications by computed tomography (CT) in a large cohort of IPMNs and correlated them with clinicopathologic characteristics. Methods: Preoperative contrast-enhanced CT imaging studies of 164 patients with surgically resected IPMN were retrospectively reviewed. Morphologic characteristics of IPMN, presence and type of calcifications, their location, the degree of dysplasia and the epithelial subtype were recorded. Symptoms at the time of diagnosis, history of smoking, and alcohol consumption were obtained from medical records. Results: Of the 164 IPMNs, 68 were branch duct type (Br-IPMN) and 96 main duct (MD-IPMN) or combined type (CT-IPMN); 78 (48%) had a malignant component (CIS and Invasive). Calcifications were present in 33 cases (20%). By type, 16 calcifications were punctate, 11 coarse and 9 eggshell, and by location, 15 were mural, 3 septal, 2 ductal, 1 in the solid component, and 13 in multiple locations. Calcifications were seen more frequently in larger lesions (44 mm vs 32 mm p = 0.002), and when MPD dilation was noted (70% vs 45%, p = 0.023). There was no association between presence of calcification and malignancy, epithelial subtype, or other clinical data. However, malignancy was present in 9/11 IPMN with coarse calcification (p = 0.04), suggesting this may be a worrisome feature. Conclusion: Calcification is found in 20% of IPMNs, and is more common in larger lesions. Although its overall presence has no correlation with malignancy, coarse calcification, when combined with other morphologic features, may be a radiologic sign of malignancy. Copyright (C) 2012, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved. C1 [Perez-Johnston, R.; Narin, O.; Sahani, V. D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mino-Kenudson, M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Ingkakul, T.; Warshaw, A. L.; Fernandez-del Castillo, C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Perez-Johnston, R (reprint author), Massachusetts Gen Hosp, 55 Fruit St,White 270, Boston, MA 02114 USA. EM rperezjohnston@partners.org; mminokenudson@partners.org; awarshaw@partners.org; cfernandez@partners.org; dsahani@partners.org NR 28 TC 3 Z9 3 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 J9 PANCREATOLOGY JI Pancreatology PD JAN-FEB PY 2013 VL 13 IS 1 BP 43 EP 47 DI 10.1016/j.pan.2012.11.306 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 098NO UT WOS:000315556200008 PM 23395569 ER PT J AU Tadros, NN Bland, L Legg, E Olyaei, A Conlin, MJ AF Tadros, Nicholas N. Bland, Lisa Legg, Edith Olyaei, Ali Conlin, Michael J. TI A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial SO BJU INTERNATIONAL LA English DT Article DE ureteroscopy; stents; urolithiasis; NSAIDs ID IN-VITRO; SYMPTOMS; CONTRACTILITY; INHIBITORS AB Objectives To determine the incidence of severe pain after ureteric stent removal. To evaluate the efficacy of a single dose of a non-steroidal anti-inflammatory drug (NSAID) in preventing this complication. Patients and Methods A prospective, randomised, double-blind, placebo-controlled trial was performed at our institution. Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal. Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal Pain medication use after ureteric stent removal was measured using morphine equivalents. Results In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed significant decrease in pain level in the NSAID group. The most common indication for ureteroscopy was urolithiasis (14 patients). The proportion of patients with severe pain (VAS score of >= 7) during the 24 h after ureteric stent removal was six of 11 (55%) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01). There were no complications related to the use of rofecoxib. Conclusions We found a 55% incidence of severe pain after ureteric stent removal. A single dose of a NSAID before stent removal prevents severe pain after ureteric stent removal. C1 [Tadros, Nicholas N.; Bland, Lisa; Legg, Edith; Olyaei, Ali] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [Conlin, Michael J.] Portland VA Med Ctr, Portland, OR USA. RP Conlin, MJ (reprint author), Oregon Hlth & Sci Univ, Div Urol & Renal Transplantat, CH 10U,3303 SW Bond Ave, Portland, OR 97239 USA. EM conlinm@ohsu.edu OI Tadros, Nick/0000-0002-2272-235X NR 11 TC 12 Z9 12 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 J9 BJU INT JI BJU Int. PD JAN PY 2013 VL 111 IS 1 BP 101 EP 105 DI 10.1111/j.1464-410X.2012.11214.x PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 092ZG UT WOS:000315160900021 PM 22578110 ER PT B AU Katz, DI Zasler, ND Zafonte, RD AF Katz, Douglas I. Zasler, Nathan D. Zafonte, Ross D. BE Zasler, ND Katz, DI Zafonte, RD TI Clinical Continuum of Care and Natural History SO BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; POSTTRAUMATIC AMNESIA; COGNITIVE REHABILITATION; VEGETATIVE STATE; FOCAL LESIONS; RECOVERY; MILD; TBI C1 [Katz, Douglas I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Katz, Douglas I.] Braintree Rehabil Hosp, Acquired Brain Injury Program, Braintree, MA USA. [Zasler, Nathan D.] Concuss Care Ctr Virginia Ltd, Richmond, VA USA. [Zasler, Nathan D.] Tree Life Serv Inc, Richmond, VA USA. [Zasler, Nathan D.] Sheltering Arms Hosp, iWalk Program, Richmond, VA USA. [Zasler, Nathan D.] VCU Dept Phys Med & Rehabil, Richmond, VA USA. [Zasler, Nathan D.] Univ Virginia, Dept Phys Med & Rehabil, Charlottesville, VA USA. [Zafonte, Ross D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Zafonte, Ross D.] Spaulding Rehabil Network, Boston, MA USA. [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Katz, DI (reprint author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. NR 57 TC 3 Z9 3 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-27-7 PY 2013 BP 2 EP 12 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA BDJ25 UT WOS:000313536100001 ER PT B AU Tenovuo, O Bullock, MR Zafonte, RD AF Tenovuo, Olli Bullock, M. Ross Zafonte, Ross D. BE Zasler, ND Katz, DI Zafonte, RD TI International Systems of Care and Research Agendas SO BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; CLINICAL-TRIALS; FOLLOW-UP; ALZHEIMERS-DISEASE; PROSPECTIVE COHORT; UNITED-STATES; MULTICENTER TRIAL C1 [Tenovuo, Olli] Univ Turku, Turku, Finland. [Tenovuo, Olli] Turku Univ Hosp, FIN-20520 Turku, Finland. [Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA. [Zafonte, Ross D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Zafonte, Ross D.] Spaulding Rehabil Network, Boston, MA USA. [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Tenovuo, O (reprint author), Univ Turku, Turku, Finland. NR 116 TC 1 Z9 1 U1 1 U2 2 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-27-7 PY 2013 BP 40 EP 52 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA BDJ25 UT WOS:000313536100004 ER PT B AU Kline, AE Cheng, JP Dixon, CE AF Kline, Anthony E. Cheng, Jeffrey P. Dixon, C. Edward BE Zasler, ND Katz, DI Zafonte, RD TI Experimental Therapeutic Approaches for Traumatic Brain Injury SO BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID 5-HT1A RECEPTOR AGONIST; CONTROLLED CORTICAL IMPACT; FIBROBLAST-GROWTH-FACTOR; CALCIUM-CHANNEL BLOCKER; FLUID-PERCUSSION INJURY; IMPROVES FUNCTIONAL RECOVERY; EXPERIMENTAL HEAD-INJURY; VESICULAR ACETYLCHOLINE TRANSPORTER; ATTENUATES COGNITIVE DYSFUNCTION; AMPHETAMINE-INDUCED RECOVERY C1 [Kline, Anthony E.; Cheng, Jeffrey P.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. [Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA. [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Kline, AE (reprint author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA. NR 263 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-27-7 PY 2013 BP 175 EP 192 PG 18 WC Clinical Neurology SC Neurosciences & Neurology GA BDJ25 UT WOS:000313536100014 ER PT B AU Cooper, RA McCue, M Schein, RM Cooper, R Sporner, ML Dodson, MB Reinsfelder, AM Yeager, AF Jinks, A LoPresti, E McClure, L Wang, HW Collinger, JL Hiremath, S Ding, D Lewis, A AF Cooper, Rory A. McCue, Michael Schein, Richard M. Cooper, Rosemarie Sporner, Michelle L. Dodson, Matthew B. Reinsfelder, Amanda M. Yeager, Arthur F. Jinks, Andrew LoPresti, Edmund McClure, Laura Wang, Hongwu Collinger, Jennifer L. Hiremath, Shivayogi Ding, Dan Lewis, Allen BE Zasler, ND Katz, DI Zafonte, RD TI Assistive Technology for People With Traumatic Brain Injuries SO BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID STAIRCASE-CLIMBING WHEELCHAIR; SPINAL-CORD INJURIES; OF-THE-ART; COGNITIVE IMPAIRMENTS; SMART HOMES; CLINICAL-APPLICATIONS; COMPUTER INTERFACES; PARAPLEGIC PATIENTS; PAGING SYSTEM; REHABILITATION C1 [Cooper, Rory A.; McCue, Michael; Schein, Richard M.; Cooper, Rosemarie; Sporner, Michelle L.; Jinks, Andrew; Wang, Hongwu; Hiremath, Shivayogi; Ding, Dan; Lewis, Allen] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Cooper, Rory A.] VA Pittsburgh Healthcare Syst, VA Rehabil Res & Dev Ctr Excellence, Pittsburgh, PA USA. [Cooper, Rosemarie] UPMC Ctr Assist Technol, Clin Serv, Pittsburgh, PA USA. [Dodson, Matthew B.] Walter Reed Natl Mil Med Ctr, TBI Sect, Occupat Therapy Dept, Bethesda, MD USA. [Reinsfelder, Amanda M.] Occupat Therapy Dept, TBI Sect, Bethesda, MD USA. [Yeager, Arthur F.] Walter Reed Natl Mil Med Ctr, Dept Orthoped & Rehabil, Bethesda, MD USA. [Jinks, Andrew] UPMC Ctr Assist Technol, Pittsburgh, PA USA. [LoPresti, Edmund] AT Sci LLC, Pittsburgh, PA USA. [McClure, Laura] Carle Fdn Hosp, Urbana, IL USA. [Collinger, Jennifer L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. NR 138 TC 0 Z9 0 U1 0 U2 4 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-27-7 PY 2013 BP 1178 EP 1199 PG 22 WC Clinical Neurology SC Neurosciences & Neurology GA BDJ25 UT WOS:000313536100071 ER PT B AU Meythaler, JM Zafonte, RD AF Meythaler, Jay M. Zafonte, Ross D. BE Zasler, ND Katz, DI Zafonte, RD TI Neuropharmacology: A Rehabilitation Perspective SO BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; PLACEBO-CONTROLLED TRIAL; 5-HT1A RECEPTOR AGONIST; WATER MAZE PERFORMANCE; DIFFUSE AXONAL INJURY; LIPID-PEROXIDATION; DOPAMINE-RECEPTORS; COGNITIVE FUNCTION; CEREBELLAR-ATAXIA C1 [Meythaler, Jay M.] Wayne State Univ, Dept Phys Med & Rehabil Oakwood, Dearborn, MI 48124 USA. [Zafonte, Ross D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Zafonte, Ross D.] Spaulding Rehabil Network, Boston, MA USA. [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Meythaler, JM (reprint author), Wayne State Univ, Dept Phys Med & Rehabil Oakwood, Dearborn, MI 48124 USA. NR 157 TC 0 Z9 0 U1 1 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-27-7 PY 2013 BP 1202 EP 1214 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA BDJ25 UT WOS:000313536100072 ER PT J AU Desai, GS Thabet, A Elias, AYA Sahani, DV AF Desai, G. S. Thabet, A. Elias, A. Y. A. Sahani, D. V. TI Comparative assessment of three image reconstruction techniques for image quality and radiation dose in patients undergoing abdominopelvic multidetector CT examinations SO BRITISH JOURNAL OF RADIOLOGY LA English DT Article ID STATISTICAL ITERATIVE RECONSTRUCTION; CROHN DISEASE; REDUCTION; ALGORITHM; ENTEROGRAPHY; PHANTOM AB Objective: To compare image quality and radiation dose of abdominal CT examinations reconstructed with three image reconstruction techniques. Methods: In this Institutional Review Board-approved study, contrast-enhanced (CE) abdominopelvic CT scans from 23 patients were reconstructed using filtered back projection (FBP), adaptive statistical iterative reconstruction (ASiR) and iterative reconstruction in image space (IRIS) and were reviewed by two blinded readers. Subjective (acceptability, sharpness, noise and artefacts) and objective (noise) measures of image quality were recorded for each image data set. Radiation doses in CT dose index (CTDI) dose-length product were also calculated for each examination type and compared. Imaging parameters were compared using the Wilcoxon signed rank test and a paired t-test. Results: All 69 CECT examinations were of diagnostic quality and similar for overall acceptability (mean grade for ASiR, 3.9 +/- 0.3; p=0.2 for Readers 1 and 2; IRIS, 3.9 +/- 0.4, p=0.2; FBP, 3.8 +/- 0.9). Objective noise was considerably lower with both iterative techniques (p<0.0001 and 0.0016 for ASiR and IRIS). Recorded mean radiation dose, i.e. CTDIvol, was 24% and 10% less with ASiR (11.4 +/- 3.4 mGy; p<0.001) and IRIS (13.5 +/- 3.7 mGy; p=0.06), respectively, than with FBP: 15.0 +/- 3.5 mGy. Conclusion: At the system parameters used in this study, abdominal CT scans reconstructed with ASiR and IRIS provide diagnostic images with reduced image noise and 10-24% lower radiation dose than FBP. Advances in knowledge: CT images reconstructed with FBP are frequently noisy on lowering the radiation dose. Newer iterative reconstruction techniques have different approaches to produce images with less noise; ASiR and IRIS provide diagnostic abdominal CT images with reduced image noise and radiation dose compared with FBP. This has been documented in this study. C1 [Desai, G. S.; Thabet, A.; Elias, A. Y. A.; Sahani, D. V.] Harvard Univ, Dept Radiol, Div Abdominal Imaging & Intervent, Sch Med, Boston, MA 02114 USA. RP Sahani, DV (reprint author), Harvard Univ, Dept Radiol, Div Abdominal Imaging & Intervent, Massachusetts Gen Hosp,Med Sch, 55 Fruit St,White 270, Boston, MA 02114 USA. EM dsahani@partners.org NR 31 TC 12 Z9 13 U1 0 U2 3 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 J9 BRIT J RADIOL JI Br. J. Radiol. PD JAN PY 2013 VL 86 IS 1021 AR UNSP 20120161 DI 10.1259/bjr.20120161 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 094MG UT WOS:000315266900010 PM 23255538 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Anesthesia by Injection SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID SUB-TENON ANESTHESIA; RETROBULBAR ANESTHESIA; SUBARACHNOID INJECTION; SCLERAL PERFORATION; COMPLICATION; PERIBULBAR; BLOCK C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 22 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 3 EP 9 PG 7 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200001 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Capsulorrhexis SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID CONTINUOUS CURVILINEAR CAPSULORHEXIS; PRIMARY POSTERIOR CAPSULORHEXIS; CATARACT-SURGERY; INTRAOCULAR-LENS; PHACOEMULSIFICATION; CAPSULOTOMY; COMPLICATIONS; IMPLANTATION C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 25 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 19 EP 27 PG 9 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200003 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Hydroseparation Maneuvers SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID POSTERIOR POLAR CATARACT; CORTICAL CLEAVING HYDRODISSECTION; PHACOEMULSIFICATION; SURGERY; NUCLEUS; RUPTURE; EYES C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 13 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 29 EP 33 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200004 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Complications of Phacoemulsification SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID DIVIDE-AND-CONQUER; PHACO-CHOP TECHNIQUES; DENSITY; ENERGY; FLIP C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 11 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 35 EP 45 PG 11 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200005 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Complications With Intraocular Lens Implantation SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID INCISION CATARACT-SURGERY; OPACIFICATION; CALCIUM; HYPHEMA C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 15 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 47 EP 56 PG 10 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200006 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Complications Arising From Equipment and Tubing SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID COAXIAL PHACOEMULSIFICATION; BIMANUAL MICROINCISION; CATARACT-SURGERY; TIP C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 14 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 57 EP 62 PG 6 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200007 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Posterior Capsule Rupture SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID CATARACT-SURGERY; VITREOUS LOSS; OUTCOMES; IMPLANTATION; RISK; LENS C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 11 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 63 EP 74 PG 12 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200008 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Anterior Vitrectomy SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID 25-GAUGE VITREOUS CUTTERS; PHACOEMULSIFICATION; MANAGEMENT C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 12 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 75 EP 80 PG 6 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200009 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Posterior Vitrectomy SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID 25-GAUGE VITREOUS CUTTERS; PARS-PLANA VITRECTOMY; ASSISTED LEVITATION; CATARACT-SURGERY; PHACOEMULSIFICATION; FRAGMENTS C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 13 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 81 EP 87 PG 7 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200010 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Endophthalmitis Following Cataract Surgery SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID INTRAOCULAR-LENS IMPLANTATION; OF-THE-LITERATURE; POSTOPERATIVE ENDOPHTHALMITIS; BACTERIAL ENDOPHTHALMITIS; STAPHYLOCOCCUS-AUREUS; INFECTIOUS ENDOPHTHALMITIS; INTRACAMERAL CEFUROXIME; INTRAVITREAL VANCOMYCIN; EUROPEAN MULTICENTER; AQUEOUS PENETRATION C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 48 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 89 EP 95 PG 7 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200011 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Cystoid Macular Edema Following Cataract Surgery SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID OPTICAL COHERENCE TOMOGRAPHY; ANTERIOR-CHAMBER LENS; IRVINE-GASS SYNDROME; DIABETIC-RETINOPATHY; IMPLANTATION; EFFICACY; PSEUDOPHAKIA; CEFUROXIME; EXTRACTION; VITRECTOMY C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 39 TC 0 Z9 0 U1 0 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 97 EP 101 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200012 ER PT B AU Buratto, L Brint, SF Romano, MR AF Buratto, Lucio Brint, Stephen F. Romano, Mario R. BA Burratto, L Brint, SF Romano, MR BF Burratto, L Brint, SF Romano, MR TI Complications in Cataract Surgery With Femtosecond Laser SO CATARACT SURGERY COMPLICATIONS LA English DT Article; Book Chapter ID IN-SITU KERATOMILEUSIS; INTRAOPERATIVE COMPLICATIONS; MICROKERATOME SUCTION; LASIK FLAPS; BENCHMARK; AUDIT; RING C1 [Buratto, Lucio] US FDA, Rockville, MD 20857 USA. [Buratto, Lucio] ESCRS, Paris, France. [Brint, Stephen F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA. [Brint, Stephen F.] Amer Coll Surg, Chicago, IL USA. [Romano, Mario R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Romano, Mario R.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England. [Romano, Mario R.] Ist Clin & Ric Humanitas, Vitreoretinal Serv, Milan, Italy. EM bookspublishing@wyanokegroup.com NR 19 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-608-7 PY 2013 BP 103 EP 107 PG 5 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BDO78 UT WOS:000314254200013 ER PT J AU Potts, JT AF Potts, John T., Jr. TI A Short History of Parathyroid Hormone, Its Biological Role, and Pathophysiology of Hormone Excess SO JOURNAL OF CLINICAL DENSITOMETRY LA English DT Article DE Parathyroid glands; parathyroid hormone; primary hyperparathyroidism ID AMINO-ACID-SEQUENCE; ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; TETANY; EXTRACTION; STATEMENT; WORKSHOP; CALCIUM AB Research on parathyroid hormone (PTH) over the preceding century was an exciting but sometimes confusing tale, with steady advances yet long periods of stalled progress, angry debates, and missed opportunities. There were sometimes fierce debates about the function of the parathyroids. These were finally resolved by 1925 when a potent biologic extract useful for testing in animals was finally made by Collip, and the role of PTH in calcium metabolism was established unequivocally. In the decades that followed, the pathophysiology of hormone excess (severe bone loss and other symptoms) was elucidated. Diagnosis can now be made with high reliability, even in the absence of clinical manifestation. The modern clinical profile of asymptomatic hyperparathyroidism is best described as a disorder in which there are neither signs nor symptoms traditionally associated with hypercalcemia or PTH excess. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Potts, JT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM Potts.john@mgh.harvard.edu NR 25 TC 3 Z9 3 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1094-6950 J9 J CLIN DENSITOM JI J. Clin. Densitom. PD JAN-MAR PY 2013 VL 16 IS 1 BP 4 EP 7 DI 10.1016/j.jocd.2012.11.002 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 093GA UT WOS:000315178500004 PM 23374734 ER PT J AU Dykes, PC Carroll, DL Hurley, AC Benoit, A Chang, F Pozzar, R Caligtan, CA AF Dykes, Patricia C. Carroll, Diane L. Hurley, Ann C. Benoit, Angela Chang, Frank Pozzar, Rachel Caligtan, Christine A. TI Building and Testing a Patient-Centric Electronic Bedside Communication Center SO JOURNAL OF GERONTOLOGICAL NURSING LA English DT Article ID ACUTE-CARE HOSPITALS; PREFERENCES; NEEDS; FALL AB In this article, the authors describe the development and pilot testing of an electronic bedside communication center (eBCC) prototype to improve access to health information for hospitalized adults and their family caregivers. Focus groups were used to identify improvements for the initial eBCC prototype developed by the research team. Face-to-face bedside interviews and questions were presented while patients used the eBCC for usability testing to drive further development. Qualitative methods within an iterative, participatory approach supported the development of an eBCC prototype that was considered both easy to use and helpful for accessing tailored patient information during an inpatient hospitalization to receive acute care. C1 [Dykes, Patricia C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Dykes, Patricia C.] Brigham & Womens Hosp, Ctr Patient Safety Res & Practice, Boston, MA 02115 USA. [Dykes, Patricia C.] Brigham & Womens Hosp, Dept Med, Ctr Nursing Excellence, Boston, MA 02115 USA. [Carroll, Diane L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pozzar, Rachel] Brigham & Womens Hosp, Boston, MA 02115 USA. [Benoit, Angela] Partners HealthCare, Wellesley, MA USA. [Caligtan, Christine A.] PatientsLikeMe, Cambridge, MA USA. RP Dykes, PC (reprint author), Brigham & Womens Hosp, Dept Med, Ctr Nursing Excellence, 75 Francis St, Boston, MA 02115 USA. EM pdykes@partners.org NR 12 TC 15 Z9 15 U1 4 U2 6 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0098-9134 J9 J GERONTOL NURS JI J. Gerontol. Nurs. PD JAN PY 2013 VL 39 IS 1 BP 15 EP 19 DI 10.3928/00989134-20121204-03 PG 5 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA 083GJ UT WOS:000314450600004 PM 23244060 ER PT J AU O'Byrne, KJ Sequist, LV Schuler, M Yamamoto, N Hirsh, V Mok, T Lungershausen, J Shahidi, M Palmer, M Yang, JCH AF O'Byrne, K. J. Sequist, L. V. Schuler, M. Yamamoto, N. Hirsh, V. Mok, T. Lungershausen, J. Shahidi, M. Palmer, M. Yang, J. C. -H. TI LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations SO LUNG CANCER LA English DT Meeting Abstract C1 [O'Byrne, K. J.] St James Hosp, Dublin 8, Ireland. [Sequist, L. V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Schuler, M.] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany. [Yamamoto, N.] Shizuoka Canc Ctr, Shizuoka, Japan. [Hirsh, V.] McGill Univ, Montreal, PQ, Canada. [Mok, T.] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Lungershausen, J.] Boehringer Ingelheim KG, Ingelheim, Germany. [Shahidi, M.] Boehringer Ingelheim Ltd, Bracknell, Berks, England. [Palmer, M.] Keele Univ, Keele ST5 5BG, Staffs, England. [Yang, J. C. -H.] Natl Taiwan Univ Hosp, Taipei, Taiwan. NR 0 TC 0 Z9 0 U1 0 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0169-5002 J9 LUNG CANCER JI Lung Cancer PD JAN PY 2013 VL 79 SU 1 MA 32 BP S11 EP S11 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 094BW UT WOS:000315239000033 ER PT J AU Liang, MR Wang, JC Chu, HY Zhu, XX He, H Liu, Q Qiu, JH Zhou, XD Guan, M Xue, Y Chen, XJ Zou, HJ AF Liang, Minrui Wang, Jiucun Chu, Haiyan Zhu, Xiaoxia He, Hang Liu, Qiong Qiu, Jianhua Zhou, Xiaodong Guan, Ming Xue, Yu Chen, Xiangjun Zou, Hejian TI Interleukin-22 Inhibits Bleomycin-Induced Pulmonary Fibrosis SO MEDIATORS OF INFLAMMATION LA English DT Article ID GROWTH-FACTOR-BETA; ALVEOLAR EPITHELIAL-CELLS; MESENCHYMAL TRANSITION; INNATE IMMUNITY; T-CELLS; IN-VIVO; IL-22; MYOFIBROBLAST; CYTOKINE; DIFFERENTIATION AB Pulmonary fibrosis is a progressive and fatal fibrotic disease of the lungs with unclear etiology. Recent insight has suggested that early injury/inflammation of alveolar epithelial cells could lead to dysregulation of tissue repair driven by multiple cytokines. Although dysregulation of interleukin-(IL-) 22 is involved in various pulmonary pathophysiological processes, the role of IL-22 in fibrotic lung diseases is still unclear and needs to be further addressed. Here we investigated the effect of IL-22 on alveolar epithelial cells in the bleomycin-(BLM-) induced pulmonary fibrosis. BLM-treated mice showed significantly decreased level of IL-22 in the lung. IL-22 produced . gamma delta T cells were also decreased significantly both in the tissues of lungs and spleens. Administration of recombinant human IL-22 to alveolar epithelial cell line A549 cells ameliorated epithelial to mesenchymal transition (EMT) and partially reversed the impaired cell viability induced by BLM. Furthermore, blockage of IL-22 deteriorated pulmonary fibrosis, with elevated EMT marker (alpha-smooth muscle actin (alpha-SMA)) and overactivated Smad2. Our results indicate that IL-22 may play a protective role in the development of BLM-induced pulmonary fibrosis and may suggest IL-22 as a novel immunotherapy tool in treating pulmonary fibrosis. C1 [Liang, Minrui; Zhu, Xiaoxia; Xue, Yu; Zou, Hejian] Fudan Univ, Huashan Hosp, Div Rheumatol, Shanghai 200040, Peoples R China. [Liang, Minrui; Wang, Jiucun; Chu, Haiyan; Zhu, Xiaoxia; Liu, Qiong; Guan, Ming; Xue, Yu; Chen, Xiangjun; Zou, Hejian] Fudan Univ, Inst Rheumatol Immunol & Allergy, Shanghai 200040, Peoples R China. [Wang, Jiucun; Chu, Haiyan] Fudan Univ, Minist Educ, Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China. [Wang, Jiucun; Chu, Haiyan] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China. [He, Hang] Fudan Univ, Huashan Hosp, Pancreat Dis Inst, Dept Pancreat Surg, Shanghai 200040, Peoples R China. [Liu, Qiong] Fudan Univ, Shanghai Med Coll, Dept Human Anat Histol & Embryol, Shanghai 200032, Peoples R China. [Qiu, Jianhua] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol & Radiol, Charlestown, MA 02129 USA. [Zhou, Xiaodong] Univ Texas Med Sch, Dept Internal Med, Div Rheumatol & Clin Immunogenet, Houston, TX 77030 USA. [Guan, Ming] Fudan Univ, Huashan Hosp, Dept Clin Lab, Shanghai 200040, Peoples R China. [Chen, Xiangjun] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai 200040, Peoples R China. RP Chen, XJ (reprint author), Fudan Univ, Inst Rheumatol Immunol & Allergy, Shanghai 200040, Peoples R China. EM xiangjunchen@hotmail.com; hjzou@fudan.edu.cn RI Wang, Jiucun/J-8744-2012 OI Wang, Jiucun/0000-0003-2765-0620 FU National Natural Science Foundation of China [81072463]; Project "211" of Fudan University [211Med-XZZD03] FX The authors also truly thank Mayes Maureen D (University of Texas-Houston Medical School) who revised the paper. This study was supported by Grants from the National Natural Science Foundation of China (no. 81072463) and Project "211" of Fudan University (no. 211Med-XZZD03). NR 33 TC 11 Z9 11 U1 2 U2 19 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0962-9351 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2013 AR 209179 DI 10.1155/2013/209179 PG 11 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 097XM UT WOS:000315506800001 ER PT J AU Barone, AAL Leonard, DA Torabi, R Mallard, C Glor, T Scalea, JR Randolph, MA Sachs, DH Cetrulo, CL AF Barone, Angelo A. Leto Leonard, David A. Torabi, Radbeh Mallard, Christopher Glor, Taylor Scalea, Joseph R. Randolph, Mark A. Sachs, David H. Cetrulo, Curtis L., Jr. TI The gracilis myocutaneous free flap in swine: An advantageous preclinical model for vascularized composite allograft transplantation research SO MICROSURGERY LA English DT Article ID TISSUE ALLOGRAFTS; OSTEOMYOCUTANEOUS FLAP; MINIATURE SWINE; BONE-MARROW; TOLERANCE; INDUCTION; ALLOTRANSPLANTATION; RECIPIENTS; CHIMERISM; FACE AB Vascularized composite allotransplantation (VCA) has become a clinical reality, prompting research aimed at improving the risk-benefit ratio of such transplants. Here, we report our experience with a gracilis myocutaneous free flap in Massachusetts General Hospital miniature swine as a preclinical VCA model. Fourteen animals underwent free transfer of a gracilis myocutaneous flap comprised of the gracilis muscle and overlying skin, each tissue supplied by independent branches of the femoral vessels. End-to-end anastomoses were performed to the common carotid artery and internal jugular vein, or to the femoral vessels of the recipients. Thirteen of fourteen flaps were successful. A single flap was lost due to compromise of venous outflow. This model allows transplantation of a substantial volume of skin, subcutaneous tissue, and muscle. The anatomy is reliable and easily identified and harvest incurs minimal donor morbidity. We find this gracilis myocutaneous flap an excellent pre-clinical model for the study of vascularized composite allotransplantation. (C) 2012 Wiley Periodicals, Inc. Microsurgery 33: 51-55,2013. C1 [Barone, Angelo A. Leto; Leonard, David A.; Torabi, Radbeh; Mallard, Christopher; Glor, Taylor; Scalea, Joseph R.; Sachs, David H.; Cetrulo, Curtis L., Jr.] Harvard Univ, Transplantat Biol Res Ctr, Sch Med, Massachusetts Gen Hosp, Boston, MA 02129 USA. [Barone, Angelo A. Leto; Leonard, David A.; Randolph, Mark A.; Cetrulo, Curtis L., Jr.] Harvard Univ, Div Plast & Reconstruct Surg, Sch Med, Massachusetts Gen Hosp, Boston, MA 02129 USA. RP Cetrulo, CL (reprint author), Harvard Univ, Transplantat Biol Res Ctr, Sch Med, Massachusetts Gen Hosp, MGH E,Bldg 149-9019,13th St, Boston, MA 02129 USA. EM ccetrulo@partners.org FU Melina Nakos Foundation; Musculoskeletal Transplant Foundation FX Grant sponsors: Melina Nakos Foundation; Musculoskeletal Transplant Foundation NR 25 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0738-1085 J9 MICROSURG JI Microsurgery PD JAN PY 2013 VL 33 IS 1 BP 51 EP 55 DI 10.1002/micr.21997 PG 5 WC Surgery SC Surgery GA 074KY UT WOS:000313812600009 ER PT J AU Cormier, J Chu, CJ AF Cormier, Justine Chu, Catherine J. TI Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age SO NEUROPSYCHIATRIC DISEASE AND TREATMENT LA English DT Review DE levetiracetam; anticonvulsant drug; partial seizures; pediatric epilepsy ID TUBEROUS SCLEROSIS COMPLEX; PLACEBO-CONTROLLED TRIAL; OPEN-LABEL EXTENSION; VESICLE PROTEIN 2A; SLOW-WAVE SLEEP; INTRAVENOUS LEVETIRACETAM; ADJUNCTIVE LEVETIRACETAM; ANTIEPILEPTIC DRUGS; REFRACTORY EPILEPSY; CENTROTEMPORAL SPIKES AB Epilepsy is a common neurological disorder in the pediatric population, affecting up to one percent of children, and for which the mainstay of treatment is anticonvulsant medication. Despite the frequent use of anticonvulsant drugs, remarkably little is known about the safety and efficacy of most of these medications in the pediatric epilepsy population. Of 34 anticonvulsants currently approved for use by the US Food and Drug Administration (FDA), only 13 have been approved for use in children. Although infants and young children are disproportionately affected by epilepsy, there are currently only three anticonvulsant medications that have been specifically evaluated and approved for use in children younger than 2 years of age. In 2012, the FDA approved levetiracetam as an adjunctive treatment for partial onset seizures in infants and children from one month of age. Here we review the available data on levetiracetam in the pediatric epilepsy population. We first discuss the pharmacological profile of levetiracetam, including its mechanism of action, formulations and dosing, and pharmacokinetics in children. We then review the available efficacy, safety, and tolerability data in children from one month of age with partial onset seizures. We conclude that the current data leading to the approval of levetiracetam for use in infants and children with partial onset seizures is encouraging, although more work needs to be done before definitive conclusions can be drawn about the efficacy of levetiracetam across different pediatric age groups. C1 [Chu, Catherine J.] Massachusetts Gen Hosp, Dept Neurol, Program Child Neurol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neurol, Program Neurophysiol, Boston, MA 02114 USA. RP Chu, CJ (reprint author), 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM cchu3@partners.org FU NINDS NIH HHS [K12 NS066225] NR 79 TC 8 Z9 9 U1 0 U2 9 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-6328 J9 NEUROPSYCH DIS TREAT JI Neuropsychiatr. Dis. Treat. PY 2013 VL 9 BP 295 EP 306 DI 10.2147/NDT.S30224 PG 12 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 094SI UT WOS:000315283700001 PM 23458993 ER PT J AU Ng, SK Lyatskaya, Y Stsepankou, D Hesser, J Bellon, JR Wong, JS Zygmanski, P AF Ng, Sook Kien Lyatskaya, Yulia Stsepankou, Dzmitry Hesser, Jurgen Bellon, Jennifer R. Wong, Julia S. Zygmanski, Piotr TI Automation of clip localization in Digital Tomosynthesis for setup of breast cancer patients SO PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS LA English DT Article DE Breast; Patient setup; Digital Tomosynthesis; CBCT ID RECONSTRUCTION; RADIOTHERAPY; IRRADIATION; TOMOGRAPHY AB The objective of this study is to develop an automatic clip localization procedure for breast cancer patient setup based on Digital Tomosynthesis (DTS) and to characterize its performance with respect to the overall registration accuracy and robustness. The study was performed under an IRB-approved protocol for 12 breast cancer patients with surgical clips implanted around the tumor cavity. The registration of DTS images to planning CTs was performed using an automatic algorithm developed to overcome specific challenges of localization and registration of clips in the breast setup images. The automatic method consisted of auto-segmentation (intensity-based thresholding with a priori knowledge about clip size and location to distinguish clips from bony features) and auto-registration of the segmented clip clusters. To determine the inherent accuracy and robustness of the registration algorithm, additional simulated DTS data was analyzed. The developed algorithm is efficient in removing false positives and negatives and provides an accuracy of better than 2.3 mm for 60 degrees and 3.3 mm for 40 degrees DTS. When incorporated in clinical software, this algorithm helps to facilitate fast and accurate setup evaluation with minimal dose delivered to patients. (C) 2011 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved. C1 [Ng, Sook Kien; Lyatskaya, Yulia; Bellon, Jennifer R.; Wong, Julia S.; Zygmanski, Piotr] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Ng, Sook Kien; Lyatskaya, Yulia; Bellon, Jennifer R.; Wong, Julia S.; Zygmanski, Piotr] Harvard Univ, Sch Med, Dana Faber Canc Inst, Boston, MA 02115 USA. [Ng, Sook Kien; Stsepankou, Dzmitry; Hesser, Jurgen] Heidelberg Univ, Mannheim Med Ctr, Dept Radiat Oncol, Mannheim, Germany. RP Ng, SK (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,ASBI L2, Boston, MA 02115 USA. EM sook_ng@dfci.harvard.edu FU Kaye's Scholars Grant FX The authors would like to acknowledge the Kaye's Scholars Grant for the support of this research project. NR 14 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1120-1797 J9 PHYS MEDICA JI Phys. Medica PD JAN PY 2013 VL 29 IS 1 BP 75 EP 82 DI 10.1016/j.ejmp.2011.12.001 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 095WW UT WOS:000315366700009 PM 22206908 ER PT J AU Stanley, SA Grant, SS Barczak, AK Hung, DT AF Stanley, Sarah A. Grant, Sarah S. Barczak, Amy K. Hung, Deborah T. TI High-throughput screening approaches to TB drug discovery SO TUBERCULOSIS LA English DT Meeting Abstract C1 [Stanley, Sarah A.; Grant, Sarah S.; Barczak, Amy K.; Hung, Deborah T.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Grant, Sarah S.] Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA. [Barczak, Amy K.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD JAN PY 2013 VL 93 IS 1 BP 110 EP 110 PG 1 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA 094UC UT WOS:000315288300023 ER PT J AU Cayabyab, MJ Qin, LZ Kashino, SS Campos-Neto, A AF Cayabyab, Mark J. Qin, Lizeng Kashino, Suely S. Campos-Neto, Antonio TI Trailing CD8+T cell vaccine development for TB SO TUBERCULOSIS LA English DT Meeting Abstract C1 [Cayabyab, Mark J.; Qin, Lizeng; Kashino, Suely S.; Campos-Neto, Antonio] Forsyth Inst, Cambridge, MA 02142 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD JAN PY 2013 VL 93 IS 1 BP 113 EP 113 PG 1 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA 094UC UT WOS:000315288300033 ER PT J AU McKee, AC Stein, TD Nowinski, CJ Stern, RA Daneshvar, DH Alvarez, VE Lee, HS Hall, G Wojtowicz, SM Baugh, CM Riley, DO Kubilus, CA Cormier, KA Jacobs, MA Martin, BR Abraham, CR Ikezu, T Reichard, RR Wolozin, BL Budson, AE Goldstein, LE Kowall, NW Cantu, RC AF McKee, Ann C. Stein, Thor D. Nowinski, Christopher J. Stern, Robert A. Daneshvar, Daniel H. Alvarez, Victor E. Lee, Hyo-Soon Hall, Garth Wojtowicz, Sydney M. Baugh, Christine M. Riley, David O. Kubilus, Caroline A. Cormier, Kerry A. Jacobs, Matthew A. Martin, Brett R. Abraham, Carmela R. Ikezu, Tsuneya Reichard, Robert Ross Wolozin, Benjamin L. Budson, Andrew E. Goldstein, Lee E. Kowall, Neil W. Cantu, Robert C. TI The spectrum of disease in chronic traumatic encephalopathy SO BRAIN LA English DT Article DE axonal injury; brain trauma; frontotemporal lobar degeneration; neurodegenerative disorders; traumatic brain injury ID FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMER-RELATED CHANGES; REPETITIVE HEAD-INJURY; FOOTBALL-LEAGUE PLAYER; NEUROPATHOLOGIC ASSESSMENT; DEMENTIA-PUGILISTICA; NATIONAL INSTITUTE; PARKINSON-DISEASE; BRAIN TRAUMA AB Chronic traumatic encephalopathy is a progressive tauopathy that occurs as a consequence of repetitive mild traumatic brain injury. We analysed post-mortem brains obtained from a cohort of 85 subjects with histories of repetitive mild traumatic brain injury and found evidence of chronic traumatic encephalopathy in 68 subjects: all males, ranging in age from 17 to 98 years (mean 59.5 years), including 64 athletes, 21 military veterans (86% of whom were also athletes) and one individual who engaged in self-injurious head banging behaviour. Eighteen age- and gender-matched individuals without a history of repetitive mild traumatic brain injury served as control subjects. In chronic traumatic encephalopathy, the spectrum of hyperphosphorylated tau pathology ranged in severity from focal perivascular epicentres of neurofibrillary tangles in the frontal neocortex to severe tauopathy affecting widespread brain regions, including the medial temporal lobe, thereby allowing a progressive staging of pathology from stages I-IV. Multifocal axonal varicosities and axonal loss were found in deep cortex and subcortical white matter at all stages of chronic traumatic encephalopathy. TAR DNA-binding protein 43 immunoreactive inclusions and neurites were also found in 85% of cases, ranging from focal pathology in stages I-III to widespread inclusions and neurites in stage IV. Symptoms in stage I chronic traumatic encephalopathy included headache and loss of attention and concentration. Additional symptoms in stage II included depression, explosivity and short-term memory loss. In stage III, executive dysfunction and cognitive impairment were found, and in stage IV, dementia, word-finding difficulty and aggression were characteristic. Data on athletic exposure were available for 34 American football players; the stage of chronic traumatic encephalopathy correlated with increased duration of football play, survival after football and age at death. Chronic traumatic encephalopathy was the sole diagnosis in 43 cases (63%); eight were also diagnosed with motor neuron disease (12%), seven with Alzheimer's disease (11%), 11 with Lewy body disease (16%) and four with frontotemporal lobar degeneration (6%). There is an ordered and predictable progression of hyperphosphorylated tau abnormalities through the nervous system in chronic traumatic encephalopathy that occurs in conjunction with widespread axonal disruption and loss. The frequent association of chronic traumatic encephalopathy with other neurodegenerative disorders suggests that repetitive brain trauma and hyperphosphorylated tau protein deposition promote the accumulation of other abnormally aggregated proteins including TAR DNA-binding protein 43, amyloid beta protein and alpha-synuclein. C1 [McKee, Ann C.; Stein, Thor D.; Wojtowicz, Sydney M.; Cormier, Kerry A.; Budson, Andrew E.; Kowall, Neil W.] VA Boston Healthcare Syst, US Dept Vet Affairs, Boston, MA 02130 USA. [McKee, Ann C.; Nowinski, Christopher J.; Stern, Robert A.; Daneshvar, Daniel H.; Alvarez, Victor E.; Wojtowicz, Sydney M.; Baugh, Christine M.; Riley, David O.; Jacobs, Matthew A.; Cantu, Robert C.] Boston Univ, Ctr Study Traumat Encephalopathy, Sch Med, Boston, MA 02118 USA. [McKee, Ann C.; Stern, Robert A.; Lee, Hyo-Soon; Kubilus, Caroline A.; Abraham, Carmela R.; Ikezu, Tsuneya; Wolozin, Benjamin L.; Budson, Andrew E.; Goldstein, Lee E.; Kowall, Neil W.] Boston Univ, Alzheimers Dis Ctr, Sch Med, Boston, MA 02118 USA. [McKee, Ann C.; Nowinski, Christopher J.; Stern, Robert A.; Daneshvar, Daniel H.; Alvarez, Victor E.; Lee, Hyo-Soon; Baugh, Christine M.; Riley, David O.; Kubilus, Caroline A.; Jacobs, Matthew A.; Ikezu, Tsuneya; Wolozin, Benjamin L.; Budson, Andrew E.; Goldstein, Lee E.; Kowall, Neil W.] Boston Univ, Dept Neurol, Sch Med, Boston, MA 02118 USA. [McKee, Ann C.; Stein, Thor D.; Kowall, Neil W.] Boston Univ, Dept Pathol, Sch Med, Boston, MA 02118 USA. [Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Waltham, MA 02451 USA. [Stern, Robert A.; Cantu, Robert C.] Boston Univ, Dept Neurosurg, Sch Med, Boston, MA 02118 USA. [Hall, Garth] Univ Massachusetts, Dept Biol Sci, Lowell, MA 01854 USA. [Martin, Brett R.] Boston Univ, Data Coordinating Ctr, Sch Publ Hlth, Boston, MA 02118 USA. [Abraham, Carmela R.] Boston Univ, Dept Biochem, Sch Med, Boston, MA 02118 USA. [Ikezu, Tsuneya; Wolozin, Benjamin L.] Boston Univ, Dept Pharmacol, Sch Med, Boston, MA 02118 USA. [Reichard, Robert Ross; Goldstein, Lee E.] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA. [Goldstein, Lee E.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02118 USA. [Goldstein, Lee E.] Boston Univ, Dept Opthamol, Sch Med, Boston, MA 02118 USA. [Goldstein, Lee E.] Boston Univ, Dept Biomed Engn, Sch Med, Boston, MA 02118 USA. [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA. RP McKee, AC (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave,151-C, Boston, MA 02130 USA. EM ann.mckee@va.gov RI Kowall, Neil/G-6364-2012; OI Kowall, Neil/0000-0002-6624-0213; Daneshvar, Daniel/0000-0003-3691-9513; Stein, Thor/0000-0001-6954-4477; Stern, Robert/0000-0002-5008-077X FU Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Aging Boston University Alzheimer's Disease Center [P30 AG13846, 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study [AG1649]; National Institute of Neurological Disorders and Stroke, National Institute of Aging, National Institute of Child Health and Human Development [NS078337]; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment FX The Department of Veterans Affairs; Veterans Affairs Biorepository (CSP 501); Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C to A. M.); National Institute of Aging Boston University Alzheimer's Disease Center [P30 AG13846 to N.W.K.; supplement 0572063345-5 to A. C. M., R. A. S.]; National Institute of Aging Boston University Framingham Heart Study R01 [AG1649]; National Institute of Neurological Disorders and Stroke, National Institute of Aging, National Institute of Child Health and Human Development R01 [NS078337 to R. A. S.]; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment, and the resources and use of facilities at the Edith Nourse Rogers Memorial Veterans Hospital in Bedford, MA. This work was also supported by an unrestricted gift from the National Football League. The funding sources were not involved in the preparation, review or approval of this manuscript. NR 82 TC 423 Z9 424 U1 24 U2 184 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD JAN PY 2013 VL 136 BP 43 EP 64 DI 10.1093/brain/aws307 PN 1 PG 22 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 089KR UT WOS:000314909900006 PM 23208308 ER PT J AU Totonchy, MB Tamura, D Pantell, MS Zalewski, C Bradford, PT Merchant, SN Nadol, J Khan, SG Schiffmann, R Pierson, TM Wiggs, E Griffith, AJ DiGiovanna, JJ Kraemer, KH Brewer, CC AF Totonchy, Mariam B. Tamura, Deborah Pantell, Matthew S. Zalewski, Christopher Bradford, Porcia T. Merchant, Saumil N. Nadol, Joseph Khan, Sikandar G. Schiffmann, Raphael Pierson, Tyler Mark Wiggs, Edythe Griffith, Andrew J. DiGiovanna, John J. Kraemer, Kenneth H. Brewer, Carmen C. TI Auditory analysis of xeroderma pigmentosum 1971-2012: hearing function, sun sensitivity and DNA repair predict neurological degeneration SO BRAIN LA English DT Article DE xeroderma pigmentosum; sensorineural hearing loss; neurodegeneration; photosensitivity; DNA repair ID COCKAYNE-SYNDROME; TRICHOTHIODYSTROPHY; DISEASE; MANIFESTATIONS; ABNORMALITIES; PHENOTYPE; SYMPTOMS; MUTATION; DEAFNESS; DAMAGE AB To assess the role of DNA repair in maintenance of hearing function and neurological integrity, we examined hearing status, neurological function, DNA repair complementation group and history of acute burning on minimal sun exposure in all patients with xeroderma pigmentosum, who had at least one complete audiogram, examined at the National Institutes of Health from 1971 to 2012. Seventy-nine patients, aged 1-61 years, were diagnosed with xeroderma pigmentosum (n = 77) or xeroderma pigmentosum/Cockayne syndrome (n = 2). A total of 178 audiograms were included. Clinically significant hearing loss (> 20 dB) was present in 23 (29%) of 79 patients. Of the 17 patients with xeroderma pigmentosum-type neurological degeneration, 13 (76%) developed hearing loss, and all 17 were in complementation groups xeroderma pigmentosum type A or type D and reported acute burning on minimal sun exposure. Acute burning on minimal sun exposure without xeroderma pigmentosum-type neurological degeneration was present in 18% of the patients (10/55). Temporal bone histology in a patient with severe xeroderma pigmentosum-type neurological degeneration revealed marked atrophy of the cochlear sensory epithelium and neurons. The 19-year mean age of detection of clinically significant hearing loss in the patients with xeroderma pigmentosum with xeroderma pigmentosum-type neurological degeneration was 54 years younger than that predicted by international norms. The four frequency (0.5/1/2/4 kHz) pure-tone average correlated with degree of neurodegeneration (P < 0.001). In patients with xeroderma pigmentosum, aged 4-30 years, a four-frequency pure-tone average epsilon 10 dB hearing loss was associated with a 39-fold increased risk (P = 0.002) of having xeroderma pigmentosum-type neurological degeneration. Severity of hearing loss parallels neurological decline in patients with xeroderma pigmentosum-type neurological degeneration. Audiometric findings, complementation group, acute burning on minimal sun exposure and age were important predictors of xeroderma pigmentosum-type neurological degeneration. These results provide evidence that DNA repair is critical in maintaining neurological integrity of the auditory system. C1 [Totonchy, Mariam B.; Tamura, Deborah; Khan, Sikandar G.; DiGiovanna, John J.; Kraemer, Kenneth H.] NCI, Dermatol Branch, Bethesda, MD 20892 USA. [Totonchy, Mariam B.; Pantell, Matthew S.] NIH, Clin Res Training Programme, Bethesda, MD 20892 USA. [Pantell, Matthew S.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Zalewski, Christopher; Griffith, Andrew J.; Brewer, Carmen C.] Natl Inst Deafness & Other Commun Disorders, Otolaryngol Branch, Bethesda, MD 20892 USA. [Bradford, Porcia T.] NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Merchant, Saumil N.; Nadol, Joseph] Harvard Univ, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. [Schiffmann, Raphael; Pierson, Tyler Mark; Wiggs, Edythe] NINDS, Bethesda, MD 20892 USA. RP Kraemer, KH (reprint author), NCI, Dermatol Branch, Bldg 37,Room 4002, Bethesda, MD 20892 USA. EM Kraemerk@nih.gov FU Center for Cancer Research, National Cancer Institute; Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Institute on Deafness and Other Communication Disorders (NIDCD); National Institute of Aging; National Institutes of Health; NIDCD [1U24DC011943-01]; Pfizer Inc FX Intramural Research Programs of the Center for Cancer Research, National Cancer Institute (M.B.T., D.T., S.G.K., J.J.D. and K.H.K.), of the Division of Cancer Epidemiology and Genetics, National Cancer Institute (P.T.B.), of the National Institute on Deafness and Other Communication Disorders (NIDCD) (C.Z., A.J.G. and C.C.B.) and of the National Institute of Aging (M. S. P.) of the National Institutes of Health and from NIDCD (1U24DC011943-01 to S.M. and J.N.). Clinical Research Training Program (to M.B.T. and M.S.P.), a public-private partnership supported jointly by the National Institutes of Health and Pfizer Inc (via a grant to the Foundation for National Institutes of Health from Pfizer Inc). NR 45 TC 14 Z9 14 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD JAN PY 2013 VL 136 BP 194 EP 208 DI 10.1093/brain/aws317 PN 1 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 089KR UT WOS:000314909900016 PM 23365097 ER PT J AU Wayne, PM Manor, B Novak, V Costa, MD Hausdorff, JM Goldberger, AL Ahn, AC Yeh, GY Peng, CK Lough, M Davis, RB Quilty, MT Lipsitz, LA AF Wayne, Peter M. Manor, Brad Novak, Vera Costa, Madelena D. Hausdorff, Jeffrey M. Goldberger, Ary L. Ahn, Andrew C. Yeh, Gloria Y. Peng, C. -K. Lough, Matthew Davis, Roger B. Quilty, Mary T. Lipsitz, Lewis A. TI A systems biology approach to studying Tai Chi, physiological complexity and healthy aging: Design and rationale of a pragmatic randomized controlled trial SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Cardiovascular health; Postural control; Gait; Mind-body exercise; Senescence; Prevention ID HEART-RATE DYNAMICS; ACUTE MYOCARDIAL-INFARCTION; MINI-MENTAL-STATE; PLANTAR PRESSURE DISTRIBUTION; LEFT-VENTRICULAR FUNCTION; RATE MULTISCALE ENTROPY; LONG-RANGE CORRELATIONS; WORD-ASSOCIATION TEST; OLDER-ADULTS; POSTURAL CONTROL AB Introduction: Aging is typically associated with progressive multi-system impairment that leads to decreased physical and cognitive function and reduced adaptability to stress. Due to its capacity to characterize complex dynamics within and between physiological systems, the emerging field of complex systems biology and its array of quantitative tools show great promise for improving our understanding of aging, monitoring senescence, and providing biomarkers for evaluating novel interventions, including promising mind-body exercises, that treat age-related disease and promote healthy aging. Material and methods: An ongoing, two-arm randomized clinical trial is evaluating the potential of Tai Chi mind-body exercise to attenuate age-related loss of complexity. A total of 60 Tai Chi-naive healthy older adults (aged 50-79) are being randomized to either six months of Tai Chi training (n = 30), or to a waitlist control receiving unaltered usual medical care (n = 30). Our primary outcomes are complexity-based measures of heart rate, standing postural sway and gait stride interval dynamics assessed at 3 and 6 months. Multiscale entropy and detrended fluctuation analysis are used as entropy- and fractal-based measures of complexity, respectively. Secondary outcomes include measures of physical and psychological function and tests of physiological adaptability also assessed at 3 and 6 months. Discussion: Results of this study may lead to novel biomarkers that help us monitor and understand the physiological processes of aging and explore the potential benefits of Tai Chi and related mind-body exercises for healthy aging. (c) 2012 Elsevier Inc. All rights reserved. C1 [Wayne, Peter M.; Quilty, Mary T.] Brigham & Womens Hosp, Osher Ctr Integrat Med, Boston, MA 02215 USA. [Wayne, Peter M.; Manor, Brad; Novak, Vera; Costa, Madelena D.; Goldberger, Ary L.; Ahn, Andrew C.; Yeh, Gloria Y.; Davis, Roger B.; Quilty, Mary T.; Lipsitz, Lewis A.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Manor, Brad; Novak, Vera; Lipsitz, Lewis A.] Beth Israel Deaconess Med Ctr, Dept Gerontol, Boston, MA 02215 USA. [Costa, Madelena D.; Goldberger, Ary L.; Peng, C. -K.] Beth Israel Deaconess Med Ctr, Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA. [Hausdorff, Jeffrey M.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Sackler Sch Med, Movement Disorders Unit, IL-69978 Tel Aviv, Israel. [Ahn, Andrew C.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Ahn, Andrew C.; Yeh, Gloria Y.; Davis, Roger B.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. [Peng, C. -K.] Natl Cent Univ, Ctr Dynam Biomarkers & Translat Med, Chungli 32054, Taiwan. [Lough, Matthew; Lipsitz, Lewis A.] Hebrew SeniorLife, Inst Aging Res, Roslindale, MA USA. RP Wayne, PM (reprint author), Brigham & Womens Hosp, Div Prevent Med, Osher Ctr Integrat Med, 900 Commonwealth Ave,3rd Fl, Boston, MA 02215 USA. EM pwayne@partners.org; bmanor@bidmc.harvard.edu; vnovak@bidmc.harvard.edu; mcosta3@bidmc.harvard.edu; jhausdor@bidmc.harvard.edu; agoldber@caregroup.harvard.edu; aahn1@partners.org; gyeh@bidmc.harvard.edu; cpeng@bidmc.harvard.edu; matthewlough@hsl.harvard.edu; rdavis@bidmc.harvard.edu; mquilty@hsph.harvard.edu; lipsitz@hsl.harvard.edu RI Peng, Chung-Kang/E-1489-2011 OI Peng, Chung-Kang/0000-0003-3666-9833 FU National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) [R21 AT005501-01A1]; National Center for Research Resources (NCRR) [UL1 RR025758] FX This publication was made possible by grant number R21 AT005501-01A1 from the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH), and from grant number UL1 RR025758 supporting the Harvard Clinical and Translational Science Center, from the National Center for Research Resources (NCRR). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, NCRR, or the NIH. We thank Jacqueline Walsh and Danielle Berkowitz for research assistance. NR 162 TC 11 Z9 11 U1 3 U2 30 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD JAN PY 2013 VL 34 IS 1 BP 21 EP 34 DI 10.1016/j.cct.2012.09.006 PG 14 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 083FO UT WOS:000314448300003 PM 23026349 ER PT J AU Zakeri, K Rose, BS Gulaya, S D'Amico, AV Mell, LK AF Zakeri, Kaveh Rose, Brent S. Gulaya, Sachin D'Amico, Anthony V. Mell, Loren K. TI Competing event risk stratification may improve the design and efficiency of clinical trials: Secondary analysis of SWOG 8794 SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Prostate cancer; Competing risks; Competing mortality; Radiation therapy ID END-POINTS; ADJUVANT RADIOTHERAPY; REGRESSION-MODELS; PROSTATE-CANCER; NECK-CANCER; SAMPLE-SIZE; DEFINITIONS; FAILURE; HEAD AB Background: Composite endpoints can be problematic in the presence of competing risks when a treatment does not affect events comprising the endpoint equally. Methods: We conducted secondary analysis of SWOG 8794 trial of adjuvant radiation therapy (RT) for high-risk post-operative prostate cancer. The primary outcome was metastasis-free survival (MFS), defined as time to first occurrence of metastasis or death from any cause (competing mortality (CM)). We developed separate risk scores for time to metastasis and CM using competing risks regression. We estimated treatment effects using Cox models adjusted for risk scores and identified an enriched subgroup of 75 patients at high risk of metastasis and low risk of CM. Results: The mean CM risk score was significantly lower in the RT arm vs. control arm (p = 0.001). The effect of RT on MFS (HR 0.70; 95% CI, 0.53-0.92; p = 0.010) was attenuated when controlling for metastasis and CM risk (HR 0.76; 95% CI, 0.58-1.00; p = 0.049), and the effect of RI on overall survival (HR 0.73; 95% CI, 0.55-0.96; p = 0.02) was no longer significant when controlling for metastasis and CM risk (HR 0.80; 95% CI, 0.60-1.06; p = 0.12). Compared to the whole sample, the enriched subgroup had the same 10-year incidence of MFS (40%; 95% CI, 22-57%), but a higher incidence of metastasis (30% (95% CI, 15-47%) vs. 20% (95% CI, 15-26%)). A randomized trial in the subgroup would have achieved 80% power with 56% less patients (313 vs. 709, respectively). Conclusion: Stratification on competing event risk may improve the efficiency of clinical trials. (c) 2012 Elsevier Inc. All rights reserved. C1 [Zakeri, Kaveh; Gulaya, Sachin; Mell, Loren K.] Univ Calif San Diego, Dept Radiat Med & Appl Sci, La Jolla, CA 92093 USA. [Rose, Brent S.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA. [D'Amico, Anthony V.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [D'Amico, Anthony V.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Mell, LK (reprint author), Univ Calif San Diego, Dept Radiat Med & Appl Sci, 3855 Hlth Sci Dr,MC0843, La Jolla, CA 92093 USA. EM lmell@ucsd.edu OI Mell, Loren/0000-0003-2277-6080 FU NCRR NIH HHS [T32 RR023254] NR 18 TC 9 Z9 9 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD JAN PY 2013 VL 34 IS 1 BP 74 EP 79 DI 10.1016/j.cct.2012.09.008 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 083FO UT WOS:000314448300010 PM 23063467 ER PT J AU Elena, JW Travis, LB Simonds, NI Ambrosone, CB Ballard-Barbash, R Bhatia, S Cerhan, JR Hartge, P Heist, RS Kushi, LH Lash, TL Morton, LM Onel, K Pierce, JP Robison, LL Rowland, JH Schrag, D Sellers, TA Seminara, D Shu, XO Thomas, NE Ulrich, CM Freedman, AN AF Elena, Joanne W. Travis, Lois B. Simonds, Naoko I. Ambrosone, Christine B. Ballard-Barbash, Rachel Bhatia, Smita Cerhan, James R. Hartge, Patricia Heist, Rebecca S. Kushi, Lawrence H. Lash, Timothy L. Morton, Lindsay M. Onel, Kenan Pierce, John P. Robison, Leslie L. Rowland, Julia H. Schrag, Deborah Sellers, Thomas A. Seminara, Daniela Shu, Xiao Ou Thomas, Nancy E. Ulrich, Cornelia M. Freedman, Andrew N. TI Leveraging Epidemiology and Clinical Studies of Cancer Outcomes: Recommendations and Opportunities for Translational Research SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID LONG-TERM SURVIVORS; 2ND MALIGNANT NEOPLASMS; DISEASE-FREE SURVIVAL; ACUTE LYMPHOBLASTIC-LEUKEMIA; TREATMENT-RELATED TOXICITY; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; BREAST-CANCER; COLORECTAL-CANCER; TESTICULAR-CANCER AB As the number of cancer survivors continues to grow, research investigating the factors that affect cancer outcomes, such as disease recurrence, risk of second malignant neoplasms, and the late effects of cancer treatments, becomes ever more important. Numerous epidemiologic studies have investigated factors that affect cancer risk, but far fewer have addressed the extent to which demographic, lifestyle, genomic, clinical, and psychosocial factors influence cancer outcomes. To identify research priorities as well as resources and infrastructure needed to advance the field of cancer outcomes and survivorship research, the National Cancer Institute sponsored a workshop titled "Utilizing Data from Cancer Survivor Cohorts: Understanding the Current State of Knowledge and Developing Future Research Priorities" on November 3, 2011, in Washington, DC. This commentary highlights recent findings presented at the workshop, opportunities to leverage existing data, and recommendations for future research, data, and infrastructure needed to address high priority clinical and research questions. Multidisciplinary teams that include epidemiologists, clinicians, biostatisticians, and bioinformaticists will be essential to facilitate future cancer outcome studies focused on improving clinical care of cancer patients, identifying those at high risk of poor outcomes, and implementing effective interventions to ultimately improve the quality and duration of survival. J Natl Cancer Inst ;2013;105:85-94 C1 [Elena, Joanne W.; Simonds, Naoko I.; Ballard-Barbash, Rachel; Seminara, Daniela; Freedman, Andrew N.] NCI, Div Canc Control & Populat Sci, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Hartge, Patricia; Morton, Lindsay M.] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Travis, Lois B.] Univ Rochester, Med Ctr, Rubin Ctr Canc Survivorship, Rochester, NY 14642 USA. [Travis, Lois B.] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA. [Ambrosone, Christine B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA. [Bhatia, Smita] City Hope Natl Med Ctr, Dept Populat Sci, Duarte, CA USA. [Cerhan, James R.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Heist, Rebecca S.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Kushi, Lawrence H.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Lash, Timothy L.] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark. [Lash, Timothy L.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Onel, Kenan] Univ Chicago, Dept Pediat, Sect Hematol Oncol, Chicago, IL 60637 USA. [Pierce, John P.] Univ Calif San Diego, Moores UCSD Canc Ctr, La Jolla, CA 92093 USA. [Robison, Leslie L.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA. [Schrag, Deborah] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Dept Adult Oncol, Boston, MA 02115 USA. [Sellers, Thomas A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Shu, Xiao Ou] Vanderbilt Univ, Med Ctr, Dept Med, Div Epidemiol, Nashville, TN USA. [Shu, Xiao Ou] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Thomas, Nancy E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Ulrich, Cornelia M.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Ulrich, Cornelia M.] German Canc Res Ctr, Heidelberg, Germany. [Ulrich, Cornelia M.] Natl Ctr Tumor Dis, Heidelberg, Germany. RP Elena, JW (reprint author), Clin & Translat Epidemiol Branch, DCCPS 6130 Execut Blvd,Rm 5136, Bethesda, MD 20892 USA. EM elenajw@mail.nih.gov RI Morton, Lindsay/B-5234-2015; OI Morton, Lindsay/0000-0001-9767-2310; Cerhan, James/0000-0002-7482-178X; Kushi, Lawrence/0000-0001-9136-1175 NR 74 TC 25 Z9 25 U1 1 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD JAN PY 2013 VL 105 IS 2 BP 85 EP 94 DI 10.1093/jnci/djs473 PG 10 WC Oncology SC Oncology GA 088VK UT WOS:000314865100006 PM 23197494 ER PT J AU Bao, Y Giovannucci, EL Kraft, P Stampfer, MJ Ogino, S Ma, J Buring, JE Sesso, HD Lee, IM Gaziano, JM Rifai, N Pollak, MN Cochrane, BB Kaklamani, V Lin, JH Manson, JE Fuchs, CS Wolpin, BM AF Bao, Ying Giovannucci, Edward L. Kraft, Peter Stampfer, Meir J. Ogino, Shuji Ma, Jing Buring, Julie E. Sesso, Howard D. Lee, I-Min Gaziano, John Michael Rifai, Nader Pollak, Michael N. Cochrane, Barbara B. Kaklamani, Virginia Lin, Jennifer H. Manson, JoAnn E. Fuchs, Charles S. Wolpin, Brian M. TI A Prospective Study of Plasma Adiponectin and Pancreatic Cancer Risk in Five US Cohorts SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID MOLECULAR-WEIGHT ADIPONECTIN; RANDOMIZED CONTROLLED-TRIAL; INSULIN-RESISTANCE; WOMENS HEALTH; INFLAMMATORY MARKERS; POSTMENOPAUSAL WOMEN; DIABETES-MELLITUS; GLUCOSE-TOLERANCE; PHYSICAL-ACTIVITY; PROSTATE-CANCER AB Background The adipocyte-secreted hormone adiponectin has insulin-sensitizing and anti-inflammatory properties. Although development of pancreatic cancer is associated with states of insulin resistance and chronic inflammation, the mechanistic basis of the associations is poorly understood. Methods To determine whether prediagnostic plasma levels of adiponectin are associated with risk of pancreatic cancer, we conducted a nested case-control study of 468 pancreatic cancer case subjects and 1080 matched control subjects from five prospective US cohorts: Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. Control subjects were matched to case subjects by prospective cohort, year of birth, smoking status, fasting status, and month of blood draw. All samples for plasma adiponectin were handled identically in a single batch. Odds ratios were calculated with conditional logistic regression, and linearity of the association between adiponectin and pancreatic cancer was modeled with restricted cubic spline regression. All statistical tests were two-sided. Results Median plasma adiponectin was lower in case subjects versus control subjects (6.2 vs 6.8 mu g/mL, P = .009). Plasma adiponectin was inversely associated with pancreatic cancer risk, which was consistent across the five prospective cohorts (P-heterogeneity = .49) and independent of other markers of insulin resistance (eg, diabetes, body mass index, physical activity, plasma C-peptide). Compared with the lowest quintile of adiponectin, individuals in quintiles 2 to 5 had multivariable odds ratios ([ORs] 95% confidence intervals [CIs]) of OR = 0.61 (95% CI = 0.43 to 0.86), OR = 0.58 (95% CI = 0.41 to 0.84), OR = 0.59 (95% CI = 0.40 to 0.87), and OR = 0.66 (95% CI = 0.44 to 0.97), respectively (P-trend = .04). Restricted cubic spline regression confirmed a nonlinear association (P-nonlinearity < .01). The association was not modified by sex, smoking, body mass index, physical activity, or C-peptide (all P-interaction > .10). Conclusions In this pooled analysis, low prediagnostic levels of circulating adiponectin were associated with an elevated risk of pancreatic cancer. J Natl Cancer Inst 2013;105:95-103 C1 [Bao, Ying; Giovannucci, Edward L.; Stampfer, Meir J.; Ogino, Shuji; Ma, Jing; Buring, Julie E.; Fuchs, Charles S.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. [Buring, Julie E.; Sesso, Howard D.; Lee, I-Min; Gaziano, John Michael; Lin, Jennifer H.; Manson, JoAnn E.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. [Wolpin, Brian M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. [Giovannucci, Edward L.; Kraft, Peter; Stampfer, Meir J.; Ma, Jing; Sesso, Howard D.; Lee, I-Min; Manson, JoAnn E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Giovannucci, Edward L.; Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA. [Rifai, Nader] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. [Pollak, Michael N.] McGill Univ, Fac Med, Dept Oncol, Canc Prevent Res Unit, Montreal, PQ, Canada. [Cochrane, Barbara B.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Kaklamani, Virginia] Northwestern Univ, Feinberg Sch Med, Dept Med, Canc Genet Program,Div Hematol Oncol, Chicago, IL 60611 USA. [Kaklamani, Virginia] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Ogino, Shuji; Fuchs, Charles S.; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Bao, Y (reprint author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA. EM ying.bao@channing.harvard.edu FU National Cancer Institute, National Institutes of Health [P01 CA87969, P01 CA55075, P50 CA127003, R01 CA124908]; NCI [K07 CA140790]; American Society of Clinical Oncology Career Development Award; Howard Hughes Medical Institute Early Career Physician-Scientist Award; Lustgarten Foundation; National Institutes of Health [CA 97193, CA 34944, CA 40360, HL 26490, HL 34595, CA047988, HL043851, HL080467]; National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221] FX The NHS and HPFS are supported by the National Cancer Institute, National Institutes of Health (grants P01 CA87969, P01 CA55075, P50 CA127003, R01 CA124908). BMW is supported by NCI K07 CA140790; an American Society of Clinical Oncology Career Development Award; a Howard Hughes Medical Institute Early Career Physician-Scientist Award; and the Lustgarten Foundation.; The PHS I is supported by the National Institutes of Health (grants CA 97193, CA 34944, CA 40360, HL 26490, and HL 34595).; The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services (contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221).; The WHS is supported by the National Institutes of Health (grants CA047988, HL043851, and HL080467). NR 65 TC 32 Z9 34 U1 1 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD JAN PY 2013 VL 105 IS 2 BP 95 EP 103 DI 10.1093/jnci/djs474 PG 9 WC Oncology SC Oncology GA 088VK UT WOS:000314865100007 PM 23243202 ER PT J AU Vandergrift, JL Niland, JC Theriault, RL Edge, SB Wong, YN Loftus, LS Breslin, TM Hudis, CA Javid, SH Rugo, HS Silver, SM Lepisto, EM Weeks, JC AF Vandergrift, Jonathan L. Niland, Joyce C. Theriault, Richard L. Edge, Stephen B. Wong, Yu-Ning Loftus, Loretta S. Breslin, Tara M. Hudis, Clifford A. Javid, Sara H. Rugo, Hope S. Silver, Samuel M. Lepisto, Eva M. Weeks, Jane C. TI Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID INITIATION; SURVIVAL; AMERICAN; SURGERY; THERAPY AB Background High-quality care must be not only appropriate but also timely. We assessed time to initiation of adjuvant chemotherapy for breast cancer as well as factors associated with delay to help identify targets for future efforts to reduce unnecessary delays. Methods Using data from the National Comprehensive Cancer Network (NCCN) Outcomes Database, we assessed the time from pathological diagnosis to initiation of chemotherapy (TTC) among 6622 women with stage I to stage III breast cancer diagnosed from 2003 through 2009 and treated with adjuvant chemotherapy in nine NCCN centers. Multivariable models were constructed to examine factors associated with TTC. All statistical tests were two-sided. Results Mean TTC was 12.0 weeks overall and increased over the study period. A number of factors were associated with a longer TTC. The largest effects were associated with therapeutic factors, including immediate postmastectomy reconstruction (2.7 weeks; P < .001), re-excision (2.1 weeks; P < .001), and use of the 21-gene reverse-transcription polymerase chain reaction assay (2.2 weeks; P < .001). In comparison with white women, a longer TTC was observed among black (1.5 weeks; P < .001) and Hispanic (0.8 weeks; P < .001) women. For black women, the observed disparity was greater among women who transferred their care to the NCCN center after diagnosis (P-interaction = .008) and among women with Medicare vs commercial insurance (P-interaction < .001). Conclusions Most observed variation in TTC was related to use of appropriate therapeutic interventions. This suggests the importance of targeted efforts to minimize potentially preventable causes of delay, including inefficient transfers in care or prolonged appointment wait times. J Natl Cancer Inst 2013;105:104-112 C1 [Vandergrift, Jonathan L.; Lepisto, Eva M.] Natl Comprehens Canc Network, Outcomes Res Grp, Ft Washington, PA USA. [Niland, Joyce C.] City Hope Natl Med Ctr, Dept Informat Sci, Duarte, CA 91010 USA. [Theriault, Richard L.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA. [Edge, Stephen B.] Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA. [Wong, Yu-Ning] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA. [Loftus, Loretta S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Med Oncol,Comprehens Breast Program, Tampa, FL 33612 USA. [Breslin, Tara M.] Univ Michigan, Ctr Comprehens Canc, Div Surg Oncol, Ann Arbor, MI 48109 USA. [Silver, Samuel M.] Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA. [Hudis, Clifford A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Javid, Sara H.] Seattle Canc Care Alliance, Dept Surg, Seattle, WA USA. [Rugo, Hope S.] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA. [Rugo, Hope S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Weeks, Jane C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Vandergrift, JL (reprint author), 275 Commerce Dr,Ste 300, Ft Washington, PA 19034 USA. EM jvandergrift78@gmail.com FU National Comprehensive Cancer Network; National Cancer Institute [P50 CA89393] FX The National Comprehensive Cancer Network provides financial and material support for the development of the NCCN Outcomes Database, which is the source of data used in the current analysis. Data collection was funded in part by the National Cancer Institute (grant P50 CA89393 to Dana-Farber Cancer Institute). NR 20 TC 43 Z9 44 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JAN PY 2013 VL 105 IS 2 BP 104 EP 112 DI 10.1093/jnci/djs506 PG 9 WC Oncology SC Oncology GA 088VK UT WOS:000314865100008 PM 23264681 ER PT J AU Keating, NL Landrum, MB Lamont, EB Bozeman, SR Shulman, LN McNeil, BJ AF Keating, Nancy L. Landrum, Mary Beth Lamont, Elizabeth B. Bozeman, Samuel R. Shulman, Lawrence N. McNeil, Barbara J. TI Tumor Boards and the Quality of Cancer Care SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID THORACIC MALIGNANCY CONFERENCE; PROSTATE-CANCER; LUNG-CANCER; CHEMOTHERAPY; LIFE; END; RADIOTHERAPY; PAMIDRONATE; CONFERENCES; CASTRATION AB Background Despite the widespread use of tumor boards, few data on their effects on cancer care exist. We assessed whether the presence of a tumor board, either general or cancer specific, was associated with recommended cancer care, outcomes, or use in the Veterans Affairs (VA) health system. Methods We surveyed 138 VA medical centers about the presence of tumor boards and linked cancer registry and administrative data to assess receipt of stage-specific recommended care, survival, or use for patients with colorectal, lung, prostate, hematologic, and breast cancers diagnosed in the period from 2001 to 2004 and followed through 2005. We used multivariable logistic regression to assess associations of tumor boards with the measures, adjusting for patient sociodemographic and clinical characteristics. All statistical tests were two-sided. Results Most facilities (75%) had at least one tumor board, and many had several cancer-specific tumor boards. Presence of a tumor board was associated with only seven of 27 measures assessed (all P < .05), and several associations were not in expected directions. Rates of some recommended care (eg, white blood cell growth factors with cyclophosphamide, adriamycin, vincristine, and prednisone in diffuse large B-cell lymphoma) were lower in centers with hematologic-specialized tumor boards (39.4%) than in centers with general tumor boards (61.3%) or no tumor boards (56.4%; P = .002). Only one of 27 measures was statistically significantly associated with tumor boards after applying a Bonferroni correction for multiple comparisons. Conclusions We observed little association of multidisciplinary tumor boards with measures of use, quality, or survival. This may reflect no effect or an effect that varies by structural and functional components and participants' expertise. J Natl Cancer Inst 2013;105:113-121 C1 [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA. [McNeil, Barbara J.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Keating, Nancy L.; Landrum, Mary Beth; Lamont, Elizabeth B.; McNeil, Barbara J.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Lamont, Elizabeth B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Bozeman, Samuel R.] Abt Associates Inc, Cambridge, MA USA. [Shulman, Lawrence N.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. EM keating@hcp.med.harvard.edu FU Department of Veterans Affairs through the Office of Policy and Planning FX This work was funded by the Department of Veterans Affairs through the Office of Policy and Planning. NR 33 TC 44 Z9 45 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD JAN PY 2013 VL 105 IS 2 BP 113 EP 121 DI 10.1093/jnci/djs502 PG 9 WC Oncology SC Oncology GA 088VK UT WOS:000314865100009 PM 23274388 ER PT J AU Ogino, S Nishihara, R Lochhead, P Imamura, Y Kuchiba, A Morikawa, T Yamauchi, M Liao, XY Qian, ZR Sun, RF Sato, K Kirkner, GJ Wang, ML Spiegelman, D Meyerhardt, JA Schernhammer, ES Chan, AT Giovannucci, E Fuchs, CS AF Ogino, Shuji Nishihara, Reiko Lochhead, Paul Imamura, Yu Kuchiba, Aya Morikawa, Teppei Yamauchi, Mai Liao, Xiaoyun Qian, Zhi Rong Sun, Ruifang Sato, Kaori Kirkner, Gregory J. Wang, Molin Spiegelman, Donna Meyerhardt, Jeffrey A. Schernhammer, Eva S. Chan, Andrew T. Giovannucci, Edward Fuchs, Charles S. TI Prospective Study of Family History and Colorectal Cancer Risk by Tumor LINE-1 Methylation Level SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; MICROSATELLITE INSTABILITY STATUS; LIFE-STYLE FACTORS; BODY-MASS INDEX; COLON-CANCER; DNA METHYLATION; PERSONALIZED MEDICINE; PHYSICAL-ACTIVITY; LYNCH SYNDROME; BRAF MUTATION AB Background Beyond known familial colorectal cancer (CRC) syndromes, the mechanisms underlying the elevated CRC risk associated with CRC family history remain largely unknown. A recent retrospective study suggests familial clustering of CRC with hypomethylation in long interspersed nucleotide element 1 (LINE-1). We tested the hypothesis that CRC family history might confer a higher risk of LINE-1 methylation-low CRC. Methods Using the Nurses' Health Study and the Health Professionals Follow-up Study, we prospectively examined the association between CRC family history and the risk of rectal and colon cancer (N = 1224) according to tumor LINE-1 methylation level by duplication method Cox proportional hazards regression. We examined microsatellite instability (MSI) status to exclude the influence of Lynch syndrome. All statistical tests were two-sided. Results The association between CRC family history and non-MSI CRC risk differed statistically significantly by LINE-1 methylation level (P-heterogeneity = .02). CRC family history was associated with a statistically significantly higher risk of LINE-1 methylation-low non-MSI cancer (multivariable hazard ratio [HR] = 1.68, 95% confidence interval [CI] = 1.19 to 2.38 for 1 vs 0 first-degree relatives with CRC; multivariable HR = 3.48, 95% CI = 1.59 to 7.6 for = 2 vs 0 first-degree relatives with CRC; P-trend < .001). In contrast, CRC family history was not statistically significantly associated with LINE-1 methylation-high non-MSI cancer (P-trend = .35). Conclusions This molecular pathological epidemiology study shows that CRC family history is associated with a higher risk of LINE-1 methylation-low CRC, suggesting previously unrecognized heritable predisposition to epigenetic alterations. Additional studies are needed to evaluate tumor LINE-1 methylation as a molecular biomarker for familial cancer risk assessment. J Natl Cancer Inst 2013;105:130-140 C1 [Ogino, Shuji; Nishihara, Reiko; Lochhead, Paul; Imamura, Yu; Kuchiba, Aya; Morikawa, Teppei; Yamauchi, Mai; Liao, Xiaoyun; Qian, Zhi Rong; Sun, Ruifang; Sato, Kaori; Meyerhardt, Jeffrey A.; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ogino, Shuji; Nishihara, Reiko; Lochhead, Paul; Imamura, Yu; Kuchiba, Aya; Morikawa, Teppei; Yamauchi, Mai; Liao, Xiaoyun; Qian, Zhi Rong; Sun, Ruifang; Sato, Kaori; Meyerhardt, Jeffrey A.; Fuchs, Charles S.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Kirkner, Gregory J.; Wang, Molin; Spiegelman, Donna; Schernhammer, Eva S.; Chan, Andrew T.; Giovannucci, Edward; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Ogino, Shuji; Spiegelman, Donna; Meyerhardt, Jeffrey A.; Schernhammer, Eva S.; Chan, Andrew T.; Giovannucci, Edward; Fuchs, Charles S.] Dana Farber Canc Inst, Canc Epidemiol Program, Boston, MA 02115 USA. [Ogino, Shuji; Spiegelman, Donna; Meyerhardt, Jeffrey A.; Schernhammer, Eva S.; Chan, Andrew T.; Giovannucci, Edward; Fuchs, Charles S.] Harvard Canc Ctr, Boston, MA USA. [Ogino, Shuji; Wang, Molin; Spiegelman, Donna; Schernhammer, Eva S.; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Wang, Molin; Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. [Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02215 USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. RP Ogino, S (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Mol Oncol Pathol,Dana Farber Canc Inst, 450 Brookline Ave,Rm JF 215C, Boston, MA 02215 USA. EM shuji_ogino@dfci.harvard.edu OI Qian, Zhi rong/0000-0003-1633-4120 FU National Institute of Health [P01 CA87969, P01 CA55075, P50 CA127003, R01 CA151993, R01 CA137178]; Bennett Family Fund for Targeted Therapies Research; National Colorectal Cancer Research Alliance; Harvard University Knox Memorial Fellowship FX This work was supported by the National Institute of Health (P01 CA87969 [to S. E. Hankinson], P01 CA55075 [to W. C. Willett], P50 CA127003 [to CSF], R01 CA151993 [to SO], and R01 CA137178 [to ATC]; the Bennett Family Fund for Targeted Therapies Research; and the National Colorectal Cancer Research Alliance. PL is a Scottish Government Clinical Academic Fellow and is supported by a Harvard University Knox Memorial Fellowship. ATC is a Damon Runyon Clinical Investigator. NR 71 TC 31 Z9 31 U1 2 U2 16 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD JAN PY 2013 VL 105 IS 2 BP 130 EP 140 DI 10.1093/jnci/djs482 PG 11 WC Oncology SC Oncology GA 088VK UT WOS:000314865100011 PM 23175808 ER PT J AU Perez, DL Dickerson, BC McGinnis, SM Sapolsky, D Johnson, K Searl, M Daffner, KR AF Perez, David L. Dickerson, Bradford C. McGinnis, Scott M. Sapolsky, Daisy Johnson, Keith Searl, Meghan Daffner, Kirk R. TI You Don't Say: Dynamic Aphasia, Another Variant of Primary Progressive Aphasia? SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Cerebrospinal fluid; magnetic resonance imaging; neurodegenerative disease; PET scan; primary progressive aphasia ID TRANSCORTICAL MOTOR APHASIA; SUPRANUCLEAR PALSY; SEMANTIC DEMENTIA; DEGENERATION; LANGUAGE; IMPAIRMENT; SPEECH; MILD AB Primary progressive aphasia (PPA) is a language predominant neurodegenerative disorder that has three recognized variants: nonfluent/agrammatic, semantic, and logopenic. This report describes a 60-year-old man who presented with a progressive decline in verbal output that does not fit the currently accepted PPA subtypes. The patient exhibited a paucity of verbal output and impaired phonemic fluency with minimal associated language, cognitive, or behavioral deficits. Focal cortical thinning/hypometabolism of the left superior frontal region and a cerebrospinal fluid profile not consistent with Alzheimer's disease pathology were identified. This case of isolated progressive dynamic aphasia extends the current boundaries of PPA diagnostic variants. C1 [Perez, David L.; McGinnis, Scott M.; Searl, Meghan; Daffner, Kirk R.] Brigham & Womens Hosp, Dept Neurol, Ctr Brain Mind Med, Boston, MA 02115 USA. [Perez, David L.; Daffner, Kirk R.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Perez, David L.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA. [Dickerson, Bradford C.; McGinnis, Scott M.; Sapolsky, Daisy] Massachusetts Gen Hosp, Dept Neurol, Frontotemporal Dementia Unit, Boston, MA 02114 USA. [Dickerson, Bradford C.; McGinnis, Scott M.; Sapolsky, Daisy] Massachusetts Gen Hosp, Dept Psychiat, Frontotemporal Dementia Unit, Boston, MA 02114 USA. [Dickerson, Bradford C.; McGinnis, Scott M.; Johnson, Keith] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Daffner, KR (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cognit & Behav Neurol, 221 Longwood Ave, Boston, MA 02115 USA. EM kdaffner@partners.org FU NINDS NIH HHS [R21 NS077059] NR 38 TC 3 Z9 3 U1 1 U2 14 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2013 VL 34 IS 1 BP 139 EP 144 DI 10.3233/JAD-121861 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 088LI UT WOS:000314835500004 PM 23168447 ER PT J AU Idelevich, A Sato, K Baron, R AF Idelevich, Anna Sato, Kazusa Baron, Roland TI What Are the Effects of Leptin on Bone and Where Are They Exerted? SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Editorial Material ID SYMPATHETIC-NERVOUS-SYSTEM; DEFICIENT OB/OB MICE; ENERGY-METABOLISM; INSULIN; OSTEOBLASTS; MASS; EXPRESSION; RECEPTOR; CELLS C1 [Idelevich, Anna; Sato, Kazusa; Baron, Roland] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Baron, Roland] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Baron, Roland] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. RP Baron, R (reprint author), Harvard Univ, Sch Dent Med, Dept Oral Med, 188 Longwood Ave, Boston, MA 02115 USA. EM roland_baron@hsdm.harvard.edu NR 22 TC 9 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2013 VL 28 IS 1 BP 18 EP 21 DI 10.1002/jbmr.1812 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 092EY UT WOS:000315103200003 PM 23188700 ER PT J AU Yuan, BZ Feng, JQ Bowman, S Liu, Y Blank, RD Lindberg, I Drezner, MK AF Yuan, Baozhi Feng, Jian Q. Bowman, Stephen Liu, Ying Blank, Robert D. Lindberg, Iris Drezner, Marc K. TI Hexa-D-Arginine Treatment Increases 7B2 center dot PC2 Activity in hyp-Mouse Osteoblasts and Rescues the HYP Phenotype SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE X-LINKED HYPOPHOSPHATEMIA; hyp-Mouse; 7B2; SPC2; HEXA-d-ARGININE; fgf-23; BONE; RICKETS; OSTEOMALACIA ID LINKED HYPOPHOSPHATEMIC RICKETS; FAMILIAL TUMORAL CALCINOSIS; DENTIN MATRIX PROTEIN-1; RENAL 25-HYDROXYVITAMIN-D-1-ALPHA-HYDROXYLASE ACTIVITY; PROHORMONE CONVERTASE PC2; GROWTH-FACTOR 23; IN-VIVO; PEX GENE; PHOSPHATE HOMEOSTASIS; ENZYMATIC-ACTIVITY AB Inactivating mutations of the "phosphate regulating gene with homologies to endopeptidases on the X chromosome" (PHEX/Phex) underlie disease in patients with X-linked hypophosphatemia (XLH) and the hyp-mouse, a murine homologue of the human disorder. Although increased serum fibroblast growth factor 23 (FGF-23) underlies the HYP phenotype, the mechanism(s) by which PHEX mutations inhibit FGF-23 degradation and/or enhance production remains unknown. Here we show that treatment of wild-type mice with the proprotein convertase (PC) inhibitor, decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (Dec), increases serum FGF-23 and produces the HYP phenotype. Because PC2 is uniquely colocalized with PHEX in osteoblasts/bone, we examined if PC2 regulates PHEX-dependent FGF-23 cleavage and production. Transfection of murine osteoblasts with PC2 and its chaperone protein 7B2 cleaved FGF-23, whereas Signe1 (7B2) RNA interference (RNAi) transfection, which limited 7B2 protein production, decreased FGF-23 degradation and increased Fgf-23 mRNA and protein. The mechanism by which decreased 7B2 center dot PC2 activity influences Fgf-23 mRNA was linked to reduced conversion of the precursor to bone morphogenetic protein 1 (proBMP1) to active BMP1, which resulted in limited cleavage of dentin matrix acidic phosphoprotein 1 (DMP1), and consequent increased Fgf-23 mRNA. The significance of decreased 7B2 center dot PC2 activity in XLH was confirmed by studies of hyp-mouse bone, which revealed significantly decreased Sgne1 (7B2) mRNA and 7B2 protein, and limited cleavage of proPC2 to active PC2. The expected downstream effects of these changes included decreased FGF-23 cleavage and increased FGF-23 synthesis, secondary to decreased BMP1-mediated degradation of DMP1. Subsequent Hexa-D-Arginine treatment of hyp-mice enhanced bone 7B2 center dot PC2 activity, normalized FGF-23 degradation and production, and rescued the HYP phenotype. These data suggest that decreased PHEX-dependent 7B2 center dot PC2 activity is central to the pathogenesis of XLH. (C) 2013 American Society for Bone and Mineral Research. C1 [Yuan, Baozhi; Bowman, Stephen; Blank, Robert D.; Drezner, Marc K.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Yuan, Baozhi; Bowman, Stephen; Blank, Robert D.; Drezner, Marc K.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res & Educ Ctr, Madison, WI USA. [Feng, Jian Q.; Liu, Ying] Texas A&M Hlth Sci Ctr, Baylor Coll Dent, Dept Biomed Sci, Dallas, TX USA. [Lindberg, Iris] Univ Maryland, Dept Anat & Neurobiol, Baltimore, MD 21201 USA. RP Drezner, MK (reprint author), Univ Wisconsin, Hlth Sci Learning Ctr 4246, Sch Med & Publ Hlth, 750 Highland Ave, Madison, WI 53705 USA. EM mkd@medicine.wisc.edu FU NIH [R01-AR27032, R01-SK65830, 1UL1RR025011, R01-DE018486, AR54753, DK049703]; Veterans Administration FX This work was funded by NIH grants (R01-AR27032, R01-SK65830, and 1UL1RR025011 to MKD; R01-DE018486 to JQF; AR54753 to RDB; and DK049703 to IL) and a Veterans Administration grant to RD Blank (Merit Award). The work reported in this article was conducted in the VAMC Geriatrics Research, Education, and Clinical Center, Madison, WI, USA. NR 71 TC 21 Z9 22 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2013 VL 28 IS 1 BP 56 EP 72 DI 10.1002/jbmr.1738 PG 17 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 092EY UT WOS:000315103200007 PM 22886699 ER PT J AU Smart, RJ Susarla, SM Kaban, LB Dodson, TB AF Smart, Ryan J. Susarla, Srinivas M. Kaban, Leonard B. Dodson, Thomas B. TI Factors Associated With Converting Scientific Abstracts to Published Manuscripts SO JOURNAL OF CRANIOFACIAL SURGERY LA English DT Article DE Scientific abstracts; publication rate; Dr. Joseph E. Murray; Massachusetts General Hospital; Harvard Oral and Maxillofacial Surgery ID AMERICAN-ASSOCIATION; PUBLICATION; PRESENTATIONS; MEETINGS; SURGEONS AB Purpose: The objective of this study was to identify factors associated with the conversion of scientific abstracts to publications in peer-reviewed journals. Methods: This was a retrospective study of abstracts presented by members of the Massachusetts General Hospital Department of Oral and Maxillofacial Surgery between 2000 and 2010. Predictor variables were categorized as abstract-or author-specific. The outcome variable was conversion of an abstract presented at a meeting to a published manuscript. Descriptive, bivariate, and multiple regression statistics were computed. P < 0.05 was significant. Results: The sample was composed of 122 abstracts presented at meetings. Ninety abstracts (73.8%) were published in a peer-reviewed literature within 5 years of presentation. The mean time between presentation to publication was 21.9 +/- 17.3 months (median, 19.0 months; range, 0-99 months). In bivariate analyses, study design, number of prior publications by the presenting author, and number of prior publications by the senior author were associated with time to publication (P < 0.06). In a multiple Cox proportional hazards model, higher levels of evidence (hazard ratio, 1.2; 95% confidence interval, 1.04-1.3; P = 0.006) and volume of prior publications by the senior author (hazard ratio, 1.007; 95% confidence interval, 1.003-1.011; P < 0.001) were associated with shorter publication times. Conclusions: Time to publication of scientific abstracts is associated with study quality, prior research experience by the presenting author, and senior author identity and experience. C1 [Smart, Ryan J.; Susarla, Srinivas M.; Kaban, Leonard B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. [Kaban, Leonard B.; Dodson, Thomas B.] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Dodson, Thomas B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Ctr Appl Clin Invest, Boston, MA 02114 USA. RP Kaban, LB (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, 55 Fruit St,WRN 1201, Boston, MA 02114 USA. EM LKaban@partners.org OI Susarla, Srinivas/0000-0003-0155-8260 NR 7 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1049-2275 J9 J CRANIOFAC SURG JI J. Craniofac. Surg. PD JAN PY 2013 VL 24 IS 1 BP 66 EP 70 DI 10.1097/SCS.0b013e318270fdef PG 5 WC Surgery SC Surgery GA 088RI UT WOS:000314853300059 PM 23348257 ER PT J AU Elangovan, S Jain, S Tsai, PC Margolis, HC Amiji, M AF Elangovan, Satheesh Jain, Shardool Tsai, Pei-Chin Margolis, Henry C. Amiji, Mansoor TI Nano-Sized Calcium Phosphate Particles for Periodontal Gene Therapy SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Biocompatible materials; gene therapy; guided tissue regeneration ID GROWTH-FACTOR; DNA DELIVERY; INTRACELLULAR TRAFFICKING; EXHIBITS SAFETY; CLINICAL-USE; PDGF; REGENERATION; VECTORS; BIODISTRIBUTION; NANOPARTICLES AB Background: Growth factors such as platelet-derived growth factor (PDGF) have significantly enhanced periodontal therapy outcomes with a high degree of variability, mostly due to the lack of continual supply for a required period of time. One method to overcome this barrier is gene therapy. The aim of this in vitro study is to evaluate PDGF-B gene delivery in fibroblasts using nano-sized calcium phosphate particles (NCaPP) as vectors. Methods: NCaPP incorporating green fluorescent protein (NCaPP-GFP) and PDGF-B (NCaPP-PDGF-B) plasmids were synthesized using an established precipitation system and characterized using transmission electron microscopy and 1.2% agarose gel electrophoresis. Biocompatibility and transfection of the nanoplexes in fibroblasts were evaluated using cytotoxicity assay and florescence microscopy, respectively. Polymerase chain reaction and enzyme-linked immunosorbent assay were performed to evaluate PDGF-B transfection after different time points of treatments, and the functionality of PDGF-B transfection was evaluated using the cell proliferation assay. Results: Synthesized NCaPP nanoplexes incorporating the genes of GFP and PDGF-B were spherical in shape and measured about 30 to 50 nm in diameter. Gel electrophoresis confirmed DNA incorporation and stability within the nanoplexes, and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reagent assay demonstrated their biocompatibility in fibroblasts. In vitro transfection studies revealed a higher and longer lasting transfection after NCaPP-PDGF-B treatment, which lasted up to 96 hours. Significantly enhanced fibroblast proliferation observed in NCaPP-PDGF-B-treated cells confirmed the functionality of these nanoplexes. Conclusion: NCaPP demonstrated higher levels of biocompatibility and efficiently transfected PDGF plasmids into fibroblasts under described in vitro conditions. J Periodontol 2013;84:117-125. C1 [Elangovan, Satheesh] Univ Iowa, Coll Dent, Dept Periodont, Iowa City, IA 52242 USA. [Jain, Shardool; Tsai, Pei-Chin; Amiji, Mansoor] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA. [Margolis, Henry C.] Forsyth Inst, Dept Biomineralizat, Cambridge, MA USA. RP Elangovan, S (reprint author), Univ Iowa, Coll Dent, Dept Periodont, Iowa City, IA 52242 USA. EM sa-theesh-elangovan@uiowa.edu RI Amiji, Mansoor/A-4365-2014 OI Amiji, Mansoor/0000-0001-6170-881X FU American Academy of Periodontology Foundation Tarrson Regeneration scholarship (Chicago, IL); University of Iowa Research start-up fund (Iowa City, IA) FX This work was supported in part by the American Academy of Periodontology Foundation Tarrson Regeneration scholarship (Chicago, IL) and partially by The University of Iowa Research start-up fund (Iowa City, IA). The authors thank Dr. Seo-Young Kwak (The Forsyth Institute, Cambridge, MA) for her help with transmission electron microscopy. The authors report no conflict of interests related to this study. NR 38 TC 12 Z9 13 U1 3 U2 21 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD JAN PY 2013 VL 84 IS 1 BP 117 EP 125 DI 10.1902/jop.2012.120012 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 087EO UT WOS:000314744300014 PM 22414259 ER PT J AU Pathiraja, V Matar, AJ Gusha, A Huang, CA Duran-Struuck, R AF Pathiraja, Vimukthi Matar, Abraham J. Gusha, Ashley Huang, Christene A. Duran-Struuck, Raimon TI Leukapheresis Protocol for Nonhuman Primates Weighing Less than 10 Kg SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Article ID HEMATOPOIETIC-CELL TRANSPLANTATION; CATHETER-RELATED THROMBOSIS; RENAL-ALLOGRAFT TOLERANCE; CYNOMOLGUS MONKEYS; MIXED CHIMERISM; THERAPEUTIC APHERESIS; CHILDREN; COLLECTION; COMPLICATIONS; ASSOCIATION AB Leukapheresis is a common procedure for hematopoietic cell transplantation in adults. The main challenge in applying this procedure to human infants and small monkeys is the large extracorporeal blood volume (165 mL on average) necessary for priming the apheresis machine. This volume represents greater than 50% of the total circulating blood volume of a human neonate or small monkey. In this report, we document a safe leukapheresis protocol developed for rhesus macaques (3.9 to 8.7 kg). To avoid sensitizing donor animals undergoing leukapheresis to third-party blood products, autologous blood collected during the weeks prior to leukapheresis was used to volume-expand the same donor while priming the machine with saline on the day of leukapheresis. During the procedures, blood pressure was controlled by monitoring the inlet volume, and critical-care support was provided by the anesthesia team. Electrolytes and hemogram parameters were monitored intermittently. Overall, our research subjects underwent effective 4, to 6-h leukapheresis. A total of 9 leukapheresis procedures were performed, which yielded 1 x 10(9) to 6 x 10(9) peripheral blood mononuclear cells containing 1.1 to 5.1 x 10(6) CD34(+) cells (assessed in 4 of 9 macaques) in a volume of 30 to 85 mL. All macaques showed decreases in Hct and platelet counts. In summary, we report a successful modified leukapheresis procedure that can be performed safely in small animals without modification of the leukapheresis machine or associated cell-collection kits. C1 [Pathiraja, Vimukthi; Matar, Abraham J.; Gusha, Ashley; Huang, Christene A.; Duran-Struuck, Raimon] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02115 USA. RP Duran-Struuck, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA 02115 USA. EM rduranst@gmail.com FU NCRR [K01RR024466]; NTH [5U19AI051731, 5T32AI007529] FX Part of this work was sponsored by NCRR K01RR024466 (RDS) and NTH 5U19AI051731 (CH) and 5T32AI007529 (VP). NR 24 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD JAN PY 2013 VL 52 IS 1 BP 70 EP 77 PG 8 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 071OQ UT WOS:000313604500013 PM 23562036 ER PT J AU Mitchell, RB Hussey, HM Setzen, G Jacobs, IN Nussenbaum, B Dawson, C Brown, CA Brandt, C Deakins, K Hartnick, C Merati, A AF Mitchell, Ron B. Hussey, Heather M. Setzen, Gavin Jacobs, Ian N. Nussenbaum, Brian Dawson, Cindy Brown, Calvin A., III Brandt, Cheryl Deakins, Kathleen Hartnick, Christopher Merati, Albert TI Clinical Consensus Statement: Tracheostomy Care SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE tracheostomy; tracheotomy; pediatric airway management; adult airway management ID PERCUTANEOUS DILATATIONAL TRACHEOSTOMY; CRITICALLY-ILL PATIENTS; SURGICAL TRACHEOSTOMY; COMPLICATIONS; TRACHEOTOMY; CHILDREN; DECANNULATION; METAANALYSIS; MANAGEMENT; POLYSOMNOGRAPHY AB Objective. This clinical consensus statement (CCS) aims to improve care for pediatric and adult patients with a tracheostomy tube. Approaches to tracheostomy care are currently inconsistent among clinicians and between different institutions. The goal is to reduce variations in practice when managing patients with a tracheostomy to minimize complications. Methods. A formal literature search was conducted to identify evidence gaps and refine the scope of this consensus statement. The modified Delphi method was used to refine expert opinion and facilitate a consensus position. Panel members were asked to complete 2 scale-based surveys addressing different aspects of pediatric and adult tracheostomy care. Each survey was followed by a conference call during which results were presented and statements discussed. Results. The panel achieved consensus on 77 statements; another 39 were dropped because of lack of consensus. Consensus was reached on statements that address initial tracheostomy tube change, management of emergencies and complications, prerequisites for decannulation, management of tube cuffs and communication devices, and specific patient and caregiver education needs. Conclusion. The consensus panel agreed on statements that address the continuum of care, from initial tube management to complications in children and adults with a tracheostomy. The panel also highlighted areas where consensus could not be reached and where more research is needed. This consensus statement should be used by physicians, nurses, and other stakeholders caring for patients with a tracheostomy. C1 [Mitchell, Ron B.] UT SW Med Ctr, Dept Otolaryngol, Dallas, TX 75207 USA. [Hussey, Heather M.] Amer Acad Otolaryngol Head & Neck Surg Fdn, Alexandria, VA USA. [Setzen, Gavin] Albany ENT & Allergy Serv, PC, Albany, NY USA. [Jacobs, Ian N.] Childrens Hosp Philadelphia, Ctr Pediat Airway Disorders, Philadelphia, PA 19104 USA. [Nussenbaum, Brian] Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA. [Dawson, Cindy] Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Iowa City, IA 52242 USA. [Brown, Calvin A., III] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Brandt, Cheryl] Univ Hosp Case Med Ctr, Ear Nose & Throat Inst, Cleveland, OH USA. [Deakins, Kathleen] Rainbow Babies & Childrens Hosp, Pediat Resp Care Dept, Cleveland, OH 44106 USA. [Hartnick, Christopher] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Merati, Albert] Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Laryngol, Seattle, WA 98195 USA. RP Mitchell, RB (reprint author), UT SW Med Ctr, Childrens Med Ctr Dallas, Dept Otolaryngol, 2350 N Stemmons Freeway, Dallas, TX 75207 USA. EM ron.mitchell@utsouthwestern.edu FU AAO-HNSF; Air Evac EMS, Inc FX The cost of developing this consensus statement was covered in full by the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF). Potential conflicts of interest for all panel members in the past 5 years were compiled and distributed before the first conference call. Last, panelists were reminded that conflicts of interest extend beyond financial relationships and may include personal experiences, how a participant earns a living, and the participant's previously established "stake'' in an issue.36 Heather M. Hussey is a salaried employee of the funding company, AAO-HNSF. Ian N. Jacobs received a fund from Karl Storz for his airway endoscopy course for residents. Calvin A. Brown III received grant funding from Air Evac EMS, Inc to evaluate a prehospital intubation database. Kathleen Deakins is with the Hill-Rom-Therapy Vest User Group and has received honoraria for lectures from the American Association for Respiratory Care (AARC).; AAO-HNSF.; AAO-HNSF. NR 37 TC 53 Z9 54 U1 4 U2 22 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2013 VL 148 IS 1 BP 6 EP 20 DI 10.1177/0194599812460376 PG 15 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 092SJ UT WOS:000315142000003 PM 22990518 ER PT J AU Wilhelm, CJ Choi, D Huckans, M Manthe, L Loftis, JM AF Wilhelm, Clare J. Choi, Dongseok Huckans, Marilyn Manthe, Laura Loftis, Jennifer M. TI Adipocytokine signaling is altered in flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Article DE Depression; Forced swim test; Hippocampus; Behavioral despair; Adipocytokine ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; GENETIC ANIMAL-MODEL; MAJOR DEPRESSION; HIPPOCAMPAL VOLUME; MOOD DISORDERS; PLASMA LEPTIN; INVENTORY-II; DSM-IV; SCHIZOPHRENIA; ANTIDEPRESSANT AB Major depression is a complex multi-factorial disorder with a lifetime diagnosis of nearly 1 out of 6. We used the Flinders Sensitive Line (FSL) of rats, a model of depression, and the parent Sprague-Dawley (SD) rats to identify genes, gene ontology categories and pathways associated with depression. Depression-like behavior was verified in the FSL line by forced swim testing, with FSL animals exhibiting greater immobility compared to SD rats. RNA samples from the hippocampus were isolated from a group of experimentally naive FSL and SD rats for microarray analysis. Microarray analysis yielded a total of 361 genes that were differentially regulated between FSL and SD rats, with catechol-O-methyltransferase (COMT) being the most up-regulated. The genes that were differentially regulated between FSL and SD rats were subjected to bioinformatic analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID), which yielded several gene ontology categories that were overrepresented. Subsequent pathway analysis indicated dysregulation of the adipocytokine signaling pathway. To test the translational impact of this pathway, metabolic factors and psychiatric symptoms were evaluated in a sample of human research participants. Results from our human subjects indicated that anxiety and a subset of depressive symptoms were correlated with adiponectin levels (but not leptin levels). Our results and those of others suggest that disruption of the adipocytokine signaling pathway may be a critical component of the depressive-like behaviors observed in the FSL rats and may also be an important indicator of depressive and anxiety symptoms in humans. Published by Elsevier Inc. C1 [Wilhelm, Clare J.; Huckans, Marilyn; Manthe, Laura; Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. [Wilhelm, Clare J.; Huckans, Marilyn; Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth & Preventat Med, Portland, OR 97201 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr R&D 16, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Clinical Sciences Research and Development FX This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center. JML, CJW and MH are supported by career development awards from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and Clinical Sciences Research and Development. We thank Dr. Amir H. Rezvani, Department of Psychiatry, Duke University Medical Center for providing the Flinders Sensitive Line rats and Dr. David Overstreet, Department of Psychiatry, University of North Carolina at Chapel Hill, for review of this manuscript. We also thank Nikki Walter and the Portland Alcohol Research Center Molecular and Bioinformatics Core for technical assistance with the quantitative real-time PCR. NR 77 TC 11 Z9 11 U1 3 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD JAN PY 2013 VL 103 IS 3 BP 643 EP 651 DI 10.1016/j.pbb.2012.11.001 PG 9 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA 087VL UT WOS:000314792100029 PM 23153628 ER PT J AU Blondon, M Harrington, L Hoppe, KK Righini, M Boehlen, F Smith, NL Bounameaux, H AF Blondon, M. Harrington, L. Hoppe, K. K. Righini, M. Boehlen, F. Smith, N. L. Bounameaux, H. TI Risk of venous thrombosis after Cesarean sections: a meta-analysis SO THROMBOSIS RESEARCH LA English DT Meeting Abstract CT 5th International Symposiam on Womens Health Issues in Thrombosis and Haemostasis CY FEB 01-03, 2013 CL Vienna, AUSTRIA C1 [Blondon, M.; Harrington, L.; Smith, N. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Hoppe, K. K.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Smith, N. L.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. [Smith, N. L.] US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, Off Res & Dev, Seattle, WA USA. [Blondon, M.; Righini, M.; Boehlen, F.; Bounameaux, H.] Univ Hosp Geneva, Div Angiol & Haemostasis, Dept Med, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD JAN PY 2013 VL 131 SU 1 BP S97 EP S97 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 087AR UT WOS:000314734100120 ER PT J AU Blondon, M Wiggins, KL Harrington, L Li, G McKnight, B Psaty, BM Smith, NL AF Blondon, M. Wiggins, K. L. Harrington, L. Li, G. McKnight, B. Psaty, B. M. Smith, N. L. TI Interactions between genetic polymorphisms and oral hormone therapy on the risk of venous thrombosis SO THROMBOSIS RESEARCH LA English DT Meeting Abstract CT 5th International Symposiam on Womens Health Issues in Thrombosis and Haemostasis CY FEB 01-03, 2013 CL Vienna, AUSTRIA C1 [Blondon, M.; Harrington, L.; Psaty, B. M.; Smith, N. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Wiggins, K. L.; Li, G.; Psaty, B. M.] Univ Washington, Dept Med, Seattle, WA USA. [McKnight, B.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Psaty, B. M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, B. M.; Smith, N. L.] Grp Hlth, Group Hlth Res Inst, Seattle, WA USA. [Smith, N. L.] US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, Off Res & Dev, Seattle, WA USA. [Blondon, M.] Univ Hosp Geneva, Dept Med, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0049-3848 J9 THROMB RES JI Thromb. Res. PD JAN PY 2013 VL 131 SU 1 BP S97 EP S98 PG 2 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 087AR UT WOS:000314734100121 ER PT J AU Cohen, SI Suri, P Amick, MM Yan, K AF Cohen, Sara I. Suri, Pradeep Amick, Melissa M. Yan, Kun TI Clinical and demographic factors associated with employment status in US military veterans returning from Iraq and Afghanistan SO WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION LA English DT Article DE Depression; OIF/OEF; pain; Polytrauma; posttraumatic stress disorder ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; WORK; DEPRESSION; OUTCOMES; SERVICE; REHABILITATION; INTEGRATION; PREDICTION AB OBJECTIVE: To determine the association between clinical and demographic factors with employment status in post-deployment US military veterans returning from Iraq and Afghanistan. PARTICIPANTS: 169 OIF/OEF veterans seen at a post-deployment clinic between December of 2009 and May of 2010. METHODS: Data was collected retrospectively on employment status, age, marital status, gender, pre-deployment education, ratings of sleep disturbance, pain, and depression, and mild traumatic brain injury (mTBI) or PTSD diagnosis. RESULTS: Unemployment was highly prevalent in this sample (45%). Of the demographic and clinical factors examined, only a self-report of global depression severity was significantly associated with a higher prevalence of unemployment in multivariate analysis (odds ratio [OR] 0.21, 95% confidence interval [CI] 0.10-0.47). Age greater than 40 demonstrated a positive association with employment status that was of borderline statistical significance ([OR] 2.8, 95% confidence interval [CI] 1.0-8.1). Prior diagnoses of mTBI or PTSD, and current sleep or pain symptoms, were not associated with employment status. CONCLUSIONS: Individuals with more severe self-reported depression had a higher prevalence of unemployment. Future prospective studies are needed to better understand which factors determine employment status in returning veterans. C1 [Cohen, Sara I.] Braintree Rehabil Hosp, Braintree, MA USA. [Suri, Pradeep; Amick, Melissa M.; Yan, Kun] VA Boston Healthcare Syst, W Roxbury, MA USA. [Suri, Pradeep] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Suri, Pradeep] Spaulding Rehabil Hosp, Boston, MA USA. [Amick, Melissa M.; Yan, Kun] Def & Vet Brain Injury Ctr, Boston, MA USA. [Amick, Melissa M.] Boston Univ, Dept Psychiat, Sch Med, Medford, MA USA. [Yan, Kun] Tufts Univ, Medford, MA USA. RP Suri, P (reprint author), PMR Serv, 1400 VFW Pkwy,MC 117, W Roxbury, MA 01232 USA. EM Pradeep.Suri@va.gov NR 36 TC 13 Z9 13 U1 1 U2 17 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1051-9815 J9 WORK JI Work PY 2013 VL 44 IS 2 BP 213 EP 219 DI 10.3233/WOR-2012-1417 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 087ZC UT WOS:000314802300011 PM 22927609 ER PT J AU McHugh, RK Murray, HW Hearon, BA Pratt, EM Pollack, MH Safren, SA Otto, MW AF McHugh, R. Kathryn Murray, Heather W. Hearon, Bridget A. Pratt, Elizabeth M. Pollack, Mark H. Safren, Steven A. Otto, Michael W. TI Predictors of Dropout from Psychosocial Treatment in Opioid-Dependent Outpatients SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID SUBSTANCE-ABUSE TREATMENT; ADDICTION SEVERITY INDEX; DISTRESS TOLERANCE; TREATMENT OUTCOMES; ANXIETY SENSITIVITY; COCAINE DEPENDENCE; RETENTION; MAINTENANCE; ATTRITION; HEROIN AB Background and Objectives Early dropout is common in substance abuse treatment settings and may lead to poorer outcomes relative to those completing a full course of treatment. Attempts to identify predictors of dropout have yielded mixed results, highlighting the need for additional research in this area to clarify risk and protective factors to guide intervention and retention efforts. This study evaluated predictors of dropout from psychosocial treatment among opioid-dependent patients on methadone maintenance therapy. Methods Participants included 78 patients who had failed to respond to at least 4 months of methadone maintenance plus group counseling with clinic substance abuse counselors, and were enrolled in a study of randomized psychosocial treatment in addition to treatment-as-usual. Several factors that have been implicated in previous studies as well as two affective variables (distress intolerance and coping motives for drug use) were examined. Results Results indicated that when controlling for various risk factors, age was the only significant predictor of dropout, with younger patients more likely to discontinue treatment early. Conclusions This study replicates previous findings in opioid-dependent samples that younger patients are at an increased risk of early treatment dropout. Conclusions and Significance Targeted intervention may be needed to retain young patients in drug abuse treatment. (Am J Addict 2013;22:18-22) C1 [McHugh, R. Kathryn] McLean Hosp, Div Alcohol & Drug Abuse, Belmont, MA 02478 USA. [McHugh, R. Kathryn; Safren, Steven A.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Murray, Heather W.; Hearon, Bridget A.; Pratt, Elizabeth M.; Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Pollack, Mark H.] Rush Univ, Med Ctr, Dept Psychiat, Chicago, IL 60612 USA. [Safren, Steven A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP McHugh, RK (reprint author), McLean Hosp, Proctor House 3,MS 222, Belmont, MA 02478 USA. EM kmchugh@mclean.harvard.edu OI McHugh, R. Kathryn/0000-0002-3011-8697 FU NIDA NIH HHS [DA017904, R01 DA017904] NR 33 TC 14 Z9 14 U1 2 U2 30 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD JAN-FEB PY 2013 VL 22 IS 1 BP 18 EP 22 DI 10.1111/j.1521-0391.2013.00317.x PG 5 WC Substance Abuse SC Substance Abuse GA 086AK UT WOS:000314655200004 PM 23398222 ER PT J AU DeMarinis, V Caplan, J Chang, G AF DeMarinis, Valerie Caplan, Jason Chang, Grace TI Brief Intervention for Risk-Drinking Women: A Mixed Methods Analysis of Content and Process SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID MOTIVATIONAL INTERVIEWING SESSIONS; BRIEF ALCOHOL INTERVENTIONS; GENDER-DIFFERENCES; USE DISORDERS; CLIENT LANGUAGE; UNITED-STATES; PRIMARY-CARE; ASSOCIATION; CONSUMPTION; POPULATION AB Background and Objectives Although brief interventions (BIs) are among the most highly promoted treatments for alcohol problems, their effective components are unknown. This may be particularly important when considering women since some reviews have suggested that BIs are more efficacious among men. The purpose of this pilot study is to utilize a mixed methods and gender analysis approach to generate hypotheses about the effective components of BIs given to women with medical problems exacerbated by problem drinking. Methods Random sample of 20 BIs given to women with diabetes, hypertension, infertility, or osteoporosis. Quantitative and qualitative analytic methods were undertaken in a stepwise progression, followed by a gender analysis using the Worldview Assessment Framework. Results Main findings include that a worldview encompassing drinking as an entitlement may be a moderator limiting the effectiveness of a BI, that understanding the impact of alcohol on infertility problems as distinct from prenatal alcohol use may be a mediator for BI effectiveness, and that providing information about sensible drinking limits in the context of a specific medical problem was feasible. Conclusions and Significance Content and process areas are important to consider when offering BI for risk-drinking women with medical problems and may help to improve treatment efficacy in this group. (Am J Addict 2013;22:67-74) C1 [DeMarinis, Valerie] Uppsala Univ, Uppsala, Sweden. [DeMarinis, Valerie] Cambridge Hlth Alliance, Div Addict, Dept Psychiat, Cambridge, MA USA. [Caplan, Jason] St Josephs Hosp, Dept Psychiat, Phoenix, AZ USA. [Caplan, Jason] Creighton Univ, Sch Med, Phoenix, AZ USA. [Chang, Grace] VA Boston Healthcare Syst, Brockton, MA USA. [Chang, Grace] Harvard Univ, Sch Med, Boston, MA USA. RP Chang, G (reprint author), Dept Vet Affairs 116A, 940 Belmont St, Brockton, MA 02301 USA. EM grace.chang2@va.gov OI DeMarinis, Valerie/0000-0002-1248-9988 FU NIAAA NIH HHS [R01 AA 014678, 2K24 AA00289] NR 39 TC 0 Z9 0 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 J9 AM J ADDICTION JI Am. J. Addict. PD JAN-FEB PY 2013 VL 22 IS 1 BP 67 EP 74 DI 10.1111/j.1521-0391.2013.00331.x PG 8 WC Substance Abuse SC Substance Abuse GA 086AK UT WOS:000314655200011 PM 23398229 ER PT J AU Benson, TE Lee, DJ Brown, MC AF Benson, Thane E. Lee, Daniel J. Brown, M. Christian TI Tensor Tympani Motoneurons Receive Mostly Excitatory Synaptic Inputs SO ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY LA English DT Article DE middle ear muscle; acoustic reflex; vesicle morphometry; dense core vesicle; electron microscopy ID TRIGEMINAL MOTOR NUCLEUS; ANTEROVENTRAL COCHLEAR NUCLEUS; SPINAL ALPHA-MOTONEURONS; MIDDLE-EAR MUSCLES; BUSHY CELL AXONS; RAT DORSAL-HORN; SUBSTANCE-P; DIFFERENTIAL DISTRIBUTION; HORSERADISH-PEROXIDASE; TRAPEZOID BODY AB The tensor tympani is a middle ear muscle that contracts in two different situations: in response to sound or during voluntary movements. To gain insight into the inputs and neural regulation of the tensor tympani, we examined the ultrastructure of synaptic terminals on labeled tensor tympani motoneurons (TTMNs) using transmission electron microscopy. Our sample of six TTMNs received 79 synaptic terminals that formed 126 synpases. Two types of synapses are associated with round vesicles and form asymmetric junctions (excitatory morphology). One of these types has vesicles that are large and round (Lg Rnd) and the other has vesicles that are smaller and round (Sm Rnd) and also contains at least one dense core vesicle. A third synapse type has inhibitory morphology because it forms symmetric synapses with pleomorphic vesicles (Pleo). These synaptic terminals can be associated with TTMN spines. Two other types of synapse are found on TTMNs but they are uncommon. Synaptic terminals of all types form multiple synapses but those from a single terminal are always the same type. Terminals with Lg Rnd vesicles formed the most synpases per terminal (avg. 2.73). Together, the synaptic terminals with Lg Rnd and Sm Rnd vesicles account for 62% of the terminals on TTMNs, and they likely represent the pathways driving the contractions in response to sound or during voluntary movements. Having a high proportion of excitatory inputs, the TTMN innervation is like that of stapedius motoneurons but proportionately different from other types of motoneurons. Anat Rec, 296: 133-145, 2013. (C) 2012 Wiley Periodicals, Inc. C1 [Benson, Thane E.; Lee, Daniel J.; Brown, M. Christian] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Lee, Daniel J.; Brown, M. Christian] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Benson, TE (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM Thane_Benson@meei.harvard.edu FU National Institutes of Health-NIDCD [DC06285, DC01089] FX Grant sponsor: National Institutes of Health-NIDCD; Grant number: DC06285 (to D.J.L.) and DC01089 (to M.C.B.). NR 71 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1932-8486 J9 ANAT REC JI Anat. Rec. PD JAN PY 2013 VL 296 IS 1 BP 133 EP 145 DI 10.1002/ar.22620 PG 13 WC Anatomy & Morphology SC Anatomy & Morphology GA 086AV UT WOS:000314656300014 PM 23165747 ER PT J AU Williams, FMK Carter, AM Hysi, PG Surdulescu, G Hodgkiss, D Soranzo, N Traylor, M Bevan, S Dichgans, M Rothwell, PMW Sudlow, C Farrall, M Silander, K Kaunisto, M Wagner, P Saarela, O Kuulasmaa, K Virtamo, J Salomaa, V Amouyel, P Arveiler, D Ferrieres, J Wiklund, PG Ikram, MA Hofman, A Boncoraglio, GB Parati, EA Helgadottir, A Gretarsdottir, S Thorsteinsdottir, U Thorleifsson, G Stefansson, K Seshadri, S DeStefano, A Gschwendtner, A Psaty, B Longstreth, W Mitchell, BD Cheng, YC Clarke, R Ferrario, M Bis, JC Levi, C Attia, J Holliday, EG Scott, RJ Fornage, M Sharma, P Furie, KL Rosand, J Nalls, M Meschia, J Mosely, TH Evans, A Palotie, A Markus, HS Grant, PJ Spector, TD AF Williams, Frances M. K. Carter, Angela M. Hysi, Pirro G. Surdulescu, Gabriela Hodgkiss, Dylan Soranzo, Nicole Traylor, Matthew Bevan, Steve Dichgans, Martin Rothwell, Peter M. W. Sudlow, Cathie Farrall, Martin Silander, Kaisa Kaunisto, Mari Wagner, Peter Saarela, Olli Kuulasmaa, Kari Virtamo, Jarmo Salomaa, Veikko Amouyel, Philippe Arveiler, Dominique Ferrieres, Jean Wiklund, Per-Gunnar Ikram, M. Arfan Hofman, Albert Boncoraglio, Giorgio B. Parati, Eugenio A. Helgadottir, Anna Gretarsdottir, Solveig Thorsteinsdottir, Unnur Thorleifsson, Gudmar Stefansson, Kari Seshadri, Sudha DeStefano, Anita Gschwendtner, Andreas Psaty, Bruce Longstreth, Will Mitchell, Braxton D. Cheng, Yu-Ching Clarke, Robert Ferrario, Marco Bis, Joshua C. Levi, Christopher Attia, John Holliday, Elizabeth G. Scott, Rodney J. Fornage, Myriam Sharma, Pankaj Furie, Karen L. Rosand, Jonathan Nalls, Mike Meschia, James Mosely, Thomas H. Evans, Alun Palotie, Aarno Markus, Hugh S. Grant, Peter J. Spector, Tim D. CA EuroCLOT Investigators Wellcome Trust Case Control Consor Int Stroke Genetics Consortium TI Ischemic Stroke Is Associated with the ABO Locus: The EuroCLOT Study SO ANNALS OF NEUROLOGY LA English DT Article ID GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; ATRIAL-FIBRILLATION; HEALTHY FAMILIES; PLASMA-LEVELS; RISK-FACTORS; BLOOD-GROUPS; FACTOR-VII; SUSCEPTIBILITY; HERITABILITY AB Objective: End-stage coagulation and the structure/function of fibrin are implicated in the pathogenesis of ischemic stroke. We explored whether genetic variants associated with end-stage coagulation in healthy volunteers account for the genetic predisposition to ischemic stroke and examined their influence on stroke subtype. Methods: Common genetic variants identified through genome-wide association studies of coagulation factors and fibrin structure/function in healthy twins (n = 2,100, Stage 1) were examined in ischemic stroke (n = 4,200 cases) using 2 independent samples of European ancestry (Stage 2). A third clinical collection having stroke subtyping (total 8,900 cases, 55,000 controls) was used for replication (Stage 3). Results: Stage 1 identified 524 single nucleotide polymorphisms (SNPs) from 23 linkage disequilibrium blocks having significant association (p < 5 x 10(-8)) with 1 or more coagulation/fibrin phenotypes. The most striking associations included SNP rs5985 with factor XIII activity (p = 2.6 x 10(-186)), rs10665 with FVII (p = 2.4 x 10(-47)), and rs505922 in the ABO gene with both von Willebrand factor (p = 4.7 x 10(-57)) and factor VIII (p = 1.2 x 10(-36)). In Stage 2, the 23 independent SNPs were examined in stroke cases/noncases using MOnica Risk, Genetics, Archiving and Monograph (MORGAM) and Wellcome Trust Case Control Consortium 2 collections. SNP rs505922 was nominally associated with ischemic stroke (odds ratio = 0.94, 95% confidence interval = 0.88-0.99, p = 0.023). Independent replication in Meta-Stroke confirmed the rs505922 association with stroke, beta (standard error, SE) = 0.066 (0.02), p = 0.001, a finding specific to large-vessel and cardioembolic stroke (p = 0.001 and p = < 0.001, respectively) but not seen with small-vessel stroke (p = 0.811). Interpretation: ABO gene variants are associated with large-vessel and cardioembolic stroke but not small-vessel disease. This work sheds light on the different pathogenic mechanisms underpinning stroke subtype. ANN NEUROL 2012;73:16-31 C1 [Williams, Frances M. K.; Hysi, Pirro G.; Surdulescu, Gabriela; Hodgkiss, Dylan; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London SE1 7EH, England. [Carter, Angela M.; Grant, Peter J.] Univ Leeds, Div Cardiovasc & Diabet Res, Leeds, W Yorkshire, England. [Soranzo, Nicole; Palotie, Aarno] Wellcome Trust Sanger Inst, Hinxton, England. [Soranzo, Nicole; Palotie, Aarno] Broad Inst Massachusetts Inst Technol & Harvard, Program Med & Populat Genet & Genet Anal Platform, Cambridge, MA USA. [Soranzo, Nicole; Palotie, Aarno] Univ Helsinki, Dept Med Genet, Helsinki, Finland. [Soranzo, Nicole; Palotie, Aarno] Univ Cent Hosp, Helsinki, Finland. [Traylor, Matthew; Bevan, Steve; Markus, Hugh S.] St Georges Univ London, Stroke & Dementia Res Ctr, London, England. [Dichgans, Martin; Gschwendtner, Andreas] Univ Munich, Klinikum Univ Munich, Inst Stroke & Dementia Res, Munich, Germany. [Rothwell, Peter M. W.] Univ Oxford, Dept Clin Neurol, Stroke Prevent Res Unit, Oxford, England. [Sudlow, Cathie] Univ Edinburgh, Div Clin Neurosci, Edinburgh, Midlothian, Scotland. [Farrall, Martin; Helgadottir, Anna] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Farrall, Martin; Helgadottir, Anna] Univ Oxford, Dept Cardiovasc Med, Oxford, England. [Silander, Kaisa; Kaunisto, Mari; Wagner, Peter; Hofman, Albert; Evans, Alun; Palotie, Aarno] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland. [Saarela, Olli; Kuulasmaa, Kari; Virtamo, Jarmo; Salomaa, Veikko] Natl Inst Hlth & Welf, Chron Dis Epidemiol & Prevent Unit, Helsinki, Finland. [Amouyel, Philippe] Pasteur Inst Lille, Dept Epidemiol & Publ Hlth, Lille, France. [Arveiler, Dominique] Univ Strasbourg, Dept Epidemiol & Publ Hlth, Strasbourg, France. [Ferrieres, Jean] Fac Med, Dept Epidemiol, Toulouse, France. [Wiklund, Per-Gunnar] Umea Univ, Dept Internal Med, Umea, Sweden. [Ikram, M. Arfan; Hofman, Albert] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Boncoraglio, Giorgio B.; Parati, Eugenio A.] Res Hosp, Neurol Inst Carlo Besta, Dept Neurol, Milan, Italy. [Helgadottir, Anna; Gretarsdottir, Solveig; Thorsteinsdottir, Unnur; Thorleifsson, Gudmar; Stefansson, Kari] DeCODE Genet, Reykjavik, Iceland. [Seshadri, Sudha; DeStefano, Anita] Boston Univ, Sch Med, Boston, MA 02118 USA. [Seshadri, Sudha; DeStefano, Anita] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Seshadri, Sudha; DeStefano, Anita] Framingham Heart Dis Epidemiol Study, Framingham, MA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce; Longstreth, Will] Univ Washington, Seattle, WA 98195 USA. [Psaty, Bruce] Grp Hlth Res Inst, Grp Hlth, Seattle, WA USA. [Psaty, Bruce] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Longstreth, Will] Univ Maryland, Dept Med, Baltimore, MD 21201 USA. [Mitchell, Braxton D.; Cheng, Yu-Ching] Univ Oxford, Clin Trial Serv Unit, Oxford, England. [Clarke, Robert] Univ Insubria, Varese, Italy. [Ferrario, Marco] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Bis, Joshua C.] Univ Newcastle, Callaghan, NSW 2308, Australia. [Levi, Christopher; Attia, John; Holliday, Elizabeth G.; Scott, Rodney J.] John Hunter Hosp, New Lambton Hts, Australia. [Levi, Christopher; Attia, John; Holliday, Elizabeth G.; Scott, Rodney J.] Hunter Med Res Inst, New Lambton, Australia. [Levi, Christopher; Attia, John; Holliday, Elizabeth G.; Scott, Rodney J.] Univ Texas Houston, Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA. [Levi, Christopher; Attia, John; Holliday, Elizabeth G.; Scott, Rodney J.] Univ Texas Houston, Hlth Sci Ctr, Inst Mol Med, Houston, TX USA. [Fornage, Myriam] Univ London Imperial Coll Sci Technol & Med, Cerebrovasc Res Unit, London, England. [Sharma, Pankaj] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Sharma, Pankaj] Harvard Univ, Sch Med, Boston, MA USA. [Furie, Karen L.; Rosand, Jonathan] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Nalls, Mike; Meschia, James] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Mosely, Thomas H.] Queens Univ Belfast, Belfast, Antrim, North Ireland. RP Williams, FMK (reprint author), Kings Coll London, Dept Twin Res & Genet Epidemiol, St Thomas Hosp Campus,3rd Floor S Wing,Block 8,We, London SE1 7EH, England. RI Attia, John/F-5376-2013; Boncoraglio, Giorgio/B-8647-2011; Blackwell, Jenefer/H-3015-2015; OI Kaunisto, Mari/0000-0002-6946-9195; Plomin, Robert/0000-0002-0756-3629; Soranzo, Nicole/0000-0003-1095-3852; Bevan, Steve/0000-0003-0490-6830; Kuulasmaa, Kari/0000-0003-2165-1411; Attia, John/0000-0001-9800-1308; Seshadri, Sudha/0000-0001-6135-2622; Williams, Frances/0000-0002-2998-2744; Ikram, Mohammad Arfan/0000-0003-0372-8585; Ferrario, Marco M/0000-0003-2741-7124; Traylor, Matthew/0000-0001-6624-8621; Gillman, Matthew/0000-0002-2340-6930; Mitchell, Braxton/0000-0003-4920-4744 FU Wellcome Trust; EU FP7; DFG/DLR; Fondation Leducq; Vasc. Dem. Res. Foundation; Jackstaedt Foundation; Corona Foundation; Georg Thieme Verlag; UpToDate; W. Kohlhammer Verlag. P.A.; Medtronic; Zoll LifeCor; US Department of Veterans Affairs; Wellcome Trust funding of TwinsUK; EU [QLRT-2001-01254]; National Institute of Health Research (NIHR) Biomedical Resource Centre; St Thomas' National Health Service (NHS) Foundation Trust; King's College London; Wellcome Trust, as part of the WTCCC2 project [085475/B/08/Z, 085475/Z/08/Z, WT084724MA]; Vascular Dementia Research Foundation; Medical Research Council; Stroke Association; Dunhill Medical Trust; NIHR; NIHR Biomedical Research Centre, Oxford; Binks Trust; Scottish Funding Council; Chief Scientist Office; European Community's Seventh Framework Programme; ENGAGE project [HEALTH-F4-2007-201413]; Academy of Finland Center of Excellence in Complex Disease Genetics; Academy of Finland [251704]; Academy of Finland, Center of Excellence in Complex Disease Genetics [213506, 129680]; European Community's Seventh Framework Program; ENGAGE Consortium [HEALTH-F4-2007-201413]; EU/SYNSYS-Synaptic Systems [242167]; Sigrid Juselius Foundation, Finland; NIH National Heart, Lung, and Blood Institute (NHLBI) [R01 HL085251, R01 HL073410]; NHLBI [HHSN268201100005C, HHSN2682011000 06C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHS N268201100011C, HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694, N01-HC-25195, N02-HL-6-4278, HL093029]; National Human Genome Research Institute [U01HG004402]; NINDS [NS17950]; NIA [AG08122, AG16495, AG033193, AG031287] FX F.M.K.W.: grants/grants pending, Wellcome Trust Fellowship 2007-12. M. D.: board membership, Boehringer Ingelheim, Ever Pharma; consultancy, Bayer Vital, Boehringer Ingelheim, Biol Heilmittel Heel, Bristol-Myers Squibb; grants/grants pending, EU FP7, DFG/DLR, Fondation Leducq, Vasc. Dem. Res. Foundation, Jackstaedt Foundation, Corona Foundation; paid manuscript preparation, Georg Thieme Verlag, UpToDate, W. Kohlhammer Verlag. P. A.: board membership, Fondation Plan Alzheimer; consultancy, Servier, Total, Alzprotect; grants/grants pending, Ipsen, Sanofi-Aventis, AstraZeneca; stock/stock options, Genoscreen. P.-G. W.: board membership, Boehringer-Ingelheim. K. St.: board membership, stock/stock options, DeCODE Genetics. B. P.: Yale University, Service on Steering Committee for YODA funded by Medtronic; University of San Francisco, Service on DSMB for a clinical trial funded by Zoll LifeCor. Y.C. C.: grants/grants pending, US Department of Veterans Affairs.; TwinsUK acknowledges the Wellcome Trust funding of TwinsUK as well as Intermediate Fellow F. M. K. W., EU Framework 6 support for funding EuroCLOT (QLRT-2001-01254), and genotyping by Wellcome Trust Sanger Centre and Sequenom/Gemini genomics, Cambridge. TwinsUK is also supported by an National Institute of Health Research (NIHR) Biomedical Resource Centre grant to Guy's and St Thomas' National Health Service (NHS) Foundation Trust and King's College London. M. Boothby and J. Surr from The Division of Cardiovascular and Diabetes Research in Leeds, United Kingdom are thanked for their contributions to this program of work. The principal funding for the WTCCC2 stroke study was provided by the Wellcome Trust, as part of the WTCCC2 project (085475/B/08/Z, 085475/Z/08/Z, and WT084724MA).; The Stroke Association provided additional support for collection of some of the St George's, London cases. Collection of the Munich cases and data analysis were supported by the Vascular Dementia Research Foundation. The Oxford cases were collected as part of the Oxford Vascular Study, which is funded by the Medical Research Council, Stroke Association, Dunhill Medical Trust, NIHR, and the NIHR Biomedical Research Centre, Oxford. The Edinburgh Stroke Study was supported by the Wellcome Trust (clinician scientist award to C. S.) and the Binks Trust. Sample processing occurred in the Genetics Core Laboratory of the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. Much of the neuroimaging occurred at the Scottish Funding Council Brain Imaging Research Centre (www.sbirc.ed.ac.uk), Division of Clinical Neurosciences, University of Edinburgh, a core area of the Wellcome Trust Clinical Research Facility and part of the SINAPSE (Scottish Imaging Network-A Platform for Scientific Excellence) collaboration (www.sinapse.ac.uk), funded by the Scottish Funding Council and the Chief Scientist Office.; The MORGAM component of this research was in part funded through the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007-201413. K. Si. has been supported by the Academy of Finland Center of Excellence in Complex Disease Genetics. MORGAM thanks K. Kaliva and T. Tuovinen for help with statistical analyses and K. Kristiansson, who processed and assessed the Metabochip data.; Grant support was provided by the Wellcome Trust (grant number 098051 to A. P.); Academy of Finland (grant number 251704 to A. P.); Academy of Finland, Center of Excellence in Complex Disease Genetics (grant numbers 213506 and 129680 to A. P.); European Community's Seventh Framework Program (FP7/2007-2013), ENGAGE Consortium (grant agreement HEALTH-F4-2007-201413); EU/SYNSYS-Synaptic Systems (grant number 242167 to A. P.); and Sigrid Juselius Foundation, Finland (to A.P.).; The Heart and Vascular Health study research was supported by NIH National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL085251 and R01 HL073410.; The Atherosclerosis Risk in Communities Study was carried out as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN2682011000 06C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHS N268201100011C, and HHSN268201100012C) and grants (R01HL087641, R01HL59367, and R01HL086694); National Human Genome Research Institute contract U01HG004402; and NIH contract HHSN268200625226C. Infrastructure was partly supported by grant number UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. Atherosclerosis Risk in Communities analyses performed as part of the MetaStroke project were supported by grant HL093029 to M. Fa. The authors thank the staff and participants of the Atherosclerosis Risk in Communities study for their important contributions.; The Australian Stroke Genetics Collaborative (ASGC) GWAS was funded by grants from the Australian National and Medical Health Research Council (NHMRC Project Grant ID: 569257), the Australian National Heart Foundation (NHF Project Grant ID: G 04S 1623), the University of Newcastle, the Gladys M Brawn Fellowship scheme and the Vincent Fairfax Family Foundation in Australia. Australian population control data was derived from the Hunter Community Study. We thank the University of Newcastle for funding and the men and women of the Hunter region who participated in this study. EGH is supported by the Australian NHMRC Fellowship scheme.; Bio-Repository of DNA in Stroke (BRAINS) is an international study recruiting highly phenotyped patients with stroke. For the purposes of the current work, all patients were Caucasians. Diagnosis of stroke was confirmed using positive imaging (MR imaging or CT). BRAINS is partly funded by a Senior Fellowship from the UK Department of Health to Dr Pankaj Sharma, the Henry Smith Charity, and the UK-India Education Research Institutive from the British Council.; The Besta Cerebrovascular Diseases Registry (CEDIR) was supported by the Italian Ministry of Health, years 2007-2010 (Annual Research Funding; Grant Numbers: RC 2007/LR6, RC 2008/LR6; RC 2009/LR8; RC 2010/LR8). Controls for CEDIR were provided by PROCARDIS, which acknowledges support from EC FP6 (LSHMCT-2007-037273) and AstraZeneca AB. M. Fa. is supported by the British Heart Foundation Centre for Research Excellence. A. He. was supported by an Intermediate Fellowship award from the Oxford BHF Centre for Research Excellence. M. Fe. acknowledges support from the Wellcome Trust core award to the Wellcome Trust Centre for Human Genetics (075491/Z/04 and 090532/Z09/Z).; Cardiovascular Health Study research was supported by NHLBI contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC15103, N01 HC-55222, N01-HC-75150, and N01HC- 45133 and NHLBI grants HL080295, HL075366, HL087652, and HL105756, with an additional contribution from the NIH National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the NIH National Institute on Aging (NIA). See also http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping were supported in part by National Center for Research Resources Clinical and Translational Sciences Institute grant UL 1RR033176 and National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center.; Framingham Heart Study research was supported by NHLBI contracts N01-HC-25195 and N02-HL-6-4278; and NINDS (NS17950), NHLBI (HL093029) and NIA (AG08122, AG16495, AG033193, AG031287).; The Genetics of Early Onset Stroke Study was supported by the National Institutes of Health Genes, Environment, and Health Initiative (GEI) grant U01 HG004436, as part of the GENEVA consortium under GEI, with additional support provided by the Mid-Atlantic Nutrition and Obesity Research Center (P30 DK072488); and the Office of Research and Development, Medical Research Service, and Baltimore Geriatrics Research, Education, and Clinical Center of the Department of Veterans Affairs. Genotyping services were provided by the Johns Hopkins University Center for Inherited Disease Research, which is fully funded through a federal contract from the NIH to Johns Hopkins University (contract HHSN268200782096C). Assistance with data cleaning was provided by the GENEVA Coordinating Center (U01 HG 004446; principal investigator, Bruce S. Weir). Study recruitment and collection of datasets were supported by a Cooperative Agreement with the Division of Adult and Community Health, Centers for Disease Control and by grants from the NINDS and the NIH Office of Research on Women's Health (R01 NS45012 and U01 NS069208-01).; The Ischemic Stroke Genetics Study (ISGS) and Siblings With Ischemic Stroke Study (SWISS) were supported in part by the Intramural Research Program of the NIA, NIH project Z01 AG-000954-06. ISGS/ SWISS used samples and clinical data from the NIHNINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds),human subjects protocol numbers 2003-081 and 2004-147. ISGS/SWISS used stroke-free participants from the Baltimore Longitudinal Study of Aging (BLSA) as controls. The inclusion of BLSA samples was supported in part by the Intramural Research Program of the NIA, NIH project Z01 AG-000015-50, human subjects protocol number 2003-078. The ISGS study was funded by NIHNINDS grant R01 NS-42733 (J. M.). The SWISS study was funded by NIH-NINDS grant R01 NS-39987 (J. M.). This study used the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (http://biowulf.nih.gov). NR 41 TC 40 Z9 40 U1 2 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD JAN PY 2013 VL 73 IS 1 BP 16 EP 31 DI 10.1002/ana.23838 PG 16 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 086CN UT WOS:000314660800007 PM 23381943 ER PT J AU Yigitkanli, K Pekcec, A Karatas, H Pallast, S Mandeville, E Joshi, N Smirnova, N Gazaryan, I Ratan, RR Witztum, JL Montaner, J Holman, TR Lo, EH van Leyen, K AF Yigitkanli, Kazim Pekcec, Anton Karatas, Hulya Pallast, Stefanie Mandeville, Emiri Joshi, Netra Smirnova, Natalya Gazaryan, Irina Ratan, Rajiv R. Witztum, Joseph L. Montaner, Joan Holman, Theodore R. Lo, Eng H. van Leyen, Klaus TI Inhibition of 12/15-Lipoxygenase as Therapeutic Strategy to Treat Stroke SO ANNALS OF NEUROLOGY LA English DT Article ID TRANSIENT FOCAL ISCHEMIA; OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; LIPOXYGENASE INHIBITORS; GLUTATHIONE DEPLETION; BRAIN EDEMA; 12-LIPOXYGENASE; RATS; BAICALEIN; DEATH AB Targeting newly identified damage pathways in the ischemic brain can help to circumvent the currently severe limitations of acute stroke therapy. Here we show that the activity of 12/15-lipoxygenase was increased in the ischemic mouse brain, and 12/15-lipoxygenase colocalized with a marker for oxidized lipids, MDA2. This colocalization was also detected in the brain of 2 human stroke patients, where it also coincided with increased apoptosis-inducing factor. A novel inhibitor of 12/15-lipoxygenase, LOXBlock-1, protected neuronal HT22 cells against oxidative stress. In a mouse model of transient focal ischemia, the inhibitor reduced infarct sizes both 24 hours and 14 days poststroke, with improved behavioral parameters. Even when treatment was delayed until at least 4 hours after onset of ischemia, LOXBlock-1 was protective. Furthermore, it reduced tissue plasminogen activator-associated hemorrhage in a clot model of ischemia/reperfusion. This study establishes inhibition of 12/15-lipoxygenase as a viable strategy for first-line stroke treatment. ANN NEUROL 2013;73:129-135 C1 [Yigitkanli, Kazim; Pekcec, Anton; Karatas, Hulya; Pallast, Stefanie; Lo, Eng H.; van Leyen, Klaus] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neuroprotect Res Lab, Charlestown, MA USA. [Joshi, Netra; Holman, Theodore R.] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA. [Smirnova, Natalya; Gazaryan, Irina; Ratan, Rajiv R.] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Burke Med Res Inst, White Plains, NY USA. [Witztum, Joseph L.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Montaner, Joan] Vall Hebron Univ Hosp, Res Inst, Neurovasc Res Lab, Barcelona, Spain. RP van Leyen, K (reprint author), Massachusetts Gen Hosp, Neuroprotect Res Lab, 149 13th St,R 2401, Charlestown, MA 02129 USA. EM klaus_vanleyen@hms.harvard.edu RI van Leyen, Klaus/C-9126-2013; Karatas, Hulya/J-1459-2013; Montaner, Joan/D-3063-2015; IBIS, NEUROVASCULAR/O-1855-2015 OI Karatas, Hulya/0000-0003-4838-6320; FU NIH NINDS [R01NS049430, NIGMS R01GM56062]; Isis Pharmacetical; Regulus; Intercept FX Support through grants from the NIH NINDS (R01NS049430, K. v. L.; NIGMS R01GM56062, T. R. H.) is gratefully acknowledged.; R.R.R.: board membership, consultancy, stocks/stock options, GliaMed. J.L.W.: consulting fees, Isis Pharmacetical, Regulus, Intercept; holding patents and patent applications for the use of oxidation-specific antibodies that are held by the University of California at San Diego; member of board of directors of Atherotope. T. R. H., E. H. L., K. v. L.: patents, US patent application No. 12/671,567. NR 33 TC 31 Z9 31 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD JAN PY 2013 VL 73 IS 1 BP 129 EP 135 DI 10.1002/ana.23734 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 086CN UT WOS:000314660800018 PM 23192915 ER PT J AU Bhagat, S Bass, J Qaddoumi, I Brennan, R Wilson, M Wu, JR Galindo, CR Paglialonga, A Tognola, G AF Bhagat, Shaum Bass, Johnnie Qaddoumi, Ibrahim Brennan, Rachel Wilson, Matthew Wu, Jianrong Galindo, Carlos-Rodriguez Paglialonga, Alessia Tognola, Gabriella TI Time-Frequency Analysis of Transient-Evoked Otoacoustic Emissions in Children Exposed to Carboplatin Chemotherapy SO AUDIOLOGY AND NEURO-OTOLOGY LA English DT Article DE Retinoblastoma; Carboplatin therapy; Hearing loss; Ototoxicity; Transient-evoked otoacoustic emissions ID CISPLATIN-INDUCED OTOTOXICITY; HEARING-LOSS; RECEIVING CARBOPLATIN; YOUNG-CHILDREN; PLATINUM CHEMOTHERAPY; RETINOBLASTOMA; NEUROBLASTOMA; VINCRISTINE; AUDIOMETRY; LATENCY AB The aims of this study were to characterize and quantify time-frequency changes in transient-evoked otoacoustic emissions (TEOAEs) recorded in children diagnosed with retinoblastoma who were receiving carboplatin chemotherapy. A signal processing technique, the wavelet transform (WT), was used to analyze TEOAE waveforms in narrow-band frequency components. Ten children (aged 3-72 months) diagnosed with unilateral or bilateral retinoblastoma were enrolled in the study. TEOAEs were acquired from the children with linear sequences of 70 dB peak equivalent SPL clicks. After WT analysis, TEOAE energy, latency and normalized energy in the narrow-band frequency components were compared before and during carboplatin chemotherapy treatment (average dose 1693 mg/m(2)). On a group basis, no significant differences (p > 0.05) in the TEOAE energy, latency or normalized energy before and after carboplatin treatment were observed. There were decreases in normalized energy on an individual basis in 10 out of 18 ears in the sample. Exposure to carboplatin chemotherapy did not cause significant changes in TEOAE energy, latency and normalized energy during treatment. However, long-term monitoring of hearing with measurements of TEOAEs is warranted, given the risks of delayed hearing loss in some children receiving carboplatin chemotherapy. Copyright (C) 2012 S. Karger AG, Basel C1 [Bhagat, Shaum] Univ Memphis, Sch Commun Sci & Disorders, Hearing Sci Lab, Memphis, TN 38105 USA. [Bhagat, Shaum; Bass, Johnnie; Qaddoumi, Ibrahim; Brennan, Rachel; Wilson, Matthew; Wu, Jianrong; Galindo, Carlos-Rodriguez] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Wilson, Matthew] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [Galindo, Carlos-Rodriguez] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Paglialonga, Alessia; Tognola, Gabriella] CNR, Ist Ingn Biomed, I-20133 Milan, Italy. RP Bhagat, S (reprint author), Univ Memphis, Sch Commun Sci & Disorders, Hearing Sci Lab, 807 Jefferson Ave, Memphis, TN 38105 USA. EM sbhagat@memphis.edu RI Paglialonga, Alessia/F-9847-2010; Tognola, Gabriella/B-9025-2015 OI Paglialonga, Alessia/0000-0002-1341-2560; Tognola, Gabriella/0000-0002-2433-449X FU US Public Health Service [CA 21765, CA 23099]; American Lebanese Syrian Associated Charities FX This work was supported in part by grants CA 21765 and CA 23099 from the US Public Health Service and by the American Lebanese Syrian Associated Charities. We wish to thank Tammy Free and Vicki Given for their contributions to this project. NR 50 TC 7 Z9 7 U1 0 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-3030 J9 AUDIOL NEURO-OTOL JI Audiol. Neuro-Otol. PY 2013 VL 18 IS 2 BP 71 EP 82 DI 10.1159/000343909 PG 12 WC Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology GA 087OP UT WOS:000314771800001 PM 23147804 ER PT J AU Wang, N De Vuyst, E Ponsaerts, R Boengler, K Palacios-Prado, N Wauman, J Lai, CP De Bock, M Decrock, E Bol, M Vinken, M Rogiers, V Tavernier, J Evans, WH Naus, CC Bukauskas, FF Sipido, KR Heusch, G Schulz, R Bultynck, G Leybaert, L AF Wang, Nan De Vuyst, Elke Ponsaerts, Raf Boengler, Kerstin Palacios-Prado, Nicolas Wauman, Joris Lai, Charles P. De Bock, Marijke Decrock, Elke Bol, Melissa Vinken, Mathieu Rogiers, Vera Tavernier, Jan Evans, W. Howard Naus, Christian C. Bukauskas, Feliksas F. Sipido, Karin R. Heusch, Gerd Schulz, Rainer Bultynck, Geert Leybaert, Luc TI Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury SO BASIC RESEARCH IN CARDIOLOGY LA English DT Article DE Connexin; Hemichannel; Gap junction; Single channel; Myocardial injury ID CONNEXIN MIMETIC PEPTIDES; METABOLIC INHIBITION; JUNCTION CHANNELS; OCULODENTODIGITAL DYSPLASIA; INTERCELLULAR COMMUNICATION; CARDIOMYOCYTE MITOCHONDRIA; MEMBRANE PERMEABILIZATION; ISCHEMIA-REPERFUSION; CARDIAC MYOCYTES; CYTOPLASMIC LOOP AB Connexin-43 (Cx43), a predominant cardiac connexin, forms gap junctions (GJs) that facilitate electrical cell-cell coupling and unapposed/nonjunctional hemichannels that provide a pathway for the exchange of ions and metabolites between cytoplasm and extracellular milieu. Uncontrolled opening of hemichannels in the plasma membrane may be deleterious for the myocardium and blocking hemichannels may confer cardioprotection by preventing ionic imbalance, cell swelling and loss of critical metabolites. Currently, all known hemichannel inhibitors also block GJ channels, thereby disturbing electrical cell-cell communication. Here we aimed to characterize a nonapeptide, called Gap19, derived from the cytoplasmic loop (CL) of Cx43 as a hemichannel blocker and examined its effect on hemichannel currents in cardiomyocytes and its influence in cardiac outcome after ischemia/reperfusion. We report that Gap 19 inhibits Cx43 hemichannels without blocking GJ channels or Cx40/pannexin-1 hemichannels. Hemichannel inhibition is due to the binding of Gap19 to the C-terminus (CT) thereby preventing intramolecular CT-CL interactions. The peptide inhibited Cx43 hemichannel unitary currents in both HeLa cells exogenously expressing Cx43 and acutely isolated pig ventricular cardiomyocytes. Treatment with Gap19 prevented metabolic inhibition-enhanced hemichannel openings, protected cardiomyocytes against volume overload and cell death following ischemia/reperfusion in vitro and modestly decreased the infarct size after myocardial ischemia/reperfusion in mice in vivo. We conclude that preventing Cx43 hemichannel opening with Gap19 confers limited protective effects against myocardial ischemia/reperfusion injury. C1 [Wang, Nan; De Vuyst, Elke; De Bock, Marijke; Decrock, Elke; Bol, Melissa; Leybaert, Luc] Univ Ghent, Dept Basic Med Sci, Physiol Grp, Fac Med & Hlth Sci, B-9000 Ghent, Belgium. [Ponsaerts, Raf; Bultynck, Geert] Katholieke Univ Leuven, KU Leuven, Dept Cellular & Mol Med, Lab Mol & Cellular Signaling, Louvain, Belgium. [Boengler, Kerstin; Schulz, Rainer] Univ Giessen, Physiol Inst, D-35390 Giessen, Germany. [Palacios-Prado, Nicolas; Bukauskas, Feliksas F.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10467 USA. [Wauman, Joris; Tavernier, Jan] Univ Ghent VIB, Dept Med Prot Res, Fac Med & Hlth Sci, Cytokine Receptor Lab, B-9000 Ghent, Belgium. [Lai, Charles P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Program,Dept Neurol, Charlestown, MA USA. [Lai, Charles P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA. [Vinken, Mathieu; Rogiers, Vera] Vrije Univ Brussel, Fac Med & Pharm, Dept Toxicol, Brussels, Belgium. [Evans, W. Howard] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF10 3AX, S Glam, Wales. [Naus, Christian C.] Univ British Columbia, Inst Life Sci, Fac Med, Dept Cellular & Physiol Sci, Vancouver, BC V5Z 1M9, Canada. [Sipido, Karin R.] Katholieke Univ Leuven, Dept Cardiovasc Dis, Div Expt Cardiol, Louvain, Belgium. [Heusch, Gerd] Univ Klinikum Essen, Inst Pathophysiol, Essen, Germany. RP Leybaert, L (reprint author), Univ Ghent, Dept Basic Med Sci, Physiol Grp, Fac Med & Hlth Sci, De Pintelaan 185,Block B,Rm 310, B-9000 Ghent, Belgium. EM Luc.Leybaert@UGent.be RI Vinken, Mathieu/H-7513-2013; Lai, Charles/D-5442-2017; Leybaert, Luc/F-4079-2015; OI Vinken, Mathieu/0000-0001-5115-8893; Bultynck, Geert/0000-0002-5968-4828; Leybaert, Luc/0000-0001-6452-6982; De Bock, Marijke/0000-0001-8823-0000 FU Fund for Scientific Research Flanders, Belgium (FWO) [G.0354.07, G.0140.08, 3G.0134.09, G.0298.11 N, G.0545.08]; Interuniversity Attraction Poles Program (Belgian Science Policy) [P6/31, P7/10, P7]; Concerted Actions program at KULeuven [GOA/09/012]; German Research Foundation [Schu 843/7-2]; BFH [PG/01/1298]; Heart & Stroke Foundation of BC Yukon; Canadian Institutes of Health Research; NIH [HL084464, NS072238] FX Special thanks to K. Leurs, K. Vermeulen and K. Welkenhuyzen for superb technical support. We express our gratitude to Dr. B. Himpens for support, to Dr. P. Zimmermann for the use of the Biacore 2000, to Dr. P. Sorgen for providing the pGEX6p2-Cx43CT plasmid, to Dr. G. Antoons for support with experiments on pig myocytes, and to Dr. D. Laird and Dr. S. Penuela for providing the anti-Panx1 antibody. We are very grateful to A. Gadicherla and Dr. B. Nilius for critically reading and commenting the manuscript. Research supported by the Fund for Scientific Research Flanders, Belgium (FWO, grant nos. G.0354.07, G.0140.08, 3G.0134.09 and G.0298.11 N to L.L. and G.0545.08 to G.B.), the Interuniversity Attraction Poles Program (Belgian Science Policy, project P6/31 and P7/10 to K.R.S and L.L., and P7 to J.T. and G.B.), the Concerted Actions program at KULeuven (grant no. GOA/09/012 to G.B.), the German Research Foundation (Schu 843/7-2 to R. S.), the BFH grant (grant no. PG/01/1298 to W.H.E), the Heart & Stroke Foundation of BC & Yukon and the Canadian Institutes of Health Research to C.C.N. and NIH grants (HL084464 and NS072238 to F. F. B.). NR 80 TC 57 Z9 62 U1 3 U2 51 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8428 J9 BASIC RES CARDIOL JI Basic Res. Cardiol. PD JAN PY 2013 VL 108 IS 1 AR 309 DI 10.1007/s00395-012-0309-x PG 16 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 085VF UT WOS:000314641700001 PM 23184389 ER PT J AU Sullivan, R AF Sullivan, R. TI The challenge of developing useful blood-based biomarkers in melanoma SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Editorial Material ID CELLS C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Sullivan, R (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM rsullivan7@partners.org NR 6 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JAN PY 2013 VL 168 IS 1 BP 3 EP 3 DI 10.1111/bjd.12088 PG 1 WC Dermatology SC Dermatology GA 083MS UT WOS:000314469000032 PM 23278557 ER PT J AU Vasquez, R Wang, D Tran, QP Adams-Huet, B Chren, MM Costner, MI Cohen, JB Werth, VP Chong, BF AF Vasquez, R. Wang, D. Tran, Q. P. Adams-Huet, B. Chren, M-M Costner, M. I. Cohen, J. B. Werth, V. P. Chong, B. F. TI A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID HEALTH SURVEY SF-36; MEDICAL OUTCOMES; SEVERITY INDEX; SKIN-DISEASE; IMPACT; EPIDEMIOLOGY; INSTRUMENT; VALIDITY; SPECTRUM; AREA AB Background A study at the University of Pennsylvania (UPenn) Medical Center demonstrated that quality of life in patients with cutaneous lupus erythematosus (CLE) is negatively impacted. Whether patients with CLE in other geographic locations have similar quality of life is unknown. Objectives We sought to compare quality of life indicators between patients with CLE at the University of Texas Southwestern (UTSW) Medical Center at Dallas and those at UPenn. Methods Patients with CLE (total n = 248) at UTSW (n = 91) and UPenn (n = 157) completed the Skindex-29 + 3 and Short Form-36 (SF-36) surveys related to quality of life. Additional information, including demographics, presence of systemic lupus erythematosus (SLE) and disease severity, was collected from UTSW patients with CLE. Results Most Skindex-29 + 3 and SF-36 subdomain scores between UTSW and UPenn patients with CLE were similar. However, UTSW patients with CLE were significantly more affected in the functioning and lupus-specific Skindex-29 + 3 domains, and physical functioning, role-physical and general health SF-36 sub-scales than UPenn patients with CLE (P < 0.05). Factors related to poor quality of life in UTSW patients with CLE include sex, income, education, presence of SLE, and skin disease activity. Conclusions Most quality of life indicators were similar between the two CLE populations. Differences in psychosocial behaviour, and a larger proportion of patients with SLE and females in the UTSW group likely attributed to differences in a minority of Skindex-29 + 3 and SF-36 subdomains. Capturing data from CLE populations in different locations provides a more thorough picture of the quality of life that patients with CLE experience on a daily basis with special attention to quality of life issues in select patients with CLE. C1 [Vasquez, R.; Wang, D.; Tran, Q. P.; Costner, M. I.; Cohen, J. B.; Chong, B. F.] Univ Texas SW Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA. [Adams-Huet, B.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Chren, M-M] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. RP Chong, BF (reprint author), Univ Texas SW Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA. EM ben.chong@utsouthwestern.edu FU NIH CTSA Grant [UL1 RR024982]; American College of Rheumatology/Arthritis Foundation Bridge Funding Grant; Celgene Corporation; Amgen Incorporated; Astion Pharma FX This project was funded in part by NIH CTSA Grant #UL1 RR024982 and the American College of Rheumatology/Arthritis Foundation Bridge Funding Grant (BFC).; V.P.W. is a consultant for Pfizer Incorporated, Medimmune, Genentech Incorporated, Novartis International AG, Celgene Corporation, Stiefel Laboratories, Incorporated, Rigel Pharmaceuticals, Amgen Incorporated, and Astion Pharma. V. P. W. has also received grants and honoraria from Celgene Corporation, Amgen Incorporated, and Astion Pharma. B. F. C. is an investigator for Celgene Corporation and Amgen Incorporated. NR 29 TC 8 Z9 9 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JAN PY 2013 VL 168 IS 1 BP 145 EP 153 DI 10.1111/j.1365-2133.2012.11106.x PG 9 WC Dermatology SC Dermatology GA 083MS UT WOS:000314469000051 PM 22708924 ER PT J AU Lubitz, SA Ellinor, PT AF Lubitz, Steven A. Ellinor, Patrick T. TI A Common Connexion Between Gap Junctions, Single Nucleotide Polymorphisms, and Atrial Fibrillation? SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Editorial Material ID RISK-FACTOR; ASSOCIATION C1 [Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Charlestown, MA 02129 USA. Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. RP Ellinor, PT (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, 149 13th St,4th Floor, Charlestown, MA 02129 USA. EM pellinor@partners.org FU NHLBI NIH HHS [1K24HL105780, 1R01HL104156, 1R01HL092577]; NIDA NIH HHS [5R21DA027021] NR 10 TC 3 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X J9 CAN J CARDIOL JI Can. J. Cardiol. PD JAN PY 2013 VL 29 IS 1 BP 3 EP 5 DI 10.1016/j.cjca.2012.09.001 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 083LI UT WOS:000314464900002 PM 23107781 ER PT J AU Geltzer, A Turalba, A Vedula, SS AF Geltzer, Arthur Turalba, Angela Vedula, Satyanarayana S. TI Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Angiogenesis Inhibitors [administration & dosage]; Choroidal Neovascularization [complications; drug therapy]; Drug Implants; Macular Degeneration [drug therapy; etiology]; Pregnadienediols [administration & dosage]; Randomized Controlled Trials as Topic; Triamcinolone Acetonide [administration & dosage]; Humans ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE ACETONIDE; RANDOMIZED CLINICAL-TRIAL; PHOTODYNAMIC THERAPY; ANECORTAVE ACETATE; ANGIOSTATIC STEROIDS; VERTEPORFIN; MACULOPATHY; SAFETY; TAP AB Background Neovascular age-related macular degeneration (AMD) is associated with rapid vision loss due to choroidal neovascularization (CNV), leakage, and scarring. Steroids have gained attention in their role for the treatment of neovascular AMD for their antiangiogenic and anti-inflammatory properties. Objectives This review aims to examine effects of steroids with antiangiogenic properties in the treatment of neovascular AMD. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 11), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to November 2012), EMBASE (January 1980 to November 2012), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to November 2012), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 21 November 2012. Selection criteria We included randomized controlled clinical trials of intra-and peri-ocular antiangiogenic steroids in people diagnosed with neovascular AMD. Data collection and analysis Two authors independently screened abstracts and full-text articles, assessed risk of bias in the included trials, and extracted data. We did not conduct a meta-analysis. Main results We included three trials after screening a total of 1503 abstracts and 21 full-text articles. The three trials included a total of 809 participants. One trial compared different doses of acetonide anecortave acetate with placebo, a second trial compared triamcinolone acetonide versus placebo, and the third trial compared anecortave acetate against photodynamic therapy (PDT). We did not conduct a meta-analysis owing to heterogeneity of interventions and comparisons. The risk ratio for loss of 3 or more lines of vision at 12 months follow-up was 0.8 (95% confidence interval (CI) 0.45 to 1.45) with 3 mg anecortave acetate, 0.45 (95% CI = 0.21 to 0.97) with 15 mg anecortave acetate, 0.91 (0.52 to 1.58) with 30 mg anecortave acetate, 0.97 (95% CI 0.74 to 1.26) with triamcinolone acetonide, all compared to placebo and 1.08 (95% CI 0.91 to 1.29) with anecortave acetate compared with PDT. Authors' conclusions Based on the included trials, we found no evidence that antiangiogenic steroids prevent visual loss in patients with neovascular AMD. With the emergence of anti-vascular endothelial growth factor modalities, based on evidence summarized in this review, it is unclear what role steroids have in treating patients with neovascular AMD. C1 [Geltzer, Arthur] Brown Univ, Providence, RI 02906 USA. [Turalba, Angela] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Vedula, Satyanarayana S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Geltzer, A (reprint author), Brown Univ, 389 Benefit St, Providence, RI 02906 USA. EM youngheeart@mac.com FU Brown University, USA; Johns Hopkins University, USA; National Eye Institute, National Institutes of Health, USA [N-01-EY-2-1003, 1 U01 EY020522-01] FX Internal sources; Brown University, USA.; Johns Hopkins University, USA.; External sources; Contract N-01-EY-2-1003, National Eye Institute, National Institutes of Health, USA.; Grant 1 U01 EY020522-01, National Eye Institute, National Institutes of Health, USA. NR 47 TC 4 Z9 4 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 1 AR CD005022 DI 10.1002/14651858.CD005022.pub3 PG 32 WC Medicine, General & Internal SC General & Internal Medicine GA 081JQ UT WOS:000314315800022 PM 23440797 ER PT J AU DiGiovanna, JJ Mauro, T Milstone, LM Schmuth, M Toro, JR AF DiGiovanna, John J. Mauro, Theodora Milstone, Leonard M. Schmuth, Matthias Toro, Jorge R. TI Systemic retinoids in the management of ichthyoses and related skin types SO DERMATOLOGIC THERAPY LA English DT Review DE acitretin; ectropion; ichthyosis; isotretinoin; retinoid ID PITYRIASIS-RUBRA-PILARIS; HAILEY-HAILEY-DISEASE; RECESSIVE CONGENITAL ICHTHYOSIS; VITAMIN-A-DEFICIENCY; DARIERS-DISEASE; ERYTHROKERATODERMIA VARIABILIS; DOUBLE-BLIND; KID SYNDROME; EPIDERMOLYTIC HYPERKERATOSIS; GENETIC-HETEROGENEITY AB The term retinoid includes both natural and synthetic derivatives of vitamin A. Retinoid-containing treatments have been used since approximate to 1550BC by the early Egyptians. Treatment of ichthyosiform disorders with retinoids dates back at least to the 1930s. Early use of high-dose vitamin A demonstrated efficacy, but because vitamin A is stored in the liver, toxicity limited usefulness. Interest turned to synthetic retinoids in an effort to enhance efficacy and limit toxicity. Acetretin, isotretinoin and, in the past etretinate, have provided the most effective therapy for ichthyosiform conditions. They have been used for a variety of ages, including in newborns with severe ichthyosis and for decades in some patients. Careful surveillance and management of mucous membrane, laboratory, skeletal, and teratogenic side effects has made systemic retinoids the mainstay of therapy for ichthyosis and related skin types. C1 [DiGiovanna, John J.] NCI, DNA Repair Sect, Dermatol Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA. [Toro, Jorge R.] NCI, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA. [Mauro, Theodora] Univ Calif San Francisco, Dept Dermatol, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA. [Mauro, Theodora] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Milstone, Leonard M.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA. [Schmuth, Matthias] Med Univ Innsbruck, Dept Dermatol & Venereol, A-6020 Innsbruck, Austria. [Toro, Jorge R.] Washington DC Vet Adm Med Ctr, Dept Dermatol, Washington, DC USA. RP DiGiovanna, JJ (reprint author), NCI, DNA Repair Sect, Dermatol Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA. EM jdigiova@mail.nih.gov OI Schmuth, Matthias/0000-0002-4064-1334 FU Intramural Research Program of the NCI, NIH, Medical Research Fund Tirol [MFF71, MFF153]; Austrian Science Fund [FWF J1901-MED, J2112-MED, P16990-B05]; European Cooperation in Science and Technology [COST Action BM0903] FX This research was supported in part by the Intramural Research Program of the NCI, NIH, Medical Research Fund Tirol (MFF71, MFF153), the Austrian Science Fund (FWF J1901-MED, J2112-MED, P16990-B05), the European Cooperation in Science and Technology (COST Action BM0903)" NR 101 TC 15 Z9 16 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1396-0296 J9 DERMATOL THER JI Dermatol. Ther. PD JAN-FEB PY 2013 VL 26 IS 1 BP 26 EP 38 DI 10.1111/j.1529-8019.2012.01527.x PG 13 WC Dermatology SC Dermatology GA 086CX UT WOS:000314661900003 PM 23384018 ER PT J AU Kahn, SE AF Kahn, Steven E. TI Quantifying beta-Cells in Health and Disease: The Past, the Present, and the Need SO DIABETES CARE LA English DT Editorial Material ID ENDOPLASMIC-RETICULUM STRESS; TYPE-2 DIABETES-MELLITUS; HUMAN PANCREATIC-ISLETS; AMYLOID DEPOSITION; APOPTOSIS; PATHOGENESIS; CONTRIBUTES; LANGERHANS C1 [Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Kahn, SE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. EM skahn@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002 FU BLRD VA [I01 BX001060]; NIDDK NIH HHS [P30 DK017047, R01 DK075998] NR 22 TC 5 Z9 5 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2013 VL 36 IS 1 BP 4 EP 5 DI 10.2337/dc12-1526 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LP UT WOS:000314465700021 PM 23264284 ER PT J AU Grant, RW O'Brien, KE Waxler, JL Vassy, JL Delahanty, LM Bissett, LG Green, RC Stember, KG Guiducci, C Park, ER Florez, JC Meigs, JB AF Grant, Richard W. O'Brien, Kelsey E. Waxler, Jessica L. Vassy, Jason L. Delahanty, Linda M. Bissett, Laurie G. Green, Robert C. Stember, Katherine G. Guiducci, Candace Park, Elyse R. Florez, Jose C. Meigs, James B. TI Personalized Genetic Risk Counseling to Motivate Diabetes Prevention A randomized trial SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; COST-EFFECTIVENESS; GENOMIC MEDICINE; BEHAVIOR-CHANGE; TYPE-2; PROGRAM; PREVALENCE; REDUCTION; COMMUNITY AB OBJECTIVE-To examine whether diabetes genetic risk testing and counseling can improve diabetes prevention behaviors. RESEARCH DESIGN AND METHODS-We conducted a randomized trial of diabetes genetic risk counseling among overweight patients at increased phenotypic risk for type 2 diabetes. Participants were randomly allocated to genetic testing versus no testing. Genetic risk was calculated by summing 36 single nucleotide polymorphisms associated with type 2 diabetes. Participants in the top and bottom score quartiles received individual genetic counseling before being enrolled with untested control participants in a 12-week, validated, diabetes prevention program. Middle-risk quartile participants were not studied further. We examined the effect of this genetic counseling intervention on patient self-reported attitudes, program attendance, and weight loss, separately comparing higher-risk and lower-risk result recipients with control participants. RESULTS-The 108 participants enrolled in the diabetes prevention program included 42 participants at higher diabetes genetic risk, 32 at lower diabetes genetic risk, and 34 untested control subjects. Mean age was 57.9 +/- 10.6 years, 61% were men, and average BMI was 34.8 kg/m(2), with no differences among randomization groups. Participants attended 6.8 +/- 4.3 group sessions and lost 8.5 +/- 10.1 pounds, with 33 of 108 (30.6%) losing >5% body weight. There were few statistically significant differences in self-reported motivation, program attendance, or mean weight loss when higher-risk recipients and lower-risk recipients were compared with control subjects (P > 0.05 for all but one comparison). CONCLUSIONS-Diabetes genetic risk counseling with currently available variants does not significantly alter self-reported motivation or prevention program adherence for overweight individuals at risk for diabetes. Diabetes Care 36:13-19, 2013 C1 [Grant, Richard W.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [O'Brien, Kelsey E.; Vassy, Jason L.; Stember, Katherine G.; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Waxler, Jessica L.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Vassy, Jason L.; Delahanty, Linda M.; Green, Robert C.; Park, Elyse R.; Florez, Jose C.; Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA. [Delahanty, Linda M.; Bissett, Laurie G.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA. [Green, Robert C.] Partners Ctr Personalized Genet Med, Boston, MA USA. [Green, Robert C.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Guiducci, Candace; Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Park, Elyse R.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. RP Grant, RW (reprint author), Kaiser Permanente No Calif, Div Res, Oakland, CA USA. EM richard.w.grant@kp.org OI Grant, Richard/0000-0002-6164-8025 FU National Institute of Diabetes and Digestive and Kidney Diseases [R21-DK84527, K24-DK080140] FX This study received funding support from National Institute of Diabetes and Digestive and Kidney Diseases Grants R21-DK84527 and K24-DK080140. No potential conflicts of interest relevant to this article were reported. NR 39 TC 53 Z9 53 U1 1 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2013 VL 36 IS 1 BP 13 EP 19 DI 10.2337/dc12-0884 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LP UT WOS:000314465700025 PM 22933432 ER PT J AU Delahanty, LM Peyrot, M Shrader, PJ Williamson, DA Meigs, JB Nathan, DM AF Delahanty, Linda M. Peyrot, Mark Shrader, Peter J. Williamson, Donald A. Meigs, James B. Nathan, David M. CA DPP Res Grp TI Pretreatment, Psychological, and Behavioral Predictors of Weight Outcomes Among Lifestyle Intervention Participants in the Diabetes Prevention Program (DPP) SO DIABETES CARE LA English DT Article ID BINGE-EATING DISORDER; SELF-EFFICACY; LOSS MAINTENANCE; QUESTIONNAIRE; WOMEN; RISK; MANAGEMENT; STRESS AB OBJECTIVE-To identify the most important pretreatment characteristics and changes in psychological and behavioral factors that predict weight outcomes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS-Approximately 25% of DPP lifestyle intervention participants (n = 274) completed questionnaires to assess weight history and psychological and behavioral factors at baseline and 6 months after completion of the 16-session core curriculum. The change in variables from baseline to 6 months was assessed with t tests. Multivariate models using hierarchical logistic regression assessed the association of weight outcomes at end of study with each demographic, weight loss history, psychological, and behavioral factor. RESULTS-At end of study, 40.5% had achieved the DPP 7% weight loss goal. Several baseline measures (older age, race, older age when first overweight, fewer self-implemented weight loss attempts, greater exercise self-efficacy, greater dietary restraint, fewer fat-related dietary behaviors, more sedentary activity level) were independent predictors of successful end-of-study weight loss with the DPP lifestyle program. The DPP core curriculum resulted in significant improvements in many psychological and behavioral targets. Changes in low-fat diet self-efficacy and dietary restraint skills predicted better long-term weight loss, and the association of low-fat diet self-efficacy with weight outcomes was explained by dietary behaviors. CONCLUSIONS-Health care providers who translate the DPP lifestyle intervention should be aware of pretreatment characteristics that may hamper or enhance weight loss, consider prioritizing strategies to improve low-fat diet self-efficacy and dietary restraint skills, and examine whether taking these actions improves weight loss outcomes. Diabetes Care 36: 34-40, 2013 C1 [Delahanty, Linda M.; Nathan, David M.] Massachusetts Gen Hosp, Dept Med, Ctr Diabet, Boston, MA 02114 USA. [Delahanty, Linda M.; Meigs, James B.; Nathan, David M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Peyrot, Mark] Loyola Univ Maryland, Dept Sociol, Baltimore, MD USA. [Shrader, Peter J.; Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Williamson, Donald A.] Pennington Biomed Res Ctr, Baton Rouge, LA USA. RP Delahanty, LM (reprint author), Massachusetts Gen Hosp, Dept Med, Ctr Diabet, Boston, MA 02114 USA. EM ldelahanty@partners.org FU American Diabetes Association; National Institute of Diabetes and Digestive and Kidney Diseases [K24 DK-080140] FX This work was supported by a research grant from the American Diabetes Association to L.M.D. J.B.M. is supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant K24 DK-080140. NR 30 TC 24 Z9 24 U1 0 U2 22 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2013 VL 36 IS 1 BP 34 EP 40 DI 10.2337/dc12-0733 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LP UT WOS:000314465700028 PM 23129133 ER PT J AU Preis, SR Pencina, MJ D'Agostino, RB Meigs, JB Vasan, RS Fox, CS AF Preis, Sarah Rosner Pencina, Michael J. D'Agostino, Ralph B., Sr. Meigs, James B. Vasan, Ramachandran S. Fox, Caroline S. TI Neck Circumference and the Development of Cardiovascular Disease Risk Factors in the Framingham Heart Study SO DIABETES CARE LA English DT Letter ID RECLASSIFICATION; PREDICTION C1 [Preis, Sarah Rosner; D'Agostino, Ralph B., Sr.; Vasan, Ramachandran S.; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Preis, Sarah Rosner; D'Agostino, Ralph B., Sr.; Vasan, Ramachandran S.; Fox, Caroline S.] Boston Univ, Framingham Heart Study, Framingham, MA USA. [Preis, Sarah Rosner; Fox, Caroline S.] NHLBI, Ctr Populat Studies, NIH, Bethesda, MD 20892 USA. [Preis, Sarah Rosner; Pencina, Michael J.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Pencina, Michael J.; D'Agostino, Ralph B., Sr.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Meigs, James B.; Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Sect Prevent Med, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Cardiol Sect, Boston, MA 02118 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol & Metab, Boston, MA 02115 USA. RP Preis, SR (reprint author), NHLBI, Framingham Heart Study, Framingham, MA USA. EM srpreis@bu.edu OI Preis, Sarah/0000-0002-9360-4166; Ramachandran, Vasan/0000-0001-7357-5970 FU NHLBI NIH HHS [N01-HC-25195, N01HC25195]; NIDDK NIH HHS [R01DK080739, K24 DK080140, R01 DK080739] NR 6 TC 18 Z9 19 U1 0 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2013 VL 36 IS 1 BP E3 EP E3 DI 10.2337/dc12-0738 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LP UT WOS:000314465700003 PM 23264305 ER EF